0001558370-24-002987.txt : 20240312 0001558370-24-002987.hdr.sgml : 20240312 20240312161650 ACCESSION NUMBER: 0001558370-24-002987 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 101 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240312 DATE AS OF CHANGE: 20240312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Enfusion, Inc. CENTRAL INDEX KEY: 0001868912 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] ORGANIZATION NAME: 06 Technology IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40949 FILM NUMBER: 24742284 BUSINESS ADDRESS: STREET 1: 125 SOUTH CLARK STREET, SUITE 750 CITY: CHICAGO STATE: IL ZIP: 60603 BUSINESS PHONE: (312) 253-9800 MAIL ADDRESS: STREET 1: 125 SOUTH CLARK STREET, SUITE 750 CITY: CHICAGO STATE: IL ZIP: 60603 10-K 1 enfn-20231231x10k.htm 10-K
00018689122023FYfalse0070860000883320004319900039199000http://fasb.org/us-gaap/2023#UsefulLifeTermOfLeaseMemberP1YP1YP1YP1Y1490000001868912enfn:PreferredUnitsMember2021-10-200001868912enfn:PreferredUnitsMember2020-12-310001868912us-gaap:CommonClassAMemberus-gaap:SubsequentEventMember2024-01-112024-01-110001868912us-gaap:CommonClassAMember2023-08-012023-08-010001868912us-gaap:CommonClassAMember2023-07-192023-07-190001868912us-gaap:CommonClassAMember2023-03-282023-03-280001868912us-gaap:CommonClassAMember2023-02-212023-02-210001868912us-gaap:CapitalUnitsMember2021-10-012021-10-310001868912srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2023-12-310001868912srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:NoncontrollingInterestMember2023-12-310001868912us-gaap:RetainedEarningsMember2023-12-310001868912us-gaap:NoncontrollingInterestMember2023-12-310001868912us-gaap:AdditionalPaidInCapitalMember2023-12-310001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001868912srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2023-12-310001868912us-gaap:RetainedEarningsMember2022-12-310001868912us-gaap:NoncontrollingInterestMember2022-12-310001868912us-gaap:AdditionalPaidInCapitalMember2022-12-310001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001868912us-gaap:RetainedEarningsMember2021-12-310001868912us-gaap:NoncontrollingInterestMember2021-12-310001868912us-gaap:AdditionalPaidInCapitalMember2021-12-310001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-10-2000018689122021-10-200001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001868912us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-12-310001868912us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-12-310001868912us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-12-310001868912us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-12-310001868912us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-12-310001868912us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-12-310001868912enfn:FtvInvestmentHoldingsMemberus-gaap:RelatedPartyMemberus-gaap:CommonClassAMember2023-06-150001868912us-gaap:EmployeeStockOptionMember2022-12-310001868912enfn:StockOptionAndIncentivePlan2021Memberus-gaap:CommonClassAMember2021-10-310001868912us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001868912enfn:PerformanceBasedRestrictedStockUnitsRSUsMember2022-12-310001868912enfn:PerformanceBasedRestrictedStockUnitsRSUsMember2021-12-310001868912enfn:ClassaCommonStockVestedAndRestrictedStockUnitsMember2022-01-012022-12-310001868912enfn:PerformanceBasedRestrictedStockUnitsRSUsMember2023-10-012023-12-310001868912enfn:ContingentlyIssuableSharesMemberus-gaap:CommonClassAMemberus-gaap:IPOMember2021-10-012021-10-310001868912us-gaap:RestrictedStockUnitsRSUMember2021-10-012021-10-310001868912enfn:PerformanceBasedRestrictedStockUnitsRSUsMember2021-10-012021-10-3100018689122027-01-012023-12-3100018689122025-01-012023-12-3100018689122024-01-012023-12-3100018689122026-01-012023-12-310001868912country:US2023-01-012023-12-310001868912country:US2022-01-012022-12-310001868912country:US2021-01-012021-12-310001868912us-gaap:SoftwareDevelopmentMember2023-12-310001868912country:US2023-12-310001868912country:US2022-12-310001868912us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-310001868912us-gaap:LeaseholdImprovementsMember2023-12-310001868912us-gaap:FurnitureAndFixturesMember2023-12-310001868912us-gaap:ComputerEquipmentMember2023-12-310001868912us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-12-310001868912us-gaap:LeaseholdImprovementsMember2022-12-310001868912us-gaap:FurnitureAndFixturesMember2022-12-310001868912us-gaap:ComputerEquipmentMember2022-12-310001868912us-gaap:RetainedEarningsMember2023-01-012023-12-310001868912us-gaap:RetainedEarningsMember2022-01-012022-12-310001868912us-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2023-08-142023-08-140001868912enfn:FtvEnfusionHoldingsIncMemberus-gaap:RelatedPartyMember2023-01-012023-03-310001868912enfn:FtvEnfusionHoldingsIncMemberus-gaap:RelatedPartyMember2023-06-272023-06-270001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-10-212021-12-310001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-10-200001868912us-gaap:StateAndLocalJurisdictionMember2023-12-310001868912us-gaap:DomesticCountryMember2023-12-310001868912us-gaap:StateAndLocalJurisdictionMember2022-12-310001868912us-gaap:DomesticCountryMember2022-12-310001868912enfn:EnfusionLtd.LlcMember2023-12-310001868912srt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberenfn:NewCreditAgreementMember2023-09-152023-09-150001868912srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberenfn:NewCreditAgreementMember2023-09-152023-09-150001868912us-gaap:RevolvingCreditFacilityMemberenfn:NewCreditAgreementMember2023-01-012023-12-310001868912us-gaap:RevolvingCreditFacilityMemberenfn:NewCreditAgreementMember2023-09-150001868912us-gaap:LetterOfCreditMemberenfn:NewCreditAgreementMember2023-09-150001868912enfn:SwinglineSubfacilityMemberenfn:NewCreditAgreementMember2023-09-150001868912enfn:NewCreditAgreementMember2023-12-310001868912us-gaap:RevolvingCreditFacilityMemberenfn:PriorCreditAgreementMember2023-09-150001868912us-gaap:RevolvingCreditFacilityMemberenfn:PriorCreditAgreementMember2023-09-152023-09-150001868912enfn:PerformanceBasedRestrictedStockUnitsRSUsMember2023-12-310001868912us-gaap:EmployeeStockOptionMember2023-12-310001868912srt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberenfn:NewCreditAgreementMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-09-152023-09-150001868912srt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberenfn:NewCreditAgreementMemberus-gaap:BaseRateMember2023-09-152023-09-150001868912srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberenfn:NewCreditAgreementMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-09-152023-09-150001868912srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberenfn:NewCreditAgreementMemberus-gaap:BaseRateMember2023-09-152023-09-150001868912us-gaap:RevolvingCreditFacilityMemberenfn:NewCreditAgreementMemberus-gaap:FederalFundsEffectiveSwapRateMember2023-09-152023-09-150001868912us-gaap:RevolvingCreditFacilityMemberenfn:NewCreditAgreementMemberenfn:OneMonthAdjustedTermSecuredOvernightFinancingRateSofrMember2023-09-152023-09-150001868912enfn:PlatformSubscriptionsMember2023-01-012023-12-310001868912enfn:OtherServicesMember2023-01-012023-12-310001868912enfn:ManagedServicesMember2023-01-012023-12-310001868912enfn:PlatformSubscriptionsMember2022-01-012022-12-310001868912enfn:OtherServicesMember2022-01-012022-12-310001868912enfn:ManagedServicesMember2022-01-012022-12-310001868912enfn:PlatformSubscriptionsMember2021-01-012021-12-310001868912enfn:OtherServicesMember2021-01-012021-12-310001868912enfn:ManagedServicesMember2021-01-012021-12-310001868912us-gaap:EMEAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-12-310001868912srt:AsiaPacificMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-12-310001868912srt:AmericasMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-12-310001868912us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-12-310001868912us-gaap:EMEAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-12-310001868912srt:AsiaPacificMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-12-310001868912srt:AmericasMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-12-310001868912us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-12-310001868912us-gaap:EMEAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-12-310001868912srt:AsiaPacificMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-12-310001868912srt:AmericasMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-12-310001868912us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-12-310001868912us-gaap:MemberUnitsMember2021-10-200001868912us-gaap:MemberUnitsMember2020-12-310001868912us-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2023-08-140001868912us-gaap:CommonClassBMember2022-12-310001868912us-gaap:CommonClassAMember2022-12-3100018689122020-12-310001868912us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001868912us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001868912us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001868912us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001868912us-gaap:CommonClassBMember2022-01-012022-12-310001868912us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001868912us-gaap:CommonClassBMember2021-01-012021-12-310001868912enfn:ContingentlyIssuableClassCommonStockMember2021-01-012021-12-310001868912srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccountingStandardsUpdate201613Member2022-12-310001868912enfn:ContingentlyIssuableSharesMemberus-gaap:CommonClassAMemberus-gaap:IPOMember2023-01-012023-12-310001868912us-gaap:SellingAndMarketingExpenseMember2023-01-012023-12-310001868912us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001868912us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310001868912us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-12-310001868912us-gaap:CostOfSalesMember2023-01-012023-12-310001868912us-gaap:SellingAndMarketingExpenseMember2022-01-012022-12-310001868912us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001868912us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001868912us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001868912us-gaap:CostOfSalesMember2022-01-012022-12-310001868912us-gaap:CommonClassAMemberus-gaap:IPOMember2021-10-012021-10-310001868912enfn:ContingentlyIssuableSharesMemberus-gaap:CommonClassAMemberus-gaap:IPOMember2021-01-012021-12-310001868912us-gaap:SellingAndMarketingExpenseMember2021-01-012021-12-310001868912us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001868912us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001868912us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001868912us-gaap:CostOfSalesMember2021-01-012021-12-310001868912enfn:PreferredUnitsMember2021-10-212021-12-310001868912enfn:PreferredUnitsMember2021-01-012021-10-200001868912enfn:EnfusionLtd.LlcMember2023-12-310001868912enfn:EnfusionLtd.LlcMember2022-12-310001868912enfn:PerformanceBasedRestrictedStockUnitsRSUsMember2022-01-012022-12-310001868912enfn:PerformanceBasedRestrictedStockUnitsRSUsMember2021-01-012021-12-310001868912enfn:ClassaCommonStockVestedAndRestrictedStockUnitsMember2023-12-310001868912enfn:ClassaCommonStockVestedAndRestrictedStockUnitsMember2022-12-310001868912enfn:ClassaCommonStockVestedAndRestrictedStockUnitsMember2023-01-012023-12-310001868912us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001868912enfn:PerformanceBasedRestrictedStockUnitsRSUsMember2023-01-012023-12-310001868912us-gaap:NoncontrollingInterestMember2023-01-012023-12-310001868912us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001868912us-gaap:NoncontrollingInterestMember2022-01-012022-12-310001868912us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001868912us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-01-012023-12-310001868912us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-01-012023-12-310001868912us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-01-012022-12-310001868912us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-01-012022-12-310001868912us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-10-212021-12-310001868912us-gaap:MemberUnitsMember2021-10-212021-12-310001868912us-gaap:AdditionalPaidInCapitalMember2021-10-212021-12-310001868912us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-10-212021-12-310001868912enfn:ContingentlyIssuableSharesMemberus-gaap:CommonClassAMemberus-gaap:IPOMember2022-01-012022-12-310001868912enfn:StockOptionAndIncentivePlan2021Member2021-10-012021-10-310001868912us-gaap:CommonClassBMember2023-12-310001868912us-gaap:CommonClassAMember2023-12-310001868912enfn:EnfusionLtd.LlcMember2023-01-012023-12-310001868912enfn:EnfusionLtd.LlcMember2022-01-012022-12-310001868912enfn:FtvInvestmentHoldingsMemberus-gaap:RelatedPartyMemberus-gaap:CommonClassAMember2023-06-152023-06-150001868912us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:CommonClassAMember2021-10-310001868912srt:MaximumMemberenfn:NewCreditAgreementMember2023-09-152023-09-150001868912enfn:MajorCustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001868912enfn:MajorCustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001868912enfn:MajorCustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001868912enfn:MajorCustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001868912us-gaap:RetainedEarningsMember2021-10-212021-12-310001868912us-gaap:NoncontrollingInterestMember2021-10-212021-12-3100018689122021-10-212021-12-310001868912enfn:NewCreditAgreementMemberus-gaap:SubsequentEventMember2024-02-290001868912enfn:NewCreditAgreementMember2023-09-1500018689122021-12-310001868912us-gaap:MemberUnitsMember2021-01-012021-10-2000018689122021-01-012021-10-200001868912us-gaap:RevolvingCreditFacilityMemberenfn:NewCreditAgreementMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-09-152023-09-150001868912us-gaap:SubsequentEventMember2024-01-112024-01-1100018689122023-08-012023-08-0100018689122023-07-192023-07-1900018689122023-03-282023-03-2800018689122023-02-212023-02-210001868912enfn:FtvFundIvMemberus-gaap:RelatedPartyMemberus-gaap:CommonClassAMember2023-06-1500018689122021-01-012021-12-3100018689122023-12-3100018689122022-12-3100018689122022-01-012022-12-310001868912enfn:OlegMovchanMember2023-12-310001868912enfn:OlegMovchanMember2023-10-012023-12-3100018689122023-06-300001868912us-gaap:CommonStockMember2024-03-080001868912us-gaap:CommonClassBMember2024-03-080001868912us-gaap:CommonClassAMember2024-03-0800018689122023-01-012023-12-31xbrli:sharesiso4217:USDxbrli:pureenfn:customerenfn:leaseenfn:subsidiaryenfn:Voteiso4217:USDxbrli:sharesenfn:segment

Item

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Transition Period From                To

Commission file number: 001-40949

ENFUSION, INC.

(Exact name of registrant as specified in its charter)

Delaware

87-1268462

(State of Other Jurisdiction of incorporation or Organization)

(I.R.S. Employer Identification No.)

125 South Clark Street, Suite 750, Chicago, IL 60603

60603

(Address of principal executive offices)

(Zip code)

Registrant’s telephone number, including area code: (312) 253-9800

Securities registered pursuant to Section 12(b) of the Act:

Name Of Each Exchange

Title of Each Class

    

Trading Symbol(s)

   

On Which Registered

Class A common stock, par value $0.001 per share

ENFN

New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes    No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes    No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x   No

Indicate by check mark whether the registrant has submitted electronically; every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.0405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes x   No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer 

Accelerated filer 

Non-accelerated filer 

Smaller reporting company 

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No x

The aggregate market value of the registrant’s Class A common stock held by non-affiliates of the registrant on June 30, 2023, based on the closing price of $11.22 for shares of the registrant’s Class A common stock as reported by the New York Stock Exchange, was $438.2 million. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.

As of March 8, 2024, the registrant had 128,069,912 shares of common stock outstanding, consisting of 89,871,145 outstanding shares of Class A common stock and 38,198,767 outstanding shares of Class B common stock.

Documents Incorporated by Reference

Portions of the registrant's Definitive Proxy Statement relating to the 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant's fiscal year ended December 31, 2023.

TABLE OF CONTENTS

    

Page

PART I

Item 1. Business

5

Item 1A. Risk Factors

12

Item 1B. Unresolved Staff Comments

40

Item 1C. Cybersecurity

40

Item 2. Properties

41

Item 3. Legal Proceedings

42

Item 4. Mine Safety Disclosures

42

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

43

Item 6. [Reserved]

44

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

45

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

58

Item 8. Financial Statements and Supplementary Data

F-1

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

59

Item 9A. Controls and Procedures

59

Item 9B. Other Information

60

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

60

PART III

Item 10. Directors, Executive Officers, and Corporate Governance

60

Item 11. Executive Compensation

60

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

60

Item 13. Certain Relationships and Related Transactions, and Director Independence

60

Item 14. Principal Accounting Fees and Services

60

PART IV

Item 15. Exhibits and Financial Statement Schedules

60

Item 16. Form 10-K Summary

61

2

CAUTIONARY STATEMENT

This Annual Report on Form 10-K contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future results of operations, financial condition, business strategy, plans and objectives of management for future operations, our market opportunity and the potential growth of that market, our liquidity and capital needs and other similar matters, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these words or other similar terms or expressions. These forward-looking statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks, and changes in circumstances that are difficult to predict. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements concerning the following:

our future financial performance, including our revenues, costs of revenues, gross profit or gross profit margin and operating expenses;
our ability to successfully expand in our existing markets and into new markets;
anticipated trends and growth rates in our business and in the markets in which we operate;
our ability to retain existing clients and onboard new clients;
our ability to sell additional products and services to our clients;
our ability to successfully identify, integrate and realize the benefits of strategic acquisitions or partnerships;
our ability to effectively manage our growth and future expenses;
our anticipated investments in our business, our anticipated capital expenditures, and our estimates regarding our capital requirements;
our ability to maintain the security and availability of the products and services that comprise our solution;
our ability to maintain, protect and enhance our intellectual property;
our ability to comply with modified or new laws and regulations applying to our business;
the attraction and retention of qualified employees and key personnel;
the impact of global financial, economic, and political events on our business and industry; and
our ability to compete effectively with existing competitors and new market entrants.

You should not rely upon forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Annual Report on Form 10-K primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations and prospects. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in Part I, Item 1A. Risk Factors and elsewhere in this Annual Report on Form 10-K. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report on Form 10-K. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements.

The forward-looking statements made in this Annual Report on Form 10-K relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Annual Report on Form 10-K to reflect events or circumstances after the date of this Annual Report on Form 10-K or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make.

3

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K. And while we believe such information provides a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.

CERTAIN DEFINITIONS

As used in this Annual Report on Form 10-K, unless the context otherwise requires:

“Blocker Companies” refer to certain entities that are taxable as corporations for U.S. federal income tax purposes in which the Pre-IPO Shareholders held interests.
“Common Units” refers to the new class of units of Enfusion Ltd. LLC created by the reclassification of the LLC interests of Enfusion Ltd. LLC as part of the Reorganization Transactions.
“Enfusion,” the “Company,” “we,” “us” and “our” and similar references refer: (1) following the consummation of the Reorganization Transactions, including our IPO, to Enfusion, Inc., and, unless otherwise stated, all of its direct and indirect subsidiaries, including Enfusion Ltd. LLC and (2) prior to the completion of the Reorganization Transactions, including our IPO, to Enfusion Ltd. LLC and, unless otherwise stated, all of its direct and indirect subsidiaries.
“IPO” refers to the Company’s initial public offering, completed on October 25, 2021.
“LLC Operating Agreement” refers to the Seventh Amended and Restated Operating Agreement of Enfusion Ltd, LLC, dated as of October 19, 2021.
“New Credit Agreement” refers to the senior secured Credit Agreement, dated September 15, 2023, which Enfusion, Inc., Enfusion Ltd. LLC and certain subsidiaries of Enfusion Ltd. LLC entered into with Bank of America, N.A., as administrative agent, swing line lender and L/C issuer, and a syndicate of lending institutions from time to time party thereto.
“Pre-IPO Owners” refer to the equity holders who were the owners of Enfusion Ltd. LLC immediately prior to the Reorganization Transactions.
“Pre-IPO Shareholders” refer to Pre-IPO Owners that received shares of Class A common stock of Enfusion, Inc. as part of the Reorganization Transactions.
“Pre-IPO Common Unitholders” refer to Pre-IPO Owners that held Common Units following the Reorganization Transactions.
“Prior Credit Agreement” refers to the amended and restated Credit Agreement with Silicon Valley Bank, dated October 19, 2021, which was terminated in connection with our entry into the New Credit Agreement.
“Reorganization Transactions” refer to our IPO and certain organizational transactions that were affected in connection with our IPO, and the application of the net proceeds therefrom. See “Initial Public Offering and Reorganization Transactions” in Note 2 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 for a description of the transactions.
“SEC” refers to the U.S. Securities & Exchange Commission.
“Tax Receivable Agreement” refers to the Tax Receivable Agreement, dated as of October 19, 2021, entered into by and among the Company and each of the other persons from time to time party thereto.
“U.S. GAAP” refers to accounting principles generally accepted in the United States of America.

4

PART I

Item 1. Business

Overview

Enfusion is a global, high-growth, software-as-a-service (“SaaS”), provider focused on transforming the investment management industry. The products and services that comprise our solution are designed to eliminate technology and information barriers, empowering investment managers to confidently make and execute better-informed investment decisions in real time. We simplify investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth. This allows stakeholders throughout the entire client organization to interact more effectively with one another across the investment management lifecycle.

We believe, by means of our purposefully-designed, interconnected systems underpinned by one dataset, we are the only solution that allows clients to see and interact with all parts of the investment management lifecycle, ranging from portfolio construction, trading, risk management, accounting, and operations through to investor reporting, seamlessly in real time, in one screen, in one solution. As a result, our solution enables clients to better align teams, optimizing their investment decision-making, operations and technology footprint, and lowering operating costs. By harnessing the efficiencies, agility, and scale inherent to our cloud-native, multi-tenant software that is integrated with a suite of technology-powered, managed services, we believe we have created the industry’s most compelling investment management solution, capable of shaping and addressing the evolving demands of the global investment management landscape.

Existing solutions in the investment management technology industry include a patchwork of “task-specific” point solutions from disparate vendors, technology stitched together through acquisitions, internally-developed technology, as well as cost-prohibitive solutions accessible only to the largest investment managers. Where available solutions are cloud-enabled, many were originally designed for on-premises installations and subsequently individually migrated to the cloud via discrete code streams, retaining single-tenant infrastructure limitations that require changes to be made for each client individually instead of delivering changes to all clients simultaneously, and leading to laborious and costly maintenance and difficult security requirements. As a result, many investment managers spend considerable time and resources managing legacy, stitched together, or disparate systems, fragmented data, complex communication networks and cumbersome workflows. Designed for the cloud from inception, Enfusion provides a flexible and simplified end-to-end alternative that allows investment managers to focus their time and resources on investment performance. This enables us to build long-term partnerships with our clients, offering a solution that is not only tailored to meet their business needs today, but also has the depth and breadth of capability to support them as they grow or enter new markets or asset classes.

Our cloud-native, multi-tenant solution provides:

Seamless unification and simplification of workflows provided through one cohesive solution;
A robust, real-time view of a client’s business that can be displayed through countless reports, and utilized across client personnel that depend on one another, but have different roles throughout the organization;
Inherent scalability and extensive integrations via client, third-party and proprietary interfaces, and APIs;
Weekly, functional enhancements provided to all clients, eliminating complicated upgrade and version control issues, and providing the agility to meet rapidly evolving industry needs;
Reduced operational risk through granular, user-defined access controls and governance capabilities; and
Anywhere access across the desktop, the web, and mobile devices.

5

Enfusion’s comprehensive solution cohesively addresses the core components of the investment lifecycle. Our portfolio management system gives clients the ability to construct and analyze portfolios and performance metrics with granularity, enabling better-informed investment decision-making. Once trade decisions are made, clients use our combined order and execution management systems to obtain market insights, run compliance checks and send electronic trade orders directly to executing brokers and exchanges. When orders are executed, execution data flows back to our solution and instantly feeds our systems, including our accounting system, enabling clients to produce a full set of financial statements in real time. The data also feeds our extensive reporting and analytics capabilities, allowing stakeholders across client organizations, including executive management, investment teams, operational support, compliance, and investor relations, to obtain differentiating insights into their investment activities and better analyze investment performance. The purposefully-designed interconnectedness of our systems removes the need for manual data processing and validating across workflows. Coupled with market data and aggregated transactional and derived data provided to or received from a full suite of a client’s supporting parties, our solution creates a single dataset and source of truth that gives our clients a real-time, comprehensive, and consistent view of their data across the investment lifecycle. Altogether, our full lifecycle, single-dataset investment management solution provides investment managers with a tailored suite of tools and investment content to make better-informed decisions, faster and with greater confidence, in one screen and one solution.

In addition to facilitating the full investment lifecycle, our robust and agile solution allows us to serve a diverse client base that ranges in investment strategies, size, and geography. Our clients include alternative investment managers such as hedge funds of all types, private equity funds, family offices and corporate investment arms, as well as institutional investment managers such as traditional asset managers and mutual funds:

Alternative Investment Managers – We enable alternative investment management clients to achieve scale efficiently, instill investor confidence, easily expand into new strategies, asset classes or geographies and significantly increase their speed to market. Clients can interact with the entire investment management lifecycle on one solution, unified by one dataset and are not burdened by costly hardware requirements or disruptive software upgrades. We generally deliver weekly upgrades through our cloud-native, multi-tenant solution, allowing us to continuously innovate and quickly adapt to meet ever-evolving client needs.
Institutional Investment Managers – We deliver an intelligent solution that can replace or supplement institutional investment management clients’ legacy systems and can be utilized as a unifying hub across other existing systems, improving our clients’ operational inefficiencies and providing access to more relevant and simplified workflows and technologies. This intelligent solution gives large, less-agile clients the ability to replace their existing systems at their own pace, as they become better positioned to reduce their costly and inefficient legacy technology dependencies.

The Enfusion Solution

Our cloud-native, purposefully-designed, end-to-end solution gives our clients the ability to easily access and analyze investment information in real time, perform complex calculations quickly and interact with markets electronically adding up to better, more informed investment decisions and actions. Our solution is highly configurable to different work streams, client segments and asset classes. Rather than relying on large, specialized workforces necessary for local or tenant-by-tenant deployments, modifications to our solution are made remotely within one code-base and without client intervention or interaction. Software enhancements developed for individual, sponsoring clients are made available to all clients at the same time. This process, where our community of clients continuously contributes to the ever-evolving nature of our solution, strengthens the value of the solution to all of our clients. Further, Enfusion’s open and flexible architecture easily integrates into clients’ existing technology stacks via APIs and other connectivity and is adaptable to our clients’ existing internal and third-party systems. With a limited footprint, wide-ranging use-cases and ‘anywhere’ access across multiple mediums, our solution increasingly serves as the operational epicenter for our clients.

Our solution, comprised of mission critical systems integrated with a suite of technology-powered, managed services, serves the full investment lifecycle, driving better insights into and control over the business activities of the investment manager and investment operations. We recognize that, despite increasing market pressures to the contrary, some clients may not be in a position to replace all of their systems at once. Therefore, we have designed our solution to allow our clients to use some or all of our solution to manage their investment lifecycle workflow and also to augment or

6

integrate into their existing workflows or systems, giving them the flexibility to expand their usage and us the ability to solve their unique needs through time.

Our solution is utilized by a variety of users including portfolio managers, traders, compliance officers, operational support staff and executive management, all of whom benefit from role-based functionality underpinned by a single dataset. This single dataset enables each of these users to generate valuable insights while operating on the same real-time information governed by appropriate access controls. The end-to-end functionality our solution provides is detailed below:

Graphic

Portfolio Management System (“PMS”): Able to comprehensively construct and re-balance investment portfolios, this system generates a real-time investment book of record (“IBOR”), for CIOs and portfolio managers, features a full suite of valuation and risk tools and allows users to analyze aggregated or decomposed portfolio data by any number of customizable dimensions.
Order and Execution Management System (“OEMS”): Intertwined with our PMS, this module offers portfolio managers, traders, compliance teams and analysts the ability to electronically communicate trade orders for a variety of asset classes and with a choice of hundreds of executing counterparties globally, manage trade orders and systemically enforce trading regulations and internal guidelines.
Accounting/General Ledger System: Underpinning our PMS and OEMS systems, our accounting system features a proper double-entry ledger that automates the posting of general ledger journal entries for all cash and securities transactions directly from our PMS—providing CFOs, COOs, accountants, and operations teams a complete, real-time accounting book of record.
Enfusion Analytics System: Connected in real time with our PMS and OEMS, the Enfusion Analytics System enables CIOs, portfolio managers, traders, and analysts to utilize the solution’s comprehensive client data insights to analyze portfolios through time horizons and automate customized visualized reports for both

7

internal and external stakeholders. This module also acts as a centralized data warehouse that may be accessed or utilized by both individual and systematic users.
Technology-Powered, Managed Services: We offer access to technology-powered, managed services designed to maximize the power of the Enfusion solution. By using expert teams empowered by technology to address time-consuming front-, middle- and back-office administrative tasks related to the investment lifecycle such as performing various fund and position level reconciliations, processing corporate actions, proactive trade break resolutions, and back up accounting against fund administrators, our clients are able to focus on their highest-value business activities and recognize the full benefit of our solution.

Our Market Opportunity

Investment managers spend significant time and resources supporting their business processes, which is intensifying as their industry continues to become more complex and subject to unprecedented pace of change. It is critical that investment managers have the tools to confidently make and execute upon better-informed investment decisions in real time and, in turn, remain competitive. Accordingly, the demand for a comprehensive investment lifecycle, cloud-native solution that simplifies workflows by unifying mission-critical systems and coalescing data into a single dataset will continue to increase.

The Enfusion solution, comprised of mission-critical systems integrated with a suite of technology-powered, managed services, is designed to eliminate the inherent constraints and maintenance demands tied to managing legacy and disparate technology as well as aggregating and validating data across workflows, allowing our clients to focus on innovation and investment returns. Our flexible architecture, built on a single codebase, gives us the ability to provide weekly software upgrades with improvements and new capabilities and, in turn, allows us to match the unprecedented pace of change and continuously evolve to meet our clients’ needs.

We believe there is a significant opportunity for us to replace competing legacy products as well as in-house proprietary technology. Our solution provides clients with flexibility to augment their existing systems, replace all legacy systems at once, or to take a more gradual approach, initially utilizing one system or limited parts of our solution and then gradually expanding utilization. Our solution is built for plug-and-play integration, with flexible APIs and other forms of connectivity that make it easy for clients to connect with other solutions or supporting parties.

Our Clients and Client Service

Enfusion has a diverse, global client base of 865 clients as of December 31, 2023, ranging from alternative investment managers such as hedge funds of all types, family offices and corporate investment arms, to institutional investment managers such as traditional investment managers, and mutual funds. Our client base spans our geographic reach; as of December 31, 2023, 54% of clients are from the Americas, 28% are from APAC, and 18% are from EMEA.

Our client-centric approach is embedded in the operating ethos across Enfusion. Our most important goal is to hold a high standard that couples both excellent ongoing innovation and excellent client experience. We believe our client-centric approach differentiates Enfusion and is made possible by our solution’s nimble, single-codebase architecture that is delivered in a one-to-many manner. In practice, our structure allows us to dedicate resources to our clients holistically, driving a superior client experience from the point of identifying a sales opportunity to product and services implementation and continuing throughout the client relationship. By providing dedicated continuity in the servicing team assigned to each client, we are able to ensure that our clients are continuously interfacing with familiar Enfusion employees that understand their business, workflows, daily needs and product use leading to increased efficiency and improved client experience. We also provide dedicated support teams and 24-hour, follow-the-sun support, six days a week, to all of our clients and with no additional charge.

Our Revenue Model

We derive the vast majority of our total revenues (99.3%, 98.9% and 98.8% for the years ended December 31, 2023, 2022, and 2021, respectively) from our recurring subscription-based revenues. Client subscription fees are

8

comprised of various components such as user fees, connectivity fees, market data fees and managed services fees, all of which take into account client size, complexity, and growth. The weekly enhancements and upgrades that we deliver and the dedicated client service are included in the price of the contract.

Our typical contract has an initial term of two or three years and generally auto-renews for one year, although actual renewal terms vary by contract, upon the completion of the initial term without an option to terminate for convenience. Certain legacy contracts have a termination for convenience clause with 30 days’ notice. Invoicing typically occurs in monthly installments at the end of each month during the subscription period.

Our Growth Strategy

We continue to advance our position as a leading technology partner to the investment management industry. The key components of our growth strategy include:

Continue Broadening Our Client Base: There are significant opportunities to expand our client base across the various client segments we serve today. We believe we are a leading cloud-native, SaaS provider within the alternative investment sector, and expect that as that sector grows, we will continue to extend our position. In addition, we continue to extend this growth through increasing adoption by larger institutional asset management clients due to increasing acceptance of cloud technology and the robust capabilities of our solution that better meet their evolving needs and address their existing pain points. Taking advantage of the unique position that allows us to sell our products and services through shorter sales cycles and on faster client implementation timelines, we continue to expand our sales efforts to aggressively capitalize on opportunities in this client segment. Our success in signing new clients is also supported by referrals from our existing clients, client stakeholders when they transition to other or launch new organizations, industry channel partners and our global, strategic partners and alliances.
Expanding Relationships with Existing Clients: We believe there is a significant opportunity to further expand our relationships with existing clients as they continue to evolve and grow in size and expand into new markets and strategies or as we provide new functionality or release new systems, features, or services. We also believe we have a significant opportunity to expand our relationship with existing clients that were not in a position to replace all of their systems at once when they first engaged with us. For those clients that elect to initially utilize some portion of our solution or only use our solution for a particular strategy or fund, we find that once they experience the advantages of our end-to-end solution, many seek opportunities to expand the breadth of their relationship with us to further help improve their investment management workflows and technology infrastructure.
Ongoing Pace of Innovation: To retain and expand our client base, we continuously evaluate opportunities to advance our solution through increased breadth and depth of functionality to enrich overall experience and better enable our clients to achieve their investment goals and solve for a broad array of business, operational and technology challenges. We invest heavily in innovation and, on a weekly basis, deliver enhancements and added functionality based on our ongoing dialogues with our clients and consistent with our commitment to grow and evolve with our clients.
Geographic Expansion: We believe there are attractive, untapped opportunities across various geographies within which we can expand our business. For the years ended December 31, 2023 and 2022, approximately 62% and 63% of our total revenues were generated from clients in the Americas and 38% and 37% were generated from clients outside of the Americas, respectively. We are globally situated in nine offices in Chicago, New York City, London, Dublin, Hong Kong, Singapore, Mumbai, Bengaluru, and Sydney. We continue to invest in expanding our presence and capitalize on opportunities in markets such as Europe, the Middle East, and Asia Pacific. In 2023, we established an entity in Dubai to facilitate business in a rapidly growing region. In 2023, we signed 148 clients across the world, representing an 18% increase in total clients from 2022.

9

Selectively Pursue Acquisitions: We may selectively pursue strategic acquisitions of complementary businesses and technologies that improve and accelerate our ability to deliver world-class investment management products and services and excellent client experience.

Our Go-To Market Strategy

We sell subscriptions to our cloud-native solution through the demand generated globally by our marketing efforts, using our direct sales force and by leveraging client referrals, industry channel partners and strategic alliances.

Our industry-experienced sales team includes sales development representatives, field sales representatives, and solution engineers. The team is responsible for managing and developing outbound leads, driving new business, and providing product demonstrations. Once a lead is identified, the team frames the unique pain points, goals, and needs of the prospective client and works with the solution engineers to map a tailored end-to-end solution molded around their workflows.

Our partnerships are an important aspect of our sales and marketing strategy. We leverage a broad network of global relationships across trading systems, fund administrators, technology providers, investment systems consultants and prime brokers to further expand our reach. Through these relationships, we often receive significant prospect referrals. Our channel partners suggest our solution to their clients because they often benefit operationally from working with clients that have unified data, superior access to information, improved workflows and a stringent control environment. Additionally, our simplified implementation process significantly increases our clients’ speed to market, which is beneficial to our partners whose services are largely dependent on our clients being active in the market.

Our go-to market strategy is supported by a marketing team that oversees all aspects of the Enfusion global demand generation engine including digital marketing, social media, public relations, segment marketing, graphic design, conferences, and events. Our marketing efforts focus on generating and facilitating quality inbound leads, optimizing the lead generation strategy, leveraging the power of client references and testimonials, building an institutionalized and recognizable brand, and promoting direct sales. We leverage online and offline marketing channels by participating in conferences, industry events and using digital marketing and social media to educate the community on who we are and the solution we provide.

Intellectual Property

We rely on a combination of trade secret, copyright, and trademark laws; a variety of contractual arrangements, such as license agreements, intellectual property assignment agreements, confidentiality, and non-disclosure agreements; and confidentiality procedures and technical measures to protect our rights and the intellectual property used in our business. We do not currently have any patents.

We have an ongoing trademark and service mark registration program pursuant to which we register our brand names and product names, taglines and logos in the United States and other countries to the extent we determine appropriate and cost-effective. We also have common law rights in some trademarks and numerous pending trademark applications in various jurisdictions. In addition, we have registered domain names for websites that we use in our business, such as https://www.enfusion.com/ and other variations.

We intend to pursue additional intellectual property protection to the extent we believe it would be beneficial and cost-effective. Despite our efforts to protect our intellectual property rights, they may not be respected in the future or may be invalidated, circumvented, or challenged.

See Part I, Item 1A. Risk Factors, including the section titled “Risks Related to Our Intellectual Property,” for a description of the risks related to our intellectual property.

10

Our Competition

The market for investment management software and services is highly competitive and we compete with new and established providers that offer products ranging from point solutions to multi-product suites. We compete on the basis of a number of factors, including:

flexibility of solution;
quality of professional services;
depth of product functionality and asset coverage;
speed of implementations and client support;
innovation and responsiveness to client needs;
return on investment and total cost of ownership;
security and reliability;
integration and interoperability with third-party systems; and
ability to support regulatory requirements and compliance.

We believe that we compete favorably with respect to these factors. However, many of our competitors have greater financial, technical, and other resources, greater brand recognition, larger sales forces and marketing budgets and broader distribution networks. They may be able to leverage these resources to gain business in a manner that discourages customers from purchasing and implementing our solution. Furthermore, we expect that our industry will continue to attract new market entrants, including smaller emerging companies, which could introduce new offerings. We may also expand into new markets and encounter additional competitors in such markets.

Incumbents such as Blackrock’s Aladdin, Broadridge, State Street Alpha, SS&C, SimCorp, Bloomberg AIM, LayerOne and Coremont may provide end-to-end systems, but many of them are single-tenant and cloud-migrated rather than cloud-native or built for the cloud, or are faced with other deployment challenges. As a result, they are not sufficiently nimble to allow for scale and often require physical provisioning, rely on large teams of specialized personnel that through time are difficult to hire, face latency issues and continue to increase the investment manager’s overall costly and inefficient legacy technology dependencies. Their single tenant and cloud-migrated structures restrict their agility and inhibit their ability to provide frequent or simultaneous upgrades to all of their clients. New entrants in the space often provide single point solutions such as trading, fund administration or portfolio analytics that are intended to be coupled with other offerings.

We believe our multi-tenant cloud-native solution, comprised of mission critical systems integrated with a suite of services, is highly differentiating. Our cloud-native, single codebase architecture allows us to serve the full investment lifecycle in a way that unifies workflows creating one dataset that accurately reflects the activities across all systems and multiple departments within a client organization in real time. Additionally, our single codebase architecture allows us to deliver faster implementation and continuously add functionality. As a result, we believe Enfusion is able to continue to innovate faster, delivering a better, more nimble solution that investment managers require in light of the global challenges they face.

Human Capital Resources and Culture

As of December 31, 2023, we had 1,102 employees across the Company. Of these employees, 330 are based in the Americas, and 772 are based internationally, of which 577 are based in India. We consider our current relationship

11

with our employees to be strong. None of our employees are represented by a labor union or are a party to a collective bargaining agreement.

We believe in our collaborative, innovative, transparent, and integrity-driven culture where, despite differences in geographic locations, titles, and responsibilities, we operate as one team and celebrate shared success. Our culture is represented by a set of core values summarized below:

Integrity: We say what we mean, and we do what we say. We are honest with our clients, colleagues, partners, and ourselves. We always strive to do the right thing.
Innovation: We are focused on what’s next and aim to win by relentlessly innovating and improving. We take pride in our efforts to anticipate our clients’ needs and design dynamic product enhancements.
Clients: We are obsessed with going above and beyond for our clients every day. Our deep understanding of the industry and their businesses is augmented by our willingness to ask our clients “Why?” We use that level of understanding to create products and services that aim to continuously improve their performance.
Collaboration: We solve complex problems for our clients, which is only possible when we pool our talents. We recognize and prize our teammates’ strengths and work together to meet challenges. We compete to win as one – One Enfusion.
Ownership: We are collectively and individually responsible for creating value for our clients and our firm. We are both the first and last line of defense. When we see a problem, we take it on and then own the solution.
Passion: We are driven by our ambition to transform our industry and lead change, which fuels personal pride in our work and our brand. We care deeply about our clients and each other.

Available Information

Enfusion, Inc. was incorporated in Delaware on June 11, 2021. Our principal executive offices are located at 125 South Clark Street, Suite 750, Chicago, IL 60603, and our telephone number is (312) 253-9800.

Our website address is https://www.enfusion.com/. In addition to the information about us and our subsidiaries contained in this Annual Report on Form 10-K, information about us can be found on our website. Our official LinkedIn account is a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Our website and our official LinkedIn account and information included in or linked to our website or our official LinkedIn account are not part of this Annual Report on Form 10-K.

Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports (including exhibits) filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are available free of charge through our website at https://ir.enfusion.com/ as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. Additionally, the SEC maintains an internet site that contains reports, proxy and information statements and other information. The address of the SEC’s website is www.sec.gov.

Item 1A. Risk Factors

A description of the risks and uncertainties associated with our business and ownership of our Class A common stock is set forth below. You should carefully consider the material and other risks and uncertainties described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and related notes and Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. The risks described below are not the only risks that we face. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and prospects. As a result, the market

12

price of our Class A common stock could decline, and you may lose all or part of your investment in our Class A common stock.

Risk Factor Summary

The following is a summary of the principal risks that could materially adversely affect our business, results of operations, and financial condition. Additional discussion of the risks included in this summary, and other risks that we face, can be found below and should be read together with other information in this Annual Report on Form 10-K and other filings we make with the SEC. This summary should not be relied upon as an exhaustive summary of the material risks facing our business.

If the adoption and acceptance of cloud-based financial solutions slows or shifts in a way we do not anticipate or are unable to support or if we do not accurately anticipate, prepare for, and promptly respond to rapidly evolving client needs, our sales will suffer, and the results of our operations will be adversely affected.
If we are unable to develop, introduce, and market new and enhanced versions of our solution or are unable to anticipate or respond to evolving technological requirements, we may be put at a competitive disadvantage and our operating results could be adversely affected.
If we continue expanding our operations but fail to effectively execute on our growth strategy, our margins and net income may decline, which may harm our business and results of operations.
We may be unable to maintain our revenue growth rate in the future.
Cyberattacks or other breaches of our security measures or those we rely on could result in unauthorized access to, use or destruction of confidential or proprietary information, including our clients’ or their clients’ data, which may materially and adversely impact our reputation, business, and results of operations.
Actual or perceived defects, errors, or vulnerabilities in our solution, including failures in connection with client market orders, could harm our reputation, result in significant costs to us, impair our ability to sell our solution and subject us to substantial liability.
Events affecting the investment management industry could materially and adversely affect us and cause our stock price to decline significantly.
Our international operations may fail, and we may fail to successfully expand internationally. In addition, sales to clients outside the United States or with international operations expose us to risks inherent to international businesses, which may include adverse impacts arising out of international regulatory changes.
Our solution is highly technical, and if we are unable to attract or retain key employees and other skilled personnel that are capable of managing our business strategy or working with our solution, we may be unable to achieve our goals and our business will suffer.
Our revenue recognition and other factors may create volatility in our financial results in any given period and make them difficult to predict.
If we are unable to protect our intellectual property, including trade secrets, or if we fail to enforce our intellectual property rights, our business could be adversely affected.

13

Although we are not subject to the same regulations as our clients, the regulatory environment in which our clients operate is subject to continual change and regulatory developments designed to increase oversight could adversely affect our business.
Our failure to comply with various data privacy, protection and security regulations could impose additional costs and liabilities on us, limit our use, storage, or processing of information and adversely affect our business.
An active, liquid trading market for our Class A common stock may not develop or be sustained, which may make it difficult for you to sell the Class A common stock you purchase.
Enfusion, Inc. is a holding company, and its only material asset is its direct and indirect interest in Enfusion Ltd. LLC, and it is accordingly dependent upon distributions from Enfusion Ltd. LLC to pay taxes, make payments under the Tax Receivable Agreement, and pay dividends.

Risks Related to Our Business and Our Industry

If the adoption and acceptance of cloud-based financial solutions slows or shifts in a way we do not anticipate or are unable to support or if we do not accurately anticipate, prepare for, and promptly respond to rapidly evolving client needs, our sales will suffer, and the results of our operations will be adversely affected.

Use of, and reliance on, cloud-based investment management technology is still at an early stage, and we do not know whether financial institutions will continue to adopt cloud-based investment management technology such as the Enfusion solution in the future, or whether the market will change in ways we do not anticipate and cannot support. Many financial institutions have invested substantial personnel and financial resources in legacy software, and these institutions may be reluctant, unwilling, or unable to convert from their existing legacy or disparate systems to our end-to-end solution. Furthermore, these financial institutions may be reluctant, unwilling, or unable to use cloud-based investment management technology due to various concerns such as data security and the reliability of the delivery model. These concerns or other considerations may cause financial institutions to choose not to adopt cloud-based investment management technology such as ours or to adopt them more slowly than we anticipate, either of which would adversely affect us. Our future success also depends on our ability to sell additional applications and functionality to our current and prospective clients. As we create new applications and enhance our existing solution, these applications and enhancements may not be attractive to clients. In addition, promoting and selling new and enhanced functionality may require increasingly costly sales and marketing efforts, and if clients choose not to adopt this functionality, our business and results of operations could suffer. If financial institutions are unwilling or unable to transition from their legacy systems, or if the demand for our solution does not meet our expectations, our results of operations and financial condition will be adversely affected.

If we are unable to develop, introduce and market new and enhanced versions of our solution or are unable to anticipate or respond to evolving technological requirements, we may be put at a competitive disadvantage and our operating results could be adversely affected.

Our ability to increase revenues will depend, in large part, on our ability to further penetrate our existing markets and to attract new clients, as well as our ability to increase sales from existing clients who do not utilize the full Enfusion solution. The success of any enhancement or new systems or service depends on several factors, including the timely completion, introduction and market acceptance of an enhanced or new system, adaptation to new industry standards and technological changes, the ability to maintain and to develop relationships with third parties, and the ability to attract, retain and effectively train sales and marketing personnel. Any new systems we develop or acquire may not be introduced in a timely or cost-effective manner and may not achieve the market acceptance necessary to generate significant revenues. Any new industry standards or practices that emerge, or any introduction by competitors of new solutions embodying new services or technologies, may cause our solution to become obsolete. Any new markets in which we attempt to sell our solution, including new countries or regions, may not be receptive or implementation may be delayed due to the COVID-19 pandemic or other similar factors beyond our control. Additionally, any expansion into new markets will require commensurate ongoing expansion of our monitoring of local laws and regulations, which increases our costs as well as the risk of our solution not incorporating in a timely fashion or at all due to a failure of our solution to comply with such

14

local laws or regulations. Our ability to further penetrate our existing markets depends on the quality of our solution and our ability to design our solution to meet changing consumer demands and industry standards, as well as our ability to assure that our clients will be satisfied with our existing and new systems. If we are unable to sell our solution into new markets or to further penetrate existing markets, or to increase sales from existing clients by expanding their relationship with us, our revenues will not grow as expected, which would have a material adverse effect on our business, financial condition, and results of operations.

We may be unable to maintain our revenue growth rate in the future.

We have grown rapidly over the last several years, and therefore, our recent revenue growth rate and financial performance may not be indicative of our future performance. Our total revenues increased from $59.0 million in 2019 to $174.5 million in 2023. We may not be able to sustain revenue growth consistent with our recent history, if at all. Furthermore, to the extent we grow in future periods, maintaining consistent rates of revenue growth may be difficult. Our revenue growth may also slow or even reverse in future periods due to a number of factors, which may include reduced client spending levels, changes in the type and size of our clients, decreasing growth of our overall market, competitive conditions, slowing demand for our solution, and general economic conditions. If we are unable to maintain consistent revenue growth, the price of our Class A common stock could be volatile, and it may be difficult for us to maintain profitability.

If we continue expanding our operations but fail to effectively execute on our growth strategy, our margins and net income may decline, which may harm our business and results of operations.

We have expanded our operations in recent years, which has resulted in an increase in our employee headcount, and an expansion of our infrastructure, our number of locations and the geographic scope of our operations. In order to continue to implement our growth strategy, innovate and improve upon our solution, and pursue high levels of client service and satisfaction, we may need to continue expanding our operations and we also expect to continue improving our IT infrastructure, and our operational and financial controls and systems. Our success will depend on our ability to plan for and manage this growth effectively. Our growth strategy may require significant capital expenditures and may divert financial resources from other projects. If we increase the size of our organization or expend significant capital resources without experiencing a corresponding increase in sales of our solution, we may experience reductions in our gross and operating margins and net income, our revenues could decline or grow more slowly than expected, and our business and results of operations could be materially and adversely affected.

We may have to invest more resources in technology and development than anticipated and our technology and development efforts or spend may prove to be fruitless or unsuccessful, which could increase our operating expenses and negatively affect our results of operations.

We may have to devote substantial resources to technology and development due to technological advances in the software industry or by competitors, the integration of our acquisitions, our entry into new markets or client segments, or other competitive factors. If we are required to invest greater resources than anticipated without a corresponding increase in revenues, our results of operations could decline. Additionally, our periodic technology and development expenses may be independent of our level of revenues, which could negatively impact our financial results.

Further, technology for which we spend a significant amount of time and resources on in our technology and development may prove to be less marketable than we expect, if at all. There can be no guarantee that our technology and development investments will result in products or enhancements that create additional revenues.

15

We may experience quarterly fluctuations in our operating results due to a number of factors, which may make our future results difficult to predict and could cause our operating results to fall below expectations or our guidance.

Our quarterly operating results have fluctuated in the past and are expected to fluctuate in the future due to a variety of factors, many of which are outside of our control. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Our past results may not be indicative of our future performance. In addition to the other risks described in this report, factors that may affect our quarterly operating results include the following:

the addition or loss of clients, including through acquisitions, consolidations, or failures;
the frequency of the use of our solution in a period and the amount of any associated revenues and expenses;
budgeting cycles of our clients and changes in spending on cloud-based investment management solution by our current or prospective clients;
changes in the competitive dynamics of our industry, including consolidation among competitors, changes to pricing, or the introduction of new products and services that limit demand for our cloud-based investment management solutions or cause clients to delay purchasing decisions;
the amount and timing of cash collections from our clients;
long or delayed implementation times for new clients, including larger clients, or other changes in the levels of client support we provide;
the amount and timing of our operating costs and capital expenditures;
changes in tax rules or the impact of new accounting pronouncements;
unexpected expenses such as those related to litigation or other disputes;
the amount and timing of costs associated with recruiting, hiring, training, integrating, and retaining new and existing employees;
the timing of our entry into new markets and client segments;
limitations on our ability to forecast our future operating results due to our limited operating history at our current scale; and
general economic conditions.

Moreover, our stock price might be based on expectations of investors or securities analysts of future performance that are inconsistent with our actual growth opportunities or that we might fail to meet and, if our revenues or operating results fall below expectations, the price of our Class A common stock could decline substantially.

We may not accurately predict the long-term client retention rate or adoption of our solution, or any resulting impact on our revenues or operating results.

Our clients have no obligation to continue to renew their subscriptions for our solution after the expiration of the initial or current subscription term, and our clients, if they choose to renew at all, may renew for fewer users or on less favorable pricing terms. Our client retention rates may decrease as a result of a number of factors, including our clients’ satisfaction with our pricing or our solution or their ability to continue their operations or spending levels. If our clients

16

terminate their agreements or do not renew their subscriptions for our solution on similar or more favorable pricing terms, our revenues may decline, and our business could suffer.

Additionally, as the market for our solution develops, we may be unable to attract new clients based on the same subscription model we have used historically. Moreover, large or influential financial institution clients may demand more favorable pricing or other contract terms from us. As a result, we may in the future be required to change our pricing model, reduce our prices, or accept other unfavorable contract terms, any of which could adversely affect our risks, revenues, gross profit margin, profitability, financial position, and/or cash flow.

Cyberattacks or other breaches of our security measures or those we rely on could result in unauthorized access to, use or destruction of confidential or proprietary information, including our clients’ or their clients’ data, which may materially and adversely impact our reputation, business, and results of operations.

We rely on information technology systems that we or our third-party providers operate to process, transmit and store electronic information in our day-to-day operations. We maintain policies, procedures, and technological safeguards designed to protect the confidentiality, integrity, and availability of our information technology systems and confidential or proprietary information that we may possess, such as our intellectual property and data, and our clients or their clients’ personally identifiable information and trading data or related strategies. However, we cannot entirely eliminate the risk of improper or unauthorized access to our information technology systems or the access to or disclosure of our confidential or proprietary information. We also may not be able to anticipate all types of security threats, implement preventative measures against all such threats, or eliminate the risk of other security events that impact the integrity or availability of our information technology systems or the protection of our confidential or proprietary information, or the related costs we may incur to mitigate the consequences from such events or with respect to any remediation efforts.

Further, the Enfusion solution is a flexible and complex software solution and there is a risk that configurations of, or defects in, the solution or errors in implementation could create vulnerabilities to security breaches. There may be unlawful attempts to disrupt or gain access to our information technology systems or our confidential or proprietary information or other data of our clients or their clients that may disrupt our or our clients’ operations. In addition, because we leverage third-party providers, including cloud, software, co-locate data center, and other critical technology vendors to deliver our solution to our clients and their clients, we rely heavily on the data security technology practices and policies adopted by these third-party providers. A vulnerability in a third-party provider’s software or systems, a failure of our third-party providers’ safeguards, policies or procedures, or a breach of a third-party provider’s software or systems could result in the compromise of the confidentiality, integrity, or availability of our systems or the data housed in our solution.

Cyberattacks and other malicious internet-based activity continue to increase and evolve, and cloud-based providers of products and services have been and are expected to continue to be targeted. In addition to traditional computer “hackers,” industrial espionage, wire fraud and other forms of cyber fraud, social engineering fraud, malicious code (such as viruses and worms), phishing, employee theft or misuse and denial-of-service attacks, sophisticated criminal networks as well as nation-state and nation-state supported actors now engage in attacks, including advanced persistent threat intrusions. Current or future criminal capabilities, discovery of existing or new vulnerabilities, and attempts to exploit those vulnerabilities or other developments, may compromise or breach our systems or solution. In the event our or our third-party providers’ protection efforts are unsuccessful and our systems or solution are compromised, we could suffer substantial harm, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss, the disclosure of corporate strategic plans, or the compromise or corruption of client data or data we rely on to provide our solution. In addition, a security breach may adversely impact our clients’ ability to use our systems to perform their day-to-day functions. Also, our reputation could suffer irreparable harm, causing our current and prospective clients to decline to use our solution in the future. Further, we could be forced to expend significant financial and operational resources in response to a security breach, including investigating, repairing system damage, increasing security protection costs by deploying additional personnel and protection technologies, and defending against and resolving legal and regulatory claims, all of which could divert resources and the attention of our management and key personnel away from our business operations.

Federal, state, and international regulations may require us or our clients to notify individuals of data security incidents involving certain types of personal data or information technology systems. Security compromises experienced

17

by others in our industry, our clients, or us may lead to public disclosures and widespread negative publicity. Any security compromise in our industry, whether actual or perceived, could erode client confidence in the effectiveness of our security measures, negatively impact our ability to attract new clients, cause existing clients to terminate our agreements or elect not to renew or expand their use of our solution, or subject us to third-party lawsuits, regulatory fines, or other actions or liabilities, which could materially and adversely affect our business and results of operations.

In addition, some of our clients contractually require notification of data security compromises and include representations and warranties in their contracts with us that our solution complies with certain legal and technical standards related to data security and privacy and meets certain service levels. In certain of our contracts, a data security compromise or operational disruption impacting us or one of our critical vendors, or system unavailability or damage due to other circumstances, may constitute a material breach and give rise to a client’s right to terminate their contract with us. In these circumstances, it may be difficult or impossible to cure such a breach in order to prevent clients from potentially terminating their contracts with us. Furthermore, although our client contracts typically include limitations on our potential liability, there can be no assurance that such limitations of liability would be adequate. We also cannot be sure that our existing liability insurance coverage and coverage for professional liability and errors or omissions will be available on acceptable terms or will be available in sufficient amounts to cover one or more claims and on the timing in which we need it, or that our insurers will not deny or attempt to deny coverage as to any future claim. The successful assertion of one or more claims against us, the inadequacy or denial of coverage under our insurance policies, litigation to pursue claims under our policies, or the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or coinsurance requirements, could materially and adversely affect our business and results of operations.

We depend on third-party co-locate facilities, data centers operated by third parties, and third-party Internet service providers, and any disruption in the operation of such facilities or access to the Internet could adversely affect our business.

We currently serve our clients from two third-party co-locate data center hosting facilities located in Chicago, Illinois and Secaucus, New Jersey and therefore cannot guarantee that our clients’ access to our solution will be uninterrupted, error-free, or secure. We may experience service and application disruptions, outages, and other performance problems. These problems may be caused by a variety of factors, including infrastructure changes, human or software errors, viruses, security attacks, fraud, spikes in client usage, and denial of service issues. In some instances, we may not be able to identify the cause or causes of these performance problems within an acceptable period of time. We do not control the operation of these data center facilities, and such facilities are vulnerable to damage or interruption from human error, intentional bad acts, power loss, hardware failures, telecommunications failures, fires, wars, terrorist attacks, floods, earthquakes, hurricanes, tornadoes, or similar catastrophic events. Both we and our service providers also could be subject to break-ins, computer viruses, sabotage, intentional acts of vandalism, and other misconduct. The occurrence of a natural disaster or an act of terrorism, a decision to close the facilities without adequate notice or terminate our hosting arrangement, or other unanticipated problems could result in lengthy interruptions in the delivery of our solution, cause system interruptions, prevent our clients’ account holders from accessing their accounts online, reputational harm and loss of critical data, prevent us from supporting our solution, or cause us to incur additional expense in arranging for new facilities and support.

In addition to third-party co-locate data centers where we host the data, we also depend on third-party data centers that host data on our behalf, and any disruption in the operation of these facilities could impair the delivery of our solution and adversely affect our business. We currently deploy portions of our solution and serve our clients using third-party data center services. While we typically control and have access to the servers we operate in co-location facilities and the components of our custom-built infrastructure that are located in those co-location facilities, we control neither the operation of these facilities nor our third-party service providers. In the event of significant physical damage to one of these facilities, it may take a significant period of time to achieve full resumption of our services, and our disaster recovery planning may not account for all eventualities. We may also incur significant costs for using alternative equipment or taking other actions in preparation for, or in reaction to, events that damage the third-party data centers that we use.

We also depend on third-party Internet service providers and continuous and uninterrupted access to the Internet through third-party bandwidth providers to operate our business. If we lose the services of one or more of our Internet

18

service or bandwidth providers for any reason or if their services are disrupted, for example due to viruses or denial of service or other attacks on their systems, or due to human error, intentional bad acts, power loss, hardware failures, telecommunications failures, fires, wars, terrorist attacks, floods, earthquakes, hurricanes, tornadoes, or similar catastrophic events, we could experience disruption in our ability to offer our solution and adverse perception of our solution’s reliability, termination of our agreements or we could be required to retain the services of replacement providers, which could increase our operating costs and harm our business and reputation.

Actual or perceived defects, errors, or vulnerabilities in our solution, including failures in connection with client market orders, could harm our reputation, result in significant costs to us, impair our ability to sell our solution and subject us to substantial liability.

Our cloud-based investment management solution is inherently complex and may contain bugs, errors, failures, defects, or other performance problems, particularly when a client is onboarded, systems are first introduced, or new versions are released. Despite extensive testing, from time-to-time we have discovered errors, failures, defects, bugs, or other performance problems in our systems. In addition, due to changes in regulatory requirements relating to our clients, we may discover deficiencies in our software processes related to those requirements. Material performance problems or defects in our systems might arise in the future.

Any such bugs, errors, failures, defects, or other performance problems could be costly for us to remedy, damage our clients’ businesses and harm our reputation, and cause our clients to seek to terminate their agreements, elect not to renew their subscriptions, delay or withhold payment, or assert liability claims against us. Any of these actions could also result in lost business, increased insurance costs, difficulty in collecting our accounts receivable, costly litigation, adverse publicity, or a loss of, or delay in, the market acceptance of our solution.

Moreover, software development is time-consuming, expensive, complex and requires regular maintenance. Unforeseen difficulties can arise including failures in connection with client market orders and failures in delivering software development in a timely manner. If we do not complete our periodic maintenance according to schedule or if clients are otherwise dissatisfied with the frequency and/or duration of our maintenance services, clients could elect not to renew, or delay or withhold payment to us or cause us to issue credits, make refunds, or pay penalties.

We believe that our reputation and name recognition are critical factors in our ability to compete in our industry and generate sales, and the occurrence or perception of the occurrence of bugs, errors, failures, defects or other performance problems in our solution or client dissatisfaction with our maintenance services may damage our reputation in the market and our relationships with our existing clients, and as a result, we may be unable to attract or retain clients, which could seriously harm our sales and our results of operations and financial condition.

We and our clients leverage third-party software, content, connectivity, and services for use with our solution. Performance issues, errors and defects, or failure to successfully integrate or license necessary third-party software, content, connectivity, or services, could cause delays, errors, or failures of our solution, cause reputational harm, increases in our expenses and reductions in our sales, each of which could materially and adversely affect our business and results of operations.

We and our clients use software and content licensed from, and services provided by, a variety of third parties in connection with the operation of our solution. Any errors, failures, defects, bugs, or other performance problems in third-party software, content, or services could result in errors or a failure of our solution, which could adversely affect our business and results of operations. In the future, we might need to license other software, content, or services to enhance our solution and meet evolving client demands and requirements. Any limitations in our ability to use third-party software, content or services could significantly increase our expenses and otherwise result in delays, a reduction in functionality, errors, or failures of our solution until equivalent technology or content is either developed by us or, if available, identified, obtained through purchase or license, and integrated into our solution. In addition, third-party licenses may expose us to increased risks, including risks associated with the integration of new technology, the diversion of resources from the development of our own proprietary technology, and our inability to generate revenues from new technology sufficient to offset associated acquisition and maintenance costs, all of which may increase our expenses and materially and adversely affect our business and results of operations.

19

Interruptions in the availability of server systems or network or communications with Internet, third-party hosting facilities or cloud-based services, interruptions in the third-party connections utilized by our clients, or failure to maintain the security, confidentiality, accessibility, or integrity of data stored on such systems, could harm our business or impair the delivery of our solution.

A significant portion of our software development personnel, source code, and computer equipment is located at operating facilities within the United States. Certain of our internal operating systems depend on data maintained on servers running third-party enterprise resource planning, account relationship management and other business operations systems. We further rely upon a variety of Internet service providers, third-party hosting facilities and cloud computing platform providers, as well as local service providers to support project teams and users in most regions and countries throughout the world, particularly with respect to our cloud service solution. Failure to maintain the security, confidentiality, accessibility, or integrity of data stored on such systems could damage our reputation in the market and our relationships with our accounts, cause us to lose revenues or market share, increase our service costs, cause us to incur substantial costs, cause us to lose accounts, subject us to liability for damages and divert our resources from other tasks, any one of which could adversely affect our business, financial condition, results of operations and prospects. Any damage to, or failure of, such systems, or communications to and between such systems, could result in interruptions in our operations, managed services, and software development activities. Such interruptions may reduce our revenues, delay billing, cause us to issue credits or pay penalties, cause accounts to terminate their subscriptions or adversely affect our attrition rates and our ability to attract new accounts. Our business would also be harmed if our accounts and potential accounts believe our products or services are unreliable. In light of our status as a critical system for our clients, service disruptions could impact their ability to operate, and in some cases, may inhibit their ability to trade.

The markets in which we participate are intensely competitive, and pricing pressure, new technologies, or other competitive dynamics could adversely affect our business and operating results.

We currently compete with providers of technology and services in the financial services industry. Certain of our competitors have significantly more financial, technical, marketing, and other resources than we have, may devote greater resources to the promotion, sale, and support of their systems than we can, have more extensive client bases and broader client relationships than we have, and have longer operating histories and greater name recognition than we have. In addition, many of our competitors expend a greater amount of funds on research and development.

We may also face competition from other companies within our markets, which may include large established businesses that decide to develop, market, or resell cloud-based investment management solutions, acquire one of our competitors, or form a strategic alliance with one of our competitors. In addition, new companies entering our markets or established companies creating or marketing new products may choose to offer cloud-based investment management applications at little or no additional cost to the client by bundling them with their existing applications, including adjacent banking technologies and core processing software. New entrants to the market might also include non-banking providers of payment solutions and other technologies. Competition from these new entrants or consolidation among new or existing competitors may result in pricing pressure or loss of market share, which could limit our growth prospects, make our business more difficult, and adversely affect our results.

If we are unable to compete in this environment, sales and renewals of our cloud-based investment management solution could decline and adversely affect our business, operating results, and financial condition. With the introduction of new technologies and potential new entrants into the cloud-based investment management solutions market, we expect competition to intensify in the future, which could harm our ability to increase sales and maintain profitability.

If we fail to effectively anticipate and respond to changes in the industry in which we operate, our ability to attract and retain clients could be impaired and our competitive position could be harmed.

The financial services industry is subject to rapid change and the introduction of new technologies to meet the needs of this industry will continue to have a significant effect on competitive conditions in our market. If we are unable to successfully expand our product offerings beyond our current solution, our clients could migrate to competitors who may offer a broader or more attractive range of products and services. Unexpected delays in releasing new or enhanced versions of our solution, or errors following their release, could result in loss of sales, delay in market acceptance, or client

20

claims against us, any of which could adversely affect our business. The success of any new system depends on several factors, including timely completion, adequate quality testing and market acceptance. We may not be able to enhance aspects of our solution successfully or introduce and gain market acceptance of new applications or improvements in a timely manner, or at all. Additionally, we must continually modify and enhance our solution to keep pace with changes in software applications, database technology, and evolving technical standards and interfaces.

Uncertainties related to our ability to introduce and improve functionality, announcements or introductions of a new or updated solution, or modifications by our competitors could adversely affect our business and results of operations.

Events affecting the investment management industry could materially and adversely affect us and cause our stock price to decline significantly.

Our revenues are diversified across our client base. During the year ended December 31, 2023, one client represented more than 4% of our total revenues, and our top 10 clients represented approximately 23.4% of our total revenues. However, our clients are concentrated within the investment management sector, and any events that have an adverse impact on that sector could materially and adversely affect us. Furthermore, our clients operate in the volatile global financial markets and are influenced by a number of factors outside of their control, including interest rate volatility, inflation, the availability of credit, issues with sovereign and large institutional obligors, changes in laws and regulations, terrorism and political unrest or uncertainty, among others. As a result, any of our clients may go out of business unexpectedly or decide to no longer use our products and services for other reasons which may be out of our control. The loss of or events affecting any one or more of these clients could materially and adversely affect us and cause our stock price to decline significantly.

If we fail to effectively train our clients to use our solution or fail to provide high-quality implementation, technical support, or managed services, it could have an adverse effect on our reputation and our ability to sell our solution to new clients and retain existing clients or renew agreements with our existing clients.

Effective client training on the Enfusion solution is critical to the successful adoption of our solution by our clients. We must also assist our clients in implementing our solution, and help our clients quickly resolve post-implementation issues. We believe that the training and implementation experience is vital to retaining clients or encouraging referrals, and that our ability to provide predictable delivery results and product expertise is critical to our ability to retain or renew agreements with our existing clients or receive referrals for new clients. If we fail to effectively provide effective training or implementation services, our ability to retain or sell additional systems and services to existing clients would be adversely affected and our reputation with potential clients could be damaged.

Once our clients are trained and our solution is implemented and integrated with our clients’ existing IT investments and data, our clients may depend on our technical support services and/or the support of service partners to resolve any issues relating to our solution. High-quality support is critical for the continued successful marketing and sale of our solution and the retention and renewal of contracts. In addition, as we continue to expand our operations internationally, our support organization will face additional challenges, including those associated with delivering support, training, and documentation in languages other than English. Many enterprise clients require higher levels of support than smaller clients. If we fail to meet the requirements of our larger clients, it may be more difficult to sell additional systems and services to these clients, a key group for the growth of our revenues and profitability. In addition, as we further expand our SaaS solution, our services and support organization will face new challenges, including hiring, training, and integrating a large number of new services or support personnel with experience in delivering high-quality support for our solution. Alleviating any of these problems could require significant expenditures which could adversely affect our results of operations and growth prospects. Our failure to maintain high-quality implementation and support services could have a material adverse effect on our business, results of operations, financial condition, and growth prospects.

21

If we are unable to effectively integrate our solution with other systems used by our clients, or if there are performance issues with such third-party systems, our solution will not operate effectively, and our business and reputation will be adversely affected.

The Enfusion solution integrates with other third-party systems used by our clients. We do not have formal arrangements with many of these third-party providers regarding the delivery and receipt of client data. If we are unable to effectively integrate with third-party systems, our clients’ operations may be disrupted, which may result in disputes with clients, negatively impact client satisfaction and harm our business. If the software of such third-party providers has performance or other problems, such issues may reflect poorly on us and the adoption and renewal of our solution, and our business and reputation may be harmed.

Our sales cycle and related client implementation, especially with regard to large financial institutions and other institutional or complex client profiles, can be lengthy and variable, depend upon factors outside our control, and could cause us to expend significant time and resources.

The timing of our sales is difficult to predict. Our sales efforts involve educating prospective clients about the use, technical capabilities and benefits of our products and services. Prospective clients may undertake a prolonged product-evaluation process. We may face significant costs, long sales cycles, and inherent unpredictability in completing client sales. A prospective client’s decision to purchase our solution may be an enterprise-wide decision and, if so, may require us to educate a significant number of people within the prospective client’s organization regarding the use and benefits of our solution. In addition, prospective clients may require customized features and functions unique to their business process and may require acceptance testing related to those unique features. As a result of these factors, we may be required to devote greater sales support and services resources to a number of individual prospective clients, increasing costs and time required to complete sales and diverting our sales and services resources to a smaller number of clients, while delaying revenues from other potential new clients until the sales cycle has been completed and the criteria for revenue recognition have been met.

Our international operations may fail, and we may fail to successfully expand internationally. In addition, sales to clients outside the United States or with international operations expose us to risks inherent to international businesses, which may include adverse impacts arising out of international regulatory changes.

Our international revenues represented approximately 40%, 38% and 34% of our total revenues for the fiscal years ended December 31, 2023, 2022, and 2021, respectively. Part of our growth strategy involves expanding our international operations and worldwide client base. We cannot assure you that our international expansion efforts will be successful and our experience in the United States may not be relevant to our ability to expand in any international market.

Operating in international markets requires significant resources and management attention and subjects us to regulatory, economic, and political risks that are different from those in the United States. Export control regulations in the United States may increasingly be implicated in our operations as we expand internationally. These regulations may limit the export of our solution and provision of our solution outside of the United States, or may require export authorizations, including by license, a license exception or other appropriate government authorizations, including annual or semi-annual reporting and the filing of an encryption registration. Changes in export or import laws, or corresponding sanctions, may delay the introduction and sale of our solution in international markets, or, in some cases, prevent the export or import of our solution to certain countries, regions, governments, persons or entities altogether, which could adversely affect our business, financial condition and results of operations.

We are also subject to various domestic and international anti-corruption laws, such as the U.S. Foreign Corrupt Practices Act (the “FCPA”) and the U.K. Bribery Act, as well as other similar anti-bribery and anti-kickback laws and regulations. These laws and regulations generally prohibit companies and their employees and intermediaries from authorizing, offering or providing improper payments or benefits to officials and other recipients for improper purposes. Although we take precautions to prevent violations of these laws, our exposure for violating these laws increases as our international presence expands and as we increase sales and operations in foreign jurisdictions.

22

In addition, we face risks in doing business internationally that could adversely affect our business, including:

unanticipated costs;
the need to localize and adapt our solution for specific countries;
complying with varying and sometimes conflicting data privacy laws and regulations;
difficulties in staffing and managing foreign operations, including employment laws and regulations;
unstable regional, economic, or political conditions, including trade sanctions, political unrest, terrorism, war, health and safety epidemics, or the threat of any of these events;
different pricing environments, longer sales cycles, and collections issues;
new and different sources of competition;
weaker protection for intellectual property and other legal rights than in the United States and practical difficulties in enforcing intellectual property and other rights outside of the United States;
laws and business practices favoring local competitors;
operational and compliance challenges related to the complexity of multiple, conflicting, and changing governmental laws and regulations, including employment, tax and anti-bribery laws and regulations and difficulties understanding and ensuring compliance with those laws by both our employees and our service partners, over whom we exert no control;
increased financial accounting and reporting burdens and complexities;
restrictions on the transfer of funds; and
differing and potentially adverse tax consequences.

The occurrence or impact of any or all of the events described above could materially and adversely affect our international operations, which could in turn materially and adversely affect our business, financial condition and results of operations.

Our solution is highly technical, and if we are unable to attract or retain key employees and other skilled personnel that are capable of managing our business strategy or working with our solution, we may be unable to achieve our goals and our business will suffer.

Our future success depends upon our ability to continue to attract, train, integrate and retain highly skilled personnel, particularly our executive officers and the personnel serving on our engineering, product, client services and sales teams. Failure to attract, train, integrate and retain such personnel could harm our ability to generate sales, successfully develop enhancements or new systems or services, and otherwise delay or prevent us from achieving our business goals.

Our United States-based personnel, which includes our executive officers and certain other key employees, are generally employed on an at-will basis, which means that these individuals could terminate their relationship with us at any time. We depend on the efforts, relationships, and reputations of our executive officers in order to successfully manage our business, and the loss of any of our executive officers could significantly delay or prevent us from achieving our business objectives.

23

Furthermore, because of the technical nature of our solution and the dynamic market in which we operate, it can be difficult to attract, train, integrate, and retain skilled personnel that are capable of managing our business strategy or working with our solution. We compete with other companies, many of which have greater resources than we have, for a limited number of personnel within our industry. Significant amounts of time and resources may be required to train and integrate such personnel to successfully manage, develop, implement, and sell our solution. We may lose them to our competitors or other technology companies before we realize the benefit of our investment in recruiting and training these individuals. In addition, if U.S. immigration policy related to skilled foreign workers were materially adjusted, such a change could hamper our efforts to hire highly skilled foreign employees, including highly specialized engineers, which would adversely impact our business. Also, to the extent that we hire personnel from competitors, we may be subject to allegations that such personnel have been improperly solicited or have divulged proprietary or other confidential information.

Furthermore, our ability to expand internationally depends, in large part, on our ability to attract, retain and integrate managers to lead the local business and employees with the appropriate skills. If we are unable to effectively hire or deploy our employees globally on a timely basis to fulfill the needs of our clients or implement our growth strategy, our reputation could suffer and our ability to retain existing clients or attract new clients may be harmed. For more information on the risks associated with our operations in India, see “—If we are unable to effectively manage certain risks and challenges related to our India operations, our business could be harmed.”

Our corporate culture has contributed to our success, and if we cannot maintain it as we grow, we could lose the innovation, creativity and teamwork fostered by our culture, and our business may be adversely affected.

We believe our corporate culture is one of our fundamental strengths, as we believe it enables us to attract and retain top talent and deliver superior results for our clients. As we grow, we may find it difficult to preserve our corporate culture, which could reduce our ability to innovate and operate effectively. In turn, the failure to preserve our culture could negatively affect our ability to attract, recruit, integrate and retain employees, continue to perform at current levels, and effectively execute our business strategy. Furthermore, our growth may require us to develop a more hierarchical structure, which may impact our ability to operate swiftly and efficiently.

Increases in labor costs, including salaries or wages, and an overall tightening of the labor market, could adversely affect our business, results of operations, or financial condition.

The labor costs associated with our business are subject to several external factors affecting our industry, including unemployment levels and the quality and the size of the labor market, prevailing salaries, health and other insurance costs, other forms of remuneration and benefits offered to prospective employees by competitor employers, and changes in employment and labor legislation or other workplace regulation. From time to time, the labor market may become increasingly competitive. If we are unable to mitigate salary or wage rate increases driven by the labor market through automation and other labor savings initiatives, our labor costs may increase, or we may have difficulty attracting or retaining personnel. Increases in labor costs could force us to increase our prices, and these increased prices or any failure to attract or retain personnel may adversely affect our business results.

Global or regional economic and market conditions may negatively impact our business, financial condition, and results of operations.

Our overall performance depends in part on economic and market conditions, which may remain challenging or uncertain for the foreseeable future. Financial developments seemingly unrelated to us or our industry may adversely affect us. Domestic and international economies have been impacted by changes in interest rates, military operations or conflicts, threatened sovereign defaults and ratings downgrades, falling demand for a variety of goods and services, restricted credit, threats to major multinational companies, poor liquidity, reduced corporate profitability, volatility in credit, equity and foreign exchange markets, bankruptcies, and overall uncertainty. These conditions affect the rate of technology spending and could adversely affect our clients’ ability or willingness to purchase our cloud-based investment management solution, delay prospective clients’ purchasing decisions, reduce the value or duration of their subscriptions, or affect renewal rates, any of which could adversely affect our operating results. We cannot predict the timing, strength, or duration of the economic recovery or any subsequent economic slowdown in the United States, the market generally or in our industry.

24

Natural or man-made disasters outside of our control and other similar events may significantly disrupt our business, and negatively impact our business, financial condition, and results of operations.

Our operating facilities and infrastructure, including our co-located data centers, may be harmed or rendered inoperable by natural or man-made disasters, including hurricanes, tornadoes, wildfires, floods, earthquakes, nuclear disasters, acts of terrorism or other criminal activities, outbreak of hostilities or military conflicts, infectious disease outbreaks or pandemic events, power outages and other infrastructure failures, which may render it difficult or impossible for us to operate our business for some period of time. Our facilities would likely be costly to repair or replace, and any such efforts would likely require substantial time. Any disruptions in our operations could adversely affect our business and results of operations and harm our reputation. Moreover, although we have disaster recovery plans, they may prove inadequate. We may not carry sufficient business insurance to compensate for losses that may occur. Any such losses or damages could have a material adverse effect on our business and results of operations. In addition, the facilities of our third-party providers may be harmed or rendered inoperable by such natural or man-made disasters, which may cause disruptions, difficulties or otherwise materially and adversely affect our business. To the extent any such disasters or other similar events adversely affect our business and financial results, it may also have the effect of heightening many of the other risks described in this “Risk Factors” section, such as our ability to maintain profitability in the future, our ability to attract new clients or continue to broaden our existing clients’ use of our solution and the impact of any decrease in technology spend by clients and potential clients in the financial services industry where we derive all of our revenues.

Failure of any of our established systems to satisfy client demands or to maintain market acceptance would harm our business, results of operations, financial condition, and growth prospects.

We derive a significant majority of our revenues and cash flows from our established solution and expect to continue to derive a substantial portion of our revenues from this source. As such, continued market acceptance of our solution and underlying systems is critical to our growth and success. Demand for our solution is affected by a number of factors, some of which are beyond our control, including the successful implementation of our solution, the timing of development and release of new enhancements and upgrades by us and our competitors, technological advances which reduce the appeal of our solution, changes in regulations that our clients must comply with in the jurisdictions in which they operate and the growth or contraction in the worldwide market for technological solutions for the investment management industry. If we are unable to continue to meet client demands, to achieve and maintain a technological advantage over competitors, or to maintain market acceptance of our solution, our business, results of operations, financial condition and growth prospects would be adversely affected.

We may acquire or invest in companies, or pursue business partnerships, which may divert our management’s attention or result in dilution to our stockholders, and we may be unable to integrate acquired businesses and technologies successfully or achieve the expected benefits of such acquisitions, investments, or partnerships.

From time to time, we consider potential strategic transactions, including acquisitions of, or investments in, businesses, technologies, services, solutions, and other assets. We also may enter into relationships with other businesses to expand our solution, which could involve preferred or exclusive licenses, additional channels of distribution, discount pricing, or investments in other companies. Negotiating these transactions can be time-consuming, difficult, and expensive, and our ability to close these transactions may be subject to approvals that are beyond our control. In addition, we do not have any experience in acquiring other businesses. If an acquired business fails to meet our expectations, our operating results, business, and financial position may suffer. We may not be able to find and identify desirable acquisition targets, we may incorrectly estimate the value of an acquisition target, and we may not be successful in entering into an agreement with any particular target. If we are successful in acquiring additional businesses, we may not achieve the anticipated benefits from the acquired business due to a number of factors, including:

our inability to integrate or benefit from acquired technologies or services;
unanticipated costs or liabilities associated with the acquisition;
difficulty integrating the technology, accounting systems, operations, control environments and personnel of the acquired business and integrating the acquired business or its employees into our culture;

25

difficulties and additional expenses associated with supporting legacy solutions and infrastructure of the acquired business;
diversion of management’s attention and other resources;
additional costs for the support or professional services model of the acquired company;
adverse effects to our existing business relationships with service partners and clients;
the issuance of additional equity securities that could dilute the ownership interests of our stockholders;
incurrence of debt on terms unfavorable to us or that we are unable to repay;
incurrence of substantial liabilities;
difficulties retaining key employees of the acquired business; and
adverse tax consequences, substantial depreciation, or deferred compensation charges.

In addition, a significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment at least annually and when indicators of impairment are present. In the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating results based on this impairment assessment process, which could adversely affect our results of operations.

If we are unable to effectively manage certain risks and challenges related to our India operations, our business could be harmed.

Our significant presence and operations in India creates certain risks that we must effectively manage. As of December 31, 2023, 577 of our 1,102 global employees were based in India. Although wage and benefit costs in India for skilled professionals are currently significantly lower than in the United States, these costs have been increasing at a faster rate in India than in the United States. There is also intense competition in India for skilled professionals, and we expect such competition to increase. As a result, we may be unable to cost-effectively retain or add to our employee base in India. Furthermore, India has experienced natural disasters, civil unrest and terrorism and, in the past, has been involved in conflicts with neighboring countries. If we are unable to effectively manage the risks related to our India operations, our operations could be impaired, which could materially and negatively impact our growth and operating results.

Financial and Accounting Related Risks

Our revenue recognition and other factors may create volatility in our financial results in any given period and make them difficult to predict.

Historically, our platform subscription contracts have typically had a one-year term and were cancellable with 30 days’ notice. Beginning in the first quarter of 2021, our default platform subscription contract has a multi-year term and does not allow termination for convenience, although each contract may be negotiated with varying term lengths, and with or without a termination for convenience clause. Quarterly and annual results are subject to volatility due to the timing of renewals between periods, timing of new sales contracts, changes in contract term and length, and conversion of existing subscription users to other commercial offerings. 

Regardless of the term of these contracts, revenues are generally billed one month in arrears based on utilization of the different attributes of platform. While utilization may be predictable for certain aspects such as user fees, connectivity fees, market data fees, and managed services fees, other aspects such as OEMS are based on actual utilization of connections, which can be canceled or reduced month to month.

26

We derive substantially all of our revenues from clients in the financial services industry and any downturn or consolidation in the financial services industry, regulatory changes concerning financial technology providers, or unfavorable economic conditions affecting regions in which a significant portion of our clients are concentrated or segments of potential clients on which we focus, could harm our business. These clients have experienced significant pressure in recent years due to economic uncertainty, liquidity concerns and increased regulation. In recent years, many financial institutions have failed, merged, or been acquired and failures and consolidations are likely to continue. Further, if our clients merge with or are acquired by other entities such as financial institutions that have in-house developed virtual investment management solutions or that are not our clients or use fewer of our systems, our clients may discontinue, reduce, or change the terms of their use of our solution. It is also possible that the larger financial institutions that result from mergers or consolidations could have greater leverage in negotiating terms with us or could decide to replace some or all of our solution. In addition, any downturn in the financial services industry may cause our clients to reduce their spending on cloud-based investment management solutions or to seek to terminate or renegotiate their contracts with us. Any of these developments could have an adverse effect on our business, results of operations and financial condition.

Our ability to raise capital in a timely manner if needed in the future may be limited, or such capital may be unavailable on acceptable terms, if at all. Our failure to raise capital if needed could adversely affect our business and results of operations, and any debt or equity issued to raise additional capital may reduce the value of our Class A common stock.

We have funded a significant portion of our operations since inception through receipts generated from customers. We cannot be certain if our operations will continue to generate sufficient cash to fund our ongoing operations or the growth of our business. We intend to continue to make investments to support our business and may require additional funds. Additional financing may not be available on favorable terms, if at all. If adequate funds are not available on acceptable terms, we may be unable to invest in future growth opportunities, which could adversely affect our business and results of operations. Under our credit facility, our existing lenders have rights senior to the holders of Class A common stock to make claims on our assets, the terms of the credit facility restrict our operations, and we may be unable to service or repay any debt that we incur under the credit facility. In addition, if we incur additional debt in the future, the lenders would also have rights senior to holders of Class A common stock to make claims on our assets, the terms of any such future debt could further restrict our operations, and we may be unable to service or repay such additional debt. Furthermore, if we issue additional equity securities, stockholders may experience dilution, and the new equity securities could have rights senior to those of our Class A common stock. Because our decision to issue securities in a future offering will depend on numerous considerations, including factors beyond our control, we cannot predict or estimate the impact any future incurrence of debt or issuance of equity securities will have on us. Any future incurrence of debt or issuance of equity securities could adversely affect the value of our Class A common stock.

Our estimates of certain operational metrics are subject to inherent challenges in measurement.

We make certain estimates with regard to certain operational metrics which we track using internal systems that are not independently verified by any third-party. While the metrics presented in this report are based on what we believe to be reasonable assumptions and estimates, our internal systems have a number of limitations, and our methodologies for tracking these metrics may change over time. If investors do not perceive our estimates of our operational metrics to be accurate, or if we discover material inaccuracies with respect to these figures, our reputation may be significantly harmed, and our results of operations and financial condition could be adversely affected.

We are subject to certain restrictive covenants under agreements relating to our credit facility. In addition, substantially all of our assets, including our intellectual property, are pledged as collateral to secure such credit facility.

Our credit facility contains certain customary covenants with which we must comply, including financial covenants relating to maintaining a specified net leverage ratio and interest coverage ratio, and restrictive covenants that, among other things, impose certain limitations on our ability to make, incur or enter into certain: liens, indebtedness, investments, fundamental changes, dispositions, restricted payments, and transactions with affiliates. Our ability to meet the ratios required by our financial covenants can be affected by operating performance or other events beyond our control, and we cannot assure you that we will meet those ratios. Certain events of default under our credit facility could allow the lenders to declare all amounts outstanding to be immediately due and payable and, therefore, could have a material adverse effect on our business.

27

We have pledged substantially all of our assets, including our intellectual property, in support of the credit facility. If we were unable to repay the amounts due under our credit facility or fail to cure any breach of the covenants contained thereunder, our lenders could proceed against the collateral granted to them to secure such indebtedness.

Risks Related to Our Intellectual Property

If we are unable to protect our intellectual property, including trade secrets, or if we fail to enforce our intellectual property rights, our business could be adversely affected.

Our success depends upon our ability to protect our intellectual property, which may require us to incur significant costs. We have developed much of our intellectual property internally, and we rely on a combination of confidentiality obligations in contracts, copyrights, trademarks, service marks, trade secret laws and other contractual restrictions to establish and protect our intellectual property and other proprietary rights. In particular, we enter into confidentiality and invention assignment agreements with our employees and consultants and enter into confidentiality agreements with the parties with whom we have business relationships in which they will have access to our confidential information. We also rely upon licenses to intellectual property from third parties. No assurance can be given that these agreements or other steps we take to protect our intellectual property or the third-party intellectual property used in our solution will be effective in controlling access to and distribution of our solution and our confidential and proprietary information. We will not be able to protect our intellectual property if we are unable to enforce our rights or if we do not detect unauthorized uses of our intellectual property.

Despite our precautions, it may be possible for third parties to copy our solution and use information that we regard as proprietary to create solutions and services that compete with ours. Third parties may also independently develop technologies that are substantially equivalent to our solution. Some license provisions protecting against unauthorized use, copying, transfer and disclosure of our solution may be unenforceable under the laws of certain jurisdictions.

In some cases, litigation may be necessary to enforce our intellectual property rights or to protect our trade secrets. Litigation could be costly, time consuming and distracting to management and could result in the impairment or loss of portions of our intellectual property. Furthermore, our efforts to enforce our intellectual property rights may be met with defenses, counterclaims and countersuits attacking the validity and enforceability of our intellectual property rights and exposing us to significant damages or injunctions. Our inability to protect our intellectual property against unauthorized copying or use, as well as any costly litigation or diversion of our management’s attention and resources, could delay sales or the implementation of our solution, impair the functionality of our solution, delay introductions of new systems, result in our substituting less-advanced or more-costly technologies into our solution or harm our reputation. In addition, we may be required to license additional intellectual property from third parties to develop and market new systems, and we cannot assure you that we could license that intellectual property on commercially reasonable terms or at all.

Despite our efforts to protect our proprietary technology and trade secrets, unauthorized parties may attempt to misappropriate, reverse engineer, or otherwise obtain and use them. In addition, others may independently discover our trade secrets, in which case we would not be able to assert trade secret rights, or develop similar technologies and processes. Further, the contractual provisions that we enter into may not prevent unauthorized use or disclosure of our proprietary technology or intellectual property rights and may not provide an adequate remedy in the event of unauthorized use or disclosure of our proprietary technology or intellectual property rights. Moreover, policing unauthorized use of our technologies, trade secrets and intellectual property is difficult, expensive, and time-consuming, particularly in foreign countries where the laws may not be as protective of intellectual property rights as those in the United States and where mechanisms for enforcement of intellectual property rights may be weak. We may be unable to determine the extent of any unauthorized use or infringement of our solution, technologies, or intellectual property rights. If we are unable to protect our intellectual property, our business could be adversely affected.

Claims or assertions by third parties of infringement or other violations by us of their intellectual property rights could result in significant costs and substantially harm our business and results of operations.

Vigorous protection and pursuit of intellectual property rights has resulted in protracted and expensive litigation for many companies in the technology industry. Although claims of this kind have not materially affected our business to

28

date, there can be no assurance such claims will not arise in the future. Any claims or proceedings against us, regardless of whether meritorious, could be time consuming, result in costly litigation, require significant amounts of management time, result in the diversion of significant operational resources, or require us to enter into royalty or licensing agreements, any of which could harm our business, financial condition, and results of operations.

Intellectual property lawsuits are subject to inherent uncertainties due to the complexity of the technical issues involved, and we cannot be certain that we will be successful in defending ourselves against intellectual property claims. In addition, we may not be able to effectively use our intellectual property portfolio to assert defenses or counterclaims in response to copyright, patent and trademark infringement claims or litigation, as well as claims for trade secret misappropriation and unfair competition, brought against us by third parties.

Many potential litigants have the capability to dedicate substantially greater resources to enforce their intellectual property rights and to defend claims that may be brought against them. Furthermore, a successful claimant could secure a judgment that requires us to pay substantial damages or prevents us from distributing certain systems or performing certain services. We might also be required to seek a license and pay royalties for the use of such intellectual property, which may not be available on commercially acceptable terms or at all. Alternatively, we may be required to develop non-infringing technology, which could require significant effort and expense and may ultimately not be successful.

If our solution infringes on the intellectual property rights of others, we may be required to obtain costly licenses, enter into unfavorable royalty agreements, be forced to terminate some clients’ agreements, or indemnify our clients for any or some damages they suffer.

We generally indemnify our clients with respect to infringement by our products of the proprietary rights of third parties. Third parties may assert infringement claims against our clients. These claims may require us to initiate or defend protracted and costly litigation on behalf of our clients, regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our clients or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our clients may stop using our products.

We use “open source” software in our solution, which may restrict how we use or distribute our solution, require that we release the source code of certain software subject to open source licenses, or subject us to litigation or other actions that could adversely affect our business.

We currently use in our solution, and may use in the future, software that is licensed under "open source," "free" or other similar licenses where the licensed software is made available to the general public on an "as-is" basis under the terms of a specific non-negotiable license. Some open source software licenses require that software subject to the license be made available to the public and that any modifications or derivative works based on the open source code be licensed in source code form under the same open source licenses. Although we monitor our use of open source software, we cannot assure you that all open source software is reviewed prior to use in our solution, that our programmers have not incorporated open source software into our solution, or that they will not do so in the future. In addition, some of our products may incorporate third-party software under commercial licenses. We cannot be certain whether such third-party software incorporates open source software without our knowledge. In the past, companies that incorporate open source software into their products have faced claims alleging noncompliance with open source license terms or infringement or misappropriation of proprietary software. Therefore, we could be subject to suits by parties claiming noncompliance with open source licensing terms or infringement or misappropriation of proprietary software. Because few courts have interpreted open source licenses, the manner in which these licenses may be interpreted and enforced is subject to some uncertainty. There is a risk that open source software licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to market or provide our solution. As a result of using open source software subject to such licenses, we could be required to release our proprietary source code, pay damages, re-engineer our products, limit or discontinue sales, or take other remedial action, any of which could adversely affect our business.

29

Risks Related to Legal and Regulatory Matters

Although we are not subject to the same regulations as our clients, the regulatory environment in which our clients operate is subject to continual change and regulatory developments designed to increase oversight could adversely affect our business.

Although we are not currently subject to the same regulations as our clients, the legislative and regulatory environment in which our clients operate undergoes continuous change, which could subject our clients to additional, more costly, and potentially more punitive regulation. New laws or regulations, or changes in the enforcement of existing laws or regulations, applicable to our clients or directly applicable to us could adversely affect our business subjecting us to additional costs. Any or all of the regulators who oversee our clients could adopt new rules or rule amendments that could substantially impact how we operate and may necessitate significant expenditures in order to adapt and comply. Our ability to support our clients in an uncertain and ever-changing regulatory environment will depend on our ability to constantly monitor and promptly react to legislative and regulatory changes, which inevitably result in intangible costs and resource drains. The compliance burden resulting from regulatory changes and uncertainty is likely to increase, particularly as regulators grow more technologically advanced and more reliant on data analytics. As a result, we may be forced to divert resources and expenditures to information technology in order to analyze data and risk in the same manner as regulators to be able to assist our clients in providing regulators with the data output they may expect going forward.

There also have been a number of highly publicized regulatory inquiries that have focused on the investment management industry. These inquiries have resulted in increased scrutiny of the industry and new rules and regulations for mutual funds and investment managers. This regulatory scrutiny may limit our ability to engage in certain activities that might be beneficial to our stockholders. Further, adverse results of regulatory investigations of mutual fund, investment advisory and financial services firms could tarnish the reputation of the financial services industry generally and mutual funds and investment advisers more specifically, causing investors to avoid further fund investments or redeem their account balances. Further, due to acts of serious fraud in the investment management industry and perceived lapses in regulatory oversight, U.S. and non-U.S. governmental and regulatory authorities may continue to increase regulatory oversight of our clients’ businesses.

This evolving, complex and often unpredictable regulatory environment could result in our failure to provide a compliant solution, which could result in clients not purchasing our solution or terminating their agreements with us or the imposition of fines or other liabilities for which we may be responsible. In addition, federal, state, local and/or foreign agencies may attempt to further regulate our activities in the future. If enacted or deemed applicable to us, such laws, rules, or regulations could be imposed on our activities or our business thereby rendering our business or operations more costly, burdensome, less efficient, or impossible, any of which could have a material adverse effect on our business, financial condition, and operating results.

Any future litigation against us could damage our reputation and be costly and time-consuming to defend.

We may become subject, from time to time, to legal proceedings and claims that arise in the ordinary course of business, such as claims brought by our clients in connection with commercial disputes or employment claims made by current or former employees. Litigation might result in reputational damage and substantial costs and may divert management’s attention and resources, which might adversely impact our business, overall financial condition, and results of operations. Insurance might not cover such claims, might not provide sufficient payments to cover all the costs to resolve one or more such claims and might not continue to be available on terms acceptable to us. Moreover, any negative impact to our reputation will not be adequately covered by any insurance recovery. A claim brought against us that is uninsured or underinsured could result in unanticipated costs, thereby reducing our results of operations and leading analysts or potential investors to reduce their expectations of our performance, which could reduce the value of our Class A common stock. While we currently are not aware of any material pending or threatened litigation against us, we can make no assurances the same will continue to be true in the future.

30

Our failure to comply with laws and regulations related to the Internet or future government regulation of the Internet could increase costs and impose constraints on the way we conduct our business.

We and our clients are subject to laws and regulations applicable to doing business over the Internet. It is often not clear how existing laws governing issues such as property ownership, sales and other taxes apply to the Internet, as these laws have in some cases failed to keep pace with technological change. Laws governing the Internet could also impact our business or the business of our clients. For instance, existing and future regulations on taxing Internet use, pricing, characterizing the types and quality of services and products, or restricting the exchange of information over the Internet or mobile devices could result in reduced growth of our business, a general decline in the use of the Internet by financial services providers, or their end users, or diminished viability of our solution and could significantly restrict our clients’ ability to use our solution. Changing laws and regulations, industry standards and industry self-regulation regarding the collection, use and disclosure of certain data may have similar effects on our and our clients’ businesses. Any such constraint on the growth in the Internet could decrease its acceptance as a medium of communication and commerce or result in increased adoption of new modes of communication and commerce that may not be supported by our solution. Any such adverse legal or regulatory developments could substantially harm our operating results and our business.

Our failure to comply with the FCPA and similar anti-bribery and anti-corruption laws associated with our activities outside the United States could subject us to penalties and other adverse consequences.

A portion of our revenues are derived from jurisdictions outside of the United States. We are subject to the FCPA, which generally prohibits U.S. companies and their intermediaries from making payments to foreign officials for the purpose of directing, obtaining, or keeping business and requires companies to maintain reasonable books and records and a system of internal accounting controls. The FCPA applies to companies and individuals alike, including company directors, officers, employees, and agents. Under the FCPA, U.S. companies may be held liable for corrupt actions taken by employees, strategic, or local partners or other representatives. In addition, the government may seek to rely on a theory of successor liability and hold us responsible for FCPA violations committed by companies or associated with assets that we acquire.

In certain foreign jurisdictions where we currently operate or plan to expand our operations, particularly countries with developing economies, it may be a local custom for businesses to engage in practices that are prohibited by the FCPA or other similar laws and regulations. There can be no assurance that our colleagues, partners, and agents, as well as those companies to which we outsource certain of our business operations, will not take actions in violation of the FCPA or our policies for which we may be ultimately held responsible. If we or our intermediaries fail to comply with the requirements of the FCPA or similar anti-bribery and anti-corruption legislation such as the United Kingdom Bribery Act and the China Unfair Competition law, governmental authorities in the United States and elsewhere could seek to impose civil and/or criminal fines and penalties, which could harm our business, financial conditions and results of operations. We may also face collateral consequences such as debarment and the loss of our export privileges.

Our failure to comply with various data privacy, protection and security regulations could impose additional costs and liabilities on us, limit our use, storage, or processing of information and adversely affect our business.

We operate in a regulatory environment in which requirements applicable to privacy, data protection and data security are continually evolving. We cannot assure you that relevant governmental authorities will not interpret or implement the laws or regulations in ways that negatively affect the cloud service industry, our clients and us. Regulatory investigations, restrictions, penalties, and sanctions, whether targeted at us or not, may negatively affect the market environment in which we operate, our existing or potential clients and our products and services, which may in turn have a material adverse effect on our business, results of operations and financial condition. It is also possible that we may become subject to additional or new laws and regulations regarding privacy, data protection and data security in connection with the data we have access to and the data products and services we provide to our clients. Moreover, we may be subject to regulatory requirements as a result of utilization of our products and services by residents of certain jurisdictions, such as the General Data Protection Regulation (the “GDPR”) of the European Union, the UK version of the GDPR, the California Consumer Privacy Act, and Virginia’s Consumer Data Protection Act. Complying with these and other regulatory requirements could force us to incur substantial costs or require us to change our business practices. Moreover, if a high profile security breach occurs with respect to our competitors, people may lose trust in the security of cloud

31

service providers generally, including us, which could damage the reputation of the industry, result in heightened regulation and strengthened regulatory enforcement and adversely affect our business and results of operations.

We expect that we will continue to face uncertainty as to whether our efforts to comply with evolving obligations under global data protection, privacy and security laws will be sufficient. Any failure or perceived failure by us to comply with applicable laws and regulations could result in reputational damage or proceedings or actions against us by governmental authorities, individuals, or others. These proceedings or actions could subject us to significant civil or criminal penalties and negative publicity, require us to change our business practices, increase our costs and materially harm our business, prospects, financial condition, and results of operations. In addition, our current and future relationships with clients, vendors and other third parties could be negatively affected by any proceedings or actions against us or current or future data protection obligations imposed on them under applicable law. Furthermore, a data breach affecting personal information could result in significant legal and financial exposure and reputational damage that could potentially have an adverse effect on our business.

Failure to comply with governmental laws and regulations could harm our business, materially and adversely affect us, and cause our stock price to decline significantly.

Our business is subject to regulation by various federal, state, local and foreign governmental agencies, including agencies responsible for monitoring and enforcing employment and labor laws, workplace safety, product safety, environmental laws, consumer protection laws, anti-bribery laws, import/export controls, federal securities laws and tax laws and regulations. In certain jurisdictions, these regulatory requirements may be more stringent than those in the United States. Noncompliance with applicable regulations or requirements could subject us to investigations, sanctions, revocation of required licenses, enforcement actions, disgorgement of profits, fines, damages, civil and criminal penalties, or injunctions. If any governmental sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, we could be materially and adversely affected. In addition, responding to any action will likely result in a significant diversion of management’s attention and resources and an increase in legal and professional costs and expenses.

We are not a registered broker-dealer and therefore we do not execute trades. We provide passive communication technology to institutional investors, such as money managers and hedge funds, that enables such investors to communicate with executing brokers, prime brokers and clearing firms. As such, we must ensure that our technology activities and our compensation structure therefore would not result in our acting as an unregistered broker-dealer or investment adviser that could subject us to, among other things, regulatory enforcement actions, monetary fines, restrictions on the conduct of our technology business and rescission/damages claims by clients who use our technology. Our failure to comply with any laws or regulations, or the costs associated with defending any action alleging our noncompliance with any laws or regulations, could materially and adversely affect us and cause our stock price to decline significantly.

Risks Related to our Class A Common Stock 

The market price and trading volume of our Class A common stock may be volatile, which could result in rapid and substantial losses for our stockholders.

The market price of our Class A common stock may be highly volatile and could be subject to wide fluctuations. In addition, the trading volume in our Class A common stock may fluctuate and cause significant price variations to occur. If the market price of our Class A common stock declines significantly, stockholders’ may be unable to resell their shares at or above their purchase price, if at all. The market price of our Class A common stock may fluctuate or decline significantly in the future. Some of the factors that could negatively affect our share price or result in fluctuations in the price or trading volume of our Class A common stock include:

variations in our quarterly or annual operating results;
our ability to attract new clients, particularly larger clients, in both domestic and international markets and our ability to increase sales to and renew agreements with our existing clients, particularly larger clients, at comparable prices;

32

the timing of our clients’ buying decisions and reductions in our clients’ budgets for IT purchases and delays in their purchasing cycles, particularly in light of recent adverse global economic conditions;
changes in our earnings estimates (if provided) or differences between our actual financial and operating results and those expected by investors and analysts;
the contents of published research reports about us or our industry or the failure of securities analysts to cover our Class A common stock;
additions to, or departures of, key management personnel;
any increased indebtedness we may incur in the future;
announcements and public filings by us or others and developments affecting us;
actions by institutional stockholders;
litigation and governmental investigations;
operating and stock performance of other companies that investors deem comparable to us (and changes in their market valuations) and overall performance of the equity markets;
speculation or reports by the press or investment community with respect to us or our industry in general;
increases in market interest rates that may lead purchasers of our shares to demand a higher yield;
announcements by us or our competitors of significant contracts, acquisitions, dispositions, strategic relationships, joint ventures, or capital commitments;
announcements or actions taken by significant stockholders;
sales of substantial amounts of our Class A common stock by significant stockholders or our insiders, or the expectation that such sales might occur;
volatility or economic downturns in the markets in which we, our clients and our partners are located caused by pandemics, including the COVID-19 pandemic and related policies and restrictions undertaken to contain the spread of such pandemics or potential pandemics; and
general market, political and economic conditions, in the investment management industry in particular, including any such conditions and local conditions in the markets in which any of our clients are located.

These broad market and industry factors may decrease the market price of our Class A common stock, regardless of our actual operating performance. The stock market in general has from time to time experienced extreme price and volume fluctuations. In addition, in the past, following periods of volatility in the overall market and the market price of a company’s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources.

An active, liquid trading market for our Class A common stock may not develop or be sustained, which may make it difficult for you to sell the Class A common stock you purchase.

We cannot assure you that the price of our Class A common stock will equal or exceed the price at which our securities have traded at any point from and after our IPO. We cannot predict the extent to which investor interest in us

33

will lead to the development of a trading market or how active and liquid that market may become. If an active and liquid trading market for our Class A common stock may not develop or continue, you may have difficulty selling any of our Class A common stock at a price above the price you purchase it or at all. If an active and liquid trading market for our Class A common stock does not develop or continue, or, if not further developed, it may not be sustained and our ability to raise capital to fund our operations by selling shares and our ability to acquire other companies or technologies by using our shares as consideration will suffer.

Future sales of shares by existing stockholders could cause our stock price to decline.

If our existing stockholders, including employees who obtain equity, sell, or indicate an intention to sell, substantial amounts of our Class A common stock in the public market, the trading price of our Class A common stock could decline. As of December 31, 2023, we had outstanding 88,332,175 shares of Class A common stock and 39,198,767 shares of Class B common stock. Sales of a substantial number of such shares or the perception that such sales may occur could cause our market price to fall or make it more difficult for you to sell your Class A common stock at a time and price that you deem appropriate. 

Future offerings of debt or equity securities by us may materially and adversely affect the market price of our Class A common stock.

In the future, we may attempt to obtain financing or to further increase our capital resources by issuing additional shares of our Class A common stock or offering debt or other equity securities, including senior or subordinated notes, debt securities convertible into equity, or shares of preferred stock. In addition, we may seek to expand operations in the future to other markets which we would expect to finance through a combination of additional issuances of equity, corporate indebtedness and/or cash from operations.

Issuing additional shares of our Class A common stock or other equity securities or securities convertible into equity may dilute the economic and voting rights of our existing stockholders or reduce the market price of our Class A common stock or both. Upon liquidation, holders of such debt securities and preferred shares, if issued, and lenders with respect to other borrowings would receive a distribution of our available assets prior to the holders of our Class A common stock. Debt securities convertible into equity could be subject to adjustments in the conversion ratio pursuant to which certain events may increase the number of equity securities issuable upon conversion. Preferred shares, if issued, could have a preference with respect to liquidating distributions or a preference with respect to dividend payments that could limit our ability to pay dividends to the holders of our Class A common stock. Our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, which may adversely affect the amount, timing, or nature of our future offerings. Thus, holders of our Class A common stock bear the risk that our future offerings may reduce the market price of our Class A common stock and dilute their stockholdings in us.

The future issuance of additional Class A common stock in connection with our incentive plans or otherwise will dilute all other stockholdings.

We may issue additional shares of Class A common stock that are authorized under our amended and restated certificate of incorporation but not currently issued or reserved for issuance under our equity incentive plans. Subject to applicable law and stock exchange rules, we may issue these shares of Class A common stock without any action or approval by our stockholders, subject to certain exceptions. Any Class A common stock issued in connection with our incentive plans, the exercise of outstanding stock options or otherwise would dilute the percentage ownership held by our Class A common stockholders.

Insiders have substantial control over us, which could limit your ability to influence the outcome of key transactions, including a change of control.

As of December 31, 2023, our directors, executive officers, and each of our stockholders who own greater than 5% of our outstanding common stock and their affiliates, in the aggregate, beneficially owned approximately 67.1% of the combined voting power of our then-outstanding common stock through their ownership of both Class A common stock and Class B common stock. As a result, these stockholders are able to influence or control matters requiring approval by

34

our stockholders, including the election of directors and the approval of mergers, acquisitions or other extraordinary transactions. They may also have interests that differ from yours and may vote in a way with which you disagree and which may be adverse to your interests. This concentration of ownership may have the effect of delaying, preventing, or deterring a change of control of our company, could deprive our stockholders of an opportunity to receive a premium for their Class A common stock as part of a sale of our company and might ultimately adversely affect the market price of our Class A common stock.

Risks Related to our Organizational Structure

Enfusion, Inc. is a holding company, and its only material asset is its direct and indirect interest in Enfusion Ltd. LLC, and it is accordingly dependent upon distributions from Enfusion Ltd. LLC to pay taxes, make payments under the Tax Receivable Agreement, and pay dividends.

Enfusion, Inc. is a holding company and after the completion of the IPO has no material assets other than its direct and/or indirect ownership of Common Units. Enfusion, Inc. has no independent means of generating revenues. Enfusion, Inc. intends to cause Enfusion Ltd. LLC to make distributions to holders of its Common Units, including directly and/or indirectly Enfusion, Inc. and our Pre-IPO Common Unitholders, in an amount sufficient to cover all applicable taxes at assumed tax rates, payments under the Tax Receivable Agreement and dividends, if any, declared by it. Deterioration in the financial condition, earnings, or cash flow of Enfusion Ltd. LLC and its subsidiaries for any reason could limit or impair their ability to pay such distributions. Additionally, to the extent that Enfusion, Inc. needs funds, and Enfusion Ltd. LLC is restricted from making such distributions under applicable law or regulation or under the terms of our financing arrangements, or is otherwise unable to provide such funds, such restriction could materially adversely affect our liquidity and financial condition.

We anticipate that Enfusion Ltd. LLC will continue to be treated as a partnership for U.S. federal income tax purposes and, as such, generally will not be subject to any entity-level U.S. federal income tax. Instead, taxable income will be allocated to holders of Common Units, including us. Accordingly, we will be required to pay income taxes on our direct and/or indirect allocable share of any net taxable income of Enfusion Ltd. LLC. Legislation that is effective for taxable years beginning after December 31, 2017 may impute liability for adjustments to a partnership’s tax return to the partnership itself in certain circumstances, absent an election to the contrary. Enfusion Ltd. LLC may be subject to material liabilities pursuant to this legislation and related guidance if, for example, its calculations of taxable income are incorrect. In addition, the income taxes on our direct and/or indirect allocable share of Enfusion Ltd. LLC’s net taxable income will increase over time as our Pre-IPO Common Unitholders exchange their Common Units for shares of our Class A common stock. Such increase in our tax expenses may have a material adverse effect on our business, results of operations and financial condition.

Under the terms of the amended and restated limited partnership agreement, Enfusion Ltd. LLC is obligated to make tax distributions to holders of Common Units, including (directly and/or indirectly) us, at certain assumed tax rates. These tax distributions may in certain periods exceed our tax liabilities and obligations to make payments under the Tax Receivable Agreement. Our board of directors, in its sole discretion, will make any determination from time to time with respect to the use of any such excess cash so accumulated, which may include, among other uses, funding repurchases of Class A common stock; acquiring additional newly issued Common Units from Enfusion Ltd. LLC at a per unit price determined by reference to the market value of the Class A common stock; paying dividends, which may include special dividends, on our Class A common stock; or any combination of the foregoing. We will have no obligation to distribute such cash (or other available cash other than any declared dividend) to our stockholders. To the extent that we do not distribute such excess cash as dividends on our Class A common stock or otherwise undertake ameliorative actions between Common Units and shares of Class A common stock and instead, for example, hold such cash balances, our Pre-IPO Common Unitholders may benefit from any value attributable to such cash balances as a result of their ownership of Class A common stock following a redemption or exchange of their Common Units, notwithstanding that such Pre-IPO Common Unitholders may previously have participated as holders of Common Units in distributions by Enfusion Ltd. LLC that resulted in such excess cash balances at Enfusion, Inc. See “Certain Relationships and Related Party Transactions—Seventh Amended and Restated Operating Agreement of Enfusion Ltd. LLC” of the definitive Proxy Statement for our 2023 Annual Meeting of Stockholders, which was filed with the SEC on May 1, 2023.

35

Payments of dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including our business, operating results and financial condition, current and anticipated cash needs, plans for expansion and any legal or contractual limitations on our ability to pay dividends. Our existing credit facilities include, and any financing arrangement that we enter into in the future may include, restrictive covenants that limit our ability to pay dividends. In addition, Enfusion Ltd. LLC is generally prohibited under Delaware law from making a distribution to a limited partner to the extent that, at the time of the distribution, after giving effect to the distribution, liabilities of Enfusion Ltd. LLC (with certain exceptions) exceed the fair value of its assets. Subsidiaries of Enfusion Ltd. LLC are generally subject to similar legal limitations on their ability to make distributions to Enfusion Ltd. LLC.

Enfusion, Inc. will be required to pay certain of our Pre-IPO Owners for most of the benefits relating to tax depreciation or amortization deductions that we may claim as a result of Enfusion, Inc.’s acquisition of existing tax basis in the IPO, increases in existing tax basis and anticipated tax basis adjustments we receive in connection with sales or exchanges (or deemed exchanges) of Common Units or distributions (or deemed distributions) with respect to Common Units after the IPO and our utilization of certain tax attributes of the Blocker Companies.

Prior to the completion of the IPO, we entered into a Tax Receivable Agreement with certain of our Pre-IPO Owners that provides for the payment by Enfusion, Inc. to such Pre-IPO Owners of 85% of the benefits, if any, that Enfusion, Inc. actually realizes, or is deemed to realize (calculated using certain assumptions), as a result of (i) existing tax basis acquired in the IPO, (ii) increases in existing tax basis and adjustments to the tax basis of the tangible and intangible assets of Enfusion Ltd. LLC as a result of sales or exchanges (or deemed exchanges) of Common Units for shares of Class A common stock or distributions (or deemed distributions) with respect to Common Units after the IPO, (iii) Enfusion, Inc.’s utilization of certain attributes of the Blocker Companies, and (iv) certain other tax benefits related to entering into the Tax Receivable Agreement, including tax benefits attributable to payments under the Tax Receivable Agreement. The existing tax basis, increases in existing tax basis and the tax basis adjustments generated over time may increase (for tax purposes) the depreciation and amortization deductions available to Enfusion, Inc. and, therefore, may reduce the amount of U.S. federal, state and local tax that Enfusion, Inc. would otherwise be required to pay in the future, although the IRS may challenge all or part of the validity of that tax basis, and a court could sustain such a challenge. The existing tax basis acquired in the IPO and the increase in existing tax basis and the anticipated tax basis adjustments upon purchases or exchanges (or deemed exchanges) of Common Units for shares of Class A common stock or distributions (or deemed distributions) with respect to Common Units may also decrease gains (or increase losses) on future dispositions of certain assets to the extent tax basis is allocated to those assets. Actual tax benefits realized by Enfusion, Inc. may differ from tax benefits calculated under the Tax Receivable Agreement as a result of the use of certain assumptions in the Tax Receivable Agreement, including the use of an assumed weighted-average state and local income tax rate to calculate tax benefits.

The payment obligation under the Tax Receivable Agreement is an obligation of Enfusion, Inc. and not of Enfusion Ltd. LLC. While the amount of existing tax basis and anticipated tax basis adjustments and utilization of tax attributes, as well as the amount and timing of any payments under the Tax Receivable Agreement, will vary depending upon a number of factors, we expect the payments that Enfusion, Inc. may make under the Tax Receivable Agreement will be substantial. The actual amounts payable will depend upon, among other things, the timing of purchases or exchanges, the price of shares of our Class A common stock at the time of such purchases or exchanges, the extent to which such purchases or exchanges are taxable, the tax rate and the amount and timing of our taxable income. As of December 31, 2023, the Company estimates the amount of total tax attributes acquired to be approximately $323.6 million. If all of the Pre-IPO Common Unitholders had exchanged or sold to us all of their outstanding Common Units as of December 31, 2023, we would have recognized a deferred tax asset of approximately $148.5 million and a liability under the Tax Receivable Agreement of approximately $126.2 million, assuming: (i) all exchanges or purchases occurred on the same day, (ii) a price of $9.70 per share, which was the price per share of Class A common stock as of December 31, 2023, (iii) a constant corporate tax rate of 29.7%, (iv) that we would have sufficient taxable income to utilize the tax benefits fully, and (v) no material changes in tax law. The payments under the Tax Receivable Agreement are not conditioned upon continued ownership of us by the Pre-IPO Owners. 

36

In certain cases, payments under the Tax Receivable Agreement may be accelerated and/or significantly exceed the actual benefits Enfusion Ltd. LLC realizes in respect of the tax attributes subject to the Tax Receivable Agreement.

Enfusion, Inc.’s payment obligations under the Tax Receivable Agreement will be accelerated in the event of certain changes of control, upon a breach by Enfusion, Inc. of a material obligation under the Tax Receivable Agreement or if Enfusion, Inc. elects to terminate the Tax Receivable Agreement early. The accelerated payments required in such circumstances will be calculated by reference to the present value (at a discount rate equal to the lesser of (i) 6.5% per annum and (ii) one-year LIBOR (or its successor rate) plus 100 basis points) of all future payments that holders of Common Units or other recipients would have been entitled to receive under the Tax Receivable Agreement, and such accelerated payments and any other future payments under the Tax Receivable Agreement will utilize certain valuation assumptions, including that Enfusion, Inc. will have sufficient taxable income to fully utilize the deductions arising from the increased tax deductions and tax basis and other benefits related to entering into the Tax Receivable Agreement and sufficient taxable income to fully utilize any remaining net operating losses subject to the Tax Receivable Agreement on a straight line basis over the shorter of the statutory expiration period for such net operating losses or the five-year period after the early termination or change of control. In addition, recipients of payments under the Tax Receivable Agreement will not reimburse us for any payments previously made under the Tax Receivable Agreement if the tax attributes or Enfusion, Inc.’s utilization of tax attributes underlying the relevant Tax Receivable Agreement payment are successfully challenged by the IRS (although any such detriment would be taken into account as an offset against future payments due to the relevant recipient under the Tax Receivable Agreement). Enfusion, Inc.’s ability to achieve benefits from any existing tax basis, tax basis adjustments, or other tax attributes, and the payments to be made under the Tax Receivable Agreement, will depend upon a number of factors, including the timing and amount of our future income. As a result, even in the absence of a change of control or an election to terminate the Tax Receivable Agreement early, payments under the Tax Receivable Agreement could be in excess of 85% of Enfusion, Inc.’s actual cash tax benefits.

Accordingly, it is possible that the actual cash tax benefits realized by Enfusion, Inc. may be significantly less than the corresponding Tax Receivable Agreement payments. It is also possible that payments under the Tax Receivable Agreement may be made years in advance of the actual realization, if any, of the anticipated future tax benefits. There may be a material negative effect on our liquidity if the payments under the Tax Receivable Agreement exceed the actual cash tax benefits that Enfusion, Inc. realizes in respect of the tax attributes subject to the Tax Receivable Agreement and/or if distributions to Enfusion, Inc. by Enfusion Ltd. LLC are not sufficient to permit Enfusion, Inc. to make payments under the Tax Receivable Agreement after it has paid taxes and other expenses. We estimate that if Enfusion, Inc. had exercised its termination right as of December 31, 2023, the aggregate amount of the early termination payments required under the Tax Receivable Agreement would have been approximately $53.3 million. The foregoing number is merely an estimate, and the actual payments could differ materially. We may need to incur additional indebtedness to finance payments under the Tax Receivable Agreement to the extent our cash resources are insufficient to meet our obligations under the Tax Receivable Agreement as a result of timing discrepancies or otherwise, and these obligations could have the effect of delaying, deferring or preventing certain mergers, asset sales, other forms of business combinations, or other changes of control.

The acceleration of payments under the Tax Receivable Agreement in the case of certain changes of control may impair our ability to consummate change of control transactions or negatively impact the value received by owners of our Class A common stock.

In the case of certain changes of control, payments under the Tax Receivable Agreement will be accelerated and may significantly exceed the actual benefits Enfusion, Inc. realizes in respect of the tax attributes subject to the Tax Receivable Agreement. We expect that the payments that we may make under the Tax Receivable Agreement in the event of a change of control will be substantial. As a result, our accelerated payment obligations and/or the assumptions adopted under the Tax Receivable Agreement in the case of a change of control may impair our ability to consummate change of control transactions or negatively impact the value received by owners of our Class A common stock in a change of control transaction.

37

General Risk Factors

As an “emerging growth company” under the Jumpstart Our Business Startups Act (the “JOBS Act”), we are permitted to, and intend to, rely on exemptions from certain disclosure requirements, which could make our Class A common stock less attractive to investors.

As an “emerging growth company” under the JOBS Act, we are relying on permitted exemptions from certain disclosure requirements. In addition, for so long as we are an emerging growth company, we will not be required to:

have an auditor report on our internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”);
comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis); and
submit certain executive compensation matters to stockholder advisory votes, such as “say on pay” and “say on frequency.”

Because of these exemptions and the other reduced disclosure obligations for emerging growth companies set forth elsewhere in this report, our stock may appear less attractive to investors and could cause our stock price to decline.

Although we intend to rely on certain of the exemptions provided in the JOBS Act, the exact implications of the JOBS Act for us are still subject to interpretations and guidance by the SEC and other regulatory agencies. Also, as our business grows, we may no longer satisfy the conditions of an emerging growth company. We will remain an "emerging growth company" until the earliest of (i) the last day of the fiscal year during which we have total annual gross revenues of $1.235 billion or more; (ii) the last day of the fiscal year following the fifth anniversary of our initial public offering; (iii) the date on which we have, during the previous three-year period, issued more than $1 billion in non-convertible debt; and (iv) the date on which we are deemed to be a "large accelerated filer" under the Exchange Act. We will be deemed a large accelerated filer on the first day of the fiscal year after the market value of our common equity held by non-affiliates exceeds $700.0 million, measured on June 30. If investors find our Class A common stock less attractive as a result of our reliance on certain of the JOBS Act exemptions, there may be a less active trading market for our Class A common stock, and our stock price may be more volatile.

In addition, section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the “Securities Act”) for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have chosen to "opt in" to such extended transition period, and as a result, we will not initially have to comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies.

As a public company, we are obligated to develop and maintain proper and effective internal control over financial reporting and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our Class A common stock.

We are required, pursuant to Section 404(a) of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting on an annual basis. This assessment must include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. Our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting until our first annual report required to be filed with the SEC following the date we are no longer an “emerging growth company,” as defined in the JOBS Act. We are and will be required to disclose significant changes made in our internal control procedures on a quarterly basis.

38

Our compliance with Section 404(a) has and will require that we incur substantial expenses, including legal, compliance, accounting, and informational technology expenses, and expend significant management efforts. We currently do not have an internal audit group, and we may need to hire additional accounting and financial staff to maintain the system and process documentation necessary to perform the evaluation needed to comply with Section 404(a).

During the evaluation and testing process of our internal controls, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition and operating results. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our Class A common stock could decline, and we could be subject to sanctions or investigations by the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.

We incur increased costs and administrative burdens in connection with operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act, which could result in sanctions or other penalties that would harm our business.

As a public company, and particularly after we are no longer an “emerging growth company,” we have and will incur significant legal, accounting, and other expenses, including costs resulting from public company reporting obligations under the Securities Act or the Exchange Act, and regulations regarding corporate governance practices. The expenses incurred by public companies generally for reporting and corporate governance purposes are greater than those for private companies. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the rules of the SEC, the listing requirements of the New York Stock Exchange, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. These requirements have and will increase our legal and financial compliance costs and make some activities more time-consuming and costly. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We cannot predict or estimate the amount of additional costs we will continue to incur as a public company or the timing of such costs. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors’ and officers’ insurance, on acceptable terms. In addition, as a public company we are and will be required to file accurate and timely quarterly and annual reports with the SEC under the Securities Act or the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the New York Stock Exchange or other adverse consequences that would materially harm our business and reputation.

Pursuant to Sarbanes-Oxley Act Section 404(a), we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm, as required by Sarbanes-Oxley Act Section 404(b). In anticipation of being subject to Sarbanes-Oxley Act Section 404(b), we will be engaged in a process of further documenting and evaluating our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed work plan to assess and document the adequacy of

39

internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Furthermore, we have hired and may continue to hire additional accounting, finance, and other personnel in connection with our becoming subject to the requirements of Section 404(b), and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. Despite our efforts, there is a risk that an independent assessment of the effectiveness of our internal controls by our independent registered public accounting firm could detect problems that our management’s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation, which could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.

Our amended and restated bylaws designate a state or federal court located within the State of Delaware as the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to choose the judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf under Delaware law, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action arising pursuant to any provision of the Delaware General Corporation Law (the “DGCL”), our amended and restated certificate of incorporation or bylaws, (4) any other action asserting a claim that is governed by the internal affairs doctrine, or (5) any other action asserting an “internal corporate claim,” as defined in Section 115 of the DGCL, shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) in all cases subject to the court having jurisdiction over indispensable parties named as defendants. These exclusive forum provisions do not apply to claims under the Securities Act or the Exchange Act.

To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.

Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. However, our amended and restated bylaws contain a federal forum provision which provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.

Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to this provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. This exclusive forum provision may limit a stockholder’s ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find the exclusive forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations.

Item 1B. Unresolved Staff Comments

None.

Item 1C. Cybersecurity

As a cloud-based SaaS provider operating within the financial services industry, cybersecurity risk management is a critical part of our overall risk management efforts. We maintain Cyber Security and Technology Risk programs that are comprised of policies and controls designed to mitigate cybersecurity and other technology risks. We continuously

40

work to enhance these Cyber Security and Technology Risk programs, though we acknowledge that, at any given time, we may face known and unknown cybersecurity risks and threats that are not fully mitigated.

In order to identify, assess, and manage our cybersecurity risks, we use a risk management framework informed by industry standards and industry-recognized practices, including the National Institute of Standards and Technology and the Secure Controls Framework. We perform periodic technology risk assessments based on these frameworks to identify and assess risks from cybersecurity threats and review the efficacy of our controls. These risk assessments include security assessments, vulnerability assessments, penetration testing, and security audits, and we also engage third-party security experts and consultants to assist with assessments and enhancements of our cybersecurity risk management processes, and provide benchmarks against industry practices. Using the results of these assessments, we have developed risk mitigation strategies that include a variety of technical and operational measures, such as cybersecurity training and compliance programs for all employees with access to our information systems. In addition, we maintain specific policies and practices governing our third-party risks, including our third-party risk management process. Our third-party risk management process uses a number of approaches, including consultation with outside specialists, to assess potential risks associated with third parties’ security controls. Generally, we also contractually require third parties who have access to our data and systems to, among other things, maintain security controls to protect our confidential information and data, and notify us of cybersecurity incidents that may impact our data.

Our Global Head of Security has over 20 years of industry experience and leads a dedicated Cybersecurity, and Governance, Risk and Compliance (“GRC”) team that is responsible for managing the cybersecurity, technology risk management, and cyber continual improvement programs, as well as other activities designed to identify, assess, manage and treat risks, and respond to threats or incidents. The Cybersecurity and GRC teams include personnel with decades of experience in managing risk and selecting, deploying, and operating cybersecurity technologies, initiatives, and processes around the world. The team gathers and relies upon threat intelligence obtained from external consultants, government sources, and technology providers.

Assessing, identifying, and managing our cybersecurity and technology risks is also part of our enterprise risk management (“ERM”) framework. Our ERM framework and associated process is designed to evaluate the Company’s most significant risks, including, as applicable, cybersecurity and technology risks. The ERM framework and associated process is directly overseen by a management-led Risk Management Committee (the “RMC”) that meets on a regular basis and is comprised of our CEO, COO, General Counsel, and Global Head of Security.

The RMC, as supported by individual risk managers for each line of business, also maintains reports regarding the assessment, identification, and management of our enterprise risks for the Board to periodically review. The Global Head of Security also presents to the Board on cybersecurity risks on an approximately annual basis and the Board, through these periodic reports it receives from the RMC and the presentations by the Global Head of Security, maintains involvement with and oversight over the Company’s cybersecurity risks. As part of our Cyber Security and Technology Risk programs, the Company has also established an incident response process to track and log cybersecurity incidents. This process provides for escalating notifications to our CEO and Board depending on the nature and severity of an incident.

In the year ended December 31, 2023, we did not identify any cybersecurity threats that have materially affected or are reasonably likely to materially affect our business strategy, results of operations, or financial condition. However, despite our efforts, we cannot eliminate all risks from cybersecurity threats, or provide assurances that we have not experienced undetected cybersecurity incidents. For more information on our cybersecurity related risks, see Part I Item 1A. Risk Factors of this Annual Report on Form 10-K.

Item 2. Properties

We are headquartered in Chicago, Illinois, pursuant to an operating lease that expires in 2025. We lease additional offices in New York City and, internationally, in London, Dublin, Hong Kong, Singapore, Mumbai, Bengaluru, and Sydney. We believe these facilities are generally suitable to meet our current needs. We intend to expand our facilities or add new facilities as we add employees and enter new geographic markets, and we believe that suitable additional or alternative space will be available as needed to accommodate any such growth.

41

Item 3. Legal Proceedings

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition, or cash flows. Regardless of the outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 4. Mine Safety Disclosures

Not applicable.

42

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information for Common Stock

Our Class A common stock has been listed on the New York Stock Exchange under the symbol “ENFN” since October 21, 2021. Prior to that date, there was no public trading market for our Class A common stock.

Our Class B common stock is neither listed nor traded.

Holders of Record

As of March 8, 2024, there were 10 holders of record of our Class A common stock. The actual number of stockholders is greater than this number and includes an indeterminate number of stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.

As of March 8, 2024, there were 5 holders of record of our Class B common stock.

Dividend Policy

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings and do not anticipate declaring or paying any cash dividends in the foreseeable future. Any future determination regarding the declaration and payment of dividends will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant.

Performance Graph

This performance graph shall not be deemed “soliciting material” or to be “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any filing of ours under the Securities Act or the Exchange Act.

The following graph compares the cumulative total return to stockholders on our Class A common stock with the cumulative total returns of the NYSE Composite Index and the S&P Software & Services Select Industry Index. An investment of $100 is assumed to have been made in our Class A common stock and in each index on October 21, 2021, the date our Class A common stock began trading on the New York Stock Exchange, and its relative performance is tracked through December 31, 2023. Data for the NYSE Composite Index and the S&P Software & Services Select Industry Index assume reinvestment of dividends.

43

The returns shown are based on historical results and are not intended to suggest future performance.

Graphic

Recent Sales of Unregistered Securities

There were no unregistered sales of equity securities during the fiscal year ended December 31, 2023 that were not previously reported in a Quarterly Report on Form 10-Q or Current Report on Form 8-K.

Issuer Purchases of Equity Securities

None.

Item 6. [Reserved]

44

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This discussion and analysis reflect historical results of operations and financial position. The following discussion and analysis is intended to highlight and supplement data and information presented elsewhere in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and other financial information. To the extent that this discussion describes prior performance, the descriptions relate only to the periods listed, which may not be indicative of our future financial outcomes. Furthermore, this discussion and analysis generally discusses results of operations and financial position for the years ended December 31, 2023 and 2022, and year-to-year comparisons between those years. Discussions of results of operations and financial position for the year ended December 31, 2021 and year to year comparisons between the years ended December 31, 2022 and 2021 are not included, and can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 10, 2023. In addition to the historical information presented, this discussion contains forward-looking statements that involve risks, uncertainties and assumptions that could cause results to differ materially from management’s expectations. Factors that could cause or contribute to such differences are discussed in the section titled “Cautionary Statement” and Part I, Item 1A. Risk Factors. We assume no obligation to update any of these forward-looking statements. All subsequent written or oral forward-looking statements attributable to us or persons acting on Enfusion’s behalf are qualified in their entirety by this paragraph.

Overview

Enfusion is a global, high-growth, software-as-a-service provider focused on transforming the investment management industry. Our solution is designed to eliminate technology and information barriers, empowering investment managers to confidently make and execute better-informed investment decisions in real time. We simplify investment and operational workflows by unifying mission critical systems and coalescing data into a single dataset resulting in a single source of truth. This allows stakeholders throughout the entire client organization to interact more effectively with one another across the investment management lifecycle.

We believe, by means of our purposefully designed interconnected systems underpinned by one dataset, we are the only solution that allows clients to see and interact with all parts of the investment management lifecycle ranging from portfolio construction, trading, risk management, accounting and operations through to investor reporting seamlessly in real time, in one screen, in one solution. As a result, our solution enables clients to better align teams, optimizing their investment decision-making operations and technology footprint, and lowering operating costs. By harnessing the efficiencies, agility, and scale inherent to our cloud-native, multi-tenant software that is integrated with a suite of technology-powered, managed services, we believe we have created the industry’s most compelling investment management solution, capable of shaping and addressing the evolving demands of the global investment management landscape.

Our Business Model

By virtue of our flexible and open architecture solution, we offer clients the ability to either replace their investment management systems using the end-to-end Enfusion solution integrated with technology-powered managed services or integrate into their existing ecosystem with an option to expand their utilization of Enfusion over time.

Additionally, our solution’s nimble, single-codebase architecture allows us to dedicate resources to our clients holistically, driving a superior client experience that is critical to our business model. All clients leverage the most current version of the Enfusion application at all times, which ensures that our development teams maintain focus on delivering new features and capabilities rather than managing compatibility across multiple platform versions. From the moment client onboarding commences, Enfusion prioritizes the customer experience. Dedicated account managers work hand-in-hand with clients through the duration of the relationship to ensure a personalized experience while product specialists regularly engage to facilitate optimal utilization of the Enfusion platform. It also fosters a partnership built on ongoing communication and feedback, which continuously informs the weekly upgrades and functional enhancements that we deliver to each of our clients. As we continue to scale and add clients, we benefit from an evolving solution that mirrors

45

the needs and demands of our clients and the market, leading to a compelling competitive advantage and in turn increased client retention and revenues from expanded and new business.

Our total revenues were approximately 99.3%, 98.9%, and 98.8% recurring subscription-based during the years ended December 31, 2023, 2022, and 2021, respectively. Generally, we charge our clients fees for various components such as user fees, connectivity fees, market data fees, and managed services fees, all of which take into account client complexity and that is subject to contract minimums. The weekly enhancements and upgrades that we deliver and the dedicated client service are included in the price of the contract.

To support our growth and capitalize on our market opportunity, we continue to invest across all aspects of our business. In technology and development, we are focused on developing additional system functionality that will open revenue opportunities across alternative and traditional investment managers. We have also further institutionalized and increased spend in our sales and marketing efforts, both in the United States and internationally.

We operate as a single operating and reportable segment, which reflects the way our chief operating decision maker reviews and assesses the performance of our business. Our total revenues were $174.5 million, $150.3 million, and $111.7 million for the years ended December 31, 2023, 2022, and 2021, respectively. Recurring subscription-based revenues from platform subscriptions and managed services were $173.3 million for the year ended December 31, 2023, or approximately 99.3% of total revenues, up approximately 16.5% from $148.7 million for the year ended December 31, 2022, or approximately 98.9% of total revenues, up approximately 34.7% from $110.4 million for the year ended December 31, 2021, or approximately 98.8% of total revenues. We had net income (loss) of $9.3 million, $(13.3) million, and $(282.2) million in the years ended December 31, 2023, 2022, and 2021, respectively.

Key Factors Affecting Our Operating Results

Breadth of Our Client Bases

Our future revenue growth depends, in part, on our ability to expand our reach to new clients. There are significant opportunities to expand our client base across the various client segments we serve today. We believe we are the leading cloud-native, SaaS provider to the global emerging fund and hedge fund sector and expect that as the alternative investment sector grows, we will continue to extend our position. We expect that our efforts in signing new clients in this sector benefit from referrals from our existing clients, client stakeholders when they transit to other or launch new organizations, industry channel partners and strategic partners. In addition, we continue to extend this growth through increasing adoption by larger institutional asset management clients due to increasing acceptance of cloud technology and the robust capabilities of our solution that better meet their evolving needs and address their existing pain points. Taking advantage of the unique position that allows us to sell our products and services through shorter sales cycles and on faster client implementation timelines, we expect to continue to expand and invest our sales efforts to capitalize on opportunities in this client segment.

Expansion of Usage with Existing Clients

We believe there is a significant opportunity to further expand our relationships with existing clients as they continue to evolve and grow in size and expand into new markets and strategies or as we provide new functionality or release new systems or services. We also believe we have a significant opportunity to expand our relationship with existing clients that were not in a position to replace all of their systems at once when they first engaged with us. For those clients that elect to initially utilize some portion of our solution or only use our solution for a particular strategy or fund, we find that once they experience the advantages of our end-to-end solution, many seek opportunities to expand the breadth of their relationship with us to further help improve their investment management workflows and technology infrastructure. We expect our revenues from existing clients to continue to increase as they broaden their use of our solution and expand utilization into other investment groups within the firm.

46

Existing Client Retention and Renewals

The growth of our revenues base from expanding relationships with our existing clients is driven by our ability to retain these clients. Our client retention also strengthens the stability and predictability of our revenue model, facilitating better management of business. Our Net Dollar Retention Rate, which is described below in the section titled “Key Metrics and Financial Measures” was 106.4%, 115.4% and 115.0% for the years ended December 31, 2023, 2022, and 2021, respectively. We believe that our delivery of excellent ongoing innovation together with superior client experience is critical to our client retention and we expect to continue to invest in both areas.

Geographic Expansion

Our future growth depends, in part, on our ability to grow our client base through geographic expansion and build on the success internationally. For the year ended December 31, 2023, we generated approximately 62.1% of our total revenues from clients in the Americas and approximately 37.9% of our total revenues from clients outside of the Americas. For the year ended December 31, 2022, we generated approximately 63.3% of our total revenues from clients in the Americas and approximately 36.7% of our total revenues from clients outside of the Americas. For the year ended December 31, 2021, we generated approximately 65.3% of our total revenues from clients in the Americas and approximately 34.7% of our total revenues from clients outside of the Americas. We are globally situated in nine offices in Chicago, New York City, London, Dublin, Hong Kong, Singapore, Mumbai, Bengaluru, and Sydney. We continue to invest in expanding our presence and capitalize on opportunities in markets such as Europe, the Middle East and Asia Pacific. We continue to make investments in our sales and marketing efforts in regions outside of the Americas to capture sizable revenue opportunities.

Leading in Ongoing Innovation & Pursuing Growth Investments

We continuously evaluate opportunities to advance our solution through increased breadth and depth of functionality to better enable our clients to achieve their investment goals and solve for a broader array of business, operational and technology challenges. Our ability to lead and compete with a differentiated solution is dependent upon our pace of innovation. We remain committed to investing in ongoing innovation which may require increased spend in technology and development.

Costs of Being a Public Company

As a recently public company, we will continue to refine and implement procedures and processes to address the standards and requirements applicable to public companies. Specifically, accounting, legal, investor relations, insurance and personnel-related expenses will continue to increase as we establish more comprehensive compliance and governance functions, establish internal controls over financial reporting in accordance with the Sarbanes-Oxley Act and prepare and distribute periodic reports in accordance with SEC rules. Our financial statements reflect the impact of these expenses.

Effects of the Reorganization Transactions on our Corporate Structure

We were incorporated as Enfusion, Inc. on June 11, 2021 and formed for the purpose of the IPO. Following the completion of the Reorganization Transactions, we became a holding company, and our sole material asset is an indirect ownership interest in Enfusion Ltd. LLC. Through our ability to control the managing members of Enfusion Ltd. LLC, we control all of the business and affairs of Enfusion Ltd. LLC. All of our business is conducted through Enfusion Ltd. LLC and its subsidiaries, and the financial results of Enfusion Ltd. LLC are included in the consolidated financial statements of Enfusion, Inc.

Enfusion Ltd. LLC has been treated as a pass-through entity for U.S. federal and state income tax purposes and accordingly has not been subject to U.S. federal or state income tax. Enfusion Ltd. LLC will continue to be treated as a pass-through entity for U.S. federal and state income tax purposes. As a result of our ownership of Common Units in Enfusion Ltd. LLC, we are subject to U.S., federal, state, and local income taxes with respect to our allocable share of any taxable income of Enfusion Ltd. LLC and will be taxed at the prevailing corporate tax rates. In addition to tax expenses, we also will incur expenses related to our operations and we will be required to make payments under the Tax Receivable

47

Agreement. Due to the uncertainty of various factors, we cannot estimate the likely tax benefits we will realize as a result of Common Unit exchanges and the resulting amounts we are likely to pay out to Common Unitholders pursuant to the Tax Receivable Agreement; however, we estimate that such payments may be substantial. We intend to cause Enfusion Ltd. LLC to make distributions in an amount sufficient to allow us to pay our tax obligations and operating expenses, including distributions to fund any ordinary course payments due under the Tax Receivable Agreement.

Components of Our Results of Operations

Revenues

Platform subscriptions revenues

Platform subscriptions revenues consist primarily of user fees to provide our clients access to our cloud-based solution. Fees consider various components such as number of users, connectivity, trading volume, data usage and product coverage. Platform subscriptions clients do not have the right to take possession of the platform’s software and do not have any general return right. Platform subscriptions revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date the client gains access to the platform. Installment payments are generally invoiced at the end of each calendar month during the subscription term. There is no financing available.

Managed services

Managed services revenues primarily consist of client-selected middle- and back-office, technology-powered services. Managed services revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the contract effective date. Clients are invoiced a set fee for managed services typically at the end of each month. Generally, invoices have a 30-day payment period in accordance with the associated contract. There is no financing available.

Other

Other revenues consist of non-subscription-based revenue, primarily including data conversion. We recognize revenues as these services are performed with invoicing generally occurring at the end of each month.

Cost of Revenues

Cost of revenues consists primarily of personnel-related costs associated with the delivery of our software and services, including base salaries, bonuses, employee benefits, and related costs. Additionally, cost of revenues includes amortization of capitalized software development costs, allocated overhead and certain direct data and hosting costs, and stock-based compensation expense. Our cost of revenues has fixed and variable components and depends on the type of revenues earned in each period. We expect our cost of revenues to increase in absolute dollars as we continue to hire personnel to provide onboarding and account management services to our growing client base. We anticipate additional expenses as a result of stock-based compensation expenses related to equity awards to be issued under our equity plans.

Operating Expenses

We present stock-based compensation expense within Cost of revenues, General and administrative, Sales and marketing, and Technology and development based on the individual employee’s department. We anticipate additional operating expenses as a result of stock-based compensation expenses related to equity awards to be issued under our equity plans.

General and administrative

General and administrative expenses primarily consist of personnel costs and related expenses for executive, finance, legal, human resources, and recruiting and administrative personnel. These personnel costs and related expenses include salaries, benefits and bonuses, fees for external legal and other consulting services, and stock-based compensation

48

expense. General and administrative expenses also include expenses for our information technology systems. We expect certain expenses to increase as we continue to operate as a publicly traded company and expand our client base and geographic footprint.

Sales and marketing

Sales and marketing expenses consist primarily of personnel and related costs associated with our sales and marketing staff, including base salaries, employee benefits, bonuses and commissions, and stock-based compensation expense.

Technology and development

Technology and development expenses consist primarily of employee-related expenses related to our software development, including the development of non-enhancing features, maintenance, quality assurance, and ongoing refinement of our existing solutions. In addition, it includes expenses related to the exploration of new technologies and costs associated with preliminary project stage activities, training, maintenance, and all other post-implementation stage activities which are expensed as incurred.

Non-Controlling Interests

Non-controlling interests represent the portion of profit or loss, net assets, and comprehensive income (loss) of Enfusion Ltd. LLC that is not allocable to the Company based on our percentage of ownership of this entity. Income or loss attributed to the non-controlling interests is based on the Common Units outstanding during the period and is presented on the consolidated statements of operations and consolidated statements of comprehensive income (loss).

Key Metrics and Financial Measures

In connection with the management of our business, we identify, measure, and assess a variety of key metrics and use certain financial measures. The key metrics and financial measures we use in managing our business are set forth below.

Annual Recurring Revenue

We calculate Annual Recurring Revenue (“ARR”) by annualizing platform subscriptions and managed services revenues recognized in the last month of the measurement period. We believe ARR provides important information about our future revenue potential, our ability to acquire new clients and our ability to maintain and expand our relationship with existing clients. ARR was $185.1 million, $164.7 million, and $127.1 million as of December 31, 2023, 2022, and 2021, respectively. ARR is included in a set of metrics we calculate monthly to review with management as well as periodically with our board of directors.

Net Dollar Retention Rate

We calculate Net Dollar Retention Rate as of a period end by starting with the ARR for all clients as of twelve months prior to such period end or Prior Period ARR. We then calculate the ARR from those same clients as of the current period end (“Current Period ARR”). Current Period ARR includes expansion within existing clients inclusive of contraction and voluntary attrition, but excluding involuntary cancellations. We define involuntary cancellations as accounts that were canceled due to the client no longer being in business. We identify involuntary cancellations based on representations made by the client at the time of cancellation. Our Net Dollar Retention Rate is equal to the Current Period ARR divided by the Prior Period ARR.

Our Net Dollar Retention Rate was 106.4%, 115.4%, and 115.0% as of December 31, 2023, 2022, and 2021, respectively. We believe Net Dollar Retention Rate is an important metric because, in addition to providing a measure of retention, it indicates our ability to grow revenues within existing client accounts. The decrease in NDR in the current year

49

is primarily driven by lower upsells and higher downgrades from our existing client base (i.e. challenges in our back book), and the increased churn in the first half of 2023.

Revenue Churn Rate and Adjusted Revenue Churn Rate

We calculate our Revenue Churn Rate by measuring the revenue contribution associated with clients that cancel all of their product and service agreements with us over the measurement year. This canceled revenue contribution for each such client is calculated as the revenues recognized for such clients over the trailing 12 months prior to the month in which the client canceled its product and service agreements. We then divide this canceled revenue contribution by the ARR calculated for the prior period to calculate our Revenue Churn Rate. Our Revenue Churn Rate for the years ended December 31, 2023, 2022, and 2021 was 7.5%, 4.5%, and 3.7%, respectively.

We also calculate an Adjusted Revenue Churn Rate which excludes all involuntary cancellations as described above. Our Adjusted Revenue Churn Rate for the years ended December 31, 2023, 2022, and 2021 was 3.4%, 1.0%, and 0.6%, respectively. The increase in churn rate was particularly steep in the first half of 2023 and primarily related to macroeconomic factors, including high market volatility. These trends stabilized in the second half of 2023. We believe our Revenue Churn Rate and Adjusted Revenue Churn Rate are important metrics because they indicate our ability to retain our existing client base.

50

Results of Operations

The results of operations presented below should be reviewed in conjunction with the consolidated financial statements and notes included elsewhere in this Annual Report on Form 10-K. The following table sets forth our consolidated results of operations for the periods shown:

    

Year Ended December 31, 

(in thousands)

    

2023

    

2022

REVENUES:

 

  

 

  

Platform subscriptions

$

161,519

$

138,868

Managed services

 

11,773

 

9,821

Other

 

1,243

 

1,660

Total revenues

174,535

 

150,349

COST OF REVENUES:

 

  

 

  

Platform subscriptions

 

50,702

 

40,017

Managed services

 

6,514

 

6,692

Other

 

425

 

391

Total cost of revenues

 

57,641

 

47,100

Gross profit

 

116,894

 

103,249

OPERATING EXPENSES:

 

  

 

  

General and administrative

 

64,635

 

68,764

Sales and marketing

 

20,418

 

29,286

Technology and development

 

19,893

 

17,163

Total operating expenses

 

104,946

 

115,213

Income (loss) from operations

 

11,948

 

(11,964)

NON-OPERATING INCOME (EXPENSE):

 

  

 

  

Payment to related party

(1,501)

Interest income, net

 

1,641

 

413

Other expense, net

(604)

(638)

Total non-operating income (expense)

 

(464)

 

(225)

Income (loss) before income taxes

 

11,484

 

(12,189)

Income taxes

 

2,231

 

1,074

Net income (loss)

9,253

(13,263)

Net income (loss) attributable to non-controlling interests

3,228

(5,609)

Net income (loss) attributable to Enfusion, Inc.

$

6,025

$

(7,654)

Revenues

Year Ended December 31, 

 

Increase (Decrease)

 

(in thousands)

    

2023

    

2022

    

Amount

    

Percent

 

Platform subscriptions

$

161,519

$

138,868

$

22,651

 

16.3

%

Managed services

 

11,773

 

9,821

 

1,952

 

19.9

%

Other

 

1,243

 

1,660

 

(417)

 

(25.1)

%

Total revenues

$

174,535

$

150,349

$

24,186

 

16.1

%

Total revenue was $174.5 million for the year ended December 31, 2023, compared to $150.3 million for the year ended December 31, 2022, representing an increase of $24.2 million, or 16.1%.

51

Platform subscriptions

Platform subscriptions revenues increased by $22.7 million, or 16.3%, from $138.9 million for the year ended December 31, 2022 to $161.5 million for the year ended December 31, 2023. The increase was primarily comprised of $16.1 million related to upsell and increased users within existing contracts and $14.3 million reflecting the full-period impact of contracts signed in prior periods. In addition, new client revenue increased by $6.5 million. Increases and upsells were offset by client churn of $9.9 million and downgrades of $4.3 million. Price changes did not materially impact period-over-period growth.

Managed services

Managed services revenues increased by $2.0 million, or 19.9%, from $9.8 million for the year ended December 31, 2022 to $11.8 million for the year ended December 31, 2023. The increase was driven by $1.4 million in new client revenue, including the full impact of contracts signed in prior periods, $1.8 million related to upsells to existing clients, and $0.2 million of favorability in credit memo reserves. This increase was offset by churn and downgrades of $1.4 million.

Other

Other revenues, primarily consisting of data conversion services, decreased by $0.4 million over the comparative period. The decrease was due primarily to a lower volume of data conversion services in the current period.

Cost of Revenues, Gross Profit and Gross Profit Margin

Year Ended December 31, 

 

Increase (Decrease)

 

(in thousands)

    

2023

    

2022

    

Amount

    

Percent

 

Cost of revenues:

 

  

 

  

 

 

  

Platform subscriptions

$

50,702

$

40,017

$

10,685

 

26.7

%

Managed services

 

6,514

 

6,692

 

(178)

 

(2.7)

%

Other

 

425

 

391

 

34

 

8.7

%

Total cost of revenues

$

57,641

$

47,100

$

10,541

 

22.4

%

Gross profit

$

116,894

$

103,249

$

13,645

 

13.2

%

Gross profit margin

 

67.0

%

 

68.7

%

 

  

 

  

Cost of Revenues

Cost of revenues increased by $10.5 million, or 22.4%, from $47.1 million for the year ended December 31, 2022 to $57.6 million for the year ended December 31, 2023. The increase was driven by $3.7 million additional market data expenses primarily attributed to a larger client base, increased usage, and increased provider rates. In addition, payroll and payroll-related expenses increased by $3.7 million from headcount additions to support our continued growth, annual employee salary increases, and increased costs of benefits. Furthermore, hosting costs increased by $1.5 million due to the expansion of our data centers, amortization of capitalized software development costs increased by $1.2 million, and depreciation expense increased by $0.4 million.

Gross profit increased by $13.6 million, from $103.2 million for the year ended December 31, 2022 to $116.9 million for the year ended December 31, 2023. Gross profit margin decreased by 1.7% primarily attributable to increased market data and hosting costs. Gross profit margin also decreased due to an increase in personnel costs from increased staffing levels across onboarding and account management, increased annual salaries, and increased cost of employee benefits.

52

Operating Expenses

Year Ended December 31, 

 

Increase (Decrease)

 

(in thousands)

    

2023

    

2022

    

Amount

    

Percent

 

General and administrative

$

64,635

$

68,764

$

(4,129)

 

(6.0)

%

Sales and marketing

 

20,418

 

29,286

 

(8,868)

 

(30.3)

%

Technology and development

 

19,893

 

17,163

 

2,730

 

15.9

%

Total operating expenses

$

104,946

$

115,213

$

(10,267)

 

(8.9)

%

General and administrative

General and administrative expenses decreased by $4.1 million, from $68.8 million for the year ended December 31, 2022 to $64.6 million for the year ended December 31, 2023. The decrease was primarily attributable to a $8.5 million decrease in stock-based compensation expense related to executive departures in the first quarter of 2023, partially offset by the impact of new grants. Additionally, professional services fees decreased by $2.2 million reflecting the growth of our in-house capabilities and insurance costs decreased by $0.7 million due to a softening of insurance market pricing favoring consumers. The decrease was partially offset by $3.8 million of additional payroll and payroll-related expenses, $1.4 million of additional depreciation expense, $0.9 million of additional U.S. state and local taxes including franchise tax in multiple jurisdictions, $0.7 million of incremental information technology systems costs to support organizational growth and increased headcount (e.g., additional licenses), and $0.5 million in additional occupancy costs.

Sales and marketing

Sales and marketing expenses decreased by $8.9 million, from $29.3 million for the year ended December 31, 2022 to $20.4 million for the year ended December 31, 2023. The decrease was primarily attributable to a $6.9 million decrease in stock-based compensation expense related to executive departures in the first quarter of 2023, partially offset by the impact of new grants. Payroll and payroll-related expenses decreased by $2.0 million attributable to lower headcount and cost-reduction measures, and travel expenses decreased by $1.2 million. The decrease was partially offset by a $1.2 million increase in commission expenses.

Technology and development

Technology and development expenses increased by $2.7 million, from $17.2 million for the year ended December 31, 2022 to $19.9 million for the year ended December 31, 2023. The increase was primarily attributable to a $3.5 million increase in payroll and payroll-related expenses attributable to increased headcount. Furthermore, there was a $0.9 million increase resulting from the write-off of capitalized labor and licenses related to a technology project which was abandoned in the fourth quarter of 2023. The increase was partially offset by a $1.7 million decrease in stock-based compensation expense related to the 2022 vesting of the Award Units associated with the IPO.

Non-Operating Income (Expense)

Non-operating expenses increased from $0.2 million during the year ended December 31, 2022 to $0.5 million for the year ended December 31, 2023. The increase was attributable to the related-party payment to FTV Fund IV of $1.5 million in the second quarter of 2023 (see Note 14, Related Party Transactions, to our consolidated financial statements, included elsewhere in this Annual Report on Form 10-K) partially offset by the $1.2 million increase in net interest income earned on cash invested in the money market account established in the third quarter of 2022 (see Note 3, Summary of Significant Accounting Policies, to our consolidated financial statements, included elsewhere in this Annual Report on Form 10-K).

Liquidity and Capital Resources

To date, we have funded our capital needs through collections from our clients, the use of debt instruments, and private and public issuances of equity. As of December 31, 2023, we had cash and cash equivalents of $35.6 million and

53

$100.0 million in available borrowing capacity under our New Credit Agreement. We believe that our current sources of liquidity, available borrowings under the New Credit Agreement cash flows from operations, and existing available cash, together with our other available external financing sources, will be adequate to fund our operating and capital needs for at least the next 12 months.

We previously had a “Deferred Share Issuance Obligation” that consisted of obligations to issue shares of Class A common stock to (i) holders of Award Units that were vested at the time of our IPO (or would have vested within one year thereof), and (ii) a non-executive employee. During the year ended December 31, 2023, we satisfied the remaining 17.2 million Deferred Share Issuance Obligation in full. We satisfied the related tax withholding obligations by utilizing $17.3 million of net proceeds from two private placements of common stock, $3.7 million of proceeds from “sell to cover” arrangements, and by using $39.4 million of cash on hand.

Our future capital requirements will depend on many factors, including those set forth under Part 1, Item 1A. Risk Factors. We expect that our future uses of cash will also include paying income taxes and obligations under our Tax Receivable Agreement.

We may in the future enter into arrangements to acquire or invest in complementary businesses or services, which could decrease our cash and cash equivalents and increase our cash requirements. As a result of these and other factors, we could use our available capital resources sooner than expected and may be required to seek additional equity or debt financing.

Cash Flow Information

The following table presents a summary of our consolidated cash flows from operating, investing, and financing activities for the periods indicated.

Year Ended December 31,

Increase (Decrease)

(in thousands)

    

2023

    

2022

    

Amount

Percent

Net cash provided by operating activities

 

$

25,634

$

14,156

$

11,478

81.1

%

Net cash used in investing activities

 

(9,671)

 

(7,931)

 

(1,740)

21.9

%

Net cash used in financing activities

 

(43,083)

 

(7,959)

 

(35,124)

441.3

%

Effect of exchange rate changes on cash and cash equivalents

 

179

 

(86)

 

265

nm

%

Net decrease in cash and cash equivalents

$

(26,941)

$

(1,820)

$

(25,121)

1,380.3

%

nm - not meaningful

Operating activities

We generated $25.6 million in cash flows from operating activities during the year ended December 31, 2023, resulting from our net income of $9.3 million, adjusted by non-cash items of $25.8 million, and offset by $9.5 million of cash used in working capital activities. Cash used in working capital activities decreased from the comparative period primarily reflecting stronger collections and improved cash flow management. Cash flows from operating activities also includes $1.5 million of cash outflow related to the payment to FTV Fund IV in the second quarter of 2023.

We generated $14.2 million in cash flows from operating activities during the year ended December 31, 2022, resulting from our net loss of $13.3 million, adjusted by non-cash items of $38.2 million, and offset by $10.7 million of cash used in working capital activities.

Investing activities

Net cash used in investing activities for the years ended December 31, 2023 and 2022 was $9.7 million and $7.9 million. For the year ended December 31, 2023, cash outflows included $5.2 million of capitalized software development

54

costs and $4.5 million of property and equipment purchases. For the year ended December 31, 2022, cash outflows included $3.9 million of capitalized software development costs and $4.0 million of property and equipment purchases.

Financing activities

We used $43.1 million in cash flows from financing activities during the year ended December 31, 2023, primarily including $60.4 million in payment of withholding taxes on stock-based compensation and $1.2 million in payments of debt issuance costs associated with the New Credit Agreement. This was partially offset by $17.3 million in net stock issuance proceeds and a $1.5 million refund from the Internal Revenue Service in the second quarter of 2023.

We used $8.0 million in cash flows from financing activities during the year ended December 31, 2022, resulting from payment of withholding taxes on stock-based compensation.

Indebtedness

On September 15, 2023, we entered into the New Credit Agreement with Bank of America and a syndicate of lending institutions. The New Credit Agreement provides for a senior secured revolving loan facility in an aggregate principal amount of up to $100.0 million, including a $10.0 million sublimit for the issuance of letters of credit and a swingline subfacility of up to $10.0 million. The New Credit Agreement also includes an uncommitted accordion feature that allows for up to $50.0 million of additional borrowing capacity, subject to obtaining lender commitments and the satisfaction of certain customary conditions. As of December 31, 2023, we were in compliance with all loan covenants and requirements and had no outstanding borrowings under the New Credit Agreement.

Concurrent with entering into the New Credit Agreement on September 15, 2023, the Company terminated its $5.0 million Prior Credit Agreement with Silicon Valley Bank, which by its terms was scheduled to mature on December 17, 2025. At the time of termination, there were no borrowings outstanding under the Prior Credit Agreement.

Refer to Note 7, Debt, to our consolidated financial statements, included elsewhere in this Annual Report on Form 10-K for more information on the New Credit Agreement.

Contractual Obligations and Commitments and Off-Balance Sheet Arrangements

As of December 31, 2023, we have operating lease agreements and have service agreements for the use of data processing facilities, which are also leases under ASC 842, Leases. Refer to Note 6, Leases, to our consolidated financial statements, included elsewhere in this Annual Report on Form 10-K.

As of December 31, 2023, we did not have any material off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that may be material to investors.

Dividend policy

Assuming Enfusion Ltd. LLC makes distributions to its members in any given year, the determination to pay dividends, if any, to our Class A common stockholders out of the portion, if any, of such distributions remaining after our payment of taxes, Tax Receivable Agreement payments, and expenses will be made at the sole discretion of our board of directors. We currently intend to retain all available funds and future earnings and do not anticipate declaring or paying any cash dividends in the foreseeable future. Our board of directors may change our dividend policy at any time.

Tax Receivable Agreement

The payment obligation under the Tax Receivable Agreement is an obligation of Enfusion, Inc. and not of Enfusion Ltd. LLC. We expect that as a result of the size of the existing tax basis and basis adjustments acquired in the IPO, the increase in existing tax basis and the anticipated tax basis adjustment of the tangible and intangible assets of Enfusion Ltd. LLC upon the purchase or exchange (or deemed exchange) of Common Units for shares of Class A common

55

stock or distributions (or deemed distributions) with respect to Common Units and our possible utilization of certain tax attributes, the payments that we may make under the Tax Receivable Agreement will be substantial. As of December 31, 2023, we estimate the total TRA attributes to be approximately $323.6 million. If all of the Pre-IPO Common Unitholders had exchanged or sold to us all of their outstanding Common Units as of December 31, 2023, we would have recognized a deferred tax asset of approximately $148.5 million and a liability under the Tax Receivable Agreement of approximately $126.2 million, assuming: (i) all exchanges or purchases occurred on the same day, (ii) a price of $9.70 per share, which was the price per share of Class A common stock as of December 31, 2023, (iii) a constant corporate tax rate of 29.7%, (iv) that we would have sufficient taxable income to utilize the tax benefits fully, and (v) no material changes in tax law.

There may be a material negative effect on our liquidity if, as a result of timing discrepancies or otherwise, the payments under the Tax Receivable Agreement exceed the actual cash tax benefits that Enfusion, Inc. realizes in respect of the tax attributes subject to the Tax Receivable Agreement and/or if distributions directly and/or indirectly to Enfusion, Inc. by Enfusion Ltd. LLC are not sufficient to permit Enfusion, Inc. to make payments under the Tax Receivable Agreement after it has paid taxes and other expenses. Late payments under the Tax Receivable Agreement generally will accrue interest at an uncapped rate equal to one-year LIBOR (or its successor rate) plus 100 basis points. The payments under the Tax Receivable Agreement are not conditioned upon continued ownership of us by the Pre-IPO owners.

Critical Accounting Policies and Estimates

Our consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the amounts of assets and liabilities at the date of the consolidated financial statement and amounts of revenues and expenses reported during the period. We evaluate our estimates and assumptions on an ongoing basis. Our estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances.

For a description of our significant accounting policies, see Note 3, Summary of Significant Accounting Policies, in the accompanying notes to the consolidated financial statements included in Part II, Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.

Critical Accounting Policies

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. The Company derives its revenues primarily from fees for platform subscriptions and managed services provided to clients. Revenues are recognized when control of these services are transferred to the Company’s clients in an amount that reflects the consideration the Company expects to be entitled to in exchange for these services. Revenues are recognized net of taxes that will be remitted to governmental agencies applicable to service contracts. Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework:

● Identification of the contract, or contracts, with a client;

● Identification of the performance obligation in the contract;

● Determination of transaction price;

● Allocation of the transaction price to the performance obligations in the contract; and

● Recognition of revenue when, or as, performance obligations are satisfied.

56

Platform subscriptions revenues

Platform subscriptions revenues consist primarily of user fees to provide our clients access to our cloud-based solution. Fees consider various components such as number of users, connectivity, trading volume, data usage and product coverage. Platform subscriptions clients do not have the right to take possession of the platform’s software and do not have any general return right. Platform subscriptions revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date the client gains access to the platform. Installed payments are generally invoiced at the end of each calendar month during the subscription term. There is no financing available.

Managed services revenues

Managed services revenues primarily consist of client-selected middle- and back-office, technology-powered services. Managed services revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the contract effective date. Clients are invoiced a set fee for managed services typically at the end of each month. Generally, invoices have a 30-day payment period in accordance with the associated contract. There is no financing available.

Other revenues

Other revenues consist of non-subscription-based revenues primarily data conversion. The Company recognizes revenues as these services are performed with invoicing generally occurring at the end of each month.

Service contracts with multiple performance obligations

Certain of the Company’s contracts provide for customers to be charged a fee for implementation services. In determining whether the implementation services, which frequently include configuration and/or interfacing, customer reporting, customizing user permissions and acceptance testing, end-user training, and establishing connections with third-party interfaces, are distinct from its platform subscription services, the Company considers, in addition to their complexity and level of customization, that these services are integral in delivering the customer desired output and are necessary for the customer to access and begin to use the hosted application. The implementation provider must be intimately familiar with its platform to effectively execute the customization required, and no other entities have access to the source code. The Company has concluded that the implementation services in its service contracts with multiple performance obligations are not distinct, and therefore, the Company recognizes fees for implementation services ratably over the non-cancelable term of the contract.

Critical Accounting Estimates

Tax Receivable Agreement

In connection with the Reorganization Transactions and the IPO, we entered into the Tax Receivable Agreement with certain of our Pre-IPO Owners that provides for the payment by Enfusion, Inc. to such Pre-IPO Owners of 85% of the benefits, if any, that Enfusion, Inc. actually realizes, or is deemed to realize (calculated using certain assumptions), as a result of: (i) existing tax basis acquired in the IPO; (ii) increases in existing tax basis and adjustments to the tax basis of the tangible and intangible assets of Enfusion Ltd. LLC as a result of sales or exchanges (or deemed exchanges) of Common Units for shares of Class A common stock or distributions (or deemed distributions) with respect to Common Units; (iii) Enfusion, Inc.’s utilization of certain tax attributes of the Blocker Companies; and (iv) certain other tax benefits related to entering into the Tax Receivable Agreement, including tax benefits attributable to payments under the Tax Receivable Agreement. The existing tax basis, increases in existing tax basis and the tax basis adjustments generated over time may increase (for tax purposes) the depreciation and amortization deductions available to Enfusion, Inc. and, therefore, may reduce the amount of U.S. federal, state and local tax that Enfusion, Inc. would otherwise be required to pay in the future, although the IRS may challenge all or part of the validity of that tax basis, and a court could sustain such a challenge.

57

The Company accounts for amounts payable under the Tax Receivable Agreement in accordance with ASC 450, Contingencies. The amounts payable under the Tax Receivable Agreement will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future. The actual tax benefits realized by the Company may differ from tax benefits calculated under the Tax Receivable Agreement as a result of the use of certain assumptions in the agreement. Any such changes in these factors or changes in the Company’s determination of the need for a valuation allowance related to the tax benefits acquired under the Tax Receivable Agreement could adjust the Tax Receivable Agreement liabilities recognized on the consolidated balance sheets. Subsequent changes in the fair value of the Tax Receivable Agreement liabilities between reporting periods, as well as any interest accrued on the Tax Receivable Agreement between annual tax filing date and the Tax Receivable Agreement payment date, are recognized in the consolidated statements of operations.

Recent Accounting Pronouncements

See Note 3, Summary of Significant Accounting Policies, in the accompanying notes to the consolidated financial statements included in Part II, Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.

Emerging Growth Company Status

We are an “emerging growth company,” as defined in the JOBS Act, and, for so long as we continue to be an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we: (i) are no longer an emerging growth company; or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in foreign currency exchange rates.

Foreign Currency Exchange Rate Risk

Our reporting currency is the U.S. dollar, and the functional currency of each of our subsidiaries is generally the local currency. Gains or losses due to transactions in foreign currencies are included in other expense in our consolidated statements of operations. We have not engaged in the hedging of foreign currency transactions to date, although we may choose to do so in the future. As of December 31, 2023 and December 31, 2022, we do not believe that a 10% increase or decrease in the relative value of the U.S. dollar to other currencies would have a material effect on operating results.

58

Item 8. Financial Statements and Supplementary Data

ENFUSION, INC.

Index to Consolidated Financial Statements

Page

Audited Consolidated Financial Statements of Enfusion, Inc.

Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)

F-2

Consolidated Balance Sheets as of December 31, 2023 and December 31, 2022

F-3

Consolidated Statements of Operations for the Years Ended December 31, 2023, 2022, and 2021

F-4

Consolidated Statements of Comprehensive Income (Loss) for the Years Ended December 31, 2023, 2022, and 2021

F-5

Consolidated Statements of Preferred Units, Stockholders’ Equity and Members’ Deficit for the Years Ended December 31, 2023, 2022, and 2021

F-6

Consolidated Statements of Cash Flows for the Years Ended December 31, 2023, 2022, and 2021

F-7

Notes to Consolidated Financial Statements

F-8

F-1

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Enfusion, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Enfusion, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income (loss), preferred units, stockholders’ equity and members’ deficit and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2020.

Chicago, Illinois

March 12, 2024

F-2

ENFUSION, INC.

CONSOLIDATED BALANCE SHEETS

(dollars and shares in thousands, except per share amounts)

December 31, 

2023

    

2022

ASSETS

  

 

  

Current assets:

  

 

  

Cash and cash equivalents

$

35,604

$

62,545

Accounts receivable, net

 

28,069

 

25,855

Prepaid expenses

 

5,009

 

6,105

Other current assets

1,170

2,303

Total current assets

 

69,852

 

96,808

Property, equipment, and software, net

 

18,314

 

15,759

Right-of-use-assets, net

14,304

6,732

Other assets

 

6,502

 

4,484

Total assets

$

108,972

$

123,783

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable

$

2,212

$

1,685

Accrued expenses and other current liabilities

13,841

11,665

Current portion of lease liabilities

 

4,256

 

4,030

Total current liabilities

 

20,309

 

17,380

Lease liabilities, net of current portion

11,181

2,959

Total liabilities

 

31,490

 

20,339

Commitment and contingencies (Note 8)

Stockholders’ Equity:

 

  

 

  

Preferred stock, $0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively

Class A common stock, $0.001 par value; 1,000,000 shares authorized, 88,332 and 70,860 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively

88

71

Class B common stock, $0.001 par value; 150,000 shares authorized, 39,199 and 43,199 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively

39

43

Additional paid-in capital

 

226,877

 

244,260

Accumulated deficit

(172,932)

(178,863)

Accumulated other comprehensive loss

 

(406)

 

(504)

Total stockholders’ equity attributable to Enfusion, Inc.

 

53,666

 

65,007

Non-controlling interests

23,816

38,437

Total stockholders’ equity

77,482

103,444

Total liabilities and stockholders’ equity

$

108,972

$

123,783

See Notes to Consolidated Financial Statements.

F-3

ENFUSION, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(dollars and shares in thousands, except per share amounts)

Year Ended December 31, 

2023

    

2022

2021

REVENUES:

  

 

  

  

Platform subscriptions

$

161,519

$

138,868

$

103,259

Managed services

 

11,773

 

9,821

 

7,119

Other

 

1,243

 

1,660

 

1,322

Total revenues

 

174,535

 

150,349

 

111,700

COST OF REVENUES:

 

  

 

  

 

  

Platform subscriptions

 

50,702

 

40,017

 

27,195

Managed services

 

6,514

 

6,692

 

4,425

Other

 

425

 

391

 

225

Total cost of revenues

 

57,641

 

47,100

 

31,845

Gross profit

 

116,894

 

103,249

 

79,855

OPERATING EXPENSES:

 

  

 

  

 

  

General and administrative

 

64,635

 

68,764

 

150,614

Sales and marketing

 

20,418

 

29,286

 

51,725

Technology and development

 

19,893

 

17,163

 

153,400

Total operating expenses

 

104,946

 

115,213

 

355,739

Income (loss) from operations

 

11,948

 

(11,964)

 

(275,884)

NON-OPERATING INCOME (EXPENSE):

 

  

 

  

 

  

Payment to related party

(1,501)

Interest income (expense), net

1,641

413

(4,594)

Other expense, net

 

(604)

 

(638)

 

(1,185)

Total non-operating income (expense)

 

(464)

 

(225)

 

(5,779)

Income (loss) before income taxes

 

11,484

 

(12,189)

 

(281,663)

Income taxes

 

2,231

 

1,074

 

579

Net income (loss)

9,253

(13,263)

(282,242)

Net income (loss) attributable to non-controlling interests

3,228

(5,609)

(123,925)

Net income (loss) attributable to Enfusion, Inc.

$

6,025

$

(7,654)

$

(158,317)

Net income (loss) per Class A common shares attributable to Enfusion, Inc.:

Basic

$

0.07

$

(0.10)

$

(2.26)

Diluted

$

0.07

$

(0.10)

$

(2.26)

Weighted Average number of Class A common shares outstanding:

Basic

88,202

85,393

83,045

Diluted

129,429

85,393

83,045

See Notes to Consolidated Financial Statements.

F-4

ENFUSION, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(dollars in thousands)

Year Ended December 31, 

2023

    

2022

    

2021

Net income (loss)

$

9,253

$

(13,263)

$

(282,242)

Other comprehensive income (loss), net of income tax:

 

  

 

  

 

  

Foreign currency translation income (loss)

 

143

 

(327)

 

(90)

Total other comprehensive income (loss)

 

9,396

 

(13,590)

 

(282,332)

Comprehensive income (loss) attributable to non-controlling interests

3,273

(5,757)

(123,902)

Total comprehensive income (loss) attributable to Enfusion, Inc.

$

6,123

$

(7,833)

$

(158,430)

See Notes to Consolidated Financial Statements.

F-5

ENFUSION, INC.

Consolidated Statements of Preferred Units, Stockholders’ Equity and Members’ Deficit

(dollars and shares in thousands)

    

  

Accumulated

Class A

Class B

Additional

Other

Non-

Total

Preferred Units

Members' Deficit

Preferred Stock

Common Stock

Common Stock

Paid-in

Accumulated

Comprehensive

Controlling

Stockholders’

Units

Amount

Units

Amount

Shares

Amount

Shares

    

Amount

    

Shares

    

Amount

    

Capital

    

Deficit

    

Loss

    

Interest

    

Equity

January 1, 2021

54

$

165,515

48

$

(233,347)

$

 

$

$

$

$

$

(212)

$

$

(233,559)

Activity prior to the Reorganization Transactions:

Net income

6,814

6,078

 

 

 

6,078

Foreign currency translation

 

(145)

(145)

Distributions to members

(1,807)

(1,476)

 

(1,476)

54

$

170,522

48

$

(228,745)

$

 

$

$

$

$

$

(357)

$

$

(229,102)

Activity subsequent to the Reorganization Transactions:

Effect of the Reorganization Transactions

(54)

(170,522)

(48)

228,745

48,744

49

52,998

53

(27,941)

(30,384)

170,522

Issuance of Class A common stock in the IPO, net of issuance costs

16,839

17

143,628

116,065

259,710

Purchase of Pre-IPO common unit holders and retirement of Class B common shares

(5,527)

(6)

(50,956)

(36,884)

(87,846)

Net Loss

(171,209)

(123,925)

(295,134)

Stock-based compensation

161,986

117,250

279,236

Foreign currency translation

 

 

32

23

 

55

December 31, 2021

$

$

$

 

65,583

$

66

47,471

$

47

$

226,717

$

(171,209)

$

(325)

$

42,145

$

97,441

Net loss

 

(7,654)

 

(5,609)

 

(13,263)

Stock-based compensation

15,043

10,550

25,593

Share exchange

4,272

4

(4,272)

(4)

5,310

(5,310)

Issuance of IPO vested Class A common stock and share-based awards

1,594

2

(2)

Tax withholdings related to net share settlements of stock-based compensation awards

(589)

(1)

(4,767)

(3,191)

(7,959)

Foreign currency translation

 

(179)

(148)

 

(327)

Other

 

1,959

1,959

December 31, 2022

$

$

$

 

70,860

$

71

43,199

$

43

$

244,260

$

(178,863)

$

(504)

$

38,437

$

103,444

Net income

 

6,025

 

3,228

 

9,253

Stock-based compensation

5,628

2,596

8,224

Share exchange

4,000

4

(4,000)

(4)

2,559

(2,559)

Issuance of IPO vested Class A common stock and share-based awards

11,272

11

1,729

(1,740)

Issuance of Class A common stock, net of issuance costs

2,200

2

12,401

4,919

17,322

Cumulative impact of adopting ASU 2016-13

(94)

(55)

(149)

Tax withholdings related to net share settlements of stock-based compensation awards

(39,497)

(20,950)

(60,447)

Foreign currency translation

 

98

45

 

143

Other

 

(203)

(105)

(308)

December 31, 2023

$

$

$

 

88,332

$

88

39,199

$

39

$

226,877

$

(172,932)

$

(406)

$

23,816

$

77,482

See Notes to Consolidated Financial Statements.

F-6

ENFUSION, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(dollars in thousands)

Year Ended December 31, 

2023

    

2022

    

2021

Cash flows from operating activities:

  

 

  

 

  

Net income (loss)

$

9,253

$

(13,263)

$

(282,242)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

 

  

 

  

 

  

Non-cash lease expense

6,882

5,351

Depreciation and amortization

 

9,987

 

6,344

3,975

Provision for credit losses

 

1,319

 

1,399

1,450

Amortization of debt-related costs

 

92

 

26

222

Loss on extinguishment of debt

78

1,215

Stock-based compensation expense

7,458

24,993

289,803

Change in operating assets and liabilities:

 

 

Accounts receivable

 

(3,679)

 

(9,031)

(7,493)

Prepaid expenses and other assets

 

(1,749)

 

(1,767)

(6,477)

Accounts payable

 

365

 

(843)

2,044

Accrued compensation

(729)

7,087

(2,081)

Accrued expenses and other liabilities

2,359

(1,029)

(734)

Lease liabilities

(6,002)

(5,111)

Net cash provided by (used in) operating activities

 

25,634

 

14,156

 

(318)

Cash flows from investing activities:

 

  

 

  

 

  

Purchases of property and equipment

 

(4,453)

 

(3,985)

 

(6,096)

Capitalization of software development costs

(5,218)

(3,946)

(1,918)

Net cash used in investing activities

 

(9,671)

 

(7,931)

 

(8,014)

Cash flows from financing activities:

 

  

 

  

 

  

Payment of debt issuance costs

(1,151)

Settlement of tax receivable acquired in reorganization transactions

1,501

Issuance of Class A common stock, net of issuance costs

17,322

260,545

Payment of withholding taxes on stock-based compensation

(60,447)

(7,959)

(10,567)

Repayment of term loan

(100,000)

Payment of member distributions

(3,283)

Purchases of common units from Pre-IPO common unit holders

(87,846)

Other financing activities

(308)

Net cash (used in) provided by financing activities

 

(43,083)

 

(7,959)

 

58,849

Effect of exchange rate changes on cash and cash equivalents

 

179

 

(86)

 

(90)

Net (decrease) increase in cash and cash equivalents

 

(26,941)

 

(1,820)

 

50,427

Cash and cash equivalents, beginning of period

 

62,545

 

64,365

 

13,938

Cash and cash equivalents, end of period

$

35,604

$

62,545

$

64,365

Supplemental disclosure of cash flow information:

 

  

 

  

Income taxes paid in cash

$

1,843

$

1,582

$

407

Interest paid in cash

$

$

$

4,813

Supplemental disclosure of non-cash activities:

Right-of-use assets obtained in exchange for lease liabilities

$

13,893

$

9,514

$

Capitalized stock-based compensation expense

$

766

$

600

$

Accrued property, equipment, and software, net

$

608

$

$

Effect of the Reorganization Transactions

$

$

$

58,223

IPO costs included in accrued expenses and other liabilities

$

$

$

835

Other

$

$

1,959

$

See Notes to Consolidated Financial Statements.

F-7

ENFUSION, INC.

Notes to Consolidated Financial Statements

Note 1   Organization and Description of Business

Enfusion is a leading provider of cloud-based order and execution management, portfolio management and risk systems. Enfusion’s clients include large global hedge fund managers, institutional asset managers, family offices and other institutional investors. Enfusion provides its clients with innovative real-time performance, risk calculations, and accounting capabilities for some of the most sophisticated financial products. The Company is headquartered in Chicago, Illinois and has offices in New York City, London, Dublin, Hong Kong, Singapore, Mumbai, Bengaluru, and Sydney.

Enfusion, Inc. was incorporated in Delaware on June 11, 2021 for the purpose of facilitating an initial public offering, which was completed on October 25, 2021, and other related transactions in order to carry on the business of Enfusion Ltd. LLC. Enfusion, Inc. is a holding company and, through its control over the managing member of Enfusion Ltd. LLC, operates and controls Enfusion Ltd. LLC. Enfusion, Inc.’s principal asset consists of Common Units.

Enfusion, Inc. has three wholly-owned subsidiaries: Enfusion US 1, Inc., Enfusion US 2, Inc., and Enfusion US 3, Inc.; as well as a controlling financial interest in Enfusion Ltd. LLC and its majority-owned subsidiary, Enfusion Softech India Private Limited, as well as the wholly-owned subsidiaries of Enfusion Ltd. LLC: Enfusion Systems UK Ltd, Enfusion HK Limited, Enfusion Software Limited, Enfusion (Singapore) Pte. Ltd., Enfusion do Brasil Tecnologia da Informacão Ltd, Enfusion (Australia) Pty. Ltd., Enfusion (Shanghai) Co., and Enfusion Tech Ltd. Enfusion, Inc., through its control over the managing member of Enfusion Ltd. LLC, manages and operates Enfusion Ltd. LLC’s business and controls its strategic decisions and day-to-day operations. As such, Enfusion, Inc. consolidates the financial results of Enfusion Ltd. LLC, and a portion of Enfusion, Inc.’s net income (loss) is allocated to non-controlling interests to reflect the entitlement to a portion of Enfusion Ltd. LLC’s net income (loss) by the other common unitholders of Enfusion, Ltd. LLC. As of December 31, 2023, Enfusion, Inc. owned 69.3% of Enfusion Ltd. LLC.

Note 2   Basis of Presentation

Principles of Consolidation

These statements have been prepared in conformity with U.S. GAAP. All intercompany balances and transactions are eliminated in consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. We base our estimates on historical experience and various other assumptions believed to be reasonable. These estimates and assumptions include, but are not limited to, judgments affecting the measurement of the payable to related parties pursuant to the Tax Receivable Agreement, amortization periods, certain assumptions used in the valuation of stock-based compensation, assessment of the allowance for credit losses, and accounting for income taxes and assessment of valuation allowances. Actual results could differ from those estimates.

The Company’s results can also be affected by economic, political, legislative, regulatory, and legal actions, including but not limited to health epidemics and pandemics and the resulting economic impact. Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, and government fiscal policies can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities and carries various levels of insurance, the Company could be affected by civil, criminal, regulatory, or administrative actions, claims, or proceedings.

F-8

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

Reclassifications

Certain amounts in prior periods have been reclassified to conform with the current period presentation.

Segments

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the CODM. While the Company operates in multiple countries, the Company’s business operates as one operating segment because most of the Company’s service offerings are delivered and supported on a global basis, the Company’s service offerings are deployed in a nearly identical way, and the Company’s CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.

Note 3   Summary of Significant Accounting Policies

The significant accounting policies of the Company and its subsidiaries are summarized below.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an initial maturity date of three months or less to be cash equivalents. Funds held as investments in money market funds are included within cash and cash equivalents. As of December 31, 2023 and 2022, respectively, the Company had $30.0 million and $50.0 million, respectively, invested in money market accounts.

Accounts Receivable

Accounts receivable includes billed and unbilled receivables, net of allowances, including the allowance for credit losses. Billed accounts receivable are initially recorded upon the invoicing to clients with payment due within 30 days. Unbilled accounts receivable represent revenue recognized on contracts for which the timing of invoicing to clients differs from the timing of revenue recognition. Unbilled accounts receivable was $2.4 million and $2.0 million as of December 31, 2023 and 2022, respectively. Contract assets included in unbilled accounts receivable were $1.7 million and $1.5 million as of December 31, 2023 and 2022, respectively.

The Company maintains an allowance for credit losses at an amount estimated to be sufficient to provide adequate protection against losses resulting from extending credit to its clients. The Company regularly determines the adequacy of the allowance based on its assessment of the collectability of the accounts receivable by considering the age of each outstanding invoice, the collection history of each client, an evaluation of the current expected risk of credit loss, and other client-specific factors with a bearing on receivables. The Company assesses collectability by reviewing accounts receivable on an aggregated basis where similar characteristics exist and on an individual basis for specific clients with historical collectability issues or known financial difficulties. Increases to the allowance are recognized as a charge to credit losses included in general and administrative expenses in the consolidated statements of operations. Accounts receivable deemed uncollectible are charged against the allowance for credit losses when identified.

F-9

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

The Company's allowance for credit losses is as follows (in thousands):

Balance at December 31, 2021

$

791

Changes to the provision

 

1,158

Accounts written off, net of recoveries

(724)

Balance at December 31, 2022

1,225

Adoption of ASU 2016-13

149

Changes to the provision

705

Accounts written off, net of recoveries

(987)

Balance at December 31, 2023

$

1,092

Leases

The Company determines at contract inception if the contract is or contains a lease. The Company records right-of-use (“ROU”) assets and lease obligations for its leases, which are initially recognized at the commencement date based on the discounted future lease payments over the term of the lease. As the rates implicit in the Company’s leases are not readily determinable, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date. Incremental borrowing rates for domestic currency leases are calculated using the Company’s credit adjusted risk-free rate. Foreign-denominated lease payments are discounted using country-specific treasury rates adjusted for credit spread.

The Company does not record an ROU asset and lease obligation for its short-term leases, which are defined as leases with an initial term of 12 months or less. The Company has elected not to separate lease and non-lease components.

Property, Equipment, and Software, Net

Property, equipment, and software is stated at historical cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the individual assets, except for leasehold improvements, which are depreciated over the shorter of the estimated useful life of the asset or the underlying lease term. Also included in property, equipment, and software are capitalized costs of software developed for internal use. The useful lives of property, equipment, and software are as follows:

Property, Equipment, and Software Asset Type

Estimated Useful Lives

Software development costs

3 years

Computers

3 years

Furniture, fixtures, and equipment

5 years

Leasehold improvements

Shorter of estimated economic useful life or remaining lease term

Maintenance and repairs are expensed as incurred. Upon retirement or disposition, the cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is included in operating income.

Software Development Costs

The Company capitalizes certain qualifying costs, including stock-based compensation expense, incurred in the development of and major enhancements to the Company's cloud-based software as a service (“SaaS”) platform and related software products. Capitalized software development costs related to the Company's platform are amortized on a straight-line basis over the developed software's estimated useful life of three years, and the related amortization expense is recorded in cost of revenues within our consolidated statements of operations.

F-10

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

Costs incurred in the preliminary stages of development are expensed as incurred. Costs incurred for post-implementation activities, training, maintenance, and minor upgrades and enhancements without adding additional functionality are expensed as incurred within technology and development expense in our consolidated statements of operations.

Impairment of Long-Lived Assets

The Company evaluates the carrying value of long-lived assets in accordance with the accounting standard for impairment or disposal of long-lived assets, which requires recognition of impairment of long-lived assets in the event that circumstances indicate impairment may have occurred and when the net carrying value of such asset group exceeds the future undiscounted cash flows attributed to such asset group. The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. No impairment of long-lived assets occurred during the years ended December 31, 2023, 2022, and 2021.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the exit price) in an orderly transaction between market participants at the measurement date. Accounting standards establish a hierarchal framework, which prioritizes and ranks the level of market price observability used in measuring assets and liabilities at fair value. Market price observability is impacted by a number of factors, including the type of investment and the characteristics specific to the investment. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on the best information available. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories:

Level 1

Inputs are quoted prices for identical instruments in active markets;

Level 2

Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets;

Level 3

Inputs are valuations derived from valuation techniques in which one or more significant inputs are unobservable.

Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The Company has investments in money market accounts, which are included in cash and cash equivalents on the consolidated balance sheets. Fair value inputs for these investments are considered Level 1 measurements within the fair value hierarchy, as money market account fair values are known and observable through daily published floating net asset values.

Annual Bonus Incentive Plan

Annual bonuses payable by the Company to its officers and employees may be funded through a combination of cash and equity, at the discretion of the Company’s Compensation Committee. We accrue and record the related corporate bonus amounts payable in cash in the period in which it is earned by the recipient. The Compensation Committee may make incentive awards based on such terms, conditions, and criteria as it considers appropriate. Stock awards issued in connection with these bonuses may or may not be subject to additional vesting conditions at the time of grant, which are subject to determination by the Compensation Committee.

F-11

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

For annual bonuses settled in cash, the Company accrues over the course of the year the annual bonuses earned by employees but paid in the following year. For annual bonuses settled in stock, in accordance with ASC 718, Stock Compensation, the Company views the authorization of the award to be the date that all approval requirements are completed (e.g., action by the Compensation Committee approving the awards and determining the number of equity instruments to be issued), and therefore, the service inception to begin at grant date. As such, stock-based compensation cost related to the Annual Bonus Incentive Plan is recognized on the grant date to the extent such awards are not subject to additional vesting conditions.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. The Company derives its revenues primarily from fees for platform subscriptions and managed services provided to clients. Revenues are recognized when control of these services are transferred to the Company’s clients in an amount that reflects the consideration the Company expects to be entitled to in exchange for these services. Revenues are recognized net of taxes that will be remitted to governmental agencies applicable to service contracts. Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework:

● Identification of the contract, or contracts, with a client;

● Identification of the performance obligation in the contract;

● Determination of transaction price;

● Allocation of the transaction price to the performance obligations in the contract; and

● Recognition of revenue when, or as, performance obligations are satisfied.

Platform subscriptions revenues

Platform subscriptions revenues consist primarily of user fees to provide our clients access to our cloud-based solution. Fees consider various components such as number of users, connectivity, trading volume, data usage and product coverage. Platform subscriptions clients do not have the right to take possession of the platform’s software and do not have any general return right. Platform subscriptions revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date the client gains access to the platform. Installed payments are generally invoiced at the end of each calendar month during the subscription term. There is no financing available.

Managed services revenues

Managed services revenues primarily consist of client-selected middle- and back-office, technology-powered services. Managed services revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the contract effective date. Clients are invoiced a set fee for managed services typically at the end of each month. Generally, invoices have a 30-day payment period in accordance with the associated contract. There is no financing available.

Other revenues

Other revenues consist of non-subscription-based revenues primarily data conversion. The Company recognizes revenues as these services are performed with invoicing generally occurring at the end of each month.

F-12

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

Service contracts with multiple performance obligations

Certain of the Company’s contracts provide for customers to be charged a fee for implementation services. In determining whether the implementation services, which frequently include configuration and/or interfacing, customer reporting, customizing user permissions and acceptance testing, end-user training, and establishing connections with third-party interfaces, are distinct from its platform subscription services, the Company considers, in addition to their complexity and level of customization, that these services are integral in delivering the customer desired output and are necessary for the customer to access and begin to use the hosted application. The implementation provider must be intimately familiar with its platform to effectively execute the customization required, and no other entities have access to the source code. The Company has concluded that the implementation services in its service contracts with multiple performance obligations are not distinct, and therefore, the Company recognizes fees for implementation services ratably over the non-cancelable term of the contract.

Remaining performance obligations

For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of December 31, 2023 was $29.1 million and is expected to be recognized based on the below schedule (in thousands).

Remaining Performance Obligation

December 31, 2023

2024

$

18,227

2025

 

8,845

2026

 

1,986

2027

 

64

2028

Total

$

29,122

Disaggregation of revenue

The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following table (in thousands):

Year Ended December 31, 

2023

2022

2021

Geographic Region

    

Amount

    

Percent

    

Amount

    

Percent

Amount

    

Percent

Americas*

$

108,506

 

62.1

%  

$

95,122

 

63.3

%

$

72,994

 

65.3

%

Europe, Middle East, and Africa (EMEA)

 

26,122

 

15.0

%  

 

20,051

 

13.3

%

 

13,491

 

12.1

%

Asia Pacific (APAC)

 

39,907

 

22.9

%  

 

35,176

 

23.4

%

 

25,215

 

22.6

%

Total revenues

$

174,535

 

100.0

%  

$

150,349

 

100.0

%

$

111,700

 

100.0

%

*

Includes revenues from clients based in the United States (country of domicile) of $104.5 million, $92.8 million, and $71.9 million for the years ended December 31, 2023, 2022, and 2021, respectively.

Deferred commissions

The Company pays sales commissions for initial contracts and expansions of existing contracts with customers. These commissions earned by certain of its sales force are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions paid where the amortization period is one year or less are expensed as incurred. All other sales commissions are deferred and then amortized on a straight-line basis over a period of benefit that the Company has determined to be three years. The Company determined the period of benefit by taking into consideration

F-13

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

its standard contract terms and conditions, rate of technological change, and other factors. Amortization expense is included in sales and marketing expenses in the accompanying consolidated statements of operations.

The balance of deferred commissions as of December 31, 2023 and December 31, 2022 was $3.5 million and $2.8 million, respectively, and is included in other assets on the consolidated balance sheets. The amount of amortization expense recognized during the years ended December 31, 2023, 2022, and 2021 was $1.4 million, $845 thousand, and $228 thousand, respectively.

Cost of Revenues

Cost of revenues consists primarily of personnel-related costs associated with the delivery of the Company’s software and services, including base salaries, bonuses, employee benefits and related costs. Additionally, cost of revenues includes amortization of capitalized software development costs, allocated overhead and certain direct data and hosting costs.

Technology and Development

Technology and development expenses consist primarily of employee-related expenses for the Company’s software development. Additional expenses include costs related to the development, maintenance, quality assurance and testing of new technologies, and ongoing refinement of the Company’s existing solutions. Technology and development expenses, other than software development costs qualifying for capitalization, including costs associated with preliminary project stage activities, training, maintenance, and all other post-implementation stage activities are expensed as incurred.

Advertising Costs

The Company expenses advertising costs as incurred. Advertising costs incurred were approximately $1.5 million, $1.5 million, and $1.2 million during the years ended December 31, 2023, 2022, and 2021, respectively.

Stock-Based Compensation

In October 2021, in connection with the IPO, the Company adopted the 2021 Stock Option and Incentive Plan, (the “2021 Plan”). The 2021 Plan allows the Company’s Compensation Committee to make incentive awards to its officers, employees, directors, and service providers. The Company also adopted the 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The Company measures stock-based compensation expense for its share-based payment awards at fair value on the grant date. The fair value of share-based payment awards is determined using the fair market value of the underlying Class A common stock on the date of grant. The Company applied a discount for lack of marketability, estimated using the Finnerty Model, to the fair value of awards with post-vesting restrictions, which includes the vested shares of Class A common stock and the Contingently Issuable Shares (as defined below) issued on the IPO effectiveness date (as defined below).

For restricted stock units (“RSUs”) for which vesting is subject to the achievement of a market condition, the Company determines the fair value of these RSUs using the Monte Carlo method. The Monte Carlo simulations used to estimate the fair value include subjective assumptions, including the fair value of the underlying common stock, expected volatility of the price of the Company’s common stock, risk-free interest rate, expected dividend yield of common stock, and the Company’s cost of equity capital.

The Company records forfeitures as they occur. The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statements of operations based on the estimated fair value of those awards on the grant date or reporting date, if required to be remeasured, and amortized on a straight-line basis over the requisite service period.

F-14

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

Income (Loss) Per Share

Income (loss) per share is computed by dividing net income (loss) attributable to the Company by the number of weighted average shares of Class A common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income (loss) attributable to the Company by the number of weighted-average shares of Class A common stock outstanding during the period after adjusting for the impact of securities that would have a dilutive effect on income (loss) per share. See Note 12, Income (Loss) Per Class A Common Share, for further discussion.

All income (loss) for the period prior to the IPO were entirely allocable to Enfusion Ltd. LLC. and its historic non-controlling interest. Due to the impact of the Reorganization Transactions, the Company’s capital structure for the pre- and post-IPO periods is not comparable. As a result, the presentation of income (loss) per share for the periods prior to the IPO and Reorganizational Transactions is not meaningful and only income (loss) per share for the period subsequent to the IPO and Reorganizational Transactions is presented herein.

Non-Controlling Interest

Non-controlling interests represent the portion of profit or loss, net assets, and comprehensive income (loss) of its consolidated subsidiaries that are not allocable to the Company based on its percentage of ownership of such entities. As noted above, in October of 2021, Enfusion US 1, Inc., a newly-formed wholly owned subsidiary of Enfusion, Inc., became the sole managing member of Enfusion Ltd. LLC in connection with the Reorganization Transactions. As of December 31, 2023, the Company holds approximately 69.3% of the outstanding Common Units of Enfusion Ltd. LLC, and approximately 30.7% of the outstanding Common Units of Enfusion Ltd. LLC are held by Pre-IPO Common Unitholders. Therefore, the Company reports non-controlling interests based on Common Units of Enfusion Ltd. LLC held by the Pre-IPO Common Unitholders on its consolidated balance sheet as of December 31, 2023. Income or loss attributed to the non-controlling interest in Enfusion Ltd. LLC is based on the Common Units outstanding during the period for which the income or loss is generated and is presented on the consolidated statements of operations and consolidated statements of comprehensive income (loss).

Income Taxes

The Company accounts for income taxes under the asset and liability method, and deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and deferred tax liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that it is believed that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations. A valuation allowance is provided if it is determined that it is more likely than not that the deferred tax asset will not be realized.

The Company evaluates and accounts for uncertain tax positions using a two-step approach. Recognition (step one) occurs when the Company concludes that a tax position, based solely on its technical merits, is more-likely-than-not to be sustainable upon examination. Measurement (step two) determines the amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. Derecognition of a tax position that was previously recognized would occur when the Company subsequently determines that a tax position no longer meets the more-likely-than-not threshold of being sustained. The Company records interest (and penalties where applicable), net of any applicable related income tax benefit, on potential income tax contingencies as a component of income tax expense in the consolidated statements of operations.

F-15

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

Tax Receivable Agreement (TRA)

The Company accounts for amounts payable under the Tax Receivable Agreement in accordance with ASC 450, Contingencies. The amounts payable under the Tax Receivable Agreement will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future. Actual tax benefits realized by the Company may differ from tax benefits calculated under the Tax Receivable Agreement as a result of the use of certain assumptions in the agreement. Any such changes in these factors or changes in the Company’s determination of the need for a valuation allowance related to the tax benefits acquired under the Tax Receivable Agreement could adjust the Tax Receivable Agreement liabilities recognized on the consolidated balance sheets. Subsequent changes in the Tax Receivable Agreement liabilities between reporting periods, as well as any interest accrued on the Tax Receivable Agreement between the Company's annual tax filing date and the Tax Receivable Agreement payment date, are recognized in the consolidated statements of operations. As of December 31, 2023 and 2022, the Company has not recorded a liability under the Tax Receivable Agreement.

Concentration of Risk

Deposits with Financial Institutions

The Company has concentrated its credit risk for cash by maintaining deposits in several financial institutions, which may at times exceed amounts covered by insurance provided by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk related to cash.

Accounts Receivable

As of December 31, 2023, the Company had one individual client that represented 10% or more of accounts receivables. For the years ended December 31, 2023, 2022, and 2021, no individual client represented more than 10% of the Company’s total revenues.

Translation of Foreign Currencies

Assets and liabilities denominated in the functional currency of the Company’s international subsidiaries are translated to its reporting currency using the exchange rates in effect at the balance sheet date. Results from operations are translated using the average exchange rates prevailing throughout the year. The effects of exchange rate fluctuations on translating foreign currency assets and liabilities into U.S. dollars are accumulated as part of the foreign currency translation adjustment in accumulated other comprehensive loss in the consolidated balance sheets.

Foreign currency balances for monetary assets and liabilities are remeasured into the entity’s functional currency at the balance sheet date, and fluctuations in value are recorded within other income (expense) in the consolidated statements of operations.

Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13 and ASU 2018-19, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU No. 2016-13”), which requires that a financial asset (or a group of financial assets) measured at an amortized cost basis be presented at the net amount expected to be collected. This approach to estimating credit losses applies to most financial assets measured at amortized cost and certain other instruments, including but not limited to, trade and other receivables. The Company adopted this guidance effective January 1, 2023 and made changes to its accounting policies related to credit loss calculations, including the consideration of forecasted economic data and the pooling of financial assets with similar risk profiles. The Company adopted the new allowance for credit losses accounting standard on January 1, 2023 by means of a cumulative-effect adjustment, where it

F-16

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

recognized the cumulative effect of initially applying the guidance as a $149 thousand addition to its existing reserve with an offsetting adjustment to accumulated deficit.

Recent Accounting Pronouncements Not Yet Adopted

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU No. 2023-07”), to expand the annual and interim disclosure requirements for reportable segments, including public entities with a single reportable segment, primarily through enhanced disclosures about significant segment expenses. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this standard.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topics 740): Improvements to Income Tax Disclosures (“ASU No. 2023-09”), to expand the disclosures in an entity’s income tax rate reconciliation table and income taxes paid both in U.S. and foreign jurisdictions. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this standard.

Note 4   Property, Equipment, and Software, Net

Property, equipment, and software, net consists of the following (in thousands):

December 31, 

2023

    

2022

Computer equipment

$

17,384

$

17,496

Software development costs

 

15,842

 

9,406

Leasehold improvements

 

1,668

 

1,831

Furniture and fixtures

 

137

 

433

Total property, equipment, and software, cost

 

35,031

 

29,166

Less accumulated depreciation and amortization

 

(16,717)

 

(13,407)

Total property, equipment, and software, net

$

18,314

$

15,759

As of December 31, 2023 and 2022, property, equipment, and software, net located in the United States was $17.0 million and $13.7 million, respectively. The remainder was located in the Company’s various international locations. Included in property, equipment, and software are the capitalized costs of software development. Software development costs capitalized during the years ended December 31, 2023 and 2022 were $6.4 million and $4.5 million, respectively.

Depreciation expense related to property and equipment, excluding software development costs, was $5.1 million, $3.3 million, and $2.4 million for the years ended December 31, 2023, 2022, and 2021, respectively. Amortization expense related to software development costs was $3.4 million, $2.2 million, and $1.3 million for the years ended December 31, 2023, 2022, and 2021, respectively.

F-17

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

Note 5   Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

December 31, 

2023

    

2022

Accrued compensation

$

10,058

$

10,268

Accrued expenses and other

 

1,385

 

1,112

Accrued taxes

 

2,398

 

285

Total accrued expenses and other current liabilities

$

13,841

$

11,665

Accrued compensation includes bonuses due to employees of $6.4 million and $7.8 million as of December 31, 2023 and 2022, respectively.

Note 6   Leases

The Company enters into leases for office space and data centers. A number of the leases include one or more options to renew the lease terms or not terminate the lease. The exercise of these options is at the Company’s discretion and is therefore recognized on the balance sheet when it is reasonably certain the Company will exercise such options.

All of the Company’s leases are considered operating leases. The Company had no finance leases as of and for the year ended December 31, 2023 and 2022, respectively.

The Company has entered into operating leases for international office spaces that are yet to commence as of December 31, 2023.

Lease commitments as of December 31, 2023 were as follows:

Amount

2024

5,197

2025

4,198

2026

3,229

2027

3,253

2028

1,671

Thereafter

654

Total lease commitments

$

18,202

Less: Interest

(2,765)

Present value of lease liabilities

$

15,437

F-18

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

The components of the Company’s operating lease cost for the twelve months ended December 31, 2023 and 2022, respectively, were as follows:

December 31, 

2023

2022

Operating lease cost

$

6,882

$

5,053

Variable lease cost

835

828

Short-term lease cost

114

Total lease cost

$

7,831

$

5,881

Variable lease costs are comprised of the Company’s proportionate share of actual costs for utilities, common area maintenance, property taxes, and insurance, which are not included in the lease liability and are recognized in the period in which they are incurred.

As of December 31, 2023 and 2022, respectively, the weighted-average remaining lease terms and weighted-average discount rates were as follows:

December 31, 

2023

2022

Weighted-average remaining lease term - operating leases

3.80 years

1.84 years

Weighted-average discount rate - operating leases

7.80%

4.43%

Under Accounting Standards Codification 840, the previous lease standard, total expense for lease arrangements and service agreements was $3.9 million and $1.1 million, respectively, for the year ended December 31, 2021.

Note 7   Debt

New Credit Agreement

On September 15, 2023, the Company entered into the New Credit Agreement with Bank of America N.A. and a syndicate of lending institutions. The New Credit Agreement provides for a senior secured revolving loan facility in an aggregate principal amount of up to $100.0 million, including a $10.0 million sublimit for the issuance of letters of credit and a swingline subfacility of up to $10.0 million. The New Credit Agreement also includes an uncommitted accordion feature that allows for up to $50.0 million of additional borrowing capacity, subject to obtaining lender commitments and the satisfaction of certain customary conditions. The New Credit Agreement matures on September 15, 2028, at which time all outstanding principal and unpaid interest will become due. Obligations under the New Credit Agreement are secured by a lien on substantially all of the assets of the Company.

Revolving loans under the New Credit Agreement will bear interest, at the Company’s option, at an annual rate benchmarked to (1) the Secured Overnight Financing Rate (“SOFR”) or (2) a “Base Rate” that is equal to the highest of (a) the federal funds rate plus 0.50%, (b) Bank of America’s prime rate and (c) one month adjusted term SOFR plus 1.00%. Loans based on SOFR bear interest at a rate equal to term SOFR for the applicable interest period plus 10 basis points plus a margin between 2.00% and 2.75%. Loans based on the Base Rate bear interest at a rate equal to the Base Rate plus a margin between 1.00% and 1.75% (such margins being referred to as the “Applicable Rate”). The Applicable Rate in each case is determined based on the Company’s consolidated net leverage ratio. The Company is also required to pay a commitment fee of between 0.20% and 0.25% per annum on the unused portion of the lenders’ commitments in respect of the revolving loans and letter of credit obligations, based on the Company’s consolidated net leverage ratio. As of December 31, 2023, the commitment fee rate was 0.20%.

The New Credit Agreement contains certain customary covenants with which the Company must comply, including financial covenants relating to a net leverage ratio covenant and an interest coverage ratio. As part of the New

F-19

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

Credit Agreement, the Company is required to establish within 120 days of the closing date and maintain thereafter a minimum required balance of $5.0 million with Bank of America, and by the first anniversary of the closing date, use commercially reasonable efforts to maintain Bank of America as its principal depository bank. The minimum required balance of $5.0 million was established in February 2024. The Company was in compliance with all loan covenants and requirements as of December 31, 2023.

Issuance costs associated with the New Credit Agreement were capitalized and included in other assets on the accompanying consolidated balance sheets.

As of December 31, 2023, the Company had no outstanding borrowings under the New Credit Agreement or material letters of credit issued.

Prior Credit Agreement

Concurrent with entering into the New Credit Agreement, on September 15, 2023, the Company terminated its $5.0 million Prior Credit Agreement with Silicon Valley Bank, which by its terms was scheduled to mature on December 17, 2025. At the time of termination, there were no borrowings outstanding under the Prior Credit Agreement. The Company recognized a loss on extinguishment of debt of $78 thousand associated with the termination of the Prior Credit Agreement.

Note 8   Commitments and Contingencies

The Company records accruals for contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. A description of a contingent payment arrangement under the Company’s Tax Receivable Agreement is included in Note 13, Income Taxes. Accruals for contingencies recorded as of December 31, 2023 and December 31, 2022, respectively, were immaterial.

Note 9   Stockholders’ Equity

Prior to the Reorganization Transactions, Enfusion Ltd. LLC was organized as a limited liability company owned by its members, each of whose membership interests consisted of an equal number of: (i) “Economic Units,” which represented a member’s economic interest in Enfusion Ltd. LLC; and (ii) “Participation Units,” which represented a member’s right to participate (vote) in the affairs of Enfusion Ltd. LLC.

As a limited liability company, Enfusion Ltd. LLC issued more than one class of units. The Class A units were considered to be members’ equity, whereas all of the other unit classes were considered to be preferred units because of provisions in the Company’s former Operating Agreement that conferred certain rights and privileges to the members owning these units, such as voting rights, redemption rights and liquidation preferences.

Holders of the Class C-1, C-2, and D preferred units had the option to require the Company to redeem their units. In accordance with the guidance in ASC 480, Distinguishing Liabilities from Equity, outstanding Class C-1, C-2, and D preferred units were classified outside of permanent equity and within temporary equity due to their optional redemption features and liquidation preferences.

In connection with the Reorganization Transactions, the Sixth Amended and Restated Operating Agreement of Enfusion Ltd. LLC was amended and restated to, among other things, modify its capital structure by reclassifying each of the outstanding Class A units and C-1, C-2, and D preferred units into the Common Units through a stock split on a 1,000,000 to 1 basis. The number of Common Units outstanding following the Reorganization Transactions reflect the 1,000,000 to 1 stock split. Pursuant to the adoption of the LLC Operating Agreement, Enfusion US 1, Inc., a newly-formed wholly owned subsidiary of Enfusion, Inc., was appointed the sole managing member of Enfusion Ltd. LLC.

F-20

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

On June 15, 2023, the company sold 1.2 million shares of Class A common stock to FTV Investment Holdings, L.P. (“FTV Holdings”) and an affiliate in a private placement. Refer to Note 14, Related Party Transactions, for more information about this placement transaction.

On August 14, 2023, the Company sold 1.0 million shares of Class A common stock of the Company, par value $0.001 per share, in a private placement at a price of $7.65 per share. Total net proceeds of the transaction were $7.6 million.

On February 21, 2023, March 28, 2023, July 19, 2023, and August 1, 2023, pursuant to the terms of the LLC Operating Agreement, Pre-IPO Common Unitholders respectively surrendered 1,000,000, 1,000,000, 1,000,000, and 1,000,000 Common Units and an equal number of shares of Class B common stock. In connection therewith, the Company respectively issued 1,000,000, 1,000,000, 1,000,000, and 1,000,000 shares of Class A common stock to each such Pre-IPO Common Unitholder, canceled an equal number of Class B common stock, and received an equal number of Common Units, increasing the Company’s ownership of Common Units by 1,000,000, 1,000,000, 1,000,000, and 1,000,000, respectively.

Amended and Restated of Certificate of Incorporation

The Amended and Restated Certificate of Incorporation of Enfusion, Inc. provides for 1,000,000,000 authorized shares of Class A common stock, 150,000,000 authorized shares of Class B common stock and 100,000,000 shares of preferred stock.

Each share of the Company’s Class A common stock is entitled to one vote per share and is not convertible into any other shares of its capital stock. Holders of shares of the Company’s Class A common stock are entitled to receive dividends when, as and if declared by the Company’s board of directors. Upon its liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors, and subject to the rights of the holders of one or more outstanding series of preferred stock, as applicable, having liquidation preferences, the holders of shares of the Company’s Class A common stock will be entitled to receive pro rata the Company’s remaining assets available for distribution. Each share of the Company’s Class B common stock is entitled to one vote per share and is not convertible or exchangeable for a share of Class A common stock or any other security. Holders of the Company’s Class B common stock do not have any right to receive dividends or to receive a distribution upon a liquidation, dissolution or winding up of Enfusion, Inc.

Preferred Stock

The Company’s board of directors have the authority, without further action by the Company’s stockholders, to issue up to 100,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Class A common stock. As of December 31, 2023 and 2022, the Company has no shares of preferred stock outstanding nor has the Company’s board of directors established the rights and privileges related to any series of preferred stock.

Note 10   Management Incentive Plan and Stock-Based Compensation

2021 Stock Option and Incentive Plan

In conjunction with the IPO, the Company established the 2021 Stock Option and Incentive Plan (the “2021 Plan”), which became effective upon the date immediately preceding the IPO effectiveness date (as defined below). The Company has initially reserved 26,400,000 shares of Class A common stock for the issuance of awards under the 2021 Plan, inclusive of awards (the “Award Units”) granted to Plan Participants (as defined below) of the Pre-IPO Change in

F-21

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

Control Bonus Plan (as defined below). The 2021 Plan provides that the number of shares of Class A common stock reserved and available for issuance under the 2021 Plan increased on January 1, 2022 and will continue to increase each January 1 thereafter, by 3% of the outstanding number of shares of the Company’s Class A common stock and Class B common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Company’s Compensation Committee. The 2021 Plan provides for potential grants of the following awards: (i) stock options, (ii) RSUs, (iii) unrestricted shares, and (iv) stock appreciation rights.

Pre-IPO Change in Control Bonus Plan

Prior to the IPO, Enfusion Ltd. LLC had a Pre-IPO Change in Control Bonus Plan (the “pre-IPO Change in Control Bonus Plan”) for certain members of management (“Plan Participants”) that provided for the payment of a cash bonus based on a specified number of Award Units in the event of a change in control (“CiC”) transaction (i.e., a liquidity event), as defined by the LLC Operating Agreement.

In anticipation of the Company’s IPO, in October 2021, the Company's board of managers elected to terminate the Pre-IPO Change in Control Bonus Plan (and all Award Units issued thereunder) upon effectiveness of the registration statement for the IPO (the “IPO effectiveness date”). Holders of Award Units that were still employed as of the IPO effectiveness date were granted one or more of the following:

The vested shares of Class A common stock as of IPO effectiveness date (“IPO vested Class A common stock”) are shares that were all issued to Plan Participants prior to the second anniversary of the IPO. No future service was required to receive the IPO vested Class A common stock. Because there was no ongoing service requirement associated with these awards, the Company recognized stock-based compensation expense for these awards on the IPO effectiveness date. The amount of stock-based compensation expense recognized for these awards was $237.3 million in 2021, which is equal to the fair value of the shares of the IPO vested Class A common stock, after applying a discount for lack of marketability due to the post-vesting restriction.

Shares of Class A common stock that vested within one year of the IPO effectiveness date are referred to as “Contingently Issuable Shares” due to continued employment requirements. Of such shares, 7.5% was distributed in 2022 with the remainder distributed in 2023. Stock-based compensation expense associated with these awards is recognized by the Company on a straight-line basis over the requisite service period for the entire award, beginning on the IPO effectiveness date. The amount of stock-based compensation expense recognized for these awards was $0, $10.2 million, and $16.7 million in the years ended December 31, 2023, 2022, and 2021, respectively, which is equal to the fair value of the shares of the IPO vested Class A common stock, after applying a discount for lack of marketability due to the post-vesting restriction.

RSUs granted to executive and non-executive employees that will vest ratably over a period of up to four years subject to the Plan Participant’s continued employment. Stock-based compensation expense associated with these awards is recognized by the Company on a straight-line basis over the requisite service period for the entire award, beginning on the IPO effectiveness date. The amount of stock-based compensation expense recognized for these awards was $7.3 million, $13.2 million, and $4.5 million in the years ended December 31, 2023, 2022, and 2021, respectively.

Performance-based restricted stock units (“PSUs”) that will vest ratably over a period of up to ten years that are subject to a market condition and the Plan Participant’s continued employment. The market condition is the achievement of certain market capitalization targets by the Company at specified measurement dates. The Company determined the fair value of these PSUs using the Monte Carlo method. The Company

F-22

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

recognizes stock-based compensation expense on a straight-line basis over the implied service period for each tranche of the award, as if the award were in-substance multiple awards.

In addition to the shares of Class A common stock, RSUs, and PSUs granted to employees that were Plan Participants in the Pre-IPO Change in Control Bonus Plan, the Company agreed to issue 2,047,064 shares of Class A common stock to an employee in exchange for termination of a profit sharing agreement. These shares were issued to the employee between the first and second anniversaries of the IPO effectiveness date. The fair value of these shares, after applying a discount for lack of marketability due to the post-vesting restriction, is $31.2 million. This amount was recognized as compensation expense on the IPO effectiveness date in 2021.

For the IPO vested Class A common stock and the Contingently Issuable Shares granted on the IPO effectiveness date, the Company applied a discount for lack of marketability, estimated using the Finnerty Model, to the fair value of awards with post-vesting restrictions. All IPO vested Class A common stock and Contingently Issuable Shares were issued to Plan Participants prior to the second anniversary of the IPO.

Restricted Stock Units

The Company measures stock-based compensation expense for its share-based payment awards at fair value on the grant date. For RSUs for which vesting is not subject to the achievement of a market condition or achievement of a specified share price, the fair value of share-based payment awards is determined using the fair market value of the underlying Class A common stock on the date of grant (i.e. share price at closing).

The Company recognizes stock-based compensation expense for these RSUs on a straight-line basis over requisite service period for the entire award.

Stock Options

The expected fair value and term of the Company’s stock options was determined utilizing the simplified method, due to lack of historical exercise data. The expected volatility was determined using a weighted-average of the historical volatility measures of a group of guideline companies and the Company's own historical volatility.

During the year ended December 31, 2023, there were 71,004 stock options granted under the 2021 Plan, at a weighted-average exercise price of $11.06 per option, and 31,474 stock options were forfeited. During the year ended December 31, 2022, there were 84,000 stock options granted under the 2021 Plan, at a weighted-average price of $9.86 per option, and 40,000 stock options were forfeited. As of December 31, 2023, there was approximately $351 thousand of unrecognized stock-based compensation expense related to the remaining stock options issued during 2022, which is expected to be recognized over a weighted-average period of approximately 2.0 years. The Black-Scholes assumptions used for the options granted under the 2021 Plan during the year ended December 31, 2022 were as follows:

Assumptions

2023

2022

Expected volatility

60.91%

64.54%

Expected term of award

6.5 years

6.5 years

Risk-free rate

3.82%

3.39%

Dividend yield

0.00%

0.00%

The shares of common stock to be issued and/or sold upon the exercise of stock options are made available from authorized and unissued common stock.

F-23

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

Performance-based Restricted Stock Units

For PSUs for which vesting is subject to the achievement of a market condition or specified price of the Company’s shares, the Company determines the fair value of these PSUs using the Monte Carlo method. The Monte Carlo simulations used to estimate the fair value include subjective assumptions, including the fair value of the underlying common stock, expected volatility of the price of the Company’s common stock, risk-free interest rate, expected dividend yield of common stock, and the Company’s cost of equity capital.

In the fourth quarter of 2023, 580,000 performance-based PSUs were granted. In the year ended December 31, 2022, 250,000 performance-based PSUs were granted. The assumptions used in the Monte Carlo simulation for the PSUs were as follows:

Assumptions

2023

2022

2021

Fair value of common stock (per share)

$9.89

$8.92

$17.00

Expected volatility

41.65%

53.40%

48.20%

Risk-free rate

4.38%

3.98%

1.65%

Dividend yield

0.00%

0.00%

0.00%

Cost of equity capital

14.10%

13.50%

11.20%

As of December 31, 2023, the total compensation cost related to unvested awards not yet recognized was $2.8 million, and weighted-average period of recognition was 2.0 years.

Stock-Based Compensation

The Company’s stock-based compensation expense was recognized in the following captions within the consolidated statements of operations:

Year Ended December 31, 

(in thousands)

2023

2022

2021

Cost of revenues

$

950

$

1,421

$

377

General and administrative

5,635

14,130

112,829

Sales and marketing

(984)

5,875

36,312

Technology and development

1,857

3,567

140,285

Total stock-based compensation expense

$

7,458

$

24,993

$

289,803

The Company recognized total stock-based compensation expense, including RSUs and stock options, for the years ended December 31, 2023, 2022, and 2021 of $7.5 million, $25.0 million, and $289.8 million, respectively, in the consolidated statements of operations.

The Company capitalized $766 thousand and $600 thousand of stock-based compensation expense to capitalized software development costs for the years ended December 31, 2023 and 2022, respectively. No amounts were capitalized relating to the year ended December 31, 2021 due to the fact that no awards were granted in conjunction with capitalizable activities.

Total unrecognized stock-based compensation expense related to unvested RSUs and stock options was $19.7 million as of December 31, 2023, which is expected to be recognized over a weighted-average period of 2.0 years.

F-24

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

The following summarizes the Company’s share-based payment award activity for all IPO vested Class A common stock, RSUs, Contingently Issuable Shares and stock options for the years ended December 31, 2023 and 2022, respectively:

   

IPO Vested Class A Common Stock, Contingently Issuable Shares and RSUs

Options

Number of Units

   

Weighted-Average Grant-Date Fair Value

   

Number of Options

   

Weighted-Average Exercise Price

Weighted-Average Remaining Contractual Term (in years)

Outstanding as of December 31, 2022

20,224,452

$

15.15

44,000

9.86

9.46

Vested as of December 31, 2022

17,225,377

-

-

Unvested as of December 31, 2022

2,999,075

44,000

9.86

Granted during the period

1,925,762

$

8.49

71,004

11.06

Forfeited during the period

(584,178)

15.32

(31,474)

10.15

Vested and issued during the period (a)

(18,374,139)

15.27

-

-

Outstanding as of December 31, 2023 (b)

3,191,897

$

9.61

83,530

$

10.77

8.89

(a) Includes shares issued and net settled to satisfy tax withholding obligations.

(b) December 31, 2023 balance is all unvested.

Note 11   Employee Benefit Plans

The Company sponsors a 401(k) Plan that covers substantially all full-time United States employees who meet eligibility requirements. The Company makes matching contributions equal to 50% of the wages that are deferred by employees, and the matching contribution is capped at 3% of wages. The Company made contributions of $1.0 million, $584 thousand, and $452 thousand for the years ended December 31, 2023, 2022, and 2021, respectively. The Company also sponsors various other benefit plans for its employees of certain international subsidiaries. The Company’s contributions to these plans are immaterial for the periods presented.

Note 12   Net Income (Loss) Per Class A Common Share

Basic income (loss) per share is computed by dividing net income (loss) attributable to Enfusion, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive shares.

Prior to the IPO, the Enfusion Ltd. LLC membership structure included Common Units and multiple classes of preferred Units. The Company analyzed the calculation of earnings per unit for periods prior to the IPO using the two-class method and determined that it resulted in values that would not be meaningful to the users of these consolidated financial statements. Therefore, earnings per share information has not been presented for periods prior to the IPO on October 20, 2021. The basic and diluted earnings per share represent only the years ended December 31, 2023 and 2022, and the period from October 21, 2021 to December 31, 2021.

F-25

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per share of Class A common stock is as follows:

Year Ended December 31, 

(in thousands, except per share amounts)

2023

    

2022

2021

Net income (loss)

$

9,253

$

(13,263)

$

(282,242)

Less: Net income attributable to Enfusion, Inc. prior to the IPO

-

-

(12,892)

Less: Net (income) loss attributable to non-controlling interests

(3,228)

5,609

123,925

Net income (loss) attributable to Enfusion, Inc.

$

6,025

$

(7,654)

$

(171,209)

Numerator:

Net income (loss) attributable to Enfusion, Inc.

$

6,025

$

(7,654)

$

(171,209)

Adjustment to loss attributable to common stockholders

306

(954)

(16,580)

Numerator for Basic Earnings per Share

$

6,331

$

(8,608)

$

(187,789)

Adjustment to Income for Dilutive Shares

2,922

-

-

Numerator for Diluted Earnings per Share

$

9,253

$

(8,608)

$

(187,789)

Denominator:

Weighted-average shares of Class A common stock outstanding

80,828

67,057

65,583

Vested shares of Class A common stock and RSUs

7,374

18,336

17,462

Weighted-average shares of Class A common stock outstanding--basic

88,202

85,393

83,045

Add: Dilutive Shares

41,227

-

-

Weighted-average shares of Class A common stock outstanding--diluted

129,429

85,393

83,045

Net income (loss) per share of Class A common stock--Basic

$

0.07

$

(0.10)

$

(2.26)

Net income (loss) per share of Class A common stock--Diluted

$

0.07

$

(0.10)

$

(2.26)

The following number of potentially dilutive shares were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive:

Year Ended December 31, 

(in thousands)

2023

    

2022

2021

Class B common stock

-

43,199

47,471

Contingently issuable shares of Class A common stock

-

-

1,726

Restricted stock units

1,048

2,999

2,905

Stock options

84

44

-

1,132

46,242

52,102

Shares of Class B common stock do not share in earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been presented. Shares of Class B common stock are, however, considered potentially dilutive shares of Class A common stock. After evaluating the potential dilutive effect under both the treasury stock method and if-converted method, shares of Class B common stock were determined to be dilutive and have therefore been included in the computation of diluted earnings per share of Class A common stock for the year ended December 31, 2023.

Note 13   Income Taxes

The Company is taxed as a corporation for income tax purposes and is subject to federal, state, and local taxes on the income allocated to it from Enfusion Ltd. LLC based upon the Company’s economic interest in Enfusion Ltd. LLC. The Company controls the sole managing member of Enfusion Ltd. LLC and, as a result, consolidates the financial results of Enfusion Ltd. LLC.

F-26

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

Enfusion Ltd. LLC is a limited liability company taxed as a partnership for income tax purposes. Enfusion Ltd. LLC does not pay any federal income taxes, as income or loss is included in the tax returns of the individual members. Additionally, certain wholly-owned entities taxed as corporations are subject to federal, state, and foreign income taxes in the jurisdictions in which they operate, and accruals for such taxes are included in the consolidated financial statements. For periods prior to the IPO, the Company’s taxes represent those of Enfusion Ltd. LLC.

The components of income (loss) before income taxes were as follows (in thousands):

Year Ended December 31, 

2023

    

2022

2021

U.S.

$

5,503

$

(16,201)

$

(279,990)

Foreign

 

5,981

 

4,012

 

(1,673)

Total

$

11,484

$

(12,189)

$

(281,663)

The income (loss) before income taxes above includes the pre- and post-IPO periods for the year ended December 31, 2021.

Prior to the IPO, the Company, through its subsidiary, Enfusion Ltd. LLC, was structured as a partnership and therefore, was primarily subject to foreign income taxes and generally not subject to U.S. income taxes. As a result of the Reorganization Transactions, the Company is now taxed as a corporation and subject to U.S. federal, state, local and foreign taxes. Significant components of income tax expense (benefit) were as follows (in thousands):

Year Ended December 31, 

2023

    

2022

2021

Current:

U.S. Federal

$

(5)

$

$

State & Local

53

Foreign

2,190

1,347

228

Total Current Income Tax Expense

2,238

1,347

228

Deferred:

U.S. Federal

State & Local

Foreign

(7)

(273)

351

Total Deferred Income Tax Expense (Benefit)

 

(7)

 

(273)

 

351

Total

$

2,231

$

1,074

$

579

F-27

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

A reconciliation of income taxes computed at the U.S. federal statutory income tax rate of 21% to the Company’s income tax expense (benefit) was as follows:

Year Ended December 31, 

2023

    

2022

2021

At U.S. Federal Statutory Tax Rate

21.0

%

21.0

%

21.0

%

State Tax, Net of Federal Benefit

38.9

%

3.1

%

4.3

%

Non-controlling Interest

(7.3)

%

(8.9)

%

(9.2)

%

Foreign Branch Taxes

10.9

%

(8.2)

%

(0.3)

%

Stock-Based Compensation

113.5

%

(10.6)

%

(2.5)

%

Foreign Rate Differential

0.3

%

0.5

%

%

Valuation Allowance

(168.8)

%

50.6

%

(14.5)

%

Change in Tax Rates

1.9

%

(59.2)

%

%

Return to Provision

6.5

%

4.0

%

0.1

%

Unrecognized Tax Benefit

2.1

%

%

%

Pass-through Loss (Income)

%

%

0.9

%

Other

0.4

%

(1.1)

%

%

Total

19.4

%

(8.8)

%

(0.2)

%

The Company’s effective tax rate for the years ended December 31, 2023, 2022, and 2021 was 19.4%, (8.8)%, and (0.2)%, respectively. The most significant items impacting the effective tax rate are explained below.

State Tax, Net of Federal Benefit

The Company’s state taxes, net of federal benefit, include the effects of state taxes currently payable and changes in state deferred income taxes, exclusive of the valuation allowance. The significant increase in state taxes, net of federal benefit, in the year ended December 31, 2023, is primarily due to the U.S. state deferred tax effect of non-deductible equity-based compensation and related tax deduction deficiencies. For the years ended December 31, 2023, 2022, and 2021, the Company recorded state tax expenses (benefit) of $4.5 million, $(0.4) million, and $(12.1) million, respectively.

Noncontrolling Interest

The Company’s sole material asset is a financial interest in Enfusion Ltd. LLC. While the Company consolidates Enfusion Ltd. LLC for financial reporting purposes, the Company will only be taxed on (benefit from) its share of earnings (losses) of Enfusion Ltd. LLC not attributed to the noncontrolling interest holders. Since noncontrolling interest holders will continue to bear (benefit from) their share of income tax expense (benefit) on its allocable earnings (losses) of Enfusion Ltd. LLC, that share of income tax expense (benefit) is not reported by the Company in its consolidated financial statements. The U.S. federal tax (benefit) expense associated with the allocation of earnings (losses) to noncontrolling interest holders for the years ended December 31, 2023, 2022, and 2021 was $(0.8) million, $1.1 million and $25.9 million, respectively.

Stock-Based Compensation

As a result of the Reorganization Transactions, a significant portion of the Company’s certain stock-based compensation expenses will be allocated to the noncontrolling interest holders and therefore will not be deductible to the Company. The remaining portion of these expenses will be subject to the tax deduction limitations as established by the U.S. tax law in respect of the executive compensation. The Company recognizes an excess tax benefit or tax deficiency when the deduction for the stock-based compensation expense of a stock award for tax purposes differs from the cumulative stock-based compensation expense recognized in the financial statements. The U.S. federal tax impact of non-deductible stock-based compensation, including tax deficiencies, for the years ended December 31, 2023, 2022, and 2021 was $13.0 million, $1.3 million, and $2.5 million, respectively.

F-28

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

Valuation Allowance

The Company’s net deferred tax benefit (expense) for the years ended December 31, 2023, 2022, and 2021 of $(19.4) million, $(6.2) million, and $40.8 million, respectively, was fully offset by the valuation allowance recorded (released) in the consolidated statements of operations for each respective year.

Foreign Branch Taxes

The Company has foreign operations that are treated as branches for U.S. tax purposes and are also subject to income taxes in those foreign jurisdictions. For the years ended December 31, 2023, 2022, and 2021, the Company recorded $1.3 million, $1.0 million, and $0.6 million, respectively, in foreign income taxes related to the pre-tax income of its branches.

Return to Provision

For the years ended December 31, 2023, 2022, and 2021 the Company recorded a tax expense (benefit) of $0.8 million, $(0.5) million, and $(0.2) million, respectively, in relation to its filed or expected to be filed U.S. and foreign income tax returns. These true-up adjustments are attributable to actual results in the Company’s tax filings as compared to the estimates included in its previously issued consolidated financial statements.

Change in Tax Rates

For the years ended December 31, 2023, and 2022, the Company reduced its deferred tax assets by $0.2 million and $7.2 million, respectively, to reflect a change in the estimated U.S. state tax rate caused by a change in the overall mix of its U.S. earnings by state.

Deferred Tax Assets

The components of deferred tax assets and liabilities are as follows (in thousands):

December 31, 

2023

    

2022

Deferred Tax Assets:

Investment in Enfusion Ltd. LLC

$

126,504

$

86,117

Stock-Based Compensation

1,542

37,912

Net Operating Losses

11,410

9,358

Other

851

794

Total Deferred Tax Assets

140,307

134,181

Valuation Allowance

(140,307)

(133,689)

Total Deferred Tax Assets Net of Valuation Allowance

492

Deferred Tax Liabilities:

Property and Equipment

(70)

(77)

Total Deferred Tax Liabilities

 

(70)

 

(77)

Net Deferred Tax Assets

$

(70)

$

415

The Company’s deferred tax assets are primarily comprised of basis differences in the investment in Enfusion Ltd. LLC, stock-based compensation, and tax attribute carryforwards. The ultimate realization of deferred tax assets is dependent upon the generation of sufficient future taxable income to realize the deferred tax assets on the Company’s income tax returns. Management determined that it is more likely than not going that the Company’s deferred tax assets will not be realized due to the Company’s three-year cumulative loss position and the generation of future taxable income is uncertain.

F-29

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

The changes in the Company’s valuation allowance for deferred tax assets were as follows (in thousands):

Year Ended December 31, 2021

$

124,526

Charged to Income Tax Expense

(6,163)

Charged to Stockholders' Equity

 

15,326

Year Ended December 31, 2022

$

133,689

Charged to Income Tax Expense

(19,381)

Charged to Stockholders' Equity

25,999

Year Ended December 31, 2023

$

140,307

As of December 31, 2023 and 2022, the Company had U.S. federal net operating losses of $43.1 million and $33.2 million, respectively, which can be carried forward indefinitely. As of December 31, 2023 and 2022, the Company had state net operating losses of $35.6 million and $31.2 million, respectively, that begin to expire in 2038.

As of December 31, 2023, the Company is not indefinitely reinvested on undistributed earnings from its foreign operations. Due to the Company's structure, the foreign operations do not qualify for the indefinite reinvestment exceptions under ASC 740-30 as the earnings from the foreign operations are subject to U.S. taxation. However, the exception may still apply to foreign withholding taxes due to dividend distributions of earnings from the Company's foreign affiliates. The Company has no plans to make distributions from its foreign operations in the future and, therefore, a deferred tax liability has not been recognized. A determination of the unrecognized deferred taxes is not practicable.

A summary of the Company’s unrecognized tax benefits are as follows (in thousands):

Year Ended December 31, 

2023

    

2022

2021

Beginning balance

$

119

$

119

$

Increases for tax positions related to the current year

30

Increases (decreases) for tax positions of prior years

 

238

 

 

89

Expiration of statute of limitations

(41)

Ending balance

$

316

$

119

$

119

Interest and penalties

128

65

65

The Company’s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. As of December 31, 2023, the Company accrued has $128 thousand of interest and penalties.

The Company files tax returns in the United States and various foreign jurisdictions. The Company is currently being audited in the U.S. and India. However, the Company is no longer subject to examination by those taxing authorities with respect to the years ended prior to 2017. Although the outcome of tax audits is always uncertain and could result in significant cash tax payments, the Company does not believe the outcome of these audits will have a material adverse effect on its consolidated financial position or results of operations.

Tax Receivable Agreement

The Company expects to obtain an increase in its share of the tax basis in the net assets of Enfusion Ltd. LLC when Common Units are redeemed from or exchanged by the Pre-IPO Common Unitholders. The Company intends to treat any redemptions and exchanges of Common Units as direct purchases of Common Units for U.S. income tax purposes. These increases in tax basis may reduce the amounts that the Company would otherwise pay in the future to U.S. federal and state tax authorities. They may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets.

F-30

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

In connection with the IPO, the Company entered into the Tax Receivable Agreement with Enfusion Ltd. LLC, the Pre-IPO Owners that will provide for the payment by the Company to the Pre-IPO Owners of 85% of the amount of tax benefits, if any, that the Company actually realizes (or in some circumstances is deemed to realize) as a result of (1) the Company’s allocable share of existing tax basis acquired in connection with the Reorganization Transactions (including the Blocker Company’s share of existing tax basis) and increases to such allocable share of existing tax basis; (2) increases in tax basis resulting from (a) the Company’s purchase of Common Units directly from Enfusion Ltd. LLC and the partial redemption of Common Units by Enfusion Ltd. LLC, (b) future redemptions or exchanges (or deemed exchanges in certain circumstances) of Common Units for Class A common stock or cash, and (c) certain distributions (or deemed distributions) by Enfusion Ltd. LLC; and (3) certain additional tax benefits arising from payments made under the Tax Receivable Agreement. The Company may benefit from the remaining 15% of any tax benefits that the Company actually realizes.

In the years ended December 31, 2023, and 2022, the Company purchased an aggregate of 4,000,000 and 4,272,204 units, respectively, of Enfusion Ltd. LLC in connection with the exchange of those units by the Pre-IPO Common Unitholders, which resulted in an increase of $46.0 million and $48.2 in the tax basis of the net assets of Enfusion Ltd. LLC that would be subject to the provisions of the Tax Receivable Agreement in the years ended December 31, 2023, and 2022, respectively.

As of December 31, 2023 and 2022, the Company has not recorded a liability under the Tax Receivable Agreement related to the tax benefits originating from the Reorganization Transactions, IPO, and subsequent purchase of Common Units, as it is not probable that the Company will realize such tax benefits. To the extent the Company had determined that it would have been able to realize the tax benefits associated with the basis adjustments, it would have recorded a liability under the Tax Receivable Agreement of $96.5 million and $83.2 million as of December 31, 2023, and 2022, respectively.

The amounts payable under the Tax Receivable Agreement will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future. Should the Company determine that the Tax Receivable Agreement liability be considered probable at a future date based on new information, any changes will be recorded at that time.

Note 14   Related Party Transactions

Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial or operating decisions. Since transactions with related parties may raise potential or actual conflicts of interest between the related party and the Company, upon the completion of the IPO, the Company implemented a related party transaction policy that requires related party transactions to be reviewed and approved by its nominating and corporate governance committee.

On June 15, 2023, the Company sold 1.2 million shares of Class A common stock to FTV Investment Holdings, L.P. (“FTV Holdings”) and an affiliate in a private placement, at a per share purchase price equal to the average of the closing price of the Class A common stock over the 20 trading days preceding the transaction, which was approximately $8.12 per share. Total net proceeds of the transactions were $9.7 million. Equity issuance costs were immaterial. FTV IV, L.P. (“FTV Fund IV”) beneficially owns more than 5% of the Company’s issued and outstanding Class A common stock. Bradford Bernstein, a member of the Company’s Board of Directors, is a managing partner of FTV Capital and, along with other members of FTV Capital, indirectly shares voting and dispositive power with regard to the shares directly held by FTV Holdings and FTV Fund IV, respectively.

In the first quarter of 2023, the Company received approximately $1.5 million from the U.S. Treasury in the form of a tax refund owed to FTV Enfusion Holdings, Inc. (“FTV Enfusion”), which prior to the Company’s initial public offering in 2021 was a Blocker Company through which FTV Fund IV held its equity interests in Enfusion Ltd. LLC. The refund was generated due to overpayments by FTV Enfusion for U.S. federal income taxes associated with FTV Enfusion’s direct ownership of Enfusion Ltd. LLC for the fiscal years ended December 31, 2017 to December 31, 2020. The Company

F-31

Table of Contents

ENFUSION, INC.

Notes to Consolidated Financial Statements

obtained the right to this refund as a result of the merger of FTV Enfusion with and into one of the Company’s subsidiaries as part of the Reorganization Transactions (which did not take into account the value of the tax refund). On June 27, 2023, the Company distributed approximately $1.5 million (the amount of the refund) to FTV Fund IV.

Note 15   Subsequent Events

Share Exchange

On January 4, 2024, a Pre-IPO Common Unitholder delivered an exchange notice pursuant to Article XII of the LLC Operating Agreement. Pursuant to the terms of the LLC Operating Agreement, on January 11, 2024, the Pre-IPO Common Unitholder surrendered 1,000,000 Common Units and an equal number of shares of Class B common stock. In connection therewith, the Company issued 1,000,000 shares of Class A common stock to such Pre-IPO Common Unitholder, canceled an equal number of shares of Class B common stock, and received an equal number of Common Units, increasing the Company’s ownership of Common Units by 1,000,000.

F-32

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation required by the Exchange Act, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(e) of the Exchange Act, as of December 31, 2023. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2023, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer and the oversight of our audit committee, has evaluated the effectiveness of our internal control over financial reporting as of December 31, 2023. In assessing the effectiveness of our internal control over financial reporting, our management used the framework established in Internal Control Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that evaluation, our management has concluded that our internal control over financial reporting was effective as of December 31, 2023.

Our independent registered public accounting firm was not required to perform an evaluation of our internal control over financial reporting as of December 31, 2023 because as an “emerging growth company” we are exempt from Section 404(b) of the Sarbanes-Oxley Act.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended December 31, 2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls in future periods are subject to the risk that those internal controls may become inadequate because of changes in business conditions, or that the degree of compliance with the policies or procedures may deteriorate.

59

Item 9B. Other Information

Trading Arrangements

Oleg Movchan, our Chief Executive Officer, adopted a pre-arranged stock trading plan (the “10b5-1 Plan”), dated December 5, 2023, that provides for the sale of up to 400,000 shares of our Class A common stock between March 14, 2024 and December 31, 2024 pursuant to the terms of his 10b5-1 Plan. The 10b5-1 Plan was designed to comply with the guidelines specified in Rule 10b5-1 promulgated under the Exchange Act and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not applicable.

PART III

Item 10. Directors, Executive Officers, and Corporate Governance

The information required by this item is incorporated by reference to the definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, which will be filed with the SEC, no later than 120 days after December 31, 2023.

Item 11. Executive Compensation

The information required by this item is incorporated by reference to the definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, which will be filed with the SEC, no later than 120 days after December 31, 2023.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this item is incorporated by reference to the definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, which will be filed with the SEC, no later than 120 days after December 31, 2023.

Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this item is incorporated by reference to the definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, which will be filed with the SEC, no later than 120 days after December 31, 2023.

Item 14. Principal Accountant’s Fees and Services

The information required by this item is incorporated by reference to the definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, which will be filed with the SEC, no later than 120 days after December 31, 2023.

PART IV

Item 15. Exhibits and Financial Statement Schedules

The following documents are filed as a part of this Annual Report on Form 10-K:

(a) Financial Statements

Our consolidated financial statements are listed in the “Index to Consolidated Financial Statements” under Part II, Item 8 of this Annual Report on Form 10-K.

60

(b) Financial Statement Schedules

All financial statement schedules are omitted because the information called for is not required or is shown either in the consolidated financial statements or in the notes thereto.

(c) Exhibits

The documents listed in the exhibit index of this Annual Report on Form 10-K are incorporated by reference or are filed with this Annual Report on Form 10-K, in each case as indicated herein (numbered in accordance with Item 601 of Regulation S-K).

Item 16. Form 10-K Summary

None.

61

Exhibit
Number

    

Description

3.1

Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40949), filed with the Securities and Exchange Commission on December 3, 2021).

3.2

Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40949), filed with the Securities and Exchange Commission on December 3, 2021).

4.1

Form of common stock certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-259635), filed with the Securities and Exchange Commission on October 12, 2021).

4.2

Registration Rights Agreement, dated as of October 20, 2021, by and among the Registrant and each of the other persons from time to time party thereto (incorporated by reference to Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K (File No. 001-40949), filed with the Securities and Exchange Commission on March 30, 2022).

4.3

Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (incorporated by reference to Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K (File No. 001-40949), filed with the Securities and Exchange Commission on March 30, 2022).

10.1#

Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit 10.1 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-259635), filed with the Securities and Exchange Commission on October 12, 2021).

10.2

Seventh Amended and Restated Operating Agreement of Enfusion Ltd. LLC, dated as of October 19, 2021 (incorporated by reference to Exhibit 10.2 to the Registrant’s Annual Report on Form 10-K (File No. 001-40949), filed with the Securities and Exchange Commission on March 30, 2022).

10.3

Tax Receivable Agreement, dated as of October 19, 2021, by and among the Registrant and each of the other persons from time to time party thereto (incorporated by reference to Exhibit 10.3 to the Registrant’s Annual Report on Form 10-K (File No. 001-40949), filed with the Securities and Exchange Commission on March 30, 2022).

10.4#

2021 Stock Option and Incentive Plan, and forms of award agreements thereunder (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-259635), filed with the Securities and Exchange Commission on October 12, 2021).

10.5#

2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-259635), filed with the Securities and Exchange Commission on October 12, 2021).

10.6#

Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.6 to the Registrant’s Annual Report on Form 10-K (File No. 001-40949), filed with the Securities and Exchange Commission on March 10, 2023).

10.7*#

Employment Agreement, effective December 22, 2022, by and between Enfusion Ltd. LLC and Oleg Movchan, as amended by Appendix 1 – Scope of Employment, effective March 1, 2024.

10.8*#

Employment Agreement, effective December 14, 2022, by and between Enfusion Ltd. LLC and Bradley Herring, as amended by Appendix 1 – Scope of Employment, dated March 1, 2024.

10.9#

Employment Agreement, effective November 7, 2023, by and between Enfusion Ltd. LLC and Neal Pawar (incorporated by reference to Exhibit 10.1 to the Registrant’s current report on Form 8-K (File No. 001-40949), filed with the Securities and Exchange Commission on November 20, 2023).

10.10*#

Employment Agreement, effective September 1, 2021, by and between Enfusion Ltd. LLC and Bronwen Bastone, as amended by Appendix 1 – Scope of Employment, effective March 1, 2024.

10.11*#†

Employment Agreement, effective February 1, 2021, by and between Enfusion Ltd. LLC and Matthew Campobasso, as amended by Appendix 1 – Scope of Employment, dated March 1, 2024.

10.12*#†

Employment Agreement, effective February 7, 2022, by and between Enfusion Ltd. LLC and Valeria Gutowski, as amended by Appendix 1 – Scope of Employment, effective January 15, 2024.

10.13

Lease, dated March 6, 2017, by and between Registrant and 125 S. Clark (Chicago) SBE, LLC, as amended (incorporated by reference to Exhibit 10.14 to the Registrant’s Registration Statement on Form S-1 (File No. 333-259635), filed with the Securities and Exchange Commission on September 28, 2021).

62

10.14

Credit Agreement dated as of September 15, 2023 among Enfusion Ltd. LLC, the Registrant, the guarantors party thereto, Bank of America, N.A. as administrative agent, swing line lender and L/C issuer and the lenders thereto (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40949), filed with the Securities and Exchange Commission on September 18, 2023).

21.1*

Subsidiaries of the Registrant.

23.1*

Consent of Ernst & Young LLP, independent registered public accounting firm.

24.1*

Power of Attorney (included in signature pages hereto).

31.1*

Certification of the Principal Executive Officer, pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

Certification of the Principal Financial Officer, pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**

Certification of the Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**

Certification of the Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

97*

Compensation Recovery Policy of the Registrant.

101.INS*

Inline XBRL Instance Document.

101.SCH*

Inline XBRL Taxonomy Extension Schema Document.

101.CAL*

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF*

Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB*

Inline XBRL Taxonomy Extension Labels Linkbase Document.

101.PRE*

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104*

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

#

Indicates management contract or compensatory plan, contract, or agreement.

*

Filed herewith.

**

Furnished herewith. The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the SEC and are not to be incorporated by reference into any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.

Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission.

63

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in Chicago, Illinois, on March 12, 2024.

ENFUSION, INC.

By:

/s/ Oleg Movchan

Oleg Movchan

Chief Executive Officer

(Principal Executive Officer)

By:

/s/ Bradley Herring

Bradley Herring

Chief Financial Officer

(Principal Financial Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Oleg Movchan and Bradley Herring, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such individual in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or the individual's substitute, may lawfully do or cause to be done by virtue hereof.

64

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below on March 12, 2024 by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

Signature

    

Title

Date

/s/ Oleg Movchan

Chief Executive Officer and Director

March 12, 2024

Oleg Movchan

(Principal Executive Officer)

/s/ Bradley Herring

Chief Financial Officer

March 12, 2024

Bradley Herring

(Principal Financial Officer)

/s/ Valeria F. Gutowski

Chief Accounting Officer

March 12, 2024

Valeria Gutowski

(Principal Accounting Officer)

/s/ Michael Spellacy

Chair and Director

March 12, 2024

Michael Spellacy

/s/ Bradford E. Bernstein

Director

March 12, 2024

Bradford E. Bernstein

/s/ Kathleen Traynor DeRose

Director

March 12, 2024

Kathleen Traynor DeRose

/s/ Jan R. Hauser

Director

March 12, 2024

Jan R. Hauser

/s/ Lawrence Leibowitz

Director

March 12, 2024

Lawrence Leibowitz

/s/ Roy Luo

Director

March 12, 2024

Roy Luo

/s/ Deirdre Somers

Director

March 12, 2024

Deirdre Somers

65

EX-10.6 2 enfn-20231231xex10d6.htm EX-10.6

Exhibit 10.6

Enfusion, Inc.

Non-Employee Director Compensation Policy

The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Enfusion, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (“Outside Directors”).  In furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as set forth below:

I.Retainers

(a)

Annual Retainer for Board Membership:  $40,000 for general availability and participation in meetings and on conference calls of our Board of Directors (the “Board of Directors”).  No additional compensation for attending individual Board of Director meetings.

(b)

Additional Annual Retainers for Committee Membership:

Board Chair (through 2025 fiscal year)

    

$

150,000

 

Board Chair (2026 fiscal year and onwards)

$

50,000

Audit Committee Chair:

$

20,000

Audit Committee member:

$

10,000

Compensation Committee Chair:

$

15,000

Compensation Committee member:

$

6,500

Nominating and Corporate Governance Committee Chair:

$

10,000

Nominating and Corporate Governance Committee member:

$

5,000

No additional compensation for attending individual committee meetings.  All cash retainers will be paid quarterly, in arrears, or upon the earlier resignation or removal of the Outside Director.  Cash retainers owing to Outsider Directors shall be annualized, meaning that with respect to Outside Directors who join the Board of Directors during the calendar year, such amounts shall be pro-rated based on the number of calendar days served by such director. The Board Chair retainer shall be paid in cash or restricted stock units, at the election of such Chair, in accordance with standard pay practices under the Policy.

II.Retainers

All grants of equity retainer awards to Outside Directors pursuant to this Policy will be automatic and nondiscretionary and will be made in accordance with the following provisions:

(a)Value. For purposes of this Policy, “Value” means with respect to (i) any award of stock options the grant date fair value of the option (i.e., Black-Scholes Value) determined in accordance with the reasonable assumptions and methodologies employed by the Company for calculating the fair value of options under ASC 718; and (ii) any award of restricted stock and restricted stock units (“RSUs’) the product of (A) the average closing market price on the New York Stock Exchange of one share of the Company’s common stock over the trailing 30-day period


up to and including the last day immediately preceding the grant date and (B) the aggregate number of shares pursuant to such award.

(b)Revisions.  The Compensation Committee (the “Compensation Committee”) in its discretion may change and otherwise revise the terms of awards to be granted under this Policy, including, without limitation, the number of shares subject thereto, for awards of the same or different type granted on or after the date the Compensation Committee determines to make any such change or revision.

(c)Sale Event Acceleration.  In the event of a Sale Event (as defined in the Company’s 2021 Stock Option and Incentive Plan (as amended from time to time, the “Stock Plan”)), the equity retainer awards granted to Outside Directors pursuant to this Policy shall become 100% vested and exercisable.

(d)Initial Grant. Upon initial election to the Board of Directors, each new Outside Director will receive an initial, one-time equity grant (the “Initial Grant”) of restricted stock units with a Value of $187,500.  The Initial Award shall vest in equal annual installments over three years from the date of grant.  This Initial Award applies only to Outside Directors who are first elected to the Board of Directors subsequent to the Effective Date.  All vesting of the Initial Grant shall cease if the director resigns from our Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

(e)Annual Grant. On the date of the Company’s Annual Meeting of Stockholders (the “Annual Meeting”),  each Outside Director who will continue as a member of the Board of Directors following such Annual Meeting will receive a restricted stock unit grant on the date of such Annual Meeting of Stockholders (the “Annual Grant”) with a Value of $125,000.  The Annual Grant shall vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the next Annual Meeting. All vesting of the Annual Grant shall cease if the director resigns from our Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

III.Expenses

The Company will reimburse all reasonable out-of-pocket expenses incurred by Outside Directors in attending meetings of the Board of Directors or any committee thereof.

IV.Maximum Annual Compensation

The aggregate amount of compensation, including both equity compensation and cash compensation, paid to any Outside Director in a calendar year period shall not exceed the limits set forth in the Stock Plan or any similar provision of a successor plan).

Date Policy Approved: January 9, 2023


EX-10.7 3 enfn-20231231xex10d7.htm EX-10.7

Exhibit 10.7

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”

EMPLOYMENT AGREEMENT

This employment agreement, which shall include and incorporate by reference any appendix attached hereto, now or in the future (collectively “Agreement”), is entered into on December 22, 2022, (“Effective Date”), by and between ENFUSION LTD. LLC (“Enfusion”), with its principal place of business located at 125 SOUTH CLARK STREET, SUITE 750, CHICAGO, ILLINOIS 60603, and Oleg Movchan, (“Employee”), an individual with a notice address of: [***] (each a “Party” or collectively, the “Parties”).

WHEREAS, Enfusion is in the business of creating and providing software and related products and services to clients in the investment and financial services industry throughout the United States and Global market with offices in Chicago and New York City and affiliate offices in London, Dublin, Hong Kong, Singapore, São Paulo, Shanghai, Sydney, Mumbai, and Bengaluru;

WHEREAS, Enfusion desires to hire Employee to perform certain services as described in this Agreement and any appendix attached hereto, and Employee desires to be hired by Enfusion to perform certain services described in this Agreement and any appendix attached hereto, each in accordance with the terms and conditions of this Agreement as may be amended or supplemented from time-to-time; and,

NOW THEREFORE, in exchange for good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the Parties covenant and agree as follows:

1.

Interpretation. Unless the context of this Agreement otherwise requires: (i) a capitalized word has the meaning assigned to it by this Agreement; (ii) “or” will be construed such that the series may include any of the items, all of the items, or any combination of the items; (iii) words in the singular include the plural, and words in the plural include the singular; (iv) provisions apply to successive events and transactions; (v) “hereof,” “hereunder,” “herein,” and “hereto” refer to the entire Agreement and not any section or subsection; (vi) references in this Agreement to sections or annexes are references to the sections of or annexes attached to this Agreement; (vii) “in writing” refers to in written or printed form, facsimile transmission, or e-mail; (viii) the term “include” does not create an exclusive list and should be interpreted, in any variation, as “includes, but is not limited to;” (ix) the phrase “any reason” should be read as “any reason or no reason;” and, (x) the headings in this Agreement are for reference only and shall not limit or otherwise affect the meaning, interpretation, or construction of this Agreement.

2.

Employment. Enfusion hereby agrees to employ Employee and Employee hereby agrees to accept Enfusion’s employment offer, each subject to and in accordance with the terms and conditions of this Agreement.

3.

Classification of Employment. Employee’s classification as Exempt or Non-Exempt under Fair Labor Standards Act (“FLSA”) shall be determined by Enfusion and any changes to the Employee’s classification shall be communicated by Enfusion to the Employee.

4.

Duties. Employee’s initial appointment and non-exhaustive description of duties are described on Appendix 1 (Scope of Employment) and are subject to the terms and conditions of this Agreement. Despite the duties described on Appendix 1, Employee understands and acknowledges that Enfusion, at its sole discretion, has the right to modify or redefine Employee’s duties or title at any time, for any reason.

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


5.

Work Hours. Enfusion’s ordinary office hours are 8:00AM to 5:00PM, Monday through Friday. Unless otherwise specified on Appendix 1, Employee’s regular workweek shall be forty (40) hours on a schedule of eight (8) working hours per day, Monday through Friday; however, Employee understands and agrees that from time-to-time and subject to applicable law, Employee may be required to work additional hours, including weekends and holidays, as necessary to support Enfusion’s business. Employee understands and agrees, Employee’s work hours and surrounding terms may be modified at Enfusion’s sole discretion to the furthest extent permitted by applicable law.

6.

Location. Employee’s assigned work location (the “Office”) will be described on Appendix 1. Subject to the terms and conditions of this Agreement and applicable law, Employee is required to be present at the Office during Work Hours (defined on Appendix 1).

7.

Performance of Duties; Exclusive Service. Employee has a duty of loyalty and care to Enfusion and agrees to perform their obligations faithfully and to the best of their ability. Similarly, Employee hereby agrees to abide by Enfusion’s policies and procedures (as amended from time-to-time) and agrees to devote their business time, attention, and efforts to Enfusion’s business (except for permitted break periods, vacation periods, and reasonable periods of illness or other incapacity). Despite the foregoing sentence, Employee may serve as a director of or otherwise participate in educational, welfare, social, religious, and civic organization, provided that Employee’ service or participation does not: (i) unreasonably interfere with performing their duties; and, (ii) violate any provision of this Agreement. For clarity, while employed by Enfusion, Employee is not allowed to perform duties or services for any other employer, business, or organization (including establishing or maintain their own business or organization) other than as permitted by this Agreement or with the written consent of an Enfusion authorized officer.

a)Business Ideas/Opportunities. During their employment, Employee may come up with or across potential business opportunities related to Enfusion’s business and services (“Business Opportunity”). If so, Employee agrees to promptly disclose any Business Opportunity to Enfusion so that Enfusion has an opportunity to pursue the Business Opportunity. Employee acknowledges and agrees that pursuing a Business Opportunity for Employee’s or another’s benefit, without first disclosing it and getting Enfusion’s prior written approval would be a violation of their duty of loyalty and care to Enfusion and that Employee is prohibited from pursuing a Business Opportunity, whether for Employee’s or another’s benefit, without Enfusion’s prior written approval. Enfusion’s reserves the right to deny Employee’s request to pursue a Business Opportunity in Enfusion’s sole discretion.

8.

Compensation and Benefits. Employee is entitled to certain compensation and benefits, which are outlined below and described further on Appendix 1.

a)Salary. Enfusion agrees to pay Employee for services rendered under this Agreement. Employee’s Salary (as defined on Appendix 1) will be paid in accordance with Enfusion’s normal payroll policies and procedures. To be clear, although Employee is paid an annual salary, Employee’s employment is “at-will” (discussed below). Enfusion, at its sole discretion, may adjust Employee’s Salary after the first twelve (12) months of employment and reserves the right to adjust Employee’s Salary from time-to-time.

b)Benefits. During Employee’s employment, except as otherwise expressly provided herein, Employee will be entitled to participate in all employee health, welfare and other benefit plans and programs (“Employee Benefit Plans”) applicable to similarly situated employees of Enfusion, as in effect from time to time, to the extent consistent with applicable law and the terms of the applicable employee

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


benefit plan. Enfusion reserves the right to amend or cancel any Employee Benefit Plans at any time in its sole and absolute discretion, subject to the terms of the employee benefit plan and applicable law.

c)Vacation. Employee will be subject to Enfusion's Flexible Time Off Policy as outlined in Appendix 1. Employee should use their best efforts not to schedule Flexible Time Off that will conflict with their duties and when possible, agrees to provide Enfusion with at least one (1) to two (2) weeks’ prior notice of any planned vacation subject to the terms of the policy. Enfusion reserves the right, in its sole discretion, to approve or deny any requested Flexible Time Off. Flexible Time Off is subject to certain restrictions on use as outlined in the Enfusion Flexible Time Off Policy.

d)Bonus.

i.Discretionary Bonus. Enfusion may, from time-to-time, in its sole discretion, choose to pay Employee additional compensation as a discretionary bonus. Whether and when a bonus is awarded, and the amount (if any) of bonus awarded, will be determined in Enfusion’s sole discretion on whatever basis and after taking into account whatever factors it considers appropriate at the time. Any bonus is not earned until paid. Therefore, to receive any bonus, Employee must be employed by Enfusion and in good standing on the bonus’s payment date and must not have indicated their intent to resign prior to or on such payment date.

ii.Other Bonus. If the Employee is eligible to receive a non-discretionary (annual performance bonus) or other type of commission-based compensation, then it will be described on Appendix 1.

e)Payments. All payments made to Employee in the course of their employment will be paid in accordance with Enfusion’s normal payroll policies and procedures. Further, all compensation payments made in the course of Employee’s employment will be subject to any applicable withholding requirements or other similar obligations.

f)Expenses. Enfusion will reimburse Employee for out-of-pocket expenses incurred by Employee in the course of their employment pursuant to Enfusion’s reimbursement policy and in each case, subject to applicable law.

Consideration. In consideration for Employee agreeing to Sections 11 and 14 of this Agreement, the Company will provide the employee consideration, including, but not limited to, an at-will employment relationship, or continued at-will employment; training; and access to, or continued access to the Company’s Confidential Information and client, customer and business relationships during Employee’s employment. Employee agrees the consideration outlined in this paragraph is sufficient consideration for Employee’s various obligations under Sections 11 and 14 of this Agreement. Employee understands that acceptance of this Agreement is a condition of employment and that the Company would not offer to employ Employee and grant Employee access to its Confidential Information and client and customer relationships, but for Employee’s acceptance of the terms of this Agreement and acknowledgment that the consideration outlined herein is sufficient consideration for Employee’s obligations under Sections 11 and 14 of this Agreement.

9.

Employment Relationship and Termination. “Termination Date” means the date on which Employee ceases work for Enfusion, whether voluntary or involuntary.

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


a)AT-WILL” EMPLOYMENT. EMPLOYEE ACKNOWLEDGES AND AGREES THAT THEIR EMPLOYMENT IS “AT-WILL.” THIS MEANS, BOTH ENFUSION AND EMPLOYEE MAY TERMINATE EMPLOYEE’S EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON, WITHOUT LIABILITY FOR BREACH OF CONTRACT, PROMISSORY ESTOPPEL, SEVERANCE PAY, OR OTHERWISE.

b)Voluntary Termination. Although Employee has the right to terminate their employment at any time for any reason, Employee, if classified as a Level 3, 4 or 5 Employee, agrees to provide Enfusion with at least thirty (30) days’ prior notice to the date on which Employee intends to cease working for Enfusion. If Employee is classified as a Level 2 Employee, Employee agrees to provide Enfusion with at least sixty (60) days’ prior notice to the date on which Employee intends to cease working for Enfusion. If Employee is classified as a Level 1 Employee, Employee agrees to provide Enfusion with at least ninety (90) days’ prior notice to the date on which Employee intends to cease working for Enfusion. Employee’s initial level is contained within Appendix 1 of this Agreement. Upon receipt of Employee's notice of their intent to cease working for Enfusion, Enfusion may, in its sole discretion, choose to reduce Employee's notice period (as described in this paragraph) without additional obligations to Employee.

c)Final Payment. Unless otherwise required by applicable state law, upon Employee’s Termination Date, Enfusion shall provide Employee with a date, no later than Enfusion’s next regular pay date, on which Employee will receive their final payment for all accrued Salary and any other pay owed through the Termination Date.

10.

Representations. Employee understands and acknowledges that the following representations and covenants are essential to Enfusion’s decision to enter into this Agreement. Employee represents and warrants to Enfusion as follows:

a)Other than as already disclosed by Employee to Enfusion, as of the Effective Date, Employee is not under any contractual or legal duty or obligation, engagement, understanding, restriction, or commitment with any prior employer, other entity or individual other than Enfusion or its Affiliates ("Other Employer”) that would limit, prohibit, or interfere with Employee’s full and faithful performance of this Agreement, including but not limited to, employment, consulting, confidentiality, non-competition, or non-solicitation agreements or restrictive covenants; Employee certifies that if they have made a disclosure of a contractual or legal duty or obligation, engagement, understanding, restriction, or commitment with any Other Employer that would limit, prohibit, or interfere with Employee’s full and faithful performance of this Agreement, including but not limited to, employment, consulting, confidentiality, non-competition, or non-solicitation agreements or restrictive covenants, that their disclosure was a complete disclosure of any applicable terms.

b)Employee does not have any inventions or intellectual property obligations which may affect assignment under Section 13, other than what Employee has disclosed in Appendix 2;

c)If applicable, Employee has disclosed any Other Employers existing as of the Effective Date;

d)If applicable, Employee has complied with all duties imposed on Employee by their former employer with respect to termination of their employment;

e)Employee is free to enter this Agreement and commence employment with Enfusion;

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


f)Employee understands and acknowledges the offer of employment made pursuant to this Agreement is made only to Employee for their personal services, and at no time has Employee been authorized to recruit, induce, entice, or offer employment at Enfusion to any other person;

g)Employee covenants not to use, disclose, or induce the use of, any trade secret, confidential information, or proprietary information that belongs to any third party in the performance of Employee’s employment under this Agreement, unless Employee has prior written consent from the owner of the protected information (which, Employee agrees to provide such written consent to Enfusion); and,

h)Employee is not aware of: (i) any pending internal, criminal, civil, regulatory, or self-regulatory organization investigations involving Employee or any of Employee’s activities at any former employer or in relation to or arising out of Employee’s prior employment ; (ii) any pending customer complaints or customer arbitrations involving any of Employee’s activities at any former employer or in relation to or arising out of Employee’s prior employment; or, (iii) any circumstances that might lead to any of the matters described in this subsection. If Employee is aware of any such issues, Employee has disclosed such in writing to Enfusion’s Chief Human Resources Officer at least seven (7) days prior to the parties entering into this Agreement.

11.

Confidential Information and Confidentiality.

a)Employee acknowledges and agrees that through their employment, he or she will be provided, obtain, or be exposed to proprietary or non-public information relating to Enfusion’s business, which is confidential in nature. Such information includes, client lists or client related information, information related to or concerning Enfusion’s products and services; fees, costs, and pricing structures; market studies; business plans and investment analyses; designs and specifications; data and analyses; drawings, photographs, and reports; computer software, object code, source code, operating systems, applications, algorithms, and program listings; flow charts, manuals, and documentation, ideas, images, text, music, movies, concepts, video, and websites; databases; accounting and business methods; inventions, devices, new developments, methods, and processes, (whether patentable or non-patentable and whether or not reduced to practice); investor or ownership information, Client and Prospective Client information; copyrightable works; technology and trade secrets; historical financial statements, financial projections, and budgets; personnel training techniques and materials; and any other personal, business, financial, or technical information, data, patents, or ideas relating to the proprietary information observed by, or disclosed to, Employee, whether in oral, written documents, memoranda, reports, or correspondence in graphic or machine-readable form, or otherwise in the course of, or in connection with, Employee’s employment with Enfusion (individually and collectively “Confidential Information”).

b)Employee hereby agrees that he or she will not disclose nor use at any time; before, during, or after their employment with Enfusion; any Confidential Information of which Employee is or becomes aware of, whether or not such information is developed by Employee, except to the extent such disclosure or use is directly related to or required for Employee’s performance of their employment duties. Further, Employee agrees he or she will take all reasonable and appropriate steps to safeguard the Confidential Information and to protect it against disclosure, misuse, espionage, loss, or theft and will not disclose or use any Confidential Information except as reasonably necessary to perform Employee's duties for the Company, or as required by law. Employee further agrees not to otherwise transmit or download any Confidential Information to Employee's personal computer, cellular telephone, or other electronic device, or otherwise remove Confidential Information from the Company's premises or Company-owned computer, unless Employee secures the Company's specific authorization in advance and takes appropriate

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


steps to protect such information. Employee understands and agrees that all Confidential Information, including documents, records, and electronic files, to which Employee has access as a result of Employee's employment by the Company are the exclusive property of the Company. Employee also acknowledges and agrees that all Confidential Information, and all copyrights, trademarks, patents and other rights in connection therewith, shall be the sole property of the Company and its assigns. For clarity, nothing herein is intended to prevent Employee from disclosing information that Employee has a legal right to disclose.

c)Exceptions. Confidential Information shall not include any information that: (i) was in the possession of, or demonstrably known by, (in each case without restriction on its use or disclosure) the Employee prior to their receipt of such information; (ii) any information independently known by Employee without access to or reliance upon any Confidential Information, including the general skills, knowledge and experience acquired by the Employee before and/or during employment with the Company; (iii) was lawfully disclosed to Employee following the end of their employment with Enfusion by a third party under no known obligation of confidentiality; (iv) is in the public domain at the time of disclosure, or thereafter becomes in the public domain, other than as a result of disclosure by Employee in violation of this Agreement.

d)In the event Employee is required under a subpoena, court order, statute, law, rule, regulation, or other similar requirement, (“Legal Requirement”) Employee shall do so only to the extent required by the Legal Requirement, must provide prompt written notice to Enfusion of the disclosure to the extent not precluded by law, and must designate the information as Confidential Information when disclosing such information. Further, when legally permissible, the Employee shall notify Enfusion of what Confidential Information was disclosed under such Legal Requirement.

e)Defend Trade Secrets Act of 2016 (DTSA) Notice. Notwithstanding any other provision of this Agreement, pursuant to Section 7 of the DTSA, the Employee cannot be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that: (1) is made: (A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. (ii) If Employee files a lawsuit for retaliation by Company for reporting a suspected violation of law, Employee may disclose Company’s trade secrets to Employee’s attorney and use the trade secret information in the court proceeding if Employee: (1) files any document containing the trade secret under seal; and (2) does not disclose the trade secret, except pursuant to court order.

f)Violation of Law. If Employee believes Enfusion has committed or is committing a violation of law, although not required, he or she is asked to first report the possible violation to Enfusion’s executive leadership so that Enfusion may take the proper corrective actions. Despite the foregoing, Employee is free to report possible violations, file a charge with, or participate or cooperate with any governmental agency or entity, including but not limited to the EEOC, the Department of Justice, the Securities and Exchange Commission, Congress, or any agency Inspector General, or make any other disclosures that are protected under the whistleblower, anti-discrimination or anti-retaliation provisions of federal, state or local law or regulation; provided further, the Employee does not need the prior authorization of the Company to make any such reports or disclosures, and the Employee is not required to notify the Company that the Employee has made such reports or disclosures.

g)Trading. Employee understands and agrees he or she is not permitted to use Enfusion’s or Clients’ Confidential Information on their behalf, on the behalf of others, or to assist others in trading securities.

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


Employee further acknowledges that to use Enfusion’s or Client’s Confidential Information for personal financial benefit or to “tip” others who might make an investment decision on the basis of this information is not only prohibited and unethical, but is also illegal.

12.

Company Property. Upon Enfusion’s request or Employee’s Termination Date, Employee shall, to the extent such materials are in Employee’s possession or under Employee’s control, promptly deliver to Enfusion: (i) all original and any copies of emails, employee training materials, records, agreements, manuals, books, blank forms, documents, letters, memoranda, notes, notebooks, reports, data, tables, or calculations, which are the property of Enfusion or its Affiliates and that relate, in any way, to the business, products, policies, practices, or techniques thereof, including any strategies; (ii) all other Enfusion property, including any Enfusion issued credit cards, identification, keys, computers, cell phone, or other equipment; (iii) all Confidential Information of Enfusion or its Affiliates, including all documents that, in whole or in part, contain any Confidential Information of Enfusion or its Affiliates or their respective clients or licensors; and (iv) all proprietary information, intellectual property and trade secrets of Enfusion or its Affiliates or their respective clients or licensors. In addition, if applicable, Employee shall promptly cancel or transfer to himself or herself any telecommunications services for which Enfusion was directly paying. Nothing in this Section shall prohibit Employee from retaining papers or materials that are solely of a personal nature, including copies of documents showing their compensation or reimbursable expenses and a copy of this Employment Agreement.

13.

Intellectual Property. (“Intellectual Property”) means any and all intellectual property in any form or stage of development, including any innovation, discovery, idea, concept, design, prototype, product configuration, invention, improvement, modification, patentable subject matter, method, process, technique, procedure, system, plan, model, program, software or code, source code, algorithms, data, specification, drawing, images, text, music, movies, video, websites, diagram, flow chart, documentation, know-how, work of authorship, copyrightable subject matter, derivative work, trademark or trade name, and any other subject matter, material, or information that qualifies or is considered by Employer to qualify for patent, copyright, trademark, trade dress, trade secret, or any other protection under any law providing or creating intellectual property rights, including the Uniform Trade Secrets Act. Intellectual Property also includes Confidential Information learned, obtained, or developed in connection with Employee’s employment, such as specifications, financial data, personnel information, market information, business arrangements, and other non-public information of Employer described in Section [11] of this Agreement. EMPLOYEE AGREES THAT ANY INTELLECTUAL PROPERTY CONCEIVED OR MADE BY EMPLOYEE, WHETHER ALONE OR WITH OTHER, DURING THE TERM OF EMPLOYEE’S EMPLOYMENT WITH ENFUSION RELATING IN ANY MANNER TO THE BUSINESS, BUSINESS PLANS, OR STRATEGIES OF ENFUSION OR ITS AFFILIATES, SHALL BE THE EXCLUSIVE PROPERTY OF ENFUSION OR SUCH AFFILIATE. WITHOUT LIMITING THE FOREGOING, TO THE EXTENT ANY COPYRIGHTABLE WORK IS INCLUDED IN THE FOREGOING, IT WILL BE DEEMED ‘A WORK MADE FOR HIRE” FOR THE BENEFIT OF ENFUSION OR SUCH AFFILIATE UNDER SECTION 201(b) OF THE 1976 U.S. COPYRIGHT ACT, AS AMENDED, OR OTHER SIMILAR APPLICABLE STATE OR FOREIGN OR INTERNATIONAL LAWS. FURTHER, EMPLOYEE AGREES THAT ALL INVENTIONS, HE OR SHE DEVELOPS OR DEVISES (WHETHER INDIVIDUALLY OR IN CONCERT WITH OTHERS): (i) USING ENFUSION’S EQUIPMENT, SUPPLIES, RESOURCES, OR CONFIDENTIAL INFORMATION; (ii) RESULTING FROM WORK HE OR SHE PERFORMS OR PERFORMED FOR ENFUSION; OR, (iii) RELATING TO ENFUSION’S CURRENT OR PLANNED RESEARCH OR DEVELOPMENT WILL BE ENFUSION’S SOLE AND EXCLUSIVE PROPERTY. ACCORDINGLY, EMPLOYEE HEREBY ASSIGNS ALL INTELLECTUAL PROPERTY RIGHTS, TITLE, AND INTERESTS TO ENFUSION AND WAIVES ANY MORAL RIGHTS IN THE INTELLECTUAL PROPERTY TO THE FURTHEST EXTENT PERMITTED BY LAW.

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


14.

Restrictive Covenants. Employee understands and recognizes that Enfusion is engaged in a highly competitive business and has spent a considerable amount of time, effort, and resources building its business, products, client base (domestically and internationally), and training its employees. Further, Employee through their employment will receive training regarding and have access to Enfusion’s (and its clients’ and licensors’) Confidential Information (as defined above), trade secrets, and sensitive proprietary business methods or data, customer lists, and other valuable business information. Employee acknowledges and agrees that Enfusion has a legitimate business interest in protecting its goodwill, client and employee base, Confidential Information, trade secrets, and other proprietary information. Accordingly, Employee agrees to be bound by the following restrictive covenants (“Restrictive Covenants”), which are reasonably tailored to protect Enfusion’s legitimate interests from improper and unfair competition, and will not unreasonably impair or infringe on Employee’s right to work or earn a living after Employee’s Termination Date:

a)Definitions: For purposes of this section, the following terms are defined as follows:

i.(“Client”) means a person or organization who has retained, in writing or otherwise, Enfusion or any of its Affiliates to perform a service for compensation, which is, is related to, or is an extension of Enfusion’s or its Affiliates’ normal line of business and which Employee was involved; and,

ii.(“Prospective Client”) means a person or entity that has not yet retained, in writing or otherwise, Enfusion or any of its Affiliates to perform a service for compensation as described above when defining Clients, but instead, is a person or entity that Enfusion or any of its Affiliates reasonably expect to do so by virtue of Prospective Client’s solicitation of Enfusion or its Affiliates or Enfusion’s or its Affiliates’ targeted, direct solicitation of that person or entity within a six (6) month period immediately prior to Employee’s Termination Date.

b)Non-solicitation of Enfusion’s Employees. Throughout Employee’s employment with Enfusion and for a period of one (1) year, to commence on Employee’s Termination Date, Employee agrees not to: directly or indirectly, through any person or entity, or as an agent for any person or entity, authorize, encourage, suggest, or approve any person or entity to employ or cause to be employed, entice, induce, or solicit employment or engagement, in any capacity, any person that Employee had contact with and who is employed by Enfusion or any of its Affiliates or was employed or engaged by Enfusion or its Affiliates within three (3) months of the solicitation. While there is no geographic restraint, Employee understands and acknowledges that the restriction prohibiting solicitation of Enfusion employees is necessary and reasonable based upon Enfusion’s global presence and to protect Enfusion’s legitimate interest in its employee base and the resources utilized in training and maintaining such employee base.

c)Non-solicitation of Enfusion’s Clients. Throughout Employee’s employment with Enfusion and for a period of one (1) year, to commence on Employee’s Termination Date, Employee agrees not to: directly or indirectly, through any person or entity, or as an agent for any person or entity, authorize, encourage, suggest, or approve any person or entity to directly or indirectly, through any person or entity, or as an agent for any person or entity, or authorize, encourage, suggest, or knowingly approve any person or entity to, induce, attempt to induce, or entice any Client (as defined above) or Prospective Client (as defined above), in whole or in part, from doing business with Enfusion or any such Affiliate, regardless of which party initiates the contact or communication; or directly or indirectly, or through any person or entity, authorize, encourage, suggest, or knowingly approve any person or entity to, solicit, communicate with, contact, sell or render assistance, services or products to any Client or Prospective Client that would

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


interfere with, take away, divert, or urge any Client or Prospective Client to discontinue, in whole or in part, business with Enfusion or any of its Affiliates. While there is no geographic restraint, Employee understands and acknowledges that the restriction prohibiting solicitation of any Enfusion Client or Prospective Client is limited to those Clients or Prospective Clients with whom Employee worked, to whom Employee marketed or sold services or products, or about whom Employee received Confidential Information, as such would give Employee an unfair competitive advantage. Employee agrees this restriction is necessary and reasonable, without regard to geographic constraint, based upon the Employee’s knowledge and/or interaction with the Client or Prospective Client and to protect Enfusion’s legitimate interest in protecting its business relationships.

d)Non-compete. Employee understands and recognizes that: (i) Enfusion has spent a considerable amount of time and resources into training Employee; and, (ii) Employee will gain access to or knowledge of confidential and proprietary information and of practices, successes, and failures during the course of their employment; and, (iii) Employee will build relationships with Enfusion clients or prospective clients through their employment with Enfusion, made possible through Enfusion’s brand and resources, each of which Enfusion has a legitimate interest in protecting and Enfusion’s competitors or prospective competitors will gain an unfair advantage by obtaining the benefit of such foregoing investments made into and interests obtained by Employee. Therefore, throughout Employee’s employment with Enfusion and throughout the Restricted Period (as defined below), Employee agrees not to, directly or indirectly, alone or in association with or on behalf of any other person or entity, engage in any Competitive Activity (as defined below) (“Restricted Employment”).

i.Restricted Period. (“Restricted Period”) means a period of twelve (12) months to commence on Employee’s Termination Date.

ii.Competitive Activity. (“Competitive Activity”) means:

1.

Engaging in a Competitive Business (as defined below) directly or indirectly, on Employee’s own behalf or on the behalf of another;

2.

Providing services, similar or related to any services Employee provided to Enfusion while employed by Enfusion, to any person engaged in a Competitive Business, whether as an employee, consultant, officer, director, manager, partner, principal, agent, representative, or in any other capacity; or,

3.

Controlling (by contract, equity ownership, or otherwise), investing in (except as the owner of up to 3% of the securities of a publicly-traded entity), or providing other financial support to any person engaged in a Competitive Business.

iii.Competitive Business. (“Competitive Business”) means:

1.

Asset Management Software, including (a) portfolio management system; (b) order management system; (c) execution management system; (d) fund accounting system; or (e) fund risk management system, or any combination of the foregoing or any software substantially similar to any new software offering Enfusion offers or proposes to offer during Employee’s employment at Enfusion and in which Employee was involved in or received Confidential Information or trade secrets regarding; or

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


2.

Any middle- or back-office services or servicing tied to Enfusion’s software that Enfusion offers or proposes to offer during Employee’s employment at Enfusion and in which Employee was involved in or received Confidential Information or trade secrets regarding, or any other similar software that is an alternative to or competes with Enfusion’s managed services offering, whether in whole or in part; or

3.

Any other business or extension of a line of business in which Enfusion was engaged at any time during Employee’s employment, or in which Enfusion plans to engage or is considering plans to engage at the time of the Termination Date (as evidenced in writing) and in which Employee was involved or about which Employee received Confidential Information or trade secrets.

e)Notice. During the Restricted Period, Employee shall notify any other employers or prospective employers of their obligations under this Agreement before Employee begins working for such employer and further, agrees to simultaneously deliver a copy of such notice to Enfusion in accordance with Section 19 (Notices). Further, Employee agrees that Enfusion may also notify such other employers or prospective employers of Employee’s obligations under this Agreement. Employee agrees to inform Enfusion of the name, address, and telephone number of Employee’s supervisor at each subsequent employer to whom Employee reports this Agreement during the Restricted Period.

f)Undue Hardship. If Employee believes in good faith that the provisions in this Section will prevent him or her from obtaining a new job due to its categorization as Restricted Employment, Employee may notify Enfusion in writing, providing reasonable details about the proposed responsibilities of the new job (without disclosing another person’s Confidential Information). The Parties agree to discuss whether appropriate accommodations can be made to balance the protection of Enfusion’s business interests and Employee’s desire to engage in Restricted Employment, and any appropriate adjustments to the payments described above. Except to the extent required by applicable law, Enfusion is under no obligation to modify the restrictions in this Section, but may do so in its sole and absolute discretion.

g)General. For the avoidance of doubt, the Restrictive Covenants contained in this Agreement are in addition to, and not in lieu of, any other restrictive covenants or similar covenants or agreements between the Employee and Enfusion. The above-described restrictions are narrowly tailored to protect Enfusion’s legitimate business interests. The restrictions shall only apply to competitive employment in a capacity that is related to or requires the same or similar skills or knowledge necessary to have performed Employee’s duties at Enfusion or any role similar or related to any role held by Employee while employed at Enfusion.

h)Client Competition. Enfusion will spend a considerable amount of time and resources making Employee an expert of Enfusion’s products and service offerings and has a legitimate interest in protecting such investment in Employee. To protect its legitimate interest and to prevent clients from circumventing and eliminating the need for Enfusion’s services, (whether explicitly or under the guise of reverse engineering) through hiring Employee, Employee agrees that for a period of six (6) months to commence on Employee’s Termination Date, Employee will not, directly or indirectly, accept employment or perform services or duties, paid or unpaid, from any of Enfusion’s Clients or Prospective Clients, provided that Employee had contact with the Client or Prospective Client during their employment and to the extent such employment would be in a capacity substantially similar to the capacity in which the Employee worked for Enfusion. Employee further acknowledges the employment opportunities that Employee could get without violating this Agreement, including, by way of example only, the immense number of hedge funds, asset

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


managers, fund administrators, fund of funds, and other financial services or investment companies, and that as such he or she will be able to earn a livelihood without violating this Agreement.

i)Extension of Restricted Period. In the event of any violation of any Restrictive Covenant, the restricted period of the covenant that was violated shall be extended by a period of time equal to the period beginning when such violation commenced and ending when the activities constituting such violation have ceased, such that Enfusion gets the full benefit of the bargain with respect to the agreed upon period of restriction.

15.

Remedies. Employee acknowledges and agrees that due to the unique nature of Enfusion’s business, Employee’s breach of any obligation may result in irreparable and continuing harm to Enfusion, for which monetary damages may be inadequate to compensate or make Enfusion whole. Therefore, Employee agrees Enfusion is entitled to seek injunctive relief or specific performance to enforce the terms of this Agreement without the necessity of posting a bond. Employee further agrees Enfusion shall also have any other right or remedy available to it under law or in equity including the right to seek and recover monetary damages for lost profits and other compensable damages. Should any court of competent jurisdiction determine that Employee has breached any of the provisions as contained in this Agreement, Enfusion shall have a right to collect, in addition to any monetary damages awarded to it, all of its reasonable attorneys’ fees and costs incurred in connection with its efforts to enforce this Agreement, including pre-litigation efforts. Employee agrees that, if Enfusion seeks preliminary or emergency injunctive relief, and obtains same in whole or in part, the Company shall be entitled to an award of its attorney fees, expenses, and costs incurred in connection therewith upon the entry of the order granting said preliminary or emergency injunctive relief, in addition to any such fees and costs that may be incurred and awarded with respect to any subsequent proceedings in said action.

16.

Voluntary Agreement. Employee represents that Employee has carefully read, considered and understands the scope and effect of the provisions of this Agreement and that Employee is fully aware of the legal and binding effect of this Agreement. This Agreement is executed voluntarily by Employee and without any duress or undue influence on the part or behalf of the Company. Employee further acknowledges and agrees that Employee has been provided sufficient time to review the Agreement and consult with an attorney or legal representative regarding the Employee’s rights and obligations under this Agreement. In doing so, Employee acknowledges and agrees, the restrictions set forth in this Agreement impose a fair and reasonable restriction on Employee, reasonably necessary to protect Enfusion’s and its officers’ directors’, members’, and employees’ interests, business, and goodwill.

17.

Severability. If any provision of this Agreement is found to be unenforceable or contrary to law; including if any provision concerning time, scope, or geographic restrictions are deemed by a court with competent jurisdiction to be overly broad; the provision in question should be reformed to the minimum extent necessary to correct any invalidity while preserving to the maximum extent, the rights and commercial expectations of the Parties. The remaining portions of this Agreement will remain in full force and effect. Further, every provision of this Agreement shall be construed as independent agreements between Enfusion and Employee. Therefore, any claim or cause of action Employee may have against Enfusion, whether predicated on this Agreement or otherwise, shall not constitute a defense to prohibit the enforcement of any other provision or covenant.

18.

Counterparts. This Agreement, and any amendment thereto, may be executed in one or more counterparts and by the Parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together, shall constitute one and the same Agreement.

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


Facsimile, PDF, and any other digital or electronic signatures to this Agreement shall have the same effect as original or wet signatures. If executed in counterparts, this Agreement or any amendment, will not be effective or enforceable until signed by both Employee and an authorized representative of Enfusion.

19.

Notices. All notices, requests, claims, demands, and other communications under this Agreement, (collectively “Notices”), must be in writing and sent to the person and address designated in this Section. Any Notices must be hand-delivered, sent by an internationally recognized overnight courier service, sent via e-mail, or sent via registered or certified mail with postage pre-paid and return receipt requested. Notices will be considered given or made upon receipt.

Notices to Enfusion:

    

Notices to Employee:

Enfusion, LLC

125 S. Clark Street, Suite 750

Chicago, IL 60603

Attn: Human Resources

Phone: 312.253.9800

E-mail: HR@enfusion.com

See Appendix 1 (Scope of Employment)

Employee agrees to provide an updated address to Enfusion at the time of termination and if that address changes during the period of restriction following the Employee’s termination to provide Enfusion the updated address. In the event Enfusion is unable to locate Employee at their last known residence, Employee agrees Enfusion may seek injunctive relief or specific performance without personal service on Employee, so long as Enfusion uses reasonable efforts to first locate Employee.

20.

Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to its subject matter and (to the extent permissible by law) supersedes all prior agreements, proposals, communications, representations, writings, negotiations, or understandings with respect to that subject matter. All terms, conditions, and warranties not stated expressly in this Agreement, and which would in the absence of this provision be implied into this Agreement by statute, common law, equity, trade, custom or usage or otherwise, are excluded to the maximum extent permitted by law.

21.

Governing Law. The legal relations between the Parties hereto and any dispute arising under or in connection with this Agreement, or breach thereof, whether sounding in contract, tort, or otherwise, shall be governed by and construed in accordance with the laws of the United States of America and the State in which the employee’s assigned Office is located (provided in Appendix 1), regardless of any laws that might otherwise govern under applicable choice-of-law principles. Any claim, legal proceeding, or litigation arising out of or in connection with this Agreement or the relationship between Enfusion and Employee will be brought solely in the jurisdiction in which the Office is located, regardless of any laws or rules that might otherwise govern under applicable forum non conveniens principles. Any claim brought in any other jurisdiction or forum is precluded. ACCORDINGLY, BOTH PARTIES HEREBY CONSENT TO THE EXCLUSIVE JURISDICTION OF THE FEDERAL AND STATE COURTS LOCATED WITHIN THE JURISDICTION IN WHICH THE OFFICE IS LOCATED.

22.

No Waiver. No waiver, of any of the terms of this Agreement, will be valid unless in writing, explicitly stated as such, and signed by the party waiving its rights. Any forbearance or delay by either party to enforce any of its rights under this Agreement will not be construed as a waiver to enforce any such rights pertaining

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


to the occurrence in question or any other occurrence. The waiver, by any Party, of any breach of covenant will not be construed as a waiver of any succeeding breach of the same or any other covenant.

23.

Assignment. Enfusion may assign this Agreement or its rights under this Agreement to - and Employee may be employed by - any affiliate or subsidiary of Enfusion, or entity that acquires all or substantially all of Enfusion’s assets or acquires a department or line of business of Enfusion that Employee works within, or that is otherwise a successor in interest to Enfusion. This Agreement may not be assigned by Employee, except that Employee’s rights to compensation and benefits hereunder, subject to the limitations of this Agreement, may be transferred by will, by operation of law or as required by the law or a court order.

24.

Compliance with Section 409A. This Employment Agreement is intended to comply with, (or be exempt from), Section 409A of the Internal Revenue Code of 1986, as amended, to the extent applicable, and shall be administered and interpreted accordingly. To further clarify, this Section is in no way intended to change that bonuses, if any, are earned upon payment.

25.

Binding Agreement. This Agreement shall be binding upon and shall inure to the benefit of both Enfusion and Employee and their respective successors, assigns, heirs, and legal representatives.

26.

Terms of Acceptance. This Agreement is conditioned upon and subject to: (i) confirmation that Employee is not a subject to any contractual or other legal restrictions that would prevent or impair their ability to perform the duties of the position offered under this Agreement; (ii) Enfusion’s satisfactory completion of a background investigation, credit check (where appropriate and allowed by law), and reference check (where appropriate); and, (iii) Enfusion’s receipt of Employee’s acceptance of the terms and conditions of this Employment Agreement on or before the close of business on December 28, 2022.

Signature Page to the Employment Agreement between Enfusion Ltd. LLC and Oleg Movchan made effective on December 22, 2022.

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed as of the Effective Date written above.

Enfusion Ltd. LLC

Employee

Signature: /s/ Bronwen Bastone

Signature: /s/ Oleg Movchan

Name: Bronwen Bastone

Name: Oleg Movchan

Title: Chief People Officer

Date: December 22, 2022

Date: December 22, 2022

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


Third Party Intellectual Property (IP) Agreement

Dear Oleg,

We are excited to have you join the Enfusion team. As a company, it is very important to us that we respect others’ intellectual property and contractual rights. As part of your onboarding process, please review this letter as it is a topic we hold dearly. Once you have reviewed, feel free to ask any questions you might have. If you do not have any questions, please acknowledge the letter by signing in the designated area located at the bottom of the page.

If you have not done so already, to the extent you may be subject to any enforceable restrictive covenants or contractual limits on: i) your ability to solicit former clients or colleagues; ii) your possession, transfer, or use of confidential information; and, iii) your possession, transfer, or use of trade secret information, Enfusion requires that you disclose the nature of such covenants or contractual limitations before you commence employment. It is important to understand, you are personally responsible for complying with such covenants and limitations until they expire (if at all).

In addition to making Enfusion aware of any covenants or limitations you are subject to, we want to reiterate that you should not remove any trade secrets or confidential written or electronic materials from your current or prior employers. Likewise, you should not bring any such materials to Enfusion. You may not use any confidential or trade secret information you obtained during any prior employment in your work with Enfusion. To the extent the information was maintained as confidential by your previous employer(s), confidential and trade secret information includes, without limitation, any information about competitor marketing strategies, product development, and pricing information, as well as customer and personnel lists and contact information.

If you receive instruction or work from anyone at Enfusion or its affiliates (e.g., Enfusion’s international offices) that you believe would cause you to violate any agreements or covenants with a prior employer or your obligations to Enfusion, you should immediately disclose the matter to your office lead or Enfusion executive leadership, including Enfusion legal. It is very important that you take action under such circumstances because failure to abide by these expectations could result in you being liable to your former employer, withdrawal of Enfusion’s conditional offer of employment, or termination of any employment accepted.

Acknowledged and Accepted:

By Employee

Signature: /s/ Oleg Movchan

Name: Oleg Movchan

Date: December 22, 2022

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


Appendix 1 – Scope of Employment

Reference is made to the “Employment Agreement” entered into by and between Enfusion Ltd. LLC (“Enfusion”) and Oleg Movchan (“Employee”) and with an Effective Date of December 22, 2022, as may be amended from time-to-time, (the “Agreement”). The Parties hereby agree that this Appendix 1 shall be subject to and controlled by the terms and conditions of the Agreement, which shall be incorporated by reference into this Appendix 1. If there is any inconsistency between the terms of the Agreement and this Appendix 1, the terms of this Appendix 1 shall prevail. Further, all capitalized terms used but not defined in this Appendix 1 shall be construed in accordance with the Agreement. This Appendix 1 shall replace, in its entirety, any prior “Appendix 1 – Scope of Employment” relating to Employee’s employment with Enfusion, including, but not limited to, the Appendix 1 - Scope of Employment signed by Employee on December 22, 2022.

1.

Commencement Date. Employee’s first day of work under the terms set forth below will be on March 5, 2024 (“Commencement Date”) unless otherwise agreed to by Enfusion and Employee in writing pursuant to the terms of the Employment Agreement.

2.

Appointment & Duties. Employee shall serve as Chief Executive Officer and report to the Board of Directors.

3.

Work Hours. During an ordinary work week, Employee shall be available during Enfusion’s ordinary office hours described under Section 5 of the Agreement (“Work Hours”).

4.

Office. Employee is assigned to Enfusion’s office located in Chicago.  Enfusion agrees to allow Employee to work from his home on a full-time basis.

5.

Status. Employee will be classified as an exempt employee, which means Employee will not be eligible for overtime pay for hours worked in excess of forty (40) hours in any given week.

6.

Pay Cycle. As an exempt employee, Employee will ordinarily receive payment for services rendered twice a month, in accordance with Enfusion’s ordinary payroll policies and procedures.

7.

Salary. Employee agrees to accept a base salary to be paid at an annualized rate of $650,000 US Dollars (less, where applicable, deductions and withholdings) (“Salary”). Employee’s Salary will be paid in accordance with Enfusion’s normal payroll policies and procedures.

8.

Voluntary Termination Notice. Employee is classified as a Level 1 Employee. Although Employee has the right to terminate their employment at any time for any reason, Employee agrees to give 90-days notice to the date on which Employee intends to cease working for Enfusion.

9.

Other.

Discretionary Bonus

In addition to Employee’s Salary, Enfusion may reward Employee’s exemplary performance and the performance of Employee’s group through the award of a discretionary bonus (“Bonus”). Bonus awards will also reflect the company’s overall performance. Employee has a target Bonus of up to $400,000 (where paid at 100% of target) (less, where applicable, deductions and withholdings). At Enfusion’s discretion, the Bonus may be paid as cash or through some combination of cash and equity award. The award of any Bonus shall be conditioned upon: (1) Employee’s satisfactory, as determined solely by Enfusion, meeting of conditions and goals (relating both to Enfusion’s performance and Employee’s individual performance) to be communicated to Employee by Enfusion upon the

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


commencement of Employee’s employment with Enfusion (and updated at times throughout Employee’s tenure); (2) Enfusion’s performance; and (3) Employee being in “active working status” at the time any Bonus is awarded. For purposes of this provision, “active working status” means that the Employee has not resigned (or given notice of Employee’s resignation) or been terminated (or been given notice of Employee’s termination).

Annual LTI Award

In connection with Enfusion’s Long-Term Incentive program, as applied to executives, you will be eligible to receive an annual grant (“LTI Award”). Based upon your current title and this year’s funding level, for 2024, you will be granted an LTI Award of $1,250,000 (“Grant Value”) of restricted stock units (“RSUs”). The Grant Value will be used to determine the total number of RSUs contained in the LTI Award. The total number of RSUs will be calculated by using the closing price of the company’s stock (traded on the New York Stock Exchange) on the grant date. The actual value you may recognize at the time of vesting may increase or decrease based upon stock movement and any applicable tax laws. All LTI Awards are subject to board approval. Any granted RSUs are subject to the terms and conditions set by the board and contained in the Stock Award Agreement. All grants are subject to the vesting schedule set forth in the Stock Award Agreement The funding level for LTI Awards for future years beyond 2024 has not yet been determined. The Grant Value of any future LTI Award you recognize may change.

10.

Vacation. In accordance with Enfusion’s Flexible Time Off policy, which may be amended from time to time, Employee is entitled to Flexible Time Off as needed each calendar year. Flexible Time Off will not accrue or vest and therefore will not be paid out at the time of separation of employment.

11.

Notices to Employee.

[***]

Acknowledged and Accepted:

By Employee

Signature:

/s/ Oleg Movchan

Name:

Oleg Movchan

Date:

March 11, 2024

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


EX-10.8 4 enfn-20231231xex10d8.htm EX-10.8

Exhibit10.8

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

EMPLOYMENT AGREEMENT

This employment agreement, which shall include and incorporate by reference any appendix attached hereto, now or in the future (collectively “Agreement”), is entered into on December 14, 2022, (“Effective Date”), by and between ENFUSION LTD. LLC (“Enfusion”), with its principal place of business located at 125 SOUTH CLARK STREET, SUITE 750, CHICAGO, ILLINOIS 60603, and Brad Herring, (“Employee”), an individual with their primary address located at: [***] (each a “Party” or collectively, the “Parties”).

WHEREAS, Enfusion is in the business of creating and providing software and related products and services to clients in the investment and financial services industry throughout the United States and Global market with offices in Chicago and New York City and affiliate offices in London, Dublin, Hong Kong, Singapore, São Paulo, Shanghai, Sydney, Mumbai, and Bengaluru;

WHEREAS, Enfusion desires to hire Employee to perform certain services as described in this Agreement and any appendix attached hereto, and Employee desires to be hired by Enfusion to perform certain services described in this Agreement and any appendix attached hereto, each in accordance with the terms and conditions of this Agreement as may be amended or supplemented from time-to-time; and,

NOW THEREFORE, in exchange for good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the Parties covenant and agree as follows:

1.

Interpretation. Unless the context of this Agreement otherwise requires: (i) a capitalized word has the meaning assigned to it by this Agreement; (ii) “or” will be construed such that the series may include any of the items, all of the items, or any combination of the items; (iii) words in the singular include the plural, and words in the plural include the singular; (iv) provisions apply to successive events and transactions;

(v) “hereof,” “hereunder,” “herein,” and “hereto” refer to the entire Agreement and not any section or subsection; (vi) references in this Agreement to sections or annexes are references to the sections of or annexes attached to this Agreement; (vii) “in writing” refers to in written or printed form, facsimile transmission, or e-mail; (viii) the term “include” does not create an exclusive list and should be interpreted, in any variation, as “includes, but is not limited to;” (ix) the phrase “any reason” should be read as “any reason or no reason;” and, (x) the headings in this Agreement are for reference only and shall not limit or otherwise affect the meaning, interpretation, or construction of this Agreement.

2.

Employment. Enfusion hereby agrees to employ Employee and Employee hereby agrees to accept Enfusion’s employment offer, each subject to and in accordance with the terms and conditions of this Agreement.

3.

Classification of Employment. Employee’s classification as Exempt or Non-Exempt under Fair Labor Standards Act (“FLSA”) shall be determined by Enfusion and any changes to the Employee’s classification shall be communicated by Enfusion to the Employee.

4.

Duties. Employee’s initial appointment and non-exhaustive description of duties are described on Appendix 1 (Scope of Employment) and are subject to the terms and conditions of this Agreement. Despite the duties described on Appendix 1, Employee understands and acknowledges that Enfusion, at its sole discretion, has the right to modify or redefine Employee’s duties or title at any time, for any reason.

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


5.

Work Hours. Enfusion’s ordinary office hours are 8:00AM to 5:00PM, Monday through Friday. Unless otherwise specified on Appendix 1, Employee’s regular workweek shall be forty (40) hours on a schedule of eight (8) working hours per day, Monday through Friday; however, Employee understands and agrees that from time-to-time and subject to applicable law, Employee may be required to work additional hours, including weekends and holidays, as necessary to support Enfusion’s business. Employee understands and agrees, Employee’s work hours and surrounding terms may be modified at Enfusion’s sole discretion to the furthest extent permitted by applicable law.

6.

Location. Employee’s assigned work location (the “Office”) will be described on Appendix 1.

7.

Performance of Duties; Exclusive Service. Employee has a duty of loyalty and care to Enfusion and agrees to perform their obligations faithfully and to the best of their ability. Similarly, Employee hereby agrees to abide by Enfusion’s policies and procedures (as amended from time-to-time) and agrees to devote their business time, attention, and efforts to Enfusion’s business (except for permitted break periods, vacation periods, and reasonable periods of illness or other incapacity). Despite the foregoing sentence, Employee may serve as a director of or otherwise participate in educational, welfare, social, religious, and civic organization, provided that Employee’ service or participation does not: (i) unreasonably interfere with performing their duties; and, (ii) violate any provision of this Agreement. For clarity, while employed by Enfusion, Employee is not allowed to perform duties or services for any other employer, business, or organization (including establishing or maintain their own business or organization) other than as permitted by this Agreement or with the written consent of an Enfusion authorized officer.

a)Business Ideas/Opportunities. During their employment, Employee may come up with or across potential business opportunities related to Enfusion’s business and services (“Business Opportunity”). If so, Employee agrees to promptly disclose any Business Opportunity to Enfusion so that Enfusion has an opportunity to pursue the Business Opportunity. Employee acknowledges and agrees that pursuing a Business Opportunity for Employee’s or another’s benefit, without first disclosing it and getting Enfusion’s prior written approval would be a violation of their duty of loyalty and care to Enfusion and that Employee is prohibited from pursuing a Business Opportunity, whether for Employee’s or another’s benefit, without Enfusion’s prior written approval. Enfusion’s reserves the right to deny Employee’s request to pursue a Business Opportunity in Enfusion’s sole discretion.

8.

Compensation and Benefits. Employee is entitled to certain compensation and benefits, which are outlined below and described further on Appendix 1.

a)Salary. Enfusion agrees to pay Employee for services rendered under this Agreement. Employee’s Salary (as defined on Appendix 1) will be paid in accordance with Enfusion’s normal payroll policies and procedures. To be clear, although Employee is paid an annual salary, Employee’s employment is “at-will” (discussed below). Enfusion, at its sole discretion, may adjust Employee’s Salary after the first twelve (12) months of employment and reserves the right to adjust Employee’s Salary from time-to-time.

b)Benefits. During Employee’s employment, except as otherwise expressly provided herein, Employee will be entitled to participate in all employee health, welfare and other benefit plans and programs (“Employee Benefit Plans”) applicable to similarly situated employees of Enfusion, as in effect from time to time, to the extent consistent with applicable law and the terms of the applicable employee benefit plan. Enfusion reserves the right to amend or cancel any Employee Benefit Plans at any time in its sole and absolute discretion, subject to the terms of the employee benefit plan and applicable law.

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


c)

Vacation. Employee will be subject to Enfusion’s Flexible Time Off Policy as outlined in Appendix

1. Employee should use their best efforts not to schedule Flexible Time Off that will conflict with their duties and when possible, agrees to provide Enfusion with at least one (1) to two (2) weeks’ prior notice of any planned vacation subject to the terms of the policy. Enfusion reserves the right, in its sole discretion, to approve or deny any requested Flexible Time Off. Flexible Time Off is subject to certain restrictions on use as outlined in the Enfusion Flexible Time Off Policy.

d)

Bonus.

i.

Discretionary Bonus. Enfusion may, from time-to-time, in its sole discretion, choose to pay Employee additional compensation as a discretionary bonus. Whether and when a bonus is awarded, and the amount (if any) of bonus awarded, will be determined in Enfusion’s sole discretion on whatever basis and after taking into account whatever factors it considers appropriate at the time. Any bonus is not earned until paid. Therefore, to receive any bonus, Employee must be employed by Enfusion and in good standing on the bonus’s payment date and must not have indicated their intent to resign prior to or on such payment date.

ii.Other Bonus. If the Employee is eligible to receive a non-discretionary or other type of commission-based compensation, then it will be described on Appendix 1.

e)Payments. All payments made to Employee in the course of their employment will be paid in accordance with Enfusion’s normal payroll policies and procedures. Further, all compensation payments made in the course of Employee’s employment will be subject to any applicable withholding requirements or other similar obligations.

f)Expenses. Enfusion will reimburse Employee for out-of-pocket expenses incurred by Employee in the course of their employment pursuant to Enfusion’s reimbursement policy and in each case, subject to applicable law.

Consideration. In consideration for Employee agreeing to Sections 11 and 14 of this Agreement, the Company will provide the employee consideration, including, but not limited to, an at-will employment relationship, or continued at-will employment; training; and access to, or continued access to the Company’s Confidential Information and client, customer and business relationships during Employee’s employment. Employee agrees the consideration outlined in this paragraph is sufficient consideration for Employee’s various obligations under Sections 11 and 14 of this Agreement. Employee understands that acceptance of this Agreement is a condition of employment and that the Company would not offer to employ Employee and grant Employee access to its Confidential Information and client and customer relationships, but for Employee’s acceptance of the terms of this Agreement and acknowledgment that the consideration outlined herein is sufficient consideration for Employee’s obligations under Sections 11 and 14 of this Agreement.

9.

Employment Relationship and Termination. “Termination Date” means the date on which Employee ceases work for Enfusion, whether voluntary or involuntary.

a)AT-WILL” EMPLOYMENT. EMPLOYEE ACKNOWLEDGES AND AGREES THAT THEIR EMPLOYMENT IS “AT-WILL.” THIS MEANS, BOTH ENFUSION AND EMPLOYEE MAY TERMINATE EMPLOYEE’S EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON, WITHOUT LIABILITY FOR BREACH OF CONTRACT, PROMISSORY ESTOPPEL, SEVERANCE PAY, OR OTHERWISE.

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


b)Voluntary Termination. Although Employee has the right to terminate their employment at any time for any reason, Employee, if classified as a Level 3, 4 or 5 Employee, agrees to provide Enfusion with at least thirty (30) days’ prior notice to the date on which Employee intends to cease working for Enfusion. If Employee is classified as a Level 2 Employee, Employee agrees to provide Enfusion with at least sixty (60) days’ prior notice to the date on which Employee intends to cease working for Enfusion. If Employee is classified as a Level 1 Employee, Employee agrees to provide Enfusion with at least ninety (90) days’ prior notice to the date on which Employee intends to cease working for Enfusion. Employee’s initial level is contained within Appendix 1 of this Agreement. Upon receipt of Employee’s notice of their intent to cease working for Enfusion, Enfusion may, in its sole discretion, choose to reduce Employee’s notice period (as described in this paragraph) without additional obligations to Employee.

c)Final Payment. Unless otherwise required by applicable state law, upon Employee’s Termination Date, Enfusion shall provide Employee with a date, no later than Enfusion’s next regular pay date, on which Employee will receive their final payment for all accrued Salary and any other pay owed through the Termination Date.

10.

Representations. Employee understands and acknowledges that the following representations and covenants are essential to Enfusion’s decision to enter into this Agreement. Employee represents and warrants to Enfusion as follows:

a)Other than as already disclosed by Employee to Enfusion, as of the Effective Date, Employee is not under any contractual or legal duty or obligation, engagement, understanding, restriction, or commitment with any prior employer, other entity or individual other than Enfusion or its Affiliates (“Other Employer”) that would limit, prohibit, or interfere with Employee’s full and faithful performance of this Agreement, including but not limited to, employment, consulting, confidentiality, non-competition, or non-solicitation agreements or restrictive covenants; Employee certifies that if they have made a disclosure of a contractual or legal duty or obligation, engagement, understanding, restriction, or commitment with a prior employer(s), other entity or individual other than Enfusion or its Affiliates (“Other Employer”) that would limit, prohibit, or interfere with Employee’s full and faithful performance of this Agreement, including but not limited to, employment, consulting, confidentiality, non-competition, or non-solicitation agreements or restrictive covenants, that their disclosure was a complete disclosure of any applicable terms.

b)Employee does not have any inventions or intellectual property obligations which may affect assignment under Section 13, other than what Employee has disclosed in Appendix 2;

c)

If applicable, Employee has disclosed any Other Employers existing as of the Effective Date;

d)If applicable, Employee has complied with all duties imposed on Employee by their former employer with respect to termination of their employment;

e)

Employee is free to enter this Agreement and commence employment with Enfusion;

f)Employee understands and acknowledges the offer of employment made pursuant to this Agreement is made only to Employee for their personal services, and at no time has Employee been authorized to recruit, induce, entice, or offer employment at Enfusion to any other person;

g)Employee covenants not to use, disclose, or induce the use of, any trade secret, confidential information, or proprietary information that belongs to any third party in the performance of Employee’s

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


employment under this Agreement, unless Employee has prior written consent from the owner of the protected information (which, Employee agrees to provide such written consent to Enfusion); and,

h)Employee is not aware of: (i) any pending internal, criminal, civil, regulatory, or self-regulatory organization investigations involving Employee or any of Employee’s activities at any former employer or in relation to or arising out of Employee’s prior employment ; (ii) any pending customer complaints or customer arbitrations involving any of Employee’s activities at any former employer or in relation to or arising out of Employee’s prior employment; or, (iii) any circumstances that might lead to any of the matters described in this subsection. If Employee is aware of any such issues, Employee has disclosed such in writing to Enfusion’s Chief Human Resources Officer at least seven (7) days prior to the parties entering into this Agreement.

11.

Confidential Information and Confidentiality.

a)Employee acknowledges and agrees that through their employment, he or she will be provided, obtain, or be exposed to proprietary or non-public information relating to Enfusion’s business, which is confidential in nature. Such information includes, client lists or client related information, information related to or concerning Enfusion’s products and services; fees, costs, and pricing structures; market studies; business plans and investment analyses; designs and specifications; data and analyses; drawings, photographs, and reports; computer software, object code, source code, operating systems, applications, algorithms, and program listings; flow charts, manuals, and documentation, ideas, images, text, music, movies, concepts, video, and websites; databases; accounting and business methods; inventions, devices, new developments, methods, and processes, (whether patentable or non-patentable and whether or not reduced to practice); investor or ownership information, Client and Prospective Client information; copyrightable works; technology and trade secrets; historical financial statements, financial projections, and budgets; personnel training techniques and materials; and any other personal, business, financial, or technical information, data, patents, or ideas relating to the proprietary information observed by, or disclosed to, Employee, whether in oral, written documents, memoranda, reports, or correspondence in graphic or machine-readable form, or otherwise in the course of, or in connection with, Employee’s employment with Enfusion (individually and collectively “Confidential Information”).

b)Employee hereby agrees that he or she will not disclose nor use at any time; before, during, or after their employment with Enfusion; any Confidential Information of which Employee is or becomes aware of, whether or not such information is developed by Employee, except to the extent such disclosure or use is directly related to or required for Employee’s performance of their employment duties. Further, Employee agrees he or she will take all reasonable and appropriate steps to safeguard the Confidential Information and to protect it against disclosure, misuse, espionage, loss, or theft and will not disclose or use any Confidential Information except as reasonably necessary to perform Employee’s duties for the Company, or as required by law. Employee further agrees not to otherwise transmit or download any Confidential Information to Employee’s personal computer, cellular telephone, or other electronic device, or otherwise remove Confidential Information from the Company’s premises or Company-owned computer, unless Employee secures the Company’s specific authorization in advance and takes appropriate steps to protect such information. Employee understands and agrees that all Confidential Information, including documents, records, and electronic files, to which Employee has access as a result of Employee’s employment by the Company are the exclusive property of the Company. Employee also acknowledges and agrees that all Confidential Information, and all copyrights, trademarks, patents and other rights in connection therewith, shall be the sole property of the Company and its assigns. For clarity, nothing herein is intended to prevent Employee from disclosing information that Employee has a legal right to disclose.

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


c)Exceptions. Confidential Information shall not include any information that: (i) was in the possession of, or demonstrably known by, (in each case without restriction on its use or disclosure) the Employee prior to their receipt of such information; (ii) any information independently known by Employee without access to or reliance upon any Confidential Information, including the general skills, knowledge and experience acquired by the Employee before and/or during employment with the Company; (iii) was lawfully disclosed to Employee following the end of their employment with Enfusion by a third party under no known obligation of confidentiality; (iv) is in the public domain at the time of disclosure, or thereafter becomes in the public domain, other than as a result of disclosure by Employee in violation of this Agreement.

d)In the event Employee is required under a subpoena, court order, statute, law, rule, regulation, or other similar requirement, (“Legal Requirement”) Employee shall do so only to the extent required by the Legal Requirement, must provide prompt written notice to Enfusion of the disclosure to the extent not precluded by law, and must designate the information as Confidential Information when disclosing such information. Further, when legally permissible, the Employee shall notify Enfusion of what Confidential Information was disclosed under such Legal Requirement.

e)Defend Trade Secrets Act of 2016 (DTSA) Notice. Notwithstanding any other provision of this Agreement, pursuant to Section 7 of the DTSA, the Employee cannot be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that: (1) is made: (A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. (ii) If Employee files a lawsuit for retaliation by Company for reporting a suspected violation of law, Employee may disclose Company’s trade secrets to Employee’s attorney and use the trade secret information in the court proceeding if Employee: (1) files any document containing the trade secret under seal; and (2) does not disclose the trade secret, except pursuant to court order.

f)Violation of Law. If Employee believes Enfusion has committed or is committing a violation of law, although not required, he or she is asked to first report the possible violation to Enfusion’s executive leadership so that Enfusion may take the proper corrective actions. Despite the foregoing, Employee is free to report possible violations, file a charge with, or participate or cooperate with any governmental agency or entity, including but not limited to the EEOC, the Department of Justice, the Securities and Exchange Commission, Congress, or any agency Inspector General, or make any other disclosures that are protected under the whistleblower, anti-discrimination or anti-retaliation provisions of federal, state or local law or regulation; provided further, the Employee does not need the prior authorization of the Company to make any such reports or disclosures, and the Employee is not required to notify the Company that the Employee has made such reports or disclosures.

g)Trading. Employee understands and agrees he or she is not permitted to use Enfusion’s or Clients’ Confidential Information on their behalf, on the behalf of others, or to assist others in trading securities. Employee further acknowledges that to use Enfusion’s or Client’s Confidential Information for personal financial benefit or to “tip” others who might make an investment decision on the basis of this information is not only prohibited and unethical, but is also illegal.

12.

Company Property. Upon Enfusion’s request or Employee’s Termination Date, Employee shall, to the extent such materials are in Employee’s possession or under Employee’s control, promptly deliver to Enfusion: (i) all original and any copies of emails, employee training materials, records, agreements,

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


manuals, books, blank forms, documents, letters, memoranda, notes, notebooks, reports, data, tables, or calculations, which are the property of Enfusion or its Affiliates and that relate, in any way, to the business, products, policies, practices, or techniques thereof, including any strategies; (ii) all other Enfusion property, including any Enfusion issued credit cards, identification, keys, computers, cell phone, or other equipment; (iii) all Confidential Information of Enfusion or its Affiliates, including all documents that, in whole or in part, contain any Confidential Information of Enfusion or its Affiliates or their respective clients or licensors; and (iv) all proprietary information, intellectual property and trade secrets of Enfusion or its Affiliates or their respective clients or licensors. In addition, if applicable, Employee shall promptly cancel or transfer to himself or herself any telecommunications services for which Enfusion was directly paying. Nothing in this Section shall prohibit Employee from retaining papers or materials that are solely of a personal nature, including copies of documents showing their compensation or reimbursable expenses and a copy of this Employment Agreement.

13.

Intellectual Property. (“Intellectual Property”) means any and all intellectual property in any form or stage of development, including any innovation, discovery, idea, concept, design, prototype, product configuration, invention, improvement, modification, patentable subject matter, method, process, technique, procedure, system, plan, model, program, software or code, source code, algorithms, data, specification, drawing, images, text, music, movies, video, websites, diagram, flow chart, documentation, know-how, work of authorship, copyrightable subject matter, derivative work, trademark or trade name, and any other subject matter, material, or information that qualifies or is considered by Employer to qualify for patent, copyright, trademark, trade dress, trade secret, or any other protection under any law providing or creating intellectual property rights, including the Uniform Trade Secrets Act. Intellectual Property also includes Confidential Information learned, obtained, or developed in connection with Employee’s employment, such as specifications, financial data, personnel information, market information, business arrangements, and other non-public information of Employer described in Section

[11] of this Agreement. EMPLOYEE AGREES THAT ANY INTELLECTUAL PROPERTY CONCEIVED OR MADE BY EMPLOYEE, WHETHER ALONE OR WITH OTHER, DURING THE TERM OF EMPLOYEE’S EMPLOYMENT WITH ENFUSION RELATING IN ANY MANNER TO THE BUSINESS, BUSINESS PLANS, OR STRATEGIES OF ENFUSION OR ITS AFFILIATES, SHALL BE THE EXCLUSIVE PROPERTY OF ENFUSION OR SUCH AFFILIATE. WITHOUT LIMITING THE FOREGOING, TO THE EXTENT ANY COPYRIGHTABLE WORK IS INCLUDED IN THE FOREGOING, IT WILL BE DEEMED ‘A WORK MADE FOR HIRE” FOR THE BENEFIT OF ENFUSION OR SUCH AFFILIATE UNDER SECTION 201(b) OF THE 1976 U.S. COPYRIGHT ACT, AS AMENDED, OR OTHER SIMILAR APPLICABLE STATE OR FOREIGN OR INTERNATIONAL LAWS. FURTHER, EMPLOYEE AGREES THAT ALL INVENTIONS, HE OR SHE DEVELOPS OR DEVISES (WHETHER INDIVIDUALLY OR IN CONCERT WITH OTHERS): (i) USING ENFUSION’S EQUIPMENT, SUPPLIES, RESOURCES, OR CONFIDENTIAL INFORMATION; (ii) RESULTING FROM WORK HE OR SHE PERFORMS OR PERFORMED FOR ENFUSION; OR, (iii) RELATING TO ENFUSION’S CURRENT OR PLANNED RESEARCH OR DEVELOPMENT WILL BE ENFUSION’S SOLE AND EXCLUSIVE PROPERTY. ACCORDINGLY, EMPLOYEE HEREBY ASSIGNS ALL INTELLECTUAL PROPERTY RIGHTS, TITLE, AND INTERESTS TO ENFUSION AND WAIVES ANY MORAL RIGHTS IN THE INTELLECTUAL PROPERTY TO THE FURTHEST EXTENT PERMITTED BY LAW.

14.

Restrictive Covenants. Employee understands and recognizes that Enfusion is engaged in a highly competitive business and has spent a considerable amount of time, effort, and resources building its business, products, client base (domestically and internationally), and training its employees. Further, Employee through their employment will receive training regarding and have access to Enfusion’s (and its clients’ and licensors’) Confidential Information (as defined above), trade secrets, and sensitive proprietary business methods or data, customer lists, and other valuable business information. Employee acknowledges and agrees that Enfusion has a legitimate business interest in protecting its goodwill, client

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


and employee base, Confidential Information, trade secrets, and other proprietary information. Accordingly, Employee agrees to be bound by the following restrictive covenants (“Restrictive Covenants”), which are reasonably tailored to protect Enfusion’s legitimate interests from improper and unfair competition, and will not unreasonably impair or infringe on Employee’s right to work or earn a living after Employee’s Termination Date:

a)

Definitions: For purposes of this section, the following terms are defined as follows:

i.

(“Client”) means a person or organization who has retained, in writing or otherwise, Enfusion or any of its Affiliates to perform a service for compensation, which is, is related to, or is an extension of Enfusion’s or its Affiliates’ normal line of business and which Employee was involved; and,

ii.(“Prospective Client”) means a person or entity that has not yet retained, in writing or otherwise, Enfusion or any of its Affiliates to perform a service for compensation as described above when defining Clients, but instead, is a person or entity that Enfusion or any of its Affiliates reasonably expect to do so by virtue of Prospective Client’s solicitation of Enfusion or its Affiliates or Enfusion’s or its Affiliates’ targeted, direct solicitation of that person or entity within a six (6) month period immediately prior to Employee’s Termination Date.

b)Non-solicitation of Enfusion’s Employees. Throughout Employee’s employment with Enfusion and for a period of one (1) year, to commence on Employee’s Termination Date, Employee agrees not to: directly or indirectly, through any person or entity, or as an agent for any person or entity, authorize, encourage, suggest, or approve any person or entity to employ or cause to be employed, entice, induce, or solicit employment or engagement, in any capacity, any person that Employee had contact with and who is employed by Enfusion or any of its Affiliates or was employed or engaged by Enfusion or its Affiliates within three (3) months of the solicitation. While there is no geographic restraint, Employee understands and acknowledges that the restriction prohibiting solicitation of Enfusion employees is necessary and reasonable based upon Enfusion’s global presence and to protect Enfusion’s legitimate interest in its employee base and the resources utilized in training and maintaining such employee base.

c)Non-solicitation of Enfusion’s Clients. Throughout Employee’s employment with Enfusion and for a period of one (1) year, to commence on Employee’s Termination Date, Employee agrees not to: directly or indirectly, through any person or entity, or as an agent for any person or entity, authorize, encourage, suggest, or approve any person or entity to directly or indirectly, through any person or entity, or as an agent for any person or entity, or authorize, encourage, suggest, or knowingly approve any person or entity to, induce, attempt to induce, or entice any Client (as defined above) or Prospective Client (as defined above), in whole or in part, from doing business with Enfusion or any such Affiliate, regardless of which party initiates the contact or communication; or directly or indirectly, or through any person or entity, authorize, encourage, suggest, or knowingly approve any person or entity to, solicit, communicate with, contact, sell or render assistance, services or products to any Client or Prospective Client that would interfere with, take away, divert, or urge any Client or Prospective Client to discontinue, in whole or in part, business with Enfusion or any of its Affiliates. While there is no geographic restraint, Employee understands and acknowledges that the restriction prohibiting solicitation of any Enfusion Client or Prospective Client is limited to those Clients or Prospective Clients with whom Employee worked, to whom Employee marketed or sold services or products, or about whom Employee received Confidential Information, as such would give Employee an unfair competitive advantage. Employee agrees this restriction is necessary and reasonable, without regard to geographic constraint, based upon the Employee’s knowledge and/or

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


interaction with the Client or Prospective Client and to protect Enfusion’s legitimate interest in protecting its business relationships.

d)Non-compete. Employee understands and recognizes that: (i) Enfusion has spent a considerable amount of time and resources into training Employee; and, (ii) Employee will gain access to or knowledge of confidential and proprietary information and of practices, successes, and failures during the course of their employment; and, (iii) Employee will build relationships with Enfusion clients or prospective clients through their employment with Enfusion, made possible through Enfusion’s brand and resources, each of which Enfusion has a legitimate interest in protecting and Enfusion’s competitors or prospective competitors will gain an unfair advantage by obtaining the benefit of such foregoing investments made into and interests obtained by Employee. Therefore, throughout Employee’s employment with Enfusion and throughout the Restricted Period (as defined below), Employee agrees not to, directly or indirectly, alone or in association with or on behalf of any other person or entity, engage in any Competitive Activity (as defined below) (“Restricted Employment”).

i.

Restricted Period. (“Restricted Period”) means a period of twelve (12) months to commence on Employee’s Termination Date.

ii.

Competitive Activity. (“Competitive Activity”) means:

1.

Engaging in a Competitive Business (as defined below) directly or indirectly, on Employee’s own behalf or on the behalf of another;

2.

Providing services, similar or related to any services Employee provided to Enfusion while employed by Enfusion, to any person engaged in a Competitive Business, whether as an employee, consultant, officer, director, manager, partner, principal, agent, representative, or in any other capacity; or,

3.

Controlling (by contract, equity ownership, or otherwise), investing in (except as the owner of up to 3% of the securities of a publicly-traded entity), or providing other financial support to any person engaged in a Competitive Business.

iii.Competitive Business. (“Competitive Business”) means:

1.

Asset Management Software, including (a) portfolio management system; (b) order management system; (c) execution management system; (d) fund accounting system; or (e) fund risk management system, or any combination of the foregoing or any software substantially similar to any new software offering Enfusion offers or proposes to offer during Employee’s employment at Enfusion and in which Employee was involved in or received Confidential Information or trade secrets regarding; or

2.

Any middle- or back-office services or servicing tied to Enfusion’s software that Enfusion offers or proposes to offer during Employee’s employment at Enfusion and in which Employee was involved in or received Confidential Information or trade secrets regarding, or any other similar software that is an alternative to or competes with Enfusion’s managed services offering, whether in whole or in part; or

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


3.

Any other business or extension of a line of business in which Enfusion was engaged at any time during Employee’s employment, or in which Enfusion plans to engage or is considering plans to engage at the time of the Termination Date (as evidenced in writing) and in which Employee was involved or about which Employee received Confidential Information or trade secrets.

e)Notice. During the Restricted Period, Employee shall notify any other employers or prospective employers of their obligations under this Agreement before Employee begins working for such employer and further, agrees to simultaneously deliver a copy of such notice to Enfusion in accordance with Section

[19] (Notices). Further, Employee agrees that Enfusion may also notify such other employers or prospective employers of Employee’s obligations under this Agreement. Employee agrees to inform Enfusion of the name, address, and telephone number of Employee’s supervisor at each subsequent employer to whom Employee reports this Agreement during the Restricted Period.

f)Undue Hardship. If Employee believes in good faith that the provisions in this Section will prevent him or her from obtaining a new job due to its categorization as Restricted Employment, Employee may notify Enfusion in writing, providing reasonable details about the proposed responsibilities of the new job (without disclosing another person’s Confidential Information). The Parties agree to discuss whether appropriate accommodations can be made to balance the protection of Enfusion’s business interests and Employee’s desire to engage in Restricted Employment, and any appropriate adjustments to the payments described above. Except to the extent required by applicable law, Enfusion is under no obligation to modify the restrictions in this Section, but may do so in its sole and absolute discretion.

g)General. For the avoidance of doubt, the Restrictive Covenants contained in this Agreement are in addition to, and not in lieu of, any other restrictive covenants or similar covenants or agreements between the Employee and Enfusion. The above-described restrictions are narrowly tailored to protect Enfusion’s legitimate business interests. The restrictions shall only apply to competitive employment in a capacity that is related to or requires the same or similar skills or knowledge necessary to have performed Employee’s duties at Enfusion or any role similar or related to any role held by Employee while employed at Enfusion.

h)Client Competition. Enfusion will spend a considerable amount of time and resources making Employee an expert of Enfusion’s products and service offerings and has a legitimate interest in protecting such investment in Employee. To protect its legitimate interest and to prevent clients from circumventing and eliminating the need for Enfusion’s services, (whether explicitly or under the guise of reverse engineering) through hiring Employee, Employee agrees that for a period of six (6) months to commence on Employee’s Termination Date, Employee will not, directly or indirectly, accept employment or perform services or duties, paid or unpaid, from any of Enfusion’s Clients or Prospective Clients, provided that Employee had contact with the Client or Prospective Client during their employment and to the extent such employment would be in a capacity substantially similar to the capacity in which the Employee worked for Enfusion. Employee further acknowledges the employment opportunities that Employee could get without violating this Agreement, including, by way of example only, the immense number of hedge funds, asset managers, fund administrators, fund of funds, and other financial services or investment companies, and that as such he or she will be able to earn a livelihood without violating this Agreement.

i)Extension of Restricted Period. In the event of any violation of any Restrictive Covenant, the restricted period of the covenant that was violated shall be extended by a period of time equal to the period beginning when such violation commenced and ending when the activities constituting such violation have

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


ceased, such that Enfusion gets the full benefit of the bargain with respect to the agreed upon period of restriction.

15.

Remedies. Employee acknowledges and agrees that due to the unique nature of Enfusion’s business, Employee’s breach of any obligation may result in irreparable and continuing harm to Enfusion, for which monetary damages may be inadequate to compensate or make Enfusion whole. Therefore, Employee agrees Enfusion is entitled to seek injunctive relief or specific performance to enforce the terms of this Agreement without the necessity of posting a bond. Employee further agrees Enfusion shall also have any other right or remedy available to it under law or in equity including the right to seek and recover monetary damages for lost profits and other compensable damages. Should any court of competent jurisdiction determine that Employee has breached any of the provisions as contained in this Agreement, Enfusion shall have a right to collect, in addition to any monetary damages awarded to it, all of its reasonable attorneys’ fees and costs incurred in connection with its efforts to enforce this Agreement, including pre- litigation efforts. Employee agrees that, if Enfusion seeks preliminary or emergency injunctive relief, and obtains same in whole or in part, the Company shall be entitled to an award of its attorney fees, expenses, and costs incurred in connection therewith upon the entry of the order granting said preliminary or emergency injunctive relief, in addition to any such fees and costs that may be incurred and awarded with respect to any subsequent proceedings in said action.

16.

Voluntary Agreement. Employee represents that Employee has carefully read, considered and understands the scope and effect of the provisions of this Agreement and that Employee is fully aware of the legal and binding effect of this Agreement. This Agreement is executed voluntarily by Employee and without any duress or undue influence on the part or behalf of the Company. Employee further acknowledges and agrees that Employee has been provided sufficient time to review the Agreement and consult with an attorney or legal representative regarding the Employee’s rights and obligations under this Agreement. In doing so, Employee acknowledges and agrees, the restrictions set forth in this Agreement impose a fair and reasonable restriction on Employee, reasonably necessary to protect Enfusion’s and its officers’ directors’, members’, and employees’ interests, business, and goodwill.

17.

Severability. If any provision of this Agreement is found to be unenforceable or contrary to law; including if any provision concerning time, scope, or geographic restrictions are deemed by a court with competent jurisdiction to be overly broad; the provision in question should be reformed to the minimum extent necessary to correct any invalidity while preserving to the maximum extent, the rights and commercial expectations of the Parties. The remaining portions of this Agreement will remain in full force and effect. Further, every provision of this Agreement shall be construed as independent agreements between Enfusion and Employee. Therefore, any claim or cause of action Employee may have against Enfusion, whether predicated on this Agreement or otherwise, shall not constitute a defense to prohibit the enforcement of any other provision or covenant.

18.

Counterparts. This Agreement, and any amendment thereto, may be executed in one or more counterparts and by the Parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together, shall constitute one and the same Agreement. Facsimile, PDF, and any other digital or electronic signatures to this Agreement shall have the same effect as original or wet signatures. If executed in counterparts, this Agreement or any amendment, will not be effective or enforceable until signed by both Employee and an authorized representative of Enfusion.

19.

Notices. All notices, requests, claims, demands, and other communications under this Agreement, (collectively “Notices”), must be in writing and sent to the person and address designated in this Section.

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


Any Notices must be hand-delivered, sent by an internationally recognized overnight courier service, sent via e-mail, or sent via registered or certified mail with postage pre-paid and return receipt requested. Notices will be considered given or made upon receipt.

Notices to Enfusion:

Notices to Employee:

Enfusion, LLC

See Appendix 1 (Scope of Employment)

125 S. Clark Street, Suite 750

Chicago, IL 60603

Attn: Human Resources Phone: 312.253.9800

E-mail: HR@enfusion.com

Employee agrees to provide an updated address to Enfusion at the time of termination and if that address changes during the period of restriction following the Employee’s termination the Employee agrees to provide Enfusion the updated address. In the event Enfusion is unable to locate Employee at their last known residence, Employee agrees Enfusion may seek injunctive relief or specific performance without personal service on Employee, so long as Enfusion uses reasonable efforts to first locate Employee.

20.

Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to its subject matter and (to the extent permissible by law) supersedes all prior agreements, proposals, communications, representations, writings, negotiations, or understandings with respect to that subject matter. All terms, conditions, and warranties not stated expressly in this Agreement, and which would in the absence of this provision be implied into this Agreement by statute, common law, equity, trade, custom or usage or otherwise, are excluded to the maximum extent permitted by law.

21.

Governing Law. The legal relations between the Parties hereto and any dispute arising under or in connection with this Agreement, or breach thereof, whether sounding in contract, tort, or otherwise, shall be governed by and construed in accordance with the laws of the United States of America and the State in which the employee’s assigned Office is located (provided in Appendix 1), regardless of any laws that might otherwise govern under applicable choice-of-law principles. Any claim, legal proceeding, or litigation arising out of or in connection with this Agreement or the relationship between Enfusion and Employee will be brought solely in the jurisdiction in which the Office is located, regardless of any laws or rules that might otherwise govern under applicable forum non conveniens principles. Any claim brought in any other jurisdiction or forum is precluded. ACCORDINGLY, BOTH PARTIES HEREBY CONSENT TO THE EXCLUSIVE JURISDICTION OF THE FEDERAL AND STATE COURTS LOCATED WITHIN THE JURISDICTION IN WHICH THE OFFICE IS LOCATED.

22.

No Waiver. No waiver, of any of the terms of this Agreement, will be valid unless in writing, explicitly stated as such, and signed by the party waiving its rights. Any forbearance or delay by either party to enforce any of its rights under this Agreement will not be construed as a waiver to enforce any such rights pertaining to the occurrence in question or any other occurrence. The waiver, by any Party, of any breach of covenant will not be construed as a waiver of any succeeding breach of the same or any other covenant.

23.

Assignment. Enfusion may assign this Agreement or its rights under this Agreement to - and Employee may be employed by - any affiliate or subsidiary of Enfusion, or entity that acquires all or substantially all of Enfusion’s assets or acquires a department or line of business of Enfusion that Employee works within, or that is otherwise a successor in interest to Enfusion. This Agreement may not be assigned by Employee,

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


except that Employee’s rights to compensation and benefits hereunder, subject to the limitations of this Agreement, may be transferred by will, by operation of law or as required by the law or a court order.

24.

Compliance with Section 409A. This Employment Agreement is intended to comply with, (or be exempt from), Section 409A of the Internal Revenue Code of 1986, as amended, to the extent applicable, and shall be administered and interpreted accordingly. To further clarify, this Section is in no way intended to change that bonuses, if any, are earned upon payment.

25.

Binding Agreement. This Agreement shall be binding upon and shall inure to the benefit of both Enfusion and Employee and their respective successors, assigns, heirs, and legal representatives.

26.

Terms of Acceptance. This Agreement is conditioned upon and subject to: (i) confirmation that Employee is not a subject to any contractual or other legal restrictions that would prevent or impair their ability to perform the duties of the position offered under this Agreement; (ii) Enfusion’s satisfactory completion of a background investigation, credit check (where appropriate and allowed by law), and reference check (where appropriate); and, (iii) Enfusion’s receipt of Employee’s acceptance of the terms and conditions of this Employment Agreement on or before the close of business on December 28, 2022.

[Signature Page to Follow]

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


Signature Page to the Employment Agreement between Enfusion Ltd. LLC and Brad Herring made effective on December 14, 2022.

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed as of the Effective Date written above.

Enfusion Ltd. LLC

Employee

Signature:  /s/ Bronwen Bastone

Signature:   /s/ Brad Herring

Name: Bronwen Bastone

Name: Brad Herring

Title: Chief People Officer

Date:   December 14, 2022

Date: December 14, 2022

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


Third Party Intellectual Property (IP) Agreement

Dear Brad,

We are excited to have you join the Enfusion team. As a company, it is very important to us that we respect others’ intellectual property and contractual rights. As part of your onboarding process, please review this letter as it is a topic we hold dearly. Once you have reviewed, feel free to ask any questions you might have. If you do not have any questions, please acknowledge the letter by signing in the designated area located at the bottom of the page.

If you have not done so already, to the extent you may be subject to any enforceable restrictive covenants or contractual limits on: i) your ability to solicit former clients or colleagues; ii) your possession, transfer, or use of confidential information; and, iii) your possession, transfer, or use of trade secret information, Enfusion requires that you disclose the nature of such covenants or contractual limitations before you commence employment. It is important to understand, you are personally responsible for complying with such covenants and limitations until they expire (if at all).

In addition to making Enfusion aware of any covenants or limitations you are subject to, we want to reiterate that you should not remove any trade secrets or confidential written or electronic materials from your current or prior employers. Likewise, you should not bring any such materials to Enfusion. You may not use any confidential or trade secret information you obtained during any prior employment in your work with Enfusion. To the extent the information was maintained as confidential by your previous employer(s), confidential and trade secret information includes, without limitation, any information about competitor marketing strategies, product development, and pricing information, as well as customer and personnel lists and contact information.

If you receive instruction or work from anyone at Enfusion or its affiliates (e.g., Enfusion’s international offices) that you believe would cause you to violate any agreements or covenants with a prior employer or your obligations to Enfusion, you should immediately disclose the matter to your office lead or Enfusion executive leadership, including Enfusion legal. It is very important that you take action under such circumstances because failure to abide by these expectations could result in you being liable to your former employer, withdrawal of Enfusion’s conditional offer of employment, or termination of any employment accepted.

Acknowledged and Accepted:

By Employee

Signature:/s/ Brad Herring

Name: Brad Herring

Date: December 14, 2022

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


Appendix 1 – Scope of Employment

Reference is made to the “Employment Agreement” entered into by and between Enfusion Ltd. LLC (“Enfusion”) and Bradley Herring (“Employee”) and with an Effective Date of December 14, 2022, as may be amended from time-to- time, (the “Agreement”). The Parties hereby agree that this Appendix 1 shall be subject to and controlled by the terms and conditions of the Agreement, which shall be incorporated by reference into this Appendix 1. If there is any inconsistency between the terms of the Agreement and this Appendix 1, the terms of this Appendix 1 shall prevail. Further, all capitalized terms used but not defined in this Appendix 1 shall be construed in accordance with the Agreement. This Appendix 1 shall replace, in its entirety, any prior “Appendix 1 – Scope of Employment” relating to Employee’s employment with Enfusion, including, but not limited to, the Appendix 1 - Scope of Employment signed by Employee on December 14, 2022.

1.

Commencement Date. Employee’s first day of work under the terms set forth below will be on March 1, 2024 (“Commencement Date”) unless otherwise agreed to by Enfusion and Employee in writing pursuant to the terms of the Employment Agreement.

2.

Appointment & Duties. Employee shall serve as Chief Financial Officer and lead the Finance Department.

3.

Work Hours. During an ordinary work week, Employee shall be present at the Office during Enfusion’s ordinary office hours described under Section 5 of the Agreement (“Work Hours”) unless otherwise agreed to, in writing, by Employee and the CEO.

4.

Office. Employee is assigned to Enfusion’s office located in Chicago. Enfusion agrees to allow Employee to work from his home in [***] on a full-time basis.

5.

Status. Employee will be classified as an exempt employee, which means Employee will not be eligible for overtime pay for hours worked in excess of forty (40) hours in any given week.

6.

Pay Cycle. As an exempt employee, Employee will ordinarily receive payment for services rendered twice a month, in accordance with Enfusion’s ordinary payroll policies and procedures.

7.

Salary. Employee agrees to accept a base salary to be paid at an annualized rate of $450,000 US Dollars (less, where applicable, deductions and withholdings) (“Salary”). Employee’s Salary will be paid in accordance with Enfusion’s normal payroll policies and procedures.

8.Voluntary Termination Notice. Employee is classified as a Level 1 Employee. Although Employee has the right to terminate their employment at any time for any reason, Employee agrees to give 90-days notice to the date on which Employee intends to cease working for Enfusion. Upon receipt of Employee’s notice of their intent to cease working for Enfusion, Enfusion may, in its sole discretion, choose to reduce Employee’s notice period (as described in this paragraph) without additional obligations to Employee.

9.

Other.

Discretionary Bonus

In addition to Employee’s Salary, Enfusion may reward Employee’s exemplary performance and the performance of Employee’s group through the award of a discretionary bonus (“Bonus”). Bonus awards will also reflect the company’s overall performance. Employee has a target Bonus of up to $275,000 (where paid at 100% of target) (less, where applicable, deductions and withholdings). At Enfusion’s discretion, the Bonus may be paid as cash or through some combination of cash and equity award. The award of any Bonus shall be conditioned upon: (1) Employee’s satisfactory, as determined solely by Enfusion, meeting of conditions and goals (relating both to Enfusion’s performance and Employee’s individual performance) to

Graphic


be communicated to Employee by Enfusion upon the commencement of Employee’s employment with Enfusion (and updated at times throughout Employee’s tenure); (2) Enfusion’s performance; and (3) Employee being in “active working status” at the time any Bonus is awarded. For purposes of this provision, “active working status” means that the Employee has not resigned (or given notice of Employee’s resignation) or been terminated (or been given notice of Employee’s termination).

Annual LTI Award

In connection with Enfusion’s Long-Term Incentive program, as applied to executives, you will be eligible to receive an annual grant (“LTI Award”). Based upon your current title and this year’s funding level, for 2024, you will be granted an LTI Award of $660,000 (“Grant Value”) of restricted stock units (“RSUs”). The Grant Value will be used to determine the total number of RSUs contained in the LTI Award. The total number of RSUs will be calculated by using the closing price of the company’s stock (traded on the New York Stock Exchange) on the grant date. The actual value you may recognize at the time of vesting may increase or decrease based upon stock movement and any applicable tax laws. All LTI Awards are subject to board approval. Any granted RSUs are subject to the terms and conditions set by the board and contained in the Stock Award Agreement. All grants are subject to the vesting schedule set forth in the Stock Award Agreement. The funding level for LTI Awards for future years beyond 2024 has not yet been determined. The Grant Value of any future LTI Award you recognize may change.

10.

Vacation. In accordance with Enfusion’s Flexible Time Off policy, which may be amended from time to time, Employee is entitled to Flexible Time Off as needed each calendar year. Flexible Time Off will not accrue or vest and therefore will not be paid out at the time of separation of employment.

11.

Notices to Employee.

Bradley Herring

[***]

Acknowledged and Accepted:

By Employee

Signature:

/s/ Bradley Herring

Name:

Bradley Herring

Date:

March 1, 2024

Graphic


EX-10.10 5 enfn-20231231xex10d10.htm EX-10.10

Exhibit 10.10

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

EMPLOYMENT AGREEMENT

This employment agreement, which shall include and incorporate by reference any appendix attached hereto, now or in the future (collectively “Agreement”), is entered into on September 1. 2021, (“Effective Date”), by and between ENFUSION LTD. LLC (“Enfusion”), with its principal place of business located at 125 SOUTH CLARK STREET, SUITE 750, CHICAGO, ILLINOIS 60603, and Bronwen Bastone, (“Employee”), an individual with their primary address located at: [***] (each a “Party” or collectively, the “Parties”).

WHEREAS, Enfusion is in the business of creating and providing software and related products and services to clients in the investment and financial services industry throughout the United States and Global market with offices in Chicago, IL, New York and affiliate offices in London, Dublin, Hong Kong, Singapore, São Paulo, Mumbai, and Bengaluru;

WHEREAS, Enfusion desires to hire Employee to perform certain services as described in this Agreement and any appendix attached hereto, and Employee desires to be hired by Enfusion to perform certain services described in this Agreement and any appendix attached hereto, each in accordance with the terms and conditions of this Agreement as may be amended or supplemented from time-to-time; and,

NOW THEREFORE, in exchange for good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the Parties covenant and agree as follows:

1.

Interpretation. Unless the context of this Agreement otherwise requires: (i) a capitalized word has the meaning assigned to it by this Agreement; (ii) “or” will be construed such that the series may include any of the items, all of the items, or any combination of the items; (iii) words in the singular include the plural, and words in the plural include the singular; (iv) provisions apply to successive events and transactions; (v) “hereof,” “hereunder,” “herein,” and “hereto” refer to the entire Agreement and not any section or subsection; (vi) references in this Agreement to sections or annexes are references to the sections of or annexes attached to this Agreement; (vii) “in writing” refers to in written or printed form, facsimile transmission, or e-mail; (viii) the term “include” does not create an exclusive list and should be interpreted, in any variation, as “includes, but is not limited to;” (ix) the phrase “any reason” should be read as “any reason or no reason;” and, (x) the headings in this Agreement are for reference only and shall not limit or otherwise affect the meaning, interpretation, or construction of this Agreement.

2.

Employment. Enfusion hereby agrees to employ Employee and Employee hereby agrees to accept Enfusion’s employment offer, each subject to and in accordance with the terms and conditions of this Agreement.

Graphic


3.

Classification of Employment. Employee’s classification as Exempt or Non-Exempt under Fair Labor Standards Act (“FLSA”) shall be determined by Enfusion and any changes to the Employee’s classification shall be communicated by Enfusion to the Employee.

4.

Duties. Employee’s initial appointment and non-exhaustive description of duties are described on Appendix 1 (Scope of Employment) and are subject to the terms and conditions of this Agreement. Despite the duties described on Appendix 1, Employee understands and acknowledges that Enfusion, at its sole discretion, has the right to modify or redefine Employee’s duties or title at any time, for any reason.

5.

Work Hours. Enfusion’s ordinary office hours are 8:00AM to 5:00PM, Monday through Friday. Unless otherwise specified on Appendix 1, Employee’s regular workweek shall be forty (40) hours on a schedule of eight (8) working hours per day, Monday through Friday; however, Employee understands and agrees that from time-to-time and subject to applicable law, Employee may be required to work additional hours, including weekends and holidays, as necessary to support Enfusion’s business. Employee understands and agrees, Employee’s work hours and surrounding terms may be modified at Enfusion’s sole discretion to the furthest extent permitted by applicable law.

6.

Location. Employee’s assigned work location (the “Office”) will be described on Appendix 1. Subject to the terms and conditions of this Agreement and applicable law, Employee is required to be present at the Office during Work Hours (defined on Appendix 1).

7.

Performance of Duties; Exclusive Service. Employee has a duty of loyalty and care to Enfusion and agrees to perform their obligations faithfully and to the best of their ability. Similarly, Employee hereby agrees to abide by Enfusion’s policies and procedures (as amended from time-to-time) and agrees to devote their business time, attention, and efforts to Enfusion’s business (except for permitted break periods, vacation periods, and reasonable periods of illness or other incapacity). Despite the foregoing sentence, Employee may serve as a director of or otherwise participate in educational, welfare, social, religious, and civic organization, provided that Employee’ service or participation does not: (i) unreasonably interfere with performing their duties; and, (ii) violate any provision of this Agreement. For clarity, while employed by Enfusion, Employee is not allowed to perform duties or services for any other employer, business, or organization (including establishing or maintain their own business or organization) other than as permitted by this Agreement or with the written consent of an Enfusion authorized officer.

a)Business Ideas/Opportunities. During their employment, Employee may come up with or across potential business opportunities related to Enfusion’s business and services (“Business Opportunity”). If so, Employee agrees to promptly disclose any Business Opportunity to Enfusion so that Enfusion has an opportunity to pursue the Business Opportunity. Employee acknowledges and agrees that pursuing a Business Opportunity for Employee’s or another’s benefit, without first disclosing it and getting Enfusion’s prior written approval would be a violation of their duty of loyalty and care to Enfusion and that Employee is prohibited from pursuing a Business Opportunity, whether for Employee’s or another’s benefit, without Enfusion’s prior written approval. Enfusion’s reserves the right to deny Employee’s request to pursue a Business Opportunity in Enfusion’s sole discretion.

Graphic


8.

Compensation and Benefits. Employee is entitled to certain compensation and benefits, which are outlined below and described further on Appendix 1.

a)Salary. Enfusion agrees to pay Employee for services rendered under this Agreement. Employee’s Salary (as defined on Appendix 1) will be paid in accordance with Enfusion’s normal payroll policies and procedures. To be clear, although Employee is paid an annual salary, Employee’s employment is “at-will” (discussed below). Enfusion, at its sole discretion, may adjust Employee’s Salary after the first twelve (12) months of employment and reserves the right to adjust Employee’s Salary from time-to-time.

b)Benefits. During Employee’s employment, except as otherwise expressly provided herein, Employee will be entitled to participate in all employee health, welfare and other benefit plans and programs (“Employee Benefit Plans”) applicable to similarly situated employees of Enfusion, as in effect from time to time, to the extent consistent with applicable law and the terms of the applicable employee benefit plan. Enfusion reserves the right to amend or cancel any Employee Benefit Plans at any time in its sole and absolute discretion, subject to the terms of the employee benefit plan and applicable law.

c)Vacation. Employee may become entitled to paid vacation days as outlined on Appendix 1, which will be pro-rated based on Employee’s Commencement Date (as defined on Appendix 1). Unaccrued vacation time may not be used without prior written approval from Enfusion in accordance with its policies. Further, subject to and to the extent permitted by Enfusion’s ordinary paid vacation policies, Employee may be entitled rollover unused accrued paid vacation days into the following year. Employee should use their best efforts not to schedule vacation time that will conflict with their duties and when possible, agrees to provide Enfusion with at least two (2) weeks’ prior notice of any planned vacation. Enfusion reserves the right, in its sole discretion, to approve or deny any requested vacation time.

d)

Bonus.

i.

Discretionary Bonus. Enfusion may, from time-to-time, in its sole discretion, choose to pay Employee additional compensation as a discretionary bonus. Whether and when a bonus is awarded, and the amount (if any) of bonus awarded, will be determined in Enfusion’s sole discretion on whatever basis and after taking into account whatever factors it considers appropriate at the time. Any bonus is not earned until paid. Therefore, to receive any bonus, Employee must be employed by Enfusion and in good standing on the bonus’s payment date and must not have indicated their intent to resign prior to or on such payment date.

ii.Other Bonus. If the Employee is eligible to receive a non-discretionary or other type of commission-based compensation, then it will be described on Appendix 1.

e)Payments. All payments made to Employee in the course of their employment will be paid in accordance with Enfusion’s normal payroll policies and procedures. Further, all compensation payments made in the course of Employee’s employment will be subject to any applicable withholding requirements or other similar obligations.

Graphic


f)Expenses. Enfusion will reimburse Employee for out-of-pocket expenses incurred by Employee in the course of their employment pursuant to Enfusion’s reimbursement policy and in each case, subject to applicable law.

g)Consideration. In consideration for Employee agreeing to Sections 11 and 14 of this Agreement, the Company will provide the employee consideration, including, but not limited to, an at-will employment relationship, or continued at-will employment; training; and access to, or continued access to the Company’s Confidential Information and client, customer and business relationships during Employee’s employment. Employee agrees the consideration outlined in this paragraph is sufficient consideration for Employee’s various obligations under Sections 11 and 14 of this Agreement. Employee understands that acceptance of this Agreement is a condition of employment and that the Company would not offer to employ Employee and grant Employee access to its Confidential Information and client and customer relationships, but for Employee’s acceptance of the terms of this Agreement and acknowledgment that the consideration outlined herein is sufficient consideration for Employee’s obligations under Sections 11 and 14 of this Agreement.

9.

Employment Relationship and Termination. “Termination Date” means the date on which Employee ceases work for Enfusion, whether voluntary or involuntary.

a)AT-WILL” EMPLOYMENT. EMPLOYEE ACKNOWLEDGES AND AGREES THAT THEIR EMPLOYMENT IS “AT-WILL.” THIS MEANS, BOTH ENFUSION AND EMPLOYEE MAY TERMINATE EMPLOYEE’S EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON, WITHOUT LIABILITY FOR BREACH OF CONTRACT, PROMISSORY ESTOPPEL, SEVERANCE PAY, OR OTHERWISE.

b)Voluntary Termination. Although Employee has the right to terminate their employment at any time for any reason, Employee agrees to provide Enfusion with at least fourteen (14) day’s prior notice to the date on which Employee intends to cease working for Enfusion.

c)Final Payment. Unless otherwise required by applicable state law, upon Employee’s Termination Date, Enfusion shall provide Employee with a date, no later than Enfusion’s next regular pay date, on which Employee will receive their final payment for all accrued Salary and vested paid vacation time through the Termination Date.

10.

Representations. Employee understands and acknowledges that the following representations and covenants are essential to Enfusion’s decision to enter into this Agreement. Employee represents and warrants to Enfusion as follows:

a)As of the Effective Date, Employee is not under any contractual or legal duty or obligation, engagement, understanding, restriction, or commitment with any prior employer, other entity or individual other than Enfusion or its Affiliates (“Other Employer”) that would limit, prohibit, or interfere with Employee’s full and faithful performance of this Agreement, including but not limited to, employment, consulting, confidentiality, non-competition, or non-solicitation agreements or restrictive covenants;

Graphic


b)Employee does not have any inventions or intellectual property obligations which may affect assignment under Section 13, other than what Employee has disclosed in Appendix 2;

c)If applicable, Employee has disclosed any Other Employers existing as of the Effective Date;

d)If applicable, Employee has complied with all duties imposed on Employee by their former employer with respect to termination of their employment;

e)

Employee is free to enter this Agreement and commence employment with Enfusion;

f)Employee understands and acknowledges the offer of employment made pursuant to this Agreement is made only to Employee for their personal services, and at no time has Employee been authorized to recruit, induce, entice, or offer employment at Enfusion to any other person;

g)Employee covenants not to use, disclose, or induce the use of, any trade secret, confidential information, or proprietary information that belongs to any third party in the performance of Employee’s employment under this Agreement, unless Employee has prior written consent from the owner of the protected information (which, Employee agrees to provide such written consent to Enfusion); and,

h)Employee is not aware of: (i) any pending internal, criminal, civil, regulatory, or self- regulatory organization investigations involving Employee or any of Employee’s activities at any former employer or in relation to or arising out of Employee’s prior employment ; (ii) any pending customer complaints or customer arbitrations involving any of Employee’s activities at any former employer or in relation to or arising out of Employee’s prior employment; or, (iii) any circumstances that might lead to any of the matters described in this subsection. If Employee is aware of any such issues, Employee has disclosed such in writing to Enfusion’s Chief Human Resources Officer at least seven (7) days prior to the parties entering into this Agreement.

11.

Confidential Information and Confidentiality.

a)Employee acknowledges and agrees that through their employment, he or she will be provided, obtain, or be exposed to proprietary or non-public information relating to Enfusion’s business, which is confidential in nature. Such information includes, client lists or client related information, information related to or concerning Enfusion’s products and services; fees, costs, and pricing structures; market studies; business plans and investment analyses; designs and specifications; data and analyses; drawings, photographs, and reports; computer software, object code, source code, operating systems, applications, algorithms, and program listings; flow charts, manuals, and documentation, ideas, images, text, music, movies, concepts, video, and websites; databases; accounting and business methods; inventions, devices, new developments, methods, and processes, (whether patentable or non-patentable and whether or not reduced to practice); investor or ownership information, Client and Prospective Client information; copyrightable works; technology and trade secrets; historical financial statements, financial projections, and budgets; personnel training techniques and materials; and any other personal, business, financial, or technical information, data, patents, or ideas relating to the proprietary information observed by,

Graphic


or disclosed to, Employee, whether in oral, written documents, memoranda, reports, or correspondence in graphic or machine-readable form, or otherwise in the course of, or in connection with, Employee’s employment with Enfusion (individually and collectively “Confidential Information”).

b)Employee hereby agrees that he or she will not disclose nor use at any time; before, during, or after their employment with Enfusion; any Confidential Information of which Employee is or becomes aware of, whether or not such information is developed by Employee, except to the extent such disclosure or use is directly related to or required for Employee’s performance of their employment duties. Further, Employee agrees he or she will take all reasonable and appropriate steps to safeguard the Confidential Information and to protect it against disclosure, misuse, espionage, loss, or theft and will not disclose or use any Confidential Information except as reasonably necessary to perform Employee’s duties for the Company, or as required by law. Employee further agrees not to otherwise transmit or download any Confidential Information to Employee’s personal computer, cellular telephone, or other electronic device, or otherwise remove Confidential Information from the Company’s premises or Company-owned computer, unless Employee secures the Company’s specific authorization in advance and takes appropriate steps to protect such information. Employee understands and agrees that all Confidential Information, including documents, records, and electronic files, to which Employee has access as a result of Employee’s employment by the Company are the exclusive property of the Company. Employee also acknowledges and agrees that all Confidential Information, and all copyrights, trademarks, patents and other rights in connection therewith, shall be the sole property of the Company and its assigns. For clarity, nothing herein in is intended to prevent Employee disclosing information that Employee has a legal right to disclose.

c)Exceptions. Confidential Information shall not include any information that: (i) was in the possession of, or demonstrably known by, (in each case without restriction on its use or disclosure) the Employee prior to their receipt of such information; (ii) any information independently known by Employee without access to or reliance upon any Confidential Information, including the general skills, knowledge and experience acquired by the Employee before and/or during employment with the Company; (iii) was lawfully disclosed to Employee following the end of their employment with Enfusion by a third party under no known obligation of confidentiality; (iv) is in the public domain at the time of disclosure, or thereafter becomes in the public domain, other than as a result of disclosure by Employee in violation of this Agreement.

d)In the event Employee is required under a subpoena, court order, statute, law, rule, regulation, or other similar requirement, (“Legal Requirement”) Employee shall do so only to the extent required by the Legal Requirement, must provide prompt written notice to Enfusion of the disclosure to the extent not precluded by law, and must designate the information as Confidential Information when disclosing such information. Further, when legally permissible, the Employee shall notify Enfusion of what Confidential Information was disclosed under such Legal Requirement.

e)Defend Trade Secrets Act of 2016 (DTSA) Notice. Notwithstanding any other provision of this Agreement, pursuant to Section 7 of the DTSA, the Employee cannot be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that: (1) is made: (A) in confidence to a federal, state, or local government official, either directly or indirectly,

Graphic


or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. (ii) If Employee files a lawsuit for retaliation by Company for reporting a suspected violation of law, Employee may disclose Company’s trade secrets to Employee’s attorney and use the trade secret information in the court proceeding if Employee: (1) files any document containing the trade secret under seal; and (2) does not disclose the trade secret, except pursuant to court order.

f)Violation of Law. If Employee believes Enfusion has committed or is committing a violation of law, although not required, he or she is asked to first report the possible violation to Enfusion’s upper-management so that Enfusion may take the proper corrective actions. Despite the foregoing, Employee is free to report possible violations, file a charge with, or participate or cooperate with any governmental agency or entity, including but not limited to the EEOC, the Department of Justice, the Securities and Exchange Commission, Congress, or any agency Inspector General, or making any other disclosures that are protected under the whistleblower, anti-discrimination or anti-retaliation provisions of federal, state or local law or regulation; provided further, the Employee does not need the prior authorization of the Company to make any such reports or disclosures, and the Employee is not required to notify the Company that the Employee has made such reports or disclosures.

g)Trading. Employee understands and agrees he or she is not permitted to use Enfusion’s or Clients’ Confidential Information on their behalf, on the behalf of others, or to assist others in trading securities. Employee further acknowledges that to use Enfusion’s or Client’s Confidential Information for personal financial benefit or to “tip” others who might make an investment decision on the basis of this information is not only prohibited and unethical, but is also illegal.

12.

Company Property. Upon Enfusion’s request or Employee’s Termination Date, Employee shall, to the extent such materials are in Employee’s possession or under Employee’s control, promptly deliver to Enfusion: (i) all original and any copies of emails, employee training materials, records, agreements, manuals, books, blank forms, documents, letters, memoranda, notes, notebooks, reports, data, tables, or calculations, which are the property of Enfusion or its Affiliates and that relate, in any way, to the business, products, policies, practices, or techniques thereof, including any strategies; (ii) all other Enfusion property, including any Enfusion issued credit cards, identification, keys, computers, cell phone, or other equipment; (iii) all Confidential Information of Enfusion or its Affiliates, including all documents that, in whole or in part, contain any Confidential Information of Enfusion or its Affiliates or their respective clients or licensors; and

(iv) all proprietary information, intellectual property and trade secrets of Enfusion or its Affiliates or their respective clients or licensors. In addition, if applicable, Employee shall promptly cancel or transfer to himself or herself any telecommunications services for which Enfusion was directly paying. Nothing in this Section shall prohibit Employee from retaining papers or materials that are solely of a personal nature, including copies of documents showing their compensation or reimbursable expenses and a copy of this Employment Agreement.

13.

Intellectual Property. (“Intellectual Property”) means any and all intellectual property in any form or stage of development, including any innovation, discovery, idea, concept, design, prototype, product configuration, invention, improvement, modification, patentable subject matter,

Graphic


method, process, technique, procedure, system, plan, model, program, software or code, source code, algorithms, data, specification, drawing, images, text, music, movies, video, websites, diagram, flow chart, documentation, know-how, work of authorship, copyrightable subject matter, derivative work, trademark or trade name, and any other subject matter, material, or information that qualifies or is considered by Employer to qualify for patent, copyright, trademark, trade dress, trade secret, or any other protection under any law providing or creating intellectual property rights, including the Uniform Trade Secrets Act. Intellectual Property also includes Confidential Information learned, obtained, or developed in connection with Employee’s employment, such as specifications, financial data, personnel information, market information, business arrangements, and other non-public information of Employer described in Section [11] of this Agreement. EMPLOYEE AGREES THAT ANY INTELLECTUAL PROPERTY CONCEIVED OR MADE BY EMPLOYEE, WHETHER ALONE OR WITH OTHER, DURING THE TERM OF EMPLOYEE’S EMPLOYMENT WITH ENFUSION RELATING IN ANY MANNER TO THE BUSINESS, BUSINESS PLANS, OR STRATEGIES OF ENFUSION OR ITS AFFILIATES, SHALL BE THE EXCLUSIVE PROPERTY OF ENFUSION OR SUCH AFFILIATE. WITHOUT LIMITING THE FOREGOING, TO THE EXTENT ANY COPYRIGHTABLE WORK IS INCLUDED IN THE FOREGOING, IT WILL BE DEEMED ‘A WORK MADE FOR HIRE” FOR THE BENEFIT OF ENFUSION OR SUCH AFFILIATE UNDER SECTION 201(b) OF THE 1976 U.S. COPYRIGHT ACT, AS AMENDED, OR OTHER SIMILAR APPLICABLE STATE OR FOREIGN OR INTERNATIONAL LAWS. FURTHER, EMPLOYEE AGREES THAT ALL INVENTIONS, HE OR SHE DEVELOPS OR DEVISES (WHETHER INDIVIDUALLY OR IN CONCERT WITH OTHERS): (i) USING ENFUSION’S EQUIPMENT, SUPPLIES, RESOURCES, OR CONFIDENTIAL INFORMATION; (ii) RESULTING FROM WORK HE OR SHE PERFORMS OR PERFORMED FOR ENFUSION; OR, (iii) RELATING TO ENFUSION’S CURRENT OR PLANNED RESEARCH OR DEVELOPMENT WILL BE ENFUSION’S SOLE AND EXCLUSIVE PROPERTY. ACCORDINGLY, EMPLOYEE HEREBY ASSIGNS ALL INTELLECTUAL PROPERTY RIGHTS, TITLE, AND INTERESTES TO ENFUSION AND WAIVES ANY MOREAL RIGHTS IN THE INTELLECTUAL PROPERTY TO THE FURTHEST EXTENT PERMITED BY LAW.

14.

Restrictive Covenants. Employee understands and recognizes that Enfusion is engaged in a highly competitive business and has spent a considerable amount of time, effort, and resources building its business, products, client base (domestically and internationally), and training its employees. Further, Employee through their employment will receive training regarding and have access to Enfusion’s (and its clients’ and licensors’) Confidential Information (as defined above), trade secrets, and sensitive proprietary business methods or data, customer lists, and other valuable business information. Employee acknowledges and agrees that Enfusion has a legitimate business interest in protecting its goodwill, client and employee base, Confidential Information, trade secrets, and other proprietary information. Accordingly, Employee agrees to be bound by the following restrictive covenants (“Restrictive Covenants”), which are reasonably tailored to protect Enfusion’s legitimate interests from improper and unfair competition, and will not unreasonably impair or infringe on Employee’s right to work or earn a living after Employee’s Termination Date:

a)

Definitions: For purposes of this section, the following terms are defined as follows:

i.

(“Client”) means a person or organization who has retained, in writing or otherwise, Enfusion or any of its Affiliates to perform a service for compensation, which is, is

Graphic


related to, or is an extension of Enfusion’s or its Affiliates’ normal line of business and which Employee was involved; and,

ii.(“Prospective Client”) means a person or entity that has not yet retained, in writing or otherwise, Enfusion or any of its Affiliates to perform a service for compensation as described above when defining Clients, but instead, is a person or entity that Enfusion or any of its Affiliates reasonably expect to do so by virtue of Prospective Client’s solicitation of Enfusion or its Affiliates or Enfusion’s or its Affiliates’ targeted, direct solicitation of that person or entity within a six (6) month period immediately prior to Employee’s Termination Date.

b)Non-solicitation of Enfusion’s Employees. Throughout Employee’s employment with Enfusion and for a period of one (1) year, to commence on Employee’s Termination Date, Employee agrees not to: directly or indirectly, through any person or entity, or as an agent for any person or entity, or authorize, encourage, suggest, or approve any person or entity to employ or cause to be employed, entice, induce, or solicit employment or engagement, in any capacity, any person that Employee had contact with and who is employed by Enfusion or any of its Affiliates or was employed or engaged by Enfusion or its Affiliates within three (3) months of the solicitation. While there is no geographic restraint, Employee understands and acknowledges that the restriction prohibiting solicitation of Enfusion employees is necessary and reasonable based upon Enfusion’s global presence and to protect Enfusion’s legitimate interest in its employee base and the resources utilized in training and maintaining such employee base.

c)Non-solicitation of Enfusion’s Clients. Throughout Employee’s employment with Enfusion and for a period of one (1) year, to commence on Employee’s Termination Date, Employee agrees not to: directly or indirectly, through any person or entity, or as an agent for any person or entity, or authorize, encourage, suggest, or approve any person or entity to directly or indirectly, through any person or entity, or as an agent for any person or entity, or authorize, encourage, suggest, or knowingly approve any person or entity to, induce, attempt to induce, or entice any Client (as defined above) or Prospective Client (as defined above), in whole or in part, from doing business with Enfusion or any such Affiliate, regardless of which party initiates the contact or communication; or directly or indirectly, or through any person or entity, or authorize, encourage, suggest, or knowingly approve any person or entity to, solicit, communicate with, contact, sell or render assistance, services or products to any Client or Prospective Client that would interfere with, take away, divert, or urge any Client or Prospective Client to discontinue, in whole or in part, business with Enfusion or any of its Affiliates. While there is no geographic restraint, Employee understands and acknowledges that the restriction prohibiting solicitation of any Enfusion Client or Prospective Client is limited to those Clients or Prospective Clients with whom Employee worked, to whom Employee marketed or sold services or products, or about whom Employee received Confidential Information, as such would give Employee an unfair competitive advantage. Employee agrees this restriction is necessary and reasonable, without regard to geographic constraint, based upon the Employee’s knowledge and/or interaction with the Client or Prospective Client and to protect Enfusion’s legitimate interest in protecting its business relationships.

d)Non-compete. Employee understands and recognizes that: (i) Enfusion has spent a considerable amount of time and resources into training Employee; and, (ii) Employee will gain

Graphic


access to or knowledge of confidential and proprietary information and of practices, successes, and failures during the course of their employment; and, (iii) Employee will build relationships with Enfusion clients or prospective clients through their employment with Enfusion, made possible through Enfusion’s brand and resources, each of which Enfusion has a legitimate interest in protecting and Enfusion’s competitors or prospective competitors will gain an unfair advantage by obtaining the benefit of such foregoing investments made into and interests obtained by Employee. Therefore, throughout Employee’s employment with Enfusion and throughout the Restricted Period (as defined below), Employee agrees not to, directly or indirectly, alone or in association with or on behalf of any other person or entity, engage in any Competitive Activity (as defined below) (“Restricted Employment”).

i.

Restricted Period. (“Restricted Period”) means a period of twelve (12) months to commence on Employee’s Termination Date.

ii.Competitive Activity. (“Competitive Activity”) means:

1.

Engaging in a Competitive Business (as defined below) directly or indirectly, on Employee’s own behalf or on the behalf of another;

2.

Providing services, similar or related to any services Employee provided to Enfusion while employed by Enfusion, to any person engaged in a Competitive Business, whether as an employee, consultant, officer, director, manager, partner, principal, agent, representative, or in any other capacity; or,

3.

Controlling (by contract, equity ownership, or otherwise), investing in (except as the owner of up to 3% of the securities of a publicly-traded entity), or providing other financial support to any person engaged in a Competitive Business.

iii.Competitive Business. (“Competitive Business”) means:

1.

Asset Management Software, including (a) portfolio management system;

(b) order management system; (c) execution management system; (d) fund accounting system; or (e) fund risk management system, or any combination of the foregoing or any software substantially similar to any new software offering Enfusion offers or proposes to offer during Employee’s employment at Enfusion and in which Employee was involved in or received Confidential Information or trade secrets regarding; or

2.

Any middle- or back-office services or servicing tied to Enfusion’s software that Enfusion offers or proposes to offer during Employee’s employment at Enfusion and in which Employee was involved in or received Confidential Information or trade secrets regarding, or any other similar software that is an alternative to or competes with Enfusion’s managed services offering, whether in whole or in part; or

Graphic


3.

Any other business or extension of a line of business in which Enfusion was engaged at any time during Employee’s employment, or in which Enfusion plans to engage or is considering plans to engage at the time of the Termination Date (as evidenced in writing) and in which Employee was involved or about which Employee received Confidential Information or trade secrets.

e)Notice. During the Restricted Period, Employee shall notify any other employers or prospective employers of their obligations under this Agreement before Employee begins working for such employer and further, agrees to simultaneously deliver a copy of such notice to Enfusion in accordance with Section 19 (Notices). Further, Employee agrees that Enfusion may also notify such other employers or prospective employers of Employee’s obligations under this Agreement. Employee agrees to inform Enfusion of the name, address, and telephone number of Employee’s supervisor at each subsequent employer to whom Employee reports this Agreement during the Restricted Period.

f)Undue Hardship. If Employee believes in good faith that the provisions in this Section will prevent him or her from obtaining a new job due to its categorization as Restricted Employment, Employee may notify Enfusion in writing, providing reasonable details about the proposed responsibilities of the new job (without disclosing another person’s Confidential Information). The Parties agree to discuss whether appropriate accommodations can be made to balance the protection of Enfusion’s business interests and Employee’s desire to engage in Restricted Employment, and any appropriate adjustments to the payments described above. Except to the extent required by applicable law, Enfusion is under no obligation to modify the restrictions in this Section but may do so in its sole and absolute discretion.

g)General. For the avoidance of doubt, the Restrictive Covenants contained in this Agreement are in addition to, and not in lieu of, any other restrictive covenants or similar covenants or agreements between the Employee and Enfusion. The above-described restrictions are narrowly tailored to protect Enfusion’s legitimate business interests. The restrictions shall only apply to competitive employment in a capacity that is related to or requires the same or similar skills or knowledge necessary to have performed Employee’s duties at Enfusion or any role similar or related to any role held by Employee while employed at Enfusion.

h)Client Competition. Enfusion will spend a considerable amount of time and resources making Employee an expert of Enfusion’s products and service offerings and has a legitimate interest in protecting such investment in Employee. To protect its legitimate interest and to prevent clients from circumventing and eliminating the need for Enfusion’s services, (whether explicitly or under the guise of reverse engineering) through hiring Employee, Employee agrees that for a period of six (6) months to commence on Employee’s Termination Date, Employee will not, directly or indirectly, accept employment or perform services or duties, paid or unpaid, from any of Enfusion’s Clients or Prospective Clients, provided that Employee had contact with during their employment and to the extent such employment would be in a capacity substantially similar the capacity in which the Employee worked for Enfusion. Employee further acknowledges the employment opportunities that Employee could get without violating this Agreement, including the immense number of hedge funds, asset managers, fund administrators, fund of funds, and other financial

Graphic


services or investment companies, and that as such he or she will be able to earn a livelihood without violating this Agreement.

i)Extension of Restricted Period. In the event of any violation of any Restrictive Covenant, the restricted period of the covenant that was violated shall be extended by a period of time equal to the period beginning when such violation commenced and ending when the activities constituting such violation have ceased, such that Enfusion gets the full benefit of the bargain with respect to the agreed upon period of restriction.

15.

Remedies. Employee acknowledges and agrees that due to the unique nature of Enfusion’s business, Employee’s breach of any obligation may result in irreparable and continuing harm to Enfusion, for which monetary damages may be inadequate to compensate or make Enfusion whole. Therefore, Employee agrees Enfusion is entitled to seek injunctive relief or specific performance to enforce the terms of this Agreement without the necessity of posting a bond. Employee further agrees Enfusion shall also have any other right or remedy available to it under law or in equity including the right to seek and recover monetary damages for lost profits and other compensable damages. Should any court of competent jurisdiction determine that Employee has breached any of the provisions as contained in this Agreement, Enfusion shall have a right to collect, in addition to any monetary damages awarded to it, all of its reasonable attorneys’ fees and costs incurred in connection with its efforts to enforce this Agreement, including pre-litigation efforts. Employee agrees that, if Enfusion seeks preliminary or emergency injunctive relief, and obtains same in whole or in part, the Company shall be entitled to an award of its attorney fees, expenses, and costs incurred in connection therewith upon the entry of the Order granting said preliminary or emergency injunctive relief, in addition to any such fees and costs that may be incurred and awarded with respect to any subsequent proceedings in said action.

16.

Voluntary Agreement. Employee represents that Employee has carefully read, considered and understands the scope and effect of the provisions of this Agreement and that Employee is fully aware of the legal and binding effect of this Agreement. This Agreement is executed voluntarily by Employee and without any duress or undue influence on the part or behalf of the Company. Employee further acknowledges and agrees that Employee has been provided sufficient time to review the Agreement and consult with an attorney or legal representative regarding the Employee’s rights and obligations under this Agreement. In doing so, Employee acknowledges and agrees, the restrictions set forth in this Agreement impose a fair and reasonable restriction on Employee, reasonably necessary to protect Enfusion’s and its officers’ directors’, members’, and employees’ interests, business, and goodwill.

17.

Severability. If any provision of this Agreement is found to be unenforceable or contrary to law; including if any provision concerning time, scope, or geographic restrictions are deemed by a court with competent jurisdiction to be overly broad; the provision in question should be reformed to the minimum extent necessary to correct any invalidity while preserving to the maximum extent, the rights and commercial expectations of the Parties. The remaining portions of this Agreement will remain in full force and effect. Further, every provision of this Agreement shall be construed as independent agreements between Enfusion and Employee. Therefore, any claim or cause of

Graphic


action Employee may have against Enfusion, whether predicated on this Agreement or otherwise, shall not constitute a defense to prohibit the enforcement of any other provision or covenant.

18.

Counterparts. This Agreement, and any amendment thereto, may be executed in one or more counterparts and by the Parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together, shall constitute one and the same Agreement. Facsimile, PDF, and any other digital or electronic signatures to this Agreement shall have the same effect as original or wet signatures. If executed in counterparts, this Agreement or any amendment, will not be effective or enforceable until signed by both Employee and an authorized representative of Enfusion.

19.

Notices. All notices, requests, claims, demands, and other communications under this Agreement, (collectively “Notices”), must be in writing and sent to the person and address designated in this Section. Any Notices must be hand-delivered, sent by an internationally recognized overnight courier service, sent via e-mail, or sent via registered or certified mail with postage pre-paid and return receipt requested. Notices will be considered given or made upon receipt.

Notices to Enfusion:

Notices to Employee:

Enfusion, LLC

125 S. Clark Street, Suite 750

Chicago, IL 60603

Attn: Human Resources Phone: 312.253.9800

E-mail: HR@enfusion.com

See Appendix 1 (Scope of Employment)

Employee agrees to provide an updated address to Enfusion at the time of termination and if that address changes during the any period of restriction following the Employee’s termination to provide Enfusion the updated address. In the event Enfusion is unable to locate Employee at their last known residence, Employee agrees Enfusion may seek injunctive relief or specific performance without personal service on Employee, so long as Enfusion uses reasonable efforts to first locate Employee.

20.

Entire Agreement. This Agreement constitute the entire agreement between the Parties with respect to its subject matter and (to the extent permissible by law) supersedes all prior agreements, proposals, communications, representations, writings, negotiations, or understandings with respect to that subject matter. All terms, conditions, and warranties not stated expressly in this Agreement, and which would in the absence of this provision be implied into this Agreement by statute, common law, equity, trade, custom or usage or otherwise, are excluded to the maximum extent permitted by law.

21.

Governing Law. The legal relations between the Parties hereto and any dispute arising under or in connection with this Agreement, or breach thereof, whether sounding in contract, tort, or

Graphic


otherwise, shall be governed by and construed in accordance with the laws of the United States of America and the State in which the employee’s assigned Office is located (provided in Appendix 1) , regardless of any laws that might otherwise govern under applicable choice-of-law principles. Any claim, legal proceeding, or litigation arising out of or in connection with this Agreement or the relationship between Enfusion and Employee will be brought solely in the jurisdiction in which the Office is located, regardless of any laws or rules that might otherwise govern under applicable forum non conveniens principles. Any claim brought in any other jurisdiction or forum is precluded. ACCORDING, BOTH PARTIES HEREBY CONSENT TO THE EXCLUSIVE JURISDICTION OF THE FEDERAL AND STATE COURTS LOCATED WITHIN THE JURISDICTION IN WHICH THE OFFICE IS LOCATED.

22.

No Waiver. No waiver, of any of the terms of this Agreement, will be valid unless in writing, explicitly stated as such, and signed by the party waiving its rights. Any forbearance or delay by either party to enforce any of its rights under this Agreement will not be construed as a waiver to enforce any such rights pertaining to the occurrence in question or any other occurrence. The waiver, by any Party, of any breach of covenant will not be construed as a waiver of any succeeding breach of the same or any other covenant.

23.

Assignment. Enfusion may assign this Agreement or its rights under this Agreement to - and Employee may be employed by - any affiliate or subsidiary of Enfusion, or entity that acquires all or substantially all of Enfusion’s assets or acquires a department or line of business of Enfusion that Employee works within, or that is otherwise a successor in interest to Enfusion. This Agreement may not be assigned by Employee, except that Employee’s rights to compensation and benefits hereunder, subject to the limitations of this Agreement, may be transferred by will, by operation of law or as required by the law or a court order.

24.

Compliance with Section 409A. This Employment Agreement is intended to comply with, (or be exempt from), Section 409A of the Internal Revenue Code of 1986, as amended, to the extent applicable, and shall be administered and interpreted accordingly. To further clarify, this Section is in no way intended to change that bonuses, if any, are earned upon payment.

25.

Binding Agreement. This Agreement shall be binding upon and shall inure to the benefit of both Enfusion and Employee and their respective successors, assigns, heirs, and legal representatives.

26.

Terms of Acceptance. This Agreement is conditioned upon and subject to: (i) confirmation that Employee is not a subject to any contractual or other legal restrictions that would prevent or impair their ability to perform the duties of the position offered under this Agreement; (ii) Enfusion’s satisfactory completion of a background investigation, credit check, and reference check (where appropriate); and, (iii) Enfusion’s receipt of Employee’s acceptance of the terms and conditions of this Employment Agreement on or before the close of business on September 10, 2021

[Signature Page to Follow]

Graphic


Signature Page to the Employment Agreement between Enfusion Ltd. LLC and Bronwen Bastone made effective on September 1, 2021

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed as of the Effective Date written above.

Enfusion Ltd. LLC

Employee

Signature:         /s/ Steve Dorton

Signature:

/s/ Bronwen Bastone

Name: Steve Dorton

Name:

Bronwen Bastone

Title: Chief Financial Officer

Date: September 1, 2021

Date:

September 29, 2021

Graphic


Appendix 1 – Scope of Employment

Reference is made to the “Employment Agreement” entered into by and between Enfusion Ltd. LLC (“Enfusion”) and Bronwen Bastone (“Employee”) and with an Effective Date of September 1, 2021, as may be amended from time-to-time, (the “Agreement”). The Parties hereby agree that this Appendix 1 shall be subject to and controlled by the terms and conditions of the Agreement, which shall be incorporated by reference into this Appendix 1. If there is any inconsistency between the terms of the Agreement and this Appendix 1, the terms of this Appendix 1 shall prevail. Further, all capitalized terms used but not defined in this Appendix 1 shall be construed in accordance with the Agreement. This Appendix 1 shall replace, in its entirety, any prior “Appendix 1 – Scope of Employment” relating to Employee’s employment with Enfusion, including, but not limited to, the Appendix 1 - Scope of Employment signed by Employee on September 8, 2021.

1.

Commencement Date. Employee’s first day of work under the terms set forth below will be on March 1, 2024 (“Commencement Date”) unless otherwise agreed to by Enfusion and Employee in writing pursuant to the terms of the Employment Agreement.

2.

Appointment & Duties. Employee shall serve as Chief People Officer and lead the Human Resources Department.

3.

Work Hours. During an ordinary work week, Employee shall be present at the Office during Enfusion’s ordinary office hours described under Section 5 of the Agreement (“Work Hours”) unless otherwise agreed to, in writing, by Employee and the CEO.

4.

Office. Employee is assigned to Enfusion’s office located in New York.

5.

Status. Employee will be classified as an exempt employee, which means Employee will not be eligible for overtime pay for hours worked in excess of forty (40) hours in any given week.

6.

Pay Cycle. As an exempt employee, Employee will ordinarily receive payment for services rendered twice a month, in accordance with Enfusion’s ordinary payroll policies and procedures.

7.

Salary. Employee agrees to accept a base salary to be paid at an annualized rate of $450,000 US Dollars (less, where applicable, deductions and withholdings) (“Salary”). Employee’s Salary will be paid in accordance with Enfusion’s normal payroll policies and procedures.

8.

Voluntary Termination Notice. Employee is classified as a Level 1 Employee. Although Employee has the right to terminate their employment at any time for any reason, in recognition of Employee’s increased compensation, Employee agrees to give 90-days notice to the date on which Employee intends to cease working for Enfusion. Upon receipt of Employee’s notice of their intent to cease working for Enfusion, Enfusion may, in its sole discretion, choose to reduce Employee’s notice period (as described in this paragraph) without additional obligations to Employee.

9.

Other.

Discretionary Bonus

In addition to Employee’s Salary, Enfusion may reward Employee’s exemplary performance and the performance of Employee’s group through the award of a discretionary bonus (“Bonus”). Bonus awards will also reflect the company’s overall performance. Employee has a target Bonus of up to $250,000 (where paid at 100% of target) (less, where applicable, deductions and withholdings). At Enfusion’s discretion, the Bonus may be paid as cash or through some combination of cash and equity award. The award of any Bonus shall be conditioned upon: (1) Employee’s satisfactory, as determined solely by Enfusion, meeting of conditions and goals (relating both to Enfusion’s performance and Employee’s individual performance) to be communicated to Employee by Enfusion upon the commencement of Employee’s employment with Enfusion (and updated at times throughout Employee’s tenure); (2) Enfusion’s performance; and (3) Employee being in “active working status” at the time any Bonus is awarded. For purposes of this provision, “active working status” means that the Employee has not resigned (or given notice of Employee’s resignation) or been terminated (or been given notice of Employee’s termination).

Annual LTI Award

Graphic


In connection with Enfusion’s Long-Term Incentive program, as applied to executives, you will be eligible to receive an annual grant (“LTI Award”). Based upon your current title and this year’s funding level, for 2024, you will be granted an LTI Award of $300,000 (“Grant Value”) of restricted stock units (“RSUs”). The Grant Value will be used to determine the total number of RSUs contained in the LTI Award. The total number of RSUs will be calculated by using the closing price of the company’s stock (traded on the New York Stock Exchange) on the grant date. The actual value you may recognize at the time of vesting may increase or decrease based upon stock movement and any applicable tax laws. All LTI Awards are subject to board approval. Any granted RSUs are subject to the terms and conditions set by the board and contained in the Stock Award Agreement. All grants are subject to the vesting schedule set forth in the Stock Award Agreement The funding level for LTI Awards for future years beyond 2024 has not yet been determined. The Grant Value of any future LTI Award you recognize may change.

10.

Vacation. In accordance with Enfusion’s Flexible Time Off policy, which may be amended from time to time, Employee is entitled to Flexible Time Off as needed each calendar year. Flexible Time Off will not accrue or vest and therefore will not be paid out at the time of separation of employment.

11.

Notices to Employee.

Bronwen Bastone

[***]

Acknowledged and Accepted:

By Employee

Signature:

/s/ Bronwen Bastone

Name:

Bronwen Bastone

Date:

March 2, 2024

Graphic


EX-10.11 6 enfn-20231231xex10d11.htm EX-10.11

Exhibit 10.11

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

Employment Agreement

This employment agreement, which shall include and incorporate by reference any appendix attached hereto, now  or in the future (collectively “Agreement”), is entered into on February 1, 2021, (“Effective Date”), by and between  ENFUSION LTD. LLC (“Enfusion”), with its principal place of business located at 125 SOUTH CLARK STREET, SUITE 750,  CHICAGO, ILLINOIS 60603, and Matthew Campobasso, (“Employee”), an individual with their primary address  located at [***] (each a “Party” or collectively, the “Parties”).

WHEREAS, Enfusion is in the business of creating and providing software and related products and services to clients  in the investment and financial services industry throughout the United States and Global market with offices in  Chicago, IL, New York and affiliate offices in London, Dublin, Hong Kong, Singapore, São Paulo, and Mumbai;

WHEREAS, Enfusion and Employee, together, desire to restate and amend the Employment Agreement between  Enfusion and Employee dated 7/21/2020 in its entirety and with an effective as of the Effective Date set forth above.  Accordingly, Enfusion desires to employ Employee to perform certain services described in this Agreement and any  appendix attached hereto, each in accordance with the terms and conditions of this Agreement as may be amended  or supplemented from time-to-time; and,

NOW THEREFORE, in exchange for good and valuable consideration including, but not limited to, Employee’s  continued employment by Enfusion, the sufficiency and receipt of which is hereby acknowledged, the Parties  covenant and agree as follows:

1. Interpretation. Unless the context of this Agreement otherwise requires: (i) a capitalized word has the  meaning assigned to it by this Agreement; (ii) “or” will be construed such that the series may include any  of the items, all of the items, or any combination of the items; (iii) words in the singular include the plural,  and words in the plural include the singular; (iv) provisions apply to successive events and transactions;  (v) “hereof,” “hereunder,” “herein,” and “hereto” refer to the entire Agreement and not any section or  subsection; (vi) references in this Agreement to sections or annexes are references to the sections of or  annexes attached to this Agreement; (vii) “in writing” refers to in written or printed form, facsimile  transmission, or e-mail; (viii) the term “include” does not create an exclusive list and should be  interpreted, in any variation, as “includes, but is not limited to;” (ix) the phrase “any reason” should be  read as “any reason or no reason;” and, (x) the headings in this Agreement are for reference only and shall  not limit or otherwise affect the meaning, interpretation, or construction of this Agreement.

2. Employment. Enfusion hereby agrees to employ Employee and Employee hereby agrees to accept  Enfusion’s employment offer, each subject to and in accordance with the terms and conditions of this  Agreement.

3. Classification of Employment. Employee’s classification as Exempt or Non-Exempt under Fair Labor  Standards Act (“FLSA”) shall be determined by Enfusion and any changes to the Employee’s classification  shall be communicated by Enfusion to the Employee.

4. Duties. Employee’s initial appointment and non-exhaustive description of duties are described on  Appendix 1 (Scope of Employment) and are subject to the terms and conditions of this Agreement. Despite  the duties described on Appendix 1, Employee understands and acknowledges that Enfusion, at its sole  discretion, has the right to modify or redefine Employee’s duties or title at any time, for any reason.

5. Work Hours. Enfusion’s ordinary office hours are 8:00AM to 5:00PM, Monday through Friday. Unless  otherwise specified on Appendix 1, Employee’s regular workweek shall be forty (40) hours on a schedule  of eight (8) working hours per day, Monday through Friday; however, Employee understands and agrees  that from time-to-time and subject to applicable law, Employee may be required to work additional hours,  including weekends and holidays, as necessary to support Enfusion’s business. Employee understands and  agrees, Employee’s work


hours and surrounding terms may be modified at Enfusion’s sole discretion to  the furthest extent permitted by applicable law.

6. Location. Employee’s assigned work location (the “Office”) will be described on Appendix 1. Subject to the  terms and conditions of this Agreement and applicable law, Employee is required to be present at the  Office during Work Hours (defined on Appendix 1).

7. Performance of Duties; Exclusive Service. Employee has a duty of loyalty and care to Enfusion and agrees  to perform their obligations faithfully and to the best of their ability. Similarly, Employee hereby agrees to  abide by Enfusion’s policies and procedures (as amended from time-to-time) and agrees to devote their  business time, attention, and efforts to Enfusion’s business (except for permitted break periods, vacation  periods, and reasonable periods of illness or other incapacity). Despite the foregoing sentence, Employee  may serve as a director of or otherwise participate in educational, welfare, social, religious, and civic  organization, provided that Employee’ service or participation does not: (i) unreasonably interfere with  performing their duties; and (ii) violate any provision of this Agreement. For clarity, while employed by  Enfusion, Employee is not allowed to perform duties or services for any other employer, business, or  organization (including establishing or maintain their own business or organization) other than as  permitted by this Agreement or with the written consent of an Enfusion authorized officer.

a) Business Ideas/Opportunities. During their employment, Employee may come up with or across  potential business opportunities related to Enfusion’s business and services (“Business Opportunity”). If  so, Employee agrees to promptly disclose any Business Opportunity to Enfusion so that Enfusion has an  opportunity to pursue the Business Opportunity. Employee acknowledges and agrees that pursuing a  Business Opportunity for Employee’s or another’s benefit, without first disclosing it and getting Enfusion’s  prior written approval would be a violation of their duty of loyalty and care to Enfusion and that Employee  is prohibited from pursuing a Business Opportunity, whether for Employee’s or another’s benefit, without  Enfusion’s prior written approval. Enfusion’s reserves the right to deny Employee’s request to pursue a  Business Opportunity in Enfusion’s sole discretion.

8. Compensation and Benefits. Employee is entitled to certain compensation and benefits, which are outlined below and described further on Appendix 1.

a) Salary. Enfusion agrees to pay Employee for services rendered under this Agreement. Employee’s  Salary (as defined on Appendix 1) will be paid in accordance with Enfusion’s normal payroll policies and  procedures. To be clear, although Employee is paid an annual salary, Employee’s employment is “at-will”  (discussed below). Enfusion, at its sole discretion, may adjust Employee’s Salary after the first twelve (12)  months of employment and reserves the right to adjust Employee’s Salary from time-to-time.

b) Benefits. During Employee’s employment, except as otherwise expressly provided herein,  Employee will be entitled to participate in all employee health, welfare and other benefit plans and  programs (“Employee Benefit Plans”) applicable to similarly situated employees of Enfusion, as in effect  from time to time, to the extent consistent with applicable law and the terms of the applicable employee  benefit plan. Enfusion reserves the right to amend or cancel any Employee Benefit Plans at any time in its sole and absolute discretion, subject to the terms of the employee benefit plan and applicable law.

c) Vacation. Employee may become entitled to paid vacation days as outlined on Appendix 1, which  will be pro-rated based on Employee’s first date of employment with Enfusion (as defined on Appendix 1).  Unaccrued vacation time may not be used without prior written approval from Enfusion in accordance with

d) Bonus.

i. Discretionary Bonus. Enfusion may, from time-to-time, in its sole discretion, choose to pay  Employee additional compensation as a discretionary bonus. Whether and when a bonus is  awarded, and the amount (if any) of bonus awarded, will be determined in Enfusion’s sole  discretion on whatever basis and after taking into account whatever factors it considers  appropriate at the time. Any bonus is not earned until paid. Therefore, to receive any bonus,

Employee must be employed by Enfusion and in good standing on the bonus’s payment date and must not have indicated their intent to resign prior to or on such payment date.


ii. Other Bonus. If the Employee is eligible to receive a non-discretionary or other type of commission-based compensation, then it will be described on Appendix 1.

e) Payments. All payments made to Employee in the course of their employment will be paid in  accordance with Enfusion’s normal payroll policies and procedures. Further, all compensation payments  made in the course of Employee’s employment will be subject to any applicable withholding requirements  or other similar obligations.

f) Expenses. Enfusion will reimburse Employee for out-of-pocket expenses incurred by Employee in  the course of their employment pursuant to Enfusion’s reimbursement policy and in each case, subject to  applicable law.

g) Consideration. In consideration for Employee agreeing to Sections 11 and 14 of this Agreement,  the Company will provide the employee consideration, including, but not limited to, an at-will employment  relationship, or continued at-will employment; training; and access to, or continued access to the Company’s Confidential Information and client, customer and business relationships during Employee’s  employment. Employee agrees the consideration outlined in this paragraph is sufficient consideration for  Employee’s various obligations under Sections 11 and 14 of this Agreement. Employee understands that  acceptance of this Agreement is a condition of employment and that the Company would not offer to  employ Employee and grant Employee access to its Confidential Information and client and customer  relationships, but for Employee’s acceptance of the terms of this Agreement and acknowledgment that the  consideration outlined herein is sufficient consideration for Employee’s obligations under Sections 11 and  14 of this Agreement.

9. Employment Relationship and Termination. “Termination Date” means the date on which Employee ceases work for Enfusion, whether voluntary or involuntary.

a) AT-WILL” EMPLOYMENT. EMPLOYEE ACKNOWLEDGES AND AGREES THAT THEIR EMPLOYMENT  IS “AT-WILL.” THIS MEANS, BOTH ENFUSION AND EMPLOYEE MAY TERMINATE EMPLOYEE’S  EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON, WITHOUT LIABILITY FOR BREACH OF  CONTRACT, PROMISSORY ESTOPPEL, SEVERANCE PAY, OR OTHERWISE.

b) Voluntary Termination. Although Employee has the right to terminate their employment at any  time for any reason, Employee agrees to provide Enfusion with at least fourteen (14) day’s prior notice to  the date on which Employee intends to cease working for Enfusion.

c) Final Payment. Unless otherwise required by applicable state law, upon Employee’s Termination  Date, Enfusion shall provide Employee with a date, no later than Enfusion’s next regular pay date, on which  Employee will receive their final payment for all accrued Salary and vested paid vacation time through the  Termination Date.

10. Representations. Employee understands and acknowledges that the following representations and  covenants are essential to Enfusion’s decision to enter into this Agreement. Employee represents and  warrants to Enfusion as follows:

a) As of the Effective Date, Employee is not under any contractual or legal duty or obligation,  engagement, understanding, restriction, or commitment with any prior employer, other entity or individual  other than Enfusion or its affiliates ("Other Employer”) that would limit, prohibit, or interfere with  Employee’s full and faithful performance of this Agreement, including but not limited to, employment,  consulting, confidentiality, non-competition, or non-solicitation agreements or restrictive covenants;

b) Employee does not have any inventions or intellectual property obligations which may affect  assignment under Section 13, other than to the extent previously disclosed by Employee to Enfusion in  writing;

c) If applicable, Employee has disclosed any Other Employers existing as of the Effective Date;

d) If applicable, Employee has complied with all duties imposed on Employee by their former employer with respect to termination of their employment;

e) Employee is free to enter this Agreement and commence employment with Enfusion;


f) Employee understands and acknowledges the offer of employment made pursuant to this  Agreement is made only to Employee for their personal services, and at no time has Employee been  authorized to recruit, induce, entice, or offer employment at Enfusion to any other person;

g) Employee covenants not to use, disclose, or induce the use of, any trade secret, confidential  information, or proprietary information that belongs to any third party in the performance of Employee’s  employment under this Agreement, unless Employee has prior written consent from the owner of the  protected information (which, Employee agrees to provide such written consent to Enfusion); and,

h) Employee is not aware of: (i) any pending internal, criminal, civil, regulatory, or self-regulatory  organization investigations involving Employee or any of Employee’s activities at any former employer or in  relation to or arising out of Employee’s prior employment; (ii) any pending customer complaints or  customer arbitrations involving any of Employee’s activities at any former employer or in relation to or  arising out of Employee’s prior employment; or, (iii) any circumstances that might lead to any of the matters  described in this subsection.

11. Confidential Information and Confidentiality.

a) Employee acknowledges and agrees that through their employment, he or she will be provided,  obtain, or be exposed to proprietary or non-public information relating to Enfusion’s business, which is  confidential in nature. Such information includes, client lists or client related information, information  related to or concerning Enfusion’s products and services; fees, costs, and pricing structures; market  studies; business plans and investment analyses; designs and specifications; data and analyses; drawings,  photographs, and reports; computer software, object code, source code, operating systems, applications,  algorithms, and program listings; flow charts, manuals, and documentation, ideas, images, text, music,  movies, concepts, video, and websites; databases; accounting and business methods; inventions, devices,  new developments, methods, and processes, (whether patentable or non-patentable and whether or not  reduced to practice); investor or ownership information, Client and Prospective Client information;  copyrightable works; technology and trade secrets; historical financial statements, financial projections,  and budgets; personnel training techniques and materials; and any other personal, business, financial, or  technical information, data, patents, or ideas relating to the proprietary information observed by, or  disclosed to, Employee, whether in oral, written documents, memoranda, reports, or correspondence in  graphic or machine-readable form, or otherwise in the course of, or in connection with, Employee’s  employment with Enfusion (individually and collectively “Confidential Information”).

b) Employee hereby agrees that he or she will not disclose nor use at any time; before, during, or  after their employment with Enfusion; any Confidential Information of which Employee is or becomes  aware of, whether or not such information is developed by Employee, except to the extent such disclosure  or use is directly related to or required for Employee’s performance of their employment duties. Further,  Employee agrees he or she will take all reasonable and appropriate steps to safeguard the Confidential  Information and to protect it against disclosure, misuse, espionage, loss, or theft and will not disclose or  use any Confidential Information except as reasonably necessary to perform Employee's duties for the  Company, or as required by law. Employee further agrees not to otherwise transmit or download any  Confidential Information to Employee's personal computer, cellular telephone, or other electronic device,  or otherwise remove Confidential Information from the Company's premises or Company-owned  computer, unless Employee secures the Company's specific authorization in advance and takes appropriate  steps to protect such information. Employee understands and agrees that all Confidential Information,  including documents, records, and electronic files, to which Employee has access as a result of Employee's  employment by the Company are the exclusive property of the Company. Employee also acknowledges and  agrees that all Confidential Information, and all copyrights, trademarks, patents and other rights in  connection therewith, shall be the sole property of the Company and its assigns. For clarity, nothing herein  is intended to prevent Employee disclosing information that Employee has a legal right to disclose.

c) Exceptions. Confidential Information shall not include any information that: (i) was in the  possession of, or demonstrably known by, (in each case without restriction on its use or disclosure) the  Employee prior to their receipt of such information; (ii) any information independently known by Employee  without access to or reliance upon any Confidential Information, including the general skills, knowledge and  experience acquired by the Employee before and/or during employment with the Company; (iii) was  lawfully disclosed to Employee following


the end of their employment with Enfusion by a third party under  no known obligation of confidentiality; (iv) is in the public domain at the time of disclosure, or thereafter  becomes in the public domain, other than as a result of disclosure by Employee in violation of this  Agreement.

d) In the event Employee is required under a subpoena, court order, statute, law, rule, regulation, or  other similar requirement (“Legal Requirement”), Employee shall do so only to the extent required by the  Legal Requirement, must provide prompt written notice to Enfusion of the disclosure to the extent not  precluded by law, and must designate the information as Confidential Information when disclosing such  information. Further, when legally permissible, the Employee shall notify Enfusion of what Confidential  Information was disclosed under such Legal Requirement.

e) Defend Trade Secrets Act of 2016 (DTSA) Notice. Notwithstanding any other provision of this  Agreement, pursuant to Section 7 of the DTSA, the Employee cannot be held criminally or civilly liable under  any federal or state trade secret law for any disclosure of a trade secret that: (1) is made: (A) in confidence  to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (B) solely  for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or  other document that is filed under seal in a lawsuit or other proceeding. If Employee files a lawsuit for  retaliation by Company for reporting a suspected violation of law, Employee may disclose Company’s trade  secrets to Employee’s attorney and use the trade secret information in the court proceeding if Employee: (1)  files any document containing the trade secret under seal; and (2) does not disclose the trade secret, except  pursuant to court order.

f) Violation of Law. If Employee believes Enfusion has committed or is committing a violation of law,  although not required, he or she is asked to first report the possible violation to Enfusion’s upper management so that Enfusion may take the proper corrective actions. Despite the foregoing, Employee is  free to report possible violations, file a charge with, or participate or cooperate with any governmental  agency or entity, including but not limited to the EEOC, the Department of Justice, the Securities and  Exchange Commission, Congress, or any agency Inspector General, or making any other disclosures that are  protected under the whistleblower, anti-discrimination or anti-retaliation provisions of federal, state or  local law or regulation; provided further, the Employee does not need the prior authorization of the  Company to make any such reports or disclosures, and the Employee is not required to notify the Company  that the Employee has made such reports or disclosures.

g) Trading. Employee understands and agrees he or she is not permitted to use Enfusion’s or Clients’  Confidential Information on their behalf, on the behalf of others, or to assist others in trading securities.  Employee further acknowledges that to use Enfusion’s or Client’s Confidential Information for personal  financial benefit or to “tip” others who might make an investment decision on the basis of this information  is not only prohibited and unethical, but is also illegal.

12. Company Property. Upon Enfusion’s request or Employee’s Termination Date, Employee shall, to the  extent such materials are in Employee’s possession or under Employee’s control, promptly deliver to  Enfusion: (i) all original and any copies of emails, employee training materials, records, agreements,  manuals, books, blank forms, documents, letters, memoranda, notes, notebooks, reports, data, tables, or  calculations, which are the property of Enfusion or its affiliates and that relate, in any way, to the business,  products, policies, practices, or techniques thereof, including any strategies; (ii) all other Enfusion  property, including any Enfusion issued credit cards, identification, keys, computers, cell phone, or other  equipment; (iii) all Confidential Information of Enfusion or its affiliates, including all documents that, in  whole or in part, contain any Confidential Information of Enfusion or its affiliates or their respective clients  or licensors; and (iv) all proprietary information, intellectual property and trade secrets of Enfusion or its  affiliates or their respective clients or licensors. In addition, if applicable, Employee shall promptly cancel  or transfer to himself or herself any telecommunications services for which Enfusion was directly paying.  Nothing in this Section shall prohibit Employee from retaining papers or materials that are solely of a  personal nature, including copies of documents showing their compensation or reimbursable expenses  and a copy of this Employment Agreement.

13. Intellectual Property. (“Intellectual Property”) means any and all intellectual property in any form or stage  of development, including any innovation, discovery, idea, concept, design, prototype, product  configuration, invention, improvement, modification, patentable subject matter, method, process,  technique, procedure, system, plan, model, program, software or code, source code, algorithms, data,  specification, drawing, images,


text, music, movies, video, websites, diagram, flow chart, documentation,  know-how, work of authorship, copyrightable subject matter, derivative work, trademark or trade name,  and any other subject matter, material, or information that qualifies or is considered by Employer to  qualify for patent, copyright, trademark, trade dress, trade secret, or any other protection under any law  providing or creating intellectual property rights, including the Uniform Trade Secrets Act. Intellectual  Property also includes Confidential Information learned, obtained, or developed in connection with  Employee’s employment, such as specifications, financial data, personnel information, market  information, business arrangements, and other non-public information of Employer described in Section  11 of this Agreement. EMPLOYEE AGREES THAT ANY INTELLECTUAL PROPERTY CONCEIVED OR MADE BY  EMPLOYEE, WHETHER ALONE OR WITH OTHER, DURING THE TERM OF EMPLOYEE’S EMPLOYMENT WITH  ENFUSION RELATING IN ANY MANNER TO THE BUSINESS, BUSINESS PLANS, OR STRATEGIES OF ENFUSION  OR ITS AFFILIATES, SHALL BE THE EXCLUSIVE PROPERTY OF ENFUSION OR SUCH AFFILIATE. WITHOUT  LIMITING THE FOREGOING, TO THE EXTENT ANY COPYRIGHTABLE WORK IS INCLUDED IN THE FOREGOING,  IT WILL BE DEEMED ‘A WORK MADE FOR HIRE” FOR THE BENEFIT OF ENFUSION OR SUCH AFFILIATE UNDER  SECTION 201(b) OF THE 1976 U.S. COPYRIGHT ACT, AS AMENDED, OR OTHER SIMILAR APPLICABLE STATE  OR FOREIGN OR INTERNATIONAL LAWS. FURTHER, EMPLOYEE AGREES THAT ALL INVENTIONS, HE OR SHE  DEVELOPS OR DEVISES (WHETHER INDIVIDUALLY OR IN CONCERT WITH OTHERS): (i) USING ENFUSION’S  EQUIPMENT, SUPPLIES, RESOURCES, OR CONFIDENTIAL INFORMATION; (ii) RESULTING FROM WORK HE  OR SHE PERFORMS OR PERFORMED FOR ENFUSION; OR (iii) RELATING TO ENFUSION’S CURRENT OR  PLANNED RESEARCH OR DEVELOPMENT WILL BE ENFUSION’S SOLE AND EXCLUSIVE PROPERTY.  ACCORDINGLY, EMPLOYEE HEREBY ASSIGNS ALL INTELLECTUAL PROPERTY RIGHTS, TITLE, AND INTERESTS TO ENFUSION AND WAIVES ANY MORAL RIGHTS IN THE INTELLECTUAL PROPERTY TO THE FURTHEST  EXTENT PERMITTED BY LAW.

14. Restrictive Covenants. Employee understands and recognizes that Enfusion is engaged in a highly  competitive business and has spent a considerable amount of time, effort, and resources building its  business, products, client base (domestically and internationally), and training its employees. Further,  Employee through their employment will receive training regarding and have access to Enfusion’s (and its  clients’ and licensors’) Confidential Information (as defined above), trade secrets, and sensitive proprietary  business methods or data, customer lists, and other valuable business information. Employee  acknowledges and agrees that Enfusion has a legitimate business interest in protecting its goodwill, client  and employee base, Confidential Information, trade secrets, and other proprietary information.  Accordingly, Employee agrees to be bound by the following restrictive covenants (“Restrictive  Covenants”), which are reasonably tailored to protect Enfusion’s legitimate interests from improper and  unfair competition, and will not unreasonably impair or infringe on Employee’s right to work or earn a  living after Employee’s Termination Date:

a) Definitions: For purposes of this section, the following terms are defined as follows:

i. (“Client”) means a person or organization who has retained, in writing or otherwise, Enfusion or any of its affiliates to perform a service for compensation, which is, is related to, or is an extension of Enfusion’s or its affiliates’ normal line of business and which Employee was involved; and,

ii. (“Prospective Client”) means a person or entity that has not yet retained, in writing or otherwise, Enfusion or any of its affiliates to perform a service for compensation as described above when defining Clients, but instead, is a person or entity that Enfusion or any of its affiliates reasonably expect to do so by virtue of Prospective Client’s solicitation of Enfusion or its affiliates or Enfusion’s or its affiliates’ targeted, direct solicitation of that person or entity within a six (6) month period immediately prior to Employee’s Termination Date.

b) Non-solicitation of Enfusion’s Employees. Throughout Employee’s employment with Enfusion and  for a period of one (1) year, to commence on Employee’s Termination Date, Employee agrees not to:  directly or indirectly, through any person or entity, or as an agent for any person or entity, or authorize,  encourage, suggest, or approve any person or entity to employ or cause to be employed, entice, induce, or  solicit employment or engagement, in any capacity, any person that Employee had contact with and who is  employed by Enfusion or any of its affiliates or was employed or engaged by Enfusion or its affiliates within  three (3) months of the solicitation. While there is no geographic restraint, Employee


understands and acknowledges that the restriction prohibiting solicitation of Enfusion employees is necessary and  reasonable based upon Enfusion’s global presence and to protect Enfusion’s legitimate interest in its  employee base and the resources utilized in training and maintaining such employee base.

c) Non-solicitation of Enfusion’s Clients. Throughout Employee’s employment with Enfusion and for  a period of one (1) year, to commence on Employee’s Termination Date, Employee agrees not to: directly  or indirectly, through any person or entity, or as an agent for any person or entity, or authorize, encourage,  suggest, or approve any person or entity to directly or indirectly, through any person or entity, or as an  agent for any person or entity, or authorize, encourage, suggest, or knowingly approve any person or entity  to, induce, attempt to induce, or entice any Client (as defined above) or Prospective Client (as defined  above), in whole or in part, from doing business with Enfusion or any such Affiliate, regardless of which  party initiates the contact or communication; or directly or indirectly, or through any person or entity, or  authorize, encourage, suggest, or knowingly approve any person or entity to, solicit, communicate with,  contact, sell or render assistance, services or products to any Client or Prospective Client that would  interfere with, take away, divert, or urge any Client or Prospective Client to discontinue, in whole or in part,  business with Enfusion or any of its affiliates. While there is no geographic restraint, Employee understands  and acknowledges that the restriction prohibiting solicitation of any Enfusion Client or Prospective Client is  limited to those Clients or Prospective Clients with whom Employee worked, to whom Employee marketed  or sold services or products, or about whom Employee received Confidential Information, as such would  give Employee an unfair competitive advantage. Employee agrees this restriction is necessary and  reasonable, without regard to geographic constraint, based upon the Employee’s knowledge and/or  interaction with the Client or Prospective Client and to protect Enfusion’s legitimate interest in protecting  its business relationships.

d) Non-compete. Employee understands and recognizes that: (i) Enfusion has spent a considerable amount of time and resources into training Employee; and, (ii) Employee will gain access to or knowledge  of confidential and proprietary information and of practices, successes, and failures during the course of  their employment; and, (iii) Employee will build relationships with Enfusion clients or prospective clients  through their employment with Enfusion, made possible through Enfusion’s brand and resources, each of  which Enfusion has a legitimate interest in protecting and Enfusion’s competitors or prospective  competitors will gain an unfair advantage by obtaining the benefit of such foregoing investments made into  and interests obtained by Employee. Therefore, throughout Employee’s employment with Enfusion and  throughout the Restricted Period (as defined below), Employee agrees not to, directly or indirectly, alone  or in association with or on behalf of any other person or entity, engage in any Competitive Activity (as  defined below) (“Restricted Employment”).

i. Restricted Period. (“Restricted Period”) means a period of twelve (12) months to commence on Employee’s Termination Date.

ii. Competitive Activity. (“Competitive Activity”) means:

1. Engaging in a Competitive Business (as defined below) directly or indirectly, on Employee’s own behalf or on the behalf of another;

2. Providing services, similar or related to any services Employee provided to Enfusion while employed by Enfusion, to any person engaged in a Competitive Business, whether as an employee, consultant, officer, director, manager, partner, principal, agent, representative, or in any other capacity; or,

3. Controlling (by contract, equity ownership, or otherwise), investing in (except as the owner of up to 3% of the securities of a publicly-traded entity), or providing other financial support to any person engaged in a Competitive Business.

iii. Competitive Business. (“Competitive Business”) means:

1. Asset Management Software, including (a) portfolio management system; (b) order management system; (c) execution management system; (d) fund accounting


system; or (e) fund risk management system, or any combination of the foregoing or any software substantially similar to any new software offering Enfusion offers or proposes to offer during Employee’s employment at Enfusion and in which Employee was involved in or received Confidential Information or trade secrets regarding; or

2. Any middle- or back-office services or servicing tied to Enfusion’s software that Enfusion offers or proposes to offer during Employee’s employment at Enfusion and in which Employee was involved in or received Confidential Information or trade secrets regarding, or any other similar software that is an alternative to or competes with Enfusion’s managed services offering, whether in whole or in part; or

3. Any other business or extension of a line of business in which Enfusion was engaged at any time during Employee’s employment, or in which Enfusion plans to engage or is considering plans to engage at the time of the Termination Date (as evidenced in writing) and in which Employee was involved or about which Employee received Confidential Information or trade secrets.

e) Notice. During the Restricted Period, Employee shall notify any other employers or prospective  employers of their obligations under this Agreement before Employee begins working for such employer  and further, agrees to simultaneously deliver a copy of such notice to Enfusion in accordance with Section  [19] (Notices). Further, Employee agrees that Enfusion may also notify such other employers or prospective  employers of Employee’s obligations under this Agreement. Employee agrees to inform Enfusion of the  name, address, and telephone number of Employee’s supervisor at each subsequent employer to whom  Employee reports this Agreement during the Restricted Period.

f) Undue Hardship. If Employee believes in good faith that the provisions in this Section will prevent  him or her from obtaining a new job due to its categorization as Restricted Employment, Employee may  notify Enfusion in writing, providing reasonable details about the proposed responsibilities of the new job  (without disclosing another person’s Confidential Information). The Parties agree to discuss whether  appropriate accommodations can be made to balance the protection of Enfusion’s business interests and  Employee’s desire to engage in Restricted Employment. Except to the extent required by applicable law,  Enfusion is under no obligation to modify the restrictions in this Section, but may do so in its sole and  absolute discretion.

g) General. For the avoidance of doubt, the Restrictive Covenants contained in this Agreement are in  addition to, and not in lieu of, any other restrictive covenants or similar covenants or agreements (other  than those set forth in any prior Employment Agreement between Enfusion and Employee) between the Employee and Enfusion. The above-described restrictions are narrowly tailored to protect Enfusion’s  legitimate business interests. The restrictions shall only apply to competitive employment in a capacity that  is related to or requires the same or similar skills or knowledge necessary to have performed Employee’s  duties at Enfusion or any role similar or related to any role held by Employee while employed at Enfusion.

h) Client Competition. Enfusion will spend a considerable amount of time and resources making  Employee an expert of Enfusion’s products and service offerings and has a legitimate interest in protecting  such investment in Employee. To protect its legitimate interest and to prevent clients from circumventing  and eliminating the need for Enfusion’s services, (whether explicitly or under the guise of reverse  engineering) through hiring Employee, Employee agrees that for a period of six (6) months to commence  on Employee’s Termination Date, Employee will not, directly or indirectly, accept employment or perform  services or duties, paid or unpaid, from any of Enfusion’s Clients or Prospective Clients, provided that  Employee had contact with during their employment and to the extent such employment would be in a  capacity substantially similar the capacity in which the Employee worked for Enfusion. Employee further  acknowledges the employment opportunities that Employee could get without violating this Agreement,  including the immense number of hedge funds, asset managers, fund administrators, fund of funds, and  other financial services or investment companies, and that as such he or she will be able to earn a livelihood  without violating this Agreement.

i) Extension of Restricted Period. In the event of any violation of any Restrictive Covenant, the  restricted period of the covenant that was violated shall be extended by a period of time equal to the period


beginning when such violation commenced and ending when the activities constituting such violation have  ceased, such that Enfusion gets the full benefit of the bargain with respect to the agreed upon period of  restriction.

15. Remedies. Employee acknowledges and agrees that due to the unique nature of Enfusion’s business,  Employee’s breach of any obligation may result in irreparable and continuing harm to Enfusion, for which  monetary damages may be inadequate to compensate or make Enfusion whole. Therefore, Employee  agrees Enfusion is entitled to seek injunctive relief or specific performance to enforce the terms of this  Agreement without the necessity of posting a bond. Employee further agrees Enfusion shall also have any  other right or remedy available to it under law or in equity including the right to seek and recover monetary  damages for lost profits and other compensable damages. Should any court of competent jurisdiction  determine that Employee has breached any of the provisions as contained in this Agreement, Enfusion  shall have a right to collect, in addition to any monetary damages awarded to it, all of its reasonable  attorneys’ fees and costs incurred in connection with its efforts to enforce this Agreement, including pre litigation efforts. Employee agrees that, if Enfusion seeks preliminary or emergency injunctive relief, and  obtains same in whole or in part, the Company shall be entitled to an award of its attorney fees, expenses,  and costs incurred in connection therewith upon the entry of the Order granting said preliminary or  emergency injunctive relief, in addition to any such fees and costs that may be incurred and awarded with  respect to any subsequent proceedings in said action.

16. Voluntary Agreement. Employee represents that Employee has carefully read, considered and  understands the scope and effect of the provisions of this Agreement and that Employee is fully aware of  the legal and binding effect of this Agreement. This Agreement is executed voluntarily by Employee and  without any duress or undue influence on the part or behalf of the Company. Employee further  acknowledges and agrees that Employee has been provided sufficient time to review the Agreement and  consult with an attorney or legal representative regarding the Employee’s rights and obligations under this  Agreement. In doing so, Employee acknowledges and agrees, the restrictions set forth in this Agreement  impose a fair and reasonable restriction on Employee, reasonably necessary to protect Enfusion’s and its  officers’, directors’, members’, and employees’ interests, business, and goodwill.

17. Severability. If any provision of this Agreement is found to be unenforceable or contrary to law; including  if any provision concerning time, scope, or geographic restrictions are deemed by a court with competent  jurisdiction to be overly broad; the provision in question should be reformed to the minimum extent  necessary to correct any invalidity while preserving to the maximum extent, the rights and commercial  expectations of the Parties. The remaining portions of this Agreement will remain in full force and effect.  Further, every provision of this Agreement shall be construed as independent agreements between Enfusion and Employee. Therefore, any claim or cause of action Employee may have against Enfusion, whether predicated on this Agreement or otherwise, shall not constitute a defense to prohibit the  enforcement of any other provision or covenant.

18. Counterparts. This Agreement, and any amendment thereto, may be executed in one or more  counterparts and by the Parties hereto in separate counterparts, each of which when executed shall be  deemed to be an original, but all of which taken together, shall constitute one and the same Agreement.  Facsimile, PDF, and any other digital or electronic signatures to this Agreement shall have the same effect  as original or wet signatures. If executed in counterparts, this Agreement or any amendment, will not be  effective or enforceable until signed by both Employee and an authorized representative of Enfusion.

19. Notices. All notices, requests, claims, demands, and other communications under this Agreement,  (collectively “Notices”), must be in writing and sent to the person and address designated in this Section.  Any Notices must be hand-delivered, sent by an internationally recognized overnight courier service, sent  via e-mail, or sent via registered or certified mail with postage pre-paid and return receipt requested.  Notices will be considered given or made upon receipt.

Notices to Enfusion: Notices to Employee:

Attn: Human Resources

Enfusion, LLC

Phone: 312.253.9800

125 S. Clark Street, Suite 750

E-mail: HR@enfusionsystems.com

Chicago, IL 60603

See Appendix 1 (Scope of Employment)


Employee agrees to provide an updated address to Enfusion at the time of termination and if that address  changes during any period of restriction following the Employee’s termination to provide Enfusion the  updated address. In the event Enfusion is unable to locate Employee at their last known residence,  Employee agrees Enfusion may seek injunctive relief or specific performance without personal service on  Employee, so long as Enfusion uses reasonable efforts to first locate Employee.

20. Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to  its subject matter and (to the extent permissible by law) supersedes all prior agreements, proposals,  communications, representations, writings, negotiations, or understandings with respect to that subject  matter. All terms, conditions, and warranties not stated expressly in this Agreement, and which would in  the absence of this provision be implied into this Agreement by statute, common law, equity, trade,  custom or usage or otherwise, are excluded to the maximum extent permitted by law.

21. Governing Law. The legal relations between the Parties hereto and any dispute arising under or in  connection with this Agreement, or breach thereof, whether sounding in contract, tort, or otherwise, shall  be governed by and construed in accordance with the laws of the United States of America and the State  in which the employee’s assigned Office is located (provided in Appendix 1), regardless of any laws that might otherwise govern under applicable choice-of-law principles. Any claim, legal proceeding, or litigation arising out of or in connection with this Agreement or the relationship between Enfusion and Employee  will be brought solely in the jurisdiction in which the Office is located, regardless of any laws or rules that  might otherwise govern under applicable forum non conveniens principles. Any claim brought in any other  jurisdiction or forum is precluded. ACCORDING, BOTH PARTIES HEREBY CONSENT TO THE EXCLUSIVE  JURISDICTION OF THE FEDERAL AND STATE COURTS LOCATED WITHIN THE JURISDICTION IN WHICH THE  OFFICE IS LOCATED.

22. No Waiver. No waiver, of any of the terms of this Agreement, will be valid unless in writing, explicitly stated  as such, and signed by the party waiving its rights. Any forbearance or delay by either party to enforce any  of its rights under this Agreement will not be construed as a waiver to enforce any such rights pertaining  to the occurrence in question or any other occurrence. The waiver, by any Party, of any breach of covenant  will not be construed as a waiver of any succeeding breach of the same or any other covenant.

23. Assignment. Enfusion may assign this Agreement or its rights under this Agreement to - and Employee  may be employed by - any affiliate or subsidiary of Enfusion, or entity that acquires all or substantially all  of Enfusion’s assets or acquires a department or line of business of Enfusion that Employee works within,  or that is otherwise a successor in interest to Enfusion. This Agreement may not be assigned by Employee,  except that Employee’s rights to compensation and benefits hereunder, subject to the limitations of this  Agreement, may be transferred by will, by operation of law or as required by the law or a court order.

24. Compliance with Section 409A. This Employment Agreement is intended to comply with, (or be exempt  from), Section 409A of the Internal Revenue Code of 1986, as amended, to the extent applicable, and shall  be administered and interpreted accordingly. To further clarify, this Section is in no way intended to  change that bonuses, if any, are earned upon payment.

25. Binding Agreement. This Agreement shall be binding upon and shall inure to the benefit of both Enfusion and Employee and their respective successors, assigns, heirs, and legal representatives.

[Signature Page to Follow]


[Signature Page to the Employment Agreement between Enfusion Ltd. LLC and Matthew Campobasso made effective on February 1, 2021]

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed as of the Effective Date written above.

Enfusion Ltd. LLC

Employee

Signature:   /s/ Tim Finney

Signature:

/s/ Matthew Campobasso

Name: Tim Finney

Name:

Matthew Campobasso

Title: Global Head of HR

Date: January 30, 2021

Date:

January 29, 2021


Third Party Intellectual Property (IP) Agreement

Dear Matthew Campobasso,

As a company, it is very important to us that we respect others’ intellectual property and contractual rights. Please  review this letter as it is a topic we hold dearly. Once you have reviewed, feel free to ask any questions you might  have. If you do not have any questions, please acknowledge the letter by signing in the designated area located at  the bottom of the page.

If you have not done so already, to the extent you may be subject to any enforceable restrictive covenants or  contractual limits on: i) your ability to solicit former clients or colleagues; ii) your possession, transfer, or use of  confidential information; and iii) your possession, transfer, or use of trade secret information, Enfusion requires that  you disclose the nature of such covenants or contractual limitations before you commence employment. It is  important to understand, you are personally responsible for complying with such covenants and limitations until  they expire (if at all).

In addition to making Enfusion aware of any covenants or limitations you are subject to, we want to reiterate that  you should not remove any trade secrets or confidential written or electronic materials from your current or prior  employers. Likewise, you should not bring any such materials to Enfusion. You may not use any confidential or trade  secret information you obtained during any prior employment in your work with Enfusion. To the extent the  information was maintained as confidential by your previous employer(s), confidential and trade secret information  includes, without limitation, any information about competitor marketing strategies, product development, and  pricing information, as well as customer and personnel lists and contact information.

If you receive instruction or work from anyone at Enfusion or its affiliates (e.g., Enfusion’s international offices) that  you believe would cause you to violate any agreements or covenants with a prior employer or your obligations to  Enfusion, you should immediately disclose the matter to your office lead or Enfusion management, including  Enfusion legal. It is very important that you take action under such circumstances because failure to abide by these  expectations could result in you being liable to your former employer or termination of employment with Enfusion.

Acknowledged and Accepted:

By Employee

Signature:

/s/ Matthew Campobasso

Name:

Matthew Campobasso

Date:

January 29, 2021


Appendix 1 – Scope of Employment

Reference is made to the “Employment Agreement” entered into by and between Enfusion Ltd. LLC (“Enfusion”) and Matthew Campobasso (“Employee”) and with an Effective Date of February 1, 2021, as may be amended from time-to-time, (the “Agreement”). The Parties hereby agree that this Appendix 1 shall be subject to and controlled by the terms and conditions of the Agreement, which shall be incorporated by reference into this Appendix 1. If there is any inconsistency between the terms of the Agreement and this Appendix 1, the terms of this Appendix 1 shall prevail. Further, all capitalized terms used but not defined in this Appendix 1 shall be construed in accordance with the Agreement. This Appendix 1 shall replace, in its entirety, any prior “Appendix 1 – Scope of Employment” relating to Employee’s employment with Enfusion, including, but not limited to, the Appendix 1 - Scope of Employment signed by Employee on January 29, 2021.

1.

Commencement Date. Employee’s first day of work under the terms set forth below will be on March 1, 2024 (“Commencement Date”) unless otherwise agreed to by Enfusion and Employee in writing pursuant to the terms of the Employment Agreement.

2.

Appointment & Duties. Employee shall serve as General Counsel and lead the Legal Department.

3.

Work Hours. During an ordinary work week, Employee shall be present at the Office during Enfusion’s ordinary office hours described under Section 5 of the Agreement (“Work Hours”) unless otherwise agreed to, in writing, by Employee and the CEO.

4.

Office. Employee is assigned to Enfusion’s office located in Chicago.

5.

Status. Employee will be classified as an exempt employee, which means Employee will not be eligible for overtime pay for hours worked in excess of forty (40) hours in any given week.

6.

Pay Cycle. As an exempt employee, Employee will ordinarily receive payment for services rendered twice a month, in accordance with Enfusion’s ordinary payroll policies and procedures.

7.

Salary. Employee agrees to accept a base salary to be paid at an annualized rate of $350,000 US Dollars (less, where applicable, deductions and withholdings) (“Salary”) effective January 1, 2024. Employee’s Salary will be paid in accordance with Enfusion’s normal payroll policies and procedures.

8.

Voluntary Termination Notice.

Employee is classified as a Level 1 Employee. Although Employee has the right to terminate their employment at any time for any reason, in recognition of Employee’s increased compensation, Employee agrees to give 90-days notice to the date on which Employee intends to cease working for Enfusion. Upon receipt of Employee’s notice of their intent to cease working for Enfusion, Enfusion may, in its sole discretion, choose to reduce Employee’s notice period (as described in this paragraph) without additional obligations to Employee.

9.

Other.

Discretionary Bonus

In addition to Employee’s Salary, Enfusion may reward Employee’s exemplary performance and the performance of Employee’s group through the award of a discretionary bonus (“Bonus”). Bonus awards will also reflect the company’s overall performance. Employee has a target Bonus of up to $150,000 (where paid at 100% of target) (less, where applicable, deductions and withholdings). At Enfusion’s discretion, the

Graphic


Bonus may be paid as cash or through some combination of cash and equity award. The award of any Bonus shall be conditioned upon: (1) Employee’s satisfactory, as determined solely by Enfusion, meeting of conditions and goals (relating both to Enfusion’s performance and Employee’s individual performance) to be communicated to Employee by Enfusion upon the commencement of Employee’s employment with Enfusion (and updated at times throughout Employee’s tenure); (2) Enfusion’s performance; and (3) Employee being in “active working status” at the time any Bonus is awarded. For purposes of this provision, “active working status” means that the Employee has not resigned (or given notice of Employee’s resignation) or been terminated (or been given notice of Employee’s termination).

Annual LTI Award

In connection with Enfusion’s Long-Term Incentive program, as applied to executives, you will be eligible to receive an annual grant (“LTI Award”). Based upon your current title and this year’s funding level, for 2024, you will be granted an LTI Award of $200,000 (“Grant Value”) of restricted stock units (“RSUs”). The Grant Value will be used to determine the total number of RSUs contained in the LTI Award. The total number of RSUs will be calculated by using the closing price of the company’s stock (traded on the New York Stock Exchange) on the grant date. The actual value you may recognize at the time of vesting may increase or decrease based upon stock movement and any applicable tax laws. All LTI Awards are subject to board approval. Any granted RSUs are subject to the terms and conditions set by the board and contained in the Stock Award Agreement. All grants are subject to the vesting schedule set forth in the Stock Award Agreement The funding level for LTI Awards for future years beyond 2024 has not yet been determined. The Grant Value of any future LTI Award you recognize may change.

10.

Vacation.

In accordance with Enfusion’s Flexible Time Off policy, which may be amended from time to time, Employee is entitled to Flexible Time Off as needed each calendar year. Flexible Time Off will not accrue or vest and therefore will not be paid out at the time of separation of employment.

11.

Notices to Employee.

Matthew Campobasso

[***]

Acknowledged and Accepted:

By Employee

Signature:

/s/ Matthew Campobasso

Name:

Matthew Campobasso

Date:

March 1, 2024

Graphic


EX-10.12 7 enfn-20231231xex10d12.htm EX-10.12

Exhibit 10.12

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

EMPLOYMENT AGREEMENT

This employment agreement, which shall include and incorporate by reference any appendix attached hereto, now or in the future (collectively “Agreement”), is entered into on February 7, 2022,(“Effective Date”), by and between ENFUSION LTD. LLC (“Enfusion”), with its principal place of business located at 125 SOUTH CLARK STREET, SUITE 750, CHICAGO, ILLINOIS 60603, and Valeria Gutowski, (“Employee”), an individual with their primary address located at:  [***] (each a “Party” or collectively, the “Parties”).

WHEREAS, Enfusion is in the business of creating and providing software and related products and services to clients in the investment and financial services industry throughout the United States and Global market with offices in Chicago, IL, New York and affiliate offices in London, Dublin, Hong Kong, Singapore, São Paulo, Mumbai, and  Bengaluru;

WHEREAS, Enfusion desires to hire Employee to perform certain services as described in this Agreement and any appendix attached hereto, and Employee desires to be hired by Enfusion to perform certain services described in this Agreement and any appendix attached hereto, each in accordance with the terms and conditions of this Agreement as may be amended or supplemented from time-to-time; and,

NOW THEREFORE, in exchange for good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the Parties covenant and agree as follows:

1.

Interpretation. Unless the context of this Agreement otherwise requires: (i) a capitalized word has the meaning assigned to it by this Agreement; (ii) “or” will be construed such that the series may include any of the items, all of the items, or any combination of the items; (iii) words in the singular include the plural, and words in the plural include the singular; (iv) provisions apply to successive events and transactions; (v) “hereof,” “hereunder,” “herein,” and “hereto” refer to the entire Agreement and not any section or subsection; (vi) references in this Agreement to sections or annexes are references to the sections of or annexes attached to this Agreement; (vii) “in writing” refers to in written or printed form, facsimile transmission, or e-mail; (viii) the term “include” does not create an exclusive list and should be interpreted, in any variation, as “includes, but is not limited to;” (ix) the phrase “any reason” should be read as “any reason or no reason;” and, (x) the headings in this Agreement are for reference only and shall not limit or otherwise affect the meaning, interpretation, or construction of this Agreement.

2.

Employment. Enfusion hereby agrees to employ Employee and Employee hereby agrees to accept Enfusion’s employment offer, each subject to and in accordance with the terms and conditions of this Agreement.

3.

Classification of Employment. Employee’s classification as Exempt or Non-Exempt under Fair Labor Standards Act (“FLSA”) shall be determined by Enfusion and any changes to the Employee’s classification shall be communicated by Enfusion to the Employee.

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


4.

Duties. Employee’s initial appointment and non-exhaustive description of duties are described on Appendix 1 (Scope of Employment) and are subject to the terms and conditions of this Agreement. Despite the duties described on Appendix 1, Employee understands and acknowledges that Enfusion, at its sole discretion, has the right to modify or redefine Employee’s duties or title at any time, for any reason.

5.

Work Hours. Enfusion’s ordinary office hours are 8:00AM to 5:00PM, Monday through Friday. Unless otherwise specified on Appendix 1, Employee’s regular workweek shall be forty (40) hours on a schedule of eight (8) working hours per day, Monday through Friday; however, Employee understands and agrees that from time-to-time and subject to applicable law, Employee may be required to work additional hours, including weekends and holidays, as necessary to support Enfusion’s business. Employee understands and agrees, Employee’s work hours and surrounding terms may be modified at Enfusion’s sole discretion to the furthest extent permitted by applicable law.

6.

Location. Employee’s assigned work location (the “Office”) will be described on Appendix 1. Subject to the terms and conditions of this Agreement and applicable law, Employee is required to be present at the Office during Work Hours (defined on Appendix 1).

7.

Performance of Duties; Exclusive Service. Employee has a duty of loyalty and care to Enfusion and agrees to perform their obligations faithfully and to the best of their ability. Similarly, Employee hereby agrees to abide by Enfusion’s policies and procedures (as amended from time-to-time) and agrees to devote their business time, attention, and efforts to Enfusion’s business (except for permitted break periods, vacation periods, and reasonable periods of illness or other incapacity). Despite the foregoing sentence, Employee may serve as a director of or otherwise participate in educational, welfare, social, religious, and civic organization, provided that Employee’ service or participation does not: (i) unreasonably interfere with performing their duties; and, (ii) violate any provision of this Agreement. For clarity, while employed by Enfusion, Employee is not allowed to perform duties or services for any other employer, business, or organization (including establishing or maintain their own business or organization) other than as permitted by this Agreement or with the written consent of an Enfusion authorized officer.

a)Business Ideas/Opportunities. During their employment, Employee may come up with or across potential business opportunities related to Enfusion’s business and services (“Business Opportunity”). If so, Employee agrees to promptly disclose any Business Opportunity to Enfusion so that Enfusion has an opportunity to pursue the Business Opportunity. Employee acknowledges and agrees that pursuing a Business Opportunity for Employee’s or another’s benefit, without first disclosing it and getting Enfusion’s prior written approval would be a violation of their duty of loyalty and care to Enfusion and that Employee is prohibited from pursuing a Business Opportunity, whether for Employee’s or another’s benefit, without Enfusion’s prior written approval. Enfusion’s reserves the right to deny Employee’s request to pursue a Business Opportunity in Enfusion’s sole discretion.

8.

Compensation and Benefits. Employee is entitled to certain compensation and benefits, which are outlined below and described further on Appendix 1.

a)Salary. Enfusion agrees to pay Employee for services rendered under this Agreement. Employee’s Salary (as defined on Appendix 1) will be paid in accordance with Enfusion’s normal payroll policies and procedures. To be clear, although Employee is paid an annual salary, Employee’s employment is “at-will” (discussed below). Enfusion, at its sole discretion, may adjust Employee’s Salary after the first twelve (12) months of employment and reserves the right to adjust Employee’s Salary from time-to-time.

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


b)Benefits. During Employee’s employment, except as otherwise expressly provided herein, Employee will be entitled to participate in all employee health, welfare and other benefit plans and programs (“Employee Benefit Plans”) applicable to similarly situated employees of Enfusion, as in effect from time to time, to the extent consistent with applicable law and the terms of the applicable employee benefit plan. Enfusion reserves the right to amend or cancel any Employee Benefit Plans at any time in its sole and absolute discretion, subject to the terms of the employee benefit plan and applicable law.

c)Vacation. Employee may become entitled to paid vacation days as outlined on Appendix 1, which will be pro-rated based on Employee’s Commencement Date (as defined on Appendix 1). Unaccrued vacation time may not be used without prior written approval from Enfusion in accordance with its policies. Further, subject to and to the extent permitted by Enfusion’s ordinary paid vacation policies, Employee may be entitled rollover unused accrued paid vacation days into the following year. Employee should use their best efforts not to schedule vacation time that will conflict with their duties and when possible, agrees to provide Enfusion with at least two (2) weeks’ prior notice of any planned vacation. Enfusion reserves the right, in its sole discretion, to approve or deny any requested vacation time.

d)Bonus.

i.Discretionary Bonus. Enfusion may, from time-to-time, in its sole discretion, choose to pay Employee additional compensation as a discretionary bonus. Whether and when a bonus is awarded, and the amount (if any) of bonus awarded, will be determined in Enfusion’s sole discretion on whatever basis and after taking into account whatever factors it considers appropriate at the time. Any bonus is not earned until paid. Therefore, to receive any bonus, Employee must be employed by Enfusion and in good standing on the bonus’s payment date and must not have indicated their intent to resign prior to or on such payment date.

ii.Other Bonus. If the Employee is eligible to receive a non-discretionary or other type of commission-based compensation, then it will be described on Appendix 1.

e)Payments. All payments made to Employee in the course of their employment will be paid in accordance with Enfusion’s normal payroll policies and procedures. Further, all compensation payments made in the course of Employee’s employment will be subject to any applicable withholding requirements or other similar obligations.

f)Expenses. Enfusion will reimburse Employee for out-of-pocket expenses incurred by Employee in the course of their employment pursuant to Enfusion’s reimbursement policy and in each case, subject to applicable law.

g)Consideration. In consideration for Employee agreeing to Sections 11 and 14 of this Agreement, the Company will provide the employee consideration, including, but not limited to, an at-will employment relationship, or continued at-will employment; training; and access to, or continued access to the Company’s Confidential Information and client, customer and business relationships during Employee’s employment. Employee agrees the consideration outlined in this paragraph is sufficient consideration for Employee’s various obligations under Sections 11 and 14 of this Agreement. Employee understands that

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


acceptance of this Agreement is a condition of employment and that the Company would not offer to employ Employee and grant Employee access to its Confidential Information and client and customer relationships, but for Employee’s acceptance of the terms of this Agreement and acknowledgment that the consideration outlined herein is sufficient consideration for Employee’s obligations under Sections 11 and 14 of this Agreement.

9.

Employment Relationship and Termination. “Termination Date” means the date on which Employee ceases work for Enfusion, whether voluntary or involuntary.

a)AT-WILL” EMPLOYMENT. EMPLOYEE ACKNOWLEDGES AND AGREES THAT THEIR EMPLOYMENT IS “AT-WILL.” THIS MEANS, BOTH ENFUSION AND EMPLOYEE MAY TERMINATE EMPLOYEE’S EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON, WITHOUT LIABILITY FOR BREACH OF CONTRACT, PROMISSORY ESTOPPEL, SEVERANCE PAY, OR OTHERWISE.

b)Voluntary Termination. Voluntary Termination. Although Employee has the right to terminate their employment at any time for any reason, Employee, if classified as a Level 3, 4 or 5 Employee, agrees to provide Enfusion with at least thirty (30) days’ prior notice to the date on which Employee intends to cease working for Enfusion. If Employee is classified as a Level 2 Employee, Employee agrees to provide Enfusion with at least sixty (60) days’ prior notice to the date on which Employee intends to cease working for Enfusion. If Employee is classified as a Level 1 Employee, Employee agrees to provide Enfusion with at least ninety (90) days’ prior notice to the date on which Employee intends to cease working for Enfusion. Employee’s initial level is contained within Appendix 1 of this Agreement. Upon receipt of Employee's notice of their intent to cease working for Enfusion, Enfusion may, in its sole discretion, choose to reduce Employee's notice period (as described in this paragraph) without additional obligations to Employee.

c)Final Payment. Unless otherwise required by applicable state law, upon Employee’s Termination Date, Enfusion shall provide Employee with a date, no later than Enfusion’s next regular pay date, on which Employee will receive their final payment for all accrued Salary and vested paid vacation time through the Termination Date.

10.

Representations. Employee understands and acknowledges that the following representations and covenants are essential to Enfusion’s decision to enter into this Agreement. Employee represents and warrants to Enfusion as follows:

a)Other than as already disclosed by Employee to Enfusion, as of the Effective Date, Employee is not under any contractual or legal duty or obligation, engagement, understanding, restriction, or commitment with any prior employer, other entity or individual other than Enfusion or its Affiliates ("Other Employer”) that would limit, prohibit, or interfere with Employee’s full and faithful performance of this Agreement, including but not limited to, employment, consulting, confidentiality, non-competition, or non-solicitation agreements or restrictive covenants; Employee certifies that if they have made a disclosure of a contractual or legal duty or obligation, engagement, understanding, restriction, or commitment with a prior employer(s), other entity or individual other than Enfusion or its Affiliates ("Other Employer”) that would limit, prohibit, or interfere with Employee’s full and faithful performance of this Agreement, including but not limited to, employment, consulting, confidentiality, non-competition, or non-solicitation agreements or restrictive covenants, that their disclosure was a complete disclosure of any applicable terms.

b)Employee does not have any inventions or intellectual property obligations which may affect assignment under Section 13, other than what Employee has disclosed in Appendix 2;

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


c)If applicable, Employee has disclosed any Other Employers existing as of the Effective Date;

d)If applicable, Employee has complied with all duties imposed on Employee by their former employer with respect to termination of their employment;

e)Employee is free to enter this Agreement and commence employment with Enfusion;

f)Employee understands and acknowledges the offer of employment made pursuant to this Agreement is made only to Employee for their personal services, and at no time has Employee been authorized to recruit, induce, entice, or offer employment at Enfusion to any other person;

g)Employee covenants not to use, disclose, or induce the use of, any trade secret, confidential information, or proprietary information that belongs to any third party in the performance of Employee’s employment under this Agreement, unless Employee has prior written consent from the owner of the protected information (which, Employee agrees to provide such written consent to Enfusion); and,

h)Employee is not aware of: (i) any pending internal, criminal, civil, regulatory, or self-regulatory organization investigations involving Employee or any of Employee’s activities at any former employer or in relation to or arising out of Employee’s prior employment ; (ii) any pending customer complaints or customer arbitrations involving any of Employee’s activities at any former employer or in relation to or arising out of Employee’s prior employment; or, (iii) any circumstances that might lead to any of the matters described in this subsection. If Employee is aware of any such issues, Employee has disclosed such in writing to Enfusion’s Chief Human Resources Officer at least seven (7) days prior to the parties entering into this Agreement.

11.

Confidential Information and Confidentiality.

a)Employee acknowledges and agrees that through their employment, he or she will be provided, obtain, or be exposed to proprietary or non-public information relating to Enfusion’s business, which is confidential in nature. Such information includes, client lists or client related information, information related to or concerning Enfusion’s products and services; fees, costs, and pricing structures; market studies; business plans and investment analyses; designs and specifications; data and analyses; drawings, photographs, and reports; computer software, object code, source code, operating systems, applications, algorithms, and program listings; flow charts, manuals, and documentation, ideas, images, text, music, movies, concepts, video, and websites; databases; accounting and business methods; inventions, devices, new developments, methods, and processes, (whether patentable or non-patentable and whether or not reduced to practice); investor or ownership information, Client and Prospective Client information; copyrightable works; technology and trade secrets; historical financial statements, financial projections, and budgets; personnel training techniques and materials; and any other personal, business, financial, or technical information, data, patents, or ideas relating to the proprietary information observed by, or disclosed to, Employee, whether in oral, written documents, memoranda, reports, or correspondence in graphic or machine-readable form, or otherwise in the course of, or in connection with, Employee’s employment with Enfusion (individually and collectively “Confidential Information”).

b)Employee hereby agrees that he or she will not disclose nor use at any time; before, during, or after their employment with Enfusion; any Confidential Information of which Employee is or becomes aware of, whether or not such information is developed by Employee, except to the extent such disclosure or use is directly related to or required for Employee’s performance of their employment duties. Further,

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


Employee agrees he or she will take all reasonable and appropriate steps to safeguard the Confidential Information and to protect it against disclosure, misuse, espionage, loss, or theft and will not disclose or use any Confidential Information except as reasonably necessary to perform Employee's duties for the Company, or as required by law. Employee further agrees not to otherwise transmit or download any Confidential Information to Employee's personal computer, cellular telephone, or other electronic device, or otherwise remove Confidential Information from the Company's premises or Company-owned computer, unless Employee secures the Company's specific authorization in advance and takes appropriate steps to protect such information. Employee understands and agrees that all Confidential Information, including documents, records, and electronic files, to which Employee has access as a result of Employee's employment by the Company are the exclusive property of the Company. Employee also acknowledges and agrees that all Confidential Information, and all copyrights, trademarks, patents and other rights in connection therewith, shall be the sole property of the Company and its assigns. For clarity, nothing herein in is intended to prevent Employee disclosing information that Employee has a legal right to disclose.

c)Exceptions. Confidential Information shall not include any information that: (i) was in the possession of, or demonstrably known by, (in each case without restriction on its use or disclosure) the Employee prior to their receipt of such information; (ii) any information independently known by Employee without access to or reliance upon any Confidential Information, including the general skills, knowledge and experience acquired by the Employee before and/or during employment with the Company; (iii) was lawfully disclosed to Employee following the end of their employment with Enfusion by a third party under no known obligation of confidentiality; (iv) is in the public domain at the time of disclosure, or thereafter becomes in the public domain, other than as a result of disclosure by Employee in violation of this Agreement.

d)In the event Employee is required under a subpoena, court order, statute, law, rule, regulation, or other similar requirement, (“Legal Requirement”) Employee shall do so only to the extent required by the Legal Requirement, must provide prompt written notice to Enfusion of the disclosure to the extent not precluded by law, and must designate the information as Confidential Information when disclosing such information. Further, when legally permissible, the Employee shall notify Enfusion of what Confidential Information was disclosed under such Legal Requirement.

e)Defend Trade Secrets Act of 2016 (DTSA) Notice. Notwithstanding any other provision of this Agreement, pursuant to Section 7 of the DTSA, the Employee cannot be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that: (1) is made: (A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. (ii) If Employee files a lawsuit for retaliation by Company for reporting a suspected violation of law, Employee may disclose Company’s trade secrets to Employee’s attorney and use the trade secret information in the court proceeding if Employee: (1) files any document containing the trade secret under seal; and (2) does not disclose the trade secret, except pursuant to court order.

f)Violation of Law. If Employee believes Enfusion has committed or is committing a violation of law, although not required, he or she is asked to first report the possible violation to Enfusion’s upper-management so that Enfusion may take the proper corrective actions. Despite the foregoing, Employee is

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


free to report possible violations, file a charge with, or participate or cooperate with any governmental agency or entity, including but not limited to the EEOC, the Department of Justice, the Securities and Exchange Commission, Congress, or any agency Inspector General, or making any other disclosures that are protected under the whistleblower, anti-discrimination or anti-retaliation provisions of federal, state or local law or regulation; provided further, the Employee does not need the prior authorization of the Company to make any such reports or disclosures, and the Employee is not required to notify the Company that the Employee has made such reports or disclosures.

g)Trading. Employee understands and agrees he or she is not permitted to use Enfusion’s or Clients’ Confidential Information on their behalf, on the behalf of others, or to assist others in trading securities. Employee further acknowledges that to use Enfusion’s or Client’s Confidential Information for personal financial benefit or to “tip” others who might make an investment decision on the basis of this information is not only prohibited and unethical, but is also illegal.

12.

Company Property. Upon Enfusion’s request or Employee’s Termination Date, Employee shall, to the extent such materials are in Employee’s possession or under Employee’s control, promptly deliver to Enfusion: (i) all original and any copies of emails, employee training materials, records, agreements, manuals, books, blank forms, documents, letters, memoranda, notes, notebooks, reports, data, tables, or calculations, which are the property of Enfusion or its Affiliates and that relate, in any way, to the business, products, policies, practices, or techniques thereof, including any strategies; (ii) all other Enfusion property, including any Enfusion issued credit cards, identification, keys, computers, cell phone, or other equipment; (iii) all Confidential Information of Enfusion or its Affiliates, including all documents that, in whole or in part, contain any Confidential Information of Enfusion or its Affiliates or their respective clients or licensors; and (iv) all proprietary information, intellectual property and trade secrets of Enfusion or its Affiliates or their respective clients or licensors. In addition, if applicable, Employee shall promptly cancel or transfer to himself or herself any telecommunications services for which Enfusion was directly paying. Nothing in this Section shall prohibit Employee from retaining papers or materials that are solely of a personal nature, including copies of documents showing their compensation or reimbursable expenses and a copy of this Employment Agreement.

13.

Intellectual Property. (“Intellectual Property”) means any and all intellectual property in any form or stage of development, including any innovation, discovery, idea, concept, design, prototype, product configuration, invention, improvement, modification, patentable subject matter, method, process, technique, procedure, system, plan, model, program, software or code, source code, algorithms, data, specification, drawing, images, text, music, movies, video, websites, diagram, flow chart, documentation, know-how, work of authorship, copyrightable subject matter, derivative work, trademark or trade name, and any other subject matter, material, or information that qualifies or is considered by Employer to qualify for patent, copyright, trademark, trade dress, trade secret, or any other protection under any law providing or creating intellectual property rights, including the Uniform Trade Secrets Act. Intellectual Property also includes Confidential Information learned, obtained, or developed in connection with Employee’s employment, such as specifications, financial data, personnel information, market information, business arrangements, and other non-public information of Employer described in Section [11] of this Agreement. EMPLOYEE AGREES THAT ANY INTELLECTUAL PROPERTY CONCEIVED OR MADE BY EMPLOYEE, WHETHER ALONE OR WITH OTHER, DURING THE TERM OF EMPLOYEE’S EMPLOYMENT WITH ENFUSION RELATING IN ANY MANNER TO THE BUSINESS, BUSINESS PLANS, OR STRATEGIES OF ENFUSION OR ITS AFFILIATES, SHALL BE THE EXCLUSIVE PROPERTY OF ENFUSION OR SUCH AFFILIATE. WITHOUT

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


LIMITING THE FOREGOING, TO THE EXTENT ANY COPYRIGHTABLE WORK IS INCLUDED IN THE FOREGOING, IT WILL BE DEEMED ‘A WORK MADE FOR HIRE” FOR THE BENEFIT OF ENFUSION OR SUCH AFFILIATE UNDER SECTION 201(b) OF THE 1976 U.S. COPYRIGHT ACT, AS AMENDED, OR OTHER SIMILAR APPLICABLE STATE OR FOREIGN OR INTERNATIONAL LAWS. FURTHER, EMPLOYEE AGREES THAT ALL INVENTIONS, HE OR SHE DEVELOPS OR DEVISES (WHETHER INDIVIDUALLY OR IN CONCERT WITH OTHERS): (i) USING ENFUSION’S EQUIPMENT, SUPPLIES, RESOURCES, OR CONFIDENTIAL INFORMATION; (ii) RESULTING FROM WORK HE OR SHE PERFORMS OR PERFORMED FOR ENFUSION; OR, (iii) RELATING TO ENFUSION’S CURRENT OR PLANNED RESEARCH OR DEVELOPMENT WILL BE ENFUSION’S SOLE AND EXCLUSIVE PROPERTY. ACCORDINGLY, EMPLOYEE HEREBY ASSIGNS ALL INTELLECTUAL PROPERTY RIGHTS, TITLE, AND INTERESTES TO ENFUSION AND WAIVES ANY MORAL RIGHTS IN THE INTELLECTUAL PROPERTY TO THE FURTHEST EXTENT PERMITED BY LAW.

14.

Restrictive Covenants. Employee understands and recognizes that Enfusion is engaged in a highly competitive business and has spent a considerable amount of time, effort, and resources building its business, products, client base (domestically and internationally), and training its employees. Further, Employee through their employment will receive training regarding and have access to Enfusion’s (and its clients’ and licensors’) Confidential Information (as defined above), trade secrets, and sensitive proprietary business methods or data, customer lists, and other valuable business information. Employee acknowledges and agrees that Enfusion has a legitimate business interest in protecting its goodwill, client and employee base, Confidential Information, trade secrets, and other proprietary information. Accordingly, Employee agrees to be bound by the following restrictive covenants (“Restrictive Covenants”), which are reasonably tailored to protect Enfusion’s legitimate interests from improper and unfair competition, and will not unreasonably impair or infringe on Employee’s right to work or earn a living after Employee’s Termination Date:

a)Definitions: For purposes of this section, the following terms are defined as follows:

i. (“Client”) means a person or organization who has retained, in writing or otherwise, Enfusion or any of its Affiliates to perform a service for compensation, which is, is related to, or is an extension of Enfusion’s or its Affiliates’ normal line of business and which Employee was involved; and,

ii.(“Prospective Client”) means a person or entity that has not yet retained, in writing or otherwise, Enfusion or any of its Affiliates to perform a service for compensation as described above when defining Clients, but instead, is a person or entity that Enfusion or any of its Affiliates reasonably expect to do so by virtue of Prospective Client’s solicitation of Enfusion or its Affiliates or Enfusion’s or its Affiliates’ targeted, direct solicitation of that person or entity within a six (6) month period immediately prior to Employee’s Termination Date.

b)Non-solicitation of Enfusion’s Employees. Throughout Employee’s employment with Enfusion and for a period of one (1) year, to commence on Employee’s Termination Date, Employee agrees not to: directly or indirectly, through any person or entity, or as an agent for any person or entity, or authorize, encourage, suggest, or approve any person or entity to employ or cause to be employed, entice, induce, or solicit employment or engagement, in any capacity, any person that Employee had contact with and who is employed by Enfusion or any of its Affiliates or was employed or engaged by Enfusion or its Affiliates within three (3) months of the solicitation. While there is no geographic restraint, Employee understands and acknowledges that the restriction prohibiting solicitation of Enfusion employees is necessary and

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


reasonable based upon Enfusion’s global presence and to protect Enfusion’s legitimate interest in its employee base and the resources utilized in training and maintaining such employee base.

c)Non-solicitation of Enfusion’s Clients. Throughout Employee’s employment with Enfusion and for a period of one (1) year, to commence on Employee’s Termination Date, Employee agrees not to: directly or indirectly, through any person or entity, or as an agent for any person or entity, or authorize, encourage, suggest, or approve any person or entity to directly or indirectly, through any person or entity, or as an agent for any person or entity, or authorize, encourage, suggest, or knowingly approve any person or entity to, induce, attempt to induce, or entice any Client (as defined above) or Prospective Client (as defined above), in whole or in part, from doing business with Enfusion or any such Affiliate, regardless of which party initiates the contact or communication; or directly or indirectly, or through any person or entity, or authorize, encourage, suggest, or knowingly approve any person or entity to, solicit, communicate with, contact, sell or render assistance, services or products to any Client or Prospective Client that would interfere with, take away, divert, or urge any Client or Prospective Client to discontinue, in whole or in part, business with Enfusion or any of its Affiliates. While there is no geographic restraint, Employee understands and acknowledges that the restriction prohibiting solicitation of any Enfusion Client or Prospective Client is limited to those Clients or Prospective Clients with whom Employee worked, to whom Employee marketed or sold services or products, or about whom Employee received Confidential Information, as such would give Employee an unfair competitive advantage. Employee agrees this restriction is necessary and reasonable, without regard to geographic constraint, based upon the Employee’s knowledge and/or interaction with the Client or Prospective Client and to protect Enfusion’s legitimate interest in protecting its business relationships.

d)Non-compete. Employee understands and recognizes that: (i) Enfusion has spent a considerable amount of time and resources into training Employee; and, (ii) Employee will gain access to or knowledge of confidential and proprietary information and of practices, successes, and failures during the course of their employment; and, (iii) Employee will build relationships with Enfusion clients or prospective clients through their employment with Enfusion, made possible through Enfusion’s brand and resources, each of which Enfusion has a legitimate interest in protecting and Enfusion’s competitors or prospective competitors will gain an unfair advantage by obtaining the benefit of such foregoing investments made into and interests obtained by Employee. Therefore, throughout Employee’s employment with Enfusion and throughout the Restricted Period (as defined below), Employee agrees not to, directly or indirectly, alone or in association with or on behalf of any other person or entity, engage in any Competitive Activity (as defined below) (“Restricted Employment”).

i.Restricted Period. (“Restricted Period”) means a period of twelve (12) months to commence on Employee’s Termination Date.

ii.Competitive Activity. (“Competitive Activity”) means:

1.

Engaging in a Competitive Business (as defined below) directly or indirectly, on Employee’s own behalf or on the behalf of another;

2.

Providing services, similar or related to any services Employee provided to Enfusion while employed by Enfusion, to any person engaged in a Competitive Business, whether as an employee, consultant, officer, director, manager, partner, principal, agent, representative, or in any other capacity; or,

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


3.

Controlling (by contract, equity ownership, or otherwise), investing in (except as the owner of up to 3% of the securities of a publicly-traded entity), or providing other financial support to any person engaged in a Competitive Business.

iii.Competitive Business. (“Competitive Business”) means:

1.

Asset Management Software, including (a) portfolio management system; (b) order management system; (c) execution management system; (d) fund accounting system; or (e) fund risk management system, or any combination of the foregoing or any software substantially similar to any new software offering Enfusion offers or proposes to offer during Employee’s employment at Enfusion and in which Employee was involved in or received Confidential Information or trade secrets regarding; or

2.

Any middle- or back-office services or servicing tied to Enfusion’s software that Enfusion offers or proposes to offer during Employee’s employment at Enfusion and in which Employee was involved in or received Confidential Information or trade secrets regarding, or any other similar software that is an alternative to or competes with Enfusion’s managed services offering, whether in whole or in part; or

3.

Any other business or extension of a line of business in which Enfusion was engaged at any time during Employee’s employment, or in which Enfusion plans to engage or is considering plans to engage at the time of the Termination Date (as evidenced in writing) and in which Employee was involved or about which Employee received Confidential Information or trade secrets.

e)Notice. During the Restricted Period, Employee shall notify any other employers or prospective employers of their obligations under this Agreement before Employee begins working for such employer and further, agrees to simultaneously deliver a copy of such notice to Enfusion in accordance with Section [19] (Notices). . Further, Employee agrees that Enfusion may also notify such other employers or prospective employers of Employee’s obligations under this Agreement. Employee agrees to inform Enfusion of the name, address, and telephone number of Employee’s supervisor at each subsequent employer to whom Employee reports this Agreement during the Restricted Period.

f)Undue Hardship. If Employee believes in good faith that the provisions in this Section will prevent him or her from obtaining a new job due to its categorization as Restricted Employment, Employee may notify Enfusion in writing, providing reasonable details about the proposed responsibilities of the new job (without disclosing another person’s Confidential Information). The Parties agree to discuss whether appropriate accommodations can be made to balance the protection of Enfusion’s business interests and Employee’s desire to engage in Restricted Employment, and any appropriate adjustments to the payments described above. Except to the extent required by applicable law, Enfusion is under no obligation to modify the restrictions in this Section, but may do so in its sole and absolute discretion.

g)General. For the avoidance of doubt, the Restrictive Covenants contained in this Agreement are in addition to, and not in lieu of, any other restrictive covenants or similar covenants or agreements between the Employee and Enfusion. The above-described restrictions are narrowly tailored to protect Enfusion’s legitimate business interests. The restrictions shall only apply to competitive employment in a capacity that is related to or requires the same or similar skills or knowledge necessary to have performed Employee’s duties at Enfusion or any role similar or related to any role held by Employee while employed at Enfusion.

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


h)Client Competition. Enfusion will spend a considerable amount of time and resources making Employee an expert of Enfusion’s products and service offerings and has a legitimate interest in protecting such investment in Employee. To protect its legitimate interest and to prevent clients from circumventing and eliminating the need for Enfusion’s services, (whether explicitly or under the guise of reverse engineering) through hiring Employee, Employee agrees that for a period of six (6) months to commence on Employee’s Termination Date, Employee will not, directly or indirectly, accept employment or perform services or duties, paid or unpaid, from any of Enfusion’s Clients or Prospective Clients, provided that Employee had contact with during their employment and to the extent such employment would be in a capacity substantially similar the capacity in which the Employee worked for Enfusion. Employee further acknowledges the employment opportunities that Employee could get without violating this Agreement, including the immense number of hedge funds, asset managers, fund administrators, fund of funds, and other financial services or investment companies, and that as such he or she will be able to earn a livelihood without violating this Agreement.

i)Extension of Restricted Period. In the event of any violation of any Restrictive Covenant, the restricted period of the covenant that was violated shall be extended by a period of time equal to the period beginning when such violation commenced and ending when the activities constituting such violation have ceased, such that Enfusion gets the full benefit of the bargain with respect to the agreed upon period of restriction.

15.

Remedies. Employee acknowledges and agrees that due to the unique nature of Enfusion’s business, Employee’s breach of any obligation may result in irreparable and continuing harm to Enfusion, for which monetary damages may be inadequate to compensate or make Enfusion whole. Therefore, Employee agrees Enfusion is entitled to seek injunctive relief or specific performance to enforce the terms of this Agreement without the necessity of posting a bond. Employee further agrees Enfusion shall also have any other right or remedy available to it under law or in equity including the right to seek and recover monetary damages for lost profits and other compensable damages. Should any court of competent jurisdiction determine that Employee has breached any of the provisions as contained in this Agreement, Enfusion shall have a right to collect, in addition to any monetary damages awarded to it, all of its reasonable attorneys’ fees and costs incurred in connection with its efforts to enforce this Agreement, including pre-litigation efforts. Employee agrees that, if Enfusion seeks preliminary or emergency injunctive relief, and obtains same in whole or in part, the Company shall be entitled to an award of its attorney fees, expenses, and costs incurred in connection therewith upon the entry of the Order granting said preliminary or emergency injunctive relief, in addition to any such fees and costs that may be incurred and awarded with respect to any subsequent proceedings in said action.

16.

Voluntary Agreement. Employee represents that Employee has carefully read, considered and understands the scope and effect of the provisions of this Agreement and that Employee is fully aware of the legal and binding effect of this Agreement. This Agreement is executed voluntarily by Employee and without any duress or undue influence on the part or behalf of the Company. Employee further acknowledges and agrees that Employee has been provided sufficient time to review the Agreement and consult with an attorney or legal representative regarding the Employee’s rights and obligations under this Agreement. In doing so, Employee acknowledges and agrees, the restrictions set forth in this Agreement impose a fair and reasonable restriction on Employee, reasonably necessary to protect Enfusion’s and its officers’ directors’, members’, and employees’ interests, business, and goodwill.

17.

Severability. If any provision of this Agreement is found to be unenforceable or contrary to law; including if any provision concerning time, scope, or geographic restrictions are deemed by a court with competent

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


jurisdiction to be overly broad; the provision in question should be reformed to the minimum extent necessary to correct any invalidity while preserving to the maximum extent, the rights and commercial expectations of the Parties. The remaining portions of this Agreement will remain in full force and effect. Further, every provision of this Agreement shall be construed as independent agreements between Enfusion and Employee. Therefore, any claim or cause of action Employee may have against Enfusion, whether predicated on this Agreement or otherwise, shall not constitute a defense to prohibit the enforcement of any other provision or covenant.

18.

Counterparts. This Agreement, and any amendment thereto, may be executed in one or more counterparts and by the Parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together, shall constitute one and the same Agreement. Facsimile, PDF, and any other digital or electronic signatures to this Agreement shall have the same effect as original or wet signatures. If executed in counterparts, this Agreement or any amendment, will not be effective or enforceable until signed by both Employee and an authorized representative of Enfusion.

19.

Notices. All notices, requests, claims, demands, and other communications under this Agreement, (collectively “Notices”), must be in writing and sent to the person and address designated in this Section. Any Notices must be hand-delivered, sent by an internationally recognized overnight courier service, sent via e-mail, or sent via registered or certified mail with postage pre-paid and return receipt requested. Notices will be considered given or made upon receipt.

Notices to Enfusion:

Notices to Employee:

Enfusion, LLC

See Appendix 1 (Scope of Employment)

125 S. Clark Street, Suite 750

Chicago, IL 60603

Attn: Human Resources

Phone: 312.253.9800

E-mail: HR@enfusionsystems.com

Employee agrees to provide an updated address to Enfusion at the time of termination and if that address changes during the any period of restriction following the Employee’s termination to provide Enfusion the updated address. In the event Enfusion is unable to locate Employee at their last known residence, Employee agrees Enfusion may seek injunctive relief or specific performance without personal service on Employee, so long as Enfusion uses reasonable efforts to first locate Employee.

20.

Entire Agreement. This Agreement constitute the entire agreement between the Parties with respect to its subject matter and (to the extent permissible by law) supersedes all prior agreements, proposals, communications, representations, writings, negotiations, or understandings with respect to that subject matter. All terms, conditions, and warranties not stated expressly in this Agreement, and which would in the absence of this provision be implied into this Agreement by statute, common law, equity, trade, custom or usage or otherwise, are excluded to the maximum extent permitted by law.

21.

Governing Law. The legal relations between the Parties hereto and any dispute arising under or in connection with this Agreement, or breach thereof, whether sounding in contract, tort, or otherwise, shall be governed by and construed in accordance with the laws of the United States of America and the State in which the employee’s assigned Office is located (provided in Appendix 1) , regardless of any laws that might otherwise govern under applicable choice-of-law principles. Any claim, legal proceeding, or litigation

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


arising out of or in connection with this Agreement or the relationship between Enfusion and Employee will be brought solely in the jurisdiction in which the Office is located, regardless of any laws or rules that might otherwise govern under applicable forum non conveniens principles. Any claim brought in any other jurisdiction or forum is precluded. ACCORDING, BOTH PARTIES HEREBY CONSENT TO THE EXCLUSIVE JURISDICTION OF THE FEDERAL AND STATE COURTS LOCATED WITHIN THE JURISDICTION IN WHICH THE OFFICE IS LOCATED.

22.

No Waiver. No waiver, of any of the terms of this Agreement, will be valid unless in writing, explicitly stated as such, and signed by the party waiving its rights. Any forbearance or delay by either party to enforce any of its rights under this Agreement will not be construed as a waiver to enforce any such rights pertaining to the occurrence in question or any other occurrence. The waiver, by any Party, of any breach of covenant will not be construed as a waiver of any succeeding breach of the same or any other covenant.

23.

Assignment. Enfusion may assign this Agreement or its rights under this Agreement to - and Employee may be employed by - any affiliate or subsidiary of Enfusion, or entity that acquires all or substantially all of Enfusion’s assets or acquires a department or line of business of Enfusion that Employee works within, or that is otherwise a successor in interest to Enfusion. This Agreement may not be assigned by Employee, except that Employee’s rights to compensation and benefits hereunder, subject to the limitations of this Agreement, may be transferred by will, by operation of law or as required by the law or a court order.

24.

Compliance with Section 409A. This Employment Agreement is intended to comply with, (or be exempt from), Section 409A of the Internal Revenue Code of 1986, as amended, to the extent applicable, and shall be administered and interpreted accordingly. To further clarify, this Section is in no way intended to change that bonuses, if any, are earned upon payment.

25.

Binding Agreement. This Agreement shall be binding upon and shall inure to the benefit of both Enfusion and Employee and their respective successors, assigns, heirs, and legal representatives.

26.

Terms of Acceptance. This Agreement is conditioned upon and subject to: (i) confirmation that Employee is not a subject to any contractual or other legal restrictions that would prevent or impair their ability to perform the duties of the position offered under this Agreement; (ii) Enfusion’s satisfactory completion of a background investigation, credit check, and reference check (where appropriate); and, (iii) Enfusion’s receipt of Employee’s acceptance of the terms and conditions of this Employment Agreement on or before the close of business on February 23, 2022.

[Signature Page to Follow]

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


Signature Page to the Employment Agreement between Enfusion Ltd. LLC and Valeria Gutowski made effective on February 7, 2022.

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed as of the Effective Date written above.

Enfusion Ltd. LLC

Employee

Signature: /s/ David Perel

Signature: /s/ Valeria Gutowski

Name:  David Perel

Name:  Valeria Gutowski

Title:  Global Head of Talent Acquisition

Date:  February 7, 2022

Date:  February 7, 2022

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


Third Party Intellectual Property (IP) Agreement

Dear Valeria,

We are excited to have you join the Enfusion team. As a company, it is very important to us that we respect others’ intellectual property and contractual rights. As part of your onboarding process, please review this letter as it is a topic we hold dearly. Once you have reviewed, feel free to ask any questions you might have. If you do not have any questions, please acknowledge the letter by signing in the designated area located at the bottom of the page.

If you have not done so already, to the extent you may be subject to any enforceable restrictive covenants or contractual limits on: i) your ability to solicit former clients or colleagues; ii) your possession, transfer, or use of confidential information; and, iii) your possession, transfer, or use of trade secret information, Enfusion requires that you disclose the nature of such covenants or contractual limitations before you commence employment. It is important to understand, you are personally responsible for complying with such covenants and limitations until they expire (if at all).

In addition to making Enfusion aware of any covenants or limitations you are subject to, we want to reiterate that you should not remove any trade secrets or confidential written or electronic materials from your current or prior employers. Likewise, you should not bring any such materials to Enfusion. You may not use any confidential or trade secret information you obtained during any prior employment in your work with Enfusion. To the extent the information was maintained as confidential by your previous employer(s), confidential and trade secret information includes, without limitation, any information about competitor marketing strategies, product development, and pricing information, as well as customer and personnel lists and contact information.

If you receive instruction or work from anyone at Enfusion or its affiliates (e.g. Enfusion’s international offices) that you believe would cause you to violate any agreements or covenants with a prior employer or your obligations to Enfusion, you should immediately disclose the matter to your office lead or Enfusion management, including Enfusion legal. It is very important that you take action under such circumstances because failure to abide by these expectations could result in you being liable to your former employer, withdrawal of Enfusion’s conditional offer of employment, or termination of any employment accepted.

Acknowledged and Accepted:

By Employee

Signature: /s/ Valeria Gutowski

Name: Valeria Gutowski

Date: February 7, 2022

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


Appendix 1 – Scope of Employment

Reference is made to the “Employment Agreement” entered into by and between Enfusion Ltd. LLC (“Enfusion”) and Valeria Gutowski (“Employee”) and with an Effective Date of February 7, 2022, as may be amended from time-to-time, (the “Agreement”). The Parties hereby agree that this Appendix 1 shall be subject to and controlled by the terms and conditions of the Agreement, which shall be incorporated by reference into this Appendix 1. If there is any inconsistency between the terms of the Agreement and this Appendix 1, the terms of this Appendix 1 shall prevail. Further, all capitalized terms used but not defined in this Appendix 1 shall be construed in accordance with the Agreement. This Appendix 1 shall replace, in its entirety, any prior “Appendix 1 – Scope of Employment” relating to Employee’s employment with Enfusion, including, but not limited to, the Appendix 1 - Scope of Employment signed by Employee on February 7, 2022.

1.

Commencement Date. Employee’s first day of work under the terms set forth below will be on January 15, 2024 (“Commencement Date”) unless otherwise agreed to by Enfusion and Employee in writing pursuant to the terms of the Employment Agreement.

2.

Appointment & Duties. Employee shall be a member of the Finance department, serve as Managing Director, Chief Accounting Officer and report to Brad Herring.

3.

Work Hours. During an ordinary work week, Employee shall be present at the Office during Enfusion’s ordinary office hours described under Section 5 of the Agreement (“Work Hours”) unless otherwise agreed to, in writing, by Employee and Employee’s manager.

4.

Office. Employee is assigned to Enfusion’s office located in Chicago.

5.

Status. Employee will be classified as an exempt employee, which means Employee will not be eligible for overtime pay for hours worked in excess of forty (40) hours in any given week.

6.

Pay Cycle. As an exempt employee, Employee will ordinarily receive payment for services rendered twice a month, in accordance with Enfusion’s ordinary payroll policies and procedures.

7.

Salary. Employee agrees to accept a base salary to be paid at an annualized rate of $310,000.00 US Dollars (less, where applicable, deductions and withholdings) (“Salary”). Employee’s Salary will be paid in accordance with Enfusion’s normal payroll policies and procedures.

8.

Voluntary Termination Notice

Employee is classified as a Level 2 Employee. Although Employee has the right to terminate their employment at any time for any reason, in recognition of Employee’s new title and pay increase, Employee agrees to give 60-days notice to the date on which Employee intends to cease working for Enfusion. If at any time Employee becomes classified as a Level 1 Employee, Employee agrees to provide Enfusion with at least ninety (90) days’ prior notice to the date on which Employee intends to cease working for Enfusion. Upon receipt of Employee’s notice of their intent to cease working for Enfusion, Enfusion may, in its sole discretion, choose to reduce Employee’s notice period (as described in this paragraph) without additional obligations to Employee.

9.

Other

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


Discretionary Bonus

In addition to Employee’s Salary, Enfusion may reward Employee’s exemplary performance and the performance of Employee’s group through the award of a discretionary bonus (“Bonus”). Bonus awards will also reflect the company’s overall performance. Employee has a target Bonus of up to 30% of earned base salary (less, where applicable, deductions and withholdings). At Enfusion’s discretion, the Bonus may be paid as cash or as stock grants or through some combination of cash and stock. The award of any Bonus shall be conditioned upon: (1) Employee’s satisfactory, as determined solely by Enfusion, meeting of conditions and goals (relating both to Enfusion’s performance and Employee’s individual performance) to be communicated to Employee by Enfusion upon the commencement of Employee’s employment with Enfusion (and updated at times throughout Employee’s tenure); (2) Enfusion’s performance; and (3) Employee being in “active working status” at the time any Bonus is awarded. For purposes of this provision, “active working status” means that the Employee has not resigned (or given notice of Employee’s resignation) or been terminated (or been given notice of Employee’s termination).

Annual LTI Award

In connection with Enfusion’s Long-Term Incentive program, you will be eligible to receive an annual grant (“LTI Award”) of restricted stock units (“RSUs”). Based upon your current level, we anticipate that at the time of the grant the LTI Award will have an annual value equal to 25% of your base salary ("Grant Value").  The Grant Value will be used to determine the total number of RSUs contained in each year’s LTI Award. The total number of RSUs will be calculated by using the closing price of the company’s stock (traded on the New York Stock Exchange) on the grant date. The actual value you may recognize at the time of vesting may increase or decrease based upon stock movement and any applicable tax laws. All LTI Awards are subject to board approval. Any granted RSUs are subject to the terms and conditions contained in Enfusion’s Long Term Incentive Plan. All grants are subject to the vesting schedule set forth in the Plan and associated documents, if any.

10.

Vacation.

In accordance with Enfusion’s Flexible Time Off policy, which may be amended from time to time, Employee is entitled to Flexible Time Off as needed each calendar year. Flexible Time Off will not accrue or vest and therefore will not be paid out at the time of separation of employment.

11.

Notices to Employee.

Valeria Gutowski

[***]

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


Acknowledged and Accepted:

By Employee

Signature:

/s/ Valeria Gutowski

Name:

Valeria Gutowski

Date:

January 16, 2024

Graphic

Chicago

125 South Clark Street

Suite 750

Chicago, IL 60603

enfusion.com


EX-21.1 8 enfn-20231231xex21d1.htm EX-21.1

EXHIBIT 21.1

SUBSIDIARIES

Subsidiary

     

Jurisdiction of Organization

Enfusion Ltd. LLC

Delaware

Enfusion US 1, Inc.

Delaware

Enfusion US 2, Inc.

Delaware

Enfusion US 3, Inc.

Delaware

Enfusion Systems UK Ltd

England and Wales

Enfusion HK Limited

Hong Kong

Enfusion Software Limited

The Republic of Ireland

Enfusion Softech India Private Limited

The Republic of India

Enfusion (Singapore) Pte. Ltd.

The Republic of Singapore

Enfusion do Brasil Tecnologia da Informacão Ltd

The Federative Republic of Brazil

Enfusion (Australia) Pty. Ltd.

New South Wales

Enfusion (Shanghai) Co., Ltd.

The People’s Republic of China

Enfusion Tech Ltd.

United Arab Emirates


EX-23.1 9 enfn-20231231xex23d1.htm EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)

Registration Statement (Form S-8 No. 333-260398) pertaining to the 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan of Enfusion, Inc.,

(2)

Registration Statement (Form S-8 No. 333-263969) pertaining to the 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan of Enfusion, Inc.,

(3)

Registration Statement (Form S-8 No. 333-270451) pertaining to the 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan of Enfusion, Inc., and

(4)

Registration Statement (Form S-3 No. 333-268477) of Enfusion, Inc.;

of our report dated March 12, 2024, with respect to the consolidated financial statements of Enfusion, Inc. included in this Annual Report (Form 10-K) of Enfusion, Inc. for the year ended December 31, 2023.

/s/ Ernst & Young LLP

Chicago, Illinois

March 12, 2024


EX-31.1 10 enfn-20231231xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Oleg Movchan, certify that:

1.

I have reviewed this annual report on Form 10-K of Enfusion, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 12, 2024

/s/ Oleg Movchan

Oleg Movchan

Chief Executive Officer

(Principal Executive Officer)


EX-31.2 11 enfn-20231231xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Bradley Herring, certify that:

1.

I have reviewed this annual report on Form 10-K of Enfusion, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 12, 2024

/s/ Bradley Herring

Bradley Herring

Chief Financial Officer

(Principal Financial Officer)


EX-32.1 12 enfn-20231231xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Oleg Movchan, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of Enfusion, Inc. for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such Annual Report on Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Enfusion, Inc.

Date: March 12, 2024

By:

/s/ Oleg Movchan

Name:

Oleg Movchan

Title:

Chief Executive Officer

(Principal Executive Officer)


EX-32.2 13 enfn-20231231xex32d2.htm EX-32.2

Exhibit 32.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Bradley Herring, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of Enfusion, Inc. for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such Annual Report on Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Enfusion, Inc.

Date: March 12, 2024

By:

/s/ Bradley Herring

Name:

Bradley Herring

Title:

Chief Financial Officer

(Principal Financial Officer)


EX-97 14 enfn-20231231xex97.htm EX-97

Exhibit 97

ENFUSION, INC.

COMPENSATION RECOVERY POLICY

Adopted as of September 21, 2023

Enfusion, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below.

1.Overview

The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance with rules issued by the United States Securities and Exchange Commission (the “SEC”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the New York Stock Exchange. Capitalized terms used and not otherwise defined herein shall have the meanings given in Section 3 below.

2.Compensation Recovery Requirement

In the event the Company is required to prepare a Financial Restatement, the Company shall recover reasonably promptly all Erroneously Awarded Compensation with respect to such Financial Restatement, and may recover all attorney’s fees incurred in connection with the recovery of such Erroneously Awarded Compensation from the party that was given such Erroneously Awarded Compensation.

3.Definitions

a.

“Applicable Recovery Period” means the three completed fiscal years immediately preceding the Restatement Date for a Financial Restatement. In addition, in the event the Company has changed its fiscal year: (i) any transition period of less than nine months occurring within or immediately following such three completed fiscal years shall also be part of such Applicable Recovery Period and (ii) any transition period of nine to 12 months will be deemed to be a completed fiscal year.

b.

“Applicable Rules” means any rules or regulations adopted by the Exchange pursuant to Rule 10D-1 under the Exchange Act and any applicable rules or regulations adopted by the SEC pursuant to Section 10D of the Exchange Act.

c.

“Board” means the Board of Directors of the Company.

d.

“Committee” means the Compensation Committee of the Board or, in the absence of such committee, a majority of independent directors serving on the Board.

e.

“Covered Person” means any Executive Officer. A person’s status as a Covered Person with respect to Erroneously Awarded Compensation shall be determined as of the time of receipt of such Erroneously Awarded Compensation regardless of the


person’s current role or status with the Company (e.g., if a person began service as an Executive Officer after the beginning of an Applicable Recovery Period, that person would not be considered a Covered Person with respect to Erroneously Awarded Compensation received before the person began service as an Executive Officer, but would be considered a Covered Person with respect to Erroneously Awarded Compensation received after the person began service as an Executive Officer where such person served as an Executive Officer at any time during the performance period for such Erroneously Awarded Compensation).

f.

“Effective Date” means October 2, 2023.

g.

“Erroneously Awarded Compensation” means the amount of any Incentive-Based Compensation received by a Covered Person on or after the Effective Date and during the Applicable Recovery Period that exceeds the amount that otherwise would have been received by the Covered Person had such compensation been determined based on the restated amounts in a Financial Restatement, computed without regard to any taxes paid. Calculation of Erroneously Awarded Compensation with respect to Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in a Financial Restatement, shall be based on a reasonable estimate of the effect of the Financial Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received, and the Company shall maintain documentation of the determination of such reasonable estimate and provide such documentation to the Exchange in accordance with the Applicable Rules. Incentive-Based Compensation is deemed received, earned or vested when the Financial Reporting Measure is attained, not when the actual payment, grant or vesting occurs.

h.

“Exchange” means the New York Stock Exchange.

i.

An “Executive Officer” means any person who served the Company as an executive officer (as defined in Rule 10D-1 under the Exchange Act) during the performance period applicable to Incentive-Based Compensation and received Incentive-Based Compensation after beginning service in any such position (regardless of whether such Incentive-Based Compensation was received during or after such person’s service in such position). Executive officers of parents or subsidiaries of the Company may be deemed executive officers of the Company if they perform such policy making functions for the Company.

j.

“Financial Reporting Measures” mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, any measures that are derived wholly or in part from such measures (including, for example, a non-GAAP financial measure), and stock price and total shareholder return.

2


k.

“Incentive-Based Compensation” means any compensation provided, directly or indirectly, by the Company or any of its subsidiaries that is granted, earned or vested based, in whole or in part, upon the attainment of a Financial Reporting Measure.

l.

A “Financial Restatement” means a restatement of previously issued financial statements of the Company due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required restatement to correct an error in previously-issued financial statements that is material to the previously-issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.

m.

“Restatement Date” means, with respect to a Financial Restatement, the earlier to occur of: (i) the date the Board, a committee of the Board or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare the Financial Restatement or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare the Financial Restatement.

4.Exception to Compensation Recovery Requirement

The Company may elect not to recover Erroneously Awarded Compensation pursuant to this Policy if the Committee determines that recovery would be impracticable, and one or more of the following conditions, together with any further requirements set forth in the Applicable Rules, are met: (i) the direct expense paid to a third party, including outside legal counsel, to assist in enforcing this Policy would exceed the amount to be recovered, and the Company has made a reasonable attempt to recover such Erroneously Awarded Compensation; or (ii) recovery would likely cause an otherwise tax-qualified retirement plan to fail to be so qualified under applicable regulations.

5.Recovery from Participating Employees.

In addition to (and without limiting) the provisions of paragraph 2 above, in the event the Company is required to prepare a Financial Restatement after the Effective Date, the Company may recover from any current or former employee of the Company who is not a Covered Person (each a “Participating Employee”) and who received Incentive-Based Compensation from the Company during the Applicable Recovery Period, the amount that exceeds what would have been paid to the Participating Employee under the Financial Restatement; provided that, this paragraph 5 will apply only to the extent the Board (or a duly established committee thereof), in its sole discretion, determines that the Participating Employee committed any act or omission that materially contributed to the circumstances requiring the Financial Restatement and such act or omission involved any of the following: (i) misconduct, wrongdoing or a violation of any of the Company’s rules or of any applicable legal or regulatory requirements in the course of the Participating Employee’s employment by the Company; or (ii) a breach of a fiduciary duty to the Company or its stockholders by the Participating Employee.

3


6.Tax Considerations

To the extent that, pursuant to this Policy, the Company is entitled to recover any Erroneously Awarded Compensation that is received by a Covered Person, the gross amount received (i.e., the amount the Covered Person received, or was entitled to receive, before any deductions for tax withholding or other payments) shall be returned by the Covered Person.

7.Method of Compensation Recovery

The Committee shall determine, in its sole discretion, the method for recovering Erroneously Awarded Compensation hereunder, which may include, without limitation, any one or more of the following:

a.

requiring reimbursement of cash Incentive-Based Compensation previously paid;

b.

seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity-based awards;

c.

canceling or rescinding some or all outstanding vested or unvested equity-based awards;

d.

adjusting or withholding from unpaid compensation or other set-off;

e.

canceling or offsetting against planned future grants of equity-based awards; and/or

f.

any other method permitted by applicable law or contract.

Notwithstanding the foregoing, a Covered Person will be deemed to have satisfied such person’s obligation to return Erroneously Awarded Compensation to the Company if such Erroneously Awarded Compensation is returned in the exact same form in which it was received; provided that equity withheld to satisfy tax obligations will be deemed to have been received in cash in an amount equal to the tax withholding payment made.

8. Policy Interpretation

This Policy shall be interpreted in a manner that is consistent with the Applicable Rules and any other applicable law. The Committee shall take into consideration any applicable interpretations and guidance of the SEC in interpreting this Policy, including, for example, in determining whether a financial restatement qualifies as a Financial Restatement hereunder. To the extent the Applicable Rules require recovery of Incentive-Based Compensation in additional circumstances besides those specified above, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover Incentive-Based Compensation to the fullest extent required by the Applicable Rules.

4


9.Policy Administration

This Policy shall be administered by the Committee. The Committee shall have such powers and authorities related to the administration of this Policy as are consistent with the governing documents of the Company and applicable law. The Committee shall have full power and authority to take, or direct the taking of, all actions and to make all determinations required or provided for under this Policy and shall have full power and authority to take, or direct the taking of, all such other actions and make all such other determinations not inconsistent with the specific terms and provisions of this Policy that the Committee deems to be necessary or appropriate to the administration of this Policy. The interpretation and construction by the Committee of any provision of this Policy and all determinations made by the Committee under this policy shall be final, binding and conclusive.

10.Compensation Recovery Repayments not Subject to Indemnification

Notwithstanding anything to the contrary set forth in any agreement with, or the organizational documents of, the Company or any of its subsidiaries, Covered Persons are not entitled to indemnification for Erroneously Awarded Compensation or for any losses arising out of or in any way related to Erroneously Awarded Compensation recovered under this Policy.

5


GRAPHIC 15 enfn-20231231x10k001.jpg GRAPHIC begin 644 enfn-20231231x10k001.jpg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end GRAPHIC 16 enfn-20231231x10k002.jpg GRAPHIC begin 644 enfn-20231231x10k002.jpg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enfn-20231231xex10d10001.jpg GRAPHIC begin 644 enfn-20231231xex10d10001.jpg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enfn-20231231xex10d11001.jpg GRAPHIC begin 644 enfn-20231231xex10d11001.jpg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end GRAPHIC 19 enfn-20231231xex10d12001.jpg GRAPHIC begin 644 enfn-20231231xex10d12001.jpg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end GRAPHIC 20 enfn-20231231xex10d7001.jpg GRAPHIC begin 644 enfn-20231231xex10d7001.jpg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enfn-20231231xex10d8001.jpg GRAPHIC begin 644 enfn-20231231xex10d8001.jpg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end EX-101.SCH 22 enfn-20231231.xsd EX-101.SCH 00100 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Property, Equipment, and Software, Net (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Leases - Lease Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Leases - commitments (Details) (Calc2) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Leases - Components of Operating Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Net Income (Loss) Per Class A Common Share - Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Income Taxes - Components of income (loss) before income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41302 - Disclosure - Income taxes - Components of income tax expense (benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 41303 - Disclosure - Income taxes - Effective income tax rate reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 41305 - Disclosure - Income taxes - Components of deferred tax assets and liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statements of Preferred Units, Stockholders' Equity and Members' Deficit link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Property, Equipment, and Software, Net link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Property, Equipment, and Software, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Management Incentive Plan and Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Summary of Significant Accounting Policies - Allowances (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Summary of Significant Accounting Policies - Useful life of property plant and equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - Summary of Significant Accounting Policies - Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - Summary of Significant Accounting Policies - Remaining Performance Obligation Default (Details) link:presentationLink link:calculationLink link:definitionLink 40305 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Property, Equipment, and Software, Net- Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Leases - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 40605 - Disclosure - Leases - Operating Leases and Service Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Debt - New Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Debt - Prior Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Management Incentive Plan and Stock-Based Compensation - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Management Incentive Plan and Stock-Based Compensation - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Management Incentive Plan and Stock-Based Compensation - Stock Compensation (Income) Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41004 - Disclosure - Management Incentive Plan and Stock-Based Compensation - RSUs and Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Employee Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Net Income (Loss) Per Class A Common Share - Dilutive shares (Details) link:presentationLink link:calculationLink link:definitionLink 41304 - Disclosure - Income taxes - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Management Incentive Plan and Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Employee Benefit Plans link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Net Income (Loss) Per Class A Common Share link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Net Income (Loss) Per Class A Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 40604 - Disclosure - Leases - Weighted-average remaining lease terms and discount rates (Details) link:presentationLink link:calculationLink link:definitionLink 41306 - Disclosure - Income taxes - Valuation allowance for deferred tax assets (Details) link:presentationLink link:calculationLink link:definitionLink 41307 - Disclosure - Income taxes - Unrecognized deferred taxes (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 23 enfn-20231231_cal.xml EX-101.CAL EX-101.DEF 24 enfn-20231231_def.xml EX-101.DEF EX-101.LAB 25 enfn-20231231_lab.xml EX-101.LAB EX-101.PRE 26 enfn-20231231_pre.xml EX-101.PRE XML 27 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Document and Entity Information - USD ($)
    $ in Millions
    12 Months Ended
    Dec. 31, 2023
    Mar. 08, 2024
    Jun. 30, 2023
    Document Information [Line Items]      
    Document Type 10-K    
    Document Annual Report true    
    Document Period End Date Dec. 31, 2023    
    Document Transition Report false    
    Entity File Number 001-40949    
    Entity Registrant Name ENFUSION, INC.    
    Entity Incorporation, State or Country Code DE    
    Entity Tax Identification Number 87-1268462    
    Entity Address State Or Province IL    
    Entity Address, Address Line One 125 South Clark Street    
    Entity Address, Address Line Two Suite 750    
    Entity Address, City or Town Chicago    
    Entity Address, Postal Zip Code 60603    
    City Area Code 312    
    Local Phone Number 253-9800    
    Entity Well-known Seasoned Issuer No    
    Entity Current Reporting Status Yes    
    Entity Voluntary Filers No    
    Entity Interactive Data Current Yes    
    Entity Public Float     $ 438.2
    Entity Filer Category Accelerated Filer    
    Entity Small Business false    
    Entity Emerging Growth Company true    
    Entity Ex Transition Period false    
    ICFR Auditor Attestation Flag false    
    Document Financial Statement Error Correction [Flag] false    
    Entity Shell Company false    
    Title of 12(b) Security Class A common stock, par value $0.001 per share    
    Trading Symbol ENFN    
    Security Exchange Name NYSE    
    Entity Central Index Key 0001868912    
    Current Fiscal Year End Date --12-31    
    Document Fiscal Year Focus 2023    
    Document Fiscal Period Focus FY    
    Amendment Flag false    
    Auditor Name Ernst & Young LLP    
    Auditor Firm ID 42    
    Auditor Location Chicago, Illinois    
    Common Stock      
    Document Information [Line Items]      
    Entity Common Stock, Shares Outstanding   128,069,912  
    Common Class A      
    Document Information [Line Items]      
    Entity Common Stock, Shares Outstanding   89,871,145  
    Common Class B      
    Document Information [Line Items]      
    Entity Common Stock, Shares Outstanding   38,198,767  
    XML 28 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Consolidated Balance Sheets - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Current assets:    
    Cash and cash equivalents $ 35,604 $ 62,545
    Accounts receivable, net 28,069 25,855
    Prepaid expenses 5,009 6,105
    Other current assets 1,170 2,303
    Total current assets 69,852 96,808
    Property, equipment, and software, net 18,314 15,759
    Right-of-use-assets, net 14,304 6,732
    Other assets 6,502 4,484
    Total assets 108,972 123,783
    Current liabilities:    
    Accounts payable 2,212 1,685
    Accrued expenses and other current liabilities 13,841 11,665
    Current portion of lease liabilities 4,256 4,030
    Total current liabilities 20,309 17,380
    Lease liabilities, net of current portion 11,181 2,959
    Total liabilities 31,490 20,339
    Commitment and contingencies (Note 8)
    Stockholders' Equity:    
    Preferred stock, $0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively
    Additional paid-in capital 226,877 244,260
    Accumulated deficit (172,932) (178,863)
    Accumulated other comprehensive loss (406) (504)
    Total stockholders' equity attributable to Enfusion, Inc. 53,666 65,007
    Non-controlling interests 23,816 38,437
    Total stockholders' equity 77,482 103,444
    Total liabilities and stockholders' equity 108,972 123,783
    Common Class A    
    Stockholders' Equity:    
    Common stock 88 71
    Common Class B    
    Stockholders' Equity:    
    Common stock $ 39 $ 43
    XML 29 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Consolidated Balance Sheets (Parenthetical) - $ / shares
    Dec. 31, 2023
    Dec. 31, 2022
    Preferred stock par value (in dollars per share) $ 0.001 $ 0.001
    Preferred stock authorized 100,000,000 100,000,000
    Preferred stock, shares issued 0 0
    Preferred stock outstanding 0 0
    Common Class A    
    Common stock par value (in dollars per share) $ 0.001 $ 0.001
    Common stock, shares authorized 1,000,000,000 1,000,000,000
    Common stock, shares issued 88,332,000 70,860,000
    Common stock, shares outstanding 88,332,000 70,860,000
    Common Class B    
    Common stock par value (in dollars per share) $ 0.001 $ 0.001
    Common stock, shares authorized 150,000,000 150,000,000
    Common stock, shares issued 39,199,000 43,199,000
    Common stock, shares outstanding 39,199,000 43,199,000
    XML 30 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Consolidated Statements of Operations - USD ($)
    shares in Thousands, $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    REVENUES:      
    Total revenues $ 174,535 $ 150,349 $ 111,700
    COST OF REVENUES:      
    Total cost of revenues 57,641 47,100 31,845
    Gross profit 116,894 103,249 79,855
    OPERATING EXPENSES:      
    General and administrative 64,635 68,764 150,614
    Sales and marketing 20,418 29,286 51,725
    Technology and development 19,893 17,163 153,400
    Total operating expenses 104,946 115,213 355,739
    Income (loss) from operations 11,948 (11,964) (275,884)
    NON-OPERATING INCOME (EXPENSE):      
    Payment to related party (1,501)    
    Interest income (expense), net 1,641 413 (4,594)
    Other expense, net (604) (638) (1,185)
    Total non-operating income (expense) (464) (225) (5,779)
    Income (loss) before income taxes 11,484 (12,189) (281,663)
    Income taxes 2,231 1,074 579
    Net income (loss) 9,253 (13,263) (282,242)
    Net income (loss) attributable to non-controlling interests 3,228 (5,609) (123,925)
    Net income (loss) attributable to Enfusion, Inc. $ 6,025 $ (7,654) $ (158,317)
    Net income (loss) per Class A common shares attributable to Enfusion, Inc.:      
    Net income (loss) per share of Class A common stock--Basic $ 0.07 $ (0.10) $ (2.26)
    Net income (loss) per share of Class A common stock--Diluted $ 0.07 $ (0.10) $ (2.26)
    Weighted Average number of Class A common shares outstanding:      
    Weighted Average number of Class A common shares outstanding, Basic 88,202 85,393 83,045
    Weighted Average number of Class A common shares outstanding, Diluted 129,429 85,393 83,045
    Platform subscriptions      
    REVENUES:      
    Total revenues $ 161,519 $ 138,868 $ 103,259
    COST OF REVENUES:      
    Total cost of revenues 50,702 40,017 27,195
    Managed services      
    REVENUES:      
    Total revenues 11,773 9,821 7,119
    COST OF REVENUES:      
    Total cost of revenues 6,514 6,692 4,425
    Other      
    REVENUES:      
    Total revenues 1,243 1,660 1,322
    COST OF REVENUES:      
    Total cost of revenues $ 425 $ 391 $ 225
    XML 31 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Consolidated Statements of Comprehensive Income (Loss) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Consolidated Statements of Comprehensive Income (Loss)      
    Net income (loss) $ 9,253 $ (13,263) $ (282,242)
    Other comprehensive income (loss), net of income tax:      
    Foreign currency translation income (loss) 143 (327) (90)
    Total other comprehensive income (loss) 9,396 (13,590) (282,332)
    Comprehensive income (loss) attributable to non-controlling interests 3,273 (5,757) (123,902)
    Total comprehensive income (loss) attributable to Enfusion, Inc. $ 6,123 $ (7,833) $ (158,430)
    XML 32 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Consolidated Statements of Preferred Units, Stockholders' Equity and Members' Deficit - USD ($)
    shares in Thousands, $ in Thousands
    Preferred Units
    Members' Equity
    Common Stock
    Common Class A
    Common Stock
    Common Class B
    Additional Paid-in Capital
    Accumulated Deficit
    Cumulative impact of adopting ASU 2016-13
    Accumulated Deficit
    Accumulated Other Comprehensive Loss
    Non-Controlling Interest
    Cumulative impact of adopting ASU 2016-13
    Non-Controlling Interest
    Cumulative impact of adopting ASU 2016-13
    Total
    Balance at beginning of period at Dec. 31, 2020 $ 165,515                      
    Balance at beginning of period (in shares) at Dec. 31, 2020 54                      
    Preferred Units                        
    Net income (loss) $ 6,814                      
    Net income (loss)   $ 6,078                   $ 6,078
    Distributions to members (1,807)                      
    Balance at end of period at Oct. 20, 2021 $ 170,522                      
    Balance at end of period (in shares) at Oct. 20, 2021 54                      
    Balance at beginning of period at Dec. 31, 2020   $ (233,347)                    
    Balance at beginning of period (Shares) at Dec. 31, 2020   48                    
    Balance at end of period at Oct. 20, 2021   $ (228,745)                    
    Balance at end of period (Shares) at Oct. 20, 2021   48                    
    Balance at Beginning of period at Dec. 31, 2020               $ (212)       (233,559)
    Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
    Distributions to members   $ (1,476)                   (1,476)
    Foreign currency translation               (145)       (145)
    Balance at end of period at Oct. 20, 2021               (357)       (229,102)
    Balance at beginning of period at Dec. 31, 2020 $ 165,515                      
    Balance at beginning of period (in shares) at Dec. 31, 2020 54                      
    Balance at beginning of period at Dec. 31, 2020   $ (233,347)                    
    Balance at beginning of period (Shares) at Dec. 31, 2020   48                    
    Balance at Beginning of period at Dec. 31, 2020               (212)       (233,559)
    Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
    Net income (loss)                       (282,242)
    Balance at end of period at Dec. 31, 2021     $ 66 $ 47 $ 226,717   $ (171,209) (325)   $ 42,145   97,441
    Balance at end of period (in shares) at Dec. 31, 2021     65,583 47,471                
    Balance at beginning of period at Oct. 20, 2021 $ 170,522                      
    Balance at beginning of period (in shares) at Oct. 20, 2021 54                      
    Preferred Units                        
    Net income (loss)             (171,209)     (123,925)   (295,134)
    Effect of the Reorganization Transactions $ (170,522)                      
    Effect of the Reorganization Transactions (Shares) (54) (48)                    
    Balance at beginning of period at Oct. 20, 2021   $ (228,745)                    
    Balance at beginning of period (Shares) at Oct. 20, 2021   48                    
    Balance at Beginning of period at Oct. 20, 2021               (357)       (229,102)
    Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
    Stock-based compensation         161,986         117,250   279,236
    Effect of the Reorganization   $ 228,745 $ 49 $ 53 (27,941)         (30,384)   170,522
    Effect of the Reorganization (in shares)     48,744 52,998                
    Issuance of Class A common stock in the IPO, net of issuance costs     $ 17   143,628         116,065   259,710
    Issuance of Class A common stock in the IPO, net of issuance costs (in shares)     16,839                  
    Purchase of Pre-IPO common unit holders and retirement of Class B common shares       $ (6) (50,956)         (36,884)   (87,846)
    Purchase of Pre-IPO common unit holders and retirement of Class B common shares (in shares)       (5,527)                
    Foreign currency translation               32   23   55
    Balance at end of period at Dec. 31, 2021     $ 66 $ 47 226,717   (171,209) (325)   42,145   97,441
    Balance at end of period (in shares) at Dec. 31, 2021     65,583 47,471                
    Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
    Net income (loss)             (7,654)     (5,609)   (13,263)
    Stock-based compensation         15,043         10,550   25,593
    Share exchange     $ 4 $ (4) 5,310         (5,310)    
    Share exchange (in shares)     4,272 (4,272)                
    Issuance of IPO vested Class A common stock and share-based awards     $ 2   (2)              
    Issuance of IPO vested Class A common stock and share-based awards (in shares)     1,594                  
    Tax withholdings related to net share settlements of stock-based compensation awards     $ (1)   (4,767)         (3,191)   (7,959)
    Tax withholdings related to net share settlements of stock-based compensation awards (in shares)     (589)                  
    Foreign currency translation               (179)   (148)   (327)
    Other         1,959             1,959
    Balance at end of period at Dec. 31, 2022     $ 71 $ 43 244,260   (178,863) (504)   38,437   103,444
    Balance at end of period (in shares) at Dec. 31, 2022     70,860 43,199                
    Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
    Net income (loss)             6,025     3,228   9,253
    Stock-based compensation         5,628         2,596   8,224
    Share exchange     $ 4 $ (4) 2,559         (2,559)    
    Share exchange (in shares)     4,000 (4,000)                
    Issuance of IPO vested Class A common stock and share-based awards     $ 11   1,729         (1,740)    
    Issuance of IPO vested Class A common stock and share-based awards (in shares)     11,272                  
    Issuance of Class A common stock in the IPO, net of issuance costs     $ 2   12,401         4,919   17,322
    Issuance of Class A common stock, net of issuance costs (in shares)     2,200                  
    Tax withholdings related to net share settlements of stock-based compensation awards         (39,497)         (20,950)   (60,447)
    Foreign currency translation               98   45   143
    Other         (203)         (105)   (308)
    Balance at end of period at Dec. 31, 2023     $ 88 $ 39 $ 226,877 $ (94) $ (172,932) $ (406) $ (55) $ 23,816 $ (149) $ 77,482
    Balance at end of period (in shares) at Dec. 31, 2023     88,332 39,199                
    XML 33 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Consolidated Statements of Cash Flows - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Cash flows from operating activities:      
    Net income (loss) $ 9,253 $ (13,263) $ (282,242)
    Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
    Non-cash lease expense 6,882 5,351  
    Depreciation and amortization 9,987 6,344 3,975
    Provision for credit losses 1,319 1,399 1,450
    Amortization of debt-related costs 92 26 222
    Loss on extinguishment of debt 78   1,215
    Stock-based compensation expense 7,458 24,993 289,803
    Change in operating assets and liabilities:      
    Accounts receivable (3,679) (9,031) (7,493)
    Prepaid expenses and other assets (1,749) (1,767) (6,477)
    Accounts payable 365 (843) 2,044
    Accrued compensation (729) 7,087 (2,081)
    Accrued expenses and other liabilities 2,359 (1,029) (734)
    Lease liabilities (6,002) (5,111)  
    Net cash provided by (used in) operating activities 25,634 14,156 (318)
    Cash flows from investing activities:      
    Purchases of property and equipment (4,453) (3,985) (6,096)
    Capitalization of software development costs (5,218) (3,946) (1,918)
    Net cash used in investing activities (9,671) (7,931) (8,014)
    Cash flows from financing activities:      
    Payment of debt issuance costs (1,151)    
    Settlement of tax receivable acquired in reorganization transactions 1,501    
    Issuance of Class A common stock, net of issuance costs 17,322   260,545
    Payment of withholding taxes on stock-based compensation (60,447) (7,959) (10,567)
    Repayment of term loan     (100,000)
    Payment of member distributions     (3,283)
    Purchases of common units from Pre-IPO common unit holders     (87,846)
    Other financing activities (308)    
    Net cash (used in) provided by financing activities (43,083) (7,959) 58,849
    Effect of exchange rate changes on cash and cash equivalents 179 (86) (90)
    Net (decrease) increase in cash and cash equivalents (26,941) (1,820) 50,427
    Cash and cash equivalents, beginning of period 62,545 64,365 13,938
    Cash and cash equivalents, end of period 35,604 62,545 64,365
    Supplemental disclosure of cash flow information:      
    Income taxes paid in cash 1,843 1,582 407
    Interest paid in cash     4,813
    Supplemental disclosure of non-cash activities:      
    Right-of-use assets obtained in exchange for lease liabilities 13,893 9,514  
    Capitalized stock-based compensation expense 766 600  
    Accrued property, equipment, and software, net $ 608    
    Effect of the Reorganization Transactions     58,223
    IPO costs included in accrued expenses and other liabilities     $ 835
    Other   $ 1,959  
    XML 34 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Organization and Description of Business
    12 Months Ended
    Dec. 31, 2023
    Organization and Description of Business  
    Organization and Description of Business

    Note 1   Organization and Description of Business

    Enfusion is a leading provider of cloud-based order and execution management, portfolio management and risk systems. Enfusion’s clients include large global hedge fund managers, institutional asset managers, family offices and other institutional investors. Enfusion provides its clients with innovative real-time performance, risk calculations, and accounting capabilities for some of the most sophisticated financial products. The Company is headquartered in Chicago, Illinois and has offices in New York City, London, Dublin, Hong Kong, Singapore, Mumbai, Bengaluru, and Sydney.

    Enfusion, Inc. was incorporated in Delaware on June 11, 2021 for the purpose of facilitating an initial public offering, which was completed on October 25, 2021, and other related transactions in order to carry on the business of Enfusion Ltd. LLC. Enfusion, Inc. is a holding company and, through its control over the managing member of Enfusion Ltd. LLC, operates and controls Enfusion Ltd. LLC. Enfusion, Inc.’s principal asset consists of Common Units.

    Enfusion, Inc. has three wholly-owned subsidiaries: Enfusion US 1, Inc., Enfusion US 2, Inc., and Enfusion US 3, Inc.; as well as a controlling financial interest in Enfusion Ltd. LLC and its majority-owned subsidiary, Enfusion Softech India Private Limited, as well as the wholly-owned subsidiaries of Enfusion Ltd. LLC: Enfusion Systems UK Ltd, Enfusion HK Limited, Enfusion Software Limited, Enfusion (Singapore) Pte. Ltd., Enfusion do Brasil Tecnologia da Informacão Ltd, Enfusion (Australia) Pty. Ltd., Enfusion (Shanghai) Co., and Enfusion Tech Ltd. Enfusion, Inc., through its control over the managing member of Enfusion Ltd. LLC, manages and operates Enfusion Ltd. LLC’s business and controls its strategic decisions and day-to-day operations. As such, Enfusion, Inc. consolidates the financial results of Enfusion Ltd. LLC, and a portion of Enfusion, Inc.’s net income (loss) is allocated to non-controlling interests to reflect the entitlement to a portion of Enfusion Ltd. LLC’s net income (loss) by the other common unitholders of Enfusion, Ltd. LLC. As of December 31, 2023, Enfusion, Inc. owned 69.3% of Enfusion Ltd. LLC.

    XML 35 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Basis of Presentation
    12 Months Ended
    Dec. 31, 2023
    Basis of Presentation  
    Basis of Presentation

    Note 2   Basis of Presentation

    Principles of Consolidation

    These statements have been prepared in conformity with U.S. GAAP. All intercompany balances and transactions are eliminated in consolidation.

    Use of Estimates

    The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. We base our estimates on historical experience and various other assumptions believed to be reasonable. These estimates and assumptions include, but are not limited to, judgments affecting the measurement of the payable to related parties pursuant to the Tax Receivable Agreement, amortization periods, certain assumptions used in the valuation of stock-based compensation, assessment of the allowance for credit losses, and accounting for income taxes and assessment of valuation allowances. Actual results could differ from those estimates.

    The Company’s results can also be affected by economic, political, legislative, regulatory, and legal actions, including but not limited to health epidemics and pandemics and the resulting economic impact. Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, and government fiscal policies can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities and carries various levels of insurance, the Company could be affected by civil, criminal, regulatory, or administrative actions, claims, or proceedings.

    Reclassifications

    Certain amounts in prior periods have been reclassified to conform with the current period presentation.

    Segments

    Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the CODM. While the Company operates in multiple countries, the Company’s business operates as one operating segment because most of the Company’s service offerings are delivered and supported on a global basis, the Company’s service offerings are deployed in a nearly identical way, and the Company’s CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.

    XML 36 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Summary of Significant Accounting Policies
    12 Months Ended
    Dec. 31, 2023
    Summary of Significant Accounting Policies  
    Summary of Significant Accounting Policies

    Note 3   Summary of Significant Accounting Policies

    The significant accounting policies of the Company and its subsidiaries are summarized below.

    Cash and Cash Equivalents

    The Company considers all highly liquid investments purchased with an initial maturity date of three months or less to be cash equivalents. Funds held as investments in money market funds are included within cash and cash equivalents. As of December 31, 2023 and 2022, respectively, the Company had $30.0 million and $50.0 million, respectively, invested in money market accounts.

    Accounts Receivable

    Accounts receivable includes billed and unbilled receivables, net of allowances, including the allowance for credit losses. Billed accounts receivable are initially recorded upon the invoicing to clients with payment due within 30 days. Unbilled accounts receivable represent revenue recognized on contracts for which the timing of invoicing to clients differs from the timing of revenue recognition. Unbilled accounts receivable was $2.4 million and $2.0 million as of December 31, 2023 and 2022, respectively. Contract assets included in unbilled accounts receivable were $1.7 million and $1.5 million as of December 31, 2023 and 2022, respectively.

    The Company maintains an allowance for credit losses at an amount estimated to be sufficient to provide adequate protection against losses resulting from extending credit to its clients. The Company regularly determines the adequacy of the allowance based on its assessment of the collectability of the accounts receivable by considering the age of each outstanding invoice, the collection history of each client, an evaluation of the current expected risk of credit loss, and other client-specific factors with a bearing on receivables. The Company assesses collectability by reviewing accounts receivable on an aggregated basis where similar characteristics exist and on an individual basis for specific clients with historical collectability issues or known financial difficulties. Increases to the allowance are recognized as a charge to credit losses included in general and administrative expenses in the consolidated statements of operations. Accounts receivable deemed uncollectible are charged against the allowance for credit losses when identified.

    The Company's allowance for credit losses is as follows (in thousands):

    Balance at December 31, 2021

    $

    791

    Changes to the provision

     

    1,158

    Accounts written off, net of recoveries

    (724)

    Balance at December 31, 2022

    1,225

    Adoption of ASU 2016-13

    149

    Changes to the provision

    705

    Accounts written off, net of recoveries

    (987)

    Balance at December 31, 2023

    $

    1,092

    Leases

    The Company determines at contract inception if the contract is or contains a lease. The Company records right-of-use (“ROU”) assets and lease obligations for its leases, which are initially recognized at the commencement date based on the discounted future lease payments over the term of the lease. As the rates implicit in the Company’s leases are not readily determinable, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date. Incremental borrowing rates for domestic currency leases are calculated using the Company’s credit adjusted risk-free rate. Foreign-denominated lease payments are discounted using country-specific treasury rates adjusted for credit spread.

    The Company does not record an ROU asset and lease obligation for its short-term leases, which are defined as leases with an initial term of 12 months or less. The Company has elected not to separate lease and non-lease components.

    Property, Equipment, and Software, Net

    Property, equipment, and software is stated at historical cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the individual assets, except for leasehold improvements, which are depreciated over the shorter of the estimated useful life of the asset or the underlying lease term. Also included in property, equipment, and software are capitalized costs of software developed for internal use. The useful lives of property, equipment, and software are as follows:

    Property, Equipment, and Software Asset Type

    Estimated Useful Lives

    Software development costs

    3 years

    Computers

    3 years

    Furniture, fixtures, and equipment

    5 years

    Leasehold improvements

    Shorter of estimated economic useful life or remaining lease term

    Maintenance and repairs are expensed as incurred. Upon retirement or disposition, the cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is included in operating income.

    Software Development Costs

    The Company capitalizes certain qualifying costs, including stock-based compensation expense, incurred in the development of and major enhancements to the Company's cloud-based software as a service (“SaaS”) platform and related software products. Capitalized software development costs related to the Company's platform are amortized on a straight-line basis over the developed software's estimated useful life of three years, and the related amortization expense is recorded in cost of revenues within our consolidated statements of operations.

    Costs incurred in the preliminary stages of development are expensed as incurred. Costs incurred for post-implementation activities, training, maintenance, and minor upgrades and enhancements without adding additional functionality are expensed as incurred within technology and development expense in our consolidated statements of operations.

    Impairment of Long-Lived Assets

    The Company evaluates the carrying value of long-lived assets in accordance with the accounting standard for impairment or disposal of long-lived assets, which requires recognition of impairment of long-lived assets in the event that circumstances indicate impairment may have occurred and when the net carrying value of such asset group exceeds the future undiscounted cash flows attributed to such asset group. The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. No impairment of long-lived assets occurred during the years ended December 31, 2023, 2022, and 2021.

    Fair Value of Financial Instruments

    Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the exit price) in an orderly transaction between market participants at the measurement date. Accounting standards establish a hierarchal framework, which prioritizes and ranks the level of market price observability used in measuring assets and liabilities at fair value. Market price observability is impacted by a number of factors, including the type of investment and the characteristics specific to the investment. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on the best information available. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories:

    Level 1

    Inputs are quoted prices for identical instruments in active markets;

    Level 2

    Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets;

    Level 3

    Inputs are valuations derived from valuation techniques in which one or more significant inputs are unobservable.

    Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

    The Company has investments in money market accounts, which are included in cash and cash equivalents on the consolidated balance sheets. Fair value inputs for these investments are considered Level 1 measurements within the fair value hierarchy, as money market account fair values are known and observable through daily published floating net asset values.

    Annual Bonus Incentive Plan

    Annual bonuses payable by the Company to its officers and employees may be funded through a combination of cash and equity, at the discretion of the Company’s Compensation Committee. We accrue and record the related corporate bonus amounts payable in cash in the period in which it is earned by the recipient. The Compensation Committee may make incentive awards based on such terms, conditions, and criteria as it considers appropriate. Stock awards issued in connection with these bonuses may or may not be subject to additional vesting conditions at the time of grant, which are subject to determination by the Compensation Committee.

    For annual bonuses settled in cash, the Company accrues over the course of the year the annual bonuses earned by employees but paid in the following year. For annual bonuses settled in stock, in accordance with ASC 718, Stock Compensation, the Company views the authorization of the award to be the date that all approval requirements are completed (e.g., action by the Compensation Committee approving the awards and determining the number of equity instruments to be issued), and therefore, the service inception to begin at grant date. As such, stock-based compensation cost related to the Annual Bonus Incentive Plan is recognized on the grant date to the extent such awards are not subject to additional vesting conditions.

    Revenue Recognition

    The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. The Company derives its revenues primarily from fees for platform subscriptions and managed services provided to clients. Revenues are recognized when control of these services are transferred to the Company’s clients in an amount that reflects the consideration the Company expects to be entitled to in exchange for these services. Revenues are recognized net of taxes that will be remitted to governmental agencies applicable to service contracts. Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework:

    ● Identification of the contract, or contracts, with a client;

    ● Identification of the performance obligation in the contract;

    ● Determination of transaction price;

    ● Allocation of the transaction price to the performance obligations in the contract; and

    ● Recognition of revenue when, or as, performance obligations are satisfied.

    Platform subscriptions revenues

    Platform subscriptions revenues consist primarily of user fees to provide our clients access to our cloud-based solution. Fees consider various components such as number of users, connectivity, trading volume, data usage and product coverage. Platform subscriptions clients do not have the right to take possession of the platform’s software and do not have any general return right. Platform subscriptions revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date the client gains access to the platform. Installed payments are generally invoiced at the end of each calendar month during the subscription term. There is no financing available.

    Managed services revenues

    Managed services revenues primarily consist of client-selected middle- and back-office, technology-powered services. Managed services revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the contract effective date. Clients are invoiced a set fee for managed services typically at the end of each month. Generally, invoices have a 30-day payment period in accordance with the associated contract. There is no financing available.

    Other revenues

    Other revenues consist of non-subscription-based revenues primarily data conversion. The Company recognizes revenues as these services are performed with invoicing generally occurring at the end of each month.

    Service contracts with multiple performance obligations

    Certain of the Company’s contracts provide for customers to be charged a fee for implementation services. In determining whether the implementation services, which frequently include configuration and/or interfacing, customer reporting, customizing user permissions and acceptance testing, end-user training, and establishing connections with third-party interfaces, are distinct from its platform subscription services, the Company considers, in addition to their complexity and level of customization, that these services are integral in delivering the customer desired output and are necessary for the customer to access and begin to use the hosted application. The implementation provider must be intimately familiar with its platform to effectively execute the customization required, and no other entities have access to the source code. The Company has concluded that the implementation services in its service contracts with multiple performance obligations are not distinct, and therefore, the Company recognizes fees for implementation services ratably over the non-cancelable term of the contract.

    Remaining performance obligations

    For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of December 31, 2023 was $29.1 million and is expected to be recognized based on the below schedule (in thousands).

    Remaining Performance Obligation

    December 31, 2023

    2024

    $

    18,227

    2025

     

    8,845

    2026

     

    1,986

    2027

     

    64

    2028

    Total

    $

    29,122

    Disaggregation of revenue

    The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following table (in thousands):

    Year Ended December 31, 

    2023

    2022

    2021

    Geographic Region

        

    Amount

        

    Percent

        

    Amount

        

    Percent

    Amount

        

    Percent

    Americas*

    $

    108,506

     

    62.1

    %  

    $

    95,122

     

    63.3

    %

    $

    72,994

     

    65.3

    %

    Europe, Middle East, and Africa (EMEA)

     

    26,122

     

    15.0

    %  

     

    20,051

     

    13.3

    %

     

    13,491

     

    12.1

    %

    Asia Pacific (APAC)

     

    39,907

     

    22.9

    %  

     

    35,176

     

    23.4

    %

     

    25,215

     

    22.6

    %

    Total revenues

    $

    174,535

     

    100.0

    %  

    $

    150,349

     

    100.0

    %

    $

    111,700

     

    100.0

    %

    *

    Includes revenues from clients based in the United States (country of domicile) of $104.5 million, $92.8 million, and $71.9 million for the years ended December 31, 2023, 2022, and 2021, respectively.

    Deferred commissions

    The Company pays sales commissions for initial contracts and expansions of existing contracts with customers. These commissions earned by certain of its sales force are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions paid where the amortization period is one year or less are expensed as incurred. All other sales commissions are deferred and then amortized on a straight-line basis over a period of benefit that the Company has determined to be three years. The Company determined the period of benefit by taking into consideration

    its standard contract terms and conditions, rate of technological change, and other factors. Amortization expense is included in sales and marketing expenses in the accompanying consolidated statements of operations.

    The balance of deferred commissions as of December 31, 2023 and December 31, 2022 was $3.5 million and $2.8 million, respectively, and is included in other assets on the consolidated balance sheets. The amount of amortization expense recognized during the years ended December 31, 2023, 2022, and 2021 was $1.4 million, $845 thousand, and $228 thousand, respectively.

    Cost of Revenues

    Cost of revenues consists primarily of personnel-related costs associated with the delivery of the Company’s software and services, including base salaries, bonuses, employee benefits and related costs. Additionally, cost of revenues includes amortization of capitalized software development costs, allocated overhead and certain direct data and hosting costs.

    Technology and Development

    Technology and development expenses consist primarily of employee-related expenses for the Company’s software development. Additional expenses include costs related to the development, maintenance, quality assurance and testing of new technologies, and ongoing refinement of the Company’s existing solutions. Technology and development expenses, other than software development costs qualifying for capitalization, including costs associated with preliminary project stage activities, training, maintenance, and all other post-implementation stage activities are expensed as incurred.

    Advertising Costs

    The Company expenses advertising costs as incurred. Advertising costs incurred were approximately $1.5 million, $1.5 million, and $1.2 million during the years ended December 31, 2023, 2022, and 2021, respectively.

    Stock-Based Compensation

    In October 2021, in connection with the IPO, the Company adopted the 2021 Stock Option and Incentive Plan, (the “2021 Plan”). The 2021 Plan allows the Company’s Compensation Committee to make incentive awards to its officers, employees, directors, and service providers. The Company also adopted the 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The Company measures stock-based compensation expense for its share-based payment awards at fair value on the grant date. The fair value of share-based payment awards is determined using the fair market value of the underlying Class A common stock on the date of grant. The Company applied a discount for lack of marketability, estimated using the Finnerty Model, to the fair value of awards with post-vesting restrictions, which includes the vested shares of Class A common stock and the Contingently Issuable Shares (as defined below) issued on the IPO effectiveness date (as defined below).

    For restricted stock units (“RSUs”) for which vesting is subject to the achievement of a market condition, the Company determines the fair value of these RSUs using the Monte Carlo method. The Monte Carlo simulations used to estimate the fair value include subjective assumptions, including the fair value of the underlying common stock, expected volatility of the price of the Company’s common stock, risk-free interest rate, expected dividend yield of common stock, and the Company’s cost of equity capital.

    The Company records forfeitures as they occur. The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statements of operations based on the estimated fair value of those awards on the grant date or reporting date, if required to be remeasured, and amortized on a straight-line basis over the requisite service period.

    Income (Loss) Per Share

    Income (loss) per share is computed by dividing net income (loss) attributable to the Company by the number of weighted average shares of Class A common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income (loss) attributable to the Company by the number of weighted-average shares of Class A common stock outstanding during the period after adjusting for the impact of securities that would have a dilutive effect on income (loss) per share. See Note 12, Income (Loss) Per Class A Common Share, for further discussion.

    All income (loss) for the period prior to the IPO were entirely allocable to Enfusion Ltd. LLC. and its historic non-controlling interest. Due to the impact of the Reorganization Transactions, the Company’s capital structure for the pre- and post-IPO periods is not comparable. As a result, the presentation of income (loss) per share for the periods prior to the IPO and Reorganizational Transactions is not meaningful and only income (loss) per share for the period subsequent to the IPO and Reorganizational Transactions is presented herein.

    Non-Controlling Interest

    Non-controlling interests represent the portion of profit or loss, net assets, and comprehensive income (loss) of its consolidated subsidiaries that are not allocable to the Company based on its percentage of ownership of such entities. As noted above, in October of 2021, Enfusion US 1, Inc., a newly-formed wholly owned subsidiary of Enfusion, Inc., became the sole managing member of Enfusion Ltd. LLC in connection with the Reorganization Transactions. As of December 31, 2023, the Company holds approximately 69.3% of the outstanding Common Units of Enfusion Ltd. LLC, and approximately 30.7% of the outstanding Common Units of Enfusion Ltd. LLC are held by Pre-IPO Common Unitholders. Therefore, the Company reports non-controlling interests based on Common Units of Enfusion Ltd. LLC held by the Pre-IPO Common Unitholders on its consolidated balance sheet as of December 31, 2023. Income or loss attributed to the non-controlling interest in Enfusion Ltd. LLC is based on the Common Units outstanding during the period for which the income or loss is generated and is presented on the consolidated statements of operations and consolidated statements of comprehensive income (loss).

    Income Taxes

    The Company accounts for income taxes under the asset and liability method, and deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and deferred tax liabilities is recognized in income in the period that includes the enactment date.

    The Company recognizes deferred tax assets to the extent that it is believed that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations. A valuation allowance is provided if it is determined that it is more likely than not that the deferred tax asset will not be realized.

    The Company evaluates and accounts for uncertain tax positions using a two-step approach. Recognition (step one) occurs when the Company concludes that a tax position, based solely on its technical merits, is more-likely-than-not to be sustainable upon examination. Measurement (step two) determines the amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. Derecognition of a tax position that was previously recognized would occur when the Company subsequently determines that a tax position no longer meets the more-likely-than-not threshold of being sustained. The Company records interest (and penalties where applicable), net of any applicable related income tax benefit, on potential income tax contingencies as a component of income tax expense in the consolidated statements of operations.

    Tax Receivable Agreement (TRA)

    The Company accounts for amounts payable under the Tax Receivable Agreement in accordance with ASC 450, Contingencies. The amounts payable under the Tax Receivable Agreement will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future. Actual tax benefits realized by the Company may differ from tax benefits calculated under the Tax Receivable Agreement as a result of the use of certain assumptions in the agreement. Any such changes in these factors or changes in the Company’s determination of the need for a valuation allowance related to the tax benefits acquired under the Tax Receivable Agreement could adjust the Tax Receivable Agreement liabilities recognized on the consolidated balance sheets. Subsequent changes in the Tax Receivable Agreement liabilities between reporting periods, as well as any interest accrued on the Tax Receivable Agreement between the Company's annual tax filing date and the Tax Receivable Agreement payment date, are recognized in the consolidated statements of operations. As of December 31, 2023 and 2022, the Company has not recorded a liability under the Tax Receivable Agreement.

    Concentration of Risk

    Deposits with Financial Institutions

    The Company has concentrated its credit risk for cash by maintaining deposits in several financial institutions, which may at times exceed amounts covered by insurance provided by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk related to cash.

    Accounts Receivable

    As of December 31, 2023, the Company had one individual client that represented 10% or more of accounts receivables. For the years ended December 31, 2023, 2022, and 2021, no individual client represented more than 10% of the Company’s total revenues.

    Translation of Foreign Currencies

    Assets and liabilities denominated in the functional currency of the Company’s international subsidiaries are translated to its reporting currency using the exchange rates in effect at the balance sheet date. Results from operations are translated using the average exchange rates prevailing throughout the year. The effects of exchange rate fluctuations on translating foreign currency assets and liabilities into U.S. dollars are accumulated as part of the foreign currency translation adjustment in accumulated other comprehensive loss in the consolidated balance sheets.

    Foreign currency balances for monetary assets and liabilities are remeasured into the entity’s functional currency at the balance sheet date, and fluctuations in value are recorded within other income (expense) in the consolidated statements of operations.

    Recently Adopted Accounting Pronouncements

    In June 2016, the FASB issued ASU 2016-13 and ASU 2018-19, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU No. 2016-13”), which requires that a financial asset (or a group of financial assets) measured at an amortized cost basis be presented at the net amount expected to be collected. This approach to estimating credit losses applies to most financial assets measured at amortized cost and certain other instruments, including but not limited to, trade and other receivables. The Company adopted this guidance effective January 1, 2023 and made changes to its accounting policies related to credit loss calculations, including the consideration of forecasted economic data and the pooling of financial assets with similar risk profiles. The Company adopted the new allowance for credit losses accounting standard on January 1, 2023 by means of a cumulative-effect adjustment, where it

    recognized the cumulative effect of initially applying the guidance as a $149 thousand addition to its existing reserve with an offsetting adjustment to accumulated deficit.

    Recent Accounting Pronouncements Not Yet Adopted

    In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU No. 2023-07”), to expand the annual and interim disclosure requirements for reportable segments, including public entities with a single reportable segment, primarily through enhanced disclosures about significant segment expenses. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this standard.

    In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topics 740): Improvements to Income Tax Disclosures (“ASU No. 2023-09”), to expand the disclosures in an entity’s income tax rate reconciliation table and income taxes paid both in U.S. and foreign jurisdictions. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this standard.

    XML 37 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Property, Equipment, and Software, Net
    12 Months Ended
    Dec. 31, 2023
    Property, Equipment, and Software, Net  
    Property, Equipment, and Software, Net

    Note 4   Property, Equipment, and Software, Net

    Property, equipment, and software, net consists of the following (in thousands):

    December 31, 

    2023

        

    2022

    Computer equipment

    $

    17,384

    $

    17,496

    Software development costs

     

    15,842

     

    9,406

    Leasehold improvements

     

    1,668

     

    1,831

    Furniture and fixtures

     

    137

     

    433

    Total property, equipment, and software, cost

     

    35,031

     

    29,166

    Less accumulated depreciation and amortization

     

    (16,717)

     

    (13,407)

    Total property, equipment, and software, net

    $

    18,314

    $

    15,759

    As of December 31, 2023 and 2022, property, equipment, and software, net located in the United States was $17.0 million and $13.7 million, respectively. The remainder was located in the Company’s various international locations. Included in property, equipment, and software are the capitalized costs of software development. Software development costs capitalized during the years ended December 31, 2023 and 2022 were $6.4 million and $4.5 million, respectively.

    Depreciation expense related to property and equipment, excluding software development costs, was $5.1 million, $3.3 million, and $2.4 million for the years ended December 31, 2023, 2022, and 2021, respectively. Amortization expense related to software development costs was $3.4 million, $2.2 million, and $1.3 million for the years ended December 31, 2023, 2022, and 2021, respectively.

    XML 38 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Accrued Expenses and Other Current Liabilities
    12 Months Ended
    Dec. 31, 2023
    Accrued Expenses and Other Current Liabilities  
    Accrued Expenses and Other Current Liabilities

    Note 5   Accrued Expenses and Other Current Liabilities

    Accrued expenses and other current liabilities consisted of the following (in thousands):

    December 31, 

    2023

        

    2022

    Accrued compensation

    $

    10,058

    $

    10,268

    Accrued expenses and other

     

    1,385

     

    1,112

    Accrued taxes

     

    2,398

     

    285

    Total accrued expenses and other current liabilities

    $

    13,841

    $

    11,665

    Accrued compensation includes bonuses due to employees of $6.4 million and $7.8 million as of December 31, 2023 and 2022, respectively.

    XML 39 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Leases
    12 Months Ended
    Dec. 31, 2023
    Leases  
    Leases

    Note 6   Leases

    The Company enters into leases for office space and data centers. A number of the leases include one or more options to renew the lease terms or not terminate the lease. The exercise of these options is at the Company’s discretion and is therefore recognized on the balance sheet when it is reasonably certain the Company will exercise such options.

    All of the Company’s leases are considered operating leases. The Company had no finance leases as of and for the year ended December 31, 2023 and 2022, respectively.

    The Company has entered into operating leases for international office spaces that are yet to commence as of December 31, 2023.

    Lease commitments as of December 31, 2023 were as follows:

    Amount

    2024

    5,197

    2025

    4,198

    2026

    3,229

    2027

    3,253

    2028

    1,671

    Thereafter

    654

    Total lease commitments

    $

    18,202

    Less: Interest

    (2,765)

    Present value of lease liabilities

    $

    15,437

    The components of the Company’s operating lease cost for the twelve months ended December 31, 2023 and 2022, respectively, were as follows:

    December 31, 

    2023

    2022

    Operating lease cost

    $

    6,882

    $

    5,053

    Variable lease cost

    835

    828

    Short-term lease cost

    114

    Total lease cost

    $

    7,831

    $

    5,881

    Variable lease costs are comprised of the Company’s proportionate share of actual costs for utilities, common area maintenance, property taxes, and insurance, which are not included in the lease liability and are recognized in the period in which they are incurred.

    As of December 31, 2023 and 2022, respectively, the weighted-average remaining lease terms and weighted-average discount rates were as follows:

    December 31, 

    2023

    2022

    Weighted-average remaining lease term - operating leases

    3.80 years

    1.84 years

    Weighted-average discount rate - operating leases

    7.80%

    4.43%

    Under Accounting Standards Codification 840, the previous lease standard, total expense for lease arrangements and service agreements was $3.9 million and $1.1 million, respectively, for the year ended December 31, 2021.

    XML 40 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Debt
    12 Months Ended
    Dec. 31, 2023
    Debt  
    Debt

    Note 7   Debt

    New Credit Agreement

    On September 15, 2023, the Company entered into the New Credit Agreement with Bank of America N.A. and a syndicate of lending institutions. The New Credit Agreement provides for a senior secured revolving loan facility in an aggregate principal amount of up to $100.0 million, including a $10.0 million sublimit for the issuance of letters of credit and a swingline subfacility of up to $10.0 million. The New Credit Agreement also includes an uncommitted accordion feature that allows for up to $50.0 million of additional borrowing capacity, subject to obtaining lender commitments and the satisfaction of certain customary conditions. The New Credit Agreement matures on September 15, 2028, at which time all outstanding principal and unpaid interest will become due. Obligations under the New Credit Agreement are secured by a lien on substantially all of the assets of the Company.

    Revolving loans under the New Credit Agreement will bear interest, at the Company’s option, at an annual rate benchmarked to (1) the Secured Overnight Financing Rate (“SOFR”) or (2) a “Base Rate” that is equal to the highest of (a) the federal funds rate plus 0.50%, (b) Bank of America’s prime rate and (c) one month adjusted term SOFR plus 1.00%. Loans based on SOFR bear interest at a rate equal to term SOFR for the applicable interest period plus 10 basis points plus a margin between 2.00% and 2.75%. Loans based on the Base Rate bear interest at a rate equal to the Base Rate plus a margin between 1.00% and 1.75% (such margins being referred to as the “Applicable Rate”). The Applicable Rate in each case is determined based on the Company’s consolidated net leverage ratio. The Company is also required to pay a commitment fee of between 0.20% and 0.25% per annum on the unused portion of the lenders’ commitments in respect of the revolving loans and letter of credit obligations, based on the Company’s consolidated net leverage ratio. As of December 31, 2023, the commitment fee rate was 0.20%.

    The New Credit Agreement contains certain customary covenants with which the Company must comply, including financial covenants relating to a net leverage ratio covenant and an interest coverage ratio. As part of the New

    Credit Agreement, the Company is required to establish within 120 days of the closing date and maintain thereafter a minimum required balance of $5.0 million with Bank of America, and by the first anniversary of the closing date, use commercially reasonable efforts to maintain Bank of America as its principal depository bank. The minimum required balance of $5.0 million was established in February 2024. The Company was in compliance with all loan covenants and requirements as of December 31, 2023.

    Issuance costs associated with the New Credit Agreement were capitalized and included in other assets on the accompanying consolidated balance sheets.

    As of December 31, 2023, the Company had no outstanding borrowings under the New Credit Agreement or material letters of credit issued.

    Prior Credit Agreement

    Concurrent with entering into the New Credit Agreement, on September 15, 2023, the Company terminated its $5.0 million Prior Credit Agreement with Silicon Valley Bank, which by its terms was scheduled to mature on December 17, 2025. At the time of termination, there were no borrowings outstanding under the Prior Credit Agreement. The Company recognized a loss on extinguishment of debt of $78 thousand associated with the termination of the Prior Credit Agreement.

    XML 41 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Commitments and Contingencies
    12 Months Ended
    Dec. 31, 2023
    Commitments and Contingencies  
    Commitments and Contingencies

    Note 8   Commitments and Contingencies

    The Company records accruals for contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. A description of a contingent payment arrangement under the Company’s Tax Receivable Agreement is included in Note 13, Income Taxes. Accruals for contingencies recorded as of December 31, 2023 and December 31, 2022, respectively, were immaterial.

    XML 42 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Stockholders' Equity
    12 Months Ended
    Dec. 31, 2023
    Stockholders' Equity  
    Stockholders' Equity

    Note 9   Stockholders’ Equity

    Prior to the Reorganization Transactions, Enfusion Ltd. LLC was organized as a limited liability company owned by its members, each of whose membership interests consisted of an equal number of: (i) “Economic Units,” which represented a member’s economic interest in Enfusion Ltd. LLC; and (ii) “Participation Units,” which represented a member’s right to participate (vote) in the affairs of Enfusion Ltd. LLC.

    As a limited liability company, Enfusion Ltd. LLC issued more than one class of units. The Class A units were considered to be members’ equity, whereas all of the other unit classes were considered to be preferred units because of provisions in the Company’s former Operating Agreement that conferred certain rights and privileges to the members owning these units, such as voting rights, redemption rights and liquidation preferences.

    Holders of the Class C-1, C-2, and D preferred units had the option to require the Company to redeem their units. In accordance with the guidance in ASC 480, Distinguishing Liabilities from Equity, outstanding Class C-1, C-2, and D preferred units were classified outside of permanent equity and within temporary equity due to their optional redemption features and liquidation preferences.

    In connection with the Reorganization Transactions, the Sixth Amended and Restated Operating Agreement of Enfusion Ltd. LLC was amended and restated to, among other things, modify its capital structure by reclassifying each of the outstanding Class A units and C-1, C-2, and D preferred units into the Common Units through a stock split on a 1,000,000 to 1 basis. The number of Common Units outstanding following the Reorganization Transactions reflect the 1,000,000 to 1 stock split. Pursuant to the adoption of the LLC Operating Agreement, Enfusion US 1, Inc., a newly-formed wholly owned subsidiary of Enfusion, Inc., was appointed the sole managing member of Enfusion Ltd. LLC.

    On June 15, 2023, the company sold 1.2 million shares of Class A common stock to FTV Investment Holdings, L.P. (“FTV Holdings”) and an affiliate in a private placement. Refer to Note 14, Related Party Transactions, for more information about this placement transaction.

    On August 14, 2023, the Company sold 1.0 million shares of Class A common stock of the Company, par value $0.001 per share, in a private placement at a price of $7.65 per share. Total net proceeds of the transaction were $7.6 million.

    On February 21, 2023, March 28, 2023, July 19, 2023, and August 1, 2023, pursuant to the terms of the LLC Operating Agreement, Pre-IPO Common Unitholders respectively surrendered 1,000,000, 1,000,000, 1,000,000, and 1,000,000 Common Units and an equal number of shares of Class B common stock. In connection therewith, the Company respectively issued 1,000,000, 1,000,000, 1,000,000, and 1,000,000 shares of Class A common stock to each such Pre-IPO Common Unitholder, canceled an equal number of Class B common stock, and received an equal number of Common Units, increasing the Company’s ownership of Common Units by 1,000,000, 1,000,000, 1,000,000, and 1,000,000, respectively.

    Amended and Restated of Certificate of Incorporation

    The Amended and Restated Certificate of Incorporation of Enfusion, Inc. provides for 1,000,000,000 authorized shares of Class A common stock, 150,000,000 authorized shares of Class B common stock and 100,000,000 shares of preferred stock.

    Each share of the Company’s Class A common stock is entitled to one vote per share and is not convertible into any other shares of its capital stock. Holders of shares of the Company’s Class A common stock are entitled to receive dividends when, as and if declared by the Company’s board of directors. Upon its liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors, and subject to the rights of the holders of one or more outstanding series of preferred stock, as applicable, having liquidation preferences, the holders of shares of the Company’s Class A common stock will be entitled to receive pro rata the Company’s remaining assets available for distribution. Each share of the Company’s Class B common stock is entitled to one vote per share and is not convertible or exchangeable for a share of Class A common stock or any other security. Holders of the Company’s Class B common stock do not have any right to receive dividends or to receive a distribution upon a liquidation, dissolution or winding up of Enfusion, Inc.

    Preferred Stock

    The Company’s board of directors have the authority, without further action by the Company’s stockholders, to issue up to 100,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Class A common stock. As of December 31, 2023 and 2022, the Company has no shares of preferred stock outstanding nor has the Company’s board of directors established the rights and privileges related to any series of preferred stock.

    XML 43 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Management Incentive Plan and Stock-Based Compensation
    12 Months Ended
    Dec. 31, 2023
    Management Incentive Plan and Stock-Based Compensation  
    Management Incentive and Stock-Based Compensation

    Note 10   Management Incentive Plan and Stock-Based Compensation

    2021 Stock Option and Incentive Plan

    In conjunction with the IPO, the Company established the 2021 Stock Option and Incentive Plan (the “2021 Plan”), which became effective upon the date immediately preceding the IPO effectiveness date (as defined below). The Company has initially reserved 26,400,000 shares of Class A common stock for the issuance of awards under the 2021 Plan, inclusive of awards (the “Award Units”) granted to Plan Participants (as defined below) of the Pre-IPO Change in

    Control Bonus Plan (as defined below). The 2021 Plan provides that the number of shares of Class A common stock reserved and available for issuance under the 2021 Plan increased on January 1, 2022 and will continue to increase each January 1 thereafter, by 3% of the outstanding number of shares of the Company’s Class A common stock and Class B common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Company’s Compensation Committee. The 2021 Plan provides for potential grants of the following awards: (i) stock options, (ii) RSUs, (iii) unrestricted shares, and (iv) stock appreciation rights.

    Pre-IPO Change in Control Bonus Plan

    Prior to the IPO, Enfusion Ltd. LLC had a Pre-IPO Change in Control Bonus Plan (the “pre-IPO Change in Control Bonus Plan”) for certain members of management (“Plan Participants”) that provided for the payment of a cash bonus based on a specified number of Award Units in the event of a change in control (“CiC”) transaction (i.e., a liquidity event), as defined by the LLC Operating Agreement.

    In anticipation of the Company’s IPO, in October 2021, the Company's board of managers elected to terminate the Pre-IPO Change in Control Bonus Plan (and all Award Units issued thereunder) upon effectiveness of the registration statement for the IPO (the “IPO effectiveness date”). Holders of Award Units that were still employed as of the IPO effectiveness date were granted one or more of the following:

    The vested shares of Class A common stock as of IPO effectiveness date (“IPO vested Class A common stock”) are shares that were all issued to Plan Participants prior to the second anniversary of the IPO. No future service was required to receive the IPO vested Class A common stock. Because there was no ongoing service requirement associated with these awards, the Company recognized stock-based compensation expense for these awards on the IPO effectiveness date. The amount of stock-based compensation expense recognized for these awards was $237.3 million in 2021, which is equal to the fair value of the shares of the IPO vested Class A common stock, after applying a discount for lack of marketability due to the post-vesting restriction.

    Shares of Class A common stock that vested within one year of the IPO effectiveness date are referred to as “Contingently Issuable Shares” due to continued employment requirements. Of such shares, 7.5% was distributed in 2022 with the remainder distributed in 2023. Stock-based compensation expense associated with these awards is recognized by the Company on a straight-line basis over the requisite service period for the entire award, beginning on the IPO effectiveness date. The amount of stock-based compensation expense recognized for these awards was $0, $10.2 million, and $16.7 million in the years ended December 31, 2023, 2022, and 2021, respectively, which is equal to the fair value of the shares of the IPO vested Class A common stock, after applying a discount for lack of marketability due to the post-vesting restriction.

    RSUs granted to executive and non-executive employees that will vest ratably over a period of up to four years subject to the Plan Participant’s continued employment. Stock-based compensation expense associated with these awards is recognized by the Company on a straight-line basis over the requisite service period for the entire award, beginning on the IPO effectiveness date. The amount of stock-based compensation expense recognized for these awards was $7.3 million, $13.2 million, and $4.5 million in the years ended December 31, 2023, 2022, and 2021, respectively.

    Performance-based restricted stock units (“PSUs”) that will vest ratably over a period of up to ten years that are subject to a market condition and the Plan Participant’s continued employment. The market condition is the achievement of certain market capitalization targets by the Company at specified measurement dates. The Company determined the fair value of these PSUs using the Monte Carlo method. The Company
    recognizes stock-based compensation expense on a straight-line basis over the implied service period for each tranche of the award, as if the award were in-substance multiple awards.

    In addition to the shares of Class A common stock, RSUs, and PSUs granted to employees that were Plan Participants in the Pre-IPO Change in Control Bonus Plan, the Company agreed to issue 2,047,064 shares of Class A common stock to an employee in exchange for termination of a profit sharing agreement. These shares were issued to the employee between the first and second anniversaries of the IPO effectiveness date. The fair value of these shares, after applying a discount for lack of marketability due to the post-vesting restriction, is $31.2 million. This amount was recognized as compensation expense on the IPO effectiveness date in 2021.

    For the IPO vested Class A common stock and the Contingently Issuable Shares granted on the IPO effectiveness date, the Company applied a discount for lack of marketability, estimated using the Finnerty Model, to the fair value of awards with post-vesting restrictions. All IPO vested Class A common stock and Contingently Issuable Shares were issued to Plan Participants prior to the second anniversary of the IPO.

    Restricted Stock Units

    The Company measures stock-based compensation expense for its share-based payment awards at fair value on the grant date. For RSUs for which vesting is not subject to the achievement of a market condition or achievement of a specified share price, the fair value of share-based payment awards is determined using the fair market value of the underlying Class A common stock on the date of grant (i.e. share price at closing).

    The Company recognizes stock-based compensation expense for these RSUs on a straight-line basis over requisite service period for the entire award.

    Stock Options

    The expected fair value and term of the Company’s stock options was determined utilizing the simplified method, due to lack of historical exercise data. The expected volatility was determined using a weighted-average of the historical volatility measures of a group of guideline companies and the Company's own historical volatility.

    During the year ended December 31, 2023, there were 71,004 stock options granted under the 2021 Plan, at a weighted-average exercise price of $11.06 per option, and 31,474 stock options were forfeited. During the year ended December 31, 2022, there were 84,000 stock options granted under the 2021 Plan, at a weighted-average price of $9.86 per option, and 40,000 stock options were forfeited. As of December 31, 2023, there was approximately $351 thousand of unrecognized stock-based compensation expense related to the remaining stock options issued during 2022, which is expected to be recognized over a weighted-average period of approximately 2.0 years. The Black-Scholes assumptions used for the options granted under the 2021 Plan during the year ended December 31, 2022 were as follows:

    Assumptions

    2023

    2022

    Expected volatility

    60.91%

    64.54%

    Expected term of award

    6.5 years

    6.5 years

    Risk-free rate

    3.82%

    3.39%

    Dividend yield

    0.00%

    0.00%

    The shares of common stock to be issued and/or sold upon the exercise of stock options are made available from authorized and unissued common stock.

    Performance-based Restricted Stock Units

    For PSUs for which vesting is subject to the achievement of a market condition or specified price of the Company’s shares, the Company determines the fair value of these PSUs using the Monte Carlo method. The Monte Carlo simulations used to estimate the fair value include subjective assumptions, including the fair value of the underlying common stock, expected volatility of the price of the Company’s common stock, risk-free interest rate, expected dividend yield of common stock, and the Company’s cost of equity capital.

    In the fourth quarter of 2023, 580,000 performance-based PSUs were granted. In the year ended December 31, 2022, 250,000 performance-based PSUs were granted. The assumptions used in the Monte Carlo simulation for the PSUs were as follows:

    Assumptions

    2023

    2022

    2021

    Fair value of common stock (per share)

    $9.89

    $8.92

    $17.00

    Expected volatility

    41.65%

    53.40%

    48.20%

    Risk-free rate

    4.38%

    3.98%

    1.65%

    Dividend yield

    0.00%

    0.00%

    0.00%

    Cost of equity capital

    14.10%

    13.50%

    11.20%

    As of December 31, 2023, the total compensation cost related to unvested awards not yet recognized was $2.8 million, and weighted-average period of recognition was 2.0 years.

    Stock-Based Compensation

    The Company’s stock-based compensation expense was recognized in the following captions within the consolidated statements of operations:

    Year Ended December 31, 

    (in thousands)

    2023

    2022

    2021

    Cost of revenues

    $

    950

    $

    1,421

    $

    377

    General and administrative

    5,635

    14,130

    112,829

    Sales and marketing

    (984)

    5,875

    36,312

    Technology and development

    1,857

    3,567

    140,285

    Total stock-based compensation expense

    $

    7,458

    $

    24,993

    $

    289,803

    The Company recognized total stock-based compensation expense, including RSUs and stock options, for the years ended December 31, 2023, 2022, and 2021 of $7.5 million, $25.0 million, and $289.8 million, respectively, in the consolidated statements of operations.

    The Company capitalized $766 thousand and $600 thousand of stock-based compensation expense to capitalized software development costs for the years ended December 31, 2023 and 2022, respectively. No amounts were capitalized relating to the year ended December 31, 2021 due to the fact that no awards were granted in conjunction with capitalizable activities.

    Total unrecognized stock-based compensation expense related to unvested RSUs and stock options was $19.7 million as of December 31, 2023, which is expected to be recognized over a weighted-average period of 2.0 years.

    The following summarizes the Company’s share-based payment award activity for all IPO vested Class A common stock, RSUs, Contingently Issuable Shares and stock options for the years ended December 31, 2023 and 2022, respectively:

       

    IPO Vested Class A Common Stock, Contingently Issuable Shares and RSUs

    Options

    Number of Units

       

    Weighted-Average Grant-Date Fair Value

       

    Number of Options

       

    Weighted-Average Exercise Price

    Weighted-Average Remaining Contractual Term (in years)

    Outstanding as of December 31, 2022

    20,224,452

    $

    15.15

    44,000

    9.86

    9.46

    Vested as of December 31, 2022

    17,225,377

    -

    -

    Unvested as of December 31, 2022

    2,999,075

    44,000

    9.86

    Granted during the period

    1,925,762

    $

    8.49

    71,004

    11.06

    Forfeited during the period

    (584,178)

    15.32

    (31,474)

    10.15

    Vested and issued during the period (a)

    (18,374,139)

    15.27

    -

    -

    Outstanding as of December 31, 2023 (b)

    3,191,897

    $

    9.61

    83,530

    $

    10.77

    8.89

    (a) Includes shares issued and net settled to satisfy tax withholding obligations.

    (b) December 31, 2023 balance is all unvested.

    XML 44 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Employee Benefit Plans
    12 Months Ended
    Dec. 31, 2023
    Employee Benefit Plans  
    Employee Benefit Plans

    Note 11   Employee Benefit Plans

    The Company sponsors a 401(k) Plan that covers substantially all full-time United States employees who meet eligibility requirements. The Company makes matching contributions equal to 50% of the wages that are deferred by employees, and the matching contribution is capped at 3% of wages. The Company made contributions of $1.0 million, $584 thousand, and $452 thousand for the years ended December 31, 2023, 2022, and 2021, respectively. The Company also sponsors various other benefit plans for its employees of certain international subsidiaries. The Company’s contributions to these plans are immaterial for the periods presented.

    XML 45 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Net Income (Loss) Per Class A Common Share
    12 Months Ended
    Dec. 31, 2023
    Net Income (Loss) Per Class A Common Share  
    Net Income (Loss) Per Class A Common Share

    Note 12   Net Income (Loss) Per Class A Common Share

    Basic income (loss) per share is computed by dividing net income (loss) attributable to Enfusion, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive shares.

    Prior to the IPO, the Enfusion Ltd. LLC membership structure included Common Units and multiple classes of preferred Units. The Company analyzed the calculation of earnings per unit for periods prior to the IPO using the two-class method and determined that it resulted in values that would not be meaningful to the users of these consolidated financial statements. Therefore, earnings per share information has not been presented for periods prior to the IPO on October 20, 2021. The basic and diluted earnings per share represent only the years ended December 31, 2023 and 2022, and the period from October 21, 2021 to December 31, 2021.

    A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per share of Class A common stock is as follows:

    Year Ended December 31, 

    (in thousands, except per share amounts)

    2023

        

    2022

    2021

    Net income (loss)

    $

    9,253

    $

    (13,263)

    $

    (282,242)

    Less: Net income attributable to Enfusion, Inc. prior to the IPO

    -

    -

    (12,892)

    Less: Net (income) loss attributable to non-controlling interests

    (3,228)

    5,609

    123,925

    Net income (loss) attributable to Enfusion, Inc.

    $

    6,025

    $

    (7,654)

    $

    (171,209)

    Numerator:

    Net income (loss) attributable to Enfusion, Inc.

    $

    6,025

    $

    (7,654)

    $

    (171,209)

    Adjustment to loss attributable to common stockholders

    306

    (954)

    (16,580)

    Numerator for Basic Earnings per Share

    $

    6,331

    $

    (8,608)

    $

    (187,789)

    Adjustment to Income for Dilutive Shares

    2,922

    -

    -

    Numerator for Diluted Earnings per Share

    $

    9,253

    $

    (8,608)

    $

    (187,789)

    Denominator:

    Weighted-average shares of Class A common stock outstanding

    80,828

    67,057

    65,583

    Vested shares of Class A common stock and RSUs

    7,374

    18,336

    17,462

    Weighted-average shares of Class A common stock outstanding--basic

    88,202

    85,393

    83,045

    Add: Dilutive Shares

    41,227

    -

    -

    Weighted-average shares of Class A common stock outstanding--diluted

    129,429

    85,393

    83,045

    Net income (loss) per share of Class A common stock--Basic

    $

    0.07

    $

    (0.10)

    $

    (2.26)

    Net income (loss) per share of Class A common stock--Diluted

    $

    0.07

    $

    (0.10)

    $

    (2.26)

    The following number of potentially dilutive shares were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive:

    Year Ended December 31, 

    (in thousands)

    2023

        

    2022

    2021

    Class B common stock

    -

    43,199

    47,471

    Contingently issuable shares of Class A common stock

    -

    -

    1,726

    Restricted stock units

    1,048

    2,999

    2,905

    Stock options

    84

    44

    -

    1,132

    46,242

    52,102

    Shares of Class B common stock do not share in earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been presented. Shares of Class B common stock are, however, considered potentially dilutive shares of Class A common stock. After evaluating the potential dilutive effect under both the treasury stock method and if-converted method, shares of Class B common stock were determined to be dilutive and have therefore been included in the computation of diluted earnings per share of Class A common stock for the year ended December 31, 2023.

    XML 46 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Income Taxes
    12 Months Ended
    Dec. 31, 2023
    Income Taxes  
    Income Taxes

    Note 13   Income Taxes

    The Company is taxed as a corporation for income tax purposes and is subject to federal, state, and local taxes on the income allocated to it from Enfusion Ltd. LLC based upon the Company’s economic interest in Enfusion Ltd. LLC. The Company controls the sole managing member of Enfusion Ltd. LLC and, as a result, consolidates the financial results of Enfusion Ltd. LLC.

    Enfusion Ltd. LLC is a limited liability company taxed as a partnership for income tax purposes. Enfusion Ltd. LLC does not pay any federal income taxes, as income or loss is included in the tax returns of the individual members. Additionally, certain wholly-owned entities taxed as corporations are subject to federal, state, and foreign income taxes in the jurisdictions in which they operate, and accruals for such taxes are included in the consolidated financial statements. For periods prior to the IPO, the Company’s taxes represent those of Enfusion Ltd. LLC.

    The components of income (loss) before income taxes were as follows (in thousands):

    Year Ended December 31, 

    2023

        

    2022

    2021

    U.S.

    $

    5,503

    $

    (16,201)

    $

    (279,990)

    Foreign

     

    5,981

     

    4,012

     

    (1,673)

    Total

    $

    11,484

    $

    (12,189)

    $

    (281,663)

    The income (loss) before income taxes above includes the pre- and post-IPO periods for the year ended December 31, 2021.

    Prior to the IPO, the Company, through its subsidiary, Enfusion Ltd. LLC, was structured as a partnership and therefore, was primarily subject to foreign income taxes and generally not subject to U.S. income taxes. As a result of the Reorganization Transactions, the Company is now taxed as a corporation and subject to U.S. federal, state, local and foreign taxes. Significant components of income tax expense (benefit) were as follows (in thousands):

    Year Ended December 31, 

    2023

        

    2022

    2021

    Current:

    U.S. Federal

    $

    (5)

    $

    $

    State & Local

    53

    Foreign

    2,190

    1,347

    228

    Total Current Income Tax Expense

    2,238

    1,347

    228

    Deferred:

    U.S. Federal

    State & Local

    Foreign

    (7)

    (273)

    351

    Total Deferred Income Tax Expense (Benefit)

     

    (7)

     

    (273)

     

    351

    Total

    $

    2,231

    $

    1,074

    $

    579

    A reconciliation of income taxes computed at the U.S. federal statutory income tax rate of 21% to the Company’s income tax expense (benefit) was as follows:

    Year Ended December 31, 

    2023

        

    2022

    2021

    At U.S. Federal Statutory Tax Rate

    21.0

    %

    21.0

    %

    21.0

    %

    State Tax, Net of Federal Benefit

    38.9

    %

    3.1

    %

    4.3

    %

    Non-controlling Interest

    (7.3)

    %

    (8.9)

    %

    (9.2)

    %

    Foreign Branch Taxes

    10.9

    %

    (8.2)

    %

    (0.3)

    %

    Stock-Based Compensation

    113.5

    %

    (10.6)

    %

    (2.5)

    %

    Foreign Rate Differential

    0.3

    %

    0.5

    %

    %

    Valuation Allowance

    (168.8)

    %

    50.6

    %

    (14.5)

    %

    Change in Tax Rates

    1.9

    %

    (59.2)

    %

    %

    Return to Provision

    6.5

    %

    4.0

    %

    0.1

    %

    Unrecognized Tax Benefit

    2.1

    %

    %

    %

    Pass-through Loss (Income)

    %

    %

    0.9

    %

    Other

    0.4

    %

    (1.1)

    %

    %

    Total

    19.4

    %

    (8.8)

    %

    (0.2)

    %

    The Company’s effective tax rate for the years ended December 31, 2023, 2022, and 2021 was 19.4%, (8.8)%, and (0.2)%, respectively. The most significant items impacting the effective tax rate are explained below.

    State Tax, Net of Federal Benefit

    The Company’s state taxes, net of federal benefit, include the effects of state taxes currently payable and changes in state deferred income taxes, exclusive of the valuation allowance. The significant increase in state taxes, net of federal benefit, in the year ended December 31, 2023, is primarily due to the U.S. state deferred tax effect of non-deductible equity-based compensation and related tax deduction deficiencies. For the years ended December 31, 2023, 2022, and 2021, the Company recorded state tax expenses (benefit) of $4.5 million, $(0.4) million, and $(12.1) million, respectively.

    Noncontrolling Interest

    The Company’s sole material asset is a financial interest in Enfusion Ltd. LLC. While the Company consolidates Enfusion Ltd. LLC for financial reporting purposes, the Company will only be taxed on (benefit from) its share of earnings (losses) of Enfusion Ltd. LLC not attributed to the noncontrolling interest holders. Since noncontrolling interest holders will continue to bear (benefit from) their share of income tax expense (benefit) on its allocable earnings (losses) of Enfusion Ltd. LLC, that share of income tax expense (benefit) is not reported by the Company in its consolidated financial statements. The U.S. federal tax (benefit) expense associated with the allocation of earnings (losses) to noncontrolling interest holders for the years ended December 31, 2023, 2022, and 2021 was $(0.8) million, $1.1 million and $25.9 million, respectively.

    Stock-Based Compensation

    As a result of the Reorganization Transactions, a significant portion of the Company’s certain stock-based compensation expenses will be allocated to the noncontrolling interest holders and therefore will not be deductible to the Company. The remaining portion of these expenses will be subject to the tax deduction limitations as established by the U.S. tax law in respect of the executive compensation. The Company recognizes an excess tax benefit or tax deficiency when the deduction for the stock-based compensation expense of a stock award for tax purposes differs from the cumulative stock-based compensation expense recognized in the financial statements. The U.S. federal tax impact of non-deductible stock-based compensation, including tax deficiencies, for the years ended December 31, 2023, 2022, and 2021 was $13.0 million, $1.3 million, and $2.5 million, respectively.

    Valuation Allowance

    The Company’s net deferred tax benefit (expense) for the years ended December 31, 2023, 2022, and 2021 of $(19.4) million, $(6.2) million, and $40.8 million, respectively, was fully offset by the valuation allowance recorded (released) in the consolidated statements of operations for each respective year.

    Foreign Branch Taxes

    The Company has foreign operations that are treated as branches for U.S. tax purposes and are also subject to income taxes in those foreign jurisdictions. For the years ended December 31, 2023, 2022, and 2021, the Company recorded $1.3 million, $1.0 million, and $0.6 million, respectively, in foreign income taxes related to the pre-tax income of its branches.

    Return to Provision

    For the years ended December 31, 2023, 2022, and 2021 the Company recorded a tax expense (benefit) of $0.8 million, $(0.5) million, and $(0.2) million, respectively, in relation to its filed or expected to be filed U.S. and foreign income tax returns. These true-up adjustments are attributable to actual results in the Company’s tax filings as compared to the estimates included in its previously issued consolidated financial statements.

    Change in Tax Rates

    For the years ended December 31, 2023, and 2022, the Company reduced its deferred tax assets by $0.2 million and $7.2 million, respectively, to reflect a change in the estimated U.S. state tax rate caused by a change in the overall mix of its U.S. earnings by state.

    Deferred Tax Assets

    The components of deferred tax assets and liabilities are as follows (in thousands):

    December 31, 

    2023

        

    2022

    Deferred Tax Assets:

    Investment in Enfusion Ltd. LLC

    $

    126,504

    $

    86,117

    Stock-Based Compensation

    1,542

    37,912

    Net Operating Losses

    11,410

    9,358

    Other

    851

    794

    Total Deferred Tax Assets

    140,307

    134,181

    Valuation Allowance

    (140,307)

    (133,689)

    Total Deferred Tax Assets Net of Valuation Allowance

    492

    Deferred Tax Liabilities:

    Property and Equipment

    (70)

    (77)

    Total Deferred Tax Liabilities

     

    (70)

     

    (77)

    Net Deferred Tax Assets

    $

    (70)

    $

    415

    The Company’s deferred tax assets are primarily comprised of basis differences in the investment in Enfusion Ltd. LLC, stock-based compensation, and tax attribute carryforwards. The ultimate realization of deferred tax assets is dependent upon the generation of sufficient future taxable income to realize the deferred tax assets on the Company’s income tax returns. Management determined that it is more likely than not going that the Company’s deferred tax assets will not be realized due to the Company’s three-year cumulative loss position and the generation of future taxable income is uncertain.

    The changes in the Company’s valuation allowance for deferred tax assets were as follows (in thousands):

    Year Ended December 31, 2021

    $

    124,526

    Charged to Income Tax Expense

    (6,163)

    Charged to Stockholders' Equity

     

    15,326

    Year Ended December 31, 2022

    $

    133,689

    Charged to Income Tax Expense

    (19,381)

    Charged to Stockholders' Equity

    25,999

    Year Ended December 31, 2023

    $

    140,307

    As of December 31, 2023 and 2022, the Company had U.S. federal net operating losses of $43.1 million and $33.2 million, respectively, which can be carried forward indefinitely. As of December 31, 2023 and 2022, the Company had state net operating losses of $35.6 million and $31.2 million, respectively, that begin to expire in 2038.

    As of December 31, 2023, the Company is not indefinitely reinvested on undistributed earnings from its foreign operations. Due to the Company's structure, the foreign operations do not qualify for the indefinite reinvestment exceptions under ASC 740-30 as the earnings from the foreign operations are subject to U.S. taxation. However, the exception may still apply to foreign withholding taxes due to dividend distributions of earnings from the Company's foreign affiliates. The Company has no plans to make distributions from its foreign operations in the future and, therefore, a deferred tax liability has not been recognized. A determination of the unrecognized deferred taxes is not practicable.

    A summary of the Company’s unrecognized tax benefits are as follows (in thousands):

    Year Ended December 31, 

    2023

        

    2022

    2021

    Beginning balance

    $

    119

    $

    119

    $

    Increases for tax positions related to the current year

    30

    Increases (decreases) for tax positions of prior years

     

    238

     

     

    89

    Expiration of statute of limitations

    (41)

    Ending balance

    $

    316

    $

    119

    $

    119

    Interest and penalties

    128

    65

    65

    The Company’s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. As of December 31, 2023, the Company accrued has $128 thousand of interest and penalties.

    The Company files tax returns in the United States and various foreign jurisdictions. The Company is currently being audited in the U.S. and India. However, the Company is no longer subject to examination by those taxing authorities with respect to the years ended prior to 2017. Although the outcome of tax audits is always uncertain and could result in significant cash tax payments, the Company does not believe the outcome of these audits will have a material adverse effect on its consolidated financial position or results of operations.

    Tax Receivable Agreement

    The Company expects to obtain an increase in its share of the tax basis in the net assets of Enfusion Ltd. LLC when Common Units are redeemed from or exchanged by the Pre-IPO Common Unitholders. The Company intends to treat any redemptions and exchanges of Common Units as direct purchases of Common Units for U.S. income tax purposes. These increases in tax basis may reduce the amounts that the Company would otherwise pay in the future to U.S. federal and state tax authorities. They may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets.

    In connection with the IPO, the Company entered into the Tax Receivable Agreement with Enfusion Ltd. LLC, the Pre-IPO Owners that will provide for the payment by the Company to the Pre-IPO Owners of 85% of the amount of tax benefits, if any, that the Company actually realizes (or in some circumstances is deemed to realize) as a result of (1) the Company’s allocable share of existing tax basis acquired in connection with the Reorganization Transactions (including the Blocker Company’s share of existing tax basis) and increases to such allocable share of existing tax basis; (2) increases in tax basis resulting from (a) the Company’s purchase of Common Units directly from Enfusion Ltd. LLC and the partial redemption of Common Units by Enfusion Ltd. LLC, (b) future redemptions or exchanges (or deemed exchanges in certain circumstances) of Common Units for Class A common stock or cash, and (c) certain distributions (or deemed distributions) by Enfusion Ltd. LLC; and (3) certain additional tax benefits arising from payments made under the Tax Receivable Agreement. The Company may benefit from the remaining 15% of any tax benefits that the Company actually realizes.

    In the years ended December 31, 2023, and 2022, the Company purchased an aggregate of 4,000,000 and 4,272,204 units, respectively, of Enfusion Ltd. LLC in connection with the exchange of those units by the Pre-IPO Common Unitholders, which resulted in an increase of $46.0 million and $48.2 in the tax basis of the net assets of Enfusion Ltd. LLC that would be subject to the provisions of the Tax Receivable Agreement in the years ended December 31, 2023, and 2022, respectively.

    As of December 31, 2023 and 2022, the Company has not recorded a liability under the Tax Receivable Agreement related to the tax benefits originating from the Reorganization Transactions, IPO, and subsequent purchase of Common Units, as it is not probable that the Company will realize such tax benefits. To the extent the Company had determined that it would have been able to realize the tax benefits associated with the basis adjustments, it would have recorded a liability under the Tax Receivable Agreement of $96.5 million and $83.2 million as of December 31, 2023, and 2022, respectively.

    The amounts payable under the Tax Receivable Agreement will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future. Should the Company determine that the Tax Receivable Agreement liability be considered probable at a future date based on new information, any changes will be recorded at that time.

    XML 47 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Related Party Transactions
    12 Months Ended
    Dec. 31, 2023
    Related Party Transactions  
    Related Party Transactions

    Note 14   Related Party Transactions

    Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial or operating decisions. Since transactions with related parties may raise potential or actual conflicts of interest between the related party and the Company, upon the completion of the IPO, the Company implemented a related party transaction policy that requires related party transactions to be reviewed and approved by its nominating and corporate governance committee.

    On June 15, 2023, the Company sold 1.2 million shares of Class A common stock to FTV Investment Holdings, L.P. (“FTV Holdings”) and an affiliate in a private placement, at a per share purchase price equal to the average of the closing price of the Class A common stock over the 20 trading days preceding the transaction, which was approximately $8.12 per share. Total net proceeds of the transactions were $9.7 million. Equity issuance costs were immaterial. FTV IV, L.P. (“FTV Fund IV”) beneficially owns more than 5% of the Company’s issued and outstanding Class A common stock. Bradford Bernstein, a member of the Company’s Board of Directors, is a managing partner of FTV Capital and, along with other members of FTV Capital, indirectly shares voting and dispositive power with regard to the shares directly held by FTV Holdings and FTV Fund IV, respectively.

    In the first quarter of 2023, the Company received approximately $1.5 million from the U.S. Treasury in the form of a tax refund owed to FTV Enfusion Holdings, Inc. (“FTV Enfusion”), which prior to the Company’s initial public offering in 2021 was a Blocker Company through which FTV Fund IV held its equity interests in Enfusion Ltd. LLC. The refund was generated due to overpayments by FTV Enfusion for U.S. federal income taxes associated with FTV Enfusion’s direct ownership of Enfusion Ltd. LLC for the fiscal years ended December 31, 2017 to December 31, 2020. The Company

    obtained the right to this refund as a result of the merger of FTV Enfusion with and into one of the Company’s subsidiaries as part of the Reorganization Transactions (which did not take into account the value of the tax refund). On June 27, 2023, the Company distributed approximately $1.5 million (the amount of the refund) to FTV Fund IV.

    XML 48 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Subsequent Events
    12 Months Ended
    Dec. 31, 2023
    Subsequent Events  
    Subsequent Events

    Note 15   Subsequent Events

    Share Exchange

    On January 4, 2024, a Pre-IPO Common Unitholder delivered an exchange notice pursuant to Article XII of the LLC Operating Agreement. Pursuant to the terms of the LLC Operating Agreement, on January 11, 2024, the Pre-IPO Common Unitholder surrendered 1,000,000 Common Units and an equal number of shares of Class B common stock. In connection therewith, the Company issued 1,000,000 shares of Class A common stock to such Pre-IPO Common Unitholder, canceled an equal number of shares of Class B common stock, and received an equal number of Common Units, increasing the Company’s ownership of Common Units by 1,000,000.

    XML 49 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Summary of Significant Accounting Policies (Policies)
    12 Months Ended
    Dec. 31, 2023
    Summary of Significant Accounting Policies  
    Principles of Consolidation

    Principles of Consolidation

    These statements have been prepared in conformity with U.S. GAAP. All intercompany balances and transactions are eliminated in consolidation.

    Use of Estimates

    Use of Estimates

    The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. We base our estimates on historical experience and various other assumptions believed to be reasonable. These estimates and assumptions include, but are not limited to, judgments affecting the measurement of the payable to related parties pursuant to the Tax Receivable Agreement, amortization periods, certain assumptions used in the valuation of stock-based compensation, assessment of the allowance for credit losses, and accounting for income taxes and assessment of valuation allowances. Actual results could differ from those estimates.

    The Company’s results can also be affected by economic, political, legislative, regulatory, and legal actions, including but not limited to health epidemics and pandemics and the resulting economic impact. Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, and government fiscal policies can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities and carries various levels of insurance, the Company could be affected by civil, criminal, regulatory, or administrative actions, claims, or proceedings.

    Reclassifications

    Reclassifications

    Certain amounts in prior periods have been reclassified to conform with the current period presentation.

    Segments

    Segments

    Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the CODM. While the Company operates in multiple countries, the Company’s business operates as one operating segment because most of the Company’s service offerings are delivered and supported on a global basis, the Company’s service offerings are deployed in a nearly identical way, and the Company’s CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.

    Cash and Cash Equivalents

    Cash and Cash Equivalents

    The Company considers all highly liquid investments purchased with an initial maturity date of three months or less to be cash equivalents. Funds held as investments in money market funds are included within cash and cash equivalents. As of December 31, 2023 and 2022, respectively, the Company had $30.0 million and $50.0 million, respectively, invested in money market accounts.

    Accounts Receivable

    Accounts Receivable

    Accounts receivable includes billed and unbilled receivables, net of allowances, including the allowance for credit losses. Billed accounts receivable are initially recorded upon the invoicing to clients with payment due within 30 days. Unbilled accounts receivable represent revenue recognized on contracts for which the timing of invoicing to clients differs from the timing of revenue recognition. Unbilled accounts receivable was $2.4 million and $2.0 million as of December 31, 2023 and 2022, respectively. Contract assets included in unbilled accounts receivable were $1.7 million and $1.5 million as of December 31, 2023 and 2022, respectively.

    The Company maintains an allowance for credit losses at an amount estimated to be sufficient to provide adequate protection against losses resulting from extending credit to its clients. The Company regularly determines the adequacy of the allowance based on its assessment of the collectability of the accounts receivable by considering the age of each outstanding invoice, the collection history of each client, an evaluation of the current expected risk of credit loss, and other client-specific factors with a bearing on receivables. The Company assesses collectability by reviewing accounts receivable on an aggregated basis where similar characteristics exist and on an individual basis for specific clients with historical collectability issues or known financial difficulties. Increases to the allowance are recognized as a charge to credit losses included in general and administrative expenses in the consolidated statements of operations. Accounts receivable deemed uncollectible are charged against the allowance for credit losses when identified.

    The Company's allowance for credit losses is as follows (in thousands):

    Balance at December 31, 2021

    $

    791

    Changes to the provision

     

    1,158

    Accounts written off, net of recoveries

    (724)

    Balance at December 31, 2022

    1,225

    Adoption of ASU 2016-13

    149

    Changes to the provision

    705

    Accounts written off, net of recoveries

    (987)

    Balance at December 31, 2023

    $

    1,092

    Leases

    Leases

    The Company determines at contract inception if the contract is or contains a lease. The Company records right-of-use (“ROU”) assets and lease obligations for its leases, which are initially recognized at the commencement date based on the discounted future lease payments over the term of the lease. As the rates implicit in the Company’s leases are not readily determinable, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date. Incremental borrowing rates for domestic currency leases are calculated using the Company’s credit adjusted risk-free rate. Foreign-denominated lease payments are discounted using country-specific treasury rates adjusted for credit spread.

    The Company does not record an ROU asset and lease obligation for its short-term leases, which are defined as leases with an initial term of 12 months or less. The Company has elected not to separate lease and non-lease components.

    Property and Equipment, Net

    Property, Equipment, and Software, Net

    Property, equipment, and software is stated at historical cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the individual assets, except for leasehold improvements, which are depreciated over the shorter of the estimated useful life of the asset or the underlying lease term. Also included in property, equipment, and software are capitalized costs of software developed for internal use. The useful lives of property, equipment, and software are as follows:

    Property, Equipment, and Software Asset Type

    Estimated Useful Lives

    Software development costs

    3 years

    Computers

    3 years

    Furniture, fixtures, and equipment

    5 years

    Leasehold improvements

    Shorter of estimated economic useful life or remaining lease term

    Maintenance and repairs are expensed as incurred. Upon retirement or disposition, the cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is included in operating income.

    Software Development Costs

    Software Development Costs

    The Company capitalizes certain qualifying costs, including stock-based compensation expense, incurred in the development of and major enhancements to the Company's cloud-based software as a service (“SaaS”) platform and related software products. Capitalized software development costs related to the Company's platform are amortized on a straight-line basis over the developed software's estimated useful life of three years, and the related amortization expense is recorded in cost of revenues within our consolidated statements of operations.

    Costs incurred in the preliminary stages of development are expensed as incurred. Costs incurred for post-implementation activities, training, maintenance, and minor upgrades and enhancements without adding additional functionality are expensed as incurred within technology and development expense in our consolidated statements of operations.

    Impairment of Long-Lived Assets

    Impairment of Long-Lived Assets

    The Company evaluates the carrying value of long-lived assets in accordance with the accounting standard for impairment or disposal of long-lived assets, which requires recognition of impairment of long-lived assets in the event that circumstances indicate impairment may have occurred and when the net carrying value of such asset group exceeds the future undiscounted cash flows attributed to such asset group. The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. No impairment of long-lived assets occurred during the years ended December 31, 2023, 2022, and 2021.

    Fair Value of Financial Instruments

    Fair Value of Financial Instruments

    Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the exit price) in an orderly transaction between market participants at the measurement date. Accounting standards establish a hierarchal framework, which prioritizes and ranks the level of market price observability used in measuring assets and liabilities at fair value. Market price observability is impacted by a number of factors, including the type of investment and the characteristics specific to the investment. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on the best information available. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories:

    Level 1

    Inputs are quoted prices for identical instruments in active markets;

    Level 2

    Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets;

    Level 3

    Inputs are valuations derived from valuation techniques in which one or more significant inputs are unobservable.

    Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

    The Company has investments in money market accounts, which are included in cash and cash equivalents on the consolidated balance sheets. Fair value inputs for these investments are considered Level 1 measurements within the fair value hierarchy, as money market account fair values are known and observable through daily published floating net asset values.

    Annual Bonus Incentive Plan

    Annual Bonus Incentive Plan

    Annual bonuses payable by the Company to its officers and employees may be funded through a combination of cash and equity, at the discretion of the Company’s Compensation Committee. We accrue and record the related corporate bonus amounts payable in cash in the period in which it is earned by the recipient. The Compensation Committee may make incentive awards based on such terms, conditions, and criteria as it considers appropriate. Stock awards issued in connection with these bonuses may or may not be subject to additional vesting conditions at the time of grant, which are subject to determination by the Compensation Committee.

    For annual bonuses settled in cash, the Company accrues over the course of the year the annual bonuses earned by employees but paid in the following year. For annual bonuses settled in stock, in accordance with ASC 718, Stock Compensation, the Company views the authorization of the award to be the date that all approval requirements are completed (e.g., action by the Compensation Committee approving the awards and determining the number of equity instruments to be issued), and therefore, the service inception to begin at grant date. As such, stock-based compensation cost related to the Annual Bonus Incentive Plan is recognized on the grant date to the extent such awards are not subject to additional vesting conditions.

    Revenue Recognition

    Revenue Recognition

    The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. The Company derives its revenues primarily from fees for platform subscriptions and managed services provided to clients. Revenues are recognized when control of these services are transferred to the Company’s clients in an amount that reflects the consideration the Company expects to be entitled to in exchange for these services. Revenues are recognized net of taxes that will be remitted to governmental agencies applicable to service contracts. Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework:

    ● Identification of the contract, or contracts, with a client;

    ● Identification of the performance obligation in the contract;

    ● Determination of transaction price;

    ● Allocation of the transaction price to the performance obligations in the contract; and

    ● Recognition of revenue when, or as, performance obligations are satisfied.

    Platform subscriptions revenues

    Platform subscriptions revenues consist primarily of user fees to provide our clients access to our cloud-based solution. Fees consider various components such as number of users, connectivity, trading volume, data usage and product coverage. Platform subscriptions clients do not have the right to take possession of the platform’s software and do not have any general return right. Platform subscriptions revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date the client gains access to the platform. Installed payments are generally invoiced at the end of each calendar month during the subscription term. There is no financing available.

    Managed services revenues

    Managed services revenues primarily consist of client-selected middle- and back-office, technology-powered services. Managed services revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the contract effective date. Clients are invoiced a set fee for managed services typically at the end of each month. Generally, invoices have a 30-day payment period in accordance with the associated contract. There is no financing available.

    Other revenues

    Other revenues consist of non-subscription-based revenues primarily data conversion. The Company recognizes revenues as these services are performed with invoicing generally occurring at the end of each month.

    Service contracts with multiple performance obligations

    Certain of the Company’s contracts provide for customers to be charged a fee for implementation services. In determining whether the implementation services, which frequently include configuration and/or interfacing, customer reporting, customizing user permissions and acceptance testing, end-user training, and establishing connections with third-party interfaces, are distinct from its platform subscription services, the Company considers, in addition to their complexity and level of customization, that these services are integral in delivering the customer desired output and are necessary for the customer to access and begin to use the hosted application. The implementation provider must be intimately familiar with its platform to effectively execute the customization required, and no other entities have access to the source code. The Company has concluded that the implementation services in its service contracts with multiple performance obligations are not distinct, and therefore, the Company recognizes fees for implementation services ratably over the non-cancelable term of the contract.

    Remaining performance obligations

    For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of December 31, 2023 was $29.1 million and is expected to be recognized based on the below schedule (in thousands).

    Remaining Performance Obligation

    December 31, 2023

    2024

    $

    18,227

    2025

     

    8,845

    2026

     

    1,986

    2027

     

    64

    2028

    Total

    $

    29,122

    Disaggregation of revenue

    The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following table (in thousands):

    Year Ended December 31, 

    2023

    2022

    2021

    Geographic Region

        

    Amount

        

    Percent

        

    Amount

        

    Percent

    Amount

        

    Percent

    Americas*

    $

    108,506

     

    62.1

    %  

    $

    95,122

     

    63.3

    %

    $

    72,994

     

    65.3

    %

    Europe, Middle East, and Africa (EMEA)

     

    26,122

     

    15.0

    %  

     

    20,051

     

    13.3

    %

     

    13,491

     

    12.1

    %

    Asia Pacific (APAC)

     

    39,907

     

    22.9

    %  

     

    35,176

     

    23.4

    %

     

    25,215

     

    22.6

    %

    Total revenues

    $

    174,535

     

    100.0

    %  

    $

    150,349

     

    100.0

    %

    $

    111,700

     

    100.0

    %

    *

    Includes revenues from clients based in the United States (country of domicile) of $104.5 million, $92.8 million, and $71.9 million for the years ended December 31, 2023, 2022, and 2021, respectively.

    Deferred commissions

    The Company pays sales commissions for initial contracts and expansions of existing contracts with customers. These commissions earned by certain of its sales force are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions paid where the amortization period is one year or less are expensed as incurred. All other sales commissions are deferred and then amortized on a straight-line basis over a period of benefit that the Company has determined to be three years. The Company determined the period of benefit by taking into consideration

    its standard contract terms and conditions, rate of technological change, and other factors. Amortization expense is included in sales and marketing expenses in the accompanying consolidated statements of operations.

    The balance of deferred commissions as of December 31, 2023 and December 31, 2022 was $3.5 million and $2.8 million, respectively, and is included in other assets on the consolidated balance sheets. The amount of amortization expense recognized during the years ended December 31, 2023, 2022, and 2021 was $1.4 million, $845 thousand, and $228 thousand, respectively.

    Cost of Revenues

    Cost of Revenues

    Cost of revenues consists primarily of personnel-related costs associated with the delivery of the Company’s software and services, including base salaries, bonuses, employee benefits and related costs. Additionally, cost of revenues includes amortization of capitalized software development costs, allocated overhead and certain direct data and hosting costs.

    Technology and Development

    Technology and Development

    Technology and development expenses consist primarily of employee-related expenses for the Company’s software development. Additional expenses include costs related to the development, maintenance, quality assurance and testing of new technologies, and ongoing refinement of the Company’s existing solutions. Technology and development expenses, other than software development costs qualifying for capitalization, including costs associated with preliminary project stage activities, training, maintenance, and all other post-implementation stage activities are expensed as incurred.

    Advertising Costs

    Advertising Costs

    The Company expenses advertising costs as incurred. Advertising costs incurred were approximately $1.5 million, $1.5 million, and $1.2 million during the years ended December 31, 2023, 2022, and 2021, respectively.

    Stock-Based Compensation

    Stock-Based Compensation

    In October 2021, in connection with the IPO, the Company adopted the 2021 Stock Option and Incentive Plan, (the “2021 Plan”). The 2021 Plan allows the Company’s Compensation Committee to make incentive awards to its officers, employees, directors, and service providers. The Company also adopted the 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The Company measures stock-based compensation expense for its share-based payment awards at fair value on the grant date. The fair value of share-based payment awards is determined using the fair market value of the underlying Class A common stock on the date of grant. The Company applied a discount for lack of marketability, estimated using the Finnerty Model, to the fair value of awards with post-vesting restrictions, which includes the vested shares of Class A common stock and the Contingently Issuable Shares (as defined below) issued on the IPO effectiveness date (as defined below).

    For restricted stock units (“RSUs”) for which vesting is subject to the achievement of a market condition, the Company determines the fair value of these RSUs using the Monte Carlo method. The Monte Carlo simulations used to estimate the fair value include subjective assumptions, including the fair value of the underlying common stock, expected volatility of the price of the Company’s common stock, risk-free interest rate, expected dividend yield of common stock, and the Company’s cost of equity capital.

    The Company records forfeitures as they occur. The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statements of operations based on the estimated fair value of those awards on the grant date or reporting date, if required to be remeasured, and amortized on a straight-line basis over the requisite service period.

    Income (Loss) Per Share

    Income (Loss) Per Share

    Income (loss) per share is computed by dividing net income (loss) attributable to the Company by the number of weighted average shares of Class A common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income (loss) attributable to the Company by the number of weighted-average shares of Class A common stock outstanding during the period after adjusting for the impact of securities that would have a dilutive effect on income (loss) per share. See Note 12, Income (Loss) Per Class A Common Share, for further discussion.

    All income (loss) for the period prior to the IPO were entirely allocable to Enfusion Ltd. LLC. and its historic non-controlling interest. Due to the impact of the Reorganization Transactions, the Company’s capital structure for the pre- and post-IPO periods is not comparable. As a result, the presentation of income (loss) per share for the periods prior to the IPO and Reorganizational Transactions is not meaningful and only income (loss) per share for the period subsequent to the IPO and Reorganizational Transactions is presented herein.

    Non-controlling interest

    Non-Controlling Interest

    Non-controlling interests represent the portion of profit or loss, net assets, and comprehensive income (loss) of its consolidated subsidiaries that are not allocable to the Company based on its percentage of ownership of such entities. As noted above, in October of 2021, Enfusion US 1, Inc., a newly-formed wholly owned subsidiary of Enfusion, Inc., became the sole managing member of Enfusion Ltd. LLC in connection with the Reorganization Transactions. As of December 31, 2023, the Company holds approximately 69.3% of the outstanding Common Units of Enfusion Ltd. LLC, and approximately 30.7% of the outstanding Common Units of Enfusion Ltd. LLC are held by Pre-IPO Common Unitholders. Therefore, the Company reports non-controlling interests based on Common Units of Enfusion Ltd. LLC held by the Pre-IPO Common Unitholders on its consolidated balance sheet as of December 31, 2023. Income or loss attributed to the non-controlling interest in Enfusion Ltd. LLC is based on the Common Units outstanding during the period for which the income or loss is generated and is presented on the consolidated statements of operations and consolidated statements of comprehensive income (loss).

    Income Taxes

    Income Taxes

    The Company accounts for income taxes under the asset and liability method, and deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and deferred tax liabilities is recognized in income in the period that includes the enactment date.

    The Company recognizes deferred tax assets to the extent that it is believed that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations. A valuation allowance is provided if it is determined that it is more likely than not that the deferred tax asset will not be realized.

    The Company evaluates and accounts for uncertain tax positions using a two-step approach. Recognition (step one) occurs when the Company concludes that a tax position, based solely on its technical merits, is more-likely-than-not to be sustainable upon examination. Measurement (step two) determines the amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. Derecognition of a tax position that was previously recognized would occur when the Company subsequently determines that a tax position no longer meets the more-likely-than-not threshold of being sustained. The Company records interest (and penalties where applicable), net of any applicable related income tax benefit, on potential income tax contingencies as a component of income tax expense in the consolidated statements of operations.

    Tax Receivable Agreement (TRA)

    Tax Receivable Agreement (TRA)

    The Company accounts for amounts payable under the Tax Receivable Agreement in accordance with ASC 450, Contingencies. The amounts payable under the Tax Receivable Agreement will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future. Actual tax benefits realized by the Company may differ from tax benefits calculated under the Tax Receivable Agreement as a result of the use of certain assumptions in the agreement. Any such changes in these factors or changes in the Company’s determination of the need for a valuation allowance related to the tax benefits acquired under the Tax Receivable Agreement could adjust the Tax Receivable Agreement liabilities recognized on the consolidated balance sheets. Subsequent changes in the Tax Receivable Agreement liabilities between reporting periods, as well as any interest accrued on the Tax Receivable Agreement between the Company's annual tax filing date and the Tax Receivable Agreement payment date, are recognized in the consolidated statements of operations. As of December 31, 2023 and 2022, the Company has not recorded a liability under the Tax Receivable Agreement.

    Concentration of Risk

    Concentration of Risk

    Deposits with Financial Institutions

    The Company has concentrated its credit risk for cash by maintaining deposits in several financial institutions, which may at times exceed amounts covered by insurance provided by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk related to cash.

    Accounts Receivable

    As of December 31, 2023, the Company had one individual client that represented 10% or more of accounts receivables. For the years ended December 31, 2023, 2022, and 2021, no individual client represented more than 10% of the Company’s total revenues.

    Translation of Foreign Currencies

    Translation of Foreign Currencies

    Assets and liabilities denominated in the functional currency of the Company’s international subsidiaries are translated to its reporting currency using the exchange rates in effect at the balance sheet date. Results from operations are translated using the average exchange rates prevailing throughout the year. The effects of exchange rate fluctuations on translating foreign currency assets and liabilities into U.S. dollars are accumulated as part of the foreign currency translation adjustment in accumulated other comprehensive loss in the consolidated balance sheets.

    Foreign currency balances for monetary assets and liabilities are remeasured into the entity’s functional currency at the balance sheet date, and fluctuations in value are recorded within other income (expense) in the consolidated statements of operations.

    Recently Adopted Pronouncements/Recent Accounting Pronouncements Not Yet Adopted

    Recently Adopted Accounting Pronouncements

    In June 2016, the FASB issued ASU 2016-13 and ASU 2018-19, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU No. 2016-13”), which requires that a financial asset (or a group of financial assets) measured at an amortized cost basis be presented at the net amount expected to be collected. This approach to estimating credit losses applies to most financial assets measured at amortized cost and certain other instruments, including but not limited to, trade and other receivables. The Company adopted this guidance effective January 1, 2023 and made changes to its accounting policies related to credit loss calculations, including the consideration of forecasted economic data and the pooling of financial assets with similar risk profiles. The Company adopted the new allowance for credit losses accounting standard on January 1, 2023 by means of a cumulative-effect adjustment, where it

    recognized the cumulative effect of initially applying the guidance as a $149 thousand addition to its existing reserve with an offsetting adjustment to accumulated deficit.

    Recent Accounting Pronouncements Not Yet Adopted

    In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU No. 2023-07”), to expand the annual and interim disclosure requirements for reportable segments, including public entities with a single reportable segment, primarily through enhanced disclosures about significant segment expenses. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this standard.

    In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topics 740): Improvements to Income Tax Disclosures (“ASU No. 2023-09”), to expand the disclosures in an entity’s income tax rate reconciliation table and income taxes paid both in U.S. and foreign jurisdictions. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this standard.

    XML 50 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Summary of Significant Accounting Policies (Tables)
    12 Months Ended
    Dec. 31, 2023
    Summary of Significant Accounting Policies  
    Schedule of accounts receivable allowance for credit loss

    The Company's allowance for credit losses is as follows (in thousands):

    Balance at December 31, 2021

    $

    791

    Changes to the provision

     

    1,158

    Accounts written off, net of recoveries

    (724)

    Balance at December 31, 2022

    1,225

    Adoption of ASU 2016-13

    149

    Changes to the provision

    705

    Accounts written off, net of recoveries

    (987)

    Balance at December 31, 2023

    $

    1,092

    Schedule of property, plant and equipment useful life

    Property, Equipment, and Software Asset Type

    Estimated Useful Lives

    Software development costs

    3 years

    Computers

    3 years

    Furniture, fixtures, and equipment

    5 years

    Leasehold improvements

    Shorter of estimated economic useful life or remaining lease term

    Schedule of remaining performance obligation

    For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of December 31, 2023 was $29.1 million and is expected to be recognized based on the below schedule (in thousands).

    Remaining Performance Obligation

    December 31, 2023

    2024

    $

    18,227

    2025

     

    8,845

    2026

     

    1,986

    2027

     

    64

    2028

    Total

    $

    29,122

    Schedule of total net revenues by geographic region

    The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following table (in thousands):

    Year Ended December 31, 

    2023

    2022

    2021

    Geographic Region

        

    Amount

        

    Percent

        

    Amount

        

    Percent

    Amount

        

    Percent

    Americas*

    $

    108,506

     

    62.1

    %  

    $

    95,122

     

    63.3

    %

    $

    72,994

     

    65.3

    %

    Europe, Middle East, and Africa (EMEA)

     

    26,122

     

    15.0

    %  

     

    20,051

     

    13.3

    %

     

    13,491

     

    12.1

    %

    Asia Pacific (APAC)

     

    39,907

     

    22.9

    %  

     

    35,176

     

    23.4

    %

     

    25,215

     

    22.6

    %

    Total revenues

    $

    174,535

     

    100.0

    %  

    $

    150,349

     

    100.0

    %

    $

    111,700

     

    100.0

    %

    *

    Includes revenues from clients based in the United States (country of domicile) of $104.5 million, $92.8 million, and $71.9 million for the years ended December 31, 2023, 2022, and 2021, respectively.

    XML 51 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Property, Equipment, and Software, Net (Tables)
    12 Months Ended
    Dec. 31, 2023
    Property, Equipment, and Software, Net  
    Schedule of Property, equipment, and software, net

    Property, equipment, and software, net consists of the following (in thousands):

    December 31, 

    2023

        

    2022

    Computer equipment

    $

    17,384

    $

    17,496

    Software development costs

     

    15,842

     

    9,406

    Leasehold improvements

     

    1,668

     

    1,831

    Furniture and fixtures

     

    137

     

    433

    Total property, equipment, and software, cost

     

    35,031

     

    29,166

    Less accumulated depreciation and amortization

     

    (16,717)

     

    (13,407)

    Total property, equipment, and software, net

    $

    18,314

    $

    15,759

    XML 52 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Accrued Expenses and Other Current Liabilities (Tables)
    12 Months Ended
    Dec. 31, 2023
    Accrued Expenses and Other Current Liabilities  
    Schedule of accrued expenses and other current liabilities

    Accrued expenses and other current liabilities consisted of the following (in thousands):

    December 31, 

    2023

        

    2022

    Accrued compensation

    $

    10,058

    $

    10,268

    Accrued expenses and other

     

    1,385

     

    1,112

    Accrued taxes

     

    2,398

     

    285

    Total accrued expenses and other current liabilities

    $

    13,841

    $

    11,665

    XML 53 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Leases (Tables)
    12 Months Ended
    Dec. 31, 2023
    Leases  
    Schedule of lease commitments

    Amount

    2024

    5,197

    2025

    4,198

    2026

    3,229

    2027

    3,253

    2028

    1,671

    Thereafter

    654

    Total lease commitments

    $

    18,202

    Less: Interest

    (2,765)

    Present value of lease liabilities

    $

    15,437

    Schedule of components of operating lease cost

    December 31, 

    2023

    2022

    Operating lease cost

    $

    6,882

    $

    5,053

    Variable lease cost

    835

    828

    Short-term lease cost

    114

    Total lease cost

    $

    7,831

    $

    5,881

    Schedule of weighted-average remaining lease terms and discount rates

    December 31, 

    2023

    2022

    Weighted-average remaining lease term - operating leases

    3.80 years

    1.84 years

    Weighted-average discount rate - operating leases

    7.80%

    4.43%

    XML 54 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Management Incentive Plan and Stock-Based Compensation (Tables)
    12 Months Ended
    Dec. 31, 2023
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
    Schedule of stock compensation expense

    Year Ended December 31, 

    (in thousands)

    2023

    2022

    2021

    Cost of revenues

    $

    950

    $

    1,421

    $

    377

    General and administrative

    5,635

    14,130

    112,829

    Sales and marketing

    (984)

    5,875

    36,312

    Technology and development

    1,857

    3,567

    140,285

    Total stock-based compensation expense

    $

    7,458

    $

    24,993

    $

    289,803

    Schedule of share-based payment award activity

       

    IPO Vested Class A Common Stock, Contingently Issuable Shares and RSUs

    Options

    Number of Units

       

    Weighted-Average Grant-Date Fair Value

       

    Number of Options

       

    Weighted-Average Exercise Price

    Weighted-Average Remaining Contractual Term (in years)

    Outstanding as of December 31, 2022

    20,224,452

    $

    15.15

    44,000

    9.86

    9.46

    Vested as of December 31, 2022

    17,225,377

    -

    -

    Unvested as of December 31, 2022

    2,999,075

    44,000

    9.86

    Granted during the period

    1,925,762

    $

    8.49

    71,004

    11.06

    Forfeited during the period

    (584,178)

    15.32

    (31,474)

    10.15

    Vested and issued during the period (a)

    (18,374,139)

    15.27

    -

    -

    Outstanding as of December 31, 2023 (b)

    3,191,897

    $

    9.61

    83,530

    $

    10.77

    8.89

    (a) Includes shares issued and net settled to satisfy tax withholding obligations.

    (b) December 31, 2023 balance is all unvested.

    Performance-Based Restricted Stock Units ("RSUs")  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
    Schedule of assumptions

    Assumptions

    2023

    2022

    2021

    Fair value of common stock (per share)

    $9.89

    $8.92

    $17.00

    Expected volatility

    41.65%

    53.40%

    48.20%

    Risk-free rate

    4.38%

    3.98%

    1.65%

    Dividend yield

    0.00%

    0.00%

    0.00%

    Cost of equity capital

    14.10%

    13.50%

    11.20%

    Employee Stock Option [Member]  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
    Schedule of assumptions

    Assumptions

    2023

    2022

    Expected volatility

    60.91%

    64.54%

    Expected term of award

    6.5 years

    6.5 years

    Risk-free rate

    3.82%

    3.39%

    Dividend yield

    0.00%

    0.00%

    XML 55 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Net Income (Loss) Per Class A Common Share (Tables)
    12 Months Ended
    Dec. 31, 2023
    Net Income (Loss) Per Class A Common Share  
    Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share

    Year Ended December 31, 

    (in thousands, except per share amounts)

    2023

        

    2022

    2021

    Net income (loss)

    $

    9,253

    $

    (13,263)

    $

    (282,242)

    Less: Net income attributable to Enfusion, Inc. prior to the IPO

    -

    -

    (12,892)

    Less: Net (income) loss attributable to non-controlling interests

    (3,228)

    5,609

    123,925

    Net income (loss) attributable to Enfusion, Inc.

    $

    6,025

    $

    (7,654)

    $

    (171,209)

    Numerator:

    Net income (loss) attributable to Enfusion, Inc.

    $

    6,025

    $

    (7,654)

    $

    (171,209)

    Adjustment to loss attributable to common stockholders

    306

    (954)

    (16,580)

    Numerator for Basic Earnings per Share

    $

    6,331

    $

    (8,608)

    $

    (187,789)

    Adjustment to Income for Dilutive Shares

    2,922

    -

    -

    Numerator for Diluted Earnings per Share

    $

    9,253

    $

    (8,608)

    $

    (187,789)

    Denominator:

    Weighted-average shares of Class A common stock outstanding

    80,828

    67,057

    65,583

    Vested shares of Class A common stock and RSUs

    7,374

    18,336

    17,462

    Weighted-average shares of Class A common stock outstanding--basic

    88,202

    85,393

    83,045

    Add: Dilutive Shares

    41,227

    -

    -

    Weighted-average shares of Class A common stock outstanding--diluted

    129,429

    85,393

    83,045

    Net income (loss) per share of Class A common stock--Basic

    $

    0.07

    $

    (0.10)

    $

    (2.26)

    Net income (loss) per share of Class A common stock--Diluted

    $

    0.07

    $

    (0.10)

    $

    (2.26)

    Schedule of effect of dilutive shares antidilutive

    Year Ended December 31, 

    (in thousands)

    2023

        

    2022

    2021

    Class B common stock

    -

    43,199

    47,471

    Contingently issuable shares of Class A common stock

    -

    -

    1,726

    Restricted stock units

    1,048

    2,999

    2,905

    Stock options

    84

    44

    -

    1,132

    46,242

    52,102

    XML 56 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Income Taxes (Tables)
    12 Months Ended
    Dec. 31, 2023
    Income Taxes  
    Schedule of components of income (loss) before income taxes

    The components of income (loss) before income taxes were as follows (in thousands):

    Year Ended December 31, 

    2023

        

    2022

    2021

    U.S.

    $

    5,503

    $

    (16,201)

    $

    (279,990)

    Foreign

     

    5,981

     

    4,012

     

    (1,673)

    Total

    $

    11,484

    $

    (12,189)

    $

    (281,663)

    Schedule of components of income tax expense (benefit) As a result of the Reorganization Transactions, the Company is now taxed as a corporation and subject to U.S. federal, state, local and foreign taxes. Significant components of income tax expense (benefit) were as follows (in thousands):

    Year Ended December 31, 

    2023

        

    2022

    2021

    Current:

    U.S. Federal

    $

    (5)

    $

    $

    State & Local

    53

    Foreign

    2,190

    1,347

    228

    Total Current Income Tax Expense

    2,238

    1,347

    228

    Deferred:

    U.S. Federal

    State & Local

    Foreign

    (7)

    (273)

    351

    Total Deferred Income Tax Expense (Benefit)

     

    (7)

     

    (273)

     

    351

    Total

    $

    2,231

    $

    1,074

    $

    579

    Schedule of reconciliation of the U.S. statutory income tax rate to our effective income tax rate

    Year Ended December 31, 

    2023

        

    2022

    2021

    At U.S. Federal Statutory Tax Rate

    21.0

    %

    21.0

    %

    21.0

    %

    State Tax, Net of Federal Benefit

    38.9

    %

    3.1

    %

    4.3

    %

    Non-controlling Interest

    (7.3)

    %

    (8.9)

    %

    (9.2)

    %

    Foreign Branch Taxes

    10.9

    %

    (8.2)

    %

    (0.3)

    %

    Stock-Based Compensation

    113.5

    %

    (10.6)

    %

    (2.5)

    %

    Foreign Rate Differential

    0.3

    %

    0.5

    %

    %

    Valuation Allowance

    (168.8)

    %

    50.6

    %

    (14.5)

    %

    Change in Tax Rates

    1.9

    %

    (59.2)

    %

    %

    Return to Provision

    6.5

    %

    4.0

    %

    0.1

    %

    Unrecognized Tax Benefit

    2.1

    %

    %

    %

    Pass-through Loss (Income)

    %

    %

    0.9

    %

    Other

    0.4

    %

    (1.1)

    %

    %

    Total

    19.4

    %

    (8.8)

    %

    (0.2)

    %

    Schedule of components of deferred tax assets and liabilities

    The components of deferred tax assets and liabilities are as follows (in thousands):

    December 31, 

    2023

        

    2022

    Deferred Tax Assets:

    Investment in Enfusion Ltd. LLC

    $

    126,504

    $

    86,117

    Stock-Based Compensation

    1,542

    37,912

    Net Operating Losses

    11,410

    9,358

    Other

    851

    794

    Total Deferred Tax Assets

    140,307

    134,181

    Valuation Allowance

    (140,307)

    (133,689)

    Total Deferred Tax Assets Net of Valuation Allowance

    492

    Deferred Tax Liabilities:

    Property and Equipment

    (70)

    (77)

    Total Deferred Tax Liabilities

     

    (70)

     

    (77)

    Net Deferred Tax Assets

    $

    (70)

    $

    415

    Schedule of valuation allowance for deferred tax assets

    The changes in the Company’s valuation allowance for deferred tax assets were as follows (in thousands):

    Year Ended December 31, 2021

    $

    124,526

    Charged to Income Tax Expense

    (6,163)

    Charged to Stockholders' Equity

     

    15,326

    Year Ended December 31, 2022

    $

    133,689

    Charged to Income Tax Expense

    (19,381)

    Charged to Stockholders' Equity

    25,999

    Year Ended December 31, 2023

    $

    140,307

    Schedule of company's uncertain tax positions

    A summary of the Company’s unrecognized tax benefits are as follows (in thousands):

    Year Ended December 31, 

    2023

        

    2022

    2021

    Beginning balance

    $

    119

    $

    119

    $

    Increases for tax positions related to the current year

    30

    Increases (decreases) for tax positions of prior years

     

    238

     

     

    89

    Expiration of statute of limitations

    (41)

    Ending balance

    $

    316

    $

    119

    $

    119

    Interest and penalties

    128

    65

    65

    XML 57 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Organization and Description of Business (Details)
    12 Months Ended
    Dec. 31, 2023
    subsidiary
    Number of wholly-owned subsidiaries 3
    Enfusion LLC  
    Ownership percentage 69.30%
    XML 58 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Basis of Presentation (Details)
    12 Months Ended
    Dec. 31, 2023
    segment
    Basis of Presentation  
    Number of operating segments 1
    XML 59 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Summary of Significant Accounting Policies - Narrative (Details)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    USD ($)
    customer
    Dec. 31, 2022
    USD ($)
    Dec. 31, 2021
    USD ($)
    Investment in money market accounts. $ 30,000 $ 50,000  
    Payment of fees upon invoice 30 days    
    Unbilled accounts receivable $ 2,400 2,000  
    Contract assets, unbilled accounts receivable 1,700 1,500  
    Impairment of long-lived assets 0 0 $ 0
    Deferred commissions 3,500 2,800  
    Amortization expense 1,400 845 228
    Advertising cost 1,500 1,500 1,200
    Allowance for credit losses 1,092 1,225 $ 791
    Accumulated deficit $ (172,932) $ (178,863)  
    Major Customer | Revenues | Customer Concentration Risk      
    Number of customers 0 0 0
    Major Customer | Accounts Receivable | Customer Concentration Risk      
    Number of customers | customer 1    
    Accounting Standards Update 2016-13 | Cumulative impact of adopting ASU 2016-13      
    Allowance for credit losses   $ 149  
    Accumulated deficit   $ (149)  
    Enfusion LLC      
    Ownership percentage 69.30%    
    Ownership percentage by noncontrolling owners 30.70%    
    XML 60 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Summary of Significant Accounting Policies - Allowances (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Accounts Receivable, Allowance for Credit Loss    
    Beginning balance $ 1,225 $ 791
    Changes to the provision 705 1,158
    Accounts written off, net of recoveries (987) (724)
    Ending balance 1,092 1,225
    Cumulative impact of adopting ASU 2016-13 | Accounting Standards Update 2016-13    
    Accounts Receivable, Allowance for Credit Loss    
    Beginning balance $ 149  
    Ending balance   $ 149
    XML 61 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Summary of Significant Accounting Policies - Useful life of property plant and equipment (Details)
    Dec. 31, 2023
    Software development costs  
    Property, Equipment, and Software, Net  
    Useful life 3 years
    Computers  
    Property, Equipment, and Software, Net  
    Useful life 3 years
    Furniture, fixtures, and equipment  
    Property, Equipment, and Software, Net  
    Useful life 5 years
    Leasehold improvements  
    Property, Equipment, and Software, Net  
    Useful life us-gaap:UsefulLifeTermOfLeaseMember
    XML 62 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Summary of Significant Accounting Policies - Remaining Performance Obligation (Details)
    $ in Thousands
    Dec. 31, 2023
    USD ($)
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction  
    Revenue remaining performance obligation $ 29,122
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01  
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction  
    Revenue remaining performance obligation $ 18,227
    Remaining performance obligation satisfaction period 1 year
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01  
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction  
    Revenue remaining performance obligation $ 8,845
    Remaining performance obligation satisfaction period 1 year
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01  
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction  
    Revenue remaining performance obligation $ 1,986
    Remaining performance obligation satisfaction period 1 year
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01  
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction  
    Revenue remaining performance obligation $ 64
    Remaining performance obligation satisfaction period 1 year
    XML 63 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Summary of Significant Accounting Policies - Disaggregation of revenue (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Disaggregation of Revenue      
    Total revenues $ 174,535 $ 150,349 $ 111,700
    Revenues | Geographic Region      
    Disaggregation of Revenue      
    Total revenues $ 174,535 $ 150,349 $ 111,700
    Total net revenues percent 100.00% 100.00% 100.00%
    Americas* | Revenues | Geographic Region      
    Disaggregation of Revenue      
    Total revenues $ 108,506 $ 95,122 $ 72,994
    Total net revenues percent 62.10% 63.30% 65.30%
    Europe, Middle East, and Africa (EMEA) | Revenues | Geographic Region      
    Disaggregation of Revenue      
    Total revenues $ 26,122 $ 20,051 $ 13,491
    Total net revenues percent 15.00% 13.30% 12.10%
    Asia Pacific (APAC) | Revenues | Geographic Region      
    Disaggregation of Revenue      
    Total revenues $ 39,907 $ 35,176 $ 25,215
    Total net revenues percent 22.90% 23.40% 22.60%
    United States      
    Disaggregation of Revenue      
    Total revenues $ 104,500 $ 92,800 $ 71,900
    XML 64 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Property, Equipment, and Software, Net (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Property, Equipment, and Software, Net    
    Total property, equipment, and software, cost $ 35,031 $ 29,166
    Less accumulated depreciation and amortization (16,717) (13,407)
    Total property, equipment, and software, net 18,314 15,759
    Computer equipment    
    Property, Equipment, and Software, Net    
    Total property, equipment, and software, cost 17,384 17,496
    Software development costs    
    Property, Equipment, and Software, Net    
    Total property, equipment, and software, cost 15,842 9,406
    Leasehold improvements    
    Property, Equipment, and Software, Net    
    Total property, equipment, and software, cost 1,668 1,831
    Furniture and fixtures    
    Property, Equipment, and Software, Net    
    Total property, equipment, and software, cost $ 137 $ 433
    XML 65 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Property, Equipment, and Software, Net- Narrative (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Property, Equipment, and Software, Net      
    Property, equipment, and software, net $ 18,314 $ 15,759  
    Capitalized software development costs 6,400 4,500  
    Depreciation and amortization expense 5,100 3,300 $ 2,400
    Amortization expense related to software development costs 3,400 2,200 $ 1,300
    United States      
    Property, Equipment, and Software, Net      
    Property, equipment, and software, net $ 17,000 $ 13,700  
    XML 66 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Accrued Expenses and Other Current Liabilities (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Accrued Expenses and Other Current Liabilities    
    Accrued compensation $ 10,058 $ 10,268
    Accrued expenses and other 1,385 1,112
    Accrued taxes 2,398 285
    Total accrued expenses and other current liabilities 13,841 11,665
    Accrued compensation includes bonuses due to employees $ 6,400 $ 7,800
    XML 67 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Leases - Narratives (Details) - lease
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Leases    
    Option to renew the lease true  
    Option to terminate the lease true  
    Number of finance leases 0 0
    XML 68 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Leases - Lease Commitments (Details)
    $ in Thousands
    Dec. 31, 2023
    USD ($)
    Leases  
    2024 $ 5,197
    2025 4,198
    2026 3,229
    2027 3,253
    2028 1,671
    Thereafter 654
    Total lease commitments 18,202
    Less: Interest (2,765)
    Present value of lease liabilities $ 15,437
    XML 69 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Leases - Components of Operating Lease Cost (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Leases    
    Operating lease cost $ 6,882 $ 5,053
    Variable lease cost 835 828
    Short-term lease cost 114  
    Total lease cost $ 7,831 $ 5,881
    XML 70 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Leases - Weighted-average remaining lease terms and discount rates (Details)
    Dec. 31, 2023
    Dec. 31, 2022
    Leases    
    Weighted-average remaining lease term (in years) 3 years 9 months 18 days 1 year 10 months 2 days
    Weighted-average discount rate (as percentage) 7.80% 4.43%
    XML 71 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Leases - Operating Leases and Service Agreements (Details)
    $ in Millions
    12 Months Ended
    Dec. 31, 2021
    USD ($)
    Leases  
    Expense related to lease arrangements $ 3.9
    Expense related to service agreements $ 1.1
    XML 72 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Debt - New Credit Agreement (Details) - New Credit Agreement - USD ($)
    12 Months Ended
    Sep. 15, 2023
    Dec. 31, 2023
    Feb. 29, 2024
    Debt      
    Additional borrowing capacity $ 50,000,000.0    
    Minimum balance to be maintained at bank as per agreement $ 5,000,000.0    
    Outstanding borrowings   $ 0  
    Subsequent Event      
    Debt      
    Minimum balance to be maintained at bank as per agreement     $ 5,000,000.0
    Maximum      
    Debt      
    Number of days to establish minimum balance with bank 120 days    
    Senior secured revolving loan facility      
    Debt      
    Maximum borrowing capacity $ 100,000,000.0    
    Percentage of unused commitment fee   0.20%  
    Senior secured revolving loan facility | Minimum      
    Debt      
    Percentage of unused commitment fee 0.20%    
    Senior secured revolving loan facility | Maximum      
    Debt      
    Percentage of unused commitment fee 0.25%    
    Senior secured revolving loan facility | Secured Overnight Financing Rate      
    Debt      
    Basis points added to variable interest rate 0.10%    
    Senior secured revolving loan facility | Secured Overnight Financing Rate | Minimum      
    Debt      
    Interest rate 2.00%    
    Senior secured revolving loan facility | Secured Overnight Financing Rate | Maximum      
    Debt      
    Interest rate 2.75%    
    Senior secured revolving loan facility | Base Rate | Minimum      
    Debt      
    Interest rate 1.00%    
    Senior secured revolving loan facility | Base Rate | Maximum      
    Debt      
    Interest rate 1.75%    
    Senior secured revolving loan facility | Federal funds rate      
    Debt      
    Interest rate 0.50%    
    Senior secured revolving loan facility | One month adjusted term SOFR      
    Debt      
    Interest rate 1.00%    
    Letters of credit      
    Debt      
    Maximum borrowing capacity $ 10,000,000.0    
    Swingline subfacility      
    Debt      
    Maximum borrowing capacity $ 10,000,000.0    
    XML 73 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Debt - Prior Credit Agreement (Details) - USD ($)
    12 Months Ended
    Sep. 15, 2023
    Dec. 31, 2023
    Dec. 31, 2021
    Debt      
    Loss on extinguishment of debt   $ 78,000 $ 1,215,000
    Prior Credit Agreement | Senior secured revolving loan facility      
    Debt      
    Facility terminated $ 5,000,000.0    
    Outstanding borrowings 0    
    Loss on extinguishment of debt $ 78,000    
    XML 74 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Stockholders' Equity (Details)
    $ / shares in Units, $ in Millions
    1 Months Ended
    Aug. 14, 2023
    USD ($)
    $ / shares
    shares
    Aug. 01, 2023
    shares
    Jul. 19, 2023
    shares
    Jun. 15, 2023
    shares
    Mar. 28, 2023
    shares
    Feb. 21, 2023
    shares
    Oct. 31, 2021
    Dec. 31, 2023
    Vote
    $ / shares
    shares
    Dec. 31, 2022
    $ / shares
    shares
    Class of Stock [Line Items]                  
    Preferred stock authorized               100,000,000 100,000,000
    Common units surrendered by Pre-IPO unitholders (in shares)   1,000,000 1,000,000   1,000,000 1,000,000      
    Increase in common units (in shares)   1,000,000 1,000,000   1,000,000 1,000,000      
    Common Class A                  
    Class of Stock [Line Items]                  
    Common stock, shares authorized               1,000,000,000 1,000,000,000
    Number of Voting Rights | Vote               1  
    Issuance of shares   1,000,000 1,000,000   1,000,000 1,000,000      
    Common stock par value (in dollars per share) | $ / shares               $ 0.001 $ 0.001
    Common Class A | Related Party | FTV Investment Holdings                  
    Class of Stock [Line Items]                  
    Issuance of shares       1,200,000          
    Common Class B                  
    Class of Stock [Line Items]                  
    Common stock, shares authorized               150,000,000 150,000,000
    Number of Voting Rights | Vote               1  
    Common stock par value (in dollars per share) | $ / shares               $ 0.001 $ 0.001
    Private placement | Common Class A                  
    Class of Stock [Line Items]                  
    Issuance of shares 1,000,000.0                
    Common stock par value (in dollars per share) | $ / shares $ 0.001                
    Price per share issued | $ / shares $ 7.65                
    Net proceeds from issuance of shares | $ $ 7.6                
    Common Units                  
    Class of Stock [Line Items]                  
    Stock exchange ratio             1,000,000    
    XML 75 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Management Incentive Plan and Stock-Based Compensation - Narratives (Details) - USD ($)
    $ / shares in Units, $ in Thousands
    1 Months Ended 3 Months Ended 12 Months Ended
    Oct. 31, 2021
    Dec. 31, 2023
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Management Incentive Plans          
    Total equity-based compensation     $ 7,458 $ 24,993 $ 289,803
    Capitalized stock compensation to capitalized software development costs     766 600  
    Stocks granted in conjunction with capitalizable activities         0
    Unrecognized stock compensation expense   $ 19,700 $ 19,700    
    Stock based compensation recognition period     2 years    
    Restricted Stock Units          
    Management Incentive Plans          
    Total equity-based compensation     $ 7,300 $ 13,200 $ 4,500
    Vesting period 4 years        
    Employee Stock Option          
    Management Incentive Plans          
    Options granted to employees     71,004 84,000  
    Weighted average grants in period     $ 11.06 $ 9.86  
    Stock options forfeited     31,474 40,000  
    Unrecognized stock compensation expense   $ 351 $ 351    
    Stock based compensation recognition period     2 years    
    Performance-Based Restricted Stock Units ("RSUs")          
    Management Incentive Plans          
    Granted during the period   580,000   250,000  
    Nonvested award option   $ 2,800 $ 2,800    
    Vesting period 10 years        
    Stock based compensation recognition period     2 years    
    Stock Option And Incentive Plan 2021          
    Management Incentive Plans          
    Percentage of Increase in Shares Outstanding Annually 3.00%        
    Common Class A | Share-based Payment Arrangement, Employee          
    Management Incentive Plans          
    Number of shares to be received in exchange for terminated employee agreements 2,047,064        
    Fair value of shares to be issued in exchange of termination of employment agreements $ 31,200        
    Common Class A | IPO          
    Management Incentive Plans          
    Total equity-based compensation $ 237,300        
    Common Class A | IPO | Contingently Issuable Shares          
    Management Incentive Plans          
    Total equity-based compensation     $ 0 $ 10,200 $ 16,700
    Percentage of shares distributed       7.50%  
    Vesting period 1 year        
    Common Class A | Stock Option And Incentive Plan 2021          
    Management Incentive Plans          
    Shares, Authorized 26,400,000        
    XML 76 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Management Incentive Plan and Stock-Based Compensation - Assumptions (Details) - $ / shares
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Performance-Based Restricted Stock Units ("RSUs")      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Fair value of common stock (per share) $ 9.89 $ 8.92 $ 17.00
    Expected volatility 41.65% 53.40% 48.20%
    Risk-free rate 4.38% 3.98% 1.65%
    Dividend yield 0.00% 0.00% 0.00%
    Cost of equity capital 14.10% 13.50% 11.20%
    Employee Stock Option [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Expected volatility 60.91% 64.54%  
    Expected term of award 6 years 6 months 6 years 6 months  
    Risk-free rate 3.82% 3.39%  
    Dividend yield 0.00% 0.00%  
    XML 77 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Management Incentive Plan and Stock-Based Compensation - Stock Compensation (Income) Expense (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Management Incentive Plans      
    Total stock-based compensation expense $ 7,458 $ 24,993 $ 289,803
    Cost of revenues      
    Management Incentive Plans      
    Total stock-based compensation expense 950 1,421 377
    General and administrative      
    Management Incentive Plans      
    Total stock-based compensation expense 5,635 14,130 112,829
    Sales and marketing      
    Management Incentive Plans      
    Total stock-based compensation expense (984) 5,875 36,312
    Technology and development      
    Management Incentive Plans      
    Total stock-based compensation expense $ 1,857 $ 3,567 $ 140,285
    XML 78 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Management Incentive Plan and Stock-Based Compensation - RSUs and Stock Options (Details) - $ / shares
    3 Months Ended 12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2023
    Dec. 31, 2022
    IPO Vested Class A Common Stock and RSUs      
    Restricted Stock Units      
    Beginning balance   20,224,452  
    Granted during the period   1,925,762  
    Forfeited during the period   (584,178)  
    Vested and issued   (18,374,139)  
    Ending balance 3,191,897 3,191,897 20,224,452
    Vested     17,225,377
    Unvested     2,999,075
    Weighted- Average Grant-Date Fair Value      
    Beginning balance   $ 15.15  
    Granted during the period   8.49  
    Forfeited during the period   15.32  
    Vested and issued   15.27  
    Ending Balance $ 9.61 $ 9.61 $ 15.15
    Performance-Based Restricted Stock Units ("RSUs")      
    Restricted Stock Units      
    Granted during the period 580,000   250,000
    Employee Stock Option      
    Options      
    Beginning balance   44,000  
    Granted during the period   71,004 84,000
    Forfeited during the period   (31,474) (40,000)
    Ending balance 83,530 83,530 44,000
    Unvested     44,000
    Weighted Average Exercise Price      
    Outstanding   $ 9.86  
    Granted during the period   11.06 $ 9.86
    Forfeited during the period   10.15  
    Outstanding $ 10.77 $ 10.77 9.86
    Unvested     $ 9.86
    Weighted Average Remaining Contractual Term (in years)   8 years 10 months 20 days 9 years 5 months 15 days
    XML 79 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Employee Benefit Plans (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Employee Benefit Plans      
    Contribution percent of employees 50.00%    
    Contribution percent of match 3.00%    
    Employer discretionary contribution Amount $ 1,000 $ 584 $ 452
    XML 80 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Net Income (Loss) Per Class A Common Share - Basic and Diluted Net Loss Per Share (Details) - USD ($)
    $ / shares in Units, shares in Thousands, $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Net Income (Loss) Per Class A Common Share      
    Net income (loss) $ 9,253 $ (13,263) $ (282,242)
    Less: Net income attributable to Enfusion, Inc. prior to the IPO     (12,892)
    Less: Net (income) loss attributable to non-controlling interests (3,228) 5,609 123,925
    Net loss attributable to Enfusion, Inc. 6,025 (7,654) (171,209)
    Numerator:      
    Net income (loss) attributable to Enfusion, Inc. 6,025 (7,654) (171,209)
    Adjustment to loss attributable to common stockholders 306 (954) (16,580)
    Numerator for Basic Earnings per Share 6,331 (8,608) (187,789)
    Adjustment to Income for Dilutive Shares 2,922    
    Numerator for Diluted Earnings per Share $ 9,253 $ (8,608) $ (187,789)
    Denominator:      
    Weighted-average shares of Class A common stock outstanding 80,828 67,057 65,583
    Vested shares of Class A common stock and RSUs 7,374 18,336 17,462
    Weighted-average shares of Class A common stock outstanding--basic 88,202 85,393 83,045
    Add: Dilutive Shares 41,227    
    Weighted-average shares of Class A common stock outstanding--diluted 129,429 85,393 83,045
    Net income (loss) per share of Class A common stock--Basic $ 0.07 $ (0.10) $ (2.26)
    Net income (loss) per share of Class A common stock--Diluted $ 0.07 $ (0.10) $ (2.26)
    XML 81 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Net Income (Loss) Per Class A Common Share - Dilutive shares (Details) - shares
    shares in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Antidilutive securities amount 1,132 46,242 52,102
    Common Class B      
    Antidilutive securities amount   43,199 47,471
    Contingently issuable shares of Class A common stock      
    Antidilutive securities amount     1,726
    Restricted Stock Units      
    Antidilutive securities amount 1,048 2,999 2,905
    Employee Stock Option      
    Antidilutive securities amount 84 44  
    XML 82 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Income Taxes - Components of income (loss) before income taxes (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Income Taxes      
    U.S. $ 5,503 $ (16,201) $ (279,990)
    Foreign 5,981 4,012 (1,673)
    Income (loss) before income taxes $ 11,484 $ (12,189) $ (281,663)
    XML 83 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Income taxes - Components of income tax expense (benefit) (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Current tax (benefit) expense      
    U.S. Federal $ (5)    
    State & Local 53    
    Foreign 2,190 $ 1,347 $ 228
    Total Current Income Tax Expense 2,238 1,347 228
    Deferred tax (benefit) expense      
    Foreign (7) (273) 351
    Total Deferred Income Tax Expense (Benefit) (7) (273) 351
    Total $ 2,231 $ 1,074 $ 579
    XML 84 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Income taxes - Effective income tax rate reconciliation (Details)
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Income Taxes      
    At U.S. Federal Statutory Tax Rate 21.00% 21.00% 21.00%
    State Tax, Net of Federal Benefit 38.90% 3.10% 4.30%
    Non-controlling Interest (7.30%) (8.90%) (9.20%)
    Foreign Branch Taxes 10.90% (8.20%) (0.30%)
    Stock-Based Compensation 113.50% (10.60%) (2.50%)
    Foreign Rate Differential 0.30% 0.50%  
    Valuation Allowance (168.80%) 50.60% (14.50%)
    Change in Tax Rates 1.90% (59.20%)  
    Return to Provision 6.50% 4.00% 0.10%
    Unrecognized Tax Benefit 2.10%    
    Pass-through Loss (Income)     0.90%
    Other 0.40% (1.10%)  
    Total 19.40% (8.80%) (0.20%)
    XML 85 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Income taxes - Narratives (Details) - USD ($)
    $ in Millions
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Operating loss carryforwards      
    U.S. statutory tax rate (as a percent) 21.00% 21.00% 21.00%
    Effective tax rate (as a percent) 19.40% (8.80%) (0.20%)
    State tax expense (benefit) $ 4.5 $ (0.4) $ (12.1)
    Tax (benefit) expense attributable to noncontrolling interest (0.8) 1.1 25.9
    Tax impact of equity-based compensation 13.0 1.3 2.5
    Net deferred tax (expense) benefit (19.4) (6.2) 40.8
    Foreign income taxes related to pre-tax income of its branch 1.3 1.0 0.6
    Income tax expense (benefit) provision related to tax returns 0.8 (0.5) $ (0.2)
    Change in tax rates $ 0.2 7.2  
    Percentage of Entity's Share of Tax Benefits Under Tax Receivable Agreement 85.00%    
    Percentage of Other's Share of Tax Benefits Under Tax Receivable Agreement 15.00%    
    Liability under the Tax Receivable Agreement $ 96.5 83.2  
    Federal      
    Operating loss carryforwards      
    Net loss carryforward 43.1 33.2  
    State      
    Operating loss carryforwards      
    Net loss carryforward $ 35.6 $ 31.2  
    Enfusion LLC      
    Operating loss carryforwards      
    Number of units purchased in connection with Pre-IPO 4,000,000 4,272,204  
    Tax basis increase in net assets under Tax Receivable Agreement $ 46.0 $ 48.2  
    XML 86 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Income taxes - Components of deferred tax assets and liabilities (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Deferred Tax Assets      
    Investment in Enfusion Ltd. LLC $ 126,504 $ 86,117  
    Stock-Based Compensation 1,542 37,912  
    Net Operating Losses 11,410 9,358  
    Other 851 794  
    Total Deferred Tax Assets 140,307 134,181  
    Valuation Allowance (140,307) (133,689) $ (124,526)
    Total Deferred Tax Assets Net of Valuation Allowance   492  
    Deferred Tax Liabilities      
    Property and Equipment (70) (77)  
    Total Deferred Tax Liabilities (70) (77)  
    Net Deferred Tax Assets   $ 415  
    Net Deferred Tax Liabilities $ (70)    
    XML 87 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Income taxes - Valuation allowance for deferred tax assets (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Valuation allowance for deferred tax assets    
    Balance at the beginning $ 133,689 $ 124,526
    Charged to Income Tax Expense (19,381) (6,163)
    Charged to Stockholders' Equity 25,999 15,326
    Balance at the end $ 140,307 $ 133,689
    XML 88 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Income taxes - Unrecognized deferred taxes (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Uncertain tax positions      
    Beginning balance $ 119 $ 119  
    Increases for tax positions related to the current year   0 $ 30
    Increases (decreases) for tax positions of prior years 238 0 89
    Expiration of statute of limitations (41) 0  
    Ending balance 316 119 119
    Interest and penalties $ 128 $ 65 $ 65
    XML 89 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Related Party Transactions (Details) - USD ($)
    $ / shares in Units, $ in Thousands
    3 Months Ended 12 Months Ended
    Aug. 01, 2023
    Jul. 19, 2023
    Jun. 27, 2023
    Jun. 15, 2023
    Mar. 28, 2023
    Feb. 21, 2023
    Mar. 31, 2023
    Dec. 31, 2023
    Dec. 31, 2021
    Related Party Transaction [Line Items]                  
    Percentage of Entity's Share of Tax Benefits Under Tax Receivable Agreement               85.00%  
    Net proceeds from issuance of common stock               $ 17,322 $ 260,545
    Related Party | FTV Enfusion Holdings, Inc                  
    Related Party Transaction [Line Items]                  
    Proceeds from income tax refunds             $ 1,500    
    Distributions to affiliates     $ 1,500            
    Common Class A                  
    Related Party Transaction [Line Items]                  
    Issuance of shares 1,000,000 1,000,000     1,000,000 1,000,000      
    Common Class A | Related Party | FTV Investment Holdings                  
    Related Party Transaction [Line Items]                  
    Issuance of shares       1,200,000          
    Share price (in dollars per share)       $ 8.12          
    Number of trading days preceding transaction       20 days          
    Net proceeds from issuance of common stock       $ 9,700          
    Common Class A | Related Party | FTV Fund IV                  
    Related Party Transaction [Line Items]                  
    Beneficial ownership percentage       5.00%          
    XML 90 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Subsequent Events (Details) - shares
    Jan. 11, 2024
    Aug. 01, 2023
    Jul. 19, 2023
    Mar. 28, 2023
    Feb. 21, 2023
    Subsequent Event          
    Common units surrendered by Pre-IPO unitholders (in shares)   1,000,000 1,000,000 1,000,000 1,000,000
    Increase in common units (in shares)   1,000,000 1,000,000 1,000,000 1,000,000
    Common Class A          
    Subsequent Event          
    Issuance of shares   1,000,000 1,000,000 1,000,000 1,000,000
    Subsequent Event          
    Subsequent Event          
    Common units surrendered by Pre-IPO unitholders (in shares) 1,000,000        
    Increase in common units (in shares) 1,000,000        
    Subsequent Event | Common Class A          
    Subsequent Event          
    Issuance of shares 1,000,000        
    XML 91 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Pay vs Performance Disclosure - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Pay vs Performance Disclosure      
    Net Income (Loss) $ 6,025 $ (7,654) $ (158,317)
    XML 92 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Insider Trading Arrangements - Oleg Movchan
    3 Months Ended
    Dec. 31, 2023
    shares
    Trading Arrangements, by Individual  
    Material Terms of Trading Arrangement

    Item 9B. Other Information

    Trading Arrangements

    Oleg Movchan, our Chief Executive Officer, adopted a pre-arranged stock trading plan (the “10b5-1 Plan”), dated December 5, 2023, that provides for the sale of up to 400,000 shares of our Class A common stock between March 14, 2024 and December 31, 2024 pursuant to the terms of his 10b5-1 Plan. The 10b5-1 Plan was designed to comply with the guidelines specified in Rule 10b5-1 promulgated under the Exchange Act and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

    Name Oleg Movchan
    Title Chief Executive Officer
    Rule 10b5-1 Arrangement Adopted true
    Adoption Date December 5, 2023
    Termination Date December 31, 2024
    Aggregate Available 400,000
    EXCEL 94 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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a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

      ^*C8'$ZK)S*' 7T(=_"C+\"&J384T237RG373 M7PEK3B 7K7$9F G\BCU]@YDX^LROV8I/'5]B9QS0]!+6T!7G VMZ"?KDBR>< MI$# A0=XVC[9(<_O;D\,?>9@@&#PS!.R!8_&@WD-S\@7L)T&4_ M(OU]?5GO3^4_X;G$IRWMZH!U[UUCEV[%G>'7"=(1W&-7=P36YYT*W_^84ZJ2C,:>HZ[=[K!A#R20L&HO_ M.^3Y&Q+D@IKG,^J]CIO]LU/?S?GP%5-BLT97UK\)/(JT /S37AB)1Y/Q.S'K MS*3$CJSY+QM:J#"$^%>WD?655O@WT",0&JQ.1CW:'_WZIXM<:&46REJ^L.9* M*ON99VK>9R.$\6M0Y>"UZ'J>Z90:]7"H5,_>*8OI#Y'NG8%^#2 =3L-$$XRR@]P>%^C^K$&R@XC$IO&YWZST6EZ>R;#24S7X:55@T18F M\!HE3QL@;%<]'QW'UF:MT="7(U6%&A815L2RSPB3=#N?CJ?[K?%33:^-7TZ# ML!"AGR M2W886:[(]=:UEMC9%$>+A+FI8$3K*2?<.DS@O4Q0$!/L0>2AU7&]SJ1;\(,O M'77KS15%@'N?)' "2R3__=49HF &[I.&O,'HR.?D2S Z\DGY$LS ?4[&!(;L M.?D2&+(GY4LP S>8@1O,\OSZ69[!3-Q@)FZ@1\%,W& F;C 3-YB)^V;KZN1= M.46"B=?/!65ZLK4^43?Q3V@6#C D[X/$A(Y\I/5*V?-\AI?YF:!K]I&/3S

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

        M_@+^^O ^$.]!#DN7]B7>9!H^.EQN%:?/ MIRIDPI-._'K2,%.,5[V&";U6ZG/E7@=16,S$QO.=33/^Z+(7.8*SRI@.7+*I MQ,8KPL!^1K0R7SA5F8!)6# W!W#5M;K"Z.CBP\"$6O$8F,O&84R&%U.=3F$* M2!;'\MI[JDGS,9AK@I1=4S9?%!GV+VYP8!"XV ,< V6;,<8I *N.4#R)0M0M MKDK"X((>F+6$@&TFY/;7.M QB%I M%9=AF<$_>2%@K:'N.L6(3&$B)_41[$Z]]3OU7G:GW@.<>J=IV)XW8M[QG/[W MS:FZ+>:F2_L@F1";]XJ-FT@ [M*(VT:9S<_G===)??8]KR";;HQ-5Y[;2%:9AF*J?;&"+)21!\1Y0?"=S(N& 4>HOT)0JV.7W*84$MXP!Q,Z0"&5[(,'4I=C(=E M;-#D1MP.4!GG?$*X7G)L#(0RYFO(# E_;L"?#G2D?,B3TQNF,'2A-DPGTRP- MP5A#IH8-[):A.Y@SJ#8;78G45X95JE!+_#'([P$IJV(?(2T%9_##I<&R%!3YS6(?X3S']'_G7 M"D7D U')3<62B?ZW20=@4AP\ M(LG-6=?]+%,&9?.X%Q/QATE,X=SA,G%C,^.$ \Q;8#BQ68MD.-(D1F;K<#($ M)OQKH0*S#E>?1/#D+W.*AY E_^*#YSEB'+03=U_D8/\!U$PD#(3FY%C?A=>(Q M$]4?LVG>"%- ",^:/=Q,W\XJE+;-M<)\#L9Y8X)0)1/*8IQFE,[-OJOL8="' M-Q)%"/Q_/ C$LY?SVW5W$L$V?7I.[J(2@XA+B4\>LP+-Z[Q*.V@(MS"=*%%. M#JE.+ MN#6]KO08(J!H;QG*[3FO!&ES0>4YBRK^!GXP+N= E<[@O'H@L<3L[M5E+XR M$'@F*CI)OGM$;MGCEC@)VM:@OC2"H""D9VV._K]*5#FK);)@9G7R5:=R[4Q; M9=/S@?!##V-AOOK18*%UMB6/0.:J)#<9/;#Q7_,V7"98R+"3(ZJ SD[+?19#]QZ/)AU.A;!B<:JO5.IUD_X$Z^ ME&"-SI:9#>RI9M++ 1[Z=FJ&OA-T:W/67]-*GCMNN97D=[G)L_US;-XJ*C.5 MNC4!>D[CX!6)$Y*E<.L"O]:VZ%.4@5#/R.&%&M5H7%?H\)5HY"<)$J7G-#$M MT75OG]T6Z 3L,OH#!6!HQQ@:J966>VY-C<_L6P#DT#F6$XFSARB54._O0 M2&,OKE&$BHW=O4TQ@;:.R1/G5T? M8X O_I'EM+Z_%UUN:I>;NDJ3T^6FKM9\=+FI76YJEYO:Y:9VN:E=;NK*E![^ MZ7TZ@]7WZ2S1&7M#)9WOQ-Z96.L-#H- &(2+]#-.U!<$/^;QK )\,+.Q%Q6T M?A'?;=R FV ZAJJ@0.CC<+ 3,KH9R&!\RE@A,'%NDE$F)S<$9]<%,>R&RZP3 M\0$[>5\(8@_=BID>%I %?Q4EA<7M;) 'Q'.V$*VH8CY0Y]0@O!=!IRSW,B=@ M4(V2O*CJ,]N\:M"'_>/9_F D\,0L"(CA1=;S$%GML'UT^+ MQ&XY-Q(%B@?P9UG4?4JMF;*FX:VM;8$2/YSGYZ<_%<+5/Q7^D O2+>X0HN,4 M*@+&U&6NCBH((N9\D2RW,;F?UW5O0Y3.@9^E6QDS[LF<1V;N8#Q*)Q.$6I); M&$L'=V$0 ^(7'Q,9AE2BQ"TVDK"X+!$T"2-1;5K!C;#?6AUKKF&61R:9A'/E"9I@,TX*:@%V+37^K01>HBV!ASG M0QB)PB_$:]D_L.S+6.%8Y6!HQHBB]L%@J!I6D\G*0"' 5J*H2RHV]C8I+36W M"&%>%- RS];P?(]6_WQ_G8) N/OA?@].P>_7#G]M\4;=8?7LOOHQJT=OK_SJ M.78B!T^E):VE2N)-D,!@+C2]6.J%XQ2AO$T0B<!<<:)WX4!=F%;?#)X M4G=L2/X%40GR6H)-@AA!@5((GN@PQH5#VR!NW@H,8OR9 **1EK'@@S&+0GJ%CJ M?:H62FP,E#1BZE?C@RK\K61$0\0),A$_%ULWEE=H#4>&=)J/>4V!6FX;9FV; M\QD^IX38HV)T_C-7[LA[+$)K#:36.>WM94FKDV&-Z9P J)A^9GQ7;J\035U= MVKC#!*RT MK:WY(6K\0]CH<1K3X6RH)/AE3EX9A[R?8MVYC1]L=PY7?W?VON!:70X-;.65 M@86;*3T9T#*O8<33LMA*AUM3F#R%_%K\=LQ)+[/,**&WW]"4G"59GVQ)^#(M MX$MQ[\ZL8DNEID(XN8/%Y&@KIWD^DETQ6OU=<62,L65%5$X29]_QL>#G/[*# MDS*44W%I*[WN[M):W7T^SS- ^B4&#J9X'M!NLY[16ORP]DJ/MX]K:M8+:@:$ M^F>XO;_#&&,"#QKKJ:W-6.BD)$*]YM4'6#I58UG' T-3&Q(91MJ\TW[O=\2+ MB"1#'9FDZY.$6$U<-E@8:QJ!$/9).C&6OTNS]EN;6^*D&\[8[?F4XW%CW*JX MEBV#.9497"RG8[0@\A*9"[0+4K?.L'LSECI-P7[W&4\X1^8V\[Z )A']ZBN, M]>MP\!T.?I4FI\/!K]9\=#CX#@??X> [''R'@^]P\"N#@W^P7-P@+C/ZT1 M5K.[V+QLM7^:?:TA7^>9(=E^;O6C^#.ZS^A<)=&.3%1F"! I:T0(4%0$<0(.]$; M*HD><.*N)_GD+0.G$?.YJ?CN:'5Z_;;^5:;+;#_M:GD]-3 MNT5Z[S^ MV9N/ER?G9_10][KWAW^*?N_B_ F/A$]GY^9#(#Z=]-^=?^R+TY/#UR>G)_T_Z?+7\//1.W'^1AR=G_4O M#H_Z@?APQ>? M3BY[VS2=7=RZ2X+]_0]W)BY7<_GY>GPXQP,V5RFR,"]4\Q%X/_.Q7@^R@IH& M0@^1%CW/324N-&I/U96*Q;- /$>MYD5U\=__8_?ESL%MDS[X:C#-J/[:LYU- MRHUI3?XPX<8%:A@!4Z.P?RF1WINL,9V("N'8%G#] M.*5\GE#I:5'':SW[E?!A-JVHB6Y>W,J@ 9OW,/*\NMJ!\AE64E +&L#E'DSF MH(6:SL6K-UVFG >T][T?'IJN [_\M)G$;S2N"P/;7,(!,U==U%6]JE=3S O< M^U0CJYRVI'*L8(E$,D5 +8*P*9^DT9BWFL)PR*J_"):2E\ MU[PL,O V1HOSOA_2D-FT!3H'X1J;NVE)(I-(7'%27SV;TV1'#;V>%9W5FV+*]EVI1")6&IEA0#Z9 M:$<;D!3ZR!5_,):"Q8-LZO4"<)9[GTEGEEE&;ZJ54\A- _/]SHOW0[QX=UF, MY[5R2#(&BR>J2I344K!/MC0E\]8CZ!H\0YTC#\4K-J/KO5C1> 8O\<#C4,>8N(I727V5:'/!@F?YECCF( MZ0 H6DDPU,!5$PGX;;4J77/* -:(H^UE*\;9PEGMD52_;'4;^M7GI\*881D7 M-'"A%PJE"B8)BUK*17##?Z5JN3.@1\!@(-VJ*WP MTK1 9IP_26DCTBZM,F,.@X=9$XT5L9%O=HOB?A=%X(XO9,2HYOQ:,@X VJ,, MDY2W&NI)0111[\RW!_*,WN44<0+ %BOD+8_SJ9,KKAR9VV4?QXJW.R:'*_1V M^98[FRC$5,^4:EP3FS9S#=,@=I\%_DZ]KI5T0L]?=8KYWI&]CFI]';O<0\@YAW$O(.8=Q#S#F+>0;:+9\.>/00/(SWM23(E:(-"H""=89_5$^F:8.JEXO<4Y@/ MVJDJAQC?G*E\:JF\O;A="UU%MY >;"'-\2(MQ4^C)9C=4*P00L M2*;P5H+LY*;.*C-;2O1;,X8 )5LEM13288(]E68P;I&AN,M*36YO!!,%Y,?' M?S%H0(VN(_N<&]]03['?D-O1+>,'6\9SA#E+6<95!-S0=I?(AF1U)1-N(C $[G#)@O0$9C)5!%OU?N,P!Y9@34:Y75T(XHRH MH,O,4C\UHCE ^!^0=CSM_HOLL))A5;:A/NK/B:LH$NLKE>_>">',!- 7;&]";465A.Y^1X8D[C;81+O1.NWF-?@J [J6&ZIA0[7MQ:X/H\/ MP[/IR,JR]( $SW%0[9I_)Q!C.I7SL?)+0%$U0SCP!YAX0@?_@.H=DD1GE='I MR 8W-"T'L0YK.B!@OFG<%Z9YA(,F(56EV4[H*E@4!A=KS=@#,53T^C0OC$T+ MXX%'!4QC!I,C&#@L\PW%V MB40V3".DE*5#UWQ M [/7#[+"S7!A[%;DAJ!G-$C,-&+\<1UGDI1TCQ@2V!\ MXO1:A&,XE>$26+JEC,VU40IJBD4VPZQ$<+;#/Q,YPA'%G1I@008=PC^P$'F8 M$R1A@;]P8:;\G&LUR.$$-4."E/;PIRE7P>J9Q[(Y4<4XC>"""J4$AJ,R/HD$ M-EB$Z5;IE,!N@;W>]0ZI9O#*#4MP@-4[$]8A[ :HOC&E/>A"3A#VJ)Y00DH2X]2BKQ0Q$]2V,PK\,R4Q@!A=$#3Z$ MO2N)BAV7*K]58T$H+K"!22SPD-R0K#8<,VAO5/+ O9($#S\I;!KJ..>!F86< M+7]<2#698ZSA5FL^'>!>)MPSW5TIK(BBK%('[31J!(9BDZR!;)$8SRN$8=-T8=,"QX).24=-,FGCX,#M MD!AH'+II@QN=##5'+I@+#OP:SXSSEV!ZL*;@B_4C05FD'RV+#&6S@Z6N$RP5 M";4P1<]3?1H*#@ICN]FQ6 *Y";V4<#BE33$BYF*F36?J(LT79_"#)/2(A?HZ MF,S-!.&<%2LL5EH9UD'SY,CGM)_<'E;UM U7I;I>]I'N]^'7W&5\BLY@Y\>S MAC;D&@9%5?8H5Q1AT&M\/@KM+D=!CTPN!T&]Y%B<+_?V\P65L.X*N1G1=!$YM-RSC"_/FQ>J"GA#G(Y5*-29I$A M@[XAT,$N9X0U8(E*.9(ZR0O/J G$1.<$!E'Y%$F"1O G_,2.&'C\D#UH\Q:@ M-0!O,MV,647>)=.MF4@4^@31K82-8Z.H275D )H&#V7YKMFBS&N<,EB[B^.M M%8J*#2@[T@;Q4GF'B@P6R02& [U7Z742IS*ZN1\>1LLTT.&SK'LXH+ G\-CQ6F9I@6?B%+7"(%5= B9L!]VEDE(6'F5^V MT!T:>>UJPF)R%:*3O>5IUF/ND&0V:"!D=$5V*RTI6*IY^\*T2ZUI>=_$Y^$Y M''#]+QH!/WW;\R!FZ-ZR[F9OD(WAQHNKGS=#75FS2>:NP<>J0Q4I([ M?RY=QRN.KVIX/?$7Q:Y/9E$:<%>HR/6"7G"T!9]-:<;HH:!XD)B:(:G+WZPN8(6)(X6!1C2G&OY@?@^,0L&>AJ;!Y\3!$@9!0 M*&7#KU3IR/L\W@Y,4\!M6/+A6YWAF_52USZZ1V<^H6%3+'N(KGJ0.%*(\()! M\%I8)UHC8D%71X)\G[&F(X+HW&XZ37U)C@T?J41E&#S[##H&B#(G(UFF?T&^ M0XH#R; Z]FL]9K\S7OX4!X8K 3:]S9Y$.S#@+YPFT!^02&16BV/YB&Q++$42 M'Z5K:ZUA/U2$;O0:P)7AJDEJQK+BZ$BA:Y'*WWO&VI]1((1JGH.?O;I1GO=)I[*6[+,2'=?)X?;*F M>'$TSF?M:=B&F0K1C=-4)3*@H"JJSA'JEACP+I'1BI@\K5]_(QYZH,71J6>-+E9)Z44,NC&,T;631-Y07NAZ MC%B 2A6!.Z9!#-1Z2.0WBUM3@][R MJJ<6S8WN3RSK]+(%G2[@W>'BK#[MI-R=7NV_ZQYEP[$:HH+0)Z#0)0.%Q&%( MQ^K>SNY+L7'T ZEW2^L6JJ[P7%1$+.F;#Q9"49"W'MU!+5'-$D?] M8F4"MKBQPT*9H$ 8(&8@CESB0TR 1DI^@#]!&4075D5L.%01:7GH]"+N7Q]/ MA0+%,]J%QH=>W>3I8/)I(-O8%S9U*7]S0).VK?R0<4Z$JQ[:,8HO5(9 M4V:E5#\,+U*:1LM%]PWE'7]B!2OETME%FB5JQIBLC=>;9#_',^>O@B&=IES& MGG%-E)Z0^7D>.#\@80B6!A*GIES!:&".@MC8VW2Y@JC[56D6U<%J?2&&3C G MSX>38(KQH!(?F9?:NX^@>0K7R39; 7ZZ GE/O+N&I.#C2N,V#F;..< _V3[> MU"4OT0&YRYPCL5D2O :TJ[O>;)Z(&7\:?C2'2"7VETG=G'%@L,+K-E(OVB?3 MBK*]QB5H!]4PR%O]O_:.:HC-.H#9:4E&;*$"2J*$W(9X+Z>@[VU!IPR[*2K&["WT MBBMP",4B5Y5!D3+F5S+Z=EL<8Y3#**KH,QBE!%3S3)]U "U^V[S[H4-\\2VC MG.L6.+ M4@81:$;YIB-EDN*0R@=)(4(]I0)]:$IQ8JNJ"HA4#C09"YCT)"1_&1>+N+G6 M KL3>^='[%@\5O@VXXH3_X5C$AJO_B5"E0PA2!*)WA=H9S(BEQ&Y_RG-,TU& MF3* -8*K<&-.$G)$P9=O.< <Y?AVXUD#PP]A,"&EH*$I-U6<<3[76&"[ZM MQU2#\9#_\H;7=8F"#T0EMGHN+HR5P'Z\UX)A3;RM61E<+34[&C+7N0M!-3(S<4XHVFV+ !&%+TI@5:!V2YGN%.$@+*6.*1;<,1/5 M-3?O&^L.N*423%=VIZZLG&NV9^L&@=?ILJ MK#6@1="6,NTX*TB7TBW%77U09&9TK+F+J.Q9&@<&P((0/16#?I[Y,0+"6QIV MQ1BCRWI$Y5DM64:83E%[)'Y6J1%>J%RM/DNYX=KKP\E=_2Z/A&60IHBU'L0R M^4RT$TB%4F'18T7<<#5:"Y!JQ),"_YB['=$%$W&0S#*T%S(.2Z>9,V[=8LU] M;/8-!==8;Y.6QX<*3N,P7&/Q:3-5%5^(9>B!OZAVF:+OF&,E]SA$B(V$L(4( M8:U4>U(CD=]/C8BEA]&DL:T.Y]II&]^\UUU 3'@()5 1'#FAI"G@T\H2^ 3B MLYH1HPWG->2<<"'F$BU 09TRRY]A^+L!5W_S:-::2X@L,]4TQ#2V8 *6B2566OJ4HV52LK'SNTL69:31A59UUF M2D\&99:3GH/(Z"2WF224&>)TJUZ%36X'Z;H/,_&'D#T^^Q[]:95Z MOWHJU(DO^):H1ZTA;GG!4"P+NSQ13,LW..1@IY9.1@"/.8Z@XY)I* M@DZ2],IRE^D071Q[ %QU! M1'ATBI%/$1GV@@957G-L8#'J*_*BT\U>CJ(YVD'=2.1$!0TVN[DQ-H>J(6YK M) G^!6N*:RA;C%*20T^S&JL3*1!\):,4>4J]'GBM,W_"L/*,U@![EGO;XB8+ MHRI4X%9TW[*_U@ ]X4;&>+9O YO!64^$^IAHVAAS &)4J5JVKW&$&$K/Q=HF MACZ2BI64_LH\)JQY8KR;>/$"-O)DWB#8]!D/#<>@8S>LJ:.&V[/VG:.;E%F& M'GYC4579K N(4JNTW:Q.R6W5N?_9W?W?EGPET7O_X?3\SUY/'+Z]Z/4N1?_= M85\ M_^F>$8A/[WK]=[T+<7AZ?M;#2SZ=]-^)<_PN$,J+?NW@OSM^X M.\WP7IHOWO?.^GQK[^S-Q\N3\S-QT3L][./M)V?4O/>'9V?PHOXY/>\U7'36 MN[P,W%_BP^GA&7R&-ESV+P[[O;U?O&[9..[UWL,U9 :]/#CDN\F\@NO%NY.+GH4;X&>R>'IGO3?PA!M-$O'Q M[!B,I$NPXO#WO9W=C<$FWH)/V/WUEY?BX_;E=M5R<7C4#\0A&$5@@4&CR7PB MZTU+L$%\'9N/IX2=X_)N/ M%VP MMN:, (G9W_ *,(]8(.]HT=>OL-!^:-W>O[A$C_#WR>7<,N&M3!/SHY/ M_C@Y!N/T]$]^,=NF%WW/YKS<9!H:M G?NG&JC,W__^/)![0UP?+[B/U"&_"B M=WG^\>*HQ[8C///-R3$V[A";"3U]3YTS,3ZX^.,I+8\W%^?O>=JJ#H#1B#=0 M!\S?,,DX@[8I!_"3K<#E+%Q86G--/?IX<8$+#9]TBJ;O,;Z[=W@!T\W#@T-E M[&9>4W//N#R'23L\.VZQ;+=AYH_.+X[A]:=_>A,%8]@# __P\A+F]]+,59M? M@)8/#%G_I'_:"^@MM!1ZEWV?PS(7EMB+B0U.@]#ZA@(CN&"4P MDGDC?51C^;L1Z!H19\N/017 H#2&7PM-#:P\E/"@,7L_L;J,<$B^B0 MPU&CEUL-ARFZV/GMMC[?H-0QIZ 7>2L.4$JF%95-**23Z)+^S*@\=D:B2SR!8&&DO*I[7,7W-H MH@W+%AC6H9/XM<,(F"\W%_NL-S!FKX;HK19R (MCL^Z5-\[A')['\^.C'YK% MB\C=32YI5YF2ZE[Y#N8K&9Q#/^I,'D(M]*) MBR6821NE:813X.:?^,]*]&6[%JSFFABQY6(-\/MCC^#8Y @R M0F9$(J*Y?"L1S'T5*[C_( &!GPO2/U< ^;JT\$G" M2?B@PZK&:,"TD+;<56"@%S)AZ+6-.O&YS=3*>+ MU<-51)ID>VVL'Y@Q]E@V]%)W]!INZ/E"H?>YN3E9UA3;DYP"-5/% ^YO(?U2 M]F1H&6)..L7AM28#SB1?)7FA9$2R8%%'OMXR3R%%#'/(U.Y$=PJ6QI7.BI)$ MPOQD.*F24[Y"<4LT_>V%4H%IT 6./ /&YUY$79SK.&*FR'&0ZR]BXR7,-2R2 M,5ZG4["&)Q,5X6LHN?, MN;-"+?KL^T'Z]MO7OL4CF=@Y[8K&?%8XMI$T<0:V8< NT0I'2W'^V+@Q2IYDU>CD9@8_,5 M4\(%MSX"N\H#Q2E;1#])OA+CJ8D"NC*D5 \L74V/-)/LCS$]+(T1<9I16%@^AHAT0^TA2G TK*4[ERM2V_+2)+U0X]N 4C-BQY M6@7X* M8ZO]F=(G#55#]'+1\S&=*JZL]Z28J6X"E:A3:B[X1 /E]K;>6PPBQLK!E6I+X/B]U:S&S# *5YE!9>-^^W;X5S MM=+G$,(E2IDXU$0$ZTO,# 9)2^>1"@Q*C2H=4[$O#"!R]45"(W!(A,K L.., M R$5A>A$Z4@TN@$%1M. MFCE4(=)I]1N\R MU;3V?^"$>G;?0B.CUNGG-3I <5Z_V^ ]HYN*3^>\W7AAC+"=E5!.YC!HN+"Q M7CB2>VS/ PO'!"2HQKCIC*WB@[!2JCJX(ZIW7YOCD.OHTB1[FIY/0.O.E5I5 MV:>T[F!]2X_S@(AL;YK&[U00&RA/M\Q9[X8NC/6TX\"])[UNKESJ:NIUO'?4 M$@)\MP6_/Y9:.K;=DH MA4QO6@!=9G#ST.:[YOWD3:L[")SPQR B<\[8.7"LPJ88N:O!Y=$&NX*'I+!$'OS9 M\M?XE:G14(&?\4%.K?YVF\6[$9NY1H@EBV"'4?E )M>= 4LU97V@XO1ZA1RA3XG%C>^Q*:J,,_-]&2JZ=AP[KE>$FO*YT[FR]0 M(Q-2P>=10_?!$O[@NV.5B++OLDR^J\K*8^G\!T>Q:SW<@<@UW"XS#H38[#2. M$%DON+-=74DUC[@ G2:Q:L5-!_9)QBI5/D5$VP[%;#G%E9HX,\Z\F((V>1D7 M$CW5Z7 (SF$ZR_%P<X@SJO5Q@[BW$&<.XAS!W'^62#.#[Q* MUM7N7C\C\[OJ<*U?-X]2JJX9HS6],9AQM4W"%6(%12PT>0V&*-?\\:DG-@,3 MJC>^J@WU!2LPH<6+_B2Z"]U)Y12MYV=_8@P2G)=F]_@G-M0YN=,YY_G[W>5 MY\#^&5A@@#E.*^"P!07S' X5H2,KK#U^ M8_%^S+F(,$W\UB(I;\+5^>Q/C-R[B%21\M_BV-$M40._IN M+H>PO)8T/K0L*&HQL/Q-K' M)&SXJ8URO?C,YA4F!X]>:U2=)BR2<# * _E)R/+&4&1NWD8\>5EPM8N^76 ] MC%/AI\_,5^N0P8592$N 9QY7V4IS8&4O!R,?2V;WQ]+6U4%IX";S"3O>#S;Y M*1W ?'-.DZEC7:^0+ :44E.]64A(I-Q)QTG[""JQ$,;:V1JH@$G-X$ M?%%IF8,]$JD8DX5L,X#4@&\9P7EDW5<&LR4)-C7Y;+Z61O-NJJ-'IA(Y)2>I M6$W'F$^3E),!NU?GVI"74U1I$H26H_BIQ-MTLS24/9PJ-X+PY_=$- M*[&C)7DPX3='W,8E*)=Z!ZH[!@B4(P9.A+W5BK:XHTY3*XV!B)Z5J&SV! M(@4Y;3RB(X4U;(4$929.,[@;&C/6$]S2%$Q AHDJ*U&23^1?Z4!@-W!?8NTB M4#-&2.;@2+);L[,"/P=_9N6)+\&,9A)X(0V/G2A"GN\X-PJ)Z0\::)3=.44U MB4*#6CEF5=O8#9L8C[P*<9IS'J>?1%=1PBQ0:#8I=5)\ /L&7T"2R3(UE$C# M8+&,4T[#1=4+)?)DDD9&V(42(<6@(;)&7]N\)Z#D.9(EKF.U&*5R M-$.I7P/XLX0.X>2 \HFHB%7+#GHD(G>T^B+WK4I4)N,ER-HWQ&P#:^PJU:QH MP6:-TG)0!+6SOU8?BREH* W!+N-*<4 '#:IN<'";/< [$Q.&X7L0YR6\(_#4 MUO9B8FGE^*E]*>V;0(:HXEJI.M]'+9F=!1SM[JUJM]?V(38WD5F67G]'8:YY M(<9OK+V!E?4T8=J?>&;2 %T011]MS.5'^2.6? MX=#+Z[P*%;=*D7+U/E,60K6)VY+/@ODR#AF*HL5@>_IYK.):;GX36^\]]C[R MD3L\^GUWN<.C=WCT#H_>X=$[/'J'1^_PZ!T>O<.CKPP>_:=WE8Y7WVXW/))' M5;'F952[=]%;='@BAU_T31Q^$_G9#^YR14\P$8M6OYUCD^7JZUQ5T&(H/U*VRP-$1UO8T1\?)+EY+N$?^W5!G83G![RW!G4(&5HPB MFZA&HA135<^C:%QN^89U@<* $/:M-FU4H+?3A[DO<76 K^!K2TDSV>].)FM'NF#D-@_@'GJ.N*A MP+\,;;.AZ5W$2;Z ZC;PTO)O+G-6Q:3J3(IF(7A.6R\RR81_1%P[4 T/RP*H M)')%VDLNN7I2RF,H$W;NUSL>,LVN*AS[[95. M8[MT?6^;CV?%%V"ER23WXX1C\@$AR!2#B82+-60#\)FAJ1&L&XT\NDCH:+Z$ M.^T]^*F9A>&M"&\#HU=+)MIR<%*G+'7PF/U48TNKB6ZYF/WZKK8\;-$QQGB^ MUNO.\WU/&1VK?X+V?$Q3"Y_;W8./[$[F(\504YIU6+%^MWG%@UJ,!YKD4<&- M*\>V85B';<%/12@B.8@'1GA%)M3DWX^'MOJKA)UG8UC\&V$R*(I)-7MIHU6- MM<<%T\7"D]V%Y/%G*BV4/D2CK8NR.I6KAY##.%1(KAWP;W4PQ4@5+-N&)77" MT;L2N1#L%:2&)>F-$4U3ZY?>C[O9$'977?4\Y]OWD$AR#^C*O6>//H_DQ5HG MDJR>$+M06 ]:+:-(2Z5)^KH&18P]U=(@&W#;@<;Q5XDAKZ*D#)#%D?E@7L=$ M8YN9IDG5JP+=&+B&K5O&7!$IR]14&M,C825.)R5*E[$$A=)#>06D0[&&!8HN M,WU'3$4J_0KG0&58O)X5B@D4I/"JG-*X30CP MHIG. ?D8%7!P7$E08LUNA6( M8C968GEM$+HFN[>N-_)#[#A8MGC$Z0QK+J-@2H5FB+,5>2:7C8W O):9H9$#"NT4'27BY-XT!X)8BE+U,Q5EA\J MLS'#%,$N,/YEEG%CH>6)\@I14$6QX9!A>?Y*6Z3Z@PF\A3 ALQO-O6VE-R3> MYY5$QOE&H]Y8QQE9AO#\; 2:PVQ^1QA[@-!3.8>?6VNY4"T-,@=FGG[C;3C, MWV^429-^AY;KMW2X M94DP=7U]0FG).HEE6DJ"V"R7IA+$#W((35C,(2A$Y$6!5U(SY;PB=&^9)P^M M&CWBA*[=EZN9C/+(U*@_TKA,2#([H;A,C]VNO$$XG3*>L"X%LQOT_?X+-:P_.A^+>##_S2Z7)WZ6'Q&IDRJ4,-!MY M_DOJ./1^_16H!5'^,K3[R@PG#%4-PX,/MHH,RJP(ZZKDQ@]:HK ;QJ5U2S+ M,B.%I**6]4Z#K[G)FJIK70E M)?S%N8E)DER?3&TD$&F9NI*P_3B^^KC:/@W M60CCV6./&]1F:/SJ])I5,F)[-2G2'(SN\U7P_TEB*MKE:?!5C;WN1V $F2+O M,&H&B-$JN*W'*7.JW&4IC: M+P(Q4>AZK#[3HCS#CL:X@XUVL-$.-MK! M1CO8: <;[6"C'6QT=<56!QM=1]CH+1$NSW?OO@]JL1ZV.3#$A.ZF+)710=TC MAKZ.OTKDF:6HC05P46!OHAS@"[%+DW)B@5\U;P986NB=(%-%)U?0RPA#7YR4 M1MZ>[(HL%O,H^<5[5% %QJR;?S)1&>&?,#H1%L;G8_Q;)HW:)@!.3'HYHKP6 M^/<(",578F<)0,&1GLI1Z)%:H'UXLT'G BU<%[U$9R0&$R*%H%!RAPVH(^<@++\1K490PY##]A'E)YQQ9/L=P M4#&<5. 4=')%:DCX-G95C4$N%2;@0P,W\4 [)A6^&JXJC[1#EJQ*H.15ARQ9 M,K]OB9Y5], O UW2;T2<'<,"?(QHLU'P%5.\3>3311.0!9 +0$^01BCT&L:A MBIDO-04_A@*?!!TIZKP'GE M9P3"I2/%TI6?X0D;;#U'8$R:M>?0?R-# @N#H/IP_*8:%Y8Y$;RT@%," \N( M*LC21(9(([,73?PB=>J\!Y%?CY_S.N#-B]B:[,7 M.&0X31V]#V,?5'V[<@4B;VU,+V57':HH]? 0!E3 9$+"%,JOKT52/(Q1Y]5? M::_^KYU7_WZ8X98ABP\-XQLEIB )!(?/2#&#?R/0(QMX?518RP05KH6QR4!L M&.@3HN]G8OT8[=T +XG$'DXR6$\F5<2P-YEYT9@-41OQ%*%4]N!G MAMH'I@Z$KFFG>_H8;MXR9'@$K2;./63SX^ H9_)(1AB$Z2@AT8KV4D*@-8R6 M:&59@95YP)660FV!11$'3!ELOLO42.<%P1-0#T;Q-T028;R20RZ(2$1Z)822 M47(/AY+AE$F8&G-:V%6GHFW7'9O,X>$?1M"EA+&9D6),EGG PQ!F/GQL8WGA M#-^A 2=J6O=GT#>U< 9]XT>(;)@E5+B(;A_;>/YJ^R&<:DW=NEV2FP%T%WT1 MM-N%%1B+9]@7+/+@6V6 7=0>/GE??(]K?F][]]6BT10OMI\;SPK]]5"^G&4. MU1TD]I*#(+QNOV'!W,^Z?K"1KR]2HX/OM\O5U=KZ/^'B[,3 #Q$#:",\9AGP M0,/^,\N0)[]7WNO3TZ-N\]\[FN'QK:!+I9SRJ)?Q2.X*[6;T+^KP1KM:WLVN M/IQBS$A_$;N_/=7+'!:Q<<^# B-/:'M'DLZ) 4OMQ&8G+>=1,]LUR$P@6G$I MG?A<3=WI\:S&3CUZ@ U_!S17M\>[/;XF(_MS[_'#HDCVQ;L2?D;&&Z:+Z_9Y MM\\?WV]UY@1L9.I[%WN_SQC>S/O]S&Q$0Q-.2RYM9P+!-DT?"*5E)Z>ANMI!BF<9Q>+V3V\-_E-=@U MC4CTZDUOL(;6J\)9*K8XQZU+-:V3Z;_]$DQZ/B ME^7@7_AQ(HO"U)?>J-.\3U%6Y["'<7O.D*1DD^L@YRI"4B4J *MK10,#4V)5 MQ@B>KB&D@UKF GUA ,#P5Z)&::'M][8( %%\$67?/,6Q+!H]8 PW<84281AS M"AK(]K7,B*$0FHWY&/!@/%VP0ULUNX;2DVS@=AK(CM2%V'N3*%'*D.ZH4 M. 0U@Z#6A%&>3T*!$<37EE@[@*J\)ESEE!E# U%D,L*?8'6GE M8YH@8KB?N M(:N+^H(\,5Z.9BVQDF>M*#B9!-[0986L+R5/ M3SD6N]BD>[1)69-E9]/5D.&%\FHS3?6C.4.$:5R;G+1-X8/\?LP&32F 6-'5 MIOGFF.Y/+%&)X9!"9MTBS?BVN2Q?$$LC&A##!&7H^CB!&=E70QC&R&FRS'DH MKUWF]<=$HS"Y1)%)7QY.8&A"Z=+WZ)=Z)0_55/ME;A+U=L'FW?7/0+#U!@3)R6G?M/B8#Y>)L>V*\ZL,[/0 MO6K>X3B%2=]*AUM(E TZ0Q+J:8SYE8(I'5=9QU6V4EQEUB3&L$DZO)5-C!C/+ELN>'U"=T (SUI3U]:EZ;9R:]3IGHRZT@K N4!FK;S2'AFE6 M3D3"O,Y7*M$JR=NM(M=TM-,= TZMY= $?A[Y(A6[!N$11T?G%\1>_UG^+H_.RR=]87_7/1?]<3O?]S=/KQ\N2/GOBOCQ.'&W=3QAJQ($VNN"0$MF31&?)%*/+,'Y M",^ZIF<%CGIO>%-5M,")/6)D!.E#4JNB6PG\1.EF1^0;O:*;)GV5X]IY4E1A696I M? @0QRM:5-"O22Z0.%MU+=12-_)GDJM;3!0(:F:L3:5-+%6G(RVS6HWW@,D" M"^3594A6^%>I,Q-\-[=5)=8-!>-\>2$L3$[::G4_R&J4SK9?.-IXKZT7Y#^G M42H*J[-S1%YS ^EG&(5*\Y4LY?*<-7M;C\@'H>FL.DGM+[90)V[V3K*OFV1_WDGV!V':121-%90V M9'_B^0$'8"!J043N@5@:@CKBHG@5'%;01?1LC$;C@& M":-+/+29(NV=(O@PU?$,NI:ZRG]A+*''LZ#&E\@]!$D+:NFLWE>"^;)\':1) M2?5AN125 1Y) A%P37DY,_"V3GZME?SZKFKS*SX@JR>_7IM2H\4NW.DP-HD=G%FJ)Z'>GR2&4DA0S^ ,O,M#* MMOJ>>2<75AITN*(5E-<9=-BW[KC#$,T45%V6O^?A@T,VVY.8=KPS9_;%AM[$ MBX8ZFY@TFV:18[2RI&\"40D2 R4LF0B?'5!V;WMU)>EIC(B&'7]ES>+)% OD MLO P938IOX?S9$@&126A)&UM9A/)PIJWI-6TF=,'T!OHSIQ!B]9=/I18&G?& M.IJR]I<45: 1R]*@KX\19($(L4)* 8J."C\'AH(97XYJ)GTI-J[12$0]+$NG M&1KGFP=X88 -:6N))6]V=%@^Z-&MA+K/UD P#4#=&9RM^BB[*0=4*X8>$<9I MWK#4*]BDO]C,VMZC_WUS/NL;-7MLKOGD]/PB(SY,8S-/< M&L:\[SYW<=##_\CDUYV#3+#K9YWUWN8)L=;+.#;7:PS0ZVV<$V.]AF!]OL M8)NK"-N<,W=(@UB6>0-R:LZ8J3@^&G;K'#+SM(BVD>R=K%]*F&L25'^7I=K6 MS#]D##]*\;8LTNO\LVZ\[NXOH-)+7D&_Y)X[Y(SQ7]@6WZ;7+?&0J"OAVZYP MD+$1NG QF+=TH2C6$?1@N-&,3(LKWVDRZB^Z+]?10K"#5HNX#N,>[Z M2SWL^I.MP/HP?W50'HT/;CU;W05$NX!H%Q#M J)=0'3U1'@7$+WOR>\"HH]4 M&>L"HH\R(+H\MVU_K+.(J0$HYRN.%0.H/V28$PK?;IQ\V/230 ;W%69I[>FZ MF"L/&WX$VQ*6I?6D+M^$#QYE0&WU._+D]T_*$J0397&1H89#6F&J?7XF-+F/2A'0D\)$KG!^E,>I=O] M4[O[#=#?Y54XYI2>FG1*:-M4AMFH, DE$L*PQ!?0<,PZPT]1[?@+FF@Z5BL409!'E?.2?*>_# MLJ'D= =36.%]V^*$6B>BE!)&Z%FU&UP;X4!,TNM812-.43#M1,)[F&=#54T9 M("JG: ;&IN&T$E%&&Z M%>QN)!Z:4(JS5NX9L 'E"%8G;$=[)^@9.6PGROZQ] U<7X*3:"A1"@\9+3%C MDFKZX.(V23_ZU@^BZ@TB5V&F"O]!025P#!^$$26TM73.Z3PXD@99!<\B,J.; MQ\>QT%->$#X+2TI0(I-R<"S8PIS07A-EKK!&0/>AP+25B^(9B3=XLC8\=28! M'O$WFD;YGUY[2AC(&'LS0Y(IK$NR@0GD!3*3;':;^8=MY@1K:6E;=&LB M/^.$5CG UY(7'NNO.GUN[6*K]'>#)U!RTT"7EO\#S-T@1..-A+J*O%.;$N\(YDNB[*/N0J-(9A)X,# M]E1_5EP#H=&. 54P#^J64\;VH)SHA-DDLU&-*G%7K(: ^^5?+ 5Y![#N%+J"KL'X_ M*V2<@V6+"V.D%=<'BDI8/I&Z4G$ZK6KMP/B$K"MXPA.Z=@V*%761"N.82D4L ML1*%XC O7$IE 3+2?T GX>I$0SS&6TI*GK0RK"#4+Z=7U,RQ; MCAXK%QMJ>[0]GWNKF68%'XI[DEA;\\U*_@RP;M^5,MG*!)FD[V&OP[Z(4581 M#Y>K7L72R,H_VI*R(5SP$M;9![')*ZX)CYK$T7 D1]B%>%8_ZTW-+;B/G\6$ MLS'A$#*?B2P!)9BW"&_&FMRF[&Q[R#>-%CL(A?R,&CJ-/*=8\QFNL["!4ES9GE"E7.N5=3M_!^U\P\K:Y"I MB@[-E.RO5T]6;$J6Y[5\79'JW:-#=E'=S*GX##'1UAV"5 M9_Q[JG-_YUPR0O,!IO#1;4?+$_3 $\98M)M0:/=*DG2+P@P[RV TZ3!J'4:M MPZAU&+4.H]9AU#J,6H=1ZS!J:R"V.HQ:AU&[R=M35:D6Y&;=/1"783I5%6-E MATS[09[2"T<^JC&>%SE&%>S/WLY!&[$*_01S2(-*-=.1]&%F"ETLXES9,$^T M([2LY76/?+JV$W=FT# CMFF(9Y8[ /-D,W=N[UI.EN]/7MID<0 N:;*7@.!: M_C3..W?N3-Q"07J"1)EJ#QSQ+.!*.!:W\-] ;'C[?8TFO YI7L:,<]4UQ%(C M232R, ],:)9CF4QU4QUFCOZ^AC$N$@KFZ.XM)EU6M;![5_W2/U0ET?8J] MYR=53-$D.[;:6B#F*U/Y!-SW)Y"V'YV*=M;+[@@3*\^4IJG.CZ;0X4WS6*PR( M1P9E9J ;2U"4U6J%=,RRTN#+YT[.=NLHPF*C)@#&"*!#N00?3"6F\ M=Q:55:W5 (1^ADCX_![:^Q[QHB@XCT'-QN(X@3@::T4UB5+,S8"?S@EKFMV] M3UP^!_&F*)Z7WYG7F8S$.Y4A@'Z[A1BQ$^J=4+_U8OVN>MR=4">A_@E5UW/GF Q26N43)!:9T1>L'*+VR0)*?0E)Z1F23W8F-I[O M;)J+, "6S,1(7ZF$5-554F@ZL;.>8N>[BG!W8H?$S@?8PT>S,%Z&3G/8+EWJ M$L58EIHH4CBG'>0(V8PH2]"IA]GG\"/V )6B:]1_I)A >\9!6PA]L?4*3T8( M@Y@2V8W*#3]"&BHP?%7>"9].^-Q5^/S2"9_OUWED#+MTF3H/N5>(1X+Y"ZB* M?:Y$3F\R=;VF4A-5FD1E)"D-N"/D M97SQ,GOW<4HTGF#^38OV:>"7<5@1)IB>6]S\V,#G^YHYK#2(%$6D89EB*KQP MG!)]&%(M@NJF%KY]"NLWC<2&]".?%N@]E1D,K)R.-QVIGZ6&1,ZM!JF97=QK MO(T[3>1'G-&_KHTFLGI*Q#E&W>]?6^CX5^Z[RQW_2L>_TO&O=/PK'?]*Q[_2 M\:]T_"L=_\HJ\J_<1*GX[.7\,KHCE:2SZ-%+^#I-$#SS@XSKY?>N46AB00BE M[O$0F;J660MVF"+R%'*9JHPH_3'&PFGRJO9=FRL&M]\4KLS()X=W2'H-4H9[ M?A5\_ !GP<6\:$ZJ,!!]Y'MSCOW(.$>X H_ MEO,!VS5*L=K'AB,00,'3"F!MKKFY-FEX[I6.J.!7=>VF"=9B.9XRT8Q^];9" M+>\5>VQ74)5!V[::%W$:B UL6SF-7!TMVJ1FBM"[-_B(V]S1N[ M3360Q,:S3=^-:ZIYF;TBF9;%NC5S @-:D@:3LD&.X&KJM=E,*MH6;[!V2YF! MH%<5P05Y>WD:;_,6AO\9BA!5WV9<><:@E#?@90S@J[RTOO+1O8GX=0C]M/7Y6P^R0P)8B-/^B3C$U;K"-L9C MG0+0)4(L\<.Y6NW0BM,4M$T,M8J3!$E,"):7I7!63;@0BP5K."0PA4\8O^=P M-'RV.07 3;I+AX+];4O7*7.T"1#N1:4T7%Q^]'4&F9OSK%ZJ*L9H%U7-@O?I M4$]=N2Q?5IJD-&X4_N4:Q-TQE1AMXZ]D7$('_\*_H7=[+_[FZDK6%(B__U6F MQ<%;>NH?> ]_ ,TYSJ95:!M3@'C M&=J@PE:1,&V:>*%7/$ B9?X>5&N"FX<%T1SQ$]4A3@&+14]WX[PQ%0$Q:?P .1Y&FJ:[R@-2RK'% A-2N-J'9]=^''UPX^[ M.UW\\?M!3#*DK^\.<.T@C2O0R[M[=+X&<'T3JR^D7.'=F*+/&->9R]!:P()) MQX2>^* ?S22!1X@7!V$JX-P=1"N#L+50;@Z"%<'X>H@7.L!X;IS_+!-C>5:% M+US)L$9C\C1_>F-E^F\P<5XM5';$B^WGU@6S_7PE M1^);3![2A![M/EF*\7?#KD'U9HVWS))MXV[?/)9]\^3W,SE1^]W)[^'(77^[BRS]<4;D?L?5 \>6[!I.O4AU]+9;\=)!&,_AG7$SB MW_\O4$L#!!0 ( !>";%A:KQBN7ED *, @ 8 96YF;BTR,#(S,3(S M,7AE>#$P9#?P[4V8S]0P62S\6+W7:1I&D7J3AL%4*[6_ MM_MZ=__@8'=O9^>W7^%9QW)3$A^JER_V#UX<[!V\4GNO#E^_.MS_65V\5UL? MAL?;=/7)^?'PTT6?7WOQX7QR]>G Q/^(=7NWO[:ICZ<1;F M81+[T8L7_;,?U ^S/%\_-R-TFG+X:7+V;Y/'KU(DJ23.\&>?## M;[_B-_!?[0>__3K7N:_&,S_-=/[W'SX,W^[\#%?D81[IWWY]8?[E:T=)L/SM MUR"\5EF^C/3??YC[Z32,=_)DI(?OM[]^>?RJS2-OX-],I^'DWX_HZBS\'PT/@F?R.PZE M8_BC>>QUF(6C, KSY>$L# (=PP7_]B\_'^R]//KU!5X(X[!H&8MQI/WT<)3D MLZ/ZL+3U]]MT(]=?\AT_"J?P5-]YHFI%1$@7P8__+ M##J=_]N_[/^X=P2+_*=?7XRXG]]ZN.O-.M9I[H>Q"F&D\W 2PEX*XTF2SGT< M,C7S,S72.E;ZRS@J OAUDB9SE<_"#+ZB1L/O8[_(M(*/\"W.@(J37,$3H"U^ MI/PXP!_RF5;Y<@'_F?DY_97J:9CEL-7@3]S'F8*W+=+P&NY42:K&23SA=OG1 MKAHXS:)'W,#5R3S,IV^/1DMH#H_19 MX5H[V#OZK[_][6__39_WC[[A1#@+9@ROU^F?7C'O+T[//[WOGPU5[_?+?A\_ M?>-%4Q$G>[O[U>;_H\A@]);\51CC8![N\%6KNS2D=3-?1,F2IL6?IEKC)T_= MS,+Q3&4S'\1]&--BXY43CY-TD:2X)F">4CW1J8;C WY<*G^QT'$0?E%^GOOC M&2X$^#5//%@'-[B$:"%H-2GR(M5J:YQ$D1ZC#(B69J9O&6;J6Z#'^'98=CMP M>Y(>_LL>_:_Q:Q3&^K" D4CQ4^-G>LEAED0ASE_/]!PG3=;9MH?[A)8%K>$\ M@7--G>BQGH]@P1X<> J.-_COUEJ;WI],> S5"4Q*M?TP0SAI(YW?X&[LG[W] M<#4X/U.GPY-==7IZO.ZFQY,B@Z^KC2;A$.8D>^)QN "918)")1,U@NMCG64J M2L:D:?BXH%^KJ_,/PW?J^+1W^1_J:@@;<.BIJP^#85_]]'K/4\?O!L>]W\\] M-3@]'9R=#Z[4CWL_[KWT:'3.(SU5[Y-K4 WBM4\F;49=FT90O6!+A]=A4,!@ MB/ $T1KBO@N"% @PO6VI$+/\V73B_X "FWNT>"8.U-#'7F M#O7NXYPM1CBOEL0?W_4O^[TK3YDM@:)'I*5=\[#^22N'4X 6[B)-8$G@7UDR MR6_\E$4TZ56:?@Z*,1[C\"6T\1J6"YS[B1I'(4@U^_PPOM99S@< 7#D)8[ ' M4%.P]\#B@QZD>"RG23&=)05K#!_B$%]TE*/TWH2AS(3PF<\,>@6](W/EP8A:1LE+><)G&0P+8\*48PI9YZET!W_P/^ M _L;>N[#4:3AX[_]R\'!3T>)NO"+"(Z;*]C*TYD?PJ=E$&M8;>^+^0C_QA>] MT7!C5*3%(ZD2?V:Z YV%*4_/##XH(PCPBX5.4==28U$.[;R E@7WC=-PY"A9 M]BCC0;WU6,8K[)N<)HPTM8)4,=O$VUKR='M^V?>P]Z#3X[(%]0B:/DV2@'I]#2O5'T4:NY^!DLRBC,5G5N!& M@8_R@2?=3^G2W\L?P-=Z3P_X$95;'^?BZU M6&-JOL@#]\)K6%<@(B(911I0,'R/H#>YWL$WZ$/H1NHOCE8_\UO::#M@/^7) M_-#Y!@UQ5Q^7*W!JVU; #[_M\ZE2Z^J&-_K7PC3H$4_@ >K6"Y !]..O+XK? M=N%,B?"LPQ4**Q[O;]GM8-3J]";,T&C]9X%2ZU!MA=N@](S]19A#9_X'75>P M8,D4)6M2^S$=G%D&/85?09RAM;RL/?L('@1/6JMFDJ2NYG2#+K<1"X \+:#I M63&>E78[+@7-XJ^TU)8\:N@&T/,,)#T\H_H-"!F\;)S,1W#BDQWO7D#C .! M@VA5!5!$ID7DI_9%^.4"CE(_XL.DLTSA%(UF> L>6::UMX>NG:SFA3&E?;@ M1*Z]37GB;BYR8."RP]6)'BC0O:JJ"SK/<*-D>LR;!/6*D?R%2Q$VB76#9"WZ M#ZYIOCKC31?K+ZB\I=J]3YI07CFI7&Q4)KJL)J^NURZPH-,W:8B&26-LJ6?R M>ZYI^-"N)XT,5$E/3?QQ%L)QIWF/S\,L(P4'+M0[UGX:BVL&) M)3V4=X&T'A7DSL671#!:.2V%(]. K? +#\]BEOK9FNUJ[ V,0U;QZSB]A]\" MIX_EY3CE<2)_'#E"PU-;TC^,SL J:]MFN)]0;SQ]Q^5!Z;[=4?%>H.[[@E3F9ZLY:%P-UKH&8],\#O?K M_D]'E8!" GLK%?L>#LU_T$9+))#P%>9^M]V>;HV^[+;;@[;;<80FY@16ASDJ M&AM0MI3=,>/J+7 V]K_ +J*#Z@Q>(']1"]1;/TS5J0\#C8[7./#1XNK!QEIO MY.+MZ57/=:7+H3M"OR)NZC"NN1.-6Y"=7E8!OFMP[&/!<)T7<;H.]ZF3%@S;-2<$1J%:I$,9A3H"-Q2(!A=0Q2.,=_67F8U.OM;C>%T;8 M!/1(TH9+ISS\]&M8D0K<#G*5C1\UL&Z<_ON_O@A_4UNW->.'WZ[&R4+716;X MVS8+BU2[2L0#M 5UHK,%;#:Z1P9H\P;'*W4M>D"&TIU[YWCO,W;\&6GG800< M@^7P3.A;")W2;+,8QR9D<. :PL/APU%&8[C$ M(^NJM-96R=7'W-X5#,S!R]V]U_= P9CKVF(Q)&IKD#>1&(RS@9_O"8%[%D@\ M5SIN+IJ0NL#G*"D20L4$,1J)WO/+KR@-=POS,WM[_YC,<4.Y7__X7?0.&;A M^ ?3"! >"QB#PS!&T;4SBI+Q9S.@+W%P>4?\:_T,I8XU0)WFP#4#^7KW%]EK M+1K";4-X\/IIAU! "M]F3S>>3F E6&8S!79"^AE4>#BD\D=ZV56!A]Y/K_<> MZ?DR5 BK8D#5IL^MEE-S%XR'%<<7R\_'%H3.A?<_8;AI_-]9:D4C* ?3- &5 MH:::.(*_^H/L:51]::?+WWMMYX,K/1FO7A&?E:\L1'WA3T%^@)KP><>?@,@\ M]*,;?YG)I/_\\^[!JW\]$I'.W^TU0.\=E'ZM4/JO[L8S-:\WQ/I\W6%&5MA, M'Q$S^"XITJSJS;8F#*RX,/;3I: (U0RO)>/QY\.]O=Y[-(5>PZ>+]YYZ#U:C M;V&-ZFT:PI\6@U+&B+*%'G-NPN89B[;CJ69LQ@V,T(W6GTM7&1AN^5)MO=K; MEM% ]YO*,*!<1&1OTPF@MGXFO,=GQ,GPA0N=*AB2%2-U!%?=Z&MT\:\V725> M@$9K X+'T3DG,+!8P"B2Y(C\&^>I@NT3M ^%P;&AB'Z6O#!NL"=H$^P!CH$V MS9CA*,(91-'56"/"!-<(X4T6"QB?YD(RN-O=NSK7,A?4.%EYU,643FAL%OLL MI$-DDX>,8V\TH&;2&Z?'I$CAGRQ7L%S0)[1 [VHN7M#J"':^SZ>3?C]VOL\' MR;/39.S _AH[R.+T:"M%XGD7T7G$=!T ?8?!P&.E)]"QJ[XL2*JFPDE[Z//GI"]\)W?B2Y,V/4 M;V$O5J.K%JIA\C9@I_-/9 E MB-/S4\S>N@46,@H#[09DK4A?0._'H60*+=)D#.HG)IQL8;8%_ATD M^MVU+\>/_8;3+3 .0H)"OLIH:%TS II /C$!89/&[JQ^'_"-2-D\I0LE.8J7HLFX0?0G':%U/^DD @ M&8=?Q'9LE@RF0TP>HWQD+9(J3),8R.IGH!\"/:_#)&(*$-?-JO)!+QX'N7)J6<7#P$#W>&# MYEOS [80=#_,9O@'7#?W82!\AL;C)KR)G9D:HU%.,]#1V ERE>Z M\]H>]U7=<-23&(5V=.2JF_+5#[_YV];]Q?\\Q4'RQJR@00 ;[L4YF;(% @<, MK."$E3!>="4TKR9IQ@D8X\5",C9AU8_3)$.)G3/?@[-4W5?87--;16PE_W2] M*"4[7N5(+2L)P&HP 6GIC(YSB,+1M,A!H*%)'B49RZ>V)U9.XBRI1NSY%(^= M@:3K%Z ?%WPNM#W2T0(J8("ZBX4>0WE.[2U#D=:PM4C,D<@I)T_'H*KGG(V/ M^;Z3, 6=0+J.+PC92ICJG!*2FZ<]G(BI%4E@3( @Q^QU P/W15[A1V>:8;XS9X7+WIGGZZFBZU MUZE27S7#5SX8$LM:BH1S^OM.8L3$M1)2M%S1%\;X[+J-TI#H_"*R>C?.'69= MF0L_;,W1:!PQ/&DX/&D"MZZP\7?5D!R%%,O&;&0\0J>SZ@F.KT2#)XZ1YB:C M86J)K3CY)6%V#U\PK"?X OKEIJ-MX:E89)D1.-N[]X!4HJ;L![C_5LXJX1W8 MNB>%*0<;'&SXK?V#;36'ELW(1^!R;I$CH4T?N.--#4])C;SF$>&7?UG!-%J+ MC5NV57>$I<6KX;PM9?T$F?1XC7_$L84=:E[P\W MLO4ST5IFSX6<\$C<%5M9,$W]^;H-0-M7&55U@2VL1'.&AXW/$S[E!1F[ MIO^TE1VI05FIFM-)[>XDERIY)TV2.4=MB0>D-\2JY&[SA(5IBN M&,TGUA3T'$04*&G7O-T,0U2?K=U-@8T1?"SRJA'>F@(J"K*U3-S6MH"9.E/Y MT4WE\3I,Y3_\-DRAM6N=I5/ZL5[^ M;SVTA_"7%Q8-\1OZ8NT)&U)!O:>*;# MF"L";(2K;I?;8OLH_$K(_"_8&((("P0&,0]HS!K(=[._S.&/ X4\_]"5W.(* M+$:#*?YF.E8@,#.\WZO&1]&O4,H&MFMS!6(7X40QNL&V:=_>)&KK8)L0VIF! MEG#T3%BM";FPI.V+(V_Q-[=M?G(]+LVXK!907D7.N**%$>C0#0*X4#R.\YTI M! ?M: S;;LM(AIG;3!,$@7;D:6C(W6*:J.KB8M8*T^Y5*_+Q1==?"[81K,6E ME\0%^_,VXHC_I44[^8JI;$NJ?XJI#'?7,)4G5GZ@4[Z;XF [@%60"%Y X<2YA>ID9^% G;A M (M/24I4E -#5-@">_'$1Z1DA@@50YJ=L6!?I,0O+S!U"IJH7KPL>X?G)!@) M,47S\C"BH-2N&J*K?$)4\WG"--O7#/^A.UTP%89L1NTP1,-[1MS>E$5$T$!A M^<<'E5 2GZ-# <,@ WXNMF[F7VNJ!L'$1WP\A^2AX[9AVH0W#%QB_O7*Z5MM;J.)MZ$>6LQ9 MJ:]A7!S8:*RKAN>+I&KQR^Q6EK"FFPO2.44>?:M,UK%5^E]PU>FZ6DJK*-7A M?$1KKH)M JMT)YGL+&!$->89\P,PDZ5(35F8^^\NPJWZ<=Z*$K&8GY_GP9Z M_U4SM89+Q"#N$R4++17CWJGX66M%:6SV"Q.65]G*J8Z90+'[UF4EQO45:[S93"6:U<:LY@0@*E\+%_F+&SB2I\I/?,L/V MS<@CGX QXR;Y,3#Q/O.^@NN G(/,]VQR%FMI2&B=E2G%+1@W6Z[$+BKR5^(2 M(9;H5?S34RI(ZB0_F'E%$_@>\\@?S5169H\7:>LHUOM:<34V,Z5M1@87?#!= M73'+C+MZ^-3^R2GM0/]?38CP2T?'YO+IT]A:MQB%Y>YPS:JW(/Z0VN'Z.EQ?A^OK<'T=KJ_#]76XOHTZ_#I<7^=277.NJ#%DP*I9 MCS'3&^Y\')R>&ONE__[B]/S3^_[9$*V:6W,A=]4=ESRFL4C-[/=5[_@_SLX_ MGO9/?N]?J=[9B>K]?MF'C\-WO2%6Q1Y<.EU2@RMC.4JW=TV_A^_@M_?]WMF5 MI]Z<#]^I_MG;#U>#\S-ZJ'W=^]XG->Q?OA^<]89]^[7X5:[<5\'K>V=P\>!] MWU-OSR_I+RS5#H^$O\[.Y0]/?1P,WYU_&*K30>_-X'0P_$27OX&?C]^I\[?J M^/QL>-D['GKJXO+\_>#JZOSRD^I?#<\O+OJGGKKJ_]&_[)T=]]5%[Y.'SS[' M:N ?!U?]79J@+A;S/>9R_F&]! WG2*^1$]VHX)++/;H98W%AU-4Z+24XQ5/A MQ);3T@$#@$[UM8[42T^]0L?%Z_)BQE'>%][)5^>SD)B&7^YM(VUP.[93?/(K M/"T$90DRADYB+5-#2.RZ703D.9A4H [M73MP^M_.ZG,;:C4+OV"'?GSL#JE[ M]67_J_H2P_K$SOSRZ)U96+ MO!H>)_AVB1JNXZ%6M](KAVF.#-<.JHY75SNT+D6&/;VB 4P#*-0.!O32".IL M6PHA!YKG.O<=\,+&A3>?N=1?2UK"VQ!G6" K+.T;%/.64;=*XIWEN!&)?[? M/=#8676WMK.LF?_="H4R&P*% NUP#^LM(X.;< TV<2[0+TLLCZA2OJLI& 1- MP/@RWH03ZK5!'=*A!-?XXW&* 5K#ER%5(!F5@F]@7D;AF4=15.]A%]!Z($?4 M_EY'8X7;\%(+3S6+V5J2T-TU]YBS%9E#&5=5>9IP:E_KV$>@%=)AP :7T'0; M\ 6:&9IZI>0W9S3SRGB\?9^DX?AI2F^J,.-ETL#LL&.H>DJOPWF%K]6/L,9] M2119!4PY$T:D(0(PZ!-Q"(I/$>,UREJ.^%/%7'ACZH]SA.N"5(WT%#XP!YRN5-\!PG'4F0,_-YF,]+.A*BWD6]L*2]%1I<)(>1*&<0PM%" MS2C[;Q9A!'"[I'ZY9]%DJ^+MY^:**.:5AA?./>-\"@$5_(LFZ3' M_:P0&#>.8*3/ICUIR+0K(.H6;%5)$MR&DG*9?! 54D0Y3=G8 ;L0@V5, S1? M@(YJYQ&_RPB-F@L2QKPVX\J?,NW7NA161VZ<&PZ[26@D7DA+<\E)!P14],KYG!/C.+.(HT[RU,7]+H77$M1=;"B9>.>:>X; KMG I$3.V_ M]%PI?5/AST5/4WE8N=;XP5&W/I[:)AU,G%WJK9JEIDS,E/X29L3&O$JMZ&;S MR1.*;YM-DM.A.,'(/)9$^W"^H$EV+'[F_B?#&E[EU"/@F^&46)C,>,=@;L'C M=VO@R5.B7%U^DK(-P#9?"YH8E1\L!E)-^7&RD!Y_ CO2OPX M8[Q27&291G!*U<,,=]@46'H"4QYI IPYO['O&.M>Q-/,+ S$;@5$][\T.?TU ME_AMG!1MM4_0S4\HAXK/HUHERY0J9)HKW'@W,6\\:D":Y'J3UO M14 1X5']'4[@;?M(X&UQX&VR-?T,5_SL%M\'E=Z\H7)/$ZX42G%&S4Q8%+.A MPJ7C-$0/%GX*KT,J7(H0E#S!@C!4>R>:[)3?56MPH@\=1MFXR"D7\]K-TE>F MK&?+DO;15\JU#0526?>VT<:TB>3"L>6G(17%0U!7VV/=4"KMER.N=.IVWR:I MDU<0JX52$*"D(4A'89XV>K7FGAS!352V57HS#M-Q,<\H=UZBB'/"KX(>%MA# MB+?W' OVIFU8N:P891RX:(=ZFD5$3Z/-'F99H;.5WG*^)B:9(#P8#40&&&1Z MHMX5L!G4I5%0+7&+9U/6:"*U0:)POC1 M,L/K J+3E%2[7"-7BZ M%QCZR9))?D/EV1/FMAHG =5JQW-'_L"0/\]'<3"1&H&\RFS1/&!+8'RPG.9X!@=3AA7LD.11K@T2.*D-@!%F!4M(PS]S?XHCBIO- M0][1< S_P$+D88Z1& <^X<),^#DW>I3!62)#@HR06,V=65E90W'XD^8:K-D M+BBA#F#V:#&&8]BD >8() O"OWCF>ML[I/_!*[<,\096)HOY-#4;H/Q&&&RY M>"CE. B 7S8/*DECO7TDLT]UV-D$(1:3RJH]+OF$+M*$HJT85I>OG4MQCA=+ M#U>% 3<#H>X]8C]+<,1/DMC,(_ MA/C'D\$%48,/8;,^UI%ER>*WADA@SCRR"/:&AV1'=>BU>";5:;=%D1 3MB)&DNTN=+4_@-_CCWQS,\XW:(!5^#$=K;BU568KB@,5OT9"1UKA/"^L":@B_62I6S2M&H5$KO M?$=KPXTA@1BFB3AJ14UY0$%GR]3# [G<0)DC"">@\%DS@QTM:%N[M$Z.ZF(/ MZ!$K-5&PR.H98QDK+7#LZ=)N\^I2.6MH%IDY"*KP:5O=LEI.D>YWT8[<97Q* MF,*NBI8U3%GX:"%_>+5H_:X#H(T/"97\*0C_+G7$ D1AFY%D$^8>)9E/X"#^Q M7(3'3_A :RX:LV9NF^VRSJCMUA*.<#RB4)G"61XD?W-X/QUJ.M>62/ M4QI4KB,-ZEVLRT-":93<:0+'H^@RM0,DA8/I^I:YM.Y/RU3)S8#[0B0>@X?) M+SNHG01.N^H^5M H4.=M>9I18&U$P>CPR@^N::G3DH*E6J'+WV3_:(MP:0,6GJ1N%MV=J.+8QVUBI-VTWD M8G842^T*1NUF)T4;C(*>,.-.XB:J,F<8Q&3N"P!.AH";,% M"PW*T)58IGA-W"M="ODH2VZ/+]S>>;J:2I&(@Q([AXY(=)!GUHU'U[%EPU?5 MG%WXBV:/%Y-,C+@K5,)K12_8R8[/IA0U-)XI3."GDAB)-#!3AQR=N6:,IQ:# MKD[&&AE,8JQRG+6&;JG.E*2E6B8E8^9V7JSODW&E3YZ)DN5AI>'-RQ=]"!+* MDC3,ZFIBK KFUAID5()1"$YS9V\P;"%X&^PE]('@_HS)H;WEEC&QO#].OC.F M>.&N*-CG4KINMJNEO%R809BZ7$AU*>E 2ZJAND CU 0&P6EAE1:&.(ELA07R MDD4A>0:(?.8V)XHK6+'A4QWK%$,8G\,( TY69+&(_8)42>2-]\>EMZ?28_90 MXN4O<&"XTD;=+^D(F"-!H> T1?X-9G@O*]$$%Y!I6#Q( *.P:ZT*Y3KLT>%: M U]IA%SH^4:$!0834 M(M&Q[U%4"IV= 7H#,6)8('T(44:E!::<"E#.@$*K!<"<\F @K=8:=CJE,_JR M;%"%I,.I=$V)L@EH&Q9J[40"7.\Q?MUXJL?%- U4%/Z=PX(RT<22!J\D,F$] MQME#U3?BZ0$*"AT?QFGME54[&4,@K(T5D>S?4L&&ZJXZ"DY#%V:ON U T/6D MY40(*4RI0"-E'%>$JCWO8%]5>DB$ *M;4P'3\1JD%C5&]R\H-,)O+3%:*@-7 M4HM#JTNMIYCFB9[@F3DD!,,5(QA4;TPGS<'>_H]JZV1XU=M69[27J+VW-!0Y MB>%*/&UM45P'EX#;-&L]G[Q*,H8ANOC)[%=L0VWUC_T8-^L(0ZA18&'&$6&G M"&H,'T'C06]VR;[K.JZ MX&"RV)V[)J3%XDKC-HZ6UB#EGTP?;^N26^#9+Y7*1EVY"J:G&E8TJ&P9?QI^ MU/E)[W.7255GM[B3W.DV\C*9)].*,KW&)6@&51A6C9);>4RR9/JKB?]U)[4]#7&UNR-._1M;;]HQUZ(0]-:LU"J$X62. MBE5 ,L3^S1NNNIM$/F^61 MAHUZ0W65H9M#/HGH1C4=1OTNNMLZ;DV6&IF2N<@+5%@:XA2Q282!MH3R MJ^&!L7C91AKLT(DG7\B?N$U(&F168071 B*>OR1MB/O"(">21QM-D-[!D];= MAPZ>U,&3.GA2!T_JX$D=/*F#)_V5X4D/4^.:V0;-EBX?XNK@-OJ;5 M3T1WP-Z,"\&32>$DJH)4WW/H$-$9[9C[5$BJ1$.]ME0RFR=+CJBPI?"2"P%* MQ4'5N(B*(R21)U%F!*3H"*1KZCHF"5TD?$01AIG"*95.,@FZXV2!CC>P$1T&!,40<@NL<^30%+?4,:X*G/>DE9])R\E7%6F6IDD_VS"!=, MKB/$.K> .F\?S4IS"38A4TU#3&,+QPCGSL-G= ![)G1T9ZKG+9-H&>^$EYR* M5["7B-RM,#MQEJ22AD[@*"E6UI8D[JTHA=#(H_]&K=J%GMKB?%0VLY7"W198 MXZT]1J00TTBUYQEAD+'W4/=L8;:6=][Q(6IC"V M55&8!\1=4Z5L*E=6-K/8NI#9K&!4K6L^U>%\5*09J0V( XPS V,F6++54?HE M$J\&26N:6L]4"7D$;^4W5$U>/D@UV>B^/(G",G!E5%5K62^P;D7#''#=7#,- MSM)F"+0+7#D4**>;X3!31JR6G"WU S*,X^3:<(6$&?)>(HL?DH18/AE/0')T MG.=)OEQH>[(S,&9:I/8D$-X8I*K!Z)P!]26!<] Z'#!9P?0ZS#9G&&4\0R;C ME0J"?!>0C&/"'8\8@NCIFM4XI-?Q+'D/!V4;O#TN+0_K2!7V(,\P!=U!MR,D M.X9@!P?0Y_>7K#Y>G<<'[=0=$,$>$<^0!*=@)(:YO1HU37UL8#V%UV3_T\U. MS7VF,88RX$B1"FUW(Q_PIKB*F,&%!!GT-.TPO1 AR=?R5 = MGE*G!T[KY",,*\]H!;5BZ!X->"B78[)$>&'\LO1-5I9P:JZ-,(UI!3%;F2Z55%DBCROS7_OY_MQ6$ M[K^_.#W_U.^KWN^7_?Z5&K[K#57O[),:G W[IZ?]X^&'WJFZN#R_Z%\./ZGC M\[/C_N"/_HDZOU3O>R=]]>:3?8:G/K[K#]_U+U7O]/RLCY=\' S?J7/\SE,G M'RX'9[_#&_IJV+]\K\[?VCME>*_DB_?]LR'?VC][^^%J<'ZF+ONGO2'>/CBC MYKWOG9W!BX;G]+PW<-%9_^K*LY_4Q6GO#/Z&-EP-+WO#_N\#Z!V^TCP1?AD, MKU3O[=O!Z0 N@(NOWO5.3]6;/CVS_Y_'IW#E'_VR][7;KSX>JH' M PFS!HVF(:<95U#8^KBU1!? 5=@GP:_\RS 2KL\Z^'K8*F= M]C["X]]^N.1%T[X^800&9W_ *,(],&_OZ)%7[W!0_NB?GE]7 %MVR9 M53DX.QG\,3B!!7WZB5_,Z_ERZ*S3JVU.4L)U]+L=IW*!_K\/@PM]WF]P3/?#DZP<3UL)O3T/75.;&*X^,,I+8^WE^?O>=K*#L!" MPQNH _(9)AEGT#3E"'XR1+%V5\#2:C3U^,/E)2XT?-(I;I<3?'>_=PG3S<.# M0R5[C==4XQE7YS!IO;.3EMVP"S-_?'YY J\__>1,%(QA'X1"[^H*YO=*YJI- MEM#R@2$;#H:G(#OP+;04^E>P+9T.T2\?>_#N*][ZYY?P&+[;;)'V-\B&X\5T M-30[#WZ$#3J$\8!VPGJ[D]_S$2$\%#XY>-FN;[N@FQVZJ,W3OO]S!YC8O)A1 M!YCH !,=8*(#3'2 B0XPT0$FGB=@XIEZP[^AK_C^M05>=;4%T$5\Z129/S:E MB>Z C&.@>1I#][):ZDR(!3"F((@"SN";@9S ^)BI>W^M'8<1/&C&SB@DU[:^ M0*9(G2.'./E_0G0ZZLDD08\GO]U4Z!@58<1I<7G6&AD6+GID)E=; 1(HT*H5 MWF4I.X.#@M]M>R:LR%$R?*B)M[^FE@>-&Y\KNE MW&@ &[8,:\ZX"K''KVVX4K[<7NU"W,+PH9Z@\U#Y(YC?[:J35'QU&3R/Y\<- MQ-:YV\G[2!Y"6YN&:/]=?]^U'Q4LAN9?>I,'F( M_ ACZ]J529LF28!38.>?B$=LNIJ/K+BKV4Q:1L0\+!FL+%MQ$3MOAEOQ:@XX(%F,=LNGEU APP'% MT1'8L7Y*:<8AEU,BGI4[042'CUI;Y:]5,:Q>2.5)#KP3E(:AI8@Z)#8R27XO M<9)2A,JK;5A8(G-&AEFAFLG/V>%&4.K]TJ(]?L72://5/<72"'>K2V.],I%A MO6V!%J](A,E88EZG1 MRLK&5%G\7C;&9NV,9D&<.W8)IZ=+[0J?$>A+G3_A1E&^6WB0E&(A7:*3 5XK M6:V"?8^S7/L!;:I5';F[98ZZ@M"W,9-1$I45:(7789H7M+>:XVFW9T8PU_R> M(,S[[^X1%UL=!SA!F3D9>$7M?4CS#4LNQE>%R9@NJ5SM;L01^IUH5_4J,D^B79WA-RL6JIWVOK6J40-30[:CD8/R_F64 M\.PA]B6SXC"'',XG),59@F;O,4<-+$,JY=)B#]R2'E"I,'*XDES). "XF&MU M?YB:)DB]-*5"QR(;FA?:.M]8TQMI=:A82U9,P306%-."\&ZM]V,_>908AD_< M0F1TBLD;E*7"3>EP1/#Q)+D#3(]$[XU!\W$2@H_^0FIG^?8ZTV[ T/%Q;NA) M M* 0NM!88#7G6(2\<^^ DZ#45">F,AC9Y,A7Y=W"F=#,"9OI"KFKP6 39\$JP6V]2]0*6SZ'G5RV M7! Z+ +F86WLI&F4C B?IC-MZ[@\S/[&>79=7>PM,P0DI;.MR&&L_T=*]1J? M%E>6"RWA%"',*D_JR$6^3Z+E>PEZ4:38G=R)^:\5\X_<0(>]:'4;4?"1J_.N MUI:G#4*#YURXS3F ^$SB5"-VTS9]U7A=2\G--J=V:SX3D\4G3((E1FMU?F'T&U&1A/[#B8U>65N4I*6A7BEFKM,1_LDT;%XDQ11L"D> M@(ZH9Q-#[QWNK,.==;BS#G?6XN+,-\=B22V."7AW6;[GX,M%' M!,B]P;ISD4[U/=17KA4%+0SC0J^P+VXW*AKNK;5[GBJ\%;=V'QI7H0LFTO.2 M,*%YAXP!C-'\V,3PS"JB68WR+N\YS:CU-J91W98[' M7"N*)MEQ[+F+P+- =C[@OZY*3#"E#O'DC.&H 3UEQ2.I/-JQDWP,F' M3I6R*%)3(J=QZY25>Z16>XO>M *RQZ"^B4L7!,("GVJXMT$Z1$1)+M7'3#$& MKH]1!WR6#6ZTF""JU7U3.RP<&IJ%LX'-U[> 3)VG>$SR;0GFS5V-#3]*.7_? MF06/Z]19/]=J\.4*$4'$\/47&=&:I,VN.3\YTVJELI7$&//AU'#N5"P[/)P3QE M*:;*X[>':P-]ELWV;@@@%MI3,A.Y*)?-0"U\+_BFW36<@HV=0VVJK^G#;YG. MMO>,\]F^AOML_SDRS/910Q!N0[^B(;PQ5FB+AK RU-HB[ZC^L6@K:;,0B1^3 M\G+TN(2#3[XF-YJE[V%.%H*R7$ M[!;#DU./7)\Q?0#3&"N411Y#2X@>F)!H.3FH/6,Q6(/ 8 D1'N%U&^R1\H8W MC+[SWNT^3H@S.\+-LS5:,H*E/*QL275*GW& MZ-!=*-F+!6Z6E_]J0:%E;3MFNR6:NFBY0RF@@1BMVY[X+PQ)(*WDDC(O*Q9< MA_!A^_!.#J=.PWZ AKUV%=M,*ZG8FV XMC>NT[,[/9L;W;\E>1TG\Y&M SJI%F6U*$_#W9L5(XQL8)P M; :CGHD$CV$V2I;?R413!* ,[N(WQJ?-2<,8BL!O3;3@-M^QFRW&WNG;4BCQ M9](:[PAXEB2]A@_?LDW@**Z;+Y!V\5U\@?M5!(_#%[C7$09N(':E VYVP,T. MN-D!-SO@9@?<[(";SQ.XV5E^3^BWWI!&]\#&F<.: &4*S0:43#OL[ZV@,/DS M 6_"JCO:8:00*ZE&@O',+*1:H1!C#E9[QP0ZH)(Q9>"U%@":@.=JJ"[;+S98 M77RK&)2E'[X%67R+S?9<=^SFN)F?JWN\9U>HQ>,BLLJE=/*;'$WE[G$KRAGW M--9\PYIT",V\>VN:@$[M@5@HB;:XH+NJM7VHX%SM"H&MTVO%65-'H5"45V,H M+![S+A=2H.W[" 4'.%ZYZ.%BXG']]']Y[@*]'M SHGX9#7-2 GP;6*M&Q<EPS@J)GC8QKLX/!B^&VLK?.?2EU)>-&[WW(P#6Q&W>,84ON1B+(;U<_H>F6>\N@":+(. ?0A#@JMWF&IX%FX8$$TF+@[/PKU-25($)LQYB-0NH\$S9W"(T"I/K# MLC@Y<7.X&2$A:H-Y#I&FK+WV0: MNV62JS W+P+#FM(/7+1YR3VSXH3?)L2_N@ U&U] 8L)D^Q68RF?@,0O.'D%= M!*7B?)X$(GG&/B+(.,T J;;\B 2F],14&6PCQ&G05W-N34/&8%7,5#L:$PSJ MBKDP]1@K[0UPXTJY9RZ-^A D)J,EJK70L:YZ*'49RQ+(6"_1X6$, MC1".$TRGIO86*W,L(B+B*D0A8H*2Q!SOT;PL8 .X>2 -H9.P4XD M/K9(G*Y#)/ZN8YWZ$F7^+)9*QV((PMRJV\1AP;*Z MR;2:HJA8C:^DGV&4SF,[Z?+HTF6V#NDBZ=#'94$!*7%BG2*H-F$" M:_"@!-:Y_]GUF3#'-M;X;3W]+7\6E]Q@>F+C$"PKHMPGYY),J3+G$7]U,AI+ M.8'':=O3;&(X*XHFVY2TQ'&8CHLY%=N6[$Z-7 Q%T9F=4PS+5_3)6Q!SUM& MD8(!(18"1N<;JTVK:1%R.BVV 3-K0=6!F:3!V+89K+.PXI5:87+6*0(KG,0/ M3X%RWF)*3MR2'#DF_:E*I&IHJ%V/.DLQ!%"' 0\%?A*6.B&,6$6AN()TP7/P MXK=3LMY)%5#:H=4\8UDICF[H."$X'98X%D:Z=E"L!%E1,K6YRCKR*L;MZ@P.&\_ (N?%I MEO07'YZEZ?ADC03YKN/,]1O,Z)A#Z!HZ%Q!MMREY=1T/WB9&E#LX50>GZN!4 M'9RJ@U-U<*H.3O4\X50;$A265$W0.SFQ(@#C)D3:,:37J\26X"G.A0HL])A*RSD ML$;YJ8C$(L?G2*S90$(<[OWHYM'_+& ;F-@)_T;Q>(J>4;DH6O5E8XV#@=FU MX,GV0O)D,]4%VJ)$ 1CF1>G'*1]"CM"Q1F) CW^K1M2G.F=+=U)0)RP;%G$8 MP )&)BVR]S&2)F6FZ/VXM81LL.RJXQ'>[0I(?WTBX.OGB =](H8EK >FZY6E M;ZT"+)%I7+Y%'/ZSP)!(7E!2WNK(JM?T[J%2Q@1WY&0K Y48>(0M4$17@S34/+]!.D%V24,$B(.VAQR MM>:RK"4($->[+J-K5(R7 C:P,$ 7_MA9!2&,!3?".10& #*U%02_Z:B M+XV#(:E$K%-C4G"^(F@^^DLGH;C@A91"IH:@"7SYKKJ:D8^0,TL+]N<+U!=& MZ!]%&F:!D,$&.B?WL6ZX8,W2TX%Q[]; &_ZM04NO/I \AF6WT2&DQU*JJXQL MTLL:(^#?^*GPBF U$(K^,4&Q \WP05:DL5[:XH 3+1MSG"!8 <:_2%-N++0\ MU@X9+161HCKM676EK7"H8O!A!V$>LAOEWC;Z71_ONN0$0/4*R/?3BI"PQKI50:U@2,9>^XU,F$AQ@G"]8I0,;A/FJ> M!,U3V!K8]LWP,[_4%VH">DBDI\)V/ K9Z'!?4@7'#JNO0&V"J!F@W=&JN,?Y9_DV+WI2Y-+=97)+GJ.UX M)6)=T7O4G1U/>';\U)T=#SH[KA"NXK,WV$*WB?K+B/,6:8ZR&\,54IJWB$4] MI@5-:83(=<;;$*R>(T=-#NM/AVMA$S(G>H@Y#'2^4')6O9J(BR<,L"GB[6*; MAL3A"JN&VXG&%!X(:>('1]4S"Z41Z(!9SO:)P8"0"3O7%C."KN=Y,3?8D8J\ M@0&F@N/8O3"^AMD,J+(XP?-('J?7U$MYE/_%>917FH!&H9V#0DSN:RZQ+E)9 M3B !?!LHY%R \(@267$"DQ^;K\3.DLN-;9KR*'=R87!9W+X(K$G!54 *5!=0 M;0XT L_HL&K"2"NYL*VL]62D1CYC_;D -/HZ>!XK4'TV(-%)F.6.,\,@M6#( M ZH/&?!A7FF\R[CGE?E0I3L3CZ% 3P@&PX<)U:$1TX8&;NZX>06T7PY7B:CM MQ/\3BO^?._'_0&*] M475'-M8>.JA\-F9,"?P9QKH<)F10ZD%P'DNM EBHZ M&Z$!Z+^Y'U%,#0.J:1*'8Y7!LPEO(#G4+:8\V=-6]16_NY]9C1J?>*-SYU'D M+'+5_ZK^WK2Y*X:$9].1R(J@]Z&[FBJLE?XD9%&.Z*7L[\$54O7HHP\4P&*-^E>AIF.44ZT6&'^W6" M](!X)?N3$22$C!6([J!,1XY*@?2+F7YKD9LUH(-=VQT#&G9"J5BU.6:X5* 9 M)B$/6.5;>&KSL*)]N X(OJ:N23S,7"3!1W>_^OE1E>&[S],GEAHNU XER*&Z MA_E0#M?!^D>+BR(T__N@?CRRBV SIUVT%)KVVB[?H-W2XNBX:R3+<,OIZ?%3 MTTRX7]VB'#0=$KL5;X2G5C@.-K,'[5Z(#6]T+\_C0_6N@-=AY@,333R'AE\@ M<=ZA>KE_L'OP^N7N+S_O/=TBN6\;^Z32P/!>_I]VC\\S.%[8N-WG#W_6E?!< MCJ!Z9Z_ @/TUK#K+:"VA 1^.'U/'[RTP2A]^4?N_O@A_4UNW-0,:2I@_RQ_) M",/PM^VU.AI[&V692U4FUV+=VM2J-G5F!'.\. M\M!) YB$*;2[UJO.K?0-:@_L=7^Q+Q?=O,(ISI -&_ MQ-@:5E@$/>%$]2-TE%6\8=4RN_2%N)?@4ZRG8$R9[PW?%F'1*4>CF1OJY[4> ML+^.DL,(VN_%32DF!9J,7&AZ, DY_P08AV71+$A/=QG@4 @F&DA$[ MRK0P.](=)1(,768@*$+R@#5=[S""^-HBUSPR< ?1DG**F,?T[? 3K+F$('%% M)JST#GX- 9'Z"T(L':AB!5_(LY;G[$*'-W2HM"<4;@^KJ;G1?7D:^E1VZ,*Y M?.K?&%B:MLD-D3C2VV2:@,I,2 S!'@3F3$.B5V;?.V?)U5/^ZEL=TSXXV980 M;TBH:K"E&<:A0R[07!9VSI,T]UJAI2 $IM0G@2Q+%@>C9EN(ZBD5QK^Q<-\/ M<8A;]PH%%'W9F\,\CWV+5J-?JO1SNJ[D^9D$TL1$6 MR9.LLVU<6Y[DQT24"<1P7AI[SB;DU%XSH3*-LHX<+NGQ+($QW4DF.YCF*\7D M(PR1]@R@V9,%7&89TF)QDD;-*D6]-9G<:YDJ(1>VNV(6+FY'6]O@Q(@X*7,B MJ#:'G:[BYBL+JK%L5HX<9D(7D7[@$(*6#>=5S#D!8%2$.L[:1](V';>.#7Q7 M6@Y-X.?18:SY;(1''!^?7YX,SGX__>2I-^?#=^JB=SD<]*_4N_YE_\TG=7Q^ M=M4_&ZKAN1J^ZZO^?QZ??K@:_-%7__?#Y>#J9' \')R?J?.W].O;_DG_LG>J M>FGX,?YVHCX/AN\$975NY'[[[^&YP_(Y^.7_[=G#< M5P-[6W(Q/ M":$ZY'P-NME)[Y?VEX]IKVWCXE8JV2^^#$;]F92L+D]$0F5.U^DPY1VFO,.4 M=YCR#E/>8\PY1VF?%V8X%K5D<)$#/RX&$UA3>D MU4]B_/;(A>H0+%6*@]*/+?ZYN\Q)V'L[51>=R:PV19U@:^UP\L1D O)#B!>1 MN2P,0C^M%%OQ.($BM^6M_+%4LZ)DZ+16RD0RI)LL.5CD@ZN!V?O!@$:3V?2K M49[9>4Z-\0A+H'"\+N0&FL);I5O0Y_V>9>SVM,5]''A$@_-)*C92ZG=6.@;* M^+Z61U%5:.JIM#IC!/_3B;Z%2J M#Z+L(TF9+'1J>8&%&=+/*I4*)0A OQC>1I1HG7OP"67AJ\X]^$!""0QV-TLN MO]K[I><03)0XLBJM$.[Z6*+8N"FC)3W&4UM$PH;)9G/8SUAD:MNK/-SH!@-. M$XG4)0*3"B1K"TA*[?_R\X\>J1ES>H57*P151B+$SV@B=X9QWC+BD6A:I)I< MDQ2Y@_&/EE2JS!#!C<%$A6'W*CDOW$,L,(JEERI])2 7RZE1$A=$N\E<21+> M]REXR)377/VTDP-/* <>1H:]T7UY$CGP1N@;:XR4PQ4<4H;MD=9WN?O"N$@M M;;9#$,\YH*W138F(AZD!!B%6T&H67+T,Q@,^X$4"!&JC3#9S,M#.L6KJH=H*M_&B22CEPIL1,*M2"ABJ6*).YEJ8%K MJ&/%&2=09MZVVHTL,GE5\$:N&I,=+# MY7#PZO%G*N^)<$FWZC@BB! T;2%SVYYD?V(;4<%9=>_V$5[H87O;&FSR1BV< MWL7HV#FOQE$%,23H16MOM*I1[*\9$9\>UP^)DJQFJ,7J!%I!U1T/?O;4P5XE M#MX>COQ6WBB.!=T"G[\C%\'0#Z@+1$+*X= Z$@T[&+&&HWG.:QH]3ZY M1MV+LW(=#@)W@ [L (5/YJ##85B=_/W#;X@@&0S/^E=7ZB-"5\[?8KJV)_4E M$"7+UC#78$$:Q:#%[>"RM_EV._;M,&#Y6 K,@Z;*-;YW-RE@N]X,Z=W7CM8E M.=+TW;?(DEY[KM)="["QIW#]/:]TK#N[:--WW9X])'MW([K8")ZYO?S>4NR^ M:8>?VU3;H_%0OJ#=I$M^ X'[C9SGHB,]N(FO=<<_KYSM'WW6"Z]?T[[E- MY)D_AX7YW/<8]Z+;6M]U_Y[;1 ZQ1-6A.IYA@N^%3L"DE^R#]-E-&II0ATUC M\OE.3K?+OI-==N?*?";]^+H)^XXY*[Z79G2X_ Z7W^'R.UQ^A\OOA!D=#;PA/#69@&#+!^5 L"O@H0P M)5R1;GUMX^/Y0LB2 P^B\IKXKK7%C<"*Y@AR)6=; G'/+H/Y85A M%"0.^FR!%.]"7R*095S"!'ZN-8V0ADY[N+(%]&:)G ?(U[:%D%^J6K>]OK4< M(\5C:+@@Y_YG[$\)MC3ENADHY@R[VS4S5N7R]E#NW,BPIAHD+E7\L[,K15=Q M]Z1ZGHCT*F=MR"1ID2K74"2PE& 4_R@@FS@N2,]8(GL;D=)):DX)X/0T_ M:R9KJK5CE'*5 ^%O*)];24GY))L9[\#E+0"ZLI68[;)BO=,;DQ'R08!<$Q9/ MKH];-I+1?C%W!!-I>'$Y23$5X8(?W5?

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end XML 103 enfn-20231231x10k_htm.xml IDEA: XBRL DOCUMENT 0001868912 enfn:PreferredUnitsMember 2021-10-20 0001868912 enfn:PreferredUnitsMember 2020-12-31 0001868912 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-01-11 2024-01-11 0001868912 us-gaap:CommonClassAMember 2023-08-01 2023-08-01 0001868912 us-gaap:CommonClassAMember 2023-07-19 2023-07-19 0001868912 us-gaap:CommonClassAMember 2023-03-28 2023-03-28 0001868912 us-gaap:CommonClassAMember 2023-02-21 2023-02-21 0001868912 us-gaap:CapitalUnitsMember 2021-10-01 2021-10-31 0001868912 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2023-12-31 0001868912 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:NoncontrollingInterestMember 2023-12-31 0001868912 us-gaap:RetainedEarningsMember 2023-12-31 0001868912 us-gaap:NoncontrollingInterestMember 2023-12-31 0001868912 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001868912 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2023-12-31 0001868912 us-gaap:RetainedEarningsMember 2022-12-31 0001868912 us-gaap:NoncontrollingInterestMember 2022-12-31 0001868912 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001868912 us-gaap:RetainedEarningsMember 2021-12-31 0001868912 us-gaap:NoncontrollingInterestMember 2021-12-31 0001868912 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-20 0001868912 2021-10-20 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001868912 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-12-31 0001868912 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001868912 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-12-31 0001868912 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001868912 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001868912 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001868912 enfn:FtvInvestmentHoldingsMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2023-06-15 0001868912 us-gaap:EmployeeStockOptionMember 2022-12-31 0001868912 enfn:StockOptionAndIncentivePlan2021Member us-gaap:CommonClassAMember 2021-10-31 0001868912 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001868912 enfn:PerformanceBasedRestrictedStockUnitsRSUsMember 2022-12-31 0001868912 enfn:PerformanceBasedRestrictedStockUnitsRSUsMember 2021-12-31 0001868912 enfn:ClassaCommonStockVestedAndRestrictedStockUnitsMember 2022-01-01 2022-12-31 0001868912 enfn:PerformanceBasedRestrictedStockUnitsRSUsMember 2023-10-01 2023-12-31 0001868912 enfn:ContingentlyIssuableSharesMember us-gaap:CommonClassAMember us-gaap:IPOMember 2021-10-01 2021-10-31 0001868912 us-gaap:RestrictedStockUnitsRSUMember 2021-10-01 2021-10-31 0001868912 enfn:PerformanceBasedRestrictedStockUnitsRSUsMember 2021-10-01 2021-10-31 0001868912 2027-01-01 2023-12-31 0001868912 2025-01-01 2023-12-31 0001868912 2024-01-01 2023-12-31 0001868912 2026-01-01 2023-12-31 0001868912 country:US 2023-01-01 2023-12-31 0001868912 country:US 2022-01-01 2022-12-31 0001868912 country:US 2021-01-01 2021-12-31 0001868912 us-gaap:SoftwareDevelopmentMember 2023-12-31 0001868912 country:US 2023-12-31 0001868912 country:US 2022-12-31 0001868912 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0001868912 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001868912 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001868912 us-gaap:ComputerEquipmentMember 2023-12-31 0001868912 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-12-31 0001868912 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001868912 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001868912 us-gaap:ComputerEquipmentMember 2022-12-31 0001868912 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001868912 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001868912 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2023-08-14 2023-08-14 0001868912 enfn:FtvEnfusionHoldingsIncMember us-gaap:RelatedPartyMember 2023-01-01 2023-03-31 0001868912 enfn:FtvEnfusionHoldingsIncMember us-gaap:RelatedPartyMember 2023-06-27 2023-06-27 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-21 2021-12-31 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-10-20 0001868912 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001868912 us-gaap:DomesticCountryMember 2023-12-31 0001868912 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0001868912 us-gaap:DomesticCountryMember 2022-12-31 0001868912 enfn:EnfusionLtd.LlcMember 2023-12-31 0001868912 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember enfn:NewCreditAgreementMember 2023-09-15 2023-09-15 0001868912 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember enfn:NewCreditAgreementMember 2023-09-15 2023-09-15 0001868912 us-gaap:RevolvingCreditFacilityMember enfn:NewCreditAgreementMember 2023-01-01 2023-12-31 0001868912 us-gaap:RevolvingCreditFacilityMember enfn:NewCreditAgreementMember 2023-09-15 0001868912 us-gaap:LetterOfCreditMember enfn:NewCreditAgreementMember 2023-09-15 0001868912 enfn:SwinglineSubfacilityMember enfn:NewCreditAgreementMember 2023-09-15 0001868912 enfn:NewCreditAgreementMember 2023-12-31 0001868912 us-gaap:RevolvingCreditFacilityMember enfn:PriorCreditAgreementMember 2023-09-15 0001868912 us-gaap:RevolvingCreditFacilityMember enfn:PriorCreditAgreementMember 2023-09-15 2023-09-15 0001868912 enfn:PerformanceBasedRestrictedStockUnitsRSUsMember 2023-12-31 0001868912 us-gaap:EmployeeStockOptionMember 2023-12-31 0001868912 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember enfn:NewCreditAgreementMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-09-15 2023-09-15 0001868912 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember enfn:NewCreditAgreementMember us-gaap:BaseRateMember 2023-09-15 2023-09-15 0001868912 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember enfn:NewCreditAgreementMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-09-15 2023-09-15 0001868912 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember enfn:NewCreditAgreementMember us-gaap:BaseRateMember 2023-09-15 2023-09-15 0001868912 us-gaap:RevolvingCreditFacilityMember enfn:NewCreditAgreementMember us-gaap:FederalFundsEffectiveSwapRateMember 2023-09-15 2023-09-15 0001868912 us-gaap:RevolvingCreditFacilityMember enfn:NewCreditAgreementMember enfn:OneMonthAdjustedTermSecuredOvernightFinancingRateSofrMember 2023-09-15 2023-09-15 0001868912 enfn:PlatformSubscriptionsMember 2023-01-01 2023-12-31 0001868912 enfn:OtherServicesMember 2023-01-01 2023-12-31 0001868912 enfn:ManagedServicesMember 2023-01-01 2023-12-31 0001868912 enfn:PlatformSubscriptionsMember 2022-01-01 2022-12-31 0001868912 enfn:OtherServicesMember 2022-01-01 2022-12-31 0001868912 enfn:ManagedServicesMember 2022-01-01 2022-12-31 0001868912 enfn:PlatformSubscriptionsMember 2021-01-01 2021-12-31 0001868912 enfn:OtherServicesMember 2021-01-01 2021-12-31 0001868912 enfn:ManagedServicesMember 2021-01-01 2021-12-31 0001868912 us-gaap:EMEAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0001868912 srt:AsiaPacificMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0001868912 srt:AmericasMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0001868912 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0001868912 us-gaap:EMEAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0001868912 srt:AsiaPacificMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0001868912 srt:AmericasMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0001868912 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0001868912 us-gaap:EMEAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0001868912 srt:AsiaPacificMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0001868912 srt:AmericasMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0001868912 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0001868912 us-gaap:MemberUnitsMember 2021-10-20 0001868912 us-gaap:MemberUnitsMember 2020-12-31 0001868912 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2023-08-14 0001868912 us-gaap:CommonClassBMember 2022-12-31 0001868912 us-gaap:CommonClassAMember 2022-12-31 0001868912 2020-12-31 0001868912 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001868912 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001868912 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001868912 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001868912 us-gaap:CommonClassBMember 2022-01-01 2022-12-31 0001868912 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001868912 us-gaap:CommonClassBMember 2021-01-01 2021-12-31 0001868912 enfn:ContingentlyIssuableClassCommonStockMember 2021-01-01 2021-12-31 0001868912 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201613Member 2022-12-31 0001868912 enfn:ContingentlyIssuableSharesMember us-gaap:CommonClassAMember us-gaap:IPOMember 2023-01-01 2023-12-31 0001868912 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-12-31 0001868912 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001868912 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001868912 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001868912 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001868912 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-12-31 0001868912 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001868912 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001868912 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001868912 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001868912 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-10-01 2021-10-31 0001868912 enfn:ContingentlyIssuableSharesMember us-gaap:CommonClassAMember us-gaap:IPOMember 2021-01-01 2021-12-31 0001868912 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-12-31 0001868912 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001868912 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001868912 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001868912 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001868912 enfn:PreferredUnitsMember 2021-10-21 2021-12-31 0001868912 enfn:PreferredUnitsMember 2021-01-01 2021-10-20 0001868912 enfn:EnfusionLtd.LlcMember 2023-12-31 0001868912 enfn:EnfusionLtd.LlcMember 2022-12-31 0001868912 enfn:PerformanceBasedRestrictedStockUnitsRSUsMember 2022-01-01 2022-12-31 0001868912 enfn:PerformanceBasedRestrictedStockUnitsRSUsMember 2021-01-01 2021-12-31 0001868912 enfn:ClassaCommonStockVestedAndRestrictedStockUnitsMember 2023-12-31 0001868912 enfn:ClassaCommonStockVestedAndRestrictedStockUnitsMember 2022-12-31 0001868912 enfn:ClassaCommonStockVestedAndRestrictedStockUnitsMember 2023-01-01 2023-12-31 0001868912 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001868912 enfn:PerformanceBasedRestrictedStockUnitsRSUsMember 2023-01-01 2023-12-31 0001868912 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0001868912 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001868912 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001868912 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001868912 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001868912 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001868912 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001868912 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001868912 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-10-21 2021-12-31 0001868912 us-gaap:MemberUnitsMember 2021-10-21 2021-12-31 0001868912 us-gaap:AdditionalPaidInCapitalMember 2021-10-21 2021-12-31 0001868912 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-10-21 2021-12-31 0001868912 enfn:ContingentlyIssuableSharesMember us-gaap:CommonClassAMember us-gaap:IPOMember 2022-01-01 2022-12-31 0001868912 enfn:StockOptionAndIncentivePlan2021Member 2021-10-01 2021-10-31 0001868912 us-gaap:CommonClassBMember 2023-12-31 0001868912 us-gaap:CommonClassAMember 2023-12-31 0001868912 enfn:EnfusionLtd.LlcMember 2023-01-01 2023-12-31 0001868912 enfn:EnfusionLtd.LlcMember 2022-01-01 2022-12-31 0001868912 enfn:FtvInvestmentHoldingsMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2023-06-15 2023-06-15 0001868912 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:CommonClassAMember 2021-10-31 0001868912 srt:MaximumMember enfn:NewCreditAgreementMember 2023-09-15 2023-09-15 0001868912 enfn:MajorCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001868912 enfn:MajorCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001868912 enfn:MajorCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001868912 enfn:MajorCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001868912 us-gaap:RetainedEarningsMember 2021-10-21 2021-12-31 0001868912 us-gaap:NoncontrollingInterestMember 2021-10-21 2021-12-31 0001868912 2021-10-21 2021-12-31 0001868912 enfn:NewCreditAgreementMember us-gaap:SubsequentEventMember 2024-02-29 0001868912 enfn:NewCreditAgreementMember 2023-09-15 0001868912 2021-12-31 0001868912 us-gaap:MemberUnitsMember 2021-01-01 2021-10-20 0001868912 2021-01-01 2021-10-20 0001868912 us-gaap:RevolvingCreditFacilityMember enfn:NewCreditAgreementMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-09-15 2023-09-15 0001868912 us-gaap:SubsequentEventMember 2024-01-11 2024-01-11 0001868912 2023-08-01 2023-08-01 0001868912 2023-07-19 2023-07-19 0001868912 2023-03-28 2023-03-28 0001868912 2023-02-21 2023-02-21 0001868912 enfn:FtvFundIvMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2023-06-15 0001868912 2021-01-01 2021-12-31 0001868912 2023-12-31 0001868912 2022-12-31 0001868912 2022-01-01 2022-12-31 0001868912 enfn:OlegMovchanMember 2023-12-31 0001868912 enfn:OlegMovchanMember 2023-10-01 2023-12-31 0001868912 2023-06-30 0001868912 us-gaap:CommonStockMember 2024-03-08 0001868912 us-gaap:CommonClassBMember 2024-03-08 0001868912 us-gaap:CommonClassAMember 2024-03-08 0001868912 2023-01-01 2023-12-31 shares iso4217:USD pure enfn:customer enfn:lease enfn:subsidiary enfn:Vote iso4217:USD shares enfn:segment 0001868912 2023 FY false 0 0 70860000 88332000 43199000 39199000 http://fasb.org/us-gaap/2023#UsefulLifeTermOfLeaseMember P1Y P1Y P1Y P1Y -149000 10-K true 2023-12-31 --12-31 false 001-40949 ENFUSION, INC. DE 87-1268462 125 South Clark Street Suite 750 Chicago IL 60603 312 253-9800 Class A common stock, par value $0.001 per share ENFN NYSE No No Yes Yes Accelerated Filer false true false false false false 438200000 128069912 89871145 38198767 42 Ernst & Young LLP Chicago, Illinois 35604000 62545000 28069000 25855000 5009000 6105000 1170000 2303000 69852000 96808000 18314000 15759000 14304000 6732000 6502000 4484000 108972000 123783000 2212000 1685000 13841000 11665000 4256000 4030000 20309000 17380000 11181000 2959000 31490000 20339000 0.001 0.001 100000000 100000000 0 0 0.001 0.001 1000000000 1000000000 88332000 70860000 88000 71000 0.001 0.001 150000000 150000000 39199000 43199000 39000 43000 226877000 244260000 -172932000 -178863000 -406000 -504000 53666000 65007000 23816000 38437000 77482000 103444000 108972000 123783000 161519000 138868000 103259000 11773000 9821000 7119000 1243000 1660000 1322000 174535000 150349000 111700000 50702000 40017000 27195000 6514000 6692000 4425000 425000 391000 225000 57641000 47100000 31845000 116894000 103249000 79855000 64635000 68764000 150614000 20418000 29286000 51725000 19893000 17163000 153400000 104946000 115213000 355739000 11948000 -11964000 -275884000 1501000 1641000 413000 -4594000 -604000 -638000 -1185000 -464000 -225000 -5779000 11484000 -12189000 -281663000 2231000 1074000 579000 9253000 -13263000 -282242000 3228000 -5609000 -123925000 6025000 -7654000 -158317000 0.07 0.07 -0.10 -2.26 0.07 -0.10 -2.26 88202000 85393000 83045000 129429000 85393000 83045000 9253000 -13263000 -282242000 143000 -327000 -90000 9396000 -13590000 -282332000 3273000 -5757000 -123902000 6123000 -7833000 -158430000 54000 165515000 48000 -233347000 -212000 -233559000 6814000 6078000 6078000 -145000 -145000 1807000 1476000 1476000 54000 170522000 48000 -228745000 -357000 -229102000 -54000 -170522000 -48000 -228745000 -48744000 -49000 -52998000 -53000 27941000 30384000 -170522000 16839000 17000 143628000 116065000 259710000 -5527000 6000 50956000 36884000 87846000 -171209000 -123925000 -295134000 161986000 117250000 279236000 32000 23000 55000 65583000 66000 47471000 47000 226717000 -171209000 -325000 42145000 97441000 -7654000 -5609000 -13263000 15043000 10550000 25593000 4272000 4000 -4272000 -4000 5310000 -5310000 1594000 2000 -2000 589000 1000 4767000 3191000 7959000 -179000 -148000 -327000 1959000 1959000 70860000 71000 43199000 43000 244260000 -178863000 -504000 38437000 103444000 6025000 3228000 9253000 5628000 2596000 8224000 4000000 4000 -4000000 -4000 2559000 -2559000 11272000 11000 1729000 -1740000 2200000 2000 12401000 4919000 17322000 -94000 -55000 -149000 39497000 20950000 60447000 98000 45000 143000 -203000 -105000 -308000 88332000 88000 39199000 39000 226877000 -172932000 -406000 23816000 77482000 9253000 -13263000 -282242000 6882000 5351000 9987000 6344000 3975000 1319000 1399000 1450000 92000 26000 222000 -78000 -1215000 7458000 24993000 289803000 3679000 9031000 7493000 1749000 1767000 6477000 365000 -843000 2044000 -729000 7087000 -2081000 2359000 -1029000 -734000 -6002000 -5111000 25634000 14156000 -318000 4453000 3985000 6096000 -5218000 -3946000 -1918000 -9671000 -7931000 -8014000 1151000 1501000 17322000 260545000 60447000 7959000 10567000 100000000 3283000 87846000 -308000 -43083000 -7959000 58849000 179000 -86000 -90000 -26941000 -1820000 50427000 62545000 64365000 13938000 35604000 62545000 64365000 1843000 1582000 407000 4813000 13893000 9514000 766000 600000 608000 58223000 835000 1959000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1   Organization and Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Enfusion is a leading provider of cloud-based order and execution management, portfolio management and risk systems. Enfusion’s clients include large global hedge fund managers, institutional asset managers, family offices and other institutional investors. Enfusion provides its clients with innovative real-time performance, risk calculations, and accounting capabilities for some of the most sophisticated financial products. The Company is headquartered in Chicago, Illinois and has offices in New York City, London, Dublin, Hong Kong, Singapore, Mumbai, Bengaluru, and Sydney. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Enfusion, Inc. was incorporated in Delaware on June 11, 2021 for the purpose of facilitating an initial public offering, which was completed on October 25, 2021, and other related transactions in order to carry on the business of Enfusion Ltd. LLC. Enfusion, Inc. is a holding company and, through its control over the managing member of Enfusion Ltd. LLC, operates and controls Enfusion Ltd. LLC. Enfusion, Inc.’s principal asset consists of Common Units.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Enfusion, Inc. has three wholly-owned subsidiaries: Enfusion US 1, Inc., Enfusion US 2, Inc., and Enfusion US 3, Inc.; as well as a controlling financial interest in Enfusion Ltd. LLC and its majority-owned subsidiary, Enfusion Softech India Private Limited, as well as the wholly-owned subsidiaries of Enfusion Ltd. LLC: Enfusion Systems UK Ltd, Enfusion HK Limited, Enfusion Software Limited, Enfusion (Singapore) Pte. Ltd., Enfusion do Brasil Tecnologia da Informacão Ltd, Enfusion (Australia) Pty. Ltd., Enfusion (Shanghai) Co., and Enfusion Tech Ltd. Enfusion, Inc., through its control over the managing member of Enfusion Ltd. LLC, manages and operates Enfusion Ltd. LLC’s business and controls its strategic decisions and day-to-day operations. As such, Enfusion, Inc. consolidates the financial results of Enfusion Ltd. LLC, and a portion of Enfusion, Inc.’s net income (loss) is allocated to non-controlling interests to reflect the entitlement to a portion of Enfusion Ltd. LLC’s net income (loss) by the other common unitholders of Enfusion, Ltd. LLC. As of December 31, 2023, Enfusion, Inc. owned 69.3% of Enfusion Ltd. LLC.</p> 3 0.693 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 2   Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Principles of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These statements have been prepared in conformity with U.S. GAAP. All intercompany balances and transactions are eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. We base our estimates on historical experience and various other assumptions believed to be reasonable. These estimates and assumptions include, but are not limited to, judgments affecting the measurement of the payable to related parties pursuant to the Tax Receivable Agreement, amortization periods, certain assumptions used in the valuation of stock-based compensation, assessment of the allowance for credit losses, and accounting for income taxes and assessment of valuation allowances. Actual results could differ from those estimates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s results can also be affected by economic, political, legislative, regulatory, and legal actions, including but not limited to health epidemics and pandemics and the resulting economic impact. Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, and government fiscal policies can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities and carries various levels of insurance, the Company could be affected by civil, criminal, regulatory, or administrative actions, claims, or proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain amounts in prior periods have been reclassified to conform with the current period presentation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the CODM. While the Company operates in multiple countries, the Company’s business operates as one operating segment because most of the Company’s service offerings are delivered and supported on a global basis, the Company’s service offerings are deployed in a nearly identical way, and the Company’s CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Principles of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These statements have been prepared in conformity with U.S. GAAP. All intercompany balances and transactions are eliminated in consolidation.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. We base our estimates on historical experience and various other assumptions believed to be reasonable. These estimates and assumptions include, but are not limited to, judgments affecting the measurement of the payable to related parties pursuant to the Tax Receivable Agreement, amortization periods, certain assumptions used in the valuation of stock-based compensation, assessment of the allowance for credit losses, and accounting for income taxes and assessment of valuation allowances. Actual results could differ from those estimates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s results can also be affected by economic, political, legislative, regulatory, and legal actions, including but not limited to health epidemics and pandemics and the resulting economic impact. Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, and government fiscal policies can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities and carries various levels of insurance, the Company could be affected by civil, criminal, regulatory, or administrative actions, claims, or proceedings.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain amounts in prior periods have been reclassified to conform with the current period presentation.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the CODM. While the Company operates in multiple countries, the Company’s business operates as one operating segment because most of the Company’s service offerings are delivered and supported on a global basis, the Company’s service offerings are deployed in a nearly identical way, and the Company’s CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.</p> 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 3   Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The significant accounting policies of the Company and its subsidiaries are summarized below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments purchased with an initial maturity date of three months or less to be cash equivalents. Funds held as investments in money market funds are included within cash and cash equivalents. As of December 31, 2023 and 2022, respectively, the Company had $30.0 million and $50.0 million, respectively, invested in money market accounts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accounts Receivable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable includes billed and unbilled receivables, net of allowances, including the allowance for credit losses. Billed accounts receivable are initially recorded upon the invoicing to clients with payment due within 30 days. Unbilled accounts receivable represent revenue recognized on contracts for which the timing of invoicing to clients differs from the timing of revenue recognition. Unbilled accounts receivable was $2.4 million and $2.0 million as of December 31, 2023 and 2022, respectively. Contract assets included in unbilled accounts receivable were $1.7 million and $1.5 million as of December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains an allowance for credit losses at an amount estimated to be sufficient to provide adequate protection against losses resulting from extending credit to its clients. The Company regularly determines the adequacy of the allowance based on its assessment of the collectability of the accounts receivable by considering the age of each outstanding invoice, the collection history of each client, an evaluation of the current expected risk of credit loss, and other client-specific factors with a bearing on receivables. The Company assesses collectability by reviewing accounts receivable on an aggregated basis where similar characteristics exist and on an individual basis for specific clients with historical collectability issues or known financial difficulties. Increases to the allowance are recognized as a charge to credit losses included in general and administrative expenses in the consolidated statements of operations. Accounts receivable deemed uncollectible are charged against the allowance for credit losses when identified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company's allowance for credit losses is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 791</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes to the provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,158</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts written off, net of recoveries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (724)</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,225</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adoption of ASU 2016-13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 149</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes to the provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 705</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts written off, net of recoveries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (987)</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,092</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines at contract inception if the contract is or contains a lease. The Company records right-of-use (“ROU”) assets and lease obligations for its leases, which are initially recognized at the commencement date based on the discounted future lease payments over the term of the lease. As the rates implicit in the Company’s leases are not readily determinable, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date. Incremental borrowing rates for domestic currency leases are calculated using the Company’s credit adjusted risk-free rate. Foreign-denominated lease payments are discounted using country-specific treasury rates adjusted for credit spread. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not record an ROU asset and lease obligation for its short-term leases, which are defined as leases with an initial term of 12 months or less. The Company has elected not to separate lease and non-lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Property, Equipment, and Software, Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property, equipment, and software is stated at historical cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the individual assets, except for leasehold improvements, which are depreciated over the shorter of the estimated useful life of the asset or the underlying lease term. Also included in property, equipment, and software are capitalized costs of software developed for internal use. The useful lives of property, equipment, and software are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.35%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Property, Equipment, and Software Asset Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated Useful Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.35%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> 3 years</p></td></tr><tr><td style="vertical-align:bottom;width:45.35%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> 3 years</p></td></tr><tr><td style="vertical-align:bottom;width:45.35%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture, fixtures, and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> 5 years</p></td></tr><tr><td style="vertical-align:bottom;width:45.35%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_byDSPfL7skOAY00D0Uz3pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Shorter of estimated economic useful life or remaining lease term</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Maintenance and repairs are expensed as incurred. Upon retirement or disposition, the cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is included in operating income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Software Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain qualifying costs, including stock-based compensation expense, incurred in the development of and major enhancements to the Company's cloud-based software as a service (“SaaS”) platform and related software products. Capitalized software development costs related to the Company's platform are amortized on a straight-line basis over the developed software's estimated useful life of three years, and the related amortization expense is recorded in cost of revenues within our consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs incurred in the preliminary stages of development are expensed as incurred. Costs incurred for post-implementation activities, training, maintenance, and minor upgrades and enhancements without adding additional functionality are expensed as incurred within technology and development expense in our consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Impairment of Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates the carrying value of long-lived assets in accordance with the accounting standard for impairment or disposal of long-lived assets, which requires recognition of impairment of long-lived assets in the event that circumstances indicate impairment may have occurred and when the net carrying value of such asset group exceeds the future undiscounted cash flows attributed to such asset group. The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. No impairment of long-lived assets occurred during the years ended December 31, 2023, 2022, and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the exit price) in an orderly transaction between market participants at the measurement date. Accounting standards establish a hierarchal framework, which prioritizes and ranks the level of market price observability used in measuring assets and liabilities at fair value. Market price observability is impacted by a number of factors, including the type of investment and the characteristics specific to the investment. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on the best information available. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:27pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Level 1</i></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Inputs are quoted prices for identical instruments in active markets;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:27pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Level 2</i></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:27pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Level 3</i></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Inputs are valuations derived from valuation techniques in which one or more significant inputs are unobservable.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">The Company has investments in money market accounts, which are included in cash and cash equivalents on the consolidated balance sheets. Fair value inputs for these investments are considered Level 1 measurements within the fair value hierarchy, as money market account fair values are known and observable through daily published floating net asset values. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Bonus Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;width:36pt;"></span>Annual bonuses payable by the Company to its officers and employees may be funded through a combination of cash and equity, at the discretion of the Company’s Compensation Committee. We accrue and record the related corporate bonus amounts payable in cash in the period in which it is earned by the recipient. The Compensation Committee may make incentive awards based on such terms, conditions, and criteria as it considers appropriate. Stock awards issued in connection with these bonuses may or may not be subject to additional vesting conditions at the time of grant, which are subject to determination by the Compensation Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;width:36pt;"></span>For annual bonuses settled in cash, the Company accrues over the course of the year the annual bonuses earned by employees but paid in the following year. For annual bonuses settled in stock, in accordance with ASC 718, <i style="font-style:italic;">Stock Compensation</i>, the Company views the authorization of the award to be the date that all approval requirements are completed (e.g., action by the Compensation Committee approving the awards and determining the number of equity instruments to be issued), and therefore, the service inception to begin at grant date. As such, stock-based compensation cost related to the Annual Bonus Incentive Plan is recognized on the grant date to the extent such awards are not subject to additional vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), <i style="font-style:italic;">Revenue from Contracts with Customers</i>. The Company derives its revenues primarily from fees for platform subscriptions and managed services provided to clients. Revenues are recognized when control of these services are transferred to the Company’s clients in an amount that reflects the consideration the Company expects to be entitled to in exchange for these services. Revenues are recognized net of taxes that will be remitted to governmental agencies applicable to service contracts. Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">● Identification of the contract, or contracts, with a client; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">● Identification of the performance obligation in the contract; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">● Determination of transaction price; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">● Allocation of the transaction price to the performance obligations in the contract; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">● Recognition of revenue when, or as, performance obligations are satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Platform subscriptions revenues </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Platform subscriptions revenues consist primarily of user fees to provide our clients access to our cloud-based solution. Fees consider various components such as number of users, connectivity, trading volume, data usage and product coverage. Platform subscriptions clients do not have the right to take possession of the platform’s software and do not have any general return right. Platform subscriptions revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date the client gains access to the platform. Installed payments are generally invoiced at the end of each calendar month during the subscription term. There is no financing available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Managed services revenues </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Managed services revenues primarily consist of client-selected middle- and back-office, technology-powered services. Managed services revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the contract effective date. Clients are invoiced a set fee for managed services typically at the end of each month. Generally, invoices have a 30-day payment period in accordance with the associated contract. There is no financing available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other revenues </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other revenues consist of non-subscription-based revenues primarily data conversion. The Company recognizes revenues as these services are performed with invoicing generally occurring at the end of each month. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Service contracts with multiple performance obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of the Company’s contracts provide for customers to be charged a fee for implementation services. In determining whether the implementation services, which frequently include configuration and/or interfacing, customer reporting, customizing user permissions and acceptance testing, end-user training, and establishing connections with third-party interfaces, are distinct from its platform subscription services, the Company considers, in addition to their complexity and level of customization, that these services are integral in delivering the customer desired output and are necessary for the customer to access and begin to use the hosted application. The implementation provider must be intimately familiar with its platform to effectively execute the customization required, and no other entities have access to the source code. The Company has concluded that the implementation services in its service contracts with multiple performance obligations are not distinct, and therefore, the Company recognizes fees for implementation services ratably over the non-cancelable term of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Remaining performance obligations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of December 31, 2023 was $29.1 million and is expected to be recognized based on the below schedule (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining Performance Obligation</b></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_1gA-N9mbikeSWgTmacgDLA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2024</span></span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 18,227</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_2UPPbhUfH0eubdF0KRUW3Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2025</span></span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,845</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_1J_qLltgXUWI8On3ZKJU2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2026</span></span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,986</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_H-sw2TADcES3MscZeN8gFA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2027</span></span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 64</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29,122</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Disaggregation of revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following table (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:42.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Geographic Region</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:42.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 108,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 62.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 95,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 63.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 72,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 65.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, Middle East, and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 26,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 20,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:42.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 39,907</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 174,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 150,349</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 111,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;vertical-align:top;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Includes revenues from clients based in the United States (country of domicile) of $104.5 million, $92.8 million, and $71.9 million for the years ended December 31, 2023, 2022, and 2021, respectively.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Deferred commissions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company pays sales commissions for initial contracts and expansions of existing contracts with customers. These commissions earned by certain of its sales force are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions paid where the amortization period is one year or less are expensed as incurred. All other sales commissions are deferred and then amortized on a straight-line basis over a period of benefit that the Company has determined to be three years. The Company determined the period of benefit by taking into consideration </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">its standard contract terms and conditions, rate of technological change, and other factors. Amortization expense is included in sales and marketing expenses in the accompanying consolidated statements of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The balance of deferred commissions as of December 31, 2023 and December 31, 2022 was $3.5 million and $2.8 million, respectively, and is included in other assets on the consolidated balance sheets. The amount of amortization expense recognized during the years ended December 31, 2023, 2022, and 2021 was $1.4 million, $845 thousand, and $228 thousand, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cost of Revenues</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cost of revenues consists primarily of personnel-related costs associated with the delivery of the Company’s software and services, including base salaries, bonuses, employee benefits and related costs. Additionally, cost of revenues includes amortization of capitalized software development costs, allocated overhead and certain direct data and hosting costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technology and Development </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Technology and development expenses consist primarily of employee-related expenses for the Company’s software development. Additional expenses include costs related to the development, maintenance, quality assurance and testing of new technologies, and ongoing refinement of the Company’s existing solutions. Technology and development expenses, other than software development costs qualifying for capitalization, including costs associated with preliminary project stage activities, training, maintenance, and all other post-implementation stage activities are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Advertising Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expenses advertising costs as incurred. Advertising costs incurred were approximately $1.5 million, $1.5 million, and $1.2 million during the years ended December 31, 2023, 2022, and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2021, in connection with the IPO, the Company adopted the 2021 Stock Option and Incentive Plan, (the “2021 Plan”). The 2021 Plan allows the Company’s Compensation Committee to make incentive awards to its officers, employees, directors, and service providers. The Company also adopted the 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The Company measures stock-based compensation expense for its share-based payment awards at fair value on the grant date. The fair value of share-based payment awards is determined using the fair market value of the underlying Class A common stock on the date of grant. The Company applied a discount for lack of marketability, estimated using the Finnerty Model, to the fair value of awards with post-vesting restrictions, which includes the vested shares of Class A common stock and the Contingently Issuable Shares (as defined below) issued on the IPO effectiveness date (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For restricted stock units (“RSUs”) for which vesting is subject to the achievement of a market condition, the Company determines the fair value of these RSUs using the Monte Carlo method. The Monte Carlo simulations used to estimate the fair value include subjective assumptions, including the fair value of the underlying common stock, expected volatility of the price of the Company’s common stock, risk-free interest rate, expected dividend yield of common stock, and the Company’s cost of equity capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company records forfeitures as they occur. The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statements of operations based on the estimated fair value of those awards on the grant date or reporting date, if required to be remeasured, and amortized on a straight-line basis over the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Income (Loss) Per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Income (loss) per share is computed by dividing net income (loss) attributable to the Company by the number of weighted average shares of Class A common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income (loss) attributable to the Company by the number of weighted-average shares of Class A common stock outstanding during the period after adjusting for the impact of securities that would have a dilutive effect on income (loss) per share. See Note 12, <i style="font-style:italic;">Income (Loss) Per Class A Common Share,</i> for further discussion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">All income (loss) for the period prior to the IPO were entirely allocable to Enfusion Ltd. LLC. and its historic non-controlling interest. Due to the impact of the Reorganization Transactions, the Company’s capital structure for the pre- and post-IPO periods is not comparable. As a result, the presentation of income (loss) per share for the periods prior to the IPO and Reorganizational Transactions is not meaningful and only income (loss) per share for the period subsequent to the IPO and Reorganizational Transactions is presented herein. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Controlling Interest</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Non-controlling interests represent the portion of profit or loss, net assets, and comprehensive income (loss) of its consolidated subsidiaries that are not allocable to the Company based on its percentage of ownership of such entities. </span>As noted above, in October of 2021, Enfusion US 1, Inc., a newly-formed wholly owned subsidiary of Enfusion, Inc., became the sole managing member of Enfusion Ltd. LLC in connection with the Reorganization Transactions. As of December 31, 2023, the Company holds approximately 69.3% of the outstanding Common Units of Enfusion Ltd. LLC, and approximately 30.7% of the outstanding Common Units of Enfusion Ltd. LLC are held by Pre-IPO Common Unitholders. Therefore, the Company reports non-controlling interests based on Common Units of Enfusion Ltd. LLC held by the Pre-IPO Common Unitholders on its consolidated balance sheet as of December 31, 2023. Income or loss attributed to the non-controlling interest in Enfusion Ltd. LLC is based on the Common Units outstanding during the period for which the income or loss is generated and is presented on the consolidated statements of operations and consolidated statements of comprehensive income (loss).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company accounts for income taxes under the asset and liability method, and deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and deferred tax liabilities is recognized in income in the period that includes the enactment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes deferred tax assets to the extent that it is believed that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations. A valuation allowance is provided if it is determined that it is more likely than not that the deferred tax asset will not be realized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company evaluates and accounts for uncertain tax positions using a two-step approach. Recognition (step one) occurs when the Company concludes that a tax position, based solely on its technical merits, is more-likely-than-not to be sustainable upon examination. Measurement (step two) determines the amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. Derecognition of a tax position that was previously recognized would occur when the Company subsequently determines that a tax position no longer meets the more-likely-than-not threshold of being sustained. The Company records interest (and penalties where applicable), net of any applicable related income tax benefit, on potential income tax contingencies as a component of income tax expense in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Receivable Agreement (TRA)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for amounts payable under the Tax Receivable Agreement in accordance with ASC 450, <i style="font-style:italic;">Contingencies</i>. The amounts payable under the Tax Receivable Agreement will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future. Actual tax benefits realized by the Company may differ from tax benefits calculated under the Tax Receivable Agreement as a result of the use of certain assumptions in the agreement. Any such changes in these factors or changes in the Company’s determination of the need for a valuation allowance related to the tax benefits acquired under the Tax Receivable Agreement could adjust the Tax Receivable Agreement liabilities recognized on the consolidated balance sheets. Subsequent changes in the Tax Receivable Agreement liabilities between reporting periods, as well as any interest accrued on the Tax Receivable Agreement between the Company's annual tax filing date and the Tax Receivable Agreement payment date, are recognized in the consolidated statements of operations. As of December 31, 2023 and 2022, the Company has not recorded a liability under the Tax Receivable Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concentration of Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Deposits with Financial Institutions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has concentrated its credit risk for cash by maintaining deposits in several financial institutions, which may at times exceed amounts covered by insurance provided by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk related to cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Accounts Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company had one individual client that represented 10% or more of accounts receivables. For the years ended December 31, 2023, 2022, and 2021, no individual client represented more than 10% of the Company’s total revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Translation of Foreign Currencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities denominated in the functional currency of the Company’s international subsidiaries are translated to its reporting currency using the exchange rates in effect at the balance sheet date. Results from operations are translated using the average exchange rates prevailing throughout the year. The effects of exchange rate fluctuations on translating foreign currency assets and liabilities into U.S. dollars are accumulated as part of the foreign currency translation adjustment in accumulated other comprehensive loss in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Foreign currency balances for monetary assets and liabilities are remeasured into the entity’s functional currency at the balance sheet date, and fluctuations in value are recorded within other income (expense) in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2016, the FASB issued ASU 2016-13 and ASU 2018-19, <i style="font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (“ASU No. 2016-13”), which requires that a financial asset (or a group of financial assets) measured at an amortized cost basis be presented at the net amount expected to be collected. This approach to estimating credit losses applies to most financial assets measured at amortized cost and certain other instruments, including but not limited to, trade and other receivables. The Company adopted this guidance effective January 1, 2023 and made changes to its accounting policies related to credit loss calculations, including the consideration of forecasted economic data and the pooling of financial assets with similar risk profiles. The Company adopted the new allowance for credit losses accounting standard on <span style="-sec-ix-hidden:Hidden_xZcseCi0IUWTK0y7WGS8_A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">January 1, 2023</span></span> by means of a cumulative-effect adjustment, where it </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">recognized the cumulative effect of initially applying the guidance as a $149 thousand addition to its existing reserve with an offsetting adjustment to accumulated deficit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i> (“ASU No. 2023-07”), to expand the annual and interim disclosure requirements for reportable segments, including public entities with a single reportable segment, primarily through enhanced disclosures about significant segment expenses. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topics 740): Improvements to Income Tax Disclosures</i> (“ASU No. 2023-09”), to expand the disclosures in an entity’s income tax rate reconciliation table and income taxes paid both in U.S. and foreign jurisdictions. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this standard.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments purchased with an initial maturity date of three months or less to be cash equivalents. Funds held as investments in money market funds are included within cash and cash equivalents. As of December 31, 2023 and 2022, respectively, the Company had $30.0 million and $50.0 million, respectively, invested in money market accounts. </p> 30000000.0 50000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accounts Receivable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable includes billed and unbilled receivables, net of allowances, including the allowance for credit losses. Billed accounts receivable are initially recorded upon the invoicing to clients with payment due within 30 days. Unbilled accounts receivable represent revenue recognized on contracts for which the timing of invoicing to clients differs from the timing of revenue recognition. Unbilled accounts receivable was $2.4 million and $2.0 million as of December 31, 2023 and 2022, respectively. Contract assets included in unbilled accounts receivable were $1.7 million and $1.5 million as of December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains an allowance for credit losses at an amount estimated to be sufficient to provide adequate protection against losses resulting from extending credit to its clients. The Company regularly determines the adequacy of the allowance based on its assessment of the collectability of the accounts receivable by considering the age of each outstanding invoice, the collection history of each client, an evaluation of the current expected risk of credit loss, and other client-specific factors with a bearing on receivables. The Company assesses collectability by reviewing accounts receivable on an aggregated basis where similar characteristics exist and on an individual basis for specific clients with historical collectability issues or known financial difficulties. Increases to the allowance are recognized as a charge to credit losses included in general and administrative expenses in the consolidated statements of operations. Accounts receivable deemed uncollectible are charged against the allowance for credit losses when identified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company's allowance for credit losses is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 791</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes to the provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,158</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts written off, net of recoveries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (724)</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,225</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adoption of ASU 2016-13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 149</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes to the provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 705</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts written off, net of recoveries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (987)</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,092</p></td></tr></table> P30D 2400000 2000000.0 1700000 1500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company's allowance for credit losses is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 791</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes to the provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,158</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts written off, net of recoveries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (724)</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,225</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adoption of ASU 2016-13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 149</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes to the provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 705</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts written off, net of recoveries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (987)</p></td></tr><tr><td style="vertical-align:bottom;width:83.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,092</p></td></tr></table> 791000 1158000 -724000 1225000 149000 705000 -987000 1092000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines at contract inception if the contract is or contains a lease. The Company records right-of-use (“ROU”) assets and lease obligations for its leases, which are initially recognized at the commencement date based on the discounted future lease payments over the term of the lease. As the rates implicit in the Company’s leases are not readily determinable, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date. Incremental borrowing rates for domestic currency leases are calculated using the Company’s credit adjusted risk-free rate. Foreign-denominated lease payments are discounted using country-specific treasury rates adjusted for credit spread. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not record an ROU asset and lease obligation for its short-term leases, which are defined as leases with an initial term of 12 months or less. The Company has elected not to separate lease and non-lease components.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Property, Equipment, and Software, Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property, equipment, and software is stated at historical cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the individual assets, except for leasehold improvements, which are depreciated over the shorter of the estimated useful life of the asset or the underlying lease term. Also included in property, equipment, and software are capitalized costs of software developed for internal use. The useful lives of property, equipment, and software are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.35%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Property, Equipment, and Software Asset Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated Useful Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.35%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> 3 years</p></td></tr><tr><td style="vertical-align:bottom;width:45.35%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> 3 years</p></td></tr><tr><td style="vertical-align:bottom;width:45.35%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture, fixtures, and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> 5 years</p></td></tr><tr><td style="vertical-align:bottom;width:45.35%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_byDSPfL7skOAY00D0Uz3pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Shorter of estimated economic useful life or remaining lease term</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Maintenance and repairs are expensed as incurred. Upon retirement or disposition, the cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is included in operating income.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.35%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Property, Equipment, and Software Asset Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated Useful Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.35%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> 3 years</p></td></tr><tr><td style="vertical-align:bottom;width:45.35%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> 3 years</p></td></tr><tr><td style="vertical-align:bottom;width:45.35%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture, fixtures, and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> 5 years</p></td></tr><tr><td style="vertical-align:bottom;width:45.35%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_byDSPfL7skOAY00D0Uz3pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Shorter of estimated economic useful life or remaining lease term</span></span></p></td></tr></table> P3Y P3Y P5Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Software Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain qualifying costs, including stock-based compensation expense, incurred in the development of and major enhancements to the Company's cloud-based software as a service (“SaaS”) platform and related software products. Capitalized software development costs related to the Company's platform are amortized on a straight-line basis over the developed software's estimated useful life of three years, and the related amortization expense is recorded in cost of revenues within our consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs incurred in the preliminary stages of development are expensed as incurred. Costs incurred for post-implementation activities, training, maintenance, and minor upgrades and enhancements without adding additional functionality are expensed as incurred within technology and development expense in our consolidated statements of operations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Impairment of Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates the carrying value of long-lived assets in accordance with the accounting standard for impairment or disposal of long-lived assets, which requires recognition of impairment of long-lived assets in the event that circumstances indicate impairment may have occurred and when the net carrying value of such asset group exceeds the future undiscounted cash flows attributed to such asset group. The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. No impairment of long-lived assets occurred during the years ended December 31, 2023, 2022, and 2021.</p> 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the exit price) in an orderly transaction between market participants at the measurement date. Accounting standards establish a hierarchal framework, which prioritizes and ranks the level of market price observability used in measuring assets and liabilities at fair value. Market price observability is impacted by a number of factors, including the type of investment and the characteristics specific to the investment. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on the best information available. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:27pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Level 1</i></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Inputs are quoted prices for identical instruments in active markets;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:27pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Level 2</i></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:27pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Level 3</i></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Inputs are valuations derived from valuation techniques in which one or more significant inputs are unobservable.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">The Company has investments in money market accounts, which are included in cash and cash equivalents on the consolidated balance sheets. Fair value inputs for these investments are considered Level 1 measurements within the fair value hierarchy, as money market account fair values are known and observable through daily published floating net asset values. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Bonus Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;width:36pt;"></span>Annual bonuses payable by the Company to its officers and employees may be funded through a combination of cash and equity, at the discretion of the Company’s Compensation Committee. We accrue and record the related corporate bonus amounts payable in cash in the period in which it is earned by the recipient. The Compensation Committee may make incentive awards based on such terms, conditions, and criteria as it considers appropriate. Stock awards issued in connection with these bonuses may or may not be subject to additional vesting conditions at the time of grant, which are subject to determination by the Compensation Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;width:36pt;"></span>For annual bonuses settled in cash, the Company accrues over the course of the year the annual bonuses earned by employees but paid in the following year. For annual bonuses settled in stock, in accordance with ASC 718, <i style="font-style:italic;">Stock Compensation</i>, the Company views the authorization of the award to be the date that all approval requirements are completed (e.g., action by the Compensation Committee approving the awards and determining the number of equity instruments to be issued), and therefore, the service inception to begin at grant date. As such, stock-based compensation cost related to the Annual Bonus Incentive Plan is recognized on the grant date to the extent such awards are not subject to additional vesting conditions.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), <i style="font-style:italic;">Revenue from Contracts with Customers</i>. The Company derives its revenues primarily from fees for platform subscriptions and managed services provided to clients. Revenues are recognized when control of these services are transferred to the Company’s clients in an amount that reflects the consideration the Company expects to be entitled to in exchange for these services. Revenues are recognized net of taxes that will be remitted to governmental agencies applicable to service contracts. Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">● Identification of the contract, or contracts, with a client; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">● Identification of the performance obligation in the contract; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">● Determination of transaction price; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">● Allocation of the transaction price to the performance obligations in the contract; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">● Recognition of revenue when, or as, performance obligations are satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Platform subscriptions revenues </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Platform subscriptions revenues consist primarily of user fees to provide our clients access to our cloud-based solution. Fees consider various components such as number of users, connectivity, trading volume, data usage and product coverage. Platform subscriptions clients do not have the right to take possession of the platform’s software and do not have any general return right. Platform subscriptions revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date the client gains access to the platform. Installed payments are generally invoiced at the end of each calendar month during the subscription term. There is no financing available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Managed services revenues </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Managed services revenues primarily consist of client-selected middle- and back-office, technology-powered services. Managed services revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the contract effective date. Clients are invoiced a set fee for managed services typically at the end of each month. Generally, invoices have a 30-day payment period in accordance with the associated contract. There is no financing available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other revenues </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other revenues consist of non-subscription-based revenues primarily data conversion. The Company recognizes revenues as these services are performed with invoicing generally occurring at the end of each month. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Service contracts with multiple performance obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of the Company’s contracts provide for customers to be charged a fee for implementation services. In determining whether the implementation services, which frequently include configuration and/or interfacing, customer reporting, customizing user permissions and acceptance testing, end-user training, and establishing connections with third-party interfaces, are distinct from its platform subscription services, the Company considers, in addition to their complexity and level of customization, that these services are integral in delivering the customer desired output and are necessary for the customer to access and begin to use the hosted application. The implementation provider must be intimately familiar with its platform to effectively execute the customization required, and no other entities have access to the source code. The Company has concluded that the implementation services in its service contracts with multiple performance obligations are not distinct, and therefore, the Company recognizes fees for implementation services ratably over the non-cancelable term of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Remaining performance obligations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of December 31, 2023 was $29.1 million and is expected to be recognized based on the below schedule (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining Performance Obligation</b></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_1gA-N9mbikeSWgTmacgDLA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2024</span></span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 18,227</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_2UPPbhUfH0eubdF0KRUW3Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2025</span></span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,845</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_1J_qLltgXUWI8On3ZKJU2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2026</span></span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,986</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_H-sw2TADcES3MscZeN8gFA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2027</span></span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 64</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29,122</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Disaggregation of revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following table (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:42.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Geographic Region</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:42.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 108,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 62.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 95,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 63.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 72,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 65.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, Middle East, and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 26,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 20,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:42.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 39,907</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 174,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 150,349</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 111,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;vertical-align:top;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Includes revenues from clients based in the United States (country of domicile) of $104.5 million, $92.8 million, and $71.9 million for the years ended December 31, 2023, 2022, and 2021, respectively.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Deferred commissions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company pays sales commissions for initial contracts and expansions of existing contracts with customers. These commissions earned by certain of its sales force are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions paid where the amortization period is one year or less are expensed as incurred. All other sales commissions are deferred and then amortized on a straight-line basis over a period of benefit that the Company has determined to be three years. The Company determined the period of benefit by taking into consideration </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">its standard contract terms and conditions, rate of technological change, and other factors. Amortization expense is included in sales and marketing expenses in the accompanying consolidated statements of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The balance of deferred commissions as of December 31, 2023 and December 31, 2022 was $3.5 million and $2.8 million, respectively, and is included in other assets on the consolidated balance sheets. The amount of amortization expense recognized during the years ended December 31, 2023, 2022, and 2021 was $1.4 million, $845 thousand, and $228 thousand, respectively.</p> P30D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of December 31, 2023 was $29.1 million and is expected to be recognized based on the below schedule (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining Performance Obligation</b></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_1gA-N9mbikeSWgTmacgDLA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2024</span></span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 18,227</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_2UPPbhUfH0eubdF0KRUW3Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2025</span></span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,845</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_1J_qLltgXUWI8On3ZKJU2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2026</span></span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,986</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_H-sw2TADcES3MscZeN8gFA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2027</span></span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 64</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29,122</p></td></tr></table> 29100000 18227000 8845000 1986000 64000 29122000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following table (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:42.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Geographic Region</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:42.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 108,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 62.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 95,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 63.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 72,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 65.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, Middle East, and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 26,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 20,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:42.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 39,907</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 174,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 150,349</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 111,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;vertical-align:top;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Includes revenues from clients based in the United States (country of domicile) of $104.5 million, $92.8 million, and $71.9 million for the years ended December 31, 2023, 2022, and 2021, respectively.</p></td></tr></table> 108506000 0.621 95122000 0.633 72994000 0.653 26122000 0.150 20051000 0.133 13491000 0.121 39907000 0.229 35176000 0.234 25215000 0.226 174535000 1.000 150349000 1.000 111700000 1.000 104500000 92800000 71900000 3500000 2800000 1400000 845000 228000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cost of Revenues</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cost of revenues consists primarily of personnel-related costs associated with the delivery of the Company’s software and services, including base salaries, bonuses, employee benefits and related costs. Additionally, cost of revenues includes amortization of capitalized software development costs, allocated overhead and certain direct data and hosting costs.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technology and Development </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Technology and development expenses consist primarily of employee-related expenses for the Company’s software development. Additional expenses include costs related to the development, maintenance, quality assurance and testing of new technologies, and ongoing refinement of the Company’s existing solutions. Technology and development expenses, other than software development costs qualifying for capitalization, including costs associated with preliminary project stage activities, training, maintenance, and all other post-implementation stage activities are expensed as incurred.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Advertising Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expenses advertising costs as incurred. Advertising costs incurred were approximately $1.5 million, $1.5 million, and $1.2 million during the years ended December 31, 2023, 2022, and 2021, respectively.</p> 1500000 1500000 1200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2021, in connection with the IPO, the Company adopted the 2021 Stock Option and Incentive Plan, (the “2021 Plan”). The 2021 Plan allows the Company’s Compensation Committee to make incentive awards to its officers, employees, directors, and service providers. The Company also adopted the 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The Company measures stock-based compensation expense for its share-based payment awards at fair value on the grant date. The fair value of share-based payment awards is determined using the fair market value of the underlying Class A common stock on the date of grant. The Company applied a discount for lack of marketability, estimated using the Finnerty Model, to the fair value of awards with post-vesting restrictions, which includes the vested shares of Class A common stock and the Contingently Issuable Shares (as defined below) issued on the IPO effectiveness date (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For restricted stock units (“RSUs”) for which vesting is subject to the achievement of a market condition, the Company determines the fair value of these RSUs using the Monte Carlo method. The Monte Carlo simulations used to estimate the fair value include subjective assumptions, including the fair value of the underlying common stock, expected volatility of the price of the Company’s common stock, risk-free interest rate, expected dividend yield of common stock, and the Company’s cost of equity capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company records forfeitures as they occur. The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statements of operations based on the estimated fair value of those awards on the grant date or reporting date, if required to be remeasured, and amortized on a straight-line basis over the requisite service period.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Income (Loss) Per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Income (loss) per share is computed by dividing net income (loss) attributable to the Company by the number of weighted average shares of Class A common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income (loss) attributable to the Company by the number of weighted-average shares of Class A common stock outstanding during the period after adjusting for the impact of securities that would have a dilutive effect on income (loss) per share. See Note 12, <i style="font-style:italic;">Income (Loss) Per Class A Common Share,</i> for further discussion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">All income (loss) for the period prior to the IPO were entirely allocable to Enfusion Ltd. LLC. and its historic non-controlling interest. Due to the impact of the Reorganization Transactions, the Company’s capital structure for the pre- and post-IPO periods is not comparable. As a result, the presentation of income (loss) per share for the periods prior to the IPO and Reorganizational Transactions is not meaningful and only income (loss) per share for the period subsequent to the IPO and Reorganizational Transactions is presented herein. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Controlling Interest</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Non-controlling interests represent the portion of profit or loss, net assets, and comprehensive income (loss) of its consolidated subsidiaries that are not allocable to the Company based on its percentage of ownership of such entities. </span>As noted above, in October of 2021, Enfusion US 1, Inc., a newly-formed wholly owned subsidiary of Enfusion, Inc., became the sole managing member of Enfusion Ltd. LLC in connection with the Reorganization Transactions. As of December 31, 2023, the Company holds approximately 69.3% of the outstanding Common Units of Enfusion Ltd. LLC, and approximately 30.7% of the outstanding Common Units of Enfusion Ltd. LLC are held by Pre-IPO Common Unitholders. Therefore, the Company reports non-controlling interests based on Common Units of Enfusion Ltd. LLC held by the Pre-IPO Common Unitholders on its consolidated balance sheet as of December 31, 2023. Income or loss attributed to the non-controlling interest in Enfusion Ltd. LLC is based on the Common Units outstanding during the period for which the income or loss is generated and is presented on the consolidated statements of operations and consolidated statements of comprehensive income (loss).</p> 0.693 0.307 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company accounts for income taxes under the asset and liability method, and deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and deferred tax liabilities is recognized in income in the period that includes the enactment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes deferred tax assets to the extent that it is believed that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations. A valuation allowance is provided if it is determined that it is more likely than not that the deferred tax asset will not be realized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company evaluates and accounts for uncertain tax positions using a two-step approach. Recognition (step one) occurs when the Company concludes that a tax position, based solely on its technical merits, is more-likely-than-not to be sustainable upon examination. Measurement (step two) determines the amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. Derecognition of a tax position that was previously recognized would occur when the Company subsequently determines that a tax position no longer meets the more-likely-than-not threshold of being sustained. The Company records interest (and penalties where applicable), net of any applicable related income tax benefit, on potential income tax contingencies as a component of income tax expense in the consolidated statements of operations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Receivable Agreement (TRA)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for amounts payable under the Tax Receivable Agreement in accordance with ASC 450, <i style="font-style:italic;">Contingencies</i>. The amounts payable under the Tax Receivable Agreement will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future. Actual tax benefits realized by the Company may differ from tax benefits calculated under the Tax Receivable Agreement as a result of the use of certain assumptions in the agreement. Any such changes in these factors or changes in the Company’s determination of the need for a valuation allowance related to the tax benefits acquired under the Tax Receivable Agreement could adjust the Tax Receivable Agreement liabilities recognized on the consolidated balance sheets. Subsequent changes in the Tax Receivable Agreement liabilities between reporting periods, as well as any interest accrued on the Tax Receivable Agreement between the Company's annual tax filing date and the Tax Receivable Agreement payment date, are recognized in the consolidated statements of operations. As of December 31, 2023 and 2022, the Company has not recorded a liability under the Tax Receivable Agreement.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concentration of Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Deposits with Financial Institutions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has concentrated its credit risk for cash by maintaining deposits in several financial institutions, which may at times exceed amounts covered by insurance provided by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk related to cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Accounts Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company had one individual client that represented 10% or more of accounts receivables. For the years ended December 31, 2023, 2022, and 2021, no individual client represented more than 10% of the Company’s total revenues.</p> 1 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Translation of Foreign Currencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities denominated in the functional currency of the Company’s international subsidiaries are translated to its reporting currency using the exchange rates in effect at the balance sheet date. Results from operations are translated using the average exchange rates prevailing throughout the year. The effects of exchange rate fluctuations on translating foreign currency assets and liabilities into U.S. dollars are accumulated as part of the foreign currency translation adjustment in accumulated other comprehensive loss in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Foreign currency balances for monetary assets and liabilities are remeasured into the entity’s functional currency at the balance sheet date, and fluctuations in value are recorded within other income (expense) in the consolidated statements of operations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2016, the FASB issued ASU 2016-13 and ASU 2018-19, <i style="font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (“ASU No. 2016-13”), which requires that a financial asset (or a group of financial assets) measured at an amortized cost basis be presented at the net amount expected to be collected. This approach to estimating credit losses applies to most financial assets measured at amortized cost and certain other instruments, including but not limited to, trade and other receivables. The Company adopted this guidance effective January 1, 2023 and made changes to its accounting policies related to credit loss calculations, including the consideration of forecasted economic data and the pooling of financial assets with similar risk profiles. The Company adopted the new allowance for credit losses accounting standard on <span style="-sec-ix-hidden:Hidden_xZcseCi0IUWTK0y7WGS8_A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">January 1, 2023</span></span> by means of a cumulative-effect adjustment, where it </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">recognized the cumulative effect of initially applying the guidance as a $149 thousand addition to its existing reserve with an offsetting adjustment to accumulated deficit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i> (“ASU No. 2023-07”), to expand the annual and interim disclosure requirements for reportable segments, including public entities with a single reportable segment, primarily through enhanced disclosures about significant segment expenses. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topics 740): Improvements to Income Tax Disclosures</i> (“ASU No. 2023-09”), to expand the disclosures in an entity’s income tax rate reconciliation table and income taxes paid both in U.S. and foreign jurisdictions. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this standard.</p> 149000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 4   Property, Equipment, and Software, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property, equipment, and software, net consists of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,496</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,406</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,831</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 433</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total property, equipment, and software, cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29,166</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,717)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,407)</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total property, equipment, and software, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 18,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15,759</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, property, equipment, and software, net located in the United States was $17.0 million and $13.7 million, respectively. The remainder was located in the Company’s various international locations. Included in property, equipment, and software are the capitalized costs of software development. Software development costs capitalized during the years ended December 31, 2023 and 2022 were $6.4 million and $4.5 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Depreciation expense related to property and equipment, excluding software development costs, was $5.1 million, $3.3 million, and $2.4 million for the years ended December 31, 2023, 2022, and 2021, respectively. Amortization expense related to software development costs was $3.4 million, $2.2 million, and $1.3 million for the years ended December 31, 2023, 2022, and 2021, respectively. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property, equipment, and software, net consists of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,496</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,406</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,831</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 433</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total property, equipment, and software, cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29,166</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,717)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,407)</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total property, equipment, and software, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 18,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15,759</p></td></tr></table> 17384000 17496000 15842000 9406000 1668000 1831000 137000 433000 35031000 29166000 16717000 13407000 18314000 15759000 17000000.0 13700000 6400000 4500000 5100000 3300000 2400000 3400000 2200000 1300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 5   Accrued Expenses and Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,058</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,268</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,112</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 285</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,665</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued compensation includes bonuses due to employees of $6.4 million and $7.8 million as of December 31, 2023 and 2022, respectively.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,058</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,268</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,112</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 285</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,665</p></td></tr></table> 10058000 10268000 1385000 1112000 2398000 285000 13841000 11665000 6400000 7800000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 6   Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company enters into leases for office space and data centers. A number of the leases include one or more options to renew the lease terms or not terminate the lease. The exercise of these options is at the Company’s discretion and is therefore recognized on the balance sheet when it is reasonably certain the Company will exercise such options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All of the Company’s leases are considered operating leases. The Company had no finance leases as of and for the year ended December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into operating leases for international office spaces that are yet to commence as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Lease commitments as of December 31, 2023 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,197</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,198</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,229</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,253</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,671</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 654</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total lease commitments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 18,202</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,765)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15,437</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of the Company’s operating lease cost for the twelve months ended December 31, 2023 and 2022, respectively, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,053</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 828</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,881</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Variable lease costs are comprised of the Company’s proportionate share of actual costs for utilities, common area maintenance, property taxes, and insurance, which are not included in the lease liability and are recognized in the period in which they are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, respectively, the weighted-average remaining lease terms and weighted-average discount rates were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">3.80 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">1.84 years</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">7.80%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">4.43%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Under Accounting Standards Codification 840, the previous lease standard, total expense for lease arrangements and service agreements was $3.9 million and $1.1 million, respectively, for the year ended December 31, 2021.</p> true true 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,197</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,198</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,229</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,253</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,671</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 654</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total lease commitments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 18,202</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,765)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15,437</p></td></tr></table> 5197000 4198000 3229000 3253000 1671000 654000 18202000 2765000 15437000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,053</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 828</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,881</p></td></tr></table> 6882000 5053000 835000 828000 114000 7831000 5881000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">3.80 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">1.84 years</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">7.80%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">4.43%</p></td></tr></table> P3Y9M18D P1Y10M2D 0.0780 0.0443 3900000 1100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 7   Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">New Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 15, 2023, the Company entered into the New Credit Agreement with Bank of America N.A. and a syndicate of lending institutions. The New Credit Agreement provides for a senior secured revolving loan facility in an aggregate principal amount of up to $100.0 million, including a $10.0 million sublimit for the issuance of letters of credit and a swingline subfacility of up to $10.0 million. The New Credit Agreement also includes an uncommitted accordion feature that allows for up to $50.0 million of additional borrowing capacity, subject to obtaining lender commitments and the satisfaction of certain customary conditions. The New Credit Agreement matures on September 15, 2028, at which time all outstanding principal and unpaid interest will become due. Obligations under the New Credit Agreement are secured by a lien on substantially all of the assets of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revolving loans under the New Credit Agreement will bear interest, at the Company’s option, at an annual rate benchmarked to (1) the Secured Overnight Financing Rate (“SOFR”) or (2) a “Base Rate” that is equal to the highest of (a) the federal funds rate plus 0.50%, (b) Bank of America’s prime rate and (c) one month adjusted term SOFR plus 1.00%. Loans based on SOFR bear interest at a rate equal to term SOFR for the applicable interest period plus 10 basis points plus a margin between 2.00% and 2.75%. Loans based on the Base Rate bear interest at a rate equal to the Base Rate plus a margin between 1.00% and 1.75% (such margins being referred to as the “Applicable Rate”). The Applicable Rate in each case is determined based on the Company’s consolidated net leverage ratio. The Company is also required to pay a commitment fee of between 0.20% and 0.25% per annum on the unused portion of the lenders’ commitments in respect of the revolving loans and letter of credit obligations, based on the Company’s consolidated net leverage ratio. As of December 31, 2023, the commitment fee rate was 0.20%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The New Credit Agreement contains certain customary covenants with which the Company must comply, including financial covenants relating to a net leverage ratio covenant and an interest coverage ratio. As part of the New </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Credit Agreement, the Company is required to establish within 120 days of the closing date and maintain thereafter a minimum required balance of $5.0 million with Bank of America, and by the first anniversary of the closing date, use commercially reasonable efforts to maintain Bank of America as its principal depository bank. The minimum required balance of $5.0 million was established in February 2024. The Company was in compliance with all loan covenants and requirements as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Issuance costs associated with the New Credit Agreement were capitalized and included in other assets on the accompanying consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company had no outstanding borrowings under the New Credit Agreement or material letters of credit issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prior Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Concurrent with entering into the New Credit Agreement, on September 15, 2023, the Company terminated its $5.0 million Prior Credit Agreement with Silicon Valley Bank, which by its terms was scheduled to mature on December 17, 2025. At the time of termination, there were no borrowings outstanding under the Prior Credit Agreement. The Company recognized a loss on extinguishment of debt of $78 thousand associated with the termination of the Prior Credit Agreement.</p> 100000000.0 10000000.0 10000000.0 50000000.0 0.0050 0.0100 0.0010 0.0200 0.0275 0.0100 0.0175 0.0020 0.0025 0.0020 P120D 5000000.0 5000000.0 0 5000000.0 0 -78000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 8   Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company records accruals for contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. A description of a contingent payment arrangement under the Company’s Tax Receivable Agreement is included in Note 13, <i style="font-style:italic;">Income Taxes</i>. Accruals for contingencies recorded as of December 31, 2023 and December 31, 2022, respectively, were immaterial.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 9   Stockholders’ Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the Reorganization Transactions, Enfusion Ltd. LLC was organized as a limited liability company owned by its members, each of whose membership interests consisted of an equal number of: (i) “Economic Units,” which represented a member’s economic interest in Enfusion Ltd. LLC; and (ii) “Participation Units,” which represented a member’s right to participate (vote) in the affairs of Enfusion Ltd. LLC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a limited liability company, Enfusion Ltd. LLC issued more than one class of units. The Class A units were considered to be members’ equity, whereas all of the other unit classes were considered to be preferred units because of provisions in the Company’s former Operating Agreement that conferred certain rights and privileges to the members owning these units, such as voting rights, redemption rights and liquidation preferences. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of the Class C-1, C-2, and D preferred units had the option to require the Company to redeem their units. In accordance with the guidance in ASC 480, <i style="font-style:italic;">Distinguishing Liabilities from Equity</i>, outstanding Class C-1, C-2, and D preferred units were classified outside of permanent equity and within temporary equity due to their optional redemption features and liquidation preferences. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Reorganization Transactions, the Sixth Amended and Restated Operating Agreement of Enfusion Ltd. LLC was amended and restated to, among other things, modify its capital structure by reclassifying each of the outstanding Class A units and C-1, C-2, and D preferred units into the Common Units through a stock split on a 1,000,000 to 1 basis. The number of Common Units outstanding following the Reorganization Transactions reflect the 1,000,000 to 1 stock split. Pursuant to the adoption of the LLC Operating Agreement, Enfusion US 1, Inc., a newly-formed wholly owned subsidiary of Enfusion, Inc., was appointed the sole managing member of Enfusion Ltd. LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 15, 2023, the company sold 1.2 million shares of Class A common stock to FTV Investment Holdings, L.P. (“FTV Holdings”) and an affiliate in a private placement. Refer to Note 14, <i style="font-style:italic;">Related Party Transactions</i>, for more information about this placement transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 14, 2023, the Company sold 1.0 million shares of Class A common stock of the Company, par value $0.001 per share, in a private placement at a price of $7.65 per share. Total net proceeds of the transaction were $7.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 21, 2023, March 28, 2023, July 19, 2023, and August 1, 2023, pursuant to the terms of the LLC Operating Agreement, Pre-IPO Common Unitholders respectively surrendered 1,000,000, 1,000,000, 1,000,000, and 1,000,000 Common Units and an equal number of shares of Class B common stock. In connection therewith, the Company respectively issued 1,000,000, 1,000,000, 1,000,000, and 1,000,000 shares of Class A common stock to each such Pre-IPO Common Unitholder, canceled an equal number of Class B common stock, and received an equal number of Common Units, increasing the Company’s ownership of Common Units by 1,000,000, 1,000,000, 1,000,000, and 1,000,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amended and Restated of Certificate of Incorporation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">The Amended and Restated Certificate of Incorporation of Enfusion, Inc. provides for 1,000,000,000 authorized shares of Class A common stock, 150,000,000 authorized shares of Class B common stock and 100,000,000 shares of preferred stock.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Each share of the Company’s Class A common stock is entitled to one vote per share and is not convertible into any other shares of its capital stock. Holders of shares of the Company’s Class A common stock are entitled to receive dividends when, as and if declared by the Company’s board of directors. Upon its liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors, and subject to the rights of the holders of one or more outstanding series of preferred stock, as applicable, having liquidation preferences, the holders of shares of the Company’s Class A common stock will be entitled to receive pro rata the Company’s remaining assets available for distribution. Each share of the Company’s Class B common stock is entitled to one vote per share and is not convertible or exchangeable for a share of Class A common stock or any other security. Holders of the Company’s Class B common stock do not have any right to receive dividends or to receive a distribution upon a liquidation, dissolution or winding up of Enfusion, Inc. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s board of directors have the authority, without further action by the Company’s stockholders, to issue up to 100,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Class A common stock. As of December 31, 2023 and 2022, the Company has no shares of preferred stock outstanding nor has the Company’s board of directors established the rights and privileges related to any series of preferred stock.</p> 1000000 1000000 1200000 1000000.0 0.001 7.65 7600000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000000 1000000000 150000000 150000000 100000000 100000000 1 1 100000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 10   Management Incentive Plan and Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2021 Stock Option and Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In conjunction with the IPO, the Company established the 2021 Stock Option and Incentive Plan (the “2021 Plan”), which became effective upon the date immediately preceding the IPO effectiveness date (as defined below). The Company has initially reserved 26,400,000 shares of Class A common stock for the issuance of awards under the 2021 Plan, inclusive of awards (the “Award Units”) granted to Plan Participants (as defined below) of the Pre-IPO Change in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Control Bonus Plan (as defined below). The 2021 Plan provides that the number of shares of Class A common stock reserved and available for issuance under the 2021 Plan increased on January 1, 2022 and will continue to increase each January 1 thereafter, by 3% of the outstanding number of shares of the Company’s Class A common stock and Class B common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Company’s Compensation Committee. The 2021 Plan provides for potential grants of the following awards: (i) stock options, (ii) RSUs, (iii) unrestricted shares, and (iv) stock appreciation rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pre-IPO Change in Control Bonus Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the IPO, Enfusion Ltd. LLC had a Pre-IPO Change in Control Bonus Plan (the “pre-IPO Change in Control Bonus Plan”) for certain members of management (“Plan Participants”) that provided for the payment of a cash bonus based on a specified number of Award Units in the event of a change in control (“CiC”) transaction (i.e., a liquidity event), as defined by the LLC Operating Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In anticipation of the Company’s IPO, in October 2021, the Company's board of managers elected to terminate the Pre-IPO Change in Control Bonus Plan (and all Award Units issued thereunder) upon effectiveness of the registration statement for the IPO (the “IPO effectiveness date”). Holders of Award Units that were still employed as of the IPO effectiveness date were granted one or more of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The vested shares of Class A common stock as of IPO effectiveness date (“IPO vested Class A common stock”) are shares that were all issued to Plan Participants prior to the second anniversary of the IPO. No future service was required to receive the IPO vested Class A common stock. Because there was no ongoing service requirement associated with these awards, the Company recognized stock-based compensation expense for these awards on the IPO effectiveness date. The amount of stock-based compensation expense recognized for these awards was </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$237.3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million in 2021, which is equal to the fair value of the shares of the IPO vested Class A common stock, after applying a discount for lack of marketability due to the post-vesting restriction.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shares of Class A common stock that vested within </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one year</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the IPO effectiveness date are referred to as “Contingently Issuable Shares” due to continued employment requirements. Of such shares, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.5%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> was distributed in 2022 with the remainder distributed in 2023. Stock-based compensation expense associated with these awards is recognized by the Company on a straight-line basis over the requisite service period for the entire award, beginning on the IPO effectiveness date. The amount of stock-based compensation expense recognized for these awards was </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$10.2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million, and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$16.7</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million in the years ended December 31, 2023, 2022, and 2021, respectively, which is equal to the fair value of the shares of the IPO vested Class A common stock, after applying a discount for lack of marketability due to the post-vesting restriction.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">RSUs granted to executive and non-executive employees that will vest ratably over a period of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> subject to the Plan Participant’s continued employment. Stock-based compensation expense associated with these awards is recognized by the Company on a straight-line basis over the requisite service period for the entire award, beginning on the IPO effectiveness date. The amount of stock-based compensation expense recognized for these awards was </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$7.3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$13.2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million, and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$4.5</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million in the years ended December 31, 2023, 2022, and 2021, respectively.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance-based restricted stock units (“PSUs”) that will vest ratably over a period of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> that are subject to a market condition and the Plan Participant’s continued employment. The market condition is the achievement of certain market capitalization targets by the Company at specified measurement dates. The Company determined the fair value of these PSUs using the Monte Carlo method. The Company </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recognizes stock-based compensation expense on a straight-line basis over the implied service period for each tranche of the award, as if the award were in-substance multiple awards.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the shares of Class A common stock, RSUs, and PSUs granted to employees that were Plan Participants in the Pre-IPO Change in Control Bonus Plan, the Company agreed to issue 2,047,064 shares of Class A common stock to an employee in exchange for termination of a profit sharing agreement. These shares were issued to the employee between the first and second anniversaries of the IPO effectiveness date. The fair value of these shares, after applying a discount for lack of marketability due to the post-vesting restriction, is $31.2 million. This amount was recognized as compensation expense on the IPO effectiveness date in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the IPO vested Class A common stock and the Contingently Issuable Shares granted on the IPO effectiveness date, the Company applied a discount for lack of marketability, estimated using the Finnerty Model, to the fair value of awards with post-vesting restrictions. All IPO vested Class A common stock and Contingently Issuable Shares were issued to Plan Participants prior to the second anniversary of the IPO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"> <i style="font-style:italic;">Restricted Stock Units</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures stock-based compensation expense for its share-based payment awards at fair value on the grant date. For RSUs for which vesting is not subject to the achievement of a market condition or achievement of a specified share price, the fair value of share-based payment awards is determined using the fair market value of the underlying Class A common stock on the date of grant (i.e. share price at closing). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes stock-based compensation expense for these RSUs on a straight-line basis over requisite service period for the entire award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The expected fair value and term of the Company’s stock options was determined utilizing the simplified method, due to lack of historical exercise data. The expected volatility was determined using a weighted-average of the historical volatility measures of a group of guideline companies and the Company's own historical volatility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, there were 71,004 stock options granted under the 2021 Plan, at a weighted-average exercise price of $11.06 per option, and 31,474 stock options were forfeited. During the year ended December 31, 2022, there were 84,000 stock options granted under the 2021 Plan, at a weighted-average price of $9.86 per option, and 40,000 stock options were forfeited. As of December 31, 2023, there was approximately $351 thousand of unrecognized stock-based compensation expense related to the remaining stock options issued during 2022, which is expected to be recognized over a weighted-average period of approximately 2.0 years. The Black-Scholes assumptions used for the options granted under the 2021 Plan during the year ended December 31, 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:20.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:16.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:58.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assumptions</b></p></td><td style="vertical-align:middle;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:20.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:middle;width:2.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:20.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">60.91%</p></td><td style="vertical-align:top;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">64.54%</p></td></tr><tr><td style="vertical-align:middle;width:58.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term of award</p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:20.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.5 years</p></td><td style="vertical-align:middle;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.5 years</p></td></tr><tr><td style="vertical-align:middle;width:58.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:20.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.82%</p></td><td style="vertical-align:middle;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.39%</p></td></tr><tr><td style="vertical-align:middle;width:58.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield </p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:20.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.00%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The shares of common stock to be issued and/or sold upon the exercise of stock options are made available from authorized and unissued common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Performance-based Restricted Stock Units</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">For PSUs for which vesting is subject to the achievement of a market condition or specified price of the Company’s shares, the Company determines the fair value of these PSUs using the Monte Carlo method. The Monte Carlo simulations used to estimate the fair value include subjective assumptions, including the fair value of the underlying common stock, expected volatility of the price of the Company’s common stock, risk-free interest rate, expected dividend yield of common stock, and the Company’s cost of equity capital. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the fourth quarter of 2023, 580,000 performance-based PSUs were granted. In the year ended December 31, 2022, 250,000 performance-based PSUs were granted. The assumptions used in the Monte Carlo simulation for the PSUs were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:48.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:16.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:14.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:14.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:48.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assumptions</b></p></td><td style="vertical-align:middle;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:middle;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:48.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value of common stock (per share)</p></td><td style="vertical-align:middle;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$9.89 </p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$8.92 </p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$17.00 </p></td></tr><tr><td style="vertical-align:middle;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:middle;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">41.65%</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">53.40%</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">48.20%</p></td></tr><tr><td style="vertical-align:middle;width:48.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:middle;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.38%</p></td><td style="vertical-align:middle;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.98%</p></td><td style="vertical-align:middle;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.65%</p></td></tr><tr><td style="vertical-align:middle;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield </p></td><td style="vertical-align:middle;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.00%</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.00%</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.00%</p></td></tr><tr><td style="vertical-align:middle;width:48.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of equity capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">14.10%</p></td><td style="vertical-align:middle;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">13.50%</p></td><td style="vertical-align:middle;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.20%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the total compensation cost related to unvested awards not yet recognized was $2.8 million, and weighted-average period of recognition was 2.0 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s stock-based compensation expense was recognized in the following captions within the consolidated statements of operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:60.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:60.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenues</p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 950</p></td><td style="vertical-align:bottom;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,421</p></td><td style="vertical-align:bottom;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 377</p></td></tr><tr><td style="vertical-align:top;width:60.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,635</p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,130</p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 112,829</p></td></tr><tr><td style="vertical-align:top;width:60.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (984)</p></td><td style="vertical-align:bottom;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,875</p></td><td style="vertical-align:bottom;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,312</p></td></tr><tr><td style="vertical-align:top;width:60.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Technology and development</p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,857</p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,567</p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 140,285</p></td></tr><tr><td style="vertical-align:top;width:60.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,458</p></td><td style="vertical-align:bottom;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24,993</p></td><td style="vertical-align:bottom;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 289,803</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized total stock-based compensation expense, including RSUs and stock options, for the years ended December 31, 2023, 2022, and 2021 of $7.5 million, $25.0 million, and $289.8 million, respectively, in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalized $766 thousand and $600 thousand of stock-based compensation expense to capitalized software development costs for the years ended December 31, 2023 and 2022, respectively. No amounts were capitalized relating to the year ended December 31, 2021 due to the fact that no awards were granted in conjunction with capitalizable activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total unrecognized stock-based compensation expense related to unvested RSUs and stock options was $19.7 million as of December 31, 2023, which is expected to be recognized over a weighted-average period of 2.0 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following summarizes the Company’s share-based payment award activity for all IPO vested Class A common stock, RSUs, Contingently Issuable Shares and stock options for the years ended December 31, 2023 and 2022, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.78%;"><tr style="height:1pt;"><td style="vertical-align:top;width:51.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </b></p></td><td colspan="4" style="vertical-align:bottom;width:19.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">IPO Vested Class A Common Stock, Contingently Issuable Shares and RSUs</b></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="6" style="vertical-align:bottom;width:26.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td></tr><tr><td style="vertical-align:middle;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </b></p></td><td colspan="2" style="vertical-align:bottom;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average Grant-Date Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Options</b></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average Exercise Price</b></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average Remaining Contractual Term (in years)</b></p></td></tr><tr><td style="vertical-align:top;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Outstanding as of December 31, 2022</b></p></td><td style="vertical-align:middle;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,224,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9pt;"> 9.46</span></p></td></tr><tr><td style="vertical-align:top;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Vested as of December 31, 2022</b></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,225,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Unvested as of December 31, 2022</b></p></td><td style="vertical-align:middle;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,999,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Granted during the period</p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,925,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 71,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Forfeited during the period</p></td><td style="vertical-align:middle;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (584,178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (31,474)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Vested and issued during the period (a)</p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (18,374,139)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Outstanding as of December 31, 2023 (b)</b></p></td><td style="vertical-align:middle;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,191,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9pt;"> 8.89</span></p></td></tr><tr><td style="vertical-align:top;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(a) Includes shares issued and net settled to satisfy tax withholding obligations.</p></td></tr><tr><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(b) December 31, 2023 balance is all unvested.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 26400000 0.03 237300000 P1Y 0.075 0 10200000 16700000 P4Y 7300000 13200000 4500000 P10Y 2047064 31200000 71004 11.06 31474 84000 9.86 40000 351000 P2Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:20.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:16.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:58.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assumptions</b></p></td><td style="vertical-align:middle;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:20.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:middle;width:2.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:20.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">60.91%</p></td><td style="vertical-align:top;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">64.54%</p></td></tr><tr><td style="vertical-align:middle;width:58.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term of award</p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:20.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.5 years</p></td><td style="vertical-align:middle;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.5 years</p></td></tr><tr><td style="vertical-align:middle;width:58.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:20.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.82%</p></td><td style="vertical-align:middle;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.39%</p></td></tr><tr><td style="vertical-align:middle;width:58.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield </p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:20.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.00%</p></td></tr></table> 0.6091 0.6454 P6Y6M P6Y6M 0.0382 0.0339 0.0000 0.0000 580000 250000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:48.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:16.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:14.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:14.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:48.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assumptions</b></p></td><td style="vertical-align:middle;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:middle;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:48.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value of common stock (per share)</p></td><td style="vertical-align:middle;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$9.89 </p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$8.92 </p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$17.00 </p></td></tr><tr><td style="vertical-align:middle;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:middle;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">41.65%</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">53.40%</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">48.20%</p></td></tr><tr><td style="vertical-align:middle;width:48.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:middle;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.38%</p></td><td style="vertical-align:middle;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.98%</p></td><td style="vertical-align:middle;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.65%</p></td></tr><tr><td style="vertical-align:middle;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield </p></td><td style="vertical-align:middle;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.00%</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.00%</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.00%</p></td></tr><tr><td style="vertical-align:middle;width:48.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of equity capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">14.10%</p></td><td style="vertical-align:middle;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">13.50%</p></td><td style="vertical-align:middle;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.20%</p></td></tr></table> 9.89 8.92 17.00 0.4165 0.5340 0.4820 0.0438 0.0398 0.0165 0.0000 0.0000 0.0000 0.1410 0.1350 0.1120 2800000 P2Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:60.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:60.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenues</p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 950</p></td><td style="vertical-align:bottom;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,421</p></td><td style="vertical-align:bottom;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 377</p></td></tr><tr><td style="vertical-align:top;width:60.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,635</p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,130</p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 112,829</p></td></tr><tr><td style="vertical-align:top;width:60.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (984)</p></td><td style="vertical-align:bottom;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,875</p></td><td style="vertical-align:bottom;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,312</p></td></tr><tr><td style="vertical-align:top;width:60.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Technology and development</p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,857</p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,567</p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 140,285</p></td></tr><tr><td style="vertical-align:top;width:60.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,458</p></td><td style="vertical-align:bottom;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24,993</p></td><td style="vertical-align:bottom;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 289,803</p></td></tr></table> 950000 1421000 377000 5635000 14130000 112829000 -984000 5875000 36312000 1857000 3567000 140285000 7458000 24993000 289803000 7500000 25000000.0 289800000 766000 600000 0 19700000 P2Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.78%;"><tr style="height:1pt;"><td style="vertical-align:top;width:51.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </b></p></td><td colspan="4" style="vertical-align:bottom;width:19.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">IPO Vested Class A Common Stock, Contingently Issuable Shares and RSUs</b></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="6" style="vertical-align:bottom;width:26.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td></tr><tr><td style="vertical-align:middle;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </b></p></td><td colspan="2" style="vertical-align:bottom;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average Grant-Date Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Options</b></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average Exercise Price</b></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average Remaining Contractual Term (in years)</b></p></td></tr><tr><td style="vertical-align:top;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Outstanding as of December 31, 2022</b></p></td><td style="vertical-align:middle;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,224,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9pt;"> 9.46</span></p></td></tr><tr><td style="vertical-align:top;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Vested as of December 31, 2022</b></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,225,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Unvested as of December 31, 2022</b></p></td><td style="vertical-align:middle;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,999,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Granted during the period</p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,925,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 71,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Forfeited during the period</p></td><td style="vertical-align:middle;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (584,178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (31,474)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Vested and issued during the period (a)</p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (18,374,139)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:51.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Outstanding as of December 31, 2023 (b)</b></p></td><td style="vertical-align:middle;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,191,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9pt;"> 8.89</span></p></td></tr><tr><td style="vertical-align:top;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(a) Includes shares issued and net settled to satisfy tax withholding obligations.</p></td></tr><tr><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(b) December 31, 2023 balance is all unvested.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 20224452 15.15 44000 9.86 P9Y5M15D 17225377 2999075 44000 9.86 1925762 8.49 71004 11.06 584178 15.32 31474 10.15 18374139 15.27 3191897 9.61 83530 10.77 P8Y10M20D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 11   Employee Benefit Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sponsors a 401(k) Plan that covers substantially all full-time United States employees who meet eligibility requirements. The Company makes matching contributions equal to 50% of the wages that are deferred by employees, and the matching contribution is capped at 3% of wages. The Company made contributions of $1.0 million, $584 thousand, and $452 thousand for the years ended December 31, 2023, 2022, and 2021, respectively. The Company also sponsors various other benefit plans for its employees of certain international subsidiaries. The Company’s contributions to these plans are immaterial for the periods presented.</p> 0.50 0.03 1000000.0 584000 452000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Note 12   Net Income (Loss) Per Class A Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Basic income (loss) per share is computed by dividing net income (loss) attributable to Enfusion, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Prior to the IPO, the Enfusion Ltd. LLC membership structure included Common Units and multiple classes of preferred Units. The Company analyzed the calculation of earnings per unit for periods prior to the IPO using the two-class method and determined that it resulted in values that would not be meaningful to the users of these consolidated financial statements. Therefore, earnings per share information has not been presented for periods prior to the IPO on October 20, 2021. The basic and diluted earnings per share represent only the years ended December 31, 2023 and 2022, and the period from October 21, 2021 to December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per share of Class A common stock is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except per share amounts)</b></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Net income (loss)</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 9,253</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (13,263)</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (282,242)</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Less: Net income attributable to Enfusion, Inc. prior to the IPO</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> -</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> -</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (12,892)</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Less: Net (income) loss attributable to non-controlling interests </span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (3,228)</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 5,609</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 123,925</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Net income (loss) attributable to Enfusion, Inc.</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 6,025</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (7,654)</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (171,209)</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-size:9.5pt;font-style:italic;">Numerator:</i></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Net income (loss) attributable to Enfusion, Inc.</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 6,025</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (7,654)</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (171,209)</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Adjustment to loss attributable to common stockholders</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 306</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (954)</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (16,580)</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Numerator for Basic Earnings per Share</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 6,331</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (8,608)</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (187,789)</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Adjustment to Income for Dilutive Shares</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 2,922</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> -</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> -</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Numerator for Diluted Earnings per Share</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 9,253</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (8,608)</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (187,789)</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-size:9.5pt;font-style:italic;">Denominator:</i></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Weighted-average shares of Class A common stock outstanding</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 80,828</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 67,057</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 65,583</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Vested shares of Class A common stock and RSUs</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 7,374</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 18,336</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 17,462</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Weighted-average shares of Class A common stock outstanding--basic</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 88,202</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 85,393</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 83,045</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Add: Dilutive Shares</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 41,227</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> -</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> -</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Weighted-average shares of Class A common stock outstanding--diluted</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 129,429</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 85,393</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 83,045</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Net income (loss) per share of Class A common stock--Basic </b></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 0.07</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (0.10)</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (2.26)</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Net income (loss) per share of Class A common stock--Diluted</b></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 0.07</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (0.10)</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (2.26)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:6pt 0pt 10pt 0pt;">The following number of potentially dilutive shares were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:53.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Class B common stock</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> -</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 43,199</p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 47,471</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingently issuable shares of Class A common stock</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> -</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> -</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,726</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,048</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,999</p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,905</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 84</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,132</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46,242</p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 52,102</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Shares of Class B common stock do not share in earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been presented. Shares of Class B common stock are, however, considered potentially dilutive shares of Class A common stock. After evaluating the potential dilutive effect under both the treasury stock method and if-converted method, shares of Class B common stock were determined to be dilutive and have therefore been included in the computation of diluted earnings per share of Class A common stock for the year ended December 31, 2023.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except per share amounts)</b></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Net income (loss)</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 9,253</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (13,263)</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (282,242)</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Less: Net income attributable to Enfusion, Inc. prior to the IPO</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> -</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> -</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (12,892)</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Less: Net (income) loss attributable to non-controlling interests </span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (3,228)</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 5,609</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 123,925</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Net income (loss) attributable to Enfusion, Inc.</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 6,025</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (7,654)</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (171,209)</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-size:9.5pt;font-style:italic;">Numerator:</i></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Net income (loss) attributable to Enfusion, Inc.</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 6,025</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (7,654)</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (171,209)</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Adjustment to loss attributable to common stockholders</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 306</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (954)</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (16,580)</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Numerator for Basic Earnings per Share</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 6,331</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (8,608)</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (187,789)</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Adjustment to Income for Dilutive Shares</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 2,922</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> -</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> -</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Numerator for Diluted Earnings per Share</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 9,253</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (8,608)</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (187,789)</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-size:9.5pt;font-style:italic;">Denominator:</i></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Weighted-average shares of Class A common stock outstanding</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 80,828</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 67,057</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 65,583</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Vested shares of Class A common stock and RSUs</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 7,374</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 18,336</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 17,462</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Weighted-average shares of Class A common stock outstanding--basic</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 88,202</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 85,393</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 83,045</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9.5pt;">Add: Dilutive Shares</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 41,227</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> -</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> -</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Weighted-average shares of Class A common stock outstanding--diluted</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 129,429</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 85,393</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 83,045</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Net income (loss) per share of Class A common stock--Basic </b></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 0.07</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (0.10)</span></p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (2.26)</span></p></td></tr><tr><td style="vertical-align:top;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Net income (loss) per share of Class A common stock--Diluted</b></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 0.07</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (0.10)</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:top;width:11.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;"> (2.26)</span></p></td></tr></table> 9253000 -13263000 -282242000 12892000 3228000 -5609000 -123925000 6025000 -7654000 -171209000 6025000 -7654000 -171209000 306000 -954000 -16580000 6331000 -8608000 -187789000 2922000 9253000 -8608000 -187789000 80828000 67057000 65583000 7374000 18336000 17462000 88202000 85393000 83045000 41227000 129429000 85393000 83045000 0.07 -0.10 -2.26 0.07 -0.10 -2.26 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:53.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Class B common stock</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> -</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 43,199</p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 47,471</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingently issuable shares of Class A common stock</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> -</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> -</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,726</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,048</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,999</p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,905</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:53.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 84</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:53.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,132</p></td><td style="vertical-align:top;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46,242</p></td><td style="vertical-align:top;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 52,102</p></td></tr></table> 43199000 47471000 1726000 1048000 2999000 2905000 84000 44000 1132000 46242000 52102000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 13   Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is taxed as a corporation for income tax purposes and is subject to federal, state, and local taxes on the income allocated to it from Enfusion Ltd. LLC based upon the Company’s economic interest in Enfusion Ltd. LLC. The Company controls the sole managing member of Enfusion Ltd. LLC and, as a result, consolidates the financial results of Enfusion Ltd. LLC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Enfusion Ltd. LLC is a limited liability company taxed as a partnership for income tax purposes. Enfusion Ltd. LLC does not pay any federal income taxes, as income or loss is included in the tax returns of the individual members. Additionally, certain wholly-owned entities taxed as corporations are subject to federal, state, and foreign income taxes in the jurisdictions in which they operate, and accruals for such taxes are included in the consolidated financial statements. For periods prior to the IPO, the Company’s taxes represent those of Enfusion Ltd. LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of income (loss) before income taxes were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,201)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (279,990)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,981</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,673)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,189)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (281,663)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The income (loss) before income taxes above includes the pre- and post-IPO periods for the year ended December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the IPO, the Company, through its subsidiary, Enfusion Ltd. LLC, was structured as a partnership and therefore, was primarily subject to foreign income taxes and generally not subject to U.S. income taxes. As a result of the Reorganization Transactions, the Company is now taxed as a corporation and subject to U.S. federal, state, local and foreign taxes. Significant components of income tax expense (benefit) were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State &amp; Local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 228</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Current Income Tax Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 228</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State &amp; Local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (273)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 351</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Income Tax Expense (Benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (273)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 351</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 579</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of income taxes computed at the U.S. federal statutory income tax rate of 21% to the Company’s income tax expense (benefit) was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At U.S. Federal Statutory Tax Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State Tax, Net of Federal Benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-controlling Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign Branch Taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-Based Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 113.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign Rate Differential</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation Allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (168.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 50.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in Tax Rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (59.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Return to Provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unrecognized Tax Benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pass-through Loss (Income)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;">The Company’s effective tax rate for the years ended December 31, 2023, 2022, and 2021 was 19.4%, (8.8)%, and (0.2)%, respectively. The most significant items impacting the effective tax rate are explained below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">State Tax, Net of Federal Benefit</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company’s state taxes, net of federal benefit, include the effects of state taxes currently payable and changes in state deferred income taxes, exclusive of the valuation allowance. The significant increase in state taxes, net of federal benefit, in the year ended December 31, 2023, is primarily due to the U.S. state deferred tax effect of non-deductible equity-based compensation and related tax deduction deficiencies. For the years ended December 31, 2023, 2022, and 2021, the Company recorded state tax expenses (benefit) of $4.5 million, $(0.4) million, and $(12.1) million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Noncontrolling Interest </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Company’s sole material asset is a financial interest in Enfusion Ltd. LLC. While the Company consolidates Enfusion Ltd. LLC for financial reporting purposes, the Company will only be taxed on (benefit from) its share of earnings (losses) of Enfusion Ltd. LLC not attributed to the noncontrolling interest holders. Since noncontrolling interest holders will continue to bear (benefit from) their share of income tax expense (benefit) on its allocable earnings (losses) of Enfusion Ltd. LLC, that share of income tax expense (benefit) is not reported by the Company in its consolidated financial statements. The U.S. federal tax (benefit) expense associated with the allocation of earnings (losses) to noncontrolling interest holders for the years ended December 31, 2023, 2022, and 2021 was $(0.8) million, $1.1 million and $25.9 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock-Based Compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the Reorganization Transactions, a significant portion of the Company’s certain stock-based compensation expenses will be allocated to the noncontrolling interest holders and therefore will not be deductible to the Company. The remaining portion of these expenses will be subject to the tax deduction limitations as established by the U.S. tax law in respect of the executive compensation. The Company recognizes an excess tax benefit or tax deficiency when the deduction for the stock-based compensation expense of a stock award for tax purposes differs from the cumulative stock-based compensation expense recognized in the financial statements. The U.S. federal tax impact of non-deductible stock-based compensation, including tax deficiencies, for the years ended December 31, 2023, 2022, and 2021 was $13.0 million, $1.3 million, and $2.5 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Valuation Allowance</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s net deferred tax benefit (expense) for the years ended December 31, 2023, 2022, and 2021 of $(19.4) million, $(6.2) million, and $40.8 million, respectively, was fully offset by the valuation allowance recorded (released) in the consolidated statements of operations for each respective year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Foreign Branch Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has foreign operations that are treated as branches for U.S. tax purposes and are also subject to income taxes in those foreign jurisdictions. For the years ended December 31, 2023, 2022, and 2021, the Company recorded $1.3 million, $1.0 million, and $0.6 million, respectively, in foreign income taxes related to the pre-tax income of its branches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Return to Provision</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2023, 2022, and 2021 the Company recorded a tax expense (benefit) of $0.8 million, $(0.5) million, and $(0.2) million, respectively, in relation to its filed or expected to be filed U.S. and foreign income tax returns. These true-up adjustments are attributable to actual results in the Company’s tax filings as compared to the estimates included in its previously issued consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Change in Tax Rates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2023, and 2022, the Company reduced its deferred tax assets by $0.2 million and $7.2 million, respectively, to reflect a change in the estimated U.S. state tax rate caused by a change in the overall mix of its U.S. earnings by state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deferred Tax Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The components of deferred tax assets and liabilities are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred Tax Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investment in Enfusion Ltd. LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 126,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 86,117</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-Based Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 37,912</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net Operating Losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,358</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 794</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 140,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 134,181</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation Allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (140,307)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133,689)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Deferred Tax Assets Net of Valuation Allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 492</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred Tax Liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (70)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (77)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (70)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (77)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Deferred Tax Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (70)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 415</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s deferred tax assets are primarily comprised of basis differences in the investment in Enfusion Ltd. LLC, stock-based compensation, and tax attribute carryforwards. The ultimate realization of deferred tax assets is dependent upon the generation of sufficient future taxable income to realize the deferred tax assets on the Company’s income tax returns. Management determined that it is more likely than not going that the Company’s deferred tax assets will not be realized due to the Company’s three-year cumulative loss position and the generation of future taxable income is uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The changes in the Company’s valuation allowance for deferred tax assets were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Year Ended December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 124,526</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Charged to Income Tax Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,163)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Charged to Stockholders' Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,326</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Year Ended December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 133,689</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Charged to Income Tax Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,381)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Charged to Stockholders' Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25,999</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Year Ended December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 140,307</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">As of December 31, 2023 and 2022, the Company had U.S. federal net operating losses of $43.1 million and $33.2 million, respectively, which can be carried forward indefinitely. As of December 31, 2023 and 2022, the Company had state net operating losses of $35.6 million and $31.2 million, respectively, that begin to expire in 2038.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">As of December 31, 2023, the Company is not indefinitely reinvested on undistributed earnings from its foreign operations. Due to the Company's structure, the foreign operations do not qualify for the indefinite reinvestment exceptions under ASC 740-30 as the earnings from the foreign operations are subject to U.S. taxation. However, the exception may still apply to foreign withholding taxes due to dividend distributions of earnings from the Company's foreign affiliates. The Company has no plans to make distributions from its foreign operations in the future and, therefore, a deferred tax liability has not been recognized. A determination of the unrecognized deferred taxes is not practicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">A summary of the Company’s unrecognized tax benefits are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Increases for tax positions related to the current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 30</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Increases (decreases) for tax positions of prior years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 89</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expiration of statute of limitations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (41)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 119</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest and penalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. As of December 31, 2023, the Company accrued has $128 thousand of interest and penalties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files tax returns in the United States and various foreign jurisdictions. The Company is currently being audited in the U.S. and India. However, the Company is no longer subject to examination by those taxing authorities with respect to the years ended prior to 2017. Although the outcome of tax audits is always uncertain and could result in significant cash tax payments, the Company does not believe the outcome of these audits will have a material adverse effect on its consolidated financial position or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Receivable Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expects to obtain an increase in its share of the tax basis in the net assets of Enfusion Ltd. LLC when Common Units are redeemed from or exchanged by the Pre-IPO Common Unitholders. The Company intends to treat any redemptions and exchanges of Common Units as direct purchases of Common Units for U.S. income tax purposes. These increases in tax basis may reduce the amounts that the Company would otherwise pay in the future to U.S. federal and state tax authorities. They may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the Company entered into the Tax Receivable Agreement with Enfusion Ltd. LLC, the Pre-IPO Owners that will provide for the payment by the Company to the Pre-IPO Owners of 85% of the amount of tax benefits, if any, that the Company actually realizes (or in some circumstances is deemed to realize) as a result of (1) the Company’s allocable share of existing tax basis acquired in connection with the Reorganization Transactions (including the Blocker Company’s share of existing tax basis) and increases to such allocable share of existing tax basis; (2) increases in tax basis resulting from (a) the Company’s purchase of Common Units directly from Enfusion Ltd. LLC and the partial redemption of Common Units by Enfusion Ltd. LLC, (b) future redemptions or exchanges (or deemed exchanges in certain circumstances) of Common Units for Class A common stock or cash, and (c) certain distributions (or deemed distributions) by Enfusion Ltd. LLC; and (3) certain additional tax benefits arising from payments made under the Tax Receivable Agreement. The Company may benefit from the remaining 15% of any tax benefits that the Company actually realizes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the years ended December 31, 2023, and 2022, the Company purchased an aggregate of 4,000,000 and 4,272,204 units, respectively, of Enfusion Ltd. LLC in connection with the exchange of those units by the Pre-IPO Common Unitholders, which resulted in an increase of $46.0 million and $48.2 in the tax basis of the net assets of Enfusion Ltd. LLC that would be subject to the provisions of the Tax Receivable Agreement in the years ended December 31, 2023, and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, the Company has not recorded a liability under the Tax Receivable Agreement related to the tax benefits originating from the Reorganization Transactions, IPO, and subsequent purchase of Common Units, as it is not probable that the Company will realize such tax benefits. To the extent the Company had determined that it would have been able to realize the tax benefits associated with the basis adjustments, it would have recorded a liability under the Tax Receivable Agreement of $96.5 million and $83.2 million as of December 31, 2023, and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The amounts payable under the Tax Receivable Agreement will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future. Should the Company determine that the Tax Receivable Agreement liability be considered probable at a future date based on new information, any changes will be recorded at that time.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of income (loss) before income taxes were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,201)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (279,990)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,981</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,673)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,189)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (281,663)</p></td></tr></table> 5503000 -16201000 -279990000 5981000 4012000 -1673000 11484000 -12189000 -281663000 As a result of the Reorganization Transactions, the Company is now taxed as a corporation and subject to U.S. federal, state, local and foreign taxes. Significant components of income tax expense (benefit) were as follows (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State &amp; Local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 228</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Current Income Tax Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 228</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State &amp; Local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (273)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 351</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Income Tax Expense (Benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (273)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 351</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 579</p></td></tr></table> -5000 53000 2190000 1347000 228000 2238000 1347000 228000 -7000 -273000 351000 -7000 -273000 351000 2231000 1074000 579000 0.21 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At U.S. Federal Statutory Tax Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State Tax, Net of Federal Benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-controlling Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign Branch Taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-Based Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 113.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign Rate Differential</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation Allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (168.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 50.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in Tax Rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (59.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Return to Provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unrecognized Tax Benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pass-through Loss (Income)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> 0.210 0.210 0.210 0.389 0.031 0.043 0.073 0.089 0.092 0.109 -0.082 -0.003 1.135 -0.106 -0.025 0.003 0.005 -1.688 0.506 -0.145 0.019 -0.592 0.065 0.040 0.001 0.021 0.009 0.004 -0.011 0.194 -0.088 -0.002 0.194 -0.088 -0.002 4500000 -400000 -12100000 -800000 1100000 25900000 13000000.0 1300000 2500000 -19400000 -6200000 40800000 1300000 1000000.0 600000 800000 -500000 -200000 -200000 -7200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The components of deferred tax assets and liabilities are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred Tax Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investment in Enfusion Ltd. LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 126,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 86,117</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-Based Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 37,912</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net Operating Losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,358</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 794</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 140,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 134,181</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation Allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (140,307)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133,689)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Deferred Tax Assets Net of Valuation Allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 492</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred Tax Liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (70)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (77)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (70)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (77)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Deferred Tax Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (70)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 415</p></td></tr></table> 126504000 86117000 1542000 37912000 11410000 9358000 851000 794000 140307000 134181000 140307000 133689000 492000 70000 77000 70000 77000 70000 415000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The changes in the Company’s valuation allowance for deferred tax assets were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Year Ended December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 124,526</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Charged to Income Tax Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,163)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Charged to Stockholders' Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,326</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Year Ended December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 133,689</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Charged to Income Tax Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,381)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Charged to Stockholders' Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25,999</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Year Ended December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 140,307</p></td></tr></table> 124526000 -6163000 15326000 133689000 -19381000 25999000 140307000 43100000 33200000 35600000 31200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">A summary of the Company’s unrecognized tax benefits are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Increases for tax positions related to the current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 30</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Increases (decreases) for tax positions of prior years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 89</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expiration of statute of limitations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (41)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 119</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest and penalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65</p></td></tr></table> 119000 119000 0 30000 238000 0 89000 41000 0 316000 119000 119000 128000 65000 65000 128000 0.85 0.15 4000000 4272204 46000000.0 48200000 96500000 83200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 14   Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial or operating decisions. Since transactions with related parties may raise potential or actual conflicts of interest between the related party and the Company, upon the completion of the IPO, the Company implemented a related party transaction policy that requires related party transactions to be reviewed and approved by its nominating and corporate governance committee. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 15, 2023, the Company sold 1.2 million shares of Class A common stock to FTV Investment Holdings, L.P. (“FTV Holdings”) and an affiliate in a private placement, at a per share purchase price equal to the average of the closing price of the Class A common stock over the 20 trading days preceding the transaction, which was approximately $8.12 per share. Total net proceeds of the transactions were $9.7 million. Equity issuance costs were immaterial. FTV IV, L.P. (“FTV Fund IV”) beneficially owns more than 5% of the Company’s issued and outstanding Class A common stock. Bradford Bernstein, a member of the Company’s Board of Directors, is a managing partner of FTV Capital and, along with other members of FTV Capital, indirectly shares voting and dispositive power with regard to the shares directly held by FTV Holdings and FTV Fund IV, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the first quarter of 2023, the Company received approximately $1.5 million from the U.S. Treasury in the form of a tax refund owed to FTV Enfusion Holdings, Inc. (“FTV Enfusion”), which prior to the Company’s initial public offering in 2021 was a Blocker Company through which FTV Fund IV held its equity interests in Enfusion Ltd. LLC. The refund was generated due to overpayments by FTV Enfusion for U.S. federal income taxes associated with FTV Enfusion’s direct ownership of Enfusion Ltd. LLC for the fiscal years ended December 31, 2017 to December 31, 2020. The Company </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">obtained the right to this refund as a result of the merger of FTV Enfusion with and into one of the Company’s subsidiaries as part of the Reorganization Transactions (which did not take into account the value of the tax refund). On June 27, 2023, the Company distributed approximately $1.5 million (the amount of the refund) to FTV Fund IV. </p> 1200000 P20D 8.12 9700000 0.05 1500000 1500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 15   Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Share Exchange</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January 4, 2024, a Pre-IPO Common Unitholder delivered an exchange notice pursuant to Article XII of the LLC Operating Agreement. Pursuant to the terms of the LLC Operating Agreement, on January 11, 2024, the Pre-IPO Common Unitholder surrendered 1,000,000 Common Units and an equal number of shares of Class B common stock. In connection therewith, the Company issued 1,000,000 shares of Class A common stock to such Pre-IPO Common Unitholder, canceled an equal number of shares of Class B common stock, and received an equal number of Common Units, increasing the Company’s ownership of Common Units by 1,000,000.</p> 1000000 1000000 1000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9B. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading Arrangements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Oleg Movchan, our Chief Executive Officer, adopted a pre-arranged stock trading plan (the “10b5-1 Plan”), dated December 5, 2023, that provides for the sale of up to 400,000 shares of our Class A common stock between March 14, 2024 and December 31, 2024 pursuant to the terms of his 10b5-1 Plan. The 10b5-1 Plan was designed to comply with the guidelines specified in Rule 10b5-1 promulgated under the Exchange Act and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</p> Oleg Movchan Chief Executive Officer true December 5, 2023 400000 December 31, 2024

      3>&X$_@+S*F?YAFLPP+/3$-^!W\BS9#U4T"Z M>WCHW]Q$O&5Z5@%FGZN PKS6D/WL!1 (L$6 NYZ/U[)ZI(;3)KMOCNI,8;K& M5P>L:X@%ZM<_R%PKUE"[^I23EUV*6?/.EM.5OLT+LBY MP8 P#B N ;'?RNJAXKRO#?8=7@XAMQ(VTDY0 L'JNO),]K([/-QQ76&WL^?8 M+(OL$K-3L$,!;=0X55@[XLP>WT6'=1!V-XV+%>$QC^=' MF%UV%VJ#35#8HC<^[K""=A*E08:&<.!*_5?PR8ZCX(Z#4:*,.G^Z< H:T*)_ MHA .XR62652%1M@_>$+$.?_T8HH8VHT%R?'TH[[G1?=6WXX.M'(!= +$�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�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�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end XML 95 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 96 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 98 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 208 398 1 false 68 0 false 9 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://enfusion.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Consolidated Balance Sheets Sheet http://enfusion.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Consolidated Statements of Operations Sheet http://enfusion.com/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://enfusion.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 5 false false R6.htm 00400 - Statement - Consolidated Statements of Preferred Units, Stockholders' Equity and Members' Deficit Sheet http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit Consolidated Statements of Preferred Units, Stockholders' Equity and Members' Deficit Statements 6 false false R7.htm 00500 - Statement - Consolidated Statements of Cash Flows Sheet http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - Organization and Description of Business Sheet http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 8 false false R9.htm 10201 - Disclosure - Basis of Presentation Sheet http://enfusion.com/role/DisclosureBasisOfPresentation Basis of Presentation Notes 9 false false R10.htm 10301 - Disclosure - Summary of Significant Accounting Policies Sheet http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 10401 - Disclosure - Property, Equipment, and Software, Net Sheet http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNet Property, Equipment, and Software, Net Notes 11 false false R12.htm 10501 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 12 false false R13.htm 10601 - Disclosure - Leases Sheet http://enfusion.com/role/DisclosureLeases Leases Notes 13 false false R14.htm 10701 - Disclosure - Debt Sheet http://enfusion.com/role/DisclosureDebt Debt Notes 14 false false R15.htm 10801 - Disclosure - Commitments and Contingencies Sheet http://enfusion.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 10901 - Disclosure - Stockholders' Equity Sheet http://enfusion.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 11001 - Disclosure - Management Incentive Plan and Stock-Based Compensation Sheet http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensation Management Incentive Plan and Stock-Based Compensation Notes 17 false false R18.htm 11101 - Disclosure - Employee Benefit Plans Sheet http://enfusion.com/role/DisclosureEmployeeBenefitPlans Employee Benefit Plans Notes 18 false false R19.htm 11201 - Disclosure - Net Income (Loss) Per Class A Common Share Sheet http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShare Net Income (Loss) Per Class A Common Share Notes 19 false false R20.htm 11301 - Disclosure - Income Taxes Sheet http://enfusion.com/role/DisclosureIncomeTaxes Income Taxes Notes 20 false false R21.htm 11401 - Disclosure - Related Party Transactions Sheet http://enfusion.com/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 21 false false R22.htm 11501 - Disclosure - Subsequent Events Sheet http://enfusion.com/role/DisclosureSubsequentEvents Subsequent Events Notes 22 false false R23.htm 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPolicies 23 false false R24.htm 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPolicies 24 false false R25.htm 30403 - Disclosure - Property, Equipment, and Software, Net (Tables) Sheet http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables Property, Equipment, and Software, Net (Tables) Tables http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNet 25 false false R26.htm 30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities 26 false false R27.htm 30603 - Disclosure - Leases (Tables) Sheet http://enfusion.com/role/DisclosureLeasesTables Leases (Tables) Tables http://enfusion.com/role/DisclosureLeases 27 false false R28.htm 31003 - Disclosure - Management Incentive Plan and Stock-Based Compensation (Tables) Sheet http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationTables Management Incentive Plan and Stock-Based Compensation (Tables) Tables http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensation 28 false false R29.htm 31203 - Disclosure - Net Income (Loss) Per Class A Common Share (Tables) Sheet http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareTables Net Income (Loss) Per Class A Common Share (Tables) Tables http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShare 29 false false R30.htm 31303 - Disclosure - Income Taxes (Tables) Sheet http://enfusion.com/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://enfusion.com/role/DisclosureIncomeTaxes 30 false false R31.htm 40101 - Disclosure - Organization and Description of Business (Details) Sheet http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails Organization and Description of Business (Details) Details http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusiness 31 false false R32.htm 40201 - Disclosure - Basis of Presentation (Details) Sheet http://enfusion.com/role/DisclosureBasisOfPresentationDetails Basis of Presentation (Details) Details http://enfusion.com/role/DisclosureBasisOfPresentation 32 false false R33.htm 40301 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 33 false false R34.htm 40302 - Disclosure - Summary of Significant Accounting Policies - Allowances (Details) Sheet http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAllowancesDetails Summary of Significant Accounting Policies - Allowances (Details) Details 34 false false R35.htm 40303 - Disclosure - Summary of Significant Accounting Policies - Useful life of property plant and equipment (Details) Sheet http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyPlantAndEquipmentDetails Summary of Significant Accounting Policies - Useful life of property plant and equipment (Details) Details 35 false false R36.htm 40304 - Disclosure - Summary of Significant Accounting Policies - Remaining Performance Obligation (Details) Sheet http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails Summary of Significant Accounting Policies - Remaining Performance Obligation (Details) Details 36 false false R37.htm 40305 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of revenue (Details) Sheet http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails Summary of Significant Accounting Policies - Disaggregation of revenue (Details) Details 37 false false R38.htm 40401 - Disclosure - Property, Equipment, and Software, Net (Details) Sheet http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails Property, Equipment, and Software, Net (Details) Details http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables 38 false false R39.htm 40402 - Disclosure - Property, Equipment, and Software, Net- Narrative (Details) Sheet http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetNarrativeDetails Property, Equipment, and Software, Net- Narrative (Details) Details 39 false false R40.htm 40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) Sheet http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities (Details) Details http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables 40 false false R41.htm 40601 - Disclosure - Leases - Narratives (Details) Sheet http://enfusion.com/role/DisclosureLeasesNarrativesDetails Leases - Narratives (Details) Details 41 false false R42.htm 40602 - Disclosure - Leases - Lease Commitments (Details) Sheet http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails Leases - Lease Commitments (Details) Details 42 false false R43.htm 40603 - Disclosure - Leases - Components of Operating Lease Cost (Details) Sheet http://enfusion.com/role/DisclosureLeasesComponentsOfOperatingLeaseCostDetails Leases - Components of Operating Lease Cost (Details) Details 43 false false R44.htm 40604 - Disclosure - Leases - Weighted-average remaining lease terms and discount rates (Details) Sheet http://enfusion.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails Leases - Weighted-average remaining lease terms and discount rates (Details) Details 44 false false R45.htm 40605 - Disclosure - Leases - Operating Leases and Service Agreements (Details) Sheet http://enfusion.com/role/DisclosureLeasesOperatingLeasesAndServiceAgreementsDetails Leases - Operating Leases and Service Agreements (Details) Details 45 false false R46.htm 40701 - Disclosure - Debt - New Credit Agreement (Details) Sheet http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails Debt - New Credit Agreement (Details) Details 46 false false R47.htm 40702 - Disclosure - Debt - Prior Credit Agreement (Details) Sheet http://enfusion.com/role/DisclosureDebtPriorCreditAgreementDetails Debt - Prior Credit Agreement (Details) Details 47 false false R48.htm 40901 - Disclosure - Stockholders' Equity (Details) Sheet http://enfusion.com/role/DisclosureStockholdersEquityDetails Stockholders' Equity (Details) Details http://enfusion.com/role/DisclosureStockholdersEquity 48 false false R49.htm 41001 - Disclosure - Management Incentive Plan and Stock-Based Compensation - Narratives (Details) Sheet http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails Management Incentive Plan and Stock-Based Compensation - Narratives (Details) Details http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationTables 49 false false R50.htm 41002 - Disclosure - Management Incentive Plan and Stock-Based Compensation - Assumptions (Details) Sheet http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails Management Incentive Plan and Stock-Based Compensation - Assumptions (Details) Details 50 false false R51.htm 41003 - Disclosure - Management Incentive Plan and Stock-Based Compensation - Stock Compensation (Income) Expense (Details) Sheet http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationStockCompensationIncomeExpenseDetails Management Incentive Plan and Stock-Based Compensation - Stock Compensation (Income) Expense (Details) Details 51 false false R52.htm 41004 - Disclosure - Management Incentive Plan and Stock-Based Compensation - RSUs and Stock Options (Details) Sheet http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails Management Incentive Plan and Stock-Based Compensation - RSUs and Stock Options (Details) Details 52 false false R53.htm 41101 - Disclosure - Employee Benefit Plans (Details) Sheet http://enfusion.com/role/DisclosureEmployeeBenefitPlansDetails Employee Benefit Plans (Details) Details http://enfusion.com/role/DisclosureEmployeeBenefitPlans 53 false false R54.htm 41201 - Disclosure - Net Income (Loss) Per Class A Common Share - Basic and Diluted Net Loss Per Share (Details) Sheet http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails Net Income (Loss) Per Class A Common Share - Basic and Diluted Net Loss Per Share (Details) Details http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareTables 54 false false R55.htm 41202 - Disclosure - Net Income (Loss) Per Class A Common Share - Dilutive shares (Details) Sheet http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails Net Income (Loss) Per Class A Common Share - Dilutive shares (Details) Details http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareTables 55 false false R56.htm 41301 - Disclosure - Income Taxes - Components of income (loss) before income taxes (Details) Sheet http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxesDetails Income Taxes - Components of income (loss) before income taxes (Details) Details 56 false false R57.htm 41302 - Disclosure - Income taxes - Components of income tax expense (benefit) (Details) Sheet http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails Income taxes - Components of income tax expense (benefit) (Details) Details 57 false false R58.htm 41303 - Disclosure - Income taxes - Effective income tax rate reconciliation (Details) Sheet http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails Income taxes - Effective income tax rate reconciliation (Details) Details 58 false false R59.htm 41304 - Disclosure - Income taxes - Narratives (Details) Sheet http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails Income taxes - Narratives (Details) Details 59 false false R60.htm 41305 - Disclosure - Income taxes - Components of deferred tax assets and liabilities (Details) Sheet http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails Income taxes - Components of deferred tax assets and liabilities (Details) Details 60 false false R61.htm 41306 - Disclosure - Income taxes - Valuation allowance for deferred tax assets (Details) Sheet http://enfusion.com/role/DisclosureIncomeTaxesValuationAllowanceForDeferredTaxAssetsDetails Income taxes - Valuation allowance for deferred tax assets (Details) Details 61 false false R62.htm 41307 - Disclosure - Income taxes - Unrecognized deferred taxes (Details) Sheet http://enfusion.com/role/DisclosureIncomeTaxesUnrecognizedDeferredTaxesDetails Income taxes - Unrecognized deferred taxes (Details) Details 62 false false R63.htm 41401 - Disclosure - Related Party Transactions (Details) Sheet http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://enfusion.com/role/DisclosureRelatedPartyTransactions 63 false false R64.htm 41501 - Disclosure - Subsequent Events (Details) Sheet http://enfusion.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://enfusion.com/role/DisclosureSubsequentEvents 64 false false R65.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Uncategorized 65 false false R66.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Cover 66 false false All Reports Book All Reports enfn-20231231.xsd enfn-20231231_cal.xml enfn-20231231_def.xml enfn-20231231_lab.xml enfn-20231231_pre.xml enfn-20231231x10k.htm enfn-20231231x10k001.jpg enfn-20231231x10k002.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 101 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "enfn-20231231x10k.htm": { "nsprefix": "enfn", "nsuri": "http://enfusion.com/20231231", "dts": { "schema": { "local": [ "enfn-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" ] }, "calculationLink": { "local": [ "enfn-20231231_cal.xml" ] }, "definitionLink": { "local": [ "enfn-20231231_def.xml" ] }, "labelLink": { "local": [ "enfn-20231231_lab.xml" ] }, "presentationLink": { "local": [ "enfn-20231231_pre.xml" ] }, "inline": { "local": [ "enfn-20231231x10k.htm" ] } }, "keyStandard": 324, "keyCustom": 74, "axisStandard": 28, "axisCustom": 0, "memberStandard": 45, "memberCustom": 19, "hidden": { "total": 20, "http://fasb.org/us-gaap/2023": 16, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 208, "entityCount": 1, "segmentCount": 68, "elementCount": 676, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 786, "http://xbrl.sec.gov/dei/2023": 41, "http://xbrl.sec.gov/ecd/2023": 7 }, "report": { "R1": { "role": "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://enfusion.com/role/StatementConsolidatedBalanceSheets", "longName": "00100 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R3": { "role": "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_gD8FW-BxrEaYHisCNuxiQg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_gD8FW-BxrEaYHisCNuxiQg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R4": { "role": "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations", "longName": "00200 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:CostOfRevenue", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R5": { "role": "http://enfusion.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss", "longName": "00300 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R6": { "role": "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit", "longName": "00400 - Statement - Consolidated Statements of Preferred Units, Stockholders' Equity and Members' Deficit", "shortName": "Consolidated Statements of Preferred Units, Stockholders' Equity and Members' Deficit", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_enfn_PreferredUnitsMember_iYEOMyiQX02OfJOj_1fzug", "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2021_To_10_20_2021_us-gaap_StatementEquityComponentsAxis_enfn_PreferredUnitsMember_2qhJrEpKVUa5GTOAnHlGFQ", "name": "us-gaap:TemporaryEquityNetIncome", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R7": { "role": "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "00500 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "enfn:NonCashChangeInOperatingLease", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R8": { "role": "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusiness", "longName": "10101 - Disclosure - Organization and Description of Business", "shortName": "Organization and Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://enfusion.com/role/DisclosureBasisOfPresentation", "longName": "10201 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "10301 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNet", "longName": "10401 - Disclosure - Property, Equipment, and Software, Net", "shortName": "Property, Equipment, and Software, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "longName": "10501 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "enfn:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "enfn:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://enfusion.com/role/DisclosureLeases", "longName": "10601 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://enfusion.com/role/DisclosureDebt", "longName": "10701 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://enfusion.com/role/DisclosureCommitmentsAndContingencies", "longName": "10801 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://enfusion.com/role/DisclosureStockholdersEquity", "longName": "10901 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensation", "longName": "11001 - Disclosure - Management Incentive Plan and Stock-Based Compensation", "shortName": "Management Incentive Plan and Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://enfusion.com/role/DisclosureEmployeeBenefitPlans", "longName": "11101 - Disclosure - Employee Benefit Plans", "shortName": "Employee Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:DefinedContributionPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:DefinedContributionPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShare", "longName": "11201 - Disclosure - Net Income (Loss) Per Class A Common Share", "shortName": "Net Income (Loss) Per Class A Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://enfusion.com/role/DisclosureIncomeTaxes", "longName": "11301 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://enfusion.com/role/DisclosureRelatedPartyTransactions", "longName": "11401 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://enfusion.com/role/DisclosureSubsequentEvents", "longName": "11501 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "20302 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "30303 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables", "longName": "30403 - Disclosure - Property, Equipment, and Software, Net (Tables)", "shortName": "Property, Equipment, and Software, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "enfn:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "enfn:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "enfn:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "enfn:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://enfusion.com/role/DisclosureLeasesTables", "longName": "30603 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R28": { "role": "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationTables", "longName": "31003 - Disclosure - Management Incentive Plan and Stock-Based Compensation (Tables)", "shortName": "Management Incentive Plan and Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareTables", "longName": "31203 - Disclosure - Net Income (Loss) Per Class A Common Share (Tables)", "shortName": "Net Income (Loss) Per Class A Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://enfusion.com/role/DisclosureIncomeTaxesTables", "longName": "31303 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R31": { "role": "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails", "longName": "40101 - Disclosure - Organization and Description of Business (Details)", "shortName": "Organization and Description of Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "enfn:NumberOfSubsidiaries", "unitRef": "Unit_Standard_subsidiary_c7N09vcEQU-UjlUFRrLeYg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "enfn:NumberOfSubsidiaries", "unitRef": "Unit_Standard_subsidiary_c7N09vcEQU-UjlUFRrLeYg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R32": { "role": "http://enfusion.com/role/DisclosureBasisOfPresentationDetails", "longName": "40201 - Disclosure - Basis of Presentation (Details)", "shortName": "Basis of Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_Ka1C3GhBZkuxFWrM5RXHJA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_Ka1C3GhBZkuxFWrM5RXHJA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R33": { "role": "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "longName": "40301 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R34": { "role": "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAllowancesDetails", "longName": "40302 - Disclosure - Summary of Significant Accounting Policies - Allowances (Details)", "shortName": "Summary of Significant Accounting Policies - Allowances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_12_31_2022_w0k1V06J3UOUVbPHwKCvuA", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:ProvisionForDoubtfulAccounts", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R35": { "role": "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyPlantAndEquipmentDetails", "longName": "40303 - Disclosure - Summary of Significant Accounting Policies - Useful life of property plant and equipment (Details)", "shortName": "Summary of Significant Accounting Policies - Useful life of property plant and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember_sH6anWPBrEm0Hk6ARr4YQg", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "enfn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember_sH6anWPBrEm0Hk6ARr4YQg", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "enfn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R36": { "role": "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails", "longName": "40304 - Disclosure - Summary of Significant Accounting Policies - Remaining Performance Obligation (Details)", "shortName": "Summary of Significant Accounting Policies - Remaining Performance Obligation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R37": { "role": "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "longName": "40305 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of revenue (Details)", "shortName": "Summary of Significant Accounting Policies - Disaggregation of revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_fHfLvcA2Y0SYTHMeixUyAA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R38": { "role": "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails", "longName": "40401 - Disclosure - Property, Equipment, and Software, Net (Details)", "shortName": "Property, Equipment, and Software, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R39": { "role": "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetNarrativeDetails", "longName": "40402 - Disclosure - Property, Equipment, and Software, Net- Narrative (Details)", "shortName": "Property, Equipment, and Software, Net- Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:CapitalizedComputerSoftwareAdditions", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R40": { "role": "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "longName": "40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "enfn:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "enfn:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "enfn:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "enfn:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://enfusion.com/role/DisclosureLeasesNarrativesDetails", "longName": "40601 - Disclosure - Leases - Narratives (Details)", "shortName": "Leases - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R42": { "role": "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails", "longName": "40602 - Disclosure - Leases - Lease Commitments (Details)", "shortName": "Leases - Lease Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R43": { "role": "http://enfusion.com/role/DisclosureLeasesComponentsOfOperatingLeaseCostDetails", "longName": "40603 - Disclosure - Leases - Components of Operating Lease Cost (Details)", "shortName": "Leases - Components of Operating Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R44": { "role": "http://enfusion.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails", "longName": "40604 - Disclosure - Leases - Weighted-average remaining lease terms and discount rates (Details)", "shortName": "Leases - Weighted-average remaining lease terms and discount rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R45": { "role": "http://enfusion.com/role/DisclosureLeasesOperatingLeasesAndServiceAgreementsDetails", "longName": "40605 - Disclosure - Leases - Operating Leases and Service Agreements (Details)", "shortName": "Leases - Operating Leases and Service Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2021_To_12_31_2021_QpTUSHOn1ECY5xYqh3iM1g", "name": "us-gaap:LeaseAndRentalExpense", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2021_To_12_31_2021_QpTUSHOn1ECY5xYqh3iM1g", "name": "us-gaap:LeaseAndRentalExpense", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R46": { "role": "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails", "longName": "40701 - Disclosure - Debt - New Credit Agreement (Details)", "shortName": "Debt - New Credit Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_9_15_2023_us-gaap_DebtInstrumentAxis_enfn_NewCreditAgreementMember_HIHutaOVxkmPJ-92E5PBjQ", "name": "enfn:LineOfCreditFacilityAdditionalBorrowingCapacity", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_15_2023_us-gaap_DebtInstrumentAxis_enfn_NewCreditAgreementMember_HIHutaOVxkmPJ-92E5PBjQ", "name": "enfn:LineOfCreditFacilityAdditionalBorrowingCapacity", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R47": { "role": "http://enfusion.com/role/DisclosureDebtPriorCreditAgreementDetails", "longName": "40702 - Disclosure - Debt - Prior Credit Agreement (Details)", "shortName": "Debt - Prior Credit Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_9_15_2023_To_9_15_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_enfn_PriorCreditAgreementMember_HsRHj9e9IUGZyhDxPtg5eQ", "name": "us-gaap:ExtinguishmentOfDebtAmount", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R48": { "role": "http://enfusion.com/role/DisclosureStockholdersEquityDetails", "longName": "40901 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit_Standard_shares_0Pqi41jle0-IWEQ-LZr0mg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_24Ct4L_a2kKkE1iKBRsoPQ", "name": "enfn:NumberOfVotingRights", "unitRef": "Unit_Standard_Vote_TP17_UOGFkOoK-OTP_AXJw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R49": { "role": "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "longName": "41001 - Disclosure - Management Incentive Plan and Stock-Based Compensation - Narratives (Details)", "shortName": "Management Incentive Plan and Stock-Based Compensation - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R50": { "role": "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails", "longName": "41002 - Disclosure - Management Incentive Plan and Stock-Based Compensation - Assumptions (Details)", "shortName": "Management Incentive Plan and Stock-Based Compensation - Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_enfn_PerformanceBasedRestrictedStockUnitsRSUsMember_j5CtzN711kuRynEIkt6GYw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "unitRef": "Unit_Divide_USD_shares_gD8FW-BxrEaYHisCNuxiQg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "enfn:ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_enfn_PerformanceBasedRestrictedStockUnitsRSUsMember_j5CtzN711kuRynEIkt6GYw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "unitRef": "Unit_Divide_USD_shares_gD8FW-BxrEaYHisCNuxiQg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "enfn:ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R51": { "role": "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationStockCompensationIncomeExpenseDetails", "longName": "41003 - Disclosure - Management Incentive Plan and Stock-Based Compensation - Stock Compensation (Income) Expense (Details)", "shortName": "Management Incentive Plan and Stock-Based Compensation - Stock Compensation (Income) Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_Fc05mfE72UuLnL38gI7lkA", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R52": { "role": "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails", "longName": "41004 - Disclosure - Management Incentive Plan and Stock-Based Compensation - RSUs and Stock Options (Details)", "shortName": "Management Incentive Plan and Stock-Based Compensation - RSUs and Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_enfn_ClassaCommonStockVestedAndRestrictedStockUnitsMember_L6JGme7wfEWfqlguklGVrw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Unit_Standard_shares_0Pqi41jle0-IWEQ-LZr0mg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_enfn_ClassaCommonStockVestedAndRestrictedStockUnitsMember_jwMfNB0_90iCinTO2ywuuA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit_Standard_shares_0Pqi41jle0-IWEQ-LZr0mg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R53": { "role": "http://enfusion.com/role/DisclosureEmployeeBenefitPlansDetails", "longName": "41101 - Disclosure - Employee Benefit Plans (Details)", "shortName": "Employee Benefit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "unitRef": "Unit_Standard_pure_xEpsjYFm70GVqZmTh8ufxA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:DefinedContributionPlanTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "unitRef": "Unit_Standard_pure_xEpsjYFm70GVqZmTh8ufxA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:DefinedContributionPlanTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R54": { "role": "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails", "longName": "41201 - Disclosure - Net Income (Loss) Per Class A Common Share - Basic and Diluted Net Loss Per Share (Details)", "shortName": "Net Income (Loss) Per Class A Common Share - Basic and Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2021_To_12_31_2021_QpTUSHOn1ECY5xYqh3iM1g", "name": "enfn:NetIncomeLossAttributableToParentPriorToIpo", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R55": { "role": "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails", "longName": "41202 - Disclosure - Net Income (Loss) Per Class A Common Share - Dilutive shares (Details)", "shortName": "Net Income (Loss) Per Class A Common Share - Dilutive shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_0Pqi41jle0-IWEQ-LZr0mg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_0Pqi41jle0-IWEQ-LZr0mg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R56": { "role": "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxesDetails", "longName": "41301 - Disclosure - Income Taxes - Components of income (loss) before income taxes (Details)", "shortName": "Income Taxes - Components of income (loss) before income taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R57": { "role": "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails", "longName": "41302 - Disclosure - Income taxes - Components of income tax expense (benefit) (Details)", "shortName": "Income taxes - Components of income tax expense (benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R58": { "role": "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails", "longName": "41303 - Disclosure - Income taxes - Effective income tax rate reconciliation (Details)", "shortName": "Income taxes - Effective income tax rate reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure_xEpsjYFm70GVqZmTh8ufxA", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "unitRef": "Unit_Standard_pure_xEpsjYFm70GVqZmTh8ufxA", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R59": { "role": "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails", "longName": "41304 - Disclosure - Income taxes - Narratives (Details)", "shortName": "Income taxes - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure_xEpsjYFm70GVqZmTh8ufxA", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R60": { "role": "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails", "longName": "41305 - Disclosure - Income taxes - Components of deferred tax assets and liabilities (Details)", "shortName": "Income taxes - Components of deferred tax assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:DeferredTaxAssetsInvestments", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_Fv_e-ClwKkWDa4yS-pisYg", "name": "us-gaap:DeferredTaxAssetsInvestments", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } }, "R61": { "role": "http://enfusion.com/role/DisclosureIncomeTaxesValuationAllowanceForDeferredTaxAssetsDetails", "longName": "41306 - Disclosure - Income taxes - Valuation allowance for deferred tax assets (Details)", "shortName": "Income taxes - Valuation allowance for deferred tax assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_12_31_2022_w0k1V06J3UOUVbPHwKCvuA", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "enfn:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseChargedToIncomeTaxExpense", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R62": { "role": "http://enfusion.com/role/DisclosureIncomeTaxesUnrecognizedDeferredTaxesDetails", "longName": "41307 - Disclosure - Income taxes - Unrecognized deferred taxes (Details)", "shortName": "Income taxes - Unrecognized deferred taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_12_31_2022_w0k1V06J3UOUVbPHwKCvuA", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_9pJmmKE2ekakHqIvqZnFxQ", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R63": { "role": "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "41401 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "enfn:PercentageOfEntitySShareOfTaxBenefitsUnderTaxReceivableAgreement", "unitRef": "Unit_Standard_pure_xEpsjYFm70GVqZmTh8ufxA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_srt_CounterpartyNameAxis_enfn_FtvEnfusionHoldingsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4qHuXO37wEiBziBsJhZ_Tw", "name": "us-gaap:ProceedsFromIncomeTaxRefunds", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R64": { "role": "http://enfusion.com/role/DisclosureSubsequentEventsDetails", "longName": "41501 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Duration_8_1_2023_To_8_1_2023_dLrwS1qAmU-n1HnrXm66RQ", "name": "enfn:CommonUnitsSurrendered", "unitRef": "Unit_Standard_shares_0Pqi41jle0-IWEQ-LZr0mg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_11_2024_To_1_11_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ew0bWGt_VkKEV56eCBaSOQ", "name": "enfn:CommonUnitsSurrendered", "unitRef": "Unit_Standard_shares_0Pqi41jle0-IWEQ-LZr0mg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "unique": true } }, "R65": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Uncategorized", "order": "65", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_KbD4rmB0TEqFRv_EJlPuGQ", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_jFiit2Eem0G4gYG3pF0N3A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true }, "uniqueAnchor": null }, "R66": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Cover", "order": "66", "firstAnchor": { "contextRef": "Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_enfn_OlegMovchanMember_lEGnXep1IU6ZzUMFbBUU0A", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_enfn_OlegMovchanMember_lEGnXep1IU6ZzUMFbBUU0A", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "enfn-20231231x10k.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201613Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate201613Member", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAllowancesDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "Accounting Standards Update 2016-13", "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." } } }, "auth_ref": [ "r294" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21", "r786" ] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of accounts receivable allowance for credit loss", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r914" ] }, "enfn_AccountsReceivableAllowanceForCreditLossWriteoffNetOfRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "AccountsReceivableAllowanceForCreditLossWriteoffNetOfRecoveries", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAllowancesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance, net of recoveries.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff Net Of Recoveries", "terseLabel": "Accounts written off, net of recoveries" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r739" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r288", "r289" ] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedBonusesCurrent", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Bonuses, Current", "terseLabel": "Accrued compensation includes bonuses due to employees", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "enfn_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued compensation", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "enfn_AccruedExpensesAndOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "AccruedExpensesAndOtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of accrued expenses and other current liabilities as on date.", "label": "Accrued Expenses And Other Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "enfn_AccruedExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "AccruedExpensesCurrent", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "enfn_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accrued expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Expenses, Current", "terseLabel": "Accrued expenses and other" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Current Liabilities" } } }, "auth_ref": [] }, "enfn_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://enfusion.com/20231231", "localname": "AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r61", "r185", "r600" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r31", "r32", "r107", "r191", "r595", "r625", "r629" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Loss", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r14", "r32", "r491", "r494", "r553", "r620", "r621", "r892", "r893", "r894", "r902", "r903", "r904" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r839" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r102", "r786", "r980" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r431", "r432", "r433", "r646", "r902", "r903", "r904", "r961", "r981" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r845" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r845" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r845" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r845" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAllowancesDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r175", "r176", "r177", "r178", "r179", "r232", "r233", "r234", "r235", "r244", "r291", "r292", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r313", "r431", "r432", "r433", "r463", "r464", "r465", "r466", "r476", "r477", "r478", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r528", "r529", "r532", "r533", "r534", "r535", "r549", "r550", "r551", "r552", "r553", "r569", "r570", "r571", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "crdr": "credit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Other", "terseLabel": "Other", "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r73", "r74", "r393" ] }, "enfn_AdjustmentsToNetIncomeLossAttributableToCommonStockholders": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "AdjustmentsToNetIncomeLossAttributableToCommonStockholders", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of adjustments to income (loss) attributable to common stockholders.", "label": "Adjustments To Net Income (Loss) Attributable To Common Stockholders", "terseLabel": "Adjustment to loss attributable to common stockholders" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Costs", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r159" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Advertising Expense", "terseLabel": "Advertising cost", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r440" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r809", "r821", "r831", "r857" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r812", "r824", "r834", "r860" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r845" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r852" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r816", "r825", "r835", "r852", "r861", "r865", "r873" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r871" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationStockCompensationIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total equity-based compensation", "verboseLabel": "Total stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r425", "r439" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAllowancesDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r192", "r290", "r305", "r306", "r308", "r976" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAllowancesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "srt_AmericasMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AmericasMember", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Americas", "terseLabel": "Americas*" } } }, "auth_ref": [ "r983", "r984", "r985", "r986" ] }, "us-gaap_AmortizationOfDeferredSalesCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDeferredSalesCommissions", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of Deferred Sales Commissions", "terseLabel": "Amortization expense", "documentation": "The amount of expense recognized in the current period for the periodic realization of capitalized fees that were paid to salespeople, distributors, brokers, and agents at the time of the conclusion of the sale. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r114" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt-related costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r111", "r352", "r530", "r897" ] }, "enfn_AnnualBonusIncentivePlanPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://enfusion.com/20231231", "localname": "AnnualBonusIncentivePlanPolicyPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the annual bonus incentive plan.", "label": "Annual Bonus Incentive Plan Policy [Policy Text Block]", "terseLabel": "Annual Bonus Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r256" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r47" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r47" ] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Asia Pacific (APAC)" } } }, "auth_ref": [ "r983", "r984", "r985", "r986" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r142", "r187", "r220", "r265", "r278", "r282", "r293", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r480", "r484", "r512", "r590", "r683", "r786", "r799", "r920", "r921", "r967" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r181", "r195", "r220", "r293", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r480", "r484", "r512", "r786", "r920", "r921", "r967" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r803", "r804", "r817" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r803", "r804", "r817" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r803", "r804", "r817" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r868" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r869" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r864" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r864" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r864" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r864" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r864" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r864" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r867" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r866" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r865" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r865" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Minimum base rate", "terseLabel": "Base Rate", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "enfn_BeneficialOwnershipPercentageOfIssuedAndOutstandingClassCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://enfusion.com/20231231", "localname": "BeneficialOwnershipPercentageOfIssuedAndOutstandingClassCommonStock", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the beneficial ownership percentage of the Company's issued and outstanding class A common stock.", "label": "Beneficial Ownership Percentage Of Issued And Outstanding Class A Common Stock", "terseLabel": "Beneficial ownership percentage" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accrued property, equipment, and software, net", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r40", "r41", "r42" ] }, "us-gaap_CapitalUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitsMember", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Capital Units", "terseLabel": "Common Units", "documentation": "Type of ownership interest in a corporation. Class of capital units or capital shares." } } }, "auth_ref": [] }, "us-gaap_CapitalizedComputerSoftwareAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedComputerSoftwareAdditions", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Capitalized Computer Software, Additions", "terseLabel": "Capitalized software development costs", "documentation": "Additions made to capitalized computer software costs during the period." } } }, "auth_ref": [ "r57" ] }, "us-gaap_CapitalizedComputerSoftwareAmortization1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedComputerSoftwareAmortization1", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Capitalized Computer Software, Amortization", "terseLabel": "Amortization expense related to software development costs", "documentation": "Amount of expense for amortization of capitalized computer software costs." } } }, "auth_ref": [ "r12", "r151" ] }, "us-gaap_CapitalizedComputerSoftwarePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedComputerSoftwarePeriodIncreaseDecrease", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Capitalized Computer Software, Period Increase (Decrease)", "terseLabel": "Capitalization of software development costs", "documentation": "Amount of increase (decrease) in capitalized computer software costs." } } }, "auth_ref": [ "r93" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r37", "r183", "r755" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r38" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r37", "r119", "r216" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r119" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash activities:" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r843" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/DisclosureStockholdersEquityDetails", "http://enfusion.com/role/DisclosureSubsequentEventsDetails", "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "http://enfusion.com/role/StatementConsolidatedBalanceSheets", "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r174", "r188", "r189", "r190", "r220", "r249", "r250", "r253", "r255", "r263", "r264", "r293", "r321", "r323", "r324", "r325", "r328", "r329", "r357", "r358", "r361", "r364", "r371", "r512", "r635", "r636", "r637", "r638", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r671", "r692", "r714", "r731", "r732", "r733", "r734", "r735", "r881", "r898", "r906" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r188", "r189", "r190", "r263", "r357", "r358", "r359", "r361", "r364", "r369", "r371", "r635", "r636", "r637", "r638", "r771", "r881", "r898" ] }, "enfn_ClassaCommonStockVestedAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ClassaCommonStockVestedAndRestrictedStockUnitsMember", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to IPO vested Class A common stock and RSUs.", "label": "ClassA Common Stock Vested And Restricted Stock Units [Member]", "terseLabel": "IPO Vested Class A Common Stock and RSUs" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r844" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r844" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies.", "terseLabel": "Commitment and contingencies (Note 8)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r28", "r91", "r591", "r670" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r128", "r315", "r316", "r740", "r917" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/DisclosureStockholdersEquityDetails", "http://enfusion.com/role/DisclosureSubsequentEventsDetails", "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "http://enfusion.com/role/StatementConsolidatedBalanceSheets", "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Common Class A", "terseLabel": "Common Class A", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r981" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails", "http://enfusion.com/role/DisclosureStockholdersEquityDetails", "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "http://enfusion.com/role/StatementConsolidatedBalanceSheets", "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Common Class B", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r981" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r789", "r790", "r791", "r793", "r794", "r795", "r796", "r902", "r903", "r961", "r979", "r981" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails", "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r101" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails", "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r101", "r671" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r101" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r15", "r101", "r671", "r689", "r981", "r982" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r101", "r593", "r786" ] }, "us-gaap_CommonUnitOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitOutstanding", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Common Unit, Outstanding", "periodEndLabel": "Balance at end of period (Shares)", "periodStartLabel": "Balance at beginning of period (Shares)", "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC)." } } }, "auth_ref": [] }, "enfn_CommonUnitsSurrendered": { "xbrltype": "sharesItemType", "nsuri": "http://enfusion.com/20231231", "localname": "CommonUnitsSurrendered", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails", "http://enfusion.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of common units surrendered.", "label": "Common Units Surrendered", "terseLabel": "Common units surrendered by Pre-IPO unitholders (in shares)" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r849" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r848" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r850" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r847" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Employee Benefit Plans" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred Tax Assets" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred Tax Liabilities" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income (loss) attributable to Enfusion, Inc.", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r33", "r197", "r199", "r206", "r586", "r608" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive income (loss) attributable to non-controlling interests", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r7", "r82", "r86", "r197", "r199", "r205", "r585", "r607" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total other comprehensive income (loss)", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r86", "r140", "r197", "r199", "r204", "r584", "r606" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer equipment", "terseLabel": "Computers", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r50", "r53", "r87", "r88", "r287", "r739" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r50", "r53", "r87", "r88", "r287", "r630", "r739" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r50", "r53", "r87", "r88", "r287", "r739", "r886" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r92", "r162" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Total net revenues percent", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r50", "r53", "r87", "r88", "r287" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r50", "r53", "r87", "r88", "r287", "r739" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r83", "r760" ] }, "enfn_ContingentlyIssuableClassCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ContingentlyIssuableClassCommonStockMember", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to contingently issuable class a common stock.", "label": "Contingently issuable shares of Class A common stock" } } }, "auth_ref": [] }, "enfn_ContingentlyIssuableSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ContingentlyIssuableSharesMember", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to shares of Class A common stock that vested within one year of the IPO date.", "label": "Contingently Issuable Shares [Member]", "terseLabel": "Contingently Issuable Shares" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "Contract assets, unbilled accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r373", "r374", "r385" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of Revenue", "terseLabel": "Total cost of revenues", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r113", "r220", "r293", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r512", "r920" ] }, "us-gaap_CostOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenueAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "COST OF REVENUES:" } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationStockCompensationIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Cost of revenues", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Revenues", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r890" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r225", "r226", "r334", "r359", "r560", "r757", "r759" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails", "http://enfusion.com/role/DisclosureDebtPriorCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails", "http://enfusion.com/role/DisclosureDebtPriorCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAllowancesDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative impact of adopting ASU 2016-13" } } }, "auth_ref": [ "r177", "r231", "r238", "r244", "r298", "r304", "r431", "r432", "r433", "r465", "r466", "r489", "r491", "r492", "r494", "r495", "r496", "r501", "r504", "r506", "r507", "r551" ] }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionAxis", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAllowancesDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "auth_ref": [ "r177", "r231", "r238", "r244", "r298", "r304", "r431", "r432", "r433", "r465", "r466", "r489", "r491", "r492", "r494", "r495", "r496", "r501", "r504", "r506", "r507", "r551" ] }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionDomain", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAllowancesDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]" } } }, "auth_ref": [ "r177", "r231", "r238", "r244", "r298", "r304", "r431", "r432", "r433", "r465", "r466", "r489", "r491", "r492", "r494", "r495", "r496", "r501", "r504", "r506", "r507", "r551" ] }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Current tax (benefit) expense" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "U.S. Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r889", "r901", "r958" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r889", "r901" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total Current Income Tax Expense", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r138", "r462", "r470", "r901" ] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State & Local", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r889", "r901", "r958" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r51", "r287" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureDebt" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r129", "r218", "r330", "r336", "r337", "r338", "r339", "r340", "r341", "r346", "r353", "r354", "r355" ] }, "enfn_DebtInstrumentAdditionalBasisPointsAddedToVariableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://enfusion.com/20231231", "localname": "DebtInstrumentAdditionalBasisPointsAddedToVariableInterestRate", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of additional basis points added to variable interest rate.", "label": "Debt Instrument, Additional Basis Points Added to Variable Interest Rate", "terseLabel": "Basis points added to variable interest rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails", "http://enfusion.com/role/DisclosureDebtPriorCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r19", "r95", "r96", "r143", "r145", "r227", "r331", "r332", "r333", "r334", "r335", "r337", "r342", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r531", "r766", "r767", "r768", "r769", "r770", "r899" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails", "http://enfusion.com/role/DisclosureDebtPriorCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r27", "r227", "r331", "r332", "r333", "r334", "r335", "r337", "r342", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r531", "r766", "r767", "r768", "r769", "r770", "r899" ] }, "enfn_DeferredCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "DeferredCommissions", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of deferred commissions.", "label": "Deferred Commissions", "terseLabel": "Deferred commissions" } } }, "auth_ref": [] }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Deferred tax (benefit) expense" } } }, "auth_ref": [] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r138", "r901", "r956" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r9", "r138", "r170", "r469", "r470", "r901" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r97", "r98", "r144", "r456" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "totalLabel": "Total Deferred Tax Assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r457" ] }, "us-gaap_DeferredTaxAssetsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInvestments", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Investments", "terseLabel": "Investment in Enfusion Ltd. LLC", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments)." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net", "totalLabel": "Net Deferred Tax Assets", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r954" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total Deferred Tax Assets Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r954" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net Operating Losses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r79", "r955" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Other", "terseLabel": "Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r79", "r955" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Stock-Based Compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r79", "r955" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails", "http://enfusion.com/role/DisclosureIncomeTaxesValuationAllowanceForDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation Allowance", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r458" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net Deferred Tax Liabilities", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r75", "r954" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Property and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r79", "r955" ] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Employer discretionary contribution Amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://enfusion.com/role/DisclosureEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Contribution percent of employees", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://enfusion.com/role/DisclosureEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Contribution percent of match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureEmployeeBenefitPlans" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan [Text Block]", "terseLabel": "Employee Benefit Plans", "documentation": "The entire disclosure for defined contribution plan." } } }, "auth_ref": [ "r388", "r389" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r9", "r60" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r9", "r268" ] }, "us-gaap_DilutiveSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DilutiveSecurities", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "us-gaap_NetIncomeLossAttributableToParentDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share", "terseLabel": "Adjustment to Income for Dilutive Shares", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities." } } }, "auth_ref": [ "r45" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r384", "r772", "r773", "r774", "r775", "r776", "r777", "r778" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r384", "r772", "r773", "r774", "r775", "r776", "r777", "r778" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of total net revenues by geographic region", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r923" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Management Incentive and Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r391", "r395", "r427", "r428", "r430", "r780" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Management Incentive Plan and Stock-Based Compensation" } } }, "auth_ref": [] }, "us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Distribution Made to Limited Liability Company (LLC) Member, Cash Distributions Paid", "negatedLabel": "Payment of member distributions", "documentation": "Amount of cash distribution paid to unit-holder of limited liability company (LLC)." } } }, "auth_ref": [ "r133" ] }, "enfn_DistributionMadeToPartners": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "DistributionMadeToPartners", "crdr": "debit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Amount of distributions made to partners.", "label": "Distribution Made To Partners", "negatedLabel": "Distributions to members" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r803", "r804", "r817" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r803", "r804", "r817", "r853" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r838" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EMEAMember", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Europe, Middle East and Africa (EMEA)", "terseLabel": "Europe, Middle East, and Africa (EMEA)", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": [ "r983", "r984", "r985", "r986" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Income (Loss) Per Class A Common Share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net income (loss) per share of Class A common stock--Basic", "verboseLabel": "Net income (loss) per share of Class A common stock--Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r207", "r236", "r237", "r238", "r239", "r240", "r246", "r249", "r253", "r254", "r255", "r259", "r507", "r508", "r587", "r609", "r761" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net income (loss) per share of Class A common stock--Diluted", "verboseLabel": "Net income (loss) per share of Class A common stock--Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r207", "r236", "r237", "r238", "r239", "r240", "r249", "r253", "r254", "r255", "r259", "r507", "r508", "r587", "r609", "r761" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Income (Loss) Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r47", "r48" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income (Loss) Per Class A Common Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r245", "r256", "r257", "r258" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r963" ] }, "enfn_EffectOfReorganizationTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "EffectOfReorganizationTransactions", "crdr": "debit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of effect of the reorganization transactions.", "label": "Effect of the Reorganization Transactions", "terseLabel": "Effect of the Reorganization Transactions" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails", "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate (as a percent)", "totalLabel": "Total", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r447" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails", "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "U.S. statutory tax rate (as a percent)", "verboseLabel": "At U.S. Federal Statutory Tax Rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r222", "r447", "r472" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Valuation Allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r952", "r959" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Change in Tax Rates", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r472", "r952" ] }, "enfn_EffectiveIncomeTaxRateReconciliationForeignBranchTaxesPercent": { "xbrltype": "percentItemType", "nsuri": "http://enfusion.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationForeignBranchTaxesPercent", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to foreign branch taxes.", "label": "Effective Income Tax Rate Reconciliation, Foreign Branch Taxes, Percent", "terseLabel": "Foreign Branch Taxes" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Foreign Rate Differential", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r952", "r959" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent", "negatedLabel": "Non-controlling Interest", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes." } } }, "auth_ref": [ "r952", "r959" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r952", "r959" ] }, "enfn_EffectiveIncomeTaxRateReconciliationRateEffectFromPassThroughEntityPercent": { "xbrltype": "percentItemType", "nsuri": "http://enfusion.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationRateEffectFromPassThroughEntityPercent", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to rate effect from pass-through entity.", "label": "Effective Income Tax Rate Reconciliation, Rate Effect From Pass Through Entity, Percent", "terseLabel": "Pass-through Loss (Income)" } } }, "auth_ref": [] }, "enfn_EffectiveIncomeTaxRateReconciliationReturnToProvision": { "xbrltype": "percentItemType", "nsuri": "http://enfusion.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvision", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to rate effect from return to provision.", "label": "Effective Income Tax Rate Reconciliation, Return To Provision", "terseLabel": "Return to Provision" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent", "terseLabel": "Stock-Based Compensation", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r882", "r952" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State Tax, Net of Federal Benefit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r952", "r959" ] }, "enfn_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitPercent": { "xbrltype": "percentItemType", "nsuri": "http://enfusion.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitPercent", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized tax benefit.", "label": "Effective Income Tax Rate Reconciliation, Unrecognized Tax Benefit, Percent", "terseLabel": "Unrecognized Tax Benefit" } } }, "auth_ref": [] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash", "crdr": "debit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Employee Benefit and Share-based Payment Arrangement, Noncash", "terseLabel": "Capitalized stock-based compensation expense", "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits." } } }, "auth_ref": [ "r9" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Amount Capitalized", "terseLabel": "Capitalized stock compensation to capitalized software development costs", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r426" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationStockCompensationIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Management Incentive Plans", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Stock based compensation recognition period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r429" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock compensation expense", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r950" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Nonvested award option", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r950" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationTables", "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "enfn_EnfusionLtd.LlcMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "EnfusionLtd.LlcMember", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails", "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Enfusion Ltd. LLC, a Delaware limited liability, and its wholly owned subsidiaries.", "label": "Enfusion LLC" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r801" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r801" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r880" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r801" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r878" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r801" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r801" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r801" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r801" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r879" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails", "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r15", "r177", "r201", "r202", "r203", "r228", "r229", "r230", "r233", "r241", "r243", "r260", "r298", "r304", "r372", "r431", "r432", "r433", "r465", "r466", "r489", "r491", "r492", "r493", "r494", "r496", "r506", "r521", "r522", "r523", "r524", "r525", "r526", "r553", "r620", "r621", "r622", "r646", "r714" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r846" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r809", "r821", "r831", "r857" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r806", "r818", "r828", "r854" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r852" ] }, "us-gaap_ExtinguishmentOfDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtAmount", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureDebtPriorCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Extinguishment of Debt, Amount", "terseLabel": "Facility terminated", "documentation": "Gross amount of debt extinguished." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r11", "r18" ] }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalFundsEffectiveSwapRateMember", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "terseLabel": "Federal funds rate", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg." } } }, "auth_ref": [ "r960" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Translation of Foreign Currencies", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r517" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r813", "r825", "r835", "r861" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r813", "r825", "r835", "r861" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r813", "r825", "r835", "r861" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r813", "r825", "r835", "r861" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r813", "r825", "r835", "r861" ] }, "enfn_FtvEnfusionHoldingsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "FtvEnfusionHoldingsIncMember", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to FTV Enfusion Holding Inc.", "label": "FTV Enfusion Holdings, Inc" } } }, "auth_ref": [] }, "enfn_FtvFundIvMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "FtvFundIvMember", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to FTV Fund IV.", "label": "FTV Fund IV" } } }, "auth_ref": [] }, "enfn_FtvInvestmentHoldingsMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "FtvInvestmentHoldingsMember", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to FTV Investment Holdings.", "label": "FTV Investment Holdings" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and fixtures", "terseLabel": "Furniture, fixtures, and equipment", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureDebtPriorCreditAgreementDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Loss from early extinguishment of debt", "negatedLabel": "Loss on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r9", "r62", "r63" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r115", "r694" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationStockCompensationIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r110" ] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Geographic Region", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r52", "r739" ] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GranteeStatusAxis", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r392", "r394", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GranteeStatusDomain", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r392", "r394", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r112", "r220", "r265", "r277", "r281", "r283", "r293", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r512", "r763", "r920" ] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IPOMember", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "IPO", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r803", "r804", "r817" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Impairment of long-lived assets", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r9", "r59", "r126" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r127" ] }, "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]", "terseLabel": "Net income (loss) per Class A common shares attributable to Enfusion, Inc.:" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S.", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r221", "r471" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxesDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r108", "r149", "r265", "r277", "r281", "r283", "r588", "r602", "r763" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r221", "r471" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Operations" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationStockCompensationIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r312", "r314", "r699" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationStockCompensationIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r314", "r699" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r222", "r442", "r448", "r454", "r460", "r467", "r473", "r474", "r475", "r640" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 }, "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "totalLabel": "Total", "verboseLabel": "Income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r157", "r171", "r242", "r243", "r269", "r446", "r468", "r610" ] }, "enfn_IncomeTaxExpenseBenefitAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "IncomeTaxExpenseBenefitAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense (benefit) attributable to noncontrolling interest.", "label": "Income Tax Expense Benefit Attributable To Noncontrolling Interest", "terseLabel": "Tax (benefit) expense attributable to noncontrolling interest" } } }, "auth_ref": [] }, "enfn_IncomeTaxExpenseBenefitRelatingToIncomeTaxReturns": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "IncomeTaxExpenseBenefitRelatingToIncomeTaxReturns", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense (benefit) relating to income tax returns.", "label": "Income Tax Expense Benefit Relating To Income Tax Returns", "terseLabel": "Income tax expense (benefit) provision related to tax returns" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r200", "r444", "r445", "r454", "r455", "r459", "r461", "r634" ] }, "enfn_IncomeTaxReconciliationForeignBranchTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "IncomeTaxReconciliationForeignBranchTaxes", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign branch taxes.", "label": "Income Tax Reconciliation, Foreign Branch Taxes", "terseLabel": "Foreign income taxes related to pre-tax income of its branch" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount", "terseLabel": "Tax impact of equity-based compensation", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r952" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes paid in cash", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r39" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r896" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r887", "r896" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Preferred Units", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "enfn_IncreaseInCommonUnits": { "xbrltype": "sharesItemType", "nsuri": "http://enfusion.com/20231231", "localname": "IncreaseInCommonUnits", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails", "http://enfusion.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of increase in common units owned by the entity.", "label": "Increase in Common Units", "terseLabel": "Increase in common units (in shares)" } } }, "auth_ref": [] }, "enfn_IncreaseOrDecreaseInDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "IncreaseOrDecreaseInDeferredTaxAssets", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred tax assets.", "label": "Increase or Decrease in Deferred Tax Assets", "negatedLabel": "Change in tax rates" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r816", "r825", "r835", "r852", "r861", "r865", "r873" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r871" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r805", "r877" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r805", "r877" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r805", "r877" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income (expense), net", "documentation": "The net amount of nonoperating interest income (expense)." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid in cash", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r211", "r214", "r215" ] }, "us-gaap_LeaseAndRentalExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseAndRentalExpense", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureLeasesOperatingLeasesAndServiceAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Leases, Rent Expense", "terseLabel": "Expense related to lease arrangements", "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureLeasesComponentsOfOperatingLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/DisclosureLeasesComponentsOfOperatingLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Lease, Cost", "totalLabel": "Total lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r541", "r785" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of components of operating lease cost", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r964" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold improvements", "terseLabel": "Leasehold improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r125" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r539" ] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [ "http://enfusion.com/role/DisclosureLeasesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Option to renew the lease", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": [ "r540" ] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate", "presentation": [ "http://enfusion.com/role/DisclosureLeasesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]", "terseLabel": "Option to terminate the lease", "documentation": "Indicates (true false) whether lessee has option to terminate operating lease." } } }, "auth_ref": [ "r540" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of lease commitments", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r965" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://enfusion.com/role/DisclosureLeasesCommitmentsDetailsCalc2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease commitments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r548" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r548" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r548" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r548" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r548" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r548" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r548" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureLeasesCommitmentsDetailsCalc2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r548" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r536" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]", "terseLabel": "Letters of credit", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r24", "r220", "r293", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r481", "r484", "r485", "r512", "r669", "r762", "r799", "r920", "r967", "r968" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r106", "r147", "r598", "r786", "r900", "r913", "r962" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r26", "r182", "r220", "r293", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r481", "r484", "r485", "r512", "r786", "r920", "r967", "r968" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails", "http://enfusion.com/role/DisclosureDebtPriorCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Line of Credit", "terseLabel": "Outstanding borrowings", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r19", "r145", "r975" ] }, "enfn_LineOfCreditFacilityAdditionalBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional borrowing capacity under the credit facility.", "label": "Line of Credit Facility, Additional Borrowing Capacity", "terseLabel": "Additional borrowing capacity" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails", "http://enfusion.com/role/DisclosureDebtPriorCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "terseLabel": "Debt", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r899" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r22" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails", "http://enfusion.com/role/DisclosureDebtPriorCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r22", "r899" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Percentage of unused commitment fee", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "enfn_MajorCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "MajorCustomerMember", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to major customers.", "label": "Major Customer" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r287", "r774", "r923", "r977", "r978" ] }, "enfn_ManagedServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ManagedServicesMember", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to managed services.", "label": "Managed services" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Maximum", "terseLabel": "Maximum" } } }, "auth_ref": [ "r317", "r318", "r319", "r320", "r390", "r566", "r617", "r661", "r662", "r722", "r724", "r726", "r727", "r729", "r750", "r751", "r765", "r771", "r779", "r788", "r922", "r969", "r970", "r971", "r972", "r973", "r974" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r844" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r844" ] }, "us-gaap_MemberUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MemberUnitsMember", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Member Units [Member]", "terseLabel": "Members' Equity", "documentation": "Ownership interest in limited liability company (LLC)." } } }, "auth_ref": [] }, "us-gaap_MembersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MembersEquity", "crdr": "credit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Members' Equity", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "documentation": "Amount of ownership interest in limited liability company (LLC), attributable to the parent entity." } } }, "auth_ref": [ "r133", "r261", "r262", "r263", "r264" ] }, "us-gaap_MembersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MembersEquityAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Members' Equity [Abstract]", "terseLabel": "Stockholders' Equity:", "verboseLabel": "Members' Equity" } } }, "auth_ref": [] }, "enfn_MinimumBalanceToBeMaintainedAtBankAsPerAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "MinimumBalanceToBeMaintainedAtBankAsPerAgreement", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of minimum balance to be maintained at bank as per agreement.", "label": "Minimum Balance to Be Maintained At Bank As Per Agreement", "terseLabel": "Minimum balance to be maintained at bank as per agreement" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum" } } }, "auth_ref": [ "r317", "r318", "r319", "r320", "r390", "r566", "r617", "r661", "r662", "r722", "r724", "r726", "r727", "r729", "r750", "r751", "r765", "r771", "r779", "r788", "r922", "r969", "r970", "r971", "r972", "r973", "r974" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interests", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r30", "r146", "r220", "r293", "r321", "r323", "r324", "r325", "r328", "r329", "r512", "r597", "r673" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "verboseLabel": "Ownership percentage by noncontrolling owners", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership percentage", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "enfn_MinorityInterestPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://enfusion.com/20231231", "localname": "MinorityInterestPolicyPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for non-controlling interest.", "label": "Minority Interest Policy [Policy Text Block]", "terseLabel": "Non-controlling interest" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r864" ] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds, at Carrying Value", "terseLabel": "Investment in money market accounts.", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r872" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": [ "r287", "r774", "r923", "r977", "r978" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r845" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "Organization and Description of Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r158", "r172" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r213" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r213" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r119", "r120", "r121" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "enfn_NetDeferredTaxBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NetDeferredTaxBenefit", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of net deferred tax benefit (expense), in which a valuation allowance has been fully allowed.", "label": "Net deferred tax (expense) benefit", "terseLabel": "Net deferred tax (expense) benefit" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to Enfusion, Inc.", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r109", "r121", "r150", "r180", "r196", "r198", "r203", "r220", "r232", "r236", "r237", "r238", "r239", "r242", "r243", "r251", "r265", "r277", "r281", "r283", "r293", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r508", "r512", "r605", "r691", "r712", "r713", "r763", "r797", "r920" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 }, "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "enfn_NetIncomeLossAttributableToParentSubsequentToIpo", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Less: Net (income) loss attributable to non-controlling interests", "terseLabel": "Net income (loss) attributable to non-controlling interests", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r85", "r141", "r196", "r198", "r242", "r243", "r604", "r894" ] }, "us-gaap_NetIncomeLossAttributableToParentDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToParentDiluted", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent, Diluted", "totalLabel": "Numerator for Diluted Earnings per Share", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions." } } }, "auth_ref": [] }, "enfn_NetIncomeLossAttributableToParentPriorToIpo": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NetIncomeLossAttributableToParentPriorToIpo", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "enfn_NetIncomeLossAttributableToParentSubsequentToIpo", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent prior to the initial public offering.", "label": "Net Income (Loss) Attributable To Parent Prior To IPO", "negatedLabel": "Less: Net income attributable to Enfusion, Inc. prior to the IPO" } } }, "auth_ref": [] }, "enfn_NetIncomeLossAttributableToParentSubsequentToIpo": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NetIncomeLossAttributableToParentSubsequentToIpo", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent subsequent to IPO.", "label": "Net Income (Loss) Attributable To Parent Subsequent To Ipo", "terseLabel": "Net income (loss) attributable to Enfusion, Inc.", "totalLabel": "Net loss attributable to Enfusion, Inc." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "us-gaap_NetIncomeLossAttributableToParentDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Numerator for Basic Earnings per Share", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r209", "r236", "r237", "r238", "r239", "r246", "r247", "r252", "r255", "r265", "r277", "r281", "r283", "r763" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "auth_ref": [] }, "enfn_NetIncomeLossExcludingPreferredUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NetIncomeLossExcludingPreferredUnits", "crdr": "credit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to net income (loss) excluding preferred units.", "label": "Net Income Loss Excluding Preferred Units", "terseLabel": "Net income (loss)" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Pronouncements/Recent Accounting Pronouncements Not Yet Adopted", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "enfn_NewCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NewCreditAgreementMember", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to new credit agreement.", "label": "New Credit Agreement [Member]", "terseLabel": "New Credit Agreement" } } }, "auth_ref": [] }, "enfn_NonCashChangeInOperatingLease": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NonCashChangeInOperatingLease", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of change in operating lease expense.", "label": "Non Cash Change In Operating Lease", "terseLabel": "Non-cash lease expense" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r844" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r813", "r825", "r835", "r852", "r861" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r842" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r841" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r852" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r872" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r872" ] }, "enfn_NoncashOther": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NoncashOther", "crdr": "debit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as other received in noncash.", "label": "Noncash Other", "terseLabel": "Other" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Non-Controlling Interest", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r80", "r372", "r902", "r903", "r904", "r981" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total non-operating income (expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r116" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "NON-OPERATING INCOME (EXPENSE):" } } }, "auth_ref": [] }, "enfn_NumberOfCustomers": { "xbrltype": "integerItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NumberOfCustomers", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of Customers.", "label": "Number of Customers", "terseLabel": "Number of customers" } } }, "auth_ref": [] }, "enfn_NumberOfDaysToEstablishMinimumBalanceWithBank": { "xbrltype": "durationItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NumberOfDaysToEstablishMinimumBalanceWithBank", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of days to establish minimum required balance, in 'PnYnMnDTnHnMnS' format.", "label": "Number of Days to Establish Minimum Balance With Bank", "terseLabel": "Number of days to establish minimum balance with bank" } } }, "auth_ref": [] }, "enfn_NumberOfFinanceLeases": { "xbrltype": "integerItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NumberOfFinanceLeases", "presentation": [ "http://enfusion.com/role/DisclosureLeasesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of finance leases.", "label": "Number of Finance Leases", "terseLabel": "Number of finance leases" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://enfusion.com/role/DisclosureBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r908" ] }, "enfn_NumberOfSharesInExchangeForTerminationOfEmploymentAgreement": { "xbrltype": "sharesItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NumberOfSharesInExchangeForTerminationOfEmploymentAgreement", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the right may be converted into shares for termination of employment agreements. Shares will be issued between first and second anniversaries of the IPO effectiveness date.", "label": "Number of Shares In Exchange For Termination Of Employment Agreement", "terseLabel": "Number of shares to be received in exchange for terminated employee agreements" } } }, "auth_ref": [] }, "enfn_NumberOfSubsidiaries": { "xbrltype": "integerItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NumberOfSubsidiaries", "presentation": [ "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of wholly-owned subsidiaries.", "label": "Number Of Subsidiaries", "terseLabel": "Number of wholly-owned subsidiaries" } } }, "auth_ref": [] }, "enfn_NumberOfTradingDaysPrecedingTransactionConsideredForClosingPrice": { "xbrltype": "durationItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NumberOfTradingDaysPrecedingTransactionConsideredForClosingPrice", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of trading days preceding the transaction considered for closing price.", "label": "Number of Trading Days Preceding the Transaction Considered for Closing Price", "terseLabel": "Number of trading days preceding transaction" } } }, "auth_ref": [] }, "enfn_NumberOfUnitsPurchasedDueToExchangeByPreIPOCommonUnitHolders": { "xbrltype": "sharesItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NumberOfUnitsPurchasedDueToExchangeByPreIPOCommonUnitHolders", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of units purchased in connection with the exchange of those units by the pre-IPO common unit holders.", "label": "Number Of Units Purchased Due To Exchange By Pre I P O Common Unit Holders", "terseLabel": "Number of units purchased in connection with Pre-IPO" } } }, "auth_ref": [] }, "enfn_NumberOfVotingRights": { "xbrltype": "integerItemType", "nsuri": "http://enfusion.com/20231231", "localname": "NumberOfVotingRights", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of Voting Rights", "label": "Number of Voting Rights", "terseLabel": "Number of Voting Rights" } } }, "auth_ref": [] }, "enfn_OlegMovchanMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "OlegMovchanMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Member stands for Oleg Movchan", "label": "Oleg Movchan [Member]", "terseLabel": "Oleg Movchan" } } }, "auth_ref": [] }, "enfn_OneMonthAdjustedTermSecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "OneMonthAdjustedTermSecuredOvernightFinancingRateSofrMember", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Interest rate based on one month adjusted term SOFR.", "label": "One month Adjusted Term Secured Overnight Financing Rate (SOFR) [Member]", "terseLabel": "One month adjusted term SOFR" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r265", "r277", "r281", "r283", "r763" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureLeasesComponentsOfOperatingLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureLeasesComponentsOfOperatingLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r542", "r785" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureLeasesCommitmentsDetailsCalc2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureLeasesLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r538" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r538" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r538" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use-assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r537" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://enfusion.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate (as percentage)", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r547", "r785" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://enfusion.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (in years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r546", "r785" ] }, "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesOfLesseeDisclosureTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Disclosure [Table Text Block]", "terseLabel": "Schedule of weighted-average remaining lease terms and discount rates", "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions." } } }, "auth_ref": [ "r152", "r153", "r154", "r155", "r156" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "terseLabel": "Net loss carryforward", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r78" ] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating loss carryforwards", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r77" ] }, "enfn_OrganizationAndDescriptionOfBusinessAbstract": { "xbrltype": "stringItemType", "nsuri": "http://enfusion.com/20231231", "localname": "OrganizationAndDescriptionOfBusinessAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Organization and Description of Business" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Basis of Presentation" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureBasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r94", "r139", "r631", "r632" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Current", "terseLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r194", "r786" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r186" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "verboseLabel": "Foreign currency translation income (loss)", "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5", "r107", "r518", "r519", "r520" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r4" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss), net of income tax:" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r117" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r844" ] }, "enfn_OtherServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "OtherServicesMember", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to other services.", "label": "Other" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r811", "r823", "r833", "r859" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r814", "r826", "r836", "r862" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r814", "r826", "r836", "r862" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r840" ] }, "enfn_PaymentForPurchaseOfCommonUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "PaymentForPurchaseOfCommonUnits", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The Cash outflow for purchase of common units from common unit holders.", "label": "Payment for Purchase of Common Units", "negatedLabel": "Purchases of common units from Pre-IPO common unit holders" } } }, "auth_ref": [] }, "enfn_PaymentToRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "PaymentToRelatedParty", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of payment to related party during the period.", "label": "Payment To Related Party", "negatedLabel": "Payment to related party" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r36" ] }, "us-gaap_PaymentsOfDistributionsToAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDistributionsToAffiliates", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Payments of Distributions to Affiliates", "terseLabel": "Distributions to affiliates", "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership." } } }, "auth_ref": [ "r34" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Payment of withholding taxes on stock-based compensation", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r210" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r118" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r843" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r843" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r842" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r852" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r845" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r841" ] }, "enfn_PercentageOfEntitySShareOfTaxBenefitsUnderTaxReceivableAgreement": { "xbrltype": "percentItemType", "nsuri": "http://enfusion.com/20231231", "localname": "PercentageOfEntitySShareOfTaxBenefitsUnderTaxReceivableAgreement", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails", "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percent of entity's share of tax benefits.", "label": "Percentage of Entity's Share of Tax Benefits Under Tax Receivable Agreement", "terseLabel": "Percentage of Entity's Share of Tax Benefits Under Tax Receivable Agreement" } } }, "auth_ref": [] }, "enfn_PercentageOfIncreaseInSharesOutstandingAnnually": { "xbrltype": "percentItemType", "nsuri": "http://enfusion.com/20231231", "localname": "PercentageOfIncreaseInSharesOutstandingAnnually", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percent of increase in shares outstanding annually.", "label": "Percentage of Increase in Shares Outstanding Annually" } } }, "auth_ref": [] }, "enfn_PercentageOfOtherSShareOfTaxBenefitsUnderTaxReceivableAgreement": { "xbrltype": "percentItemType", "nsuri": "http://enfusion.com/20231231", "localname": "PercentageOfOtherSShareOfTaxBenefitsUnderTaxReceivableAgreement", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percent of other's share of tax benefits.", "label": "Percentage of Other's Share of Tax Benefits Under Tax Receivable Agreement", "terseLabel": "Percentage of Other's Share of Tax Benefits Under Tax Receivable Agreement" } } }, "auth_ref": [] }, "enfn_PercentageOfSharesDistributed": { "xbrltype": "percentItemType", "nsuri": "http://enfusion.com/20231231", "localname": "PercentageOfSharesDistributed", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of shares distributed in current period.", "label": "Percentage of Shares Distributed", "terseLabel": "Percentage of shares distributed" } } }, "auth_ref": [] }, "enfn_PerformanceBasedRestrictedStockUnitsRSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "PerformanceBasedRestrictedStockUnitsRSUsMember", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to performance-based restricted stock units (\"RSUs\").", "label": "Performance-Based Restricted Stock Units (\"RSUs\")", "terseLabel": "Performance-Based Restricted Stock Units (\"RSUs\")" } } }, "auth_ref": [] }, "enfn_PeriodForPaymentOfFeesAfterInvoiceDate": { "xbrltype": "durationItemType", "nsuri": "http://enfusion.com/20231231", "localname": "PeriodForPaymentOfFeesAfterInvoiceDate", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Period for payment of fees after invoice date.", "label": "Period for Payment of Fees After Invoice Date", "terseLabel": "Payment of fees upon invoice" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949" ] }, "enfn_PlatformSubscriptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "PlatformSubscriptionsMember", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to platform subscriptions.", "label": "Platform subscriptions" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r100", "r357" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails", "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r100", "r671" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r100", "r357" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r100", "r671", "r689", "r981", "r982" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r100", "r592", "r786" ] }, "enfn_PreferredUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "PreferredUnitsMember", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to preferred units", "label": "Preferred Units" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r193", "r309", "r310", "r756" ] }, "enfn_PriorCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "PriorCreditAgreementMember", "presentation": [ "http://enfusion.com/role/DisclosureDebtPriorCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to prior credit agreement.", "label": "Prior Credit Agreement [Member]", "terseLabel": "Prior Credit Agreement" } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r891" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "terseLabel": "Private placement", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIncomeTaxRefunds": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIncomeTaxRefunds", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Income Tax Refunds", "terseLabel": "Proceeds from income tax refunds", "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r39", "r120" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Issuance of Class A common stock, net of issuance costs", "verboseLabel": "Net proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Net proceeds from issuance of shares", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from (Payments for) Other Financing Activities", "verboseLabel": "Other financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r883", "r895" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r284", "r568", "r611", "r612", "r613", "r614", "r615", "r616", "r753", "r772", "r787", "r888", "r918", "r919", "r923", "r977" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r284", "r568", "r611", "r612", "r613", "r614", "r615", "r616", "r753", "r772", "r787", "r888", "r918", "r919", "r923", "r977" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "enfn_NetIncomeLossAttributableToParentSubsequentToIpo", "weight": 1.0, "order": 1.0 }, "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://enfusion.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows", "http://enfusion.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss", "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Net income (loss)", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r180", "r196", "r198", "r212", "r220", "r232", "r242", "r243", "r265", "r277", "r281", "r283", "r293", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r479", "r482", "r483", "r508", "r512", "r588", "r603", "r645", "r691", "r712", "r713", "r763", "r783", "r784", "r798", "r894", "r920" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNet" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Equipment, and Software, Net", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r124", "r163", "r168", "r169" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property, equipment, and software, cost", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r125", "r184", "r601" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails", "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetNarrativeDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Equipment, and Software, Net", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails", "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetNarrativeDetails", "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, equipment, and software, net", "totalLabel": "Total property, equipment, and software, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r10", "r589", "r601", "r786" ] }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNetAbstract", "lang": { "en-us": { "role": { "label": "Property, Equipment, and Software, Net" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment, Net", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r10", "r163", "r168", "r599" ] }, "us-gaap_PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Preproduction Design and Development Costs [Policy Text Block]", "verboseLabel": "Software Development Costs", "documentation": "Disclosure of accounting policy for the preproduction design and development costs it incurs related to long-term supply arrangements, including whether such costs are capitalized or expensed as incurred. The entity also may disclose the aggregate amount of (1) assets recognized for agreements that contractually reimburse the entity for its pre-production design and development costs (2) assets recognized for molds, dies and other tools that the entity owns and (3) assets recognized for molds, dies and other tools that the entity does not own." } } }, "auth_ref": [ "r311" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property, equipment, and software, net", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r125" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Estimated Useful Lives", "terseLabel": "Useful life", "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value." } } }, "auth_ref": [ "r915" ] }, "enfn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://enfusion.com/20231231", "localname": "PropertyPlantAndEquipmentUsefulLifeTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of useful life of property plant and equipment.", "label": "Property, Plant and Equipment, Useful life [Table Text Block]", "terseLabel": "Schedule of property, plant and equipment useful life" } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAllowancesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "verboseLabel": "Changes to the provision", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r208", "r307" ] }, "us-gaap_ProvisionForOtherCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForOtherCreditLosses", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Provision for Other Credit Losses", "terseLabel": "Provision for credit losses", "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions." } } }, "auth_ref": [ "r8", "r148" ] }, "enfn_PurchaseOfCommonUnits": { "xbrltype": "sharesItemType", "nsuri": "http://enfusion.com/20231231", "localname": "PurchaseOfCommonUnits", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Purchase of common units from common unit holders.", "label": "Purchase of common units from Pre-IPO common unit holders and retirement of Class B common shares (in Shares)", "terseLabel": "Purchase of Pre-IPO common unit holders and retirement of Class B common shares (in shares)" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r840" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r840" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r317", "r318", "r319", "r320", "r386", "r390", "r421", "r422", "r423", "r565", "r566", "r617", "r661", "r662", "r722", "r724", "r726", "r727", "r729", "r750", "r751", "r765", "r771", "r779", "r788", "r791", "r916", "r922", "r970", "r971", "r972", "r973", "r974" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r317", "r318", "r319", "r320", "r386", "r390", "r421", "r422", "r423", "r565", "r566", "r617", "r661", "r662", "r722", "r724", "r726", "r727", "r729", "r750", "r751", "r765", "r771", "r779", "r788", "r791", "r916", "r922", "r970", "r971", "r972", "r973", "r974" ] }, "enfn_ReceiptOfTaxRefund": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ReceiptOfTaxRefund", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.", "label": "Receipt of Tax Refund", "terseLabel": "Settlement of tax receivable acquired in reorganization transactions" } } }, "auth_ref": [] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r909", "r910", "r911", "r912" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesUnrecognizedDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Uncertain tax positions", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r806", "r818", "r828", "r854" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r387", "r557", "r558", "r664", "r665", "r666", "r667", "r668", "r688", "r690", "r721" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Related Party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r223", "r224", "r557", "r558", "r559", "r560", "r664", "r665", "r666", "r667", "r668", "r688", "r690", "r721" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transactions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r695", "r696", "r699" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r387", "r557", "r558", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r664", "r665", "r666", "r667", "r668", "r688", "r690", "r721", "r966" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r554", "r555", "r556", "r558", "r561", "r641", "r642", "r643", "r697", "r698", "r699", "r718", "r720" ] }, "enfn_ReorganizationTransactionAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ReorganizationTransactionAdjustments", "crdr": "debit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Amount of adjustment during the period towards reorganization transactions.", "label": "Reorganization Transaction Adjustments", "negatedLabel": "Effect of the Reorganization" } } }, "auth_ref": [] }, "enfn_ReorganizationTransactionAdjustmentsShares": { "xbrltype": "sharesItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ReorganizationTransactionAdjustmentsShares", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Reorganization Transaction Adjustments Shares.", "label": "Reorganization Transaction Adjustments Shares", "negatedLabel": "Effect of the Reorganization (in shares)" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Secured Debt", "negatedLabel": "Repayment of term loan", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r35" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r225", "r226", "r334", "r359", "r560", "r758", "r759" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationStockCompensationIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Technology and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Technology and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r441" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r807", "r819", "r829", "r855" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r808", "r820", "r830", "r856" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r815", "r827", "r837", "r863" ] }, "enfn_RestrictedStockSharesIssuedUponExchangeOfSharesInShares": { "xbrltype": "sharesItemType", "nsuri": "http://enfusion.com/20231231", "localname": "RestrictedStockSharesIssuedUponExchangeOfSharesInShares", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Number of restricted stock issued upon exchange of shares.", "label": "Restricted Stock, Shares Issued Upon Exchange of Shares (in Shares)", "verboseLabel": "Share exchange (in shares)" } } }, "auth_ref": [] }, "enfn_RestrictedStockSharesIssuedUponExchangeOfSharesValue": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "RestrictedStockSharesIssuedUponExchangeOfSharesValue", "crdr": "credit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Amount of restricted stock issued upon exchange of shares.", "label": "Restricted Stock, Shares Issued Upon Exchange of Shares, Value", "terseLabel": "Share exchange" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationTables", "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units", "terseLabel": "Restricted Stock Units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r103", "r133", "r596", "r624", "r629", "r639", "r672", "r786" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r177", "r228", "r229", "r230", "r233", "r241", "r243", "r298", "r304", "r431", "r432", "r433", "r465", "r466", "r489", "r492", "r493", "r496", "r506", "r620", "r622", "r646", "r981" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "verboseLabel": "Total revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r266", "r267", "r276", "r279", "r280", "r284", "r285", "r287", "r383", "r384", "r568" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Revenues", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r287", "r885" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r173", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r752" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue remaining performance obligation", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r166" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Remaining performance obligation satisfaction period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r167" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r167" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]", "terseLabel": "Schedule of remaining performance obligation", "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [ "r884" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "REVENUES:" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails", "http://enfusion.com/role/DisclosureDebtPriorCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Revolving Debt", "terseLabel": "Senior secured revolving loan facility", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r545", "r785" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r872" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r872" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share issued", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "enfn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of accrued expenses and other current liabilities.", "label": "Schedule of Accrued Expenses And Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of effect of dilutive shares antidilutive", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of components of income tax expense (benefit)", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r137" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of components of deferred tax assets and liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r136" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]", "terseLabel": "Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share", "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share." } } }, "auth_ref": [ "r46", "r49", "r905" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of the U.S. statutory income tax rate to our effective income tax rate", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r135" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationStockCompensationIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r72" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r72" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of components of income (loss) before income taxes", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r901" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails", "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetNarrativeDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r89", "r90", "r695", "r696", "r699" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r392", "r394", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of share-based payment award activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r71" ] }, "enfn_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of share-based award, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of assumptions" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r64", "r65", "r66", "r67", "r68", "r69", "r70", "r131", "r132", "r133", "r188", "r189", "r190", "r263", "r357", "r358", "r359", "r361", "r364", "r369", "r371", "r635", "r636", "r637", "r638", "r771", "r881", "r898" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of company's uncertain tax positions", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r782", "r953" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of estimated future amortization of capitalized software development costs", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r58" ] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "Secured Overnight Financing Rate", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r960" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r800" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r802" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetNarrativeDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r285", "r286", "r658", "r659", "r660", "r723", "r725", "r728", "r730", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r754", "r773", "r791", "r923", "r977" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r275", "r285", "r764" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationStockCompensationIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Sales and marketing", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r110" ] }, "enfn_ServiceAgreementsExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ServiceAgreementsExpense", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureLeasesOperatingLeasesAndServiceAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense incurred under service agreements.", "label": "Service Agreements, Expense", "terseLabel": "Expense related to service agreements" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based compensation expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r780" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited during the period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited during the period", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted during the period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r411" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted, Weighted average fair value per RSU at grant date", "verboseLabel": "Granted during the period", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r411" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "verboseLabel": "Unvested", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r408", "r409" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Stock Units", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted- Average Grant-Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r412" ] }, "enfn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingAndIssuanceInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingAndIssuanceInPeriod", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were vesting and issuance during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vesting And Issuance In Period", "negatedLabel": "Vested and issued" } } }, "auth_ref": [] }, "enfn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingAndIssuanceInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingAndIssuanceInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right and issuance of shares during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vesting and Issuance in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested and issued" } } }, "auth_ref": [] }, "enfn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested and vested award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning balance" } } }, "auth_ref": [] }, "enfn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity": { "xbrltype": "percentItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The cost of equity capital used as assumption in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Cost of Equity", "terseLabel": "Cost of equity capital" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price", "terseLabel": "Fair value of common stock (per share)", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r422" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r423" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Management Incentive Plans", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r392", "r394", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r16", "r17" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares, Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r781" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited during the period", "terseLabel": "Stock options forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r406" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted to employees", "verboseLabel": "Granted during the period", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r404" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r400", "r401" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding", "periodStartLabel": "Outstanding", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r400", "r401" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited during the period", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r406" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average grants in period", "verboseLabel": "Granted during the period", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r404" ] }, "enfn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardSharesGrantedCapitalizableActivities": { "xbrltype": "sharesItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardSharesGrantedCapitalizableActivities", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares granted in conjunction with capitalizable activities under share-based payment arrangement.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Shares Granted, Capitalizable Activities", "terseLabel": "Stocks granted in conjunction with capitalizable activities" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r391", "r399", "r418", "r419", "r420", "r421", "r424", "r434", "r435", "r436", "r437" ] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Employee", "terseLabel": "Employee", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r394", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Share price (in dollars per share)", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term of award", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r420" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "terseLabel": "Unvested", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "verboseLabel": "Unvested", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationRsusAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r134" ] }, "enfn_SharesInExchangeForTerminationOfEmploymentAgreementFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "SharesInExchangeForTerminationOfEmploymentAgreementFairValue", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of shares to be issued in exchange for termination of employment agreements.", "label": "Shares In Exchange For Termination Of Employment Agreement Fair Value", "terseLabel": "Fair value of shares to be issued in exchange of termination of employment agreements" } } }, "auth_ref": [] }, "enfn_SharesIssuedDuringInitialPublicOffering": { "xbrltype": "sharesItemType", "nsuri": "http://enfusion.com/20231231", "localname": "SharesIssuedDuringInitialPublicOffering", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during Initial Public Offering.", "label": "Shares Issued During Initial Public Offering", "terseLabel": "Issuance of Class A common stock in the IPO, net of issuance costs (in shares)" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at Beginning of period (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureLeasesComponentsOfOperatingLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureLeasesComponentsOfOperatingLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r543", "r785" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r122", "r217" ] }, "enfn_SignificantChangeInTaxReceivableAgreementIfDeterminedReasonablyPossibleAmountOfUnrecordedTaxLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "SignificantChangeInTaxReceivableAgreementIfDeterminedReasonablyPossibleAmountOfUnrecordedTaxLiability", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of the unrecognized tax liability of a position taken if determined to be reasonably possible under the Tax Receivable Agreement.", "label": "Significant Change in Tax Receivable Agreement If Determined Reasonably Possible, Amount of Unrecorded Tax Liability", "verboseLabel": "Liability under the Tax Receivable Agreement" } } }, "auth_ref": [] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" ], "lang": { "en-us": { "role": { "label": "Software development costs", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_SoftwareDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoftwareDevelopmentMember", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Software development cost", "terseLabel": "Software development costs", "documentation": "Internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "State and Local Income Tax Expense (Benefit), Continuing Operations", "terseLabel": "State tax expense (benefit)", "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r901", "r951", "r957" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "terseLabel": "State", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/DisclosureStockholdersEquityDetails", "http://enfusion.com/role/DisclosureSubsequentEventsDetails", "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "http://enfusion.com/role/StatementConsolidatedBalanceSheets", "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r174", "r188", "r189", "r190", "r220", "r249", "r250", "r253", "r255", "r263", "r264", "r293", "r321", "r323", "r324", "r325", "r328", "r329", "r357", "r358", "r361", "r364", "r371", "r512", "r635", "r636", "r637", "r638", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r671", "r692", "r714", "r731", "r732", "r733", "r734", "r735", "r881", "r898", "r906" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails", "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r29", "r177", "r201", "r202", "r203", "r228", "r229", "r230", "r233", "r241", "r243", "r260", "r298", "r304", "r372", "r431", "r432", "r433", "r465", "r466", "r489", "r491", "r492", "r493", "r494", "r496", "r506", "r521", "r522", "r523", "r524", "r525", "r526", "r553", "r620", "r621", "r622", "r646", "r714" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetNarrativeDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r285", "r286", "r658", "r659", "r660", "r723", "r725", "r728", "r730", "r738", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r754", "r773", "r791", "r923", "r977" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails", "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAllowancesDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://enfusion.com/role/StatementConsolidatedBalanceSheets", "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r228", "r229", "r230", "r260", "r568", "r633", "r657", "r663", "r664", "r665", "r666", "r667", "r668", "r671", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r684", "r685", "r686", "r687", "r688", "r690", "r693", "r694", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r714", "r792" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Comprehensive Income (Loss)" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Preferred Units, Stockholders' Equity and Members' Deficit" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails", "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAllowancesDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://enfusion.com/role/StatementConsolidatedBalanceSheets", "http://enfusion.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r228", "r229", "r230", "r260", "r568", "r633", "r657", "r663", "r664", "r665", "r666", "r667", "r668", "r671", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r684", "r685", "r686", "r687", "r688", "r690", "r693", "r694", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r714", "r792" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r810", "r822", "r832", "r858" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "enfn_StockIssueCostsIncludedInAccruedExpensesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "StockIssueCostsIncludedInAccruedExpensesAndOtherLiabilities", "crdr": "debit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "IPO costs included in Accrued expenses and other liabilities.", "label": "Stock Issue Costs Included In Accrued Expenses And Other Liabilities", "terseLabel": "IPO costs included in accrued expenses and other liabilities" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/DisclosureStockholdersEquityDetails", "http://enfusion.com/role/DisclosureSubsequentEventsDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of Class A common stock, net of issuance costs (in shares)", "verboseLabel": "Issuance of shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r15", "r100", "r101", "r133", "r635", "r714", "r732" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of IPO vested Class A common stock and share-based awards (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r15", "r100", "r101", "r133" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of Class A common stock in the IPO, net of issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r15", "r100", "r101", "r133", "r646", "r714", "r732", "r798" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of IPO vested Class A common stock and share-based awards", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r15", "r133" ] }, "enfn_StockOptionAndIncentivePlan2021Member": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "StockOptionAndIncentivePlan2021Member", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to stock option and incentive plan 2021.", "label": "Stock Option And Incentive Plan 2021" } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Purchase of Pre-IPO common unit holders and retirement of Class B common shares", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r15", "r100", "r101", "r133", "r646", "r714", "r734", "r798" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity attributable to Enfusion, Inc.", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r101", "r104", "r105", "r123", "r673", "r689", "r715", "r716", "r786", "r799", "r900", "r913", "r962", "r981" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://enfusion.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedBalanceSheets", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at Beginning of period", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r80", "r81", "r84", "r177", "r178", "r202", "r228", "r229", "r230", "r233", "r241", "r298", "r304", "r372", "r431", "r432", "r433", "r465", "r466", "r489", "r491", "r492", "r493", "r494", "r496", "r506", "r521", "r522", "r526", "r553", "r621", "r622", "r644", "r673", "r689", "r715", "r716", "r736", "r798", "r900", "r913", "r962", "r981" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r130", "r219", "r356", "r358", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r370", "r372", "r497", "r717", "r719", "r737" ] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stock exchange ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r20" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://enfusion.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r527", "r563" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails", "http://enfusion.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r527", "r563" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://enfusion.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r527", "r563" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails", "http://enfusion.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r527", "r563" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails", "http://enfusion.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r527", "r563" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r562", "r564" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://enfusion.com/role/DisclosureManagementIncentivePlanAndStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Summary of Valuation Allowance [Table Text Block]", "terseLabel": "Schedule of valuation allowance for deferred tax assets", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": [ "r76" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "enfn_SwinglineSubfacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://enfusion.com/20231231", "localname": "SwinglineSubfacilityMember", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to swingline subfacility.", "label": "Swingline Subfacility [Member]", "terseLabel": "Swingline subfacility" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r851" ] }, "enfn_TaxReceivableAgreementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://enfusion.com/20231231", "localname": "TaxReceivableAgreementPolicyPolicyTextBlock", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy relating to tax receivable agreement.", "label": "Tax Receivable Agreement Policy [Policy Text Block]", "terseLabel": "Tax Receivable Agreement (TRA)" } } }, "auth_ref": [] }, "enfn_TaxReceivableAgreementTaxBasisIncreaseOfNetAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "TaxReceivableAgreementTaxBasisIncreaseOfNetAssets", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of tax basis of net assets increase under tax receivable agreement.", "label": "Tax Receivable Agreement, Tax Basis Increase Of Net Assets", "terseLabel": "Tax basis increase in net assets under Tax Receivable Agreement" } } }, "auth_ref": [] }, "enfn_TaxWithholdingsRelatedToNetShareSettlementsOfStockBasedCompensationAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "TaxWithholdingsRelatedToNetShareSettlementsOfStockBasedCompensationAwards", "crdr": "debit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Value of shares tax withholdings related to net share settlements of stock-based compensation awards.", "label": "Tax Withholdings Related To Net Share Settlements Of Stock Based Compensation Awards", "negatedLabel": "Tax withholdings related to net share settlements of stock-based compensation awards" } } }, "auth_ref": [] }, "enfn_TaxWithholdingsRelatedToNetShareSettlementsOfStockBasedCompensationAwardsShares": { "xbrltype": "sharesItemType", "nsuri": "http://enfusion.com/20231231", "localname": "TaxWithholdingsRelatedToNetShareSettlementsOfStockBasedCompensationAwardsShares", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in connection with Tax withholdings related to net share settlements of stock-based compensation awards.", "label": "Tax Withholdings Related To Net Share Settlements Of Stock Based Compensation Awards Shares", "negatedLabel": "Tax withholdings related to net share settlements of stock-based compensation awards (in shares)" } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "enfn_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Taxes Payable, Current", "terseLabel": "Accrued taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23" ] }, "enfn_TechnologyAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "TechnologyAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense relating to technology and development during the period.", "label": "Technology And Development Expense", "terseLabel": "Technology and development" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureStockholdersEquityDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "terseLabel": "Preferred units carrying amount", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r321", "r323", "r324", "r325", "r328", "r329", "r438", "r594" ] }, "enfn_TemporaryEquityDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "TemporaryEquityDistributions", "crdr": "debit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in temporary equity from distributions.", "label": "Temporary Equity, Distributions", "negatedLabel": "Distributions to members" } } }, "auth_ref": [] }, "enfn_TemporaryEquityEffectOfReorganizationTransactionsShares": { "xbrltype": "sharesItemType", "nsuri": "http://enfusion.com/20231231", "localname": "TemporaryEquityEffectOfReorganizationTransactionsShares", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in shares classified as temporary equity due to the effect of reorganization transaction.", "label": "Effect of the Reorganization Transactions (Shares)" } } }, "auth_ref": [] }, "enfn_TemporaryEquityEffectOfReorganizationTransactionsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "TemporaryEquityEffectOfReorganizationTransactionsValue", "crdr": "credit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in temporary equity due to the effect of reorganization transaction.", "label": "Temporary Equity, Effect Of Reorganization Transactions, Value", "terseLabel": "Effect of the Reorganization Transactions" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityNetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityNetIncome", "crdr": "credit", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Net Income", "terseLabel": "Net income (loss)", "documentation": "The portion of net income or loss attributable to temporary equity interest." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://enfusion.com/role/StatementConsolidatedStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r99" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r843" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r850" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r871" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r873" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r874" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r875" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r873" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r873" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r876" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r874" ] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfAdoptionMember", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAllowancesDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r175", "r176", "r177", "r178", "r179", "r232", "r233", "r234", "r235", "r244", "r291", "r292", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r313", "r431", "r432", "r433", "r463", "r464", "r465", "r466", "r476", "r477", "r478", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r528", "r529", "r532", "r533", "r534", "r535", "r549", "r550", "r551", "r552", "r553", "r569", "r570", "r571", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://enfusion.com/role/DisclosurePropertyEquipmentAndSoftwareNetNarrativeDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "United States" } } }, "auth_ref": [] }, "us-gaap_UnbilledContractsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnbilledContractsReceivable", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Unbilled Contracts Receivable", "terseLabel": "Unbilled accounts receivable", "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet." } } }, "auth_ref": [ "r567" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r870" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesUnrecognizedDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r443", "r450" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesUnrecognizedDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Interest and penalties", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r449" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesUnrecognizedDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increases for tax positions related to the current year", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r452" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesUnrecognizedDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increases (decreases) for tax positions of prior years", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r451" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesUnrecognizedDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedLabel": "Expiration of statute of limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r453" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r54", "r55", "r56", "r160", "r161", "r164", "r165" ] }, "us-gaap_ValuationAllowanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceAbstract", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesValuationAllowanceForDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance [Abstract]", "terseLabel": "Valuation allowance", "verboseLabel": "Valuation allowance for deferred tax assets" } } }, "auth_ref": [] }, "enfn_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseChargedToIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ValuationAllowanceDeferredTaxAssetIncreaseDecreaseChargedToIncomeTaxExpense", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesValuationAllowanceForDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset charged to income tax expense.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Charged to Income Tax Expense", "terseLabel": "Charged to Income Tax Expense" } } }, "auth_ref": [] }, "enfn_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseChargedToStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://enfusion.com/20231231", "localname": "ValuationAllowanceDeferredTaxAssetIncreaseDecreaseChargedToStockholdersEquity", "crdr": "credit", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesValuationAllowanceForDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset charged to stockholders' equity.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Charged to Stockholders' Equity", "terseLabel": "Charged to Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://enfusion.com/role/DisclosureLeasesComponentsOfOperatingLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureLeasesComponentsOfOperatingLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r544", "r785" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://enfusion.com/role/DisclosureDebtNewCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Add: Dilutive Shares", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r907" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted Average number of Class A common shares outstanding, Diluted", "totalLabel": "Weighted-average shares of Class A common stock outstanding--diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r248", "r255" ] }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesIssuedBasic", "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Issued, Basic", "terseLabel": "Weighted-average shares of Class A common stock outstanding", "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)." } } }, "auth_ref": [ "r43", "r44" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted Average number of Class A common shares outstanding, Basic", "totalLabel": "Weighted-average shares of Class A common stock outstanding--basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r246", "r255" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails", "http://enfusion.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted Average number of Class A common shares outstanding:", "verboseLabel": "Denominator:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesRestrictedStock", "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares, Restricted Stock", "terseLabel": "Vested shares of Class A common stock and RSUs", "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends." } } }, "auth_ref": [ "r44" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a-c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "SubTopic": "20", "Topic": "985", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB TOPIC 4.C)", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Subparagraph": "(Note 3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715-70/tableOfContent" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r881": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org//705/tableOfContent" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-3" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 102 0001558370-24-002987-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-002987-xbrl.zip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